0001437749-24-03261410-Q PULSE BIOSCIENCES, INC. 20241030202410301607161607161607160716 0 0001437749-24-032614 10-Q 66 20240930 20241030 20241030 PULSE BIOSCIENCES, INC. 0001625101 3841 465696597 DE 1231 10-Q 34 001-37744 241410314 3957 POINT EDEN WAY HAYWARD CA 94545 510-906-4600 3957 POINT EDEN WAY HAYWARD CA 94545 Pulse Biosciences, Inc. 20151210 Electroblate, Inc. 20141113 10-Q 1 plse20240930c_10q.htm FORM 10-Q plse20240930c_10q.htm 0001625101 Pulse Biosciences, Inc. false --12-31 Q3 2024 0.001 0.001 50,000 50,000 0 0 0 0 0.001 0.001 500,000 500,000 61,516 61,516 55,144 55,144 364 24 364 24 6 9 0 0 0.1 0.4 0 6 1 2 0.5 6000000 0.5 1 1 1 5 10 1 1 0.3 0 0 0 0 0 0 0 0 0 0 â€” â€” 5 0.6 1 1 7 http://fasb.org/us-gaap/2024#CostsAndExpenses false false false false false 0001625101024-01-012024-09-30 xbrli:shares 0001625101024-10-25 thunderdome:item iso4217:USD 0001625101024-09-30 0001625101021-12-31 iso4217:USDxbrli:shares 0001625101024-07-012024-09-30 0001625101023-07-012023-09-30 0001625101023-01-012023-09-30 0001625101023-12-31 0001625101022-12-31 0001625101023-09-30 0001625101us-gaap:CommonStockMember2024-06-30 0001625101us-gaap:AdditionalPaidInCapitalMember2024-06-30 0001625101us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-06-30 0001625101us-gaap:RetainedEarningsMember2024-06-30 0001625101024-06-30 0001625101plse:RightsOfferingMember2024-07-012024-09-30 0001625101us-gaap:CommonStockMemberplse:RightsOfferingMember2024-07-012024-09-30 0001625101us-gaap:AdditionalPaidInCapitalMemberplse:RightsOfferingMember2024-07-012024-09-30 0001625101us-gaap:AccumulatedOtherComprehensiveIncomeMemberplse:RightsOfferingMember2024-07-012024-09-30 0001625101us-gaap:RetainedEarningsMemberplse:RightsOfferingMember2024-07-012024-09-30 0001625101us-gaap:CommonStockMember2024-07-012024-09-30 0001625101us-gaap:AdditionalPaidInCapitalMember2024-07-012024-09-30 0001625101us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-07-012024-09-30 0001625101us-gaap:RetainedEarningsMember2024-07-012024-09-30 0001625101plse:AtmOfferingMember2024-07-012024-09-30 0001625101us-gaap:CommonStockMemberplse:AtmOfferingMember2024-07-012024-09-30 0001625101us-gaap:AdditionalPaidInCapitalMemberplse:AtmOfferingMember2024-07-012024-09-30 0001625101us-gaap:AccumulatedOtherComprehensiveIncomeMemberplse:AtmOfferingMember2024-07-012024-09-30 0001625101us-gaap:RetainedEarningsMemberplse:AtmOfferingMember2024-07-012024-09-30 0001625101us-gaap:CommonStockMember2024-09-30 0001625101us-gaap:AdditionalPaidInCapitalMember2024-09-30 0001625101us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-09-30 0001625101us-gaap:RetainedEarningsMember2024-09-30 0001625101us-gaap:CommonStockMember2023-12-31 0001625101us-gaap:AdditionalPaidInCapitalMember2023-12-31 0001625101us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-12-31 0001625101us-gaap:RetainedEarningsMember2023-12-31 0001625101plse:RightsOfferingMember2024-01-012024-09-30 0001625101us-gaap:CommonStockMemberplse:RightsOfferingMember2024-01-012024-09-30 0001625101us-gaap:AdditionalPaidInCapitalMemberplse:RightsOfferingMember2024-01-012024-09-30 0001625101us-gaap:AccumulatedOtherComprehensiveIncomeMemberplse:RightsOfferingMember2024-01-012024-09-30 0001625101us-gaap:RetainedEarningsMemberplse:RightsOfferingMember2024-01-012024-09-30 0001625101us-gaap:CommonStockMember2024-01-012024-09-30 0001625101us-gaap:AdditionalPaidInCapitalMember2024-01-012024-09-30 0001625101us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-01-012024-09-30 0001625101us-gaap:RetainedEarningsMember2024-01-012024-09-30 0001625101plse:AtmOfferingMember2024-01-012024-09-30 0001625101us-gaap:CommonStockMemberplse:AtmOfferingMember2024-01-012024-09-30 0001625101us-gaap:AdditionalPaidInCapitalMemberplse:AtmOfferingMember2024-01-012024-09-30 0001625101us-gaap:AccumulatedOtherComprehensiveIncomeMemberplse:AtmOfferingMember2024-01-012024-09-30 0001625101us-gaap:RetainedEarningsMemberplse:AtmOfferingMember2024-01-012024-09-30 0001625101us-gaap:CommonStockMember2023-06-30 0001625101us-gaap:AdditionalPaidInCapitalMember2023-06-30 0001625101us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-06-30 0001625101us-gaap:RetainedEarningsMember2023-06-30 0001625101023-06-30 0001625101us-gaap:CommonStockMember2023-07-012023-09-30 0001625101us-gaap:AdditionalPaidInCapitalMember2023-07-012023-09-30 0001625101us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-07-012023-09-30 0001625101us-gaap:RetainedEarningsMember2023-07-012023-09-30 0001625101us-gaap:CommonStockMember2023-09-30 0001625101us-gaap:AdditionalPaidInCapitalMember2023-09-30 0001625101us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-09-30 0001625101us-gaap:RetainedEarningsMember2023-09-30 0001625101us-gaap:CommonStockMember2022-12-31 0001625101us-gaap:AdditionalPaidInCapitalMember2022-12-31 0001625101us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-31 0001625101us-gaap:RetainedEarningsMember2022-12-31 0001625101us-gaap:PrivatePlacementMember2023-01-012023-09-30 0001625101us-gaap:CommonStockMemberus-gaap:PrivatePlacementMember2023-01-012023-09-30 0001625101us-gaap:AdditionalPaidInCapitalMemberus-gaap:PrivatePlacementMember2023-01-012023-09-30 0001625101us-gaap:AccumulatedOtherComprehensiveIncomeMemberus-gaap:PrivatePlacementMember2023-01-012023-09-30 0001625101us-gaap:RetainedEarningsMemberus-gaap:PrivatePlacementMember2023-01-012023-09-30 0001625101us-gaap:CommonStockMember2023-01-012023-09-30 0001625101us-gaap:AdditionalPaidInCapitalMember2023-01-012023-09-30 0001625101us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-01-012023-09-30 0001625101us-gaap:RetainedEarningsMember2023-01-012023-09-30 0001625101us-gaap:WarrantMember2024-01-012024-09-30 0001625101us-gaap:WarrantMember2023-01-012023-09-30 0001625101us-gaap:EmployeeStockOptionMember2024-01-012024-09-30 0001625101us-gaap:EmployeeStockOptionMember2023-01-012023-09-30 0001625101us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Member2024-09-30 0001625101us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel2Member2024-09-30 0001625101us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel3Member2024-09-30 0001625101us-gaap:MoneyMarketFundsMember2024-09-30 0001625101us-gaap:FairValueInputsLevel1Member2024-09-30 0001625101us-gaap:FairValueInputsLevel2Member2024-09-30 0001625101us-gaap:FairValueInputsLevel3Member2024-09-30 0001625101us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Member2023-12-31 0001625101us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel2Member2023-12-31 0001625101us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel3Member2023-12-31 0001625101us-gaap:MoneyMarketFundsMember2023-12-31 0001625101us-gaap:FairValueInputsLevel1Member2023-12-31 0001625101us-gaap:FairValueInputsLevel2Member2023-12-31 0001625101us-gaap:FairValueInputsLevel3Member2023-12-31 0001625101023-01-012023-12-31 0001625101us-gaap:LeaseholdImprovementsMember2024-09-30 0001625101us-gaap:LeaseholdImprovementsMember2023-12-31 0001625101plse:LaboratoryEquipmentMember2024-09-30 0001625101plse:LaboratoryEquipmentMember2023-12-31 0001625101us-gaap:FurnitureAndFixturesMember2024-09-30 0001625101us-gaap:FurnitureAndFixturesMember2023-12-31 0001625101us-gaap:SoftwareAndSoftwareDevelopmentCostsMember2024-09-30 0001625101us-gaap:SoftwareAndSoftwareDevelopmentCostsMember2023-12-31 0001625101us-gaap:ConstructionInProgressMember2024-09-30 0001625101us-gaap:ConstructionInProgressMember2023-12-31 utr:Y 0001625101plse:AcquiredPatentsAndLicensesMember2024-09-30 0001625101plse:AcquiredPatentsAndLicensesMember2023-12-31 xbrli:pure 0001625101us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember2014-01-012014-12-31 0001625101us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember2014-12-31 0001625101plse:The2024RightOfferingMember2024-03-28 0001625101plse:WarrantsIssuedIn2024RightsOfferingMember2024-03-28 0001625101plse:The2024RightOfferingMember2024-03-282024-03-28 0001625101plse:RightsOfferingMember2024-07-03 0001625101plse:RightsOfferingMember2024-07-032024-07-03 0001625101plse:RightsOfferingWarrantsMember2024-07-03 0001625101plse:RightsOfferingMemberplse:RobertWDugganMember2024-07-032024-07-03 0001625101plse:RobertWDugganMemberus-gaap:PrivatePlacementMember2023-04-302023-04-30 0001625101plse:RobertWDugganMemberus-gaap:PrivatePlacementMember2023-04-30 0001625101plse:LoanAgreementMember2023-04-302023-04-30 0001625101plse:RightsOfferingMember2022-06-092022-06-09 0001625101plse:RightsOfferingMember2022-06-09 0001625101plse:RightsOfferingWarrantsMember2022-06-09 0001625101plse:RightsOfferingMembersrt:BoardOfDirectorsChairmanMember2022-06-09 0001625101plse:RightsOfferingWarrantsMemberplse:VestingOfFirstHalfMember2024-07-03 0001625101plse:RightsOfferingWarrantsMemberplse:VestingOfSecondHalfMember2024-07-03 0001625101plse:RightsOfferingWarrantsMember2024-09-30 0001625101plse:RightsOfferingWarrantsMember2023-12-31 utr:D 0001625101plse:RightsOfferingWarrantsMember2023-01-012023-12-31 0001625101plse:RightsOfferingWarrantsMember2023-01-012023-06-15 0001625101plse:RightsOfferingWarrantsMember2023-09-30 0001625101plse:The2017PlanMember2017-01-012017-12-31 0001625101plse:The2017PlanMember2017-12-31 0001625101plse:The2017PlanMember2023-01-012023-01-01 0001625101plse:The2017PlanMember2023-12-012023-12-31 0001625101plse:The2017PlanMember2024-09-30 0001625101plse:The2017InducementEquityIncentivePlanMember2017-11-30 0001625101plse:The2017InducementEquityIncentivePlanMember2017-11-012017-11-30 0001625101us-gaap:EmployeeStockOptionMemberplse:The2017InducementEquityIncentivePlanMembersrt:MaximumMember2017-11-012017-11-30 0001625101plse:The2017InducementEquityIncentivePlanMemberus-gaap:ShareBasedCompensationAwardTrancheOneMember2017-11-012017-11-30 0001625101plse:The2017InducementEquityIncentivePlanMember2021-05-012021-05-31 0001625101plse:The2017InducementEquityIncentivePlanMember2024-03-012024-03-31 0001625101plse:The2017InducementEquityIncentivePlanMember2024-09-30 0001625101plse:The2015Plan2017PlanAndInducementPlanMember2023-12-31 0001625101plse:The2015Plan2017PlanAndInducementPlanMember2023-01-012023-09-30 0001625101plse:The2015Plan2017PlanAndInducementPlanMember2024-01-012024-09-30 0001625101plse:The2015Plan2017PlanAndInducementPlanMember2024-09-30 0001625101plse:TimebasedOptionsMemberus-gaap:ShareBasedCompensationAwardTrancheOneMember2024-01-012024-09-30 0001625101plse:TimebasedOptionsMember2023-12-31 0001625101plse:TimebasedOptionsMember2023-01-012023-12-31 0001625101plse:TimebasedOptionsMember2024-01-012024-09-30 0001625101plse:TimebasedOptionsMember2024-09-30 0001625101plse:PerformanceOptionsMember2023-12-31 0001625101plse:PerformanceOptionsMember2023-01-012023-12-31 0001625101plse:PerformanceOptionsMember2024-01-012024-09-30 0001625101plse:PerformanceOptionsMember2024-09-30 0001625101plse:PerformancebasedOptionsMember2024-01-012024-09-30 0001625101plse:MarketbasedOptionsMember2023-12-31 0001625101plse:MarketbasedOptionsMember2023-01-012023-12-31 0001625101plse:MarketbasedOptionsMember2024-01-012024-09-30 0001625101plse:MarketbasedOptionsMember2024-09-30 0001625101plse:TimebasedAndPerformanceOptionsMembersrt:MinimumMember2024-07-012024-09-30 0001625101plse:TimebasedAndPerformanceOptionsMembersrt:MaximumMember2024-07-012024-09-30 0001625101plse:TimebasedAndPerformanceOptionsMember2023-07-012023-09-30 0001625101plse:TimebasedAndPerformanceOptionsMembersrt:MinimumMember2024-01-012024-09-30 0001625101plse:TimebasedAndPerformanceOptionsMembersrt:MaximumMember2024-01-012024-09-30 0001625101plse:TimebasedAndPerformanceOptionsMembersrt:MinimumMember2023-01-012023-09-30 0001625101plse:TimebasedAndPerformanceOptionsMembersrt:MaximumMember2023-01-012023-09-30 0001625101plse:TimebasedAndPerformanceOptionsMember2024-07-012024-09-30 0001625101plse:TimebasedAndPerformanceOptionsMember2024-01-012024-09-30 0001625101plse:TimebasedAndPerformanceOptionsMember2023-01-012023-09-30 0001625101plse:MarketbasedOptionsMembersrt:MinimumMember2024-07-012024-09-30 0001625101plse:MarketbasedOptionsMembersrt:MaximumMember2024-07-012024-09-30 0001625101plse:MarketbasedOptionsMembersrt:MinimumMember2023-07-012023-09-30 0001625101plse:MarketbasedOptionsMembersrt:MaximumMember2023-07-012023-09-30 0001625101plse:MarketbasedOptionsMembersrt:MinimumMember2024-01-012024-09-30 0001625101plse:MarketbasedOptionsMembersrt:MaximumMember2024-01-012024-09-30 0001625101plse:MarketbasedOptionsMembersrt:MinimumMember2023-01-012023-09-30 0001625101plse:MarketbasedOptionsMembersrt:MaximumMember2023-01-012023-09-30 0001625101plse:MarketbasedOptionsMember2024-07-012024-09-30 0001625101plse:MarketbasedOptionsMember2023-07-012023-09-30 0001625101plse:MarketbasedOptionsMember2023-01-012023-09-30 0001625101plse:The2017EmployeeStockPurchasePlanMember2017-12-31 0001625101plse:The2017EmployeeStockPurchasePlanMember2024-09-30 0001625101plse:The2017EmployeeStockPurchasePlanMember2024-01-012024-09-30 0001625101plse:The2017EmployeeStockPurchasePlanMembersrt:MinimumMember2024-07-012024-09-30 0001625101plse:The2017EmployeeStockPurchasePlanMembersrt:MaximumMember2024-07-012024-09-30 0001625101plse:The2017EmployeeStockPurchasePlanMembersrt:MinimumMember2023-07-012023-09-30 0001625101plse:The2017EmployeeStockPurchasePlanMembersrt:MaximumMember2023-07-012023-09-30 0001625101plse:The2017EmployeeStockPurchasePlanMembersrt:MinimumMember2024-01-012024-09-30 0001625101plse:The2017EmployeeStockPurchasePlanMembersrt:MaximumMember2024-01-012024-09-30 0001625101plse:The2017EmployeeStockPurchasePlanMembersrt:MinimumMember2023-01-012023-09-30 0001625101plse:The2017EmployeeStockPurchasePlanMembersrt:MaximumMember2023-01-012023-09-30 0001625101plse:The2017EmployeeStockPurchasePlanMember2024-07-012024-09-30 0001625101plse:The2017EmployeeStockPurchasePlanMember2023-07-012023-09-30 0001625101plse:The2017EmployeeStockPurchasePlanMember2023-01-012023-09-30 0001625101us-gaap:ResearchAndDevelopmentExpenseMember2024-07-012024-09-30 0001625101us-gaap:ResearchAndDevelopmentExpenseMember2023-07-012023-09-30 0001625101us-gaap:ResearchAndDevelopmentExpenseMember2024-01-012024-09-30 0001625101us-gaap:ResearchAndDevelopmentExpenseMember2023-01-012023-09-30 0001625101us-gaap:GeneralAndAdministrativeExpenseMember2024-07-012024-09-30 0001625101us-gaap:GeneralAndAdministrativeExpenseMember2023-07-012023-09-30 0001625101us-gaap:GeneralAndAdministrativeExpenseMember2024-01-012024-09-30 0001625101us-gaap:GeneralAndAdministrativeExpenseMember2023-01-012023-09-30 0001625101plse:TimebasedOptionsMember2024-07-012024-09-30 0001625101plse:TimebasedOptionsMember2023-07-012023-09-30 0001625101plse:TimebasedOptionsMember2023-01-012023-09-30 0001625101plse:PerformancebasedOptionsMember2024-07-012024-09-30 0001625101plse:PerformancebasedOptionsMember2023-07-012023-09-30 0001625101plse:PerformancebasedOptionsMember2023-01-012023-09-30 0001625101plse:EmployeeStokPurchasePlanMember2024-07-012024-09-30 0001625101plse:EmployeeStokPurchasePlanMember2023-07-012023-09-30 0001625101plse:EmployeeStokPurchasePlanMember2024-01-012024-09-30 0001625101plse:EmployeeStokPurchasePlanMember2023-01-012023-09-30 0001625101plse:TwoThousandTwentyTowLoanAgreementMemberplse:RobertWDugganMember2022-09-20 0001625101plse:TwoThousandTwentyTowLoanAgreementMemberplse:RobertWDugganMember2023-01-012023-12-31 0001625101plse:LoanAgreementMember2023-04-30 0001625101plse:CorporateHeadquartersInHaywardCaliforniaMember2017-07-31 utr:sqft 0001625101plse:CorporateHeadquartersInHaywardCaliforniaMemberplse:ExpansionPremises1Member2019-05-31 0001625101plse:CorporateHeadquartersInHaywardCaliforniaMemberplse:ExpansionPremises2Member2019-05-31 0001625101plse:LetterAgreementMemberplse:RobertWDugganMember2022-05-312022-05-31 0001625101plse:LetterAgreementMemberplse:RobertWDugganMember2023-05-312023-05-31 0001625101plse:LetterAgreementMemberplse:RobertWDugganMember2024-09-30 0001625101plse:LetterAgreementMemberplse:RobertWDugganMember2022-09-202022-09-20 0001625101us-gaap:EmployeeSeveranceMember2023-02-012023-02-28 0001625101023-02-012023-02-28 0001625101plse:NextOneToFourYearsMemberus-gaap:SubsequentEventMember2024-10-012024-10-31 0001625101us-gaap:EmployeeStockOptionMember2024-01-012024-09-30 Â Â Table of Contents UNITED STATES SECURITIESÂ ANDÂ EXCHANGEÂ COMMISSION Washington,Â D.C. 20549 Â Â FormÂ 10-Q Â Â (Mark One) Â â˜’ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Â For the quarterly period ended September 30, 2024 Â Or Â â˜ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Â For the transition period fromÂ Â Â Â Â Â Â Â Â Â Â Â Â Â Â to Â Commission File Number: 001-34899 Â Â PulseÂ Biosciences,Â Inc. (Exact name of registrant as specified in its charter) Â Delaware 46-5696597 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) Â Â 601Â Brickell Key Drive Miami, FL 33131 (Address of principal executive offices) (Zip Code) Â (510)Â 906-4600 (Registrantâ€™s telephone number, including area code) Â Securities registered pursuant to Section 12(b) of the Act: Â Â Â Â Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $0.001 per share PLSE The Nasdaq Stock Market Â Indicate by check mark whether the registrant (1)Â has filed all reports required to be filed by SectionÂ 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12Â months (or for such shorter period

that the registrant was required to file such reports), and (2)Â has been subject to such filing requirements for the past 90Â days. Â Â Â YesÂ â˜’Â Â Â NoÂ â˜Â Â Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (Â§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Â Â Â Â YesÂ â˜’Â Â Â NoÂ â˜Â Â Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of â€œlarge accelerated filer,â€ â€œaccelerated filer,â€ â€œsmaller reporting companyâ€ and â€œemerging growth companyâ€ in Rule 12b-2 of the Exchange Act.Â Â LargeÂ acceleratedÂ filerÂ Â Â â˜ Accelerated filer â˜ Non-accelerated filerÂ Â Â â˜’Â SmallerÂ reportingÂ companyÂ Â Â â˜’Â Â Â Emerging growth company â˜ Â If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. â˜ Â Indicate by check mark whether the registrant is a shell company (as defined in RuleÂ 12b-2 of the Exchange Act). Â Â Â YesÂ â˜Â Â NoÂ â˜’Â The number of shares outstanding of the registrantâ€™s common stock as of October 25, 2024: 61,516,677 Â Â Table of Contents Â Â TABLE OF CONTENTS Â Â PAGE Â No. PART I. FINANCIAL INFORMATION ItemÂ 1. Financial Statements (unaudited): 3 Condensed Consolidated Balance Sheets as of September 30, 2024 and DecemberÂ 31, 2023 3 Condensed Consolidated Statements of Operations and Comprehensive Loss for the Three- and Nine-MonthÂ Periods Ended SeptemberÂ 30, 2024 and 2023 4 Condensed Consolidated Statements of Cash Flows for the Nine-MonthÂ Periods Ended SeptemberÂ 30, 2024 and 2023 5 Condensed Consolidated Statements of Stockholdersâ€™Â Equity for the Three- and Nine-Month Periods Ended SeptemberÂ 30, 2024 and 2023 6 Notes to Condensed Consolidated Financial Statements 7 ItemÂ 2. Managementâ€™s Discussion and Analysis of Financial Condition and Results of Operations 18 ItemÂ 3. Quantitative and Qualitative Disclosures About Market Risk 25 ItemÂ 4. Controls and Procedures 25 Â Â PART II. OTHER INFORMATION ItemÂ 1. Legal Proceedings 26 Item 1A. Risk Factors 26 ItemÂ 2. Unregistered Sales of Equity Securities and Use of Proceeds 48 Item 3. Default Upon Senior Securities 48 ItemÂ 4. Mine Safety Disclosures 48 Item 5. Other Information 48 ItemÂ 6. Exhibits 48 Signatures 49 Â â€œPulse Biosciences,â€ the Pulse logos and other trademarks or service marks that we use in connection with the operation of our business appearing in this quarterlyÂ report on FormÂ 10-QÂ (this "QuarterlyÂ Report"), including CellFX, CellFX CloudConnect, CellFX Marketplace, Nano-pulse Stimulation, nsPFA, nano-PFA, CellFX nsPFA, and NPS, are the property of Pulse Biosciences, Inc. Solely for your convenience, some of our trademarks and trade names referred to in this QuarterlyÂ Report are listed without the Â® and TMÂ symbols, but we will assert, to the fullest extent under applicable law, our rights to our trademarks and trade names. Also, this QuarterlyÂ Report may contain additional trade names, trademarks or service marks of others, which are the property of their respective owners. We do not intend our use or display of any other companyâ€™s trade names, trademarks or service marks to imply a relationship with, or endorsement or sponsorship of us by, any of these other companies. Â Unless expressly indicated or the context requires otherwise, the terms â€œPulse,â€ â€œCompany,â€ â€œwe,â€ â€œus,â€ and â€œour,â€ in this document refer to Pulse Biosciences, Inc., a Delaware corporation, and, where appropriate, its wholly owned subsidiaries. Â Â 2 Table of Contents Â Â PART I. FINANCIAL INFORMATION Â ItemÂ 1. Financial Statements Â PULSE BIOSCIENCES, INC. Condensed Consolidated Balance Sheets (In thousands, except per share amounts) (Unaudited) Â Â Â September 30, Â Â December 31, Â Â Â 2024 Â Â 2023 Â ASSETS Â Â Â Â Â Â Â Â Current assets: Â Â Â Â Â Â Â Â Cash and cash equivalents Â $79,033Â Â $44,365Â Prepaid expenses and other current assets Â Â 1,381Â Â Â 963Â Total current assets Â Â 80,414Â Â Â 45,328Â Â Â Â Â Â Â Â Â Property and equipment, net Â Â 1,221Â Â Â 1,528Â Intangible assets, net Â Â 1,386Â Â Â 1,886Â Goodwill Â Â 2,791Â Â Â 2,791Â Right-of-use assets Â Â 6,588Â Â Â 7,256Â Other assets Â Â 646Â Â Â 365Â Total assets Â $93,046Â Â $59,154Â Â Â Â Â Â Â Â Â LIABILITIES AND STOCKHOLDERSâ€™ EQUITY Â Â Â Â Â Â Â Â Current liabilities: Â Â Â Â Â Â Â Â Accounts payable Â $1,727Â Â $1,836Â Accrued expenses Â Â 3,821Â Â Â 3,814Â Lease liability, current Â Â 1,193Â Â Â 1,058Â Total current liabilities Â Â 6,741Â Â Â 6,708Â Â Â Â Â Â Â Â Â Lease liability, less current portion Â Â 7,174Â Â Â 8,086Â Total liabilities Â Â 13,915Â Â Â 14,794Â Â Â Â Â Â Â Â Â Â Commitments and contingencies (Note 7) Â Stockholdersâ€™ equity: Â Â Â Â Â Â Â Â Preferred stock, $0.001 par value; authorized â€“ 50,000 shares; no shares issued and outstanding Â Â â€“Â Â Â â€“Â Common stock, $0.001 par value; authorized â€“ 500,000 shares; issued and outstanding â€“ 61,516 shares and 55,144 shares at September 30, 2024 and December 31, 2023, respectively Â Â 62Â Â Â 55Â Additional paid-in capital Â Â 450,184Â Â Â 381,220Â Accumulated other comprehensive income (loss) Â Â â€“Â Â Â â€“Â Accumulated deficit Â Â (371,115)Â Â (336,915) Total stockholdersâ€™ equity Â Â 79,131Â Â Â 44,360Â Total liabilities and stockholdersâ€™ equity Â $93,046Â Â $59,154Â Â See accompanying notes to the condensed consolidated financial statements. Â 3 Table of Contents Â PULSE BIOSCIENCES, INC. Condensed Consolidated Statements of Operations and Comprehensive Loss (In thousands, except per share amounts) (Unaudited) Â Â Three Months Ended September 30, Â Â Nine Months Ended September 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Revenues: Â Product revenues Â $ â€“ Â Â $ â€“ Â Â $ â€“ Â Â $ â€“ Â Total revenues Â Â â€“ Â Â Â â€“ Â Â Â â€“ Â Â Â â€“ Â Cost and expenses: Â Research and development Â Â 7,703 Â Â Â 7,472 Â Â Â 21,674 Â Â Â 19,998 Â General and administrative Â Â 5,952 Â Â Â 3,780 Â Â Â 14,322 Â Â Â 11,043 Â Total cost and expenses Â Â 13,655 Â Â Â 11,252 Â Â Â 35,996 Â Â Â 31,041 Â Loss from operations Â Â (13,655) Â Â (11,252) Â Â (35,996) Â Â (31,041) Other income: Â Interest income, net Â Â 975 Â Â Â 686 Â Â Â 1,796 Â Â Â 764 Â Total other income Â Â 975 Â Â Â 686 Â Â Â 1,796 Â Â Â 764 Â Loss from operations, before income taxes Â Â (12,680) Â Â (10,566) Â Â (34,200) Â Â (30,277) Income tax benefit Â Â â€“ Â Â Â â€“ Â Â Â â€“ Â Â Â â€“ Â Net loss Â Â (12,680) Â Â (10,566) Â Â (34,200) Â Â (30,277) Comprehensive loss Â $ (12,680) Â $ (10,566) Â $ (34,200) Â $ (30,277) Net loss per share: Â Basic and diluted net loss per share Â $ (0.21) Â $ (0.19) Â $ (0.60) Â $ (0.64) Weighted average shares used to compute net loss per common share â€“ basic and diluted Â Â 61,066 Â Â Â 56,866 Â Â Â 57,169 Â Â Â 47,288 Â See accompanying notes to the condensed consolidated financial statements. Â 4 Table of Contents Â Â PULSE BIOSCIENCES, INC. Condensed Consolidated Statements of Cash Flows (In thousands) (Unaudited) Â Â Â Nine Months Ended September 30, Â Â Â 2024 Â Â 2023 Â Cash flows from operating activities: Â Â Â Â Â Â Â Â Net loss Â $ (34,200) Â $ (30,277) Adjustments to reconcile net loss to net cash used in operating activities: Â Â Â Â Â Â Â Â Depreciation Â Â 391 Â Â Â 404 Â Amortization of intangible assets Â Â 500 Â Â Â 499 Â Stock-based compensation Â Â 6,793 Â Â Â 3,837 Â Changes in operating assets and liabilities: Â Â Â Â Â Â Â Â Prepaid expenses and other current assets Â Â (394) Â Â (343) Other receivables Â Â 7 Â Â Â 114 Â Right-of-use assets Â Â 668 Â Â Â 596 Â Accounts payable Â Â (194) Â Â (174) Accrued expenses Â Â 7 Â Â Â 409 Â Lease liabilities Â Â (777) Â Â (656) Accrued interest on related party note payable Â Â â€“ Â Â Â (668) Net cash used in operating activities Â Â (27,199) Â Â (26,259) Cash flows from investing activities: Â Â Â Â Â Â Â Â Purchases of property and equipment Â Â (72) Â Â (78) Net cash used in investing activities Â Â (72) Â Â (78) Cash flows from financing activities: Â Â Â Â Â Â Â Â Proceeds from issuance of common stock under employee stock purchase plan Â Â 478 Â Â Â 395 Â Proceeds from issuance of common stock and warrants in relation to rights offering, net of issuance costs Â Â 59,649 Â Â Â â€“ Â Proceeds from exercises of warrants Â Â 1,536 Â Â Â 14,828 Â Proceeds from exercises of stock options Â Â 498 Â Â Â 367 Â Issuance cost in relation to related party note extinguishment Â Â â€“ Â Â Â (6) Deferred issuance costs in relation to future at-the-market equity offering Â Â (222) Â Â â€“ Â Net cash provided by financing activities Â Â 61,939 Â Â Â 15,584 Â Net increase (decrease) in cash and cash equivalents Â Â 34,668 Â Â Â (10,753) Cash and cash equivalents at beginning of period Â Â 44,365 Â Â Â 61,139 Â Cash and cash equivalents at end of period Â $ 79,033 Â Â $ 50,386 Â Â Â Â Â Â Â Â Â Â Supplemental disclosure of noncash investing and financing activities: Â Â Â Â Â Â Â Â Equipment purchases included in accounts payable and accrued expenses Â $ 13 Â Â $ 13 Â Rights offering deemed pro-rata distribution to shareholders Â $ 47,700 Â Â $ â€“ Â Principal and accrued interest of related party note settled via issuance of common stock Â $ â€“ Â Â $ 65,249 Â Other receivable from exercises of warrants Â $ 30 Â Â $ â€“ Â Rights offering and at-the-market issuance costs in accounts payable Â $ 72 Â Â $ â€“ Â Â See accompanying notes to the condensed consolidated financial statements.Â Â 5 Table of Contents Â Â PULSE BIOSCIENCES, INC. Condensed Consolidated Statements of Stockholdersâ€™ EquityÂ (Deficit) (In thousands) (Unaudited) Â Â Â Â Â Â Â Â Â Â Additional Â Â Accumulated Other Â Â Â Â Â Â Total Â Â Â Common Stock Â Â Paid-in Â Â Comprehensive Â Â Accumulated Â Â Stockholdersâ€™ Â Â Â Shares Â Â Amount Â Â Capital Â Â Loss Â Â Deficit Â Â Equity Â Balance, June 30, 2024 Â Â 55,228Â Â $55Â Â $385,349Â Â $â€“Â Â $(358,435)Â $26,969Â Issuance of common stock and warrants in connection with rights offering, net of issuance costs of $364 Â Â 6,000Â Â Â 6Â Â Â 59,630Â Â Â â€“Â Â Â â€“Â Â Â 59,636Â Issuance of common stock upon exercise of warrants Â Â 142Â Â Â 1Â Â Â 1,565Â Â Â â€“Â Â Â â€“Â Â Â 1,566Â Issuance of common stock upon exercise of stock options Â Â 105Â Â Â â€“Â Â Â 476Â Â Â â€“Â Â Â â€“Â Â Â 476Â Issuance of shares under employee stock purchase plan Â Â 40Â Â Â â€“Â Â Â 182Â Â Â â€“Â Â Â â€“Â Â Â 182Â Issuance of shares in at-the-market offering, net of issuance costs of $24 Â Â 1Â Â Â â€“Â Â Â â€“Â Â Â â€“Â Â Â â€“Â Â Â â€“Â Stock-based compensation expense Â Â â€“Â Â Â â€“Â Â Â 2,982Â Â Â â€“Â Â Â â€“Â Â Â 2,982Â Net loss Â Â â€“Â Â Â â€“Â Â Â â€“Â Â Â â€“Â Â Â (12,680)Â Â (12,680) Balance, September 30, 2024 Â Â 61,516Â Â $62Â Â $450,184Â Â $â€“Â Â $(371,115)Â $79,131Â Â Â Â Â Â Â Â Â Â Additional Â Â Accumulated Other Â Â Â Â Â Â Total Â Â Â Common Stock Â Â Paid-in Â Â Comprehensive Â Â Accumulated Â Â Stockholdersâ€™ Â Â Â Shares Â Â Amount Â Â Capital Â Â Loss Â Â Deficit Â Â Equity Â Balance, December 31, 2023 Â Â 55,144Â Â $55Â Â $381,220Â Â $â€“Â Â $(336,915)Â $44,360Â Issuance of common stock and warrants in connection with rights offering, net of issuance costs of $364 Â Â 6,000Â Â Â 6Â Â Â 59,630Â Â Â â€“Â Â Â â€“Â Â Â 59,636Â Issuance of common stock upon exercise of warrants Â Â 142Â Â Â 1Â Â Â 1,565Â Â Â â€“Â Â Â â€“Â Â Â 1,566Â Issuance of common stock upon exercise of stock options Â Â 111Â Â Â â€“Â Â Â 498Â Â Â â€“Â Â Â â€“Â Â Â 498Â Issuance of shares under employee stock purchase plan Â Â 118Â Â Â â€“Â Â Â 478Â Â Â â€“Â Â Â â€“Â Â Â 478Â Issuance of shares in at-the-market offering, net of issuance costs of $24 Â Â 1Â Â Â â€“Â Â Â â€“Â Â Â â€“Â Â Â â€“Â Â Â â€“Â Issuance of equity-classified subscription rights as part of rights offering (Note 6) Â Â â€“Â Â Â â€“Â Â Â 47,700Â Â Â â€“Â Â Â â€“Â Â Â 47,700Â Rights offering deemed pro-rata distribution to shareholders (Note 6) Â Â â€“Â Â Â â€“Â Â Â (47,700)Â Â â€“Â Â Â â€“Â Â Â (47,700) Stock-based compensation expense Â Â â€“Â Â Â â€“Â Â Â 6,793Â Â Â â€“Â Â Â â€“Â Â Â 6,793Â Net loss Â Â â€“Â Â Â â€“Â Â Â â€“Â Â Â â€“Â Â Â (34,200)Â Â (34,200) Balance, September 30, 2024 Â Â 61,516Â Â $62Â Â $450,184Â Â $â€“Â Â $(371,115)Â $79,131Â Â Â Â Â Â Â Â Â Â Additional Â Â Accumulated Other Â Â Â Â Â Â Total Â Â Â Common Stock Â Â Paid-in Â Â Comprehensive Â Â Accumulated Â Â Stockholdersâ€™ Â Â Â Shares Â Â Amount Â Â Capital Â Â Loss Â Â Deficit Â Â Equity Â Balance, June 30, 2023 Â Â 54,771Â Â $55Â Â $374,861Â Â $â€“Â Â $(314,416)Â $60,500Â Issuance of common stock upon exercise of stock options Â Â 135Â Â Â â€“Â Â Â 309Â Â Â â€“Â Â Â â€“Â Â Â 309Â Issuance of shares under employee stock purchase plan Â Â 85Â Â Â â€“Â Â Â 103Â Â Â â€“Â Â Â â€“Â Â Â 103Â Warrant exercise, issuance cost adjustment Â Â â€“Â Â Â â€“Â Â Â 1Â Â Â â€“Â Â Â â€“Â Â Â 1Â Stock-based compensation expense Â Â â€“Â Â Â â€“Â Â Â 1,798Â Â Â â€“Â Â Â â€“Â Â Â 1,798Â Net loss Â Â â€“Â Â Â â€“Â Â Â â€“Â Â Â â€“Â Â Â (10,566)Â Â (10,566) Balance, September 30, 2023 Â Â 54,991Â Â $55Â Â $377,072Â Â $â€“Â Â $(324,982)Â $52,145Â Â Â Â Â Â Â Â Â Â Additional Â Â Accumulated Other Â Â Â Â Â Â Total Â Â Â Common Stock Â Â Paid-in Â Â Comprehensive Â Â Accumulated Â Â Stockholdersâ€™ Â Â Â Shares Â Â Amount Â Â Capital Â Â Loss Â Â Deficit Â Â (Deficit) Equity Â Balance, December 31, 2022 Â Â 37,235Â Â $37Â Â $292,420Â Â $â€“Â Â $(294,705)Â $(2,248) Issuance of common stock as part of debt extinguishment, net of issuance costs of $6 Â Â 10,023Â Â Â 10Â Â Â 65,233Â Â Â â€“Â Â Â â€“Â Â Â 65,243Â Issuance of shares upon exercise of warrants, net of issuance costs of $9 Â Â 7,238Â Â Â 7Â Â Â 14,821Â Â Â â€“Â Â Â â€“Â Â Â 14,828Â Issuance of shares under employee stock purchase plan Â Â 347Â Â Â 1Â Â Â 394Â Â Â â€“Â Â Â â€“Â Â Â 395Â Issuance of common stock upon exercise of stock options Â Â 148Â Â Â â€“Â Â Â 367Â Â Â â€“Â Â Â â€“Â Â Â 367Â Stock-based compensation expense Â Â â€“Â Â Â â€“Â Â Â 3,837Â Â Â â€“Â Â Â â€“Â Â Â 3,837Â Net loss Â Â â€“Â Â Â â€“Â Â Â â€“Â Â Â â€“Â Â Â (30,277)Â Â (30,277) Balance, September 30, 2023 Â Â 54,991Â Â $55Â Â $377,072Â Â $â€“Â Â $(324,982)Â $52,145Â Â See accompanying notes to the condensed consolidated financial statements. Â 6 Table of Contents Â PULSE BIOSCIENCES, INC. Notes to Condensed Consolidated Financial Statements (Unaudited) Â Â 1. Description of the Business Â Pulse Biosciences, Inc. is a novel bioelectric medicine company committed to health innovation using its patented Nano-pulse Stimulation ("NPS")Â technology, a revolutionary energy modality that delivers nanosecond-duration pulses of electrical energy, each less than aÂ millionth of a second long, to nonthermally clear targeted cells while sparing adjacent noncellular materials. NPS technology, also referred to asÂ Nanosecond Pulsed-Field AblationÂ ("nsPFA" or "nano-PFA")Â technology when used to ablate cellular tissue, can be used to treat a variety of medical conditions for which an optimal solution remains unfulfilled. The Company developed its proprietary CellFX System, a novel nano-PFA delivery platform, and commercialized the initial application of its nano-PFA technology to treat benign lesions of the skin. In parallel, the Company has designed a variety of applicators, or disposables, to explore the potential use of the CellFX platform to treat disorders in other medical specialties, such as cardiology, gastroenterology, gynecology, and ear, nose and throat. These applicators include devices for open surgical procedures, endoscopic or minimally invasive procedures, and endoluminal catheters, and each has been used in preclinical studies. Based on our preclinical experience and the potential to significantly improve outcomes for patients in a large and growing market, the Company decided in 2022 to focus its primary efforts on the use of nsPFA energy and the CellFX platform in the treatment of atrial fibrillation ("AF") and in a select few other markets where it could have a profound positive impact on healthcare for both patients and providers, such as soft tissue ablation. Â The Company was incorporated in Nevada on May 19, 2014. On June 18, 2018, the Company reincorporated from the State of Nevada to the State of Delaware. The Company is located in Miami, Florida, and continues to maintain its offices in Hayward, California. The Company maintains a website at www.pulsebiosciences.com where general information about the Company is available. Â The Companyâ€™s activities are subject to significant risks and uncertainties, including the need for additional capital. The Company does not currently have any material cash flows from operations. ItÂ currently generates no revenue and will need to raise additional capital to finance its operations. However, there can be no assurances that the Company will be able to obtain additional financing on acceptable terms and in the amounts necessary to fully fund its operating requirements. Â 2. Summary of Significant Accounting Policies Â Basis of Presentation Â The accompanying unaudited condensed consolidated financial statements have been prepared on a basis consistent with the Companyâ€™sÂ December 31, 2023 audited Consolidated Financial Statements and include all adjustments, consisting of only normal recurring adjustments, necessary to fairly state the information set forth herein. The condensed consolidated financial statements have been prepared in accordance with the applicable rules and regulations of the Securities and Exchange Commission (the â€œSECâ€) and, as permitted by such rules and regulations, omit certain information and footnote disclosures necessary to present the financial statements in accordance with accounting principles generally accepted in the United States (â€œU.S. GAAPâ€). The condensed consolidated balance sheet as ofÂ December 31, 2023 was derived from the audited consolidated financial statements as of that date but does not include all of the information and footnotes required by U.S. GAAP for complete financial statements. These condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Companyâ€™s Annual Report on Form 10-K for the year ended December 31, 2023. The results of operations for the three-month and nine-month periods ended September 30, 2024, are not necessarily indicative of the results to be expected for the entire year or any future periods. Â Principles of Consolidation Â The accompanying condensed consolidated financial statements include the financial statements of Pulse Biosciences, Inc. and its wholly-owned subsidiaries. Intercompany balances and transactions, if any, have been eliminated in consolidation. Â 7 Table of Contents Â Use of Estimates Â The preparation of financial statements in conformity with U.S. GAAP requires the Company to make estimates that affect the amounts reported in the financial statements and accompanying notes to the financial statements. Estimates include, but areÂ notÂ limited to, the valuation and recognition of stock-based compensation, the valuation of equity-classified subscription rights, inventory valuation, warranty obligations, income taxes, and the useful lives assigned to long-lived assets. The Company evaluates its estimates and assumptions based on historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances dictate. Actual results could differ materially from these estimates. Â Significant Accounting Policies Â The Companyâ€™s significant accounting policies are described in the Companyâ€™s Annual Report on Form 10-K for the year ended December 31, 2023. The Company continually evaluates the accounting policies and estimates used in preparing the consolidated financial statements. During both the year ended December 31, 2023, and the nine-month period ended September 30, 2024, theÂ Company issuedÂ stock options to certain employees which contain market conditions related to overall market capitalization. Additionally, the Company has issued stock options to certain employees which contain performance conditions related to certain financial measures and achievements of strategic and operational milestones. Â Stock-Based Compensation Â The Company's stock-based compensation programs include stock options and an employee stock purchase program. Â The Company periodically issues stock optionsÂ to officers, directors, employees, and consultants for services rendered. Such issuances vest and expire according to terms established at the issuance date. Stock-based payments to officers, directors and employees, including grants of employee stock options, are recognized in the financial statements based on

their grant date fair values, which are estimated using the Black-Scholes option-pricing model. Stock-based compensation expenseÂ is charged to operations on a straight-line basis over the vesting period. The CompanyÂ hasÂ granted stock options with both time-based as well as performance-based vesting conditions.Â For stock awards with performance-based vesting conditions,Â the Company doesÂ notÂ recognize compensation expense until it is probable that the performance-based vesting condition will be achieved.Â TheÂ analysis to determine such probabilityÂ involves estimates and judgements from management and the estimate of expenseÂ mayÂ beÂ revised periodically.Â Â The Company hasÂ also issued certain stock options withÂ market-based vesting conditions. These vesting conditions relate to the achievement ofÂ certainÂ market capitalization targetsÂ of the Company. The grant date fair value for these stock options was determined using a Monte Carlo simulation. The expense is recognized over the requisite service period for each tranche of the awards. The requisite service period is the service period derived from the Monte Carlo simulation model. If the market capitalization targets are met sooner than the derived service period, the CompanyÂ will accelerate the recognition of stock-based compensation expense to reflect the cumulative expense associated with the vested shares.Â The Monte Carlo simulation requires the Company to make assumptions and judgements about the variables used in the calculation including the expected term, volatility of the Company's common stock, an assumed risk-free interest rate, and cost of equity. The assumptions used in theÂ option-pricing modelÂ represent managementâ€™s best estimates. If factors change and different assumptions are used, the Company'sÂ stock-based compensation expense could be materially different in the future. Â See NoteÂ 6Â for a detailed discussion of the Companyâ€™s stock plans and stock-based compensation expense. Â Product Warranty Â The Company provides a standard warranty on eligible products which provides the customer assurances that the products comply with the agreed-upon specifications. The standard warranty doesÂ notÂ provide any services in addition to those assurances. The Company accrued a warranty reserve for products sold based upon the best estimate of the nature, frequency, and costs of future claims. These estimates are inherently uncertain given the short history of sales, and changes to the historical or projected warranty experienceÂ mayÂ cause material changes to the warranty reserve in the future. In June 2023, the Company reduced the accrued warranty liability to zero. Based upon the Company's shift in focus, there are a limited number of consoles currently covered under the standard warranty. All inventory has been fully written off, therefore the only incremental costs to fulfill a warranty claim in 2024 would be shipping costs or the costs to replace the CellFX nsPFA electrode, which wouldÂ be immaterial in nature. Â 8 Table of Contents Â Warranty accrual activity consisted of the following for the three-month and nine-month periods endedÂ September 30, 2024 and 2023Â (in thousands): Â Â Â Three Months Ended September 30, Â Â Â Nine Months Ended September 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Beginning balance Â $â€”Â Â $â€”Â Â $â€”Â Â $50Â Add: Accruals for warranties issued during the period Â Â â€”Â Â Â â€”Â Â Â â€”Â Â Â â€”Â Less: Adjustment for inventory at cost and excessive and obsolete inventory Â Â â€”Â Â Â â€”Â Â Â â€”Â Â Â (50) Ending balance Â $â€”Â Â $â€”Â Â $â€”Â Â $â€”Â Â Net Loss per Share Â The Company calculates basic net loss per share by dividing net loss by the weighted-average number of shares of common stock outstanding during the period. Diluted net loss per share is computed by giving effect to all potential dilutive common stock equivalents outstanding during the period. For purposes of this calculation, options to purchase common stock and common stock warrants are considered common stock equivalents. Potential common shares that have an anti-dilutive effect (i.e., those that increase income per share or decrease loss per share) are excluded from the calculation of diluted net loss per share. Â Based on the Accounting Standards Codification ("ASC") 260-10-55,Â Earnings Per Share - Implementation Guidance and Illustrations, the Company determined that theÂ 2024Â Rights Offering (Note 6), contained a bonus element. A rights offering is deemed to have a bonus element when the exercise price at issuance is less than fair value of the Company's stock. The Company has retroactively adjusted earnings per share and weighted average number of shares outstanding forÂ the bonus elementÂ for priorÂ periods presented. Â Basic and diluted net loss per common share is the same for all periods presented because all warrants, stock options and restricted stock units outstanding are anti-dilutive. Â The following outstanding stock options, and warrantsÂ were excluded from the computation of diluted net loss per share for the periods presented because including them would have had an anti-dilutive effect: Â Â Â Nine Months Ended September 30, Â Â Â 2024 Â Â 2023 Â Common stock warrants Â Â 5,857,680Â Â Â â€”Â Common stock options Â Â 12,327,332Â Â Â 7,902,948Â Total Â Â 18,185,012Â Â Â 7,902,948Â Â Recent Accounting Pronouncements Not Yet Adopted Â In March 2024, the FASB issued ASU No. 2024-02,Â Codification Improvements - Amendments to Remove References to the Concepts Statements, an amendment of the FASB Accounting Standards Codification. The amendments in this ASU are related to the removal of various references to FASB Concept Statements from the codification to make clear distinctions between authoritative and non-authoritative literature in the codification. This ASU is effective for fiscal years beginning after December 15, 2024, with early adoption permitted. The Company does not believe this standard will have an impact on its consolidated financial statements and related disclosures. Â As of September 30, 2024, there were no additional material changes to the information provided regarding recent accounting pronouncements in Note 2, â€œSummary of Significant Accounting Policiesâ€ in the Companyâ€™s Form 10-K for the fiscal year ended December 31, 2023. Â 3. Fair Value of Financial Instruments Â The authoritative guidance with respect to fair value established a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three levels, and requires that assets and liabilities carried at fair value be classified and disclosed in one of three categories, as presented below. Â Level 1 - Observable inputs such as quoted prices in active markets for an identical asset or liability that the Company has the ability to access as of the measurement date. Financial assets and liabilities utilizing Level 1 inputs include money market funds. Â Level 2 - Inputs, other than quoted prices included within Level 1, which are directly observable for the asset or liability or indirectly observable through corroboration with observable market data. The Company didÂ notÂ classify any of its investments within LevelÂ 2Â of the fair value hierarchy. Â Level 3 - Unobservable inputs for which there is little or no market data for the asset or liability which requires the reporting entity to develop its own assumptions. The Company didÂ notÂ classify any of its investments within Level 3Â of the fair value hierarchy. Â 9 Table of Contents Â The following table sets forth the fair value of the Companyâ€™s financial instruments measured on a recurring basis as of September 30, 2024 and December 31, 2023, respectively (in thousands): Â Â Â Â September 30, 2024 Â Assets Classification Â Level 1 Â Â Level 2 Â Â Level 3 Â Â Total Â Money market funds Cash and cash equivalents Â $76,386Â Â $â€”Â Â $â€”Â Â $76,386Â Total assets measured at fair value Â $76,386Â Â $â€”Â Â $â€”Â Â $76,386Â Â Â Â Â Â December 31, 2023 Â Assets Classification Â Level 1 Â Â Level 2 Â Â Level 3 Â Â Total Â Money market funds Cash and cash equivalents Â $41,184Â Â $â€”Â Â $â€”Â Â $41,184Â Total assets measured at fair value Â $41,184Â Â $â€”Â Â $â€”Â Â $41,184Â Â The Company did not have any financial liabilities measured on a recurring basis as ofÂ September 30, 2024 or December 31, 2023. Â 4. Balance Sheet Components Â Property and Equipment, Net Â Property and equipment, net consisted of the following (in thousands): Â Â Â September 30, Â Â December 31, Â Â Â 2024 Â Â 2023 Â Leasehold improvements Â $2,519Â Â $2,519Â Laboratory equipment Â Â 1,318Â Â Â 1,247Â Furniture, fixtures and equipment Â Â 966Â Â Â 966Â Software Â Â 272Â Â Â 272Â Construction in progress Â Â 14Â Â Â â€”Â Total property and equipment Â Â 5,089Â Â Â 5,004Â Less: Accumulated depreciation and amortization Â Â (3,868)Â Â (3,476) Total property and equipment, net Â $1,221Â Â $1,528Â Â Depreciation expense was $0.1Â millionÂ for each of the three-month periods ended September 30, 2024 and 2023, and $0.4Â million forÂ each of the nine-month periods ended September 30, 2024 and 2023, respectively. Â Intangible Assets, Net Â Intangible assets primarily consist of acquired licenses to utilize certain patents, know-how and technology relating to the Companyâ€™s NPS technology for biomedical applications acquired from Old Dominion University Research Foundation (â€œODURFâ€), Eastern Virginia Medical School, and the University of Southern California. In addition, the Company entered into a Sponsored Research Agreement with Old Dominion Universityâ€™s Frank Reidy Research Center for Bioelectrics, which includes certain intellectual property rights arising from the research. The Company is amortizing the intangible assets over an estimated useful life of 12 years. Â 10 Table of Contents Â Intangible assets, net consisted of the following (in thousands): Â Â Â September 30, Â Â December 31, Â Â Â 2024 Â Â 2023 Â Acquired patents and licenses Â $7,985Â Â $7,985Â Less: Accumulated amortization Â Â (6,599)Â Â (6,099) Total intangible assets, net Â $1,386Â Â $1,886Â Â Â A schedule of the amortization of intangible assets for the remainder of 2024Â and the succeeding twoÂ fiscal years is as follows (in thousands): Â Years ending December 31: Â Â Â Â 2024 (remaining 3 months) Â $165Â 2025 Â Â 665Â 2026 Â Â 556Â Total Â $1,386Â Â Accrued Expenses Â Accrued expenses consisted of the following (in thousands): Â Â Â September 30, Â Â December 31, Â Â Â 2024 Â Â 2023 Â Compensation expense Â $3,111Â Â $3,199Â Clinical trial fees and costs Â Â 80Â Â Â 84Â Professional fees Â Â 424Â Â Â 343Â Other Â Â 206Â Â Â 188Â Total accrued expenses Â $3,821Â Â $3,814Â Â 5. Goodwill Â In 2014, the Company acquired three companies (the â€œAcquisitionsâ€) for aggregate consideration of $5.5Â million. In accordance with ASC Topic 805, Business Combinations, the Company recorded goodwill of $2.8Â million in connection with the Acquisitions as the consideration paid exceeded the fair value of the net tangible assets and the intangible assets acquired. Â In accordance with ASC Topic 350, Intangibles-Goodwill and Other (as amended by Accounting Standards Update 2017-04), the Company reviews goodwill for impairment at least annually or whenever any events or circumstances indicate that it is more likely than not that the fair value of a reporting unit is less than its carrying amount. As of September 30, 2024, there were no indicators of impairment and it was determined that no impairment of goodwill existed. Â 11 Table of Contents Â Â 6. Stockholdersâ€™ Equity and Stock-Based Compensation Â 2024 Rights Offering and Subscription Rights Â On March 28, 2024, the Company announced that itsÂ Board of Directors ("Board") unanimously approved plans to initiate a rights offering, whereby the Company would distribute non-transferable subscription rights at no charge to all holders of the Company's common stock, par value $0.001 per share (the "Common Stock"),Â as of the close of business on a record date to be determined. On May 20, 2024, the Company announced that the Board had set May 31, 2024 as the record date (the "Record Date"). All holders of Common Stock as of the Record Date receivedÂ non-transferable subscription rightsÂ to purchase up to an aggregate of six million units (the â€œ2024 Unitsâ€) with an aggregate offering value of up to $60 million (the "2024 Rights Offering") at a price per 2024 Unit equal to the lesser of: (i) $10 (the â€œInitial Priceâ€) and (ii) the volume weighted average price of the Common Stock for the ten trading day period through and including the expiration date, June 26, 2024 (the "Expiration Date"), of the Rights Offering (the â€œAlternate Priceâ€). Each subscription right entitled the holder to purchase 0.10864186 2024 Units for each share of Common Stock owned as of the Record Date.Â Each 2024 Unit consisted of one share of Common Stock and two warrants, each being a warrant to purchase one-half of one share of Common Stock. The subscription rights were to expire and have no value if they were not exercised prior to the Expiration Date. The Company determined that the equity-classified subscription rights representÂ a pro-rata distributionÂ issued to existing stockholders as of the Record Date, which is based on a purchase price of $10 per 2024 Unit as compared to (1) the price of $11.55 per one share of Common Stock on the Record Date, plus (2) the value of the warrants on the Record Date.Â The Company determined the fair value of the equity-classified subscription rights as of the Record Date, which involved the use of a Monte Carlo simulationÂ to value the underlying warrants.Â The Monte Carlo simulation was based on certain significant unobservable inputs, such as aÂ risk-free interest rate, stock price volatility, dividend yield, and expected term of the rights offering. The fair value of the equity-classified subscription rights was $47.7 million and was recorded inÂ equity on the balance sheet as part ofÂ additional paid-in capital. The deemed pro-rata distribution to shareholders of $47.7 million was reflected as an offsetting reduction in additional paid-in capital. The Company is in an accumulated deficit position and has elected a policy ofÂ recognizingÂ the deemed pro-rata distribution to shareholders as a reduction to additional paid-in capital rather than a further increase to its accumulated deficit.Â Â On July 3, 2024, the Company announced the closing of its 2024 Rights Offering. The 2024 Rights Offering resulted in the sale of six millionÂ 2024 Units, at a price of $10.00 per 2024 Unit. Each 2024 Unit consisted of one share of the Companyâ€™s common stock, par value $0.001 per share, and two warrants, each being a warrant to purchase one-half of one share of common stock. The common stock and warrants comprising the 2024 Units separated upon the closing of the 2024 Rights Offering and were issued individually. A total of 5,999,998Â shares of common stock and warrants to acquire up to approximately an additional six million shares of common stock were issued in the offering. The Company received aggregate gross proceeds from the 2024 Rights Offering of $60 million. If exercised, additional gross proceeds of up to $66 million may be received through the exercise of warrants issued in the 2024 Rights Offering. See 2024 Rights Offering Warrants below for additional details of the warrants.Â Robert W. Duggan, the Companyâ€™s majority stockholder and Co-Chairman, purchased approximately 88% of the units offered through theÂ 2024Â Rights Offering. Â Private Placement Securities Purchase Agreement Â OnÂ April 30, 2023,Â the Company entered into a Securities Purchase Agreement with Robert W. Duggan, the Companyâ€™s majorityÂ stockholder and Co-Chairman, pursuant to which the Company agreed to issue and sell to Mr. DugganÂ 10,022,937Â shares of the Companyâ€™s common stock, par value $0.001Â per share, in a Private Placement, at a price per share of $6.51. The parties completed the Private Placement onÂ May 9, 2023,Â after satisfying all pre-closing conditions, and the CompanyÂ issued the full number of shares to Mr. Duggan. TheÂ shares were paid for through the cancellation of the principal sum of $65.0Â million borrowed by the Company pursuant to theÂ 2022Â Loan Agreement (See Note 7),Â together with all accrued and unpaid interest outstanding owed at the time of closing.Â Â 2022 Rights Offering Â OnÂ JuneÂ 9,Â 2022,Â the Company completed a rights offering (theÂ â€œ2022Â Rights Offering") resulting in the sale ofÂ 7,317,072Â units (the â€œ2022 Unitsâ€), at a price of $2.05Â per 2022 Unit, with each 2022 Unit consisting ofÂ oneÂ share of the Companyâ€™s common stock, par value $0.001Â per share, andÂ oneÂ warrant (theÂ â€œ2022Â Rights Offering Warrantsâ€) to purchaseÂ oneÂ share of common stock at a price of $2.05Â per share. The common stock and warrants comprising the 2022 Units separated upon the closing of theÂ 2022Â Rights Offering and were issued individually.Â 7,317,072Â shares of common stock and warrants to acquire up to an additionalÂ 7,317,072Â shares of common stock were issued in theÂ 2022Â Rights Offering. The Company received aggregate gross proceeds from theÂ 2022Â Rights Offering of $15Â million.Â InÂ May 2023,Â the Company delivered an irrevocable notice of redemption to warrant holders and, onÂ June 16, 2023,Â it redeemed the last of the outstandingÂ 2022Â Rights Offering Warrants at a price of $0.01Â per warrant share. See theÂ Common Stock WarrantsÂ section below for further details. Robert W. Duggan, the Companyâ€™s majority stockholder and Co-Chairman, purchased approximatelyÂ 56% of the shares offered through theÂ 2022Â Rights Offering. Â Common Stock Warrants Â 2024Â Rights Offering Warrants Â In connection with the 2024Â Rights Offering, the Company issued 2024Â Rights Offering Warrants to purchase a total of 5,999,999Â shares of its common stock at anÂ exercise price ofÂ $11.00 per whole share, which equals 110% of the subscription price for the Units. The aggregate number of shares of our common stockÂ issuable upon the exercise of each set of warrants included in a given subscription for Units was rounded up to the nearest whole share. Warrants are exercisable immediately and will expire on the fifth anniversary of the closing of the 2024 Rights Offering. Half of the warrants issued in the rights offering are redeemable for $0.01 per underlying share of common stock, on not less than thirty daysâ€™ written notice, if the volume weighted average price of the Companyâ€™s common stock equalsÂ or exceedsÂ 150% of the exercise price for the warrants, or $16.50, for twenty consecutive trading days. The other half of the warrants issued in the rights offering are redeemable for $0.01 per underlying share of common stock, on not less than thirty daysâ€™ written notice, if the volume weighted average price of the Companyâ€™s common stock equalsÂ or exceeds 200% of the exercise price for the warrants,Â or $22.00, for twenty consecutive trading days.Â In both cases the Company canÂ not redeem the warrants prior to the date that is three months after the issuance date.Â As of September 30, 2024, there were 2024Â Rights Offering Warrants to purchase up to 5,857,680 shares of common stock, in aggregate, outstanding. Â 2022 Rights Offering Warrants Â In connection with the 2022 Rights Offering, the Company issued 2022 Rights Offering Warrants to purchase a total of 7,317,072 shares of its common stock at an exercise price of $2.05. The 2022 Rights Offering WarrantsÂ wereÂ subject to redemption by the Company for $0.01 per underlying share of common stock, on not less than 30 days written notice, if the volume weighted average price of the Companyâ€™s common stock equaledÂ or exceededÂ 200% of the exercise price for the warrants, subject to adjustment, per share, for 20 consecutive trading days, provided that the Company couldÂ not redeem the warrants prior to the date that wasÂ three months after the issuance date. On May 10, 2023, the Company issued a press release announcing that on May 9, 2023 the terms for warrant redemption had been met. Pursuant to the redemption, the Company redeemed 66,175Â warrants on the redemption date, June 16, 2023. Prior to the redemption date, warrants to purchaseÂ 7,250,897 sharesÂ were exercised, generating approximately $14.9Â million of total gross proceeds to the Company. As of September 30, 2024, there wereÂ noÂ 2022 Rights Offering Warrants outstanding. Â Equity Plans Â 2017 Equity Incentive Plan and 2017 Inducement Equity Incentive Plan Â The BoardÂ previously adopted, and the Companyâ€™s stockholders approved, the Companyâ€™s 2017 Equity Incentive Plan (the â€œ2017 Planâ€). Â TheÂ 2017Â Plan has aÂ 10-year termÂ and provides for the grant of stock options, stock appreciation rights, restricted stock, RSUs, performance units, and performance shares to employees, directors and consultants of the Company and any parent or subsidiary of the Company, as the Compensation Committee of the BoardÂ mayÂ determine.Â Subject to an annual evergreen increase and adjustment in the case of certain capitalization events, the Company initially reservedÂ 1,500,000Â shares of the Companyâ€™s common stock for issuance pursuant to awards under theÂ 2017Â Plan. In addition, shares remaining available under the Companyâ€™sÂ 2015Â Equity Incentive Plan, as amended (theÂ â€œ2015Â Planâ€), and shares reserved butÂ notÂ issued pursuant to outstanding equity awards that expire or terminate without being exercised or that are forfeited or repurchased by the Company will be added to the shares of common stock available for issuance under theÂ 2017Â Plan. TheÂ 2017Â Plan is administered by the Boardâ€™s Compensation Committee. Effective atÂ both January 1, 2024Â andÂ 2023,Â the number of shares of common stock available under theÂ 2017Â Plan increased

byÂ 1,200,000, respectively, pursuant to the evergreen provision of theÂ 2017Â Plan. Under the evergreen provision of theÂ 2017Â Plan, the share increase is determined based on the least of (i)Â 1,200,000Â shares, (ii)Â 4% of the Companyâ€™s common stock outstanding atÂ December 31Â of the immediately preceding year, or (iii) such number of shares as determined by the Board. Additionally,Â the number of shares of common stock available under theÂ 2017Â Plan increased byÂ 1,375,000Â shares as a result of a stockholder vote held at a special meeting of stockholders in December 2023. As of September 30, 2024, a total of 78,490Â shares of common stock remained available for issuance under the 2017 Plan. Â During November 2017, the Board adopted the 2017 Inducement Equity Incentive Plan (the â€œInducement Planâ€) and reserved 1,000,000 shares of the Companyâ€™s common stock for issuance pursuant to equity awards granted under the Inducement Plan. The Inducement Plan was adopted without stockholder approval. Â The Inducement Plan has aÂ 10-year term and provides for the grant of equity-based awards, including non-statutory stock options, RSUs, restricted stock, stock appreciation rights, performance shares, and performance units, and its terms are substantially similar to theÂ 2017Â Plan, including with respect to treatment of equity awards in the event of a â€œmergerâ€ or â€œchange in controlâ€ as defined under the Inducement Plan. Options issued under the Inducement PlanÂ mayÂ have a term up toÂ tenÂ years and have variable vesting provisions. New hire grants toÂ non-executive employees generally vestÂ 25% per year starting upon theÂ firstÂ anniversary of the grant. New hire grants to executive employees generally consist of both time-vesting and performance-vesting options. Equity-based awards issued under the Inducement Plan are only issuable to individualsÂ notÂ previously engaged as employees or individuals returning to employment with the Company following a bona-fide period of non-employment. InÂ May 2021,Â the Board approved an amendment to the Inducement Plan to reserve an additionalÂ 1,000,000Â shares of the Companyâ€™s common stock for issuance pursuant to the Inducement Plan. And, inÂ March 2024,Â the Board approved aÂ secondÂ amendment to the Inducement Plan to reserve an additionalÂ 2,000,000Â shares of the Companyâ€™s common stock for issuance pursuant to the Inducement Plan. As of September 30, 2024, 1,642,626Â shares of common stock remained available for issuance under the Inducement Plan. Â A summary of stock option activity under the 2015 Plan, 2017 Plan, and Inducement Plan for the nine-months endedÂ September 30, 2024 is presented below: Â Â Â Stock Options Outstanding Â Â Â Number of shares Â Â Weighted average exercise price Â Â Weighted average remaining life (in years) Â Balances â€” December 31, 2023 Â Â 9,466,036Â Â $9.01Â Â Â 7.78Â Options granted Â Â 3,017,643Â Â Â 10.38Â Â Â Â Â Options exercised Â Â (110,847)Â Â 4.49Â Â Â Â Â Options canceled Â Â (9,542)Â Â 15.19Â Â Â Â Â Options expired Â Â (35,958)Â Â 19.82Â Â Â Â Â Balances â€” September 30, 2024 Â Â 12,327,332Â Â $9.35Â Â Â 7.67Â Exercisable â€” September 30, 2024 Â Â 4,178,088Â Â $13.32Â Â Â 5.06Â Â 12 Table of Contents Â Time-based Options Â The Company awards time-based options which vest and become exercisable, subject to the individualâ€™s continued employment or service through the applicable vesting date. Time-based options can have various vesting schedules, most commonly new hire grants which generally vest 25% per year starting upon the first anniversary of the grant. Â A summary of the time-based stock option activity under the 2015 Plan, 2017 Plan and Inducement Plan for the nine-months endedÂ September 30, 2024 is presented below: Â Â Â Stock Options Outstanding Â Â Â Number of shares Â Â Weighted average exercise price Â Â Weighted average remaining life (in years) Â Balances â€” December 31, 2023 Â Â 6,141,906Â Â $10.48Â Â Â 7.07Â Options granted Â Â 2,123,643Â Â Â 11.3Â Â Â Â Â Options exercised Â Â (100,897)Â Â 4.65Â Â Â Â Â Options canceled Â Â (6,542)Â Â 20.82Â Â Â Â Â Options expired Â Â (34,958)Â Â 20.3Â Â Â Â Â Balances â€” September 30, 2024 Â Â 8,123,152Â Â $10.71Â Â Â 7.18Â Exercisable â€” September 30, 2024 Â Â 3,745,410Â Â $13.97Â Â Â 4.84Â Â The fair value of the time-based options granted during the nine-month periodÂ endedÂ September 30, 2024 was $18.7Â million. Â Performance-based Options Â Certain stock options awarded byÂ the CompanyÂ contain performance conditions related to certain financial measures and achievements of strategic and operational milestones. Once a specific performance condition is fulfilled, the associated options will fully vest and become exercisable. Â A summary of the performance-based option activity under the 2017 Plan and Inducement Plan for the nine-months endedÂ September 30, 2024 is presented below: Â Â Â Stock Options Outstanding Â Â Â Number of shares Â Â Weighted average exercise price Â Â Weighted average remaining life (in years) Â Balances â€” December 31, 2023 Â Â 1,224,130Â Â $5.51Â Â Â 8.53Â Â Options granted Â Â 39,000Â Â Â 8.44Â Â Â Â Â Options exercised Â Â (9,950)Â Â 2.92Â Â Â Â Â Options canceled Â Â (3,000)Â Â 2.92Â Â Â Â Â Options expired Â Â (1,000)Â Â 2.92Â Â Â Â Â Balances â€” September 30, 2024 Â Â 1,249,180Â Â $5.63Â Â Â 7.84Â Exercisable â€” September 30, 2024 Â Â 432,678Â Â $7.69Â Â Â 6.98Â Â The fair value of the performance-basedÂ options granted during the nine-month periodÂ endedÂ September 30, 2024 was $0.3Â million. Â Market-based Options Â Certain stock options awarded byÂ the Company contain market conditions related to achievement of certain market capitalization targets.Â The options will vest and become exercisable once the specific market capitalization targets are fulfilled.Â Â A summary of theÂ market-based option activity under the 2017 PlanÂ for the nine-months endedÂ September 30, 2024 is presented below: Â Â Â Stock Options Outstanding Â Â Â Number of shares Â Â Weighted average exercise price Â Â Weighted average remaining life (in years) Â Balances â€” December 31, 2023 Â Â 2,100,000Â Â $6.78Â Â Â 9.44Â Options granted Â Â 855,000Â Â Â 8.16Â Â Â Â Â Options exercised Â Â â€”Â Â Â â€”Â Â Â Â Â Options canceled Â Â â€”Â Â Â â€”Â Â Â Â Â Options expired Â Â â€”Â Â Â â€”Â Â Â Â Â Balances â€” September 30, 2024 Â Â 2,955,000Â Â $7.18Â Â Â 8.95Â Exercisable â€” September 30, 2024 Â Â â€”Â Â Â â€”Â Â Â â€”Â Â The fair value of the market-based options granted during the nine-month periodÂ endedÂ September 30, 2024 was $5.3Â million. Â 13 Table of Contents Â The Company estimates the fair value of time-based and performance-based stock options on the grant date using the Black-Scholes option pricing model. The estimated fair value of these employee stock options is amortized on a straight-line basis over the requisite service period of the awards. The Company reviews, and when deemed appropriate, updates the assumptions used on a periodic basis.Â The fair value ofÂ time-based and performance-based stock options was estimated using the following weighted-average assumptions: Â Â Â Three Months Ended September 30, Â Â Nine Months Ended September 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Expected term in years Â Â 5.0 - 6.3Â Â Â 5.0Â Â Â 5.0 - 6.3Â Â Â 5.0 - 6.3Â Expected volatility Â Â 93% - 97%Â Â Â 93%Â Â Â 91% - 97%Â Â Â 89% - 94%Â Risk-free interest rate Â Â 4.5% Â Â Â 3.7% Â Â Â 4.0% - 4.5%Â Â Â 3.7% - 3.8% Â Dividend yield Â Â â€”Â Â Â â€”Â Â Â â€”Â Â Â â€”Â The Company estimates the fair value of market-based stock options on the grant date using a Monte Carlo simulation model. The estimated fair value of these employee stock options is amortized over the requisite service period for each tranche of the awards. The requisite service period is the service period derived from the Monte Carlo simulation model. If the market capitalization targets are met sooner than the derived service period, the CompanyÂ will accelerate the recognition of stock-based compensation expense to reflect the cumulative expense associated with the vested shares.Â The fair value of market-basedÂ stock options was estimated using the following weighted-average assumptions: Â Â Â Three Months Ended September 30, Â Â Nine Months Ended September 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Expected term in years Â Â 2.2 - 4.2Â Â Â 4.0 - 6.3Â Â Â 2.2 - 5.8Â Â Â 4.0 - 6.3Â Expected volatility Â Â 90% Â Â Â 90% Â Â Â 90% Â Â Â 90% Â Risk-free interest rate Â Â 3.9% Â Â Â 3.7 - 3.8% Â Â Â 3.9% - 4.4% Â Â Â 3.4 - 3.8% Â Dividend yield Â Â â€”Â Â Â â€”Â Â Â â€”Â Â Â â€”Â Â 2017 Employee Stock Purchase Plan Â The Board previously adopted, and the Company's stockholders approved, the Companyâ€™s 2017 Employee Stock Purchase Plan (the â€œ2017 ESPPâ€). Â The 2017 ESPP is a broad-based plan that provides employees of the Company and its designated affiliates with the opportunity to become stockholders through periodic payroll deductions that are applied towards the purchase of Company common shares at a discount from the then-current market price. Subject to adjustment in the case of certain capitalization events, a total of 250,000 common shares of the Company were available for purchase at adoption of the 2017 ESPP. Pursuant to the 2017 ESPP, the annual share increase pursuant to the evergreen provision is determined based on the least of (i) 450,000 shares, (ii) 1.5% of the Companyâ€™s common stock outstanding at DecemberÂ 31 of the immediately preceding year, or (iii)Â such number of shares as determined by the Board. In 2024, the Company reserved an additional 450,000 shares under the 2017 ESPP pursuant to the evergreen provision. In 2023, the Board waived the evergreen provision and no additional shares were reserved under the 2017 ESPP. During the nineÂ months ended September 30, 2024,Â the Company issued 117,539Â shares of common stock under the 2017 ESPP. As of September 30, 2024, 445,779Â shares of common stock remained available for issuance under the 2017 ESPP. Â The Company estimates the fair value of ESPP grants on their grant date using the Black-Scholes option pricing model. The estimated fair value of ESPP grants is amortized on a straight-line basis over the requisite service period of the grants. The Company reviews, and when deemed appropriate, updates the assumptions used on a periodic basis. The Company utilizes its estimated volatility in the Black-Scholes option pricing model to determine the fair value of ESPP grants. The fair value of ESPP grants was estimated using the following weighted-average assumptions: Â Â Â Three Months Ended September 30, Â Â Nine Months Ended September 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Expected term in years Â Â 0.5 - 1.0Â Â Â 0.5 - 1.0Â Â Â 0.5 - 1.0Â Â Â 0.5 - 1.0Â Expected volatility Â Â 98% Â Â Â 83% Â Â Â 98% Â Â Â 83% Â Risk-free interest rate Â Â 4.4% - 5.3%Â Â Â 5.4% - 5.5%Â Â Â 4.9% - 5.3%Â Â Â 5.1% - 5.5%Â Dividend yield Â Â â€”Â Â Â â€”Â Â Â â€”Â Â Â â€”Â Â 14 Table of Contents Â Stock-based Compensation Â Total stock-based compensation expense consisted of the following (in thousands): Â Â Â Three Months Ended September 30, Â Â Nine Months Ended September 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Research and development Â Â 1,108Â Â Â 982Â Â Â 3,058Â Â Â 1,758Â General and administrative Â Â 1,874Â Â Â 816Â Â Â 3,735Â Â Â 2,079Â Total stock-based compensation expense Â $2,982Â Â $1,798Â Â $6,793Â Â $3,837Â Â As of September 30, 2024, not all of the performance conditions of the performance options are probable to be achieved. Compensation expense has only been recognized for those conditions that are assumed to be probable. Â Total stock-based compensation expense by award type was as follows (in thousands): Â Â Â Three Months Ended September 30, Â Â Nine Months Ended September 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Time-based options Â $2,131Â Â $1,200Â Â $4,609Â Â $2,754Â Performance-based options Â Â 5Â Â Â 87Â Â Â 27Â Â Â 292Â Market-based options Â Â 788Â Â Â 464Â Â Â 1,978Â Â Â 622Â ESPP Â Â 58Â Â Â 47Â Â Â 179Â Â Â 169Â Total stock-based compensation expense Â $2,982Â Â $1,798Â Â $6,793Â Â $3,837Â Â Â 7. Commitments and Contingencies Â 2022 Loan Agreement Â OnÂ SeptemberÂ 20,Â 2022,Â the Company and Robert W. Duggan, the Company's majority stockholder and Co-Chairman, entered into a Loan Agreement (â€œ2022Â Loan Agreementâ€) in connection with Mr. Duggan lending the principal sum of $65.0Â million to the Company. TheÂ 2022Â Loan Agreement boreÂ interest at a rate per annum equal toÂ 5.0%, payable quarterly commencing onÂ JanuaryÂ 1,Â 2023,Â with theÂ principal sumÂ payable onÂ March 20, 2024.Â OnÂ March 17, 2023,Â the Company and Mr. Duggan amended certainÂ terms of theÂ 2022Â Loan Agreement. There wereÂ noÂ changes to the interest rate, but the principal sum repayment date was changed toÂ September 30, 2024.Â During the year endedÂ December 31, 2023, the Company madeÂ cash payments of $1.7Â million for accrued interest on the loan, andÂ recorded an additional $1.1Â million of interest expense in relation to theÂ 2022Â Loan Agreement. OnÂ April 30, 2023,Â the Company entered into a Securities Purchase Agreement with Mr. Duggan, pursuant to which the Company agreed to issue and sell to Mr. DugganÂ 10,022,937Â shares of the Companyâ€™s common stock, par value $0.001Â per share, in a Private Placement, at a price per share of $6.51. These shares were paid for through the cancellation of the amounts then owed by the Company under theÂ 2022Â Loan Agreement, the principal sum of $65.0Â million and all accrued and unpaid interest outstanding, which totaled approximately $0.2Â million as ofÂ April 30, 2023.Â The parties completed the Private Placement onÂ May 9, 2023Â and, upon closingÂ and satisfaction of the outstanding debt, theÂ 2022Â Loan Agreement terminated, without early termination fees or penalties being owed by the Company.Â NoÂ additional amounts are owed to Mr. Duggan under theÂ 2022Â Loan Agreement. Â 15 Table of Contents Â Operating Leases Â In January 2017, the Company entered into a five-year lease (the â€œExisting Leaseâ€) for approximately 15,700 square feet for its corporate headquarters located in Hayward, California. The lease commenced in July 2017. Â In May 2019, the Company entered into Lease Amendment 1 (the â€œLease Amendmentâ€) in relation to the Existing Lease and added the lease of new premises of approximately 13,300 square feet and 21,300 square feet, (â€œExpansion Premises 1â€ and â€œExpansion Premises 2â€, respectively). Additionally, the term of the Existing Lease was extended to October 2029 to be coterminous with Expansion Premises 1 and Expansion Premises 2. Â The Company evaluated the lease amendment under the provisions of ASC 842. It concluded that the Lease Amendment would be accounted for as a single contract with the Existing Lease because the additional lease payments due to the Lease Amendment was not commensurate with the right-of-use asset granted to the Company. Though the Lease Amendment was accounted for as a single contract, the Existing Premises, Expansion Premises 1 (occupied in November 2019) and Expansion Premises 2 (occupied in May 2020) are accounted for as separate lease components. Accordingly, the Company measured and allocated consideration to each lease component as of the modification date. Â Supplemental balance sheet information related to leases (in thousands): Â Â Â September 30, Â Â December 31, Â Assets: Â 2024 Â Â 2023 Â Right-of-use assets Â $6,588Â Â $7,256Â Â Â Â Â September 30, Â Â December 31, Â Liabilities: Â 2024 Â Â 2023 Â Current operating lease liabilities Â $1,193Â Â $1,058Â Non-current operating lease liabilities Â Â 7,174Â Â Â 8,086Â Total lease liabilities Â $8,367Â Â $9,144Â Â Total cash paid for operating lease liabilitiesÂ (in thousands): Â Â Â Nine Months Ended September 30, Â Â Â 2024 Â Â 2023 Â Cash paid for operating lease liabilities Â $1,425Â Â $1,376Â Â Maturities of operating lease liabilities were as follows (in thousands): Â Year ending December 31: Â Â Â Â 2024 (remaining 3 months) Â $485Â 2025 Â Â 1,977Â 2026 Â Â 2,046Â 2027 Â Â 2,117Â Thereafter Â Â 4,074Â Total lease payments Â Â 10,699Â Less imputed interest Â Â (2,332) Total lease liabilities Â $8,367Â Â Weighted-average remaining lease term and discount rate, as of September 30, 2024,Â were as follows: Â Weighted-average remaining lease term Â Â 5.08Â Weighted-average discount rate Â Â 10% Â Rent expense, including common area maintenance charges, was approximately $0.6Â millionÂ for each of the three-month periods ended September 30, 2024 and 2023, respectively, and was approximatelyÂ $1.8Â million and $1.7Â million for the nine-month periods ended September 30, 2024 and 2023, respectively. Â Legal Proceedings Â From time to time, weÂ mayÂ be involved in a variety of claims, lawsuits, investigations, and proceedings relating to securities laws, product liability, patent infringement, contract disputes, and other matters relating to various claims that arise in the normal course of our business, including the matter described below. The outcome of any legal proceedings is unpredictable but, regardless of outcome, they can have an adverse impact on us because of defense and settlement costs, diversion of management resources, negative publicity, reputational harm, and other factors. We maintain insurance thatÂ mayÂ provide coverage for such matters, including customary employment practices liability insurance. Â InÂ November 2022,Â the employment of our former Chief Financial Officer, Sandra Gardiner, terminated. Ms. Gardinerâ€™s departure wasÂ notÂ the result of any disagreement with the Company on any matter relating to its operations, accounting policies or practices, although the Company determined that she wasÂ notÂ eligible to receive any severance benefits under the terms and conditions of her then existing employment agreement. InÂ March 2023,Â Ms. Gardiner filed an arbitration demand with JAMS seeking severance benefits and other remedies, alleging breach of contract and unlawful termination in violation of public policy, among other things. We believe that Ms. Gardinerâ€™s claims are without merit and we intend to vigorously defend ourselves against them.Â Because of the difficulty in predicting the outcome of any legal proceeding, the Company isÂ notÂ able to conclude that a liability is probable and cannot predict what the final outcome of Ms. Gardinerâ€™s arbitration proceeding will likely be or provide a reasonable estimate for the range of ultimate possible loss, if any. However, at this time, we believe that the final resolution of this matter willÂ notÂ adversely affect our consolidated position, results of operations, or cash flows. Â 16 Table of Contents Â Â 8. Segment Reporting Â The Company operates and manages the business as one reportable and operating segment. The Companyâ€™s Chief Executive Officer acts as the chief operating decision makerÂ (â€œCODMâ€) of the Company. The CODM reviews the results of the Company on a consolidated basis. All of the Companyâ€™s long-lived assets are based in the United States. Â 9. Â Â Related Party Transactions Â InÂ May 2022,Â the Company determinedÂ notÂ to renew its annual director and officer liability insurance policy due to disproportionately high premiums quoted by insurance companies. Instead, onÂ May 31, 2022,Â the Company and Robert W. Duggan, majority stockholder and Co-Chairman, entered into a letter agreement (the â€œLetter Agreementâ€) pursuant to which Mr. DugganÂ agreed with the Company to personally provide indemnity coverage for aÂ one-year period, and heÂ agreed to deposit cash and/or marketable securities into aÂ third-party escrow, as security for these obligations, if requested by the Company. OnÂ May 31, 2023,Â the last day of theÂ one-year period, the Company paid Mr. Duggan a fee of $1.0Â million in consideration of the obligations set forth in the Letter Agreement. As ofÂ September 30, 2024, there wereÂ noÂ additional amounts owed to Mr. Duggan under the Letter Agreement. Â OnÂ SeptemberÂ 20,Â 2022,Â the Company and Robert W. Duggan, the Company's majority stockholder and Co-Chairman, entered into theÂ 2022Â Loan Agreement in connection with Mr. Duggan lending the principal sum of $65.0Â million to the Company. OnÂ April 30, 2023,Â the Company entered into a Securities Purchase Agreement with Mr. Duggan, pursuant to which the Company agreed to issue and sell to Mr. DugganÂ 10,022,937Â shares of the Companyâ€™s common stock, par value $0.001Â per share, in a Private Placement, at a price per share of $6.51. These shares were paid for through the cancellation of the amounts then owed by the Company under theÂ 2022Â Loan Agreement, the principal sum of $65.0Â million and all accrued and unpaid interest outstanding, which totaled approximately $0.2Â million as ofÂ April 30, 2023.Â Upon closing of the Private Placement and satisfaction of the outstanding debt, theÂ 2022Â Loan Agreement terminated, without early termination fees or penalties being owed by the Company.Â NoÂ additional amounts are owed to Mr. Duggan under theÂ 2022Â Loan Agreement. See Note 7Â for further details. Â 10. Â Â Restructuring Charges Â In February 2023, the Company eliminated seven positions and incurredÂ a discrete restructuring related charge of $0.1Â million which was fully recorded in February 2023 and the related expenses are included within total cost and expenses on the condensed consolidated statement of operations for the nineÂ months

ended September 30, 2023. This charge represents the total amountÂ incurred in connection with the activity. Â Â 11. Â Â Subsequent Events Â In October 2024, theÂ Board approved changes to the performance-based vesting conditions of certain unvested outstanding common stock option awards that were improbable of vesting. Specifically, certain performance-based stock option awards were changed to time-based vesting criteria and certain performance-based stock option awards were changed to market-based vesting criteria. Based on our preliminary analysis, the Company estimates it will recognize approximately $12 millionÂ of stock-based compensation expense over the next 1 to 4Â years from these modified stock option awards.Â Â 17 Table of Contents Â Â ItemÂ 2. Managementâ€™s Discussion and Analysis of Financial Condition and Results of Operations. Â You should read the following discussion and analysis of our financial condition and results of operations together with our condensed consolidated financial statements and the related notes included in this Quarterly Report and those in our Annual Report on Form 10-K. Â Special Note Regarding Forward-Looking Statements Â This report contains â€œforward-looking statementsâ€ within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the â€œExchange Actâ€). Forward-looking statements relate to expectations concerning matters that are not historical facts. Words such as â€œanticipates,â€ â€œbelieves,â€ â€œcould,â€ â€œestimates,â€ â€œexpects,â€ â€œintends,â€ â€œmay,â€ â€œmight,â€ â€œplans,â€ â€œprojects,â€ â€œwill,â€ â€œwould,â€ and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements include, but are not limited to, statements related to our expected business, new product introductions, results of clinical studies, expectations regarding regulatory clearance and the timing of FDA or non-US filings or approvals including meetings with FDA or non-US regulatory bodies, procedures and procedure adoption, future results of operations, future financial position, our ability to generate revenues, our financing plans and future capital requirements, anticipated costs of revenue, anticipated expenses, the effect of recent accounting pronouncements, our anticipated cash flows, our ability to finance operations from cash flows or otherwise, and statements based on current expectations, estimates, forecasts, and projections about the economies and markets in which we operate and intend to operate and our beliefs and assumptions regarding these economies and markets. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements that we make. You should read the â€œRisk Factorsâ€ section of this Quarterly Report for a discussion of important factors that could cause actual results to differ materially from the results described in or implied by the forward-looking statements contained herein. We do not assume any obligation to update any forward-looking statements. Â In addition, statements that â€œwe believeâ€ and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this QuarterlyÂ Report, and although we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted a thorough inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain and investors are cautioned not to unduly rely upon these statements. This QuarterlyÂ Report and any documents incorporated by reference may contain market data that we obtain from industry sources. These sources do not guarantee the accuracy or completeness of the information. Although we believe that our industry sources are reliable, we do not independently verify the information. The market data may include projections that are based on other projections. While we believe these assumptions and projections areÂ reasonable and sound, as of the date of this QuarterlyÂ Report, actual results may differ from the projections. Â Overview Â We are a novel ablation company committed to health innovation using our patented Nano-pulse Stimulation (â€œNPSâ€) technology, a revolutionary energy modality that delivers nanosecond-duration pulses of electrical energy, each less than a millionth of a second long, to nonthermally clear or kill targeted cells. NPS technology, also referred to as Nanosecond Pulsed-Field Ablation (â€œnsPFAâ€ or "nano-PFA") technology when used to ablate cellular tissue, can be used to treat a variety of medical conditions for which an optimal solution remains unfulfilled. We developed our proprietary CellFX System, a novel nsPFA delivery platform, and commercialized the initial application of its nsPFA technology to treat benign lesions of the skin. In parallel, we have designed a variety of applicators, or disposables, to explore the potential use of the CellFX platform to treat disorders in other medical specialties, such as cardiology, gastroenterology, gynecology, and ear, nose and throat. These applicators include devices for open surgical procedures, endoscopic or minimally invasive procedures, and endoluminal catheters, and each has been used in preclinical studies. Based on our preclinical experience and the potential to significantly improve outcomes for patients in a large and growing market, we decided in 2022 to focus our primary efforts on the use of nano-PFA energy and the CellFX platform in the treatment of atrial fibrillation and in a select few other markets where it could have a profound positive impact on healthcare for both patients and providers, such as soft tissue ablation. Â CellFX nsPFA Percutaneous Electrode System Â Our firstÂ product for soft tissue ablation in a surgical setting, the CellFX nsPFA Percutaneous Electrode System, consists of a disposable, percutaneous, needle electrode for use with our proprietary CellFX nsPFA Console. ThisÂ novel electrode is designed to harness and deliver the key advantages of nsPFA energy, enabling precise nonthermal removal of cellular tissue without inducing thermal necrosis. Â After years of preclinical development and testing, in June 2023, we initiated a first-in-human study using our proprietary nsPFA-enabled percutaneous electrode. This study, which is still ongoing, is being conducted by Professor Stefano Spiezia at the Ospedale del Mare in Naples, Italy, to help us better understand and confirm the mechanism of action and tissue response of nano-PFA energy in internal organs such as the thyroid. To date, we have treated thirty study subjects, all of whom tolerated the procedure well with no reported serious side effects. Ultrasound images post procedure have shown that the treated portions of the benign thyroid nodules have mostly been resorbed with no sign of scarring or fibrosis, which can be a side effect of other ablation modalities. We expect to complete this study in 2025. Â In parallel, in November 2023, we filed a premarket notification 510(k) with the FDA for clearance to commercialize our novel CellFX nsPFA Percutaneous Electrode System in the United States. In March 2024, we received FDA 510(k) clearance for our CellFX nsPFA Percutaneous Electrode System for use in the ablation of soft tissue in percutaneous and intraoperative surgical procedures.Â More recently, in July 2024, we received FDA 510(k) clearance for a second size of the percutaneous electrode needle, which we believe will provide our customers with an additionalÂ treatment option for their patients.Â Â Having secured 510(k) clearance to market and sell the CellFX nsPFA Percutaneous Electrode System in the United States with different sizes of percutaneous electrode needles, we have engaged with experts in the field of soft tissue ablation to gather information that will help shape our future commercial endeavors. To date, we have placed our CellFX System with seven sites in the United States and these sites have been performing initial patient treatments and evaluating the CellFX System under short-term evaluation agreements. To date, the clinicians in our pilot program have completed more than twenty-five patient procedures. We expect to pursue more clinical evidenced-based milestones throughout 2024 and into 2025 in connection with evaluating the early pilot commercialization of our percutaneous electrodes, and we expect to commence a pivotal clinical trial in mid-2025 to support a specific labeling indication to commercialize the Percutaneous Electrode System in the United States as a treatment for benign thyroid nodules. Â Our Cardiac Surgical Program Â Atrial fibrillation (â€œAFâ€) is a type of heart arrythmia, or irregular heartbeat, caused by faulty electrical signals in the heart. AF is a highly prevalent condition and is growing significantly with an ageing population. It is estimated that 43 million people worldwide are affected by AF. Treatment requires the precise and safe ablation of heart tissue to block or otherwise prevent these faulty electrical signals from causing the irregular heartbeat, and we believe nano-PFA technology is uniquely suited to perform an integral role for this application and that it will prove to be highly differentiated from standard thermal energy modalities in use today. Â The results of preclinical and clinical testing of both our nano-PFA cardiac products, namely our surgical ablation clamp and our endocardial ablation catheter, have exceeded our expectations and initial data have beenÂ presented at physician andÂ industry conferences. While these devices serve different physicians, the application of the energy to safely and effectively ablate cardiac tissue and the treatment of AF are the same, and we believe there will be important synergies realized through their contemporaneous development. The Companyâ€™s cardiac surgical ablation clamp and cardiac endocardial ablation catheter both generate our proprietary nano-PFA pulses of electrical energy. We discuss each of these products under development in more detail below. Â 18 Table of Contents Â CellFX nsPFA Cardiac Clamp Â Our surgical cardiac ablation clamp is designed for use by cardiac surgeons during the surgical treatment of AF. The standard of care surgical procedure for the treatment of AF is performed by cardiac surgeons and called the Cox-Maze procedure. The Cox-Maze procedure typically uses thermal ablation technologies, such as heat with radiofrequency ablation or cold with cryoablation, to create specific ablation lines in the heart muscle. These ablation lines block the conduction of electrical impulses and can cure patients of their AF. Â We believe our nsPFA technology can provide important advantages over todayâ€™s thermal modalities in creating these ablation lines. For example, surgeons using the CellFX System should be able to deliver faster ablations through thicker tissue than thermal modalities because of the nonthermal mechanism of action that nano-PFA employs, which is not affected by heatsinks such asÂ blood in the heart. In preclinical studies, our nsPFA Cardiac Clamp has consistently achieved transmural ablations in less than two seconds, independent of tissue type or thickness. Moreover, thermal modalities canÂ cause char formation on electrode surfaces which can cause gaps in the ablation lines that might lead to treatment failure. This should not be an issue with nano-PFA ablation given its nonthermal nature. We believe these advantages will be important to cardiac surgeons, so we are working with leaders in the field to develop this technology quickly. Â Over the last several years, we have been developing the cardiac ablation clamp from proof-of-concept to prototype, and we now have what we believe is our initial clinical design. We plan to pursue a PMA application for FDA approval to market the cardiac clamp, which will require pivotal clinical data to support the application. With PMA approval, we expect that we would commercialize the nsPFA Cardiac Surgical System in the United States specifically as a treatment for AF. If granted by the FDA, a specific treatment indication would permit direct marketing of the treatment benefits provided by the device. We expect to begin our pivotal clinical trial for AF in mid-2025. In parallel, we have initiated a multi-site clinical study to treat up to 30 patients in the Netherlands. The first five patients in this cardiac clamp study tolerated the procedure well and acute data have been encouraging. This study should provide information on first-in-human effectiveness and safety with our cardiac surgical ablation clamp. Â In July 2024, we received Breakthrough Device Designation from the FDA for our CellFX nsPFA Cardiac Surgery System for the treatment of AF. The FDAâ€™s Breakthrough Devices Program is a voluntary program for certain medical devices that potentially provide for more effective treatment or diagnosis of a life-threatening or irreversibly debilitating disease or condition. More recently, our Cardiac Surgery System wasÂ enrolled in the FDAâ€™s Total Product Life Cycle (TPLC) Advisory Program (TAP). The FDAâ€™s Center for Devices and Radiological Health (CDRH) launched the TAP program to help generate more rapid development of high-quality, safe, effective, and innovative medical devices that are critical to public health. TAPâ€™s primary goal is to expedite patient access to innovative medical devices by providing early, frequent and strategic communications with the FDA and facilitating engagement with other key parties for developers of devices of public health importance.Â BothÂ programs are designed to expedite theÂ development, assessment, and review of medical devices for premarket approval, 510(k) clearance, or De Novo marketing authorization. Breakthrough Devices, even those enrolled in the FDAâ€™s TAP Program, must still meet the FDAâ€™s rigorous standards for device safety and effectiveness in order to be authorized for marketing, however. Â CellFX nsPFA 360Â° Cardiac Catheter Â We believe our cardiac, endocardial, catheter ablation device will have many of the same advantages that theÂ surgical ablation clamp appears to have with respect to both performance and safety compared to standard thermal modalities. Our catheter is uniquely designed to provide a circumferential, or circular, ablation in a single treatment cycle. We believe this will enable faster treatment times compared to what is currently performed with thermal modalities, especially when ablating around the pulmonary veins, a common treatment approach for AF. Â In recent years, Pulsed Field Ablation (â€œPFAâ€) has gained attention in electrophysiology for the treatment of AF because of its safety profile and speed. Current clinical products employing PFA in AF treatment differ from CellFX nsPFA technology in that the pulse widths are longer, typically in theÂ microsecond domain. We believe CellFX nsPFA technology, which delivers pulses of electrical energy that are each less than a millionth of a second long, can offer similar safety advantages as PFA and may provide improved efficacy advantages based on the circumferential design of our catheter and because it appears CellFX nsPFA technology can create deeper ablations. Â Similar to the cardiac ablation clamp, our proprietary catheter has been in development for several years and we have been working with leaders in the electrophysiology field to test the catheter in preclinical studies. After seeing encouraging preclinical results, in December 2023, we initiated a clinical study in Prague, Czech Republic, to test our CellFX nsPFA 360Â° Cardiac Catheter in patients with AF and early acute data and remapping data from this study have been promising. We have therefore expanded the initial clinical protocol to enroll up to 60 patients, from 30, and to include participation by two additional sites. The study is now almost fully enrolled. Investigators have successfully remapped the first half of the study participants and we have been encouraged by the preliminary results seen in the study. We believe the catheter will need to go through the PMA process for FDA approval to market and sell our cardiac endocardial catheter in the United States. WeÂ expect to commence a U.S. IDE pivotal clinical study sometime in the middle of 2025. Â The CellFX Console Â The CellFX Console is a tunable, software-enabled, console-based platform, designed to accommodate the clinical workflow preferred by physicians. The CellFX System is configured to accept a variety of disposable end-effectors or electrodes across a range of clinical applications. In February 2021, we received 510(k) clearance from the FDA for the CellFX System for dermatologic procedures requiring ablation and resurfacing of the skin. In January 2021, we received ConformitÃ© EuropÃ©ene (â€œCEâ€) marking approval for the CellFX System, which allows for marketing of the system in the European Union (â€œEUâ€). Shortly after these regulatory clearances, we began commercializing the CellFX System in dermatology for the treatment of benign skin lesions. However, in September 2022, we announced a shift in our focus from dermatology to cardiology and the treatment of AF. We have ceased all commercial sales and marketing operations in dermatology. At the present time, we continue to support our remaining commercial users and remain open to a potential commercial partnership. The CellFX System is being used for our current efforts in the treatment of AF and as part of the CellFX nsPFA Percutaneous Electrode System. Â We continue to believe nano-PFA ablation, as well as NPS technology more broadly, has the potential to provide superior outcomes across a variety of medical disciplines and we may seek partnership opportunities to develop additional applications.Â Â Â Â Â Financing Our Business Â Over the past few years, Robert Duggan, our majority stockholder and Co-Chairman, has made significant investments in our Company to fund its operations. In June 2022, we completed a common stock rights offering to our existing stockholders, which raised $15 million in aggregate. Mr. Duggan purchased approximately 56% of the shares offered through this offering. Then, in September 2022, we entered into a loan agreement with Mr. Duggan pursuant to which he lent us $65 million to fund our product development operations. In April 2023, this loan agreement was terminated whenÂ Mr. Duggan and the CompanyÂ enteredÂ into a Securities Purchase Agreement whereby the shares were paid for through the cancellation of both the principal sum of $65.0 million and all accrued and unpaid interest owed at the time under the 2022 loan agreement, which totaled approximately $0.2 million. In June 2024, we completed a rights offering of units (each unit comprising a share of our common stock and two warrants, each to purchase a one-half share of our common stock) to our existing stockholders, which raised $60 million in aggregate. Mr. Duggan purchased approximately 88% of the shares offered through this offering. Mr. Duggan may or may not elect to participate in any number of future fundraisings by the Company, whether similar to those described above or otherwise, and he may choose to invest more than his current pro rata share in any of these fundraisings, or alternatively he may offer to provide additional debt financing as may be needed in order to maintain the Company as a going concern. Â The source, timing and availability of any future financing will depend largely upon market conditions and perceived progress in the Companyâ€™s on-going product development initiatives, as well as future clinical and regulatory developments concerning the CellFX System and our other NPS-based technologies. Funding may not be available when needed, at all or on terms acceptable to us. Lack of necessary funds may require us to, among other things, delay, scale back or eliminate some or all of our commercial activities, reduce headcount, trim research and product development programs, discontinue clinical trials, stop all or some of our manufacturing operations, defer capital expenditures, deregister from being a publicly traded company and delist from Nasdaq, or license our potential products or technologies to third parties, possibly on terms that cannot sustain our current business. In addition, economic instability caused by the armed conflicts in the Middle East and UkraineÂ and high interest rates, together with other market factors, could have an adverse impact on potential sources of future financing. Â We have incurred substantial operating losses and have used cash in our operating activities since inception. To fund our business, we may utilize some combination of public or private equity offerings, debt financings, or potential new collaborations in the future. There can be no assurance, however, that any additional financing or any revenue-generating collaboration will be available when needed or that we will be able to obtain financing or enter into a collaboration on terms acceptable to us. Â 19 Table of Contents Â Critical Accounting Policies and Estimates Â The discussion and analysis of our financial condition and results of operations are based upon our unaudited condensed consolidated financial statements, which have been prepared in accordance with the rules and regulations of the U.S. Securities and Exchange Commission. The preparation of these condensed consolidated financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues, and expenses. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these

estimates under different assumptions or conditions. On an ongoing basis, we evaluate our critical accounting policies and estimates. Our critical accounting policies and estimates are described in our Annual Report on Form 10-K for the year ended December 31, 2023. Â Stock-Based Compensation Â Our stock-based compensation programs include stock options and an employee stock purchase program.Â We periodically issue stock optionsÂ to officers, directors, employees, and consultants for their services to the Company. Such issuances vest and expire according to terms established at the issuance date. Stock-based payments to officers, directors and employees, including grants of employee stock options, are recognized in the financial statements based on their grant date fair values, which are estimated using the Black-Scholes option-pricing model. Stock-based compensation expenseÂ is charged to operations on a straight-line basis over the requisite service period. We have granted stock options withÂ time-based,Â performance-based, and market-based vesting conditions.Â In October 2024, our Board approved changes to the vesting conditions of certain outstanding common stock option awards so thatÂ theÂ performance-based vesting criteria of those particular awards will be changed to either time-based or market-based vesting criteria. Â For stock optionsÂ with performance-based vesting conditions, we do not recognize compensation expense until it is probable that the performance-based vesting condition will be achieved. TheÂ analysis to determine such probabilityÂ involves estimates and judgements from management. The estimate of expense may beÂ revised periodically based on the probability of achieving the required performance targets.Â Â TheÂ vesting conditions for stock options with market-based vesting conditions relate to the achievement ofÂ certainÂ market capitalization targetsÂ of the Company. The grant date fair value for these stock options was determined using a Monte Carlo simulation. The expense is recognized over the requisite service period for each tranche of the awards. The requisite service period is the service period derived from the Monte Carlo simulation model. If the market capitalization targets are met sooner than the derived service period, we will accelerate the recognition of stock-based compensation expense to reflect the cumulative expense associated with the vested shares.Â The Monte Carlo simulation requires the Company to make assumptions and judgements about the variables used in the calculation including the expected term, volatility of the Company's common stock, an assumed risk-free interest rate, and cost of equity. Â Recent Accounting Pronouncements Â Refer to â€œRecent Accounting Pronouncementsâ€ in Note 2 of Notes to Condensed Consolidated Financial Statements of this Quarterly Report. Â Segment and Geographical Information Â We operate and manage our business as one reportable and operating segment. Our Chief Operating Decision Maker ("CODM") reviews financial information on an aggregate basis for purposes of allocating resources and evaluating financial performance. All of our long-lived assets are based in the United States. Â 20 Table of Contents Â Results of Operations Â Comparison of the three-month periods ended September 30, 2024 and 2023 Â Our condensed consolidated statements of operations as discussed herein are presented below: Â Â Â Three Months Ended Â Â Â Â Â Â Â September 30, Â Â Â Â Â (in thousands) Â 2024 Â Â 2023 Â Â $ Change Â Revenues: Â Â Â Â Â Â Â Â Â Â Â Â Â Product revenues Â $ â€” Â Â $ â€” Â Â $ â€” Â Total revenues Â Â â€” Â Â Â Â â€” Â Â Â â€” Â Cost and expenses: Â Â Â Â Â Â Â Â Â Â Â Â Â Research and development Â Â 7,703 Â Â Â 7,472 Â Â Â 231 Â General and administrative Â Â 5,952 Â Â Â 3,780 Â Â Â 2,172 Â Total cost and expenses Â Â 13,655 Â Â Â 11,252 Â Â Â 2,403 Â Loss from operations Â Â (13,655) Â Â (11,252) Â Â (2,403) Other income: Â Â Â Â Â Â Â Â Â Â Â Â Interest income, net Â Â 975 Â Â Â 686 Â Â Â 289 Â Total other income Â Â 975 Â Â Â 686 Â Â Â 289 Â Loss from operations, before income taxes Â Â (12,680) Â Â (10,566) Â Â (2,114) Income tax benefit Â Â â€” Â Â Â Â â€” Â Â Â Â â€” Â Net loss Â $ (12,680) Â $ (10,566) Â $ (2,114) Â Revenues Â There were no revenues for the three-month periods endedÂ September 30, 2024 and 2023. Â Research and Development Â Research and development expenses consist of compensation and other employee related expenses for research and development personnel, clinical trials and consulting costs related to the design, development and enhancement of our potential future products, prototype material and devices. Research and development expenses increased by $0.2Â million to $7.7Â million for the three-month period ended September 30, 2024, compared to $7.5Â million during the same period inÂ 2023 primarily due to increases of $0.4Â million in supplies, $0.3Â million inÂ compensation and other employee-related expenses, and $0.1Â million in stock-based compensation;Â partially offset byÂ a decrease of $0.6Â million in paid services. Â 21 Table of Contents Â General and Administrative Â General and administrative expenses consist of compensation and other related employee expenses for executives, finance, legal, human resources, information technology, and administrative personnel, professional fees, patent fees and costs, insurance costs and other general corporate expenses. General and administrative expenses increased by $2.2Â million to $6.0Â million for the three-month period ended September 30, 2024, compared to $3.8Â million during the same period inÂ 2023 primarily due toÂ increases of $1.1Â million in stock-based compensation, $0.6Â million inÂ compensation and other employee-related expenses, and $0.5Â million in paid services and general administrative costs. Â Other Income, net Â Interest income, net, increased by $0.3 million to $1.0 million forÂ the three-month period endedÂ September 30, 2024, compared to $0.7 million during the same period inÂ 2023. Interest income increased by $0.3 million, driven by increasedÂ returns on higherÂ cash balances. Â Comparison of theÂ nine-month periods ended September 30, 2024 and 2023 Â Our condensed consolidated statements of operations as discussed herein are presented below: Â Â Â Nine Months Ended Â Â Â Â Â Â Â September 30, Â Â Â Â Â (in thousands) Â 2024 Â Â 2023 Â Â $ Change Â Revenues: Â Â Â Â Â Â Â Â Â Â Â Â Â Product revenues Â $ â€” Â Â $ â€” Â Â $ â€” Â Total revenues Â Â â€” Â Â Â Â â€” Â Â Â â€” Â Cost and expenses: Â Â Â Â Â Â Â Â Â Â Â Â Â Research and development Â Â 21,674 Â Â Â 19,998 Â Â Â 1,676 Â General and administrative Â Â 14,322 Â Â Â 11,043 Â Â Â 3,279 Â Total cost and expenses Â Â 35,996 Â Â Â 31,041 Â Â Â 4,955 Â Loss from operations Â Â (35,996) Â Â (31,041) Â Â (4,955) Other income: Â Â Â Â Â Â Â Â Â Â Â Â Interest income, net Â Â 1,796 Â Â Â 764 Â Â Â 1,032 Â Total other income Â Â 1,796 Â Â Â 764 Â Â Â 1,032 Â Loss from operations, before income taxes Â Â (34,200) Â Â (30,277) Â Â (3,923) Income tax benefit Â Â â€” Â Â Â Â â€” Â Â Â Â â€” Â Net loss Â $ (34,200) Â $ (30,277) Â $ (3,923) Â Revenues Â There were no revenues for the nine-month periods endedÂ September 30, 2024 and 2023. Â Research and Development Â Research and development expenses consist of compensation and other employee related expenses for research and development personnel, clinical trials and consulting costs related to the design, development and enhancement of our potential future products, prototype material and devices. Research and development expenses increased by $1.7Â million to $21.7Â million for the nine-month period ended September 30, 2024, compared to $20.0Â million during the same period inÂ 2023 primarily due to increases of $1.3Â million inÂ stock-based compensation,Â $0.9Â million inÂ compensation and other employee-related expenses, and $0.3Â million inÂ supplies. These increases were partially offset by a decreaseÂ of $0.8Â million in paid services. Â 22 Table of Contents Â General and Administrative Â General and administrative expenses consist of compensation and other related employee expenses for executives, finance, legal, human resources, information technology, and administrative personnel, professional fees, patent fees and costs, insurance costs and other general corporate expenses. General and administrative expenses increased by $3.3Â million to $14.3Â million for the nine-month period ended September 30, 2024, compared to $11.0Â million during the same period inÂ 2023 primarily due toÂ increases of $1.7Â million in stock-based compensation,Â $0.8Â million in compensation and other employee-related expenses, $0.6Â million in paid services, and $0.2 million in facilities and IT cost allocations driven by our shift in focus. Â Other Income, net Â Interest income, net, increased by $1.0Â million to $1.8Â million forÂ the nine-month period endedÂ September 30, 2024, compared to $0.8Â millionÂ during the same period in 2023. Interest income decreased by $0.1 million to $1.8 million for the nine-month period endedÂ September 30, 2024, compared to $1.9 million during the same period inÂ 2023.Â Interest expense decreased by $1.1Â million to zeroÂ forÂ the nine-month period endedÂ September 30, 2024, compared to $1.1Â millionÂ during the same period in 2023Â driven by the extinguishment of the 2022 Loan Agreement. Â Liquidity and Capital Resources Â To date, we have not generated significant revenues from product sales. Since inception, we have funded our business primarily through the issuance of equity securities and debt. Over the next few years, we intend to invest in research and development to develop additional commercially viable products and to assess the feasibility of potential future products. Â On JuneÂ 9, 2022, we completed the 2022 Rights Offering resulting in the sale of 7,317,072 Units, at a price of $2.05 per Unit, with each Unit consisting of one share of the Companyâ€™s common stock, par value $0.001 per share, and one warrant to purchase one share of common stock at $2.05 per share. 7,317,072 shares of common stock and warrants to acquire up to an additional 7,317,072 shares of common stock were issued in the 2022 Rights Offering. The Company received aggregate gross proceeds from the 2022 Rights Offering of $15 million. In May 2023, the Company delivered an irrevocable notice of redemption to warrant holders and, on June 16, 2023, it redeemed the last of the outstanding 2022 Rights Offering Warrants at a price of $0.01 per warrant share.Â Prior to the redemption date, warrants to purchase 7,250,897 shares were exercised, generating approximately $14.9 million of total gross proceeds to the Company. As of SeptemberÂ 30, 2023, there were no 2022 Rights Offering Warrants outstanding. Robert W. Duggan, the Companyâ€™s majority stockholder and Co-Chairman, purchased approximately 56% of the shares offered through the 2022 Rights Offering. Â In September 2022, we entered into the 2022 Loan Agreement with Robert W. Duggan, our majority stockholder and Co-Chairman, in connection with Mr. Duggan lending the principal sum of $65.0Â million to the Company. The 2022 Loan Agreement hadÂ a maturity date of MarchÂ 20, 2024. Under the 2022 Loan Agreement, Mr. Duggan provided us, subject to certain conditions, an unsecured term loan facility in an original aggregate principal amount of $65.0Â million. The 2022 Loan Agreement bore interest at a rate per annum equal to 5.0%, payable quarterly, commencing on JanuaryÂ 1, 2023. On March 17, 2023, the Company and Mr. Duggan amended certainÂ terms of the Loan Agreement. There were no changes to the interest rate, the principal sum repayment date was changed to September 30, 2024. However, on April 30, 2023, weÂ entered into a Securities Purchase Agreement with Mr. Duggan, pursuant to which we agreed to issue and sell to Mr. DugganÂ 10,022,937 shares of our common stock, par value $0.001 per share, in a Private Placement, at a price per share of $6.51. These shares were paid for through the cancellation of the amounts then owed by the Company under the 2022 Loan Agreement, the principal sum of $65.0 million and all accrued and unpaid interest outstanding, which totaled approximately $0.2 million as of April 30, 2023.Â The parties completed the Private Placement on May 9, 2023 and, upon closing and satisfaction of the outstanding debt, the 2022 Loan Agreement terminated, without early termination fees or penalties being owed by the Company. No additional amounts are owed to Mr. Duggan under the 2022 Loan Agreement. Â On July 3, 2024, we announced the closing of ourÂ 2024 Rights Offering. The 2024 Rights Offering resulted in the sale of six millionÂ 2024 Units, at a price of $10.00 per 2024 Unit. Each 2024 Unit consisted of one share of ourÂ common stock, par value $0.001 per share, and two warrants, each being a warrant to purchase one-half of one share of common stock. The common stock and warrants comprising the 2024 Units separated upon the closing of the 2024 Rights Offering and were issued individually. A total of 5,999,998Â shares of common stock and warrants to acquire up to approximately an additional six million shares of common stock were issued in the offering. We received aggregate gross proceeds from the 2024 Rights Offering of $60 million. If exercised, additional gross proceeds of up to $66 million may be received through the exercise of warrants issued in the 2024 Rights Offering. Each warrant will be exercisable for $11.00 per whole share, which equals 110% of the subscription price for the Units. Warrants are exercisable immediately and will expire on the fifth anniversary of the closing of the 2024 Rights Offering. Half of the warrants issued in the rights offering are redeemable by us if our stock trading price exceeds $16.50 for twenty consecutive trading days and the other half of the warrants issued in the rights offering are redeemable by us if our stock trading price exceeds $22.00 for twenty consecutive trading days. As ofÂ September 30, 2024, we have received $1.5Â million in gross proceeds from exercises of the 2024 Rights Offering warrants.Â Â Our condensed consolidated statements of cash flows as discussed herein are presented below: Â Â Â Nine Months Ended September 30, Â (in thousands) Â 2024 Â Â 2023 Â Net cash used in operating activities Â $ (27,199) Â $ (26,259) Net cash used in investing activities Â Â (72) Â Â (78) Net cash provided by financing activities Â Â 61,939 Â Â Â 15,584 Â Net increase (decrease) in cash and cash equivalents Â $ 34,668 Â Â $ (10,753) Â To date, we have generated limited revenue and used cash in our operating activities. As a result, we have incurred significant operating losses in each year since our inception and we may continue to incur additional losses for the next several years. As ofÂ September 30, 2024, we had cash and cash equivalents of $79.0Â million. We believe that our existing cash and cash equivalents will be sufficient to fund our projected operating requirements for at least the next twelve months from the filing date of this Quarterly Report on Form 10-Q. However, we plan to raise additional capital in the future. We can give no assurance, at this time, that additional financing or a collaboration will be available when needed on terms acceptable to us, however. Â These expectations are based on our current operating and financing plans which are subject to change. Until we are able to generate sustainable product revenues at profitable levels, we expect to finance our future cash needs through public or private equity offerings, debt financings,Â and/or potential new collaborations. Such additional funds may not be available on terms acceptable to us or at all. If we raise funds by issuing equity or equity-linked securities, the ownership of some or all of our stockholders mayÂ be diluted, and the holders of new equity securities may have priority rights over our existing stockholders. If adequate funds are not available, we may be required to curtail operations significantly or obtain funds by entering into agreements on unattractive terms. Our inability to raise capital could have a material adverse effect on our business, financial condition, results of operations and cash flows. For example, lack of necessary funds may require us to, among other things,Â reduce headcount, trim research and product development programs, discontinue clinical trials,Â defer capital expenditures, deregister from being a publicly traded company and delist from Nasdaq, or license our potential products or technologies to third parties, possibly on terms that cannot sustain our current business. In addition, instability in economic activity caused by the armed conflicts in the Middle East and UkraineÂ and high interest rates, together with other market factors, could have an adverse impact on potential sources of future financing. Â 23 Table of Contents Â Operating Activities Â During the nine months ended September 30, 2024, we used cash in the amount of $27.2Â million in operating activities. The difference between cash used in operating activities and net loss consisted primarily of stock-based compensation, depreciation and amortization, as well as a decreases in accounts payable and an increase in prepaids and other current assets. Â During the nine months ended September 30, 2023, we used cash in the amount of $26.3Â million in operating activities. The difference between cash used in operating activities and net loss consisted primarily of stock-based compensation, depreciation and amortization, as well as increases in accrued expensesÂ and right-of-use assets, offset by accrued interest on related party note payable and lease liabilities. Â ï»¿Investing Activities Â Our investing activities consist primarily of investment purchases, sales and maturities and capital expenditures. Â During the nine months ended September 30, 2024, $0.1Â million of cash used in investing activities was driven by the purchase of property and equipment. Â During the nine months ended September 30, 2023, $0.1Â million of cash used in investing activities was driven by the purchase of property and equipment. Â Financing Activities Â During the nine months ended September 30, 2024, cash provided by financing activities was $61.9Â million, primarily due to $59.6 million of net proceeds from the 2024 Rights Offering, $1.5Â million of proceeds from the exercise of warrants, $0.5Â millionÂ of proceeds from issuance of common stock under employee stock purchase plan and $0.5Â million of proceeds from the exercise of stock options, offset by $0.2Â million of deferred issuance costs in relation to a futureÂ at-the-market equity offering.Â Â Â During the nine months ended September 30, 2023, cash provided by financing activities was $15.6Â million, primarily due to $14.8Â million of proceeds from the exercise of warrants, $0.4Â millionÂ of proceeds from issuance of common stock under employee stock purchase plan and $0.4Â million of proceeds from the exercise of stock options. Â Contractual Obligations Â There have been no material changes outside the ordinary course of our business to the contractual obligations disclosed in our Annual Report on Form 10-K for the year ended December 31, 2023. Â Off-Balance-Sheet Arrangements Â At September 30, 2024, we did not have any transactions, obligations or relationships that constitute off-balance sheet arrangements. Â In the ordinary course of business, we enter into standard indemnification arrangements. Pursuant to these arrangements, we indemnify, hold harmless, and agree to reimburse the indemnified parties for losses suffered or incurred by the indemnified party in connection with any trade secret, copyright, patent or other intellectual property infringement claim by any third party with respect to its technology, or from claims relating to our performance or non-performance under a contract. The maximum potential amount of future payments we could be required to make under these agreements is not determinable because it involves claims that may be made against us in future periods, but have not yet been made. To date, we have not incurred costs to defend lawsuits or settle claims related to these indemnification agreements. Â We also enter and have entered into indemnification agreements with our directors and officers that may require us to indemnify them against liabilities that arise by reason of their status or service as directors or officers, except as prohibited by applicable law. In addition, we may have obligations to hold harmless and indemnify third parties involved with our fundraising efforts and their respective affiliates, directors, officers, employees, agents or other representatives against any and all losses, claims, damages and liabilities related to claims arising against such parties pursuant to the terms of agreements entered into between us and such third parties in connection with such fundraising efforts. No liability associated with such indemnification agreements has been recorded as of September 30, 2024. Â Trends, Events and Uncertainties Â Research and development of new technologies are, by their nature, unpredictable. Although we undertake development efforts with commercially reasonable diligence, there can be no assurance that the net proceeds from our financings will be sufficient to enable us to develop our technology to the extent needed to generate future sales to sustain our operations. If we do not continue to have enough funds to sustain our operations, we will consider other options to continue the research and development of our technology, including, but not limited to, additional financing through follow-on stock offerings, debt financings, or co-development agreements and /or other alternatives. Â We cannot assure investors that our technology will be adopted or that we will ever achieve sustainable revenues sufficient to support our operations. Even if we are able to generate revenues, there can be no assurances that we will be able to

achieve profitability or positive operating cash flows. There can be no assurances that we will be able to secure additional financing in the future on acceptable terms or at all. If our technology cannot be used to successfully treat AF or tumors and nodules or if our cash resources are insufficient to satisfy our ongoing cash needs, we would be required to, among other things, delay, scale back or eliminate some or all of our activities, reduce headcount, trim research and product development programs, discontinue clinical trials, stop all or some of our manufacturing operations, defer capital expenditures, deregister from being a publicly traded company and delist from Nasdaq, license our potential products or technologies to third parties, possibly on terms that cannot sustain our current business, or curtail, suspend or discontinue our operations entirely. Â Other than as discussed above and elsewhere in this QuarterlyÂ Report, we are not currently aware of any trends, events or uncertainties that are likely to have a material effect on our financial condition in the near term, although it is possible that new trends or events may develop in the future that could have a material effect on our financial condition. Â 24 Table of Contents Â ItemÂ 3. Quantitative and Qualitative Disclosures About Market Risk Â There have been no material changes in market risk from the information provided in our Annual Report on Form 10-K for the year ended December 31, 2023. We are exposed to market risk in the ordinary course of our business. Market risk represents the risk of loss that may impact our financial position due to adverse changes in financial market prices and rates. Our market risk exposure is primarily a result of fluctuations in interest rates. We do not hold financial instruments for trading purposes. Â ItemÂ 4. Controls and Procedures Â Evaluation of Disclosure Controls and Procedures Â Our management, under the supervision and with the participation of our Chief Executive Officer, who is our principal executive officer and principal financial officer, conducted an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act of 1934, as amended, as of the end of the period covered by this Quarterly Report. Based on this evaluation, our Chief Executive Officer has concluded that, as of September 30, 2024, our disclosure controls and procedures were effective (a)Â to ensure that information that we are required to disclose in reports that we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in SEC rules and forms and (b)Â to include, without limitation, controls and procedures designed to ensure that information required to be disclosed by us in reports filed or submitted under the Exchange Act is accumulated and communicated to our management, including our Chief Executive Officer, as appropriate, to allow timely decisions regarding required disclosure. Â Changes in Internal Control Over Financial Reporting Â There have been no changes in our internal control over financial reporting identified in connection with the evaluation required by Rule 13a-15(d) and 15d-15(d) of the Exchange Act, as amended, that occurred during the quarter endedÂ September 30, 2024 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. Internal control over financial reporting means a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with U.S. GAAP. Â Inherent Limitations on Effectiveness of Controls Â Our management does not expect that our disclosure controls and procedures or our internal control over financial reporting will prevent all errors and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of a simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by management override of the controls. The design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions; over time, controls may become inadequate because of changes in conditions, or the degree of compliance with policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected. Â 25 Table of Contents Â PART II. OTHER INFORMATION Â Item 1. Legal Proceedings Â From time to time, we may be involved in a variety of claims, lawsuits, investigations, and proceedings relating to securities laws, product liability, patent infringement, contract disputes, and other matters relating to various claims that arise in the normal course of our business, including the matter described below. The outcome of any legal proceedings is unpredictable but, regardless of outcome, they can have an adverse impact on us because of defense and settlement costs, diversion of management resources, negative publicity, reputational harm, and other factors. We maintain insurance that may provide coverage for such matters, including customary employment practices liability insurance. Â In November 2022, the employment of our former Chief Financial Officer, Sandra Gardiner, terminated. Ms. Gardinerâ€™s departure was not the result of any disagreement with the Company on any matter relating to its operations, accounting policies or practices, although the Company determined that she was not eligible to receive any severance benefits under the terms and conditions of her then existing employment agreement. In March 2023, Ms. Gardiner filed an arbitration demand with JAMS seeking severance benefits and other remedies, alleging breach of contract and unlawful termination in violation of public policy, among other things. We believe that Ms. Gardinerâ€™s claims are without merit and we intend to vigorously defend ourselves against them.Â Because of the difficulty in predicting the outcome of any legal proceeding, the Company is not able to conclude that a liability is probable and cannot predict what the final outcome of Ms. Gardinerâ€™s arbitration proceeding will likely be or provide a reasonable estimate for the range of ultimate possible loss, if any.Â However, at this time, we believe that the final resolution of this matter will not adversely affect our consolidated position, results of operation, or cash flows. Â ItemÂ 1A. Risk Factors Â Summary Â Below is a summary of the principal factors that make an investment in Pulse Biosciences, Inc. speculative or risky. The following summary does not contain all of the information that may be important to you, and you should read the below summary in conjunction with the more detailed discussion of risks set forth following the summary. Â Risks Related to Our Financial Position and Need for Additional Capital Â Â â— We will need to obtain additional funding to finance our operations and complete the development and any commercialization of our products. If we do not receive substantial capital when needed, we may be forced to restrict our operations or delay, reduce or eliminate our product development programs. Â Â â— We depend heavily on the success of NPS to nonthermally clear targeted cells while sparing adjacent noncellular tissue. If we are unable to successfully develop and commercialize this patented technology, or experience significant delays in doing so, we may extend the period in which we will incur significant financial losses as an organization. Â Â â— We are a development-stage company with very limited experience commercializing products. WeÂ have incurred significant losses since our inception. We anticipate that we will continue to incur losses for at least the next several years and may never generate profits from operations or maintain profitability. Â Â â— We will need to raise additional capital, which may result in further dilution to our investors, or incur additional indebtedness. The servicing of future debt may impair our liquidity position. Â Risks Related to the Development and Commercialization of our Medical Products Â Â â— We can provide no assurance that our clinical product candidates, including our product candidates for the treatment of atrial fibrillation ("AF"), our CellFX nsPFA Cardiac Clamp and our CellFX nsPFA 360Â°Â Cardiac Catheter and our soft tissue ablation product specifically indicated for treatment of benign thyroid nodules, will obtain regulatory approval or that the results of clinical studies will be favorable. Â Â â— Medical device development and commercialization is a complex, time-consuming and expensive process. Our industryÂ is fraught with risk and a high rate of failure. Â Â â— We have very limited sales and marketing experience and no experience commercializing our CellFX nsPFA Percutaneous Electrode System or either of our cardiac products currently under development. We can give no assurances that our devices will be adopted by surgeons or other physicians to treat any medical condition. Â Â â— Regulatory requirements and timelines may affect the scope and timeline of our trials and the potential market for our product candidates, including the possibility of significant delays to any product launch. Â Â â— The medical device industry is characterized by intense competition, rapid technological changes, new product introductions and enhancements, and evolving industry standards.Â If we do not develop and obtain regulatory clearances or approvals for new products or product enhancements in time to meet market demand, or if there is insufficient demand for our products or enhancements, our results of operations will suffer. Â Â â— If we experience any number of possible unforeseen events in connection with our clinical trials, potential marketing approval or commercialization of our product candidates could be delayed or prevented. Â Â â— If clinical trials of our product candidates fail to demonstrate safety and efficacy to the satisfaction of applicable regulatory bodies, such as theÂ U.S. Food and Drug AdministrationÂ or the European Medicines Agency,Â we may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of our medical devices. Â Â â— Regulatory requirements and timelines may affect the scope and timeline of our trials and the potential market for our product candidates. Â 26 Table of Contents Â Risks Related to Our Industry and Market Â Â â— We face substantial competition, which may result in others developing or commercializing products beforeÂ or more successfully than we do. Â Â â— We compete against well-established incumbent technologies offering products in cardiology, oncology, and dermatology, as well as in minimally invasive procedures. All of these companies currently have greater financial, technical, research, and/or other resources than we do and have larger and more established manufacturing capabilities and marketing, sales, and support functions. Â Â â— We may pursue business development opportunities to expand or enhance our pipeline of potential products, including through potential acquisitions of and/or collaborations with other entities or the acquisition of products unrelated to NPS technology, which may not achieve intended results or could increase the number of our outstanding shares or amount of outstanding debt or result in a change of control. Â Legal, Tax, Regulatory, and Compliance Risks Â Â â— Our ability to commercialize any of our product candidates is subject to substantial regulatory and legislative uncertainty, including as to pricing, reimbursement practices or other healthcare initiatives which could harm our business. Â Â â— We may face costly legal claims, in particular related to product liability and intellectual property infringement. Â Â â— We are subject to certain U.S. and foreign anti-corruption, anti-money laundering, export control, sanctions, and other trade laws and regulations. We can face serious consequences for violations. Â Risks Related to Our Intellectual Property, Cybersecurity and Data Privacy Â Â â— We rely upon patents to protect our technology. We may be unable to protect our intellectual property rights and we may be liable for infringing the intellectual property rights of others. Â Â â— Our actual or perceived failure to comply with stringent and changing obligations related to data privacy and security could lead to regulatory investigations and actions, litigation, fines and penalties, disruptions to our business operations, reputational harm, loss of revenue and profits, and other adverse business impacts. Â Â â— We are exposed to risks related to cybersecurity and data privacy threats and incidents and we are subject to restrictions and changes in laws and regulations governing our data privacy and data protection, any of which could have a material adverse effect on our business. Â Risks Related to Corporate Governance and Employee Relations Â Â â— Our future success depends on our ability to retain our Chief Executive Officer, our Chief Technology Officer, our Chief Commercial Officer, our Chief Strategy Officer, and other key executives and to attract, retain and motivate qualified personnel. Â Â â— Our Co-Chairman owns more than a majority of the voting power of the outstanding shares of our common stockÂ and, as a result, investors may have limited ability to affect either the corporate governance of the Company or the taking of certain major decisions. Â Risks Related to Owning Our Common Stock Â Â â— Substantial future sales of our shares of common stock in the public market, or the perception that these sales could occur, could cause the price of the shares to decline significantly, even if our business is doing well. Â Â â— The prices of our shares of common stock may be volatile and fluctuate substantially, which could result in substantial losses for our stockholders. Â Â â— 73% of our outstanding shares are owned by our Co-Chairman, Robert Duggan, and his affiliates, which can reduce liquidity of our stock. Historically, our trading volume on Nasdaq has been low. Â 27 Table of Contents Â Investing in our common stock involves a high degree of risk. You should carefully consider the risks and uncertainties described below, together with all of the other information in this QuarterlyÂ Report, including our financial statements and related notes, which could have a material adverse effect on our business, financial condition, results of operations, and prospects. The risks described below are not the only risks facing us. Risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially affect our business, financial condition, results of operations, and prospects. In addition, any worsening of the economic environment may exacerbate the risks described below, any of which could have a material impact on us. Â Risks Relating to Our Business, Industry and Financial Condition Â Because we have a limited operating history and no significant revenue stream, it is difficult to evaluate the future of our business. Â We are a bioelectric medicine technology company with no significantÂ revenue producing operations. To date, our operations on a consolidated basis have consisted almost entirely of the continued development and clinical studies of our technologies and implementation of the early parts of our business plan. We have incurred significant operating losses in each year since our inception and we may continue to incur additional losses for the next several years. In addition, a high percentage of our expenses will continue to be fixed; accordingly, our losses may be greater than expected and our operating results may suffer. We have limited historical financial data upon which we may base our projected revenue and base our planned operating expenses. Our limited operating history makes it difficult to evaluate our technology, operations, and business prospects. Â We have not generated significantÂ revenue, and we may never become profitable. Â To date, we have not generated significant revenue, and we have historically relied on financing from the sale of equity securities and loans to fund our operations. We expect that our future financial results will depend primarily on our success in launching, selling, and supporting our therapies and procedures using our NPS technology. We expect to expend significant resources on hiring of personnel, continued scientific and product research and development, potential product testing and preclinical and clinical investigation, intellectual property development and prosecution, capital expenditures, working capital, general and administrative expenses, and fees and expenses associated with our capital raising efforts. We expect to incur costs and expenses related to consulting costs, laboratory development costs, hiring of scientists, engineers, sales representatives, and other operational personnel, and the continued development of relationships with potential partners. We are incurring significant operating losses, we expect to continue to incur additional losses for at least the next several years, and we cannot assure you that we will generate substantial revenue or be profitable in the future. There are no assurances that our future products will be cleared or approved or become commercially viable or accepted for use. Even with commercially viable applications of our technology, which may include licensing, we may never recover our research and development expenses. Â Investment in medical technology is highly speculative because it entails substantial upfront capital expenditures and significant risk that any potential product will fail to demonstrate adequate efficacy or clinical utility. Our past successes in dermatology may not translate into similar results in cardiology or elsewhere. Investors should evaluate an investment in us in light of the uncertainties typically encountered by developing medical technology companies in a competitive environment. There can be no assurance that our efforts will be successful, either in cardiology or otherwise, or that we will ultimately be able to achieve profitability. Even if we achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. Our failure to become and remain profitable could adversely affect the market price of our common stock and could significantly impair our ability to raise capital, expand our business, or continue to implement our business plan. Â We can give no assurance that our internal and external sources of liquidity will be sufficient for our cash requirements. Â We must have sufficient sources of liquidity to fund our working capital requirements and execute on our strategic initiatives. Future new product launches or investments in other growth initiatives may demand increased working capital before any long-term return is realized from increased revenue. Our ability to achieve our business and cash flow plans is based on a number of assumptions which involve significant judgments and estimates of future performance, borrowing capacity and credit availability, and financing opportunities which cannot at all times be assured. There is no assurance that cash flows from operations and other internal and external sources of liquidity will at all times be sufficient for our cash requirements. If necessary, we may need to consider actions and steps to improve our cash position and mitigate any potential liquidity shortfall, such as modifying our business plans, pursuing additional financing to the extent available, reducing capital expenditures, suspending certain activities or programs, pursuing and evaluating other alternatives and opportunities to obtain additional sources of liquidity, and other potential actions to reduce costs. There can be no assurance that any of these actions would be successful, sufficient or available on favorable terms. Any inability to generate or obtain sufficient levels of liquidity to meet our cash requirements at the level and times needed could have a material adverse impact on our business and financial position. Â If we are unable to obtain sufficient funding, we may be unable to execute our business plan and fund operations. We may not be able to obtain additional financing on commercially reasonable terms, or at all. Â We have experienced operating losses, and we expect toÂ continue to incur operating losses for the next several years as we implement our business plan. Currently, we have no significant revenue from operations, andÂ we do not have arrangements in place for all the anticipated financing that would be required to fully implement our business plan. Our prior losses, combined with expected future losses, have had, and will continue to have, for the foreseeable future, an adverse effect on our stockholdersâ€™ equity and working capital. Â We will need to raise additional capital in order to continue to execute our business plan. If we are unable to raise sufficient additional funds, we may need to scale back our future operations. Also, the ongoing armed conflicts in the Middle East, Ukraine,Â and elsewhere, which have negatively impacted the global macroeconomic environment and capital markets, may make it more difficult for us to raise additional funds. Â We cannot give any assurance that we will be able to obtain all the necessary funding that we may need. In addition, we believe that we will require additional capital in the future to fully develop and bring to

market our technologies and planned products. We have pursued and may pursue additional funding through various financing sources, including the private sale of our equity securities, debt financings, licensing fees for our technology, joint ventures with capital partners, and project type financing. If we raise funds by issuing equity or equity-linked securities, dilution to some or all our stockholders would result. Any equity securities issued may also provide for rights, preferences or privileges senior to those of holders of our common stock. The terms of debt securities issued or borrowings could impose significant restrictions on our operations. We also may seek government-based financing, such as development and research grants. There can be no assurance that funds will be available on commercially reasonable terms, if at all. Â Any future indebtedness could impose on us restrictive covenants, including further limitations on our ability to incur additional debt, limitations on our ability to issue additional equity, limitations on our ability to acquire or license intellectual property rights, and other operating restrictions that could adversely affect our ability to conduct our business. In addition, the issuance of additional equity securities by us, or the possibility of such issuance, may cause the market price of our common stock to decline. Also, in the event that we enter into collaborations or licensing arrangements to raise capital, we may be required to accept unfavorable terms. These agreements may require that we relinquish, or license to a third party on unfavorable terms, our rights to technologies or product candidates that we otherwise would seek to develop or commercialize ourselves or reserve certain opportunities for future potential arrangements when we might otherwise be able to achieve more favorable terms. In addition, we may be forced to work with a partner on one or more of our products or market development programs, which could lower the economic value of those programs to us. Â If we are unable to obtain adequate financing or financing on terms satisfactory to us when we require it, we may beÂ required to, among other things, delay, scale back or eliminate some or all of our activities, reduce headcount, trim research and product development programs, discontinue clinical trials, stop all or some of our manufacturing operations, defer capital expenditures, deregister from being a publicly traded company and delist from Nasdaq, or license our potential products or technologies to third parties, possibly on terms that cannot sustain our current business, or curtail, suspend or discontinue our operations entirely. If any of these things were to occur, our ability to grow and support our business and to respond to market challenges could be significantly limited or we may be unable to continue operations, in which case you could lose your entire investment. Â 28 Table of Contents Â Because our business is not profitable, from time to time, we may undergo a reduction in force to reduce our operating expenses. However, any corporate restructuring or headcount reduction may not result in anticipated savings, could result in total costs and expenses and attrition that are greater than expected and could disrupt our business. Â As a consequence of our corporate realignment, we experienced employee turnover in 2022 higher than industry norms, and in February 2023 we continued to reduce headcount by eliminating another seven positions at the Company. If we decide to further reduce headcount to lower our operating expenses, we may not realize, in full or in part, the anticipated benefits, savings and improvements in our cost structure from such a restructuring because of unforeseen difficulties, delays or unexpected costs. If we are unable to realize the expected operational efficiencies and cost savings from such a restructuring, our operating results and financial condition would be adversely affected. Any restructuring activities would be disruptive to our operations and could result in material delays in our new product development programs. Also, any headcount reductions could yield unanticipated consequences, such as attrition beyond planned staff reductions, or increase difficulties in our day-to-day operations. Headcount reductions could also harm our ability to attract and retain qualified management, scientific, clinical, regulatory, manufacturing, engineering, and other personnel who are critical to our business. Any failure to attract or retain qualified personnel could prevent us from successfully developing and commercializing our new product candidates in the future. Â Our revenues and future profitability are entirely dependent upon one family of products, the CellFX System, and one platform technology, Nano-pulse Stimulation. Â Our revenue to date has beenÂ generated entirely from the CellFX System, which consists of a console, connectors and end-effectors, and these products and all our potential products under development are based upon the same patented platform technology, Nano-pulse Stimulation (â€œNPSâ€). Our future revenue is therefore dependent on the success of these products under development and platform technology. Reliance on a single family of products and single platform technology could negatively affect our results of operations and financial condition. Our ability to become profitable will depend upon the commercial success of these future products and platform technology. Â We intend to market the CellFX nsPFA Percutaneous Electrode System primarily to Otolaryngologists, Endocrine Surgeons, and Interventional Radiologists (â€œsurgeonsâ€) who may be slow or fail to adopt our products or who may use our products in only a small percentage of their eligible patients for a variety of reasons, including but not limited to: Â Â â— lack of experience with our products; Â Â â— lack of adequate reimbursement or cost to the patient; Â Â â— lack of conviction regarding evidence supporting cost benefits or cost effectiveness of our products over existing alternatives; Â Â â— lack of clinical data showing longer-term patient benefits; Â Â â— the possible introduction of new technologies competitive to our products; and Â Â â— liability risks generally associated with the use of new products and procedures. Â Moreover, our products, including our platform NPS technology, could be rendered obsolete or economically impractical by numerous factors, many of which are beyond our control, including but not limited to: Â Â â— entrance of new competitors into our markets; Â Â â— technological advancements of alternative technologies; Â Â â— loss of key relationships with suppliers, group purchasing organizations, or end-user customers; Â Â â— manufacturing or supply interruptions; Â Â â— product liability claims; Â Â â— our reputation and product market acceptance; Â Â â— loss of existing regulatory approvals or the imposition of new requirements to maintain such approvals or to receive new approvals; and Â Â â— product recalls or safety alerts. Â 29 Table of Contents Â We may fail to meet our publicly announced guidance or other expectations about our business and future operating results, which could cause our stock price to decline. Â The Company may, from time to time, provide financial guidance about its business and future operating results. In developing this guidance, the Companyâ€™s management must make certain assumptions and judgments about its future operating performance, including but not limited to projected hiring of sales professionals, growth of revenue in the relevant device markets, increase or decrease of its market share, costs of production of its recently introduced products, and stability of the macro-economic environment in the Companyâ€™s key markets. Furthermore, analysts and investors may develop and publish their own projections of the Companyâ€™s business, which may form a consensus about the Companyâ€™s future performance. The Companyâ€™s business results may vary significantly from such guidance or that consensus due to a number of factors, many of which are outside of the Companyâ€™s control, and which could adversely affect its operations and operating results. Furthermore, if the Company makes downward revisions of its own previously announced guidance, or if the Companyâ€™s publicly announced guidance of future operating results fails to meet expectations of securities analysts, investors or other interested parties, the price of the Companyâ€™s common stock could decline. Â Our operating results may fluctuate significantly, which makes our future operating results difficult to predict and could cause our operating results to fall below expectations. Â Our quarterly and annual operating results may fluctuate significantly, which makes it difficult for us to predict our future operating results. These fluctuations may occur due to a variety of factors, many of which are outside of our control and may be difficult to predict, including: Â Â â— the timing and cost of, and level of investment in, research, development, and commercialization activities relating to our product and product candidates, which may change from time to time; Â Â â— the timing of receipt of approvals or clearances for our product candidates from regulatory authorities internationally or in the United States, such as the U.S. FDA; Â Â â— the timing and status of enrollment for our clinical trials; Â Â â— coverage and reimbursement policies with respect to our product and product candidates, including the degree to which procedures using our products are covered and receive adequate reimbursement from third-party payors, and potential future drugs or devices that compete with our products; Â Â â— the costs of manufacturing our products, as well as building out our supply chain, which may vary depending on the quantity of production and which will vary significantly depending upon the terms of our agreements with manufacturers; Â Â â— expenditures that we may incur to acquire, develop or commercialize additional product candidates and technologies; Â Â â— the level of demand for our product and any product candidates, if approved or cleared, which may vary significantly over time; Â Â â— litigation, including patent, employment, securities class action, stockholder derivative, general commercial, and other lawsuits; Â Â â— future accounting pronouncements or changes in our accounting policies; and Â Â â— the timing and success or failure of nonclinical studies and clinical trials for our product candidates or competing product candidates, or any other change in the competitive landscape of our industry, including consolidation among our competitors or partners. Â The cumulative effects of these factors could result in large fluctuations and unpredictability in our quarterly and annual operating results. As a result, comparing our operating results on a period-to-period basis may not be meaningful. Investors should not rely on our past results as an indication of our future performance. Â This variability and unpredictability could also result in our failing to meet the expectations of industry or financial analysts or investors for any period. If our revenue or operating results fall below the expectations of analysts or investors or below any forecasts we may provide to the market, or if the forecasts we provide to the market are below the expectations of analysts or investors, the price of our common stock could decline substantially. Such a stock price decline could occur even when we have met our previously publicly stated revenue or earnings guidance. Â 30 Table of Contents Â Because we operate in highly competitive markets, we can expect to face competition from largeÂ well-established manufacturers of medical technologies, devices and similar products; we may not be able to compete effectively against companies with significantly more resources. Â The medical technology, medical device, biotechnology, and pharmaceutical industries are characterized by intense and dynamic competition to develop new technologies and proprietary therapies. We face competition from a number of sources, such as pharmaceutical companies, medical device companies, generic drug companies, biotechnology companies, and academic and research institutions. For example, Abbott Laboratories, AtriCure, Inc., Boston Scientific Corporation, Johnson & Johnson (Biosense Webster), Medtronic plc, and several other companies all sell ablation-based surgical and catheter-based medical devices for the treatment of heart arrhythmias, including AF, and additionally, many of these companies are also actively developing PFA products for the treatment of AF. We willÂ find ourselves in competition with one or more of these companies, all of which mayÂ have competitive advantages over us, such as: Â Â â— significantly greater name recognition; Â Â â— established relationships with healthcare professionals, customers, and third-party payers; Â Â â— competitive products with greater efficacy or better safety profiles; Â Â â— established distribution networks; Â Â â— additional lines of products and the ability to offer rebates, higher discounts, or incentives to gain a competitive advantage; Â Â â— greater experience in obtaining patents and regulatory approvals for product candidates; Â Â â— greater experience conducting new product research and development, manufacturing therapies, conducting clinical trials, obtaining regulatory approval for products, and marketing approved products; and Â Â â— greater financial and human resources for product development, sales and marketing. Â We may also face increased competition in the future as new companies enter our markets and as scientific developments surrounding electro-signaling therapeutics continue to accelerate. For example, the current standard of care in cardiac tissue ablation for the treatment of AF is the use of thermal ablation modalities, primarily the use of radiofrequency ablation but has recently seen increased use of a different type of PFA called micro-PFA. While we will seek to expand our technological capabilities to remain competitive, research and development by others may render our technology or product candidates obsolete or noncompetitive or result in treatments or cures superior to any therapy developed by us. Â We may rely on third parties for our sales, marketing, manufacturing, and/or distribution activities, and these third parties may not perform satisfactorily. Â To be able to commercialize our products and planned products, we may elect to internally develop aspects of sales, marketing, large-scale manufacturing, or distribution, or we may elect to use third parties with respect to one or more of these functions. Our reliance on these third parties may reduce our control over these functions; however, reliance on third parties does not relieve us of our responsibility to ensure compliance with all required legal, regulatory, and scientific standards. Any failure of these third parties to perform satisfactorily and in compliance with relevant laws and regulations could lead to delays in the development of our products or planned products, including delays in our clinical trials, or failure to obtain necessary regulatory approvals, or failure to successfully commercialize our products or other future products. Some of these events could be the basis for FDA or other regulatory action, including injunction, recall, seizure, or total or partial suspension of production. Â We believe that developing the commercialization aspects of a company will take a substantial amount of capital and commitment of time and effort. We may seek development and marketing partners and license our technology to others in order to avoid our having to provide the marketing, manufacturing, and distribution capabilities within our organization. There can be no assurance that we will find any development and marketing partners or companies that are interested in licensing our technology. If we are unable to establish and maintain adequate sales, marketing, manufacturing, and distribution capabilities, independently or with others, we will not be able to generate product revenueÂ and may not become profitable. Â 31 Table of Contents Â If we lose key management personnel, our ability to identify, develop and commercialize new or next generation product candidates will be impaired, could result in loss of markets or market share and could make us less competitive. Â We are highly dependent upon the principal members of our management team, including our Chief Executive Officer, Burke Barrett, our Chief CommercialÂ Officer, Kevin Danahy, and our Chief Technology Officer, Darrin Uecker, and members of ourÂ scientific and engineering teams. These persons have significant experience and knowledge with sub-microsecond pulsed electric fields and more broadly in life sciencesÂ and medical technologies. The loss of any team member could impair our ability to design, identify, and develop new intellectual property and new scientific or product ideas. The loss of a key employee, the failure of a key employee to perform in his or her current position, or our inability to attract and retain skilled employees could result in our inability to continue to grow our business or to implement our business strategy. We compete for qualified management and scientific personnel with other life science companies, academic institutions, and research institutions. Our employees could leave our Company with little or no prior notice. They are free to work for a competitor. If one or more of our senior executives or other key personnel were unable or unwilling to continue in their present positions, we may not be able to replace them easily or at all, and other senior management may be required to divert attention from other aspects of the business. In addition, we do not have â€œkey personâ€ life insurance policies covering any member of our management team or other key personnel. The loss of any of these individuals or any inability to attract or retain qualified personnel, including scientists, engineers, and others, could prevent us from pursuing collaborations and materially and adversely affect our product development and introductions, business growth prospects, results of operations, and financial condition. Â There is a limited talent pool of experienced professionals in our industry. If we are not able to retain and recruit personnel with the requisite technical skills, we may be unable to successfully execute our business strategy. Â The specialized nature of our industry results in an inherent scarcity of experienced personnel in the field. Our future success depends upon our ability to attract and retain highly skilled personnel, including scientific, technical, commercial, business, regulatory, and administrative personnel, necessary to support our anticipated growth, develop our business and perform certain contractual obligations. Given the scarcity of professionals with the scientific knowledge we require and the intense competition that exists for qualified personnel among life science businesses, we may not succeed in attracting or retaining the personnel we require to continue and grow our operations. Â We have very limited experience selling the CellFX System. Â Successfully commercializing medical devices such as ours is a complex and uncertain process. We began marketing and selling the CellFX System in the United States, Canada, and certain limited European markets in late 2021 to dermatologists through a limited direct sales force. In January 2022, we established an operating company in the Netherlands to further enhance our operations in Europe. However, in 2022 and 2023 we eliminated all of our full-time sales and marketing positions and, as of December 31, 2023, we had no U.S. or international sales force. We have only just recently begun to hire employees to help market and sell our CellFX nsPFA Percutaneous Electrode System.Â We therefore have limited experience marketing and selling the CellFX System and our revenues and cash flows have been volatile and difficult to predict. Â We intend to hire and train a very limited number of sales representatives and clinical specialists with backgrounds and experience in the relevant markets, especially those familiar with energy-based therapies and who have existing relationships with otolaryngologists, endocrine surgeons, interventional radiologists, and cardiothoracic surgeons. However, we expect that our sales force will require lead time in the field to grow their network of accounts and achieve the productivity levels we expect them to reach in any individual territory. Furthermore, the use of our product will often require or benefit from direct support from us. Â Our commercialization efforts depend on the efforts of our management and sales team, our third-party manufacturers and suppliers, physicians and medical clinics, and general economic conditions, among other factors, including the following: Â Â â— the effectiveness of our marketing and sales efforts in the United States and internationally; Â Â â— our success in educating surgeons and other physicians and patients about the benefits, administration and use of our products; Â Â â— the acceptance by physicians and patients of the safety and effectiveness of our products; Â Â â— the availability, perceived advantages, relative cost, relative safety, and relative efficacy of alternative and competing therapies; and Â Â â— our ability to achieve and maintain compliance with all regulatory requirements applicable to our products. Â While few in number, we expect our direct sales representatives to develop long-lasting relationships with the surgeons they serve. Our future success will depend largely on our ability to continue to hire, train, retain and motivate skilled direct sales representatives with significant technical knowledge in various areas, such as cardiology, minimally invasive surgery, and ablation technologies. New hires require training and take time to achieve full productivity. If we fail to train new hires adequately, or if we experience high turnover in our sales force in the future, we cannot be certain that new hires will become as productive as may be necessary to maintain or increase our sales. Also, if our direct sales representatives or third-party distributors fail to adequately promote, market and sell our products or decide to leave or cease to do business with us,

our sales could significantly decrease or grow at a rate too slow to become profitable. In addition, our future sales will largely depend on our ability to increase our marketing efforts and adequately address our customersâ€™ needs. If we are unable to adequately address our customersâ€™ needs, it could negatively impact sales and market acceptance of our products, and we may not generate sufficient revenue to become profitable. If we are unable to expand our sales and marketing capabilities domestically and internationally, we may not be able to effectively commercialize our products, which would adversely affect our business, results of operations, and financial condition. Â Rapidly changing technology in life sciences could make the products we are developing obsolete.Â Â Â The life sciences industries are characterized by rapid and significant technological changes, frequent new product introductions and enhancements, and evolving industry standards. Our future success will depend on our ability to continually develop and then improve the products that we design and to develop and introduce new products that address the evolving needs of our customers on a timely and cost-effective basis. Also, we will need to pursue new market opportunities that develop as a result of technological and scientific advances. These new market opportunities may be outside the scope of our proven expertise or in areas which have unproven market demand. Any new products developed by us may not be accepted in the intended markets. Our inability to gain market acceptance of new products could harm our future operating results. Â 32 Table of Contents Â If we are unable to manage the anticipated growth of our business, our future revenue and operating results may be harmed. Â From time to time, we have experienced rapid growth in our business. Recent and future growth imposes significant added responsibilities on management, including the need to identify, recruit, train, and integrate additional employees. Rapid expansion in personnel could mean that fewer experienced people carry out our research and development activities, manufacture, market, and sell CellFX Systems and NPS therapies and procedures, which could result in inefficiencies and unanticipated costs, reduced quality, and disruptions to our operations. In addition, rapid and significant growth may strain our administrative and operational infrastructure, and the failure to continue to upgrade our technical, administrative, operating, and financial control systems, or the occurrence of other unexpected expansion difficulties, could have a material adverse effect on our business, financial condition and results of operations, and our ability to timely execute our business plan. We may be unable to maintain the quality of, or delivery timelines of, our products or satisfy customer demand as it grows. Our ability to manage our growth properly will require us to continue to improve our operational, financial and management controls, as well as our reporting systems and procedures. We may implement new enterprise software systems in a number of areas affecting a broad range of business processes and functional areas. The time and resources required to implement these new systems is uncertain and failure to complete this in a timely and efficient manner could harm our business. We cannot guarantee that any of the personnel, systems, procedures, and controls we put in place will be adequate to support the manufacture and distribution of our products. If we are unable to manage our growth effectively, it may be difficult for us to execute our business strategy and our business could be harmed. Â We must successfully educate and train surgeons and their staff on the proper use of the CellFX System; if our customers do not adopt our technology into their medical practices, or adopt our technology slower than expected, our business could suffer. Â Although most surgeons may have adequate knowledge on how to use our novel CellFX System based on their clinical training and experience, we believe that the most effective way to introduce and build market demand for our products is by directly training surgeons and other physicians in the use of our products. Convincing them to dedicate the time and energy necessary for adequate training is challenging, and we cannot assure you that we will succeed in these efforts. If surgeons and other physicians are not properly trained, they may not use our products and, as a result, we may not maintain or grow our sales or achieve or sustain profitability. If surgeons and other physicians are not properly trained, they may also misuse or ineffectively use our products, which may result in unsatisfactory patient outcomes, patient injury, negative publicity, or lawsuits against us, any of which could have a significant adverse effect on our business, financial condition and results of operations. Â Additionally, our strategy includes educating key opinion leaders in the industry. If these key opinion leaders determine that alternative technologies are more effective or that the benefits offered by our products are not sufficient to justify their higher cost, or if we encounter difficulty promoting adoption or establishing these systems as a standard of care, our ability to achieve market acceptance of the products we introduce could be significantly limited and our business could suffer. Â We may encounter manufacturing problems or delays that could result in lost revenue or slower than anticipated product development. Additionally, we currently rely on third-party suppliers for critical components needed to manufacture the CellFX System and related applicators. Any problems experienced by these suppliers could result in a delay or interruption of their supply to us and, as a result, we may face delays in the development and commercialization of products. Â We currently rely upon third-party suppliers to manufacture and supply components for the CellFX System and for our products under development. We perform final assembly of our CellFX devices at our facility in California. The manufacture of the CellFX components in compliance with the FDAâ€™s regulations requires significant expertise and capital investment, including the development of advanced manufacturing techniques and process controls. Manufacturers of medical device products often encounter difficulties in production, including difficulties with production costs and yields, quality control, quality assurance testing, shortages of qualified personnel, as well as compliance with applicable regulations, both foreign and domestic. Â We do not control the manufacturing process of, and are completely dependent on, our contract manufacturing partners for compliance with applicable regulatory requirements, and if our contract manufacturers cannot successfully manufacture the components needed for our products and products under development in a manner that conforms to our specifications and these strict regulatory requirements, we may not be able to rely on their manufacturing facilities in the future. In addition, we have limited control over the ability of our contract manufacturers to maintain adequate quality control, quality assurance and qualified personnel. If the FDA or a comparable foreign regulatory authority finds these facilities inadequate for the manufacture of our components or if such facilities are subject to enforcement action in the future or are otherwise inadequate with respect to complying with applicable regulatory requirements, we may need to find alternative manufacturing facilities, which would significantly impact our ability to develop and market our product or to obtain regulatory approval or clearance for our product candidates. Â We currently purchase components for our productsÂ under purchase orders and do not have long-term contracts with most of the suppliers of these materials. If suppliers were to delay or stop producing our components, or if the prices they charge us were to increase significantly, or if they elected not to sell to us, we would need to identify other suppliers and we may not be able to secure alternative suppliers on favorable terms, or at all. Any failure of these suppliers to perform satisfactorily could adversely impact our business and results of operations and we may experience delays in manufacturing of our devices while finding another acceptable supplier. Â 33 Table of Contents Â We may not become commercially viable if our ultimate commercialized products or related treatments fail to obtain an adequate level of reimbursement by Medicare and other third-party payers. Â We believe that the commercial viability of the CellFX System and any potential devices and products and related treatments, and therefore our commercial success as a company, may be affected by the availability of government reimbursement and medical insurance coverage and reimbursement for newly approved medical therapies, technologies, and devices. Insurance coverage and reimbursement are not assured. It typically takes a period of use in the marketplace before coverage and reimbursement are granted, if it is granted at all. In the United States and in many other jurisdictions, surgeons and other physicians and other healthcare providers generally rely on insurance coverage and reimbursement for their revenues, therefore this is an important factor in the overall commercialization plans of a proposed product and whether it will be accepted for use in the marketplace. Without insurance coverage and reimbursement for our planned products, we would expect to earn only diminished revenues, if any revenues are earned. Â Medicare, Medicaid, health maintenance organizations, and other third-party payers are increasingly attempting to contain healthcare costs by limiting both the scope of coverage and the level of reimbursement of new medical technologies and products. As a result, they may not cover or provide adequate payment for the use of the CellFX System or planned products in development. In order to obtain satisfactory reimbursement arrangements, we may have to agree to reduce our fee or sales price below what we currently expect to charge customers, which could adversely affect our profit margins. Moreover, each plan may separately require us to provide scientific and clinical support for the use of our products and, as a result, the coverage determination process is often a time-consuming and costly process with no assurance that coverage and adequate reimbursement will be applied consistently or obtained at all. Even if Medicare and other third-party payers decide to cover procedures involving the CellFX System and our proposed devices and products, we cannot be certain that the reimbursement levels will be adequate. Accordingly, even if these products are approved for commercial sale, unless government and other third-party payers provide adequate coverage and reimbursement for our devices and products, some surgeons and other physicians may be discouraged from using them, and our sales would suffer. Â Medicare reimburses for medical technologies and products in a variety of ways, depending on where and how the item is used. However, Medicare only provides reimbursement if CMS determines that the item should be covered and that the use of the device or product is consistent with the coverage criteria. A coverage determination can be made at the local level by the Medicare administrative contractor, a private contractor that processes and pays claims on behalf of CMS for the geographic area where the services were rendered, or at the national level by CMS through a national coverage determination. There are statutory provisions intended to facilitate coverage determinations for new technologies, but it is unclear how these provisionsÂ might apply to the CellFX System or to any of our proposed devices and products, as they are still largely in the development stages. Coverage presupposes that the technology, device, or product has been cleared or approved by the FDA and further, that the coverage will be consistent with the approved intended uses of the device or product as approved or cleared by the FDA, but coverage can be narrower. A coverage determination may be so limited that relatively few patients will qualify for a covered use of a device or product. Â Obtaining a coverage determination, whether local or national, is a time-consuming, expensive and highly uncertain proposition, especially for a new technology, and inconsistent local determinations are possible. On average, Medicare coverage determinations for medical devices and products lag behind FDA approval or clearance. The Medicare statutory framework is also subject to administrative rulings, interpretations and discretion that affect the amount and timing of reimbursement made under Medicare. Medicaid coverage determinations and reimbursement levels are determined on a state-by-state basis, because Medicaid, unlike Medicare, is administered by the states under a state plan filed with the Secretary of the U.S. Department of Health and Human Services (â€œHHSâ€). Medicaid generally reimburses at lower levels than Medicare. Moreover, Medicaid programs and private insurers are frequently influenced by Medicare coverage determinations. Â Our ability to utilize our net operating loss carryforwards and certain other tax attributes may be limited. Â We have incurred net losses since our inception and anticipate that we may continue to incur significant losses for the foreseeable future. If not utilized, some of our federal and state net operating losses (â€œNOLsâ€) carryforwards will begin to expire in various years beginning after 2034. Under the Internal Revenue Code of 1986, as amended, or the Code, and certain similar state tax provisions, we are generally allowed to carry forward our NOLs from a prior taxable year to offset our future taxable income, if any, until such NOLs are used or expire, subject to certain limitations. The same is true of other unused tax attributes, such as tax credits. Â In addition, under Section 382 of the Code, a corporation that undergoes an â€œownership changeâ€ is subject to limitations on its ability to utilize its pre-change NOLs to offset future taxable income. We believe that we have had one or more ownership changes, and, as a result, a portion of our existing NOLs may be subject to limitation. Future changes in our stock ownership could result in additional limitations. We may not be able to utilize a material portion of our NOLs even if we attain profitability. Â We have a substantial amount of goodwill and intangible assets which over time may have to be written down as we make the required periodic assessments as to their value as reflected in our financial statements.Â Â Â A significant portion of our total assets are comprised of goodwill and intangibles that arose from our 2014 business acquisitions. We review goodwill for impairment at least annually or whenever changes in circumstances indicate that the carrying value of the goodwill may not be recoverable. We also review our intangible assets for impairment at each fiscal year end or when events or changes in circumstances indicate the carrying value of these assets may exceed their current fair values. If we take an impairment charge for either goodwill or intangible assets, the overall assets will be reduced. Such an impairment charge may result in a change in the perceived value of the Company and ultimately may be reflected as a reduction in the market price of our securities. Additionally, an impairment charge may also adversely influence our ability to raise capital in the future. Â 34 Table of Contents Â Risks Related to Product Development and Product-Related Risks Â Our CellFX System and any future product candidates may cause serious adverse side effects or have other properties that could delay or prevent their regulatory approval, limit their commercial desirability or result in significant negative consequences. Â The risk of failure of clinical development is high. For example, the vast majority of our in vivo data has been a result of animal testing outside of cardiac animal models, and we have only completed a limited number of feasibility studies in humans. Undesirable side effects caused by the CellFX System, NPS pulses, or any of our planned future products could cause us, any partners of ours, or regulatory authorities to interrupt, delay or halt clinical trials or to revoke previously granted regulatory approvals. Undesirable side effects could also result in more restrictive labeling requirements or the delay or denial of regulatory approval of planned future products by the FDA or other comparable foreign regulatory authority.Â Â Additionally, if we or others identify undesirable side effects caused by the CellFX System, a number of potentially significant negative consequences could result, including: Â Â â— we may be forced to recall such product and suspend the marketing of such product; Â Â â— regulatory authorities may withdraw their approvals of such product; Â Â â— regulatory authorities may require additional warnings on the label and/or narrow the indication of use for the product which could diminish the usage or otherwise limit the commercial success of such product; Â Â â— the FDA or other regulatory authorities may issue safety alerts, â€œDear Healthcare Providerâ€Â letters, press releases, or other communications containing warnings about such product; Â Â â— the FDA may restrict distribution of our product and impose burdensome implementation requirements on us; Â Â â— we may be required to change the way the product is administered or conduct additional clinical trials; Â Â â— we could be sued and held liable for harm caused to subjects or patients; and Â Â â— our reputation could suffer. Â Any of these events could prevent us from achieving or maintaining market acceptance of the CellFX System or of any future particular planned product, if approved. Â Clinical development involves a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results. Â Clinical testing is expensive and can take many years to complete, and its outcome is inherently uncertain. Failure or delay can occur at any time during the clinical trial process. For example, success in nonclinical studies and early feasibility clinical studies does not ensure that the expanded clinical trials needed to support regulatory submissions will be successful. Setbacks can be caused by, among other things, nonclinical findings made while clinical trials are underway, safety or efficacy observations made in clinical trials, including previously unreported adverse events, or post-approval observations. Even if our clinical trials are completed, the results may not be sufficient to obtain regulatory approval or clearance for our product candidates or to expand the existing approvals or clearances for our existing products. To date, we have had only preclinical experience using NPS technology in animal models of cardiac disease and very limited clinical experience treating AF with our CellFX nsPFA 360Â° Cardiac Catheter; our past successes in dermatology may not translate into similar results in cardiology. In particular, the safety and efficacy data we have generated using NPS technology and the CellFX System to treatÂ benign lesions in the skin and the preliminary feasibility results we have seen in benign thyroid nodules might not be replicated in other areas of medicine, including the use of CellFX nsPFAÂ technology and the CellFX System to treat AF or other cardiac disease. Â 35 Table of Contents Â Our long-term growth depends on our ability to develop marketable products to treat AF, tumors and nodules through our research and development efforts, and if we fail to do so we may be unable to compete effectively or we may decide to scale back or eliminate some or all of our activities or otherwise curtail, suspend or discontinue our operations entirely. Â The medical device industry is characterized by intense competition, rapid technological changes, new product introductions and enhancements, and evolving industry standards. Our business prospects depend in part on our ability to develop new products and applications for our NPS technology, including in new markets that develop as a result of technological and scientific advances. New technologies, techniques or products could emerge that might offer better combinations of price and performance than our products. It is important that we anticipate changes in technology and market demand, as well as physician, hospital, and healthcare provider practices to successfully develop, obtain clearance or approval, if required, and successfully introduce new, enhanced and competitive technologies to meet our prospective customersâ€™ needs on a timely and cost-effective basis. Â If we do not develop and obtain regulatory clearances or approvals for new products or product enhancements in time to meet market demand, or if there is insufficient demand for these products or enhancements, our results of operations will suffer. Our research and development efforts may require a substantial investment of time and resources before we are adequately able to determine the commercial viability of a new product, technology, material, or other innovation. In addition, even if we are able to develop enhancements or new generations of our products successfully, these enhancements or new generations of products may not produce sales in excess of the costs of development and they may be quickly rendered obsolete by changing customer preferences or the introduction by our competitors of products embodying new technologies or features. Â Moreover, if our technology cannot be used to successfully treat AF, we may decide to, among other things, delay, scale back or eliminate some or all of our activities, reduce headcount, trim research and product development programs, discontinue clinical trials, stop all or some of our manufacturing operations, defer capital expenditures, deregister from being a publicly traded company and delist from Nasdaq, or license our potential products or technologies to third parties, possibly on terms that cannot sustain our current business, or curtail, suspend or discontinue our operations entirely. Â InterimÂ â€œtop-lineâ€Â and preliminary results from our clinical trials that we announce or publish from

time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data. Â From time to time, we may publish interim top-line or preliminary results from our clinical trials. Interim results from clinical trials that we may announce are subject to the risk that one or more of the clinical outcomes may materially change as more follow-up data are gathered, patient enrollment continues and more patient data become available. Preliminary or top-line results, including our preliminary data from our feasibility thyroid nodule study and our first-in-human cardiac catheter study, also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously published or announced. As a result, interim and preliminary data should be viewed with caution until the final data are available. Differences between preliminary or interim data and final data could significantly harm our business prospects and may cause the trading price of our common stock to fluctuate significantly. Â If we fail to maintain necessary regulatory clearance for our products, or if clearances or approvals for future devices and indications are delayed or not issued, the commercial prospects for our CellFX System and other NPS technologies would be harmed. Â Our product candidates under development are medical devices that are subject to extensive regulation by the FDA in the United States and by regulatory agencies in other countries where we do business. Government regulations specific to medical devices are wide-ranging and govern, among other things: Â Â â— device design, development and manufacture; Â Â â— laboratory, preclinical and clinical testing, labeling, packaging, and storage; Â Â â— premarketing clearance or approval; Â Â â— record keeping; Â Â â— device marketing, promotion and advertising, sales and distribution; and Â Â â— post-marketing surveillance, including reporting of deaths and serious injuries and recalls and correction and removals. Â Before a new medical device, or a new intended use for an existing device, can be marketed in the United States, the deviceâ€™s manufacturer must first submit and receive either 510(k) clearance or Premarket Approval (â€œPMAâ€) from the FDA, unless an exemption applies. In the 510(k)-clearance process, the FDA will determine that a proposed device is â€œsubstantially equivalentâ€ to a device legally on the market, known as a â€œpredicateâ€ device, with respect to intended use, technology and safety and effectiveness, in order to clear the proposed device for marketing. Clinical data is sometimes required to support substantial equivalence. The PMA pathway requires an applicant to demonstrate reasonable safety and effectiveness of the device based on extensive data, including, but not limited to, technical, preclinical, clinical trial, manufacturing, and labeling data. The PMA process is typically required for devices that are deemed to pose the greatest risk, such as life-sustaining, life-supporting, or implantable devices. Products that are approved through a PMA application generally need FDA approval before they can be modified. Similarly, some modifications made to products cleared through a 510(k) may require a new 510(k). Either process can be expensive, lengthy and unpredictable.Â Â 36 Table of Contents Â The FDA may not approve or clear our 510(k), de novo, or PMA applications on a timely basis or at all. Such delays or refusals could have a material adverse effect on our business operations and financial condition. The FDA may also change its clearance and approval policies, adopt additional regulations or revise existing regulations, or take other action which may prevent or delay approval or clearance of our products under development. Any of these actions could have a material adverse effect on our business operations and financial condition. Â The FDA and the U.S. Federal Trade Commission (â€œFTCâ€) also regulate the advertising and promotion of our devices to ensure that the claims we make are consistent with our regulatory clearances or approvals, that there are adequate and reasonable data to substantiate the claims and that our promotional labeling and advertising is neither false nor misleading in any respect. If the FDA or the FTC determines that any of our advertising or promotional claims are misleading, not substantiated or not permissible, we may be subject to enforcement actions, including FDA warning letters, and we may be required to revise our promotional claims and make other corrections or restitutions. Â FDA and state authorities have broad enforcement powers. Our failure to comply with applicable regulatory requirements could result in enforcement action by the FDA or state agencies, which may include any of the following sanctions, among others: Â Â â— adverse publicity, warning letters, fines, injunctions, consent decrees, and civil penalties; Â Â â— obligations to repair, replace, refund, or recall our marketed devices, or government seizure of them; Â Â â— operating restrictions, partial suspension, or total shutdown of production; Â Â â— refusing our requests for 510(k) clearance or premarket approval of new devices, new intended uses or modifications to existing devices; Â Â â— withdrawing 510(k) clearance or premarket approvals that have already been granted; and Â Â â— criminal prosecution. Â If any of these events were to occur, our business and financial condition would be harmed. Â The mechanism of action of NPS technology platform has not been fully determined or validated. Â The exact mechanism(s) of action(s) of ourÂ NPS technology platform, including nano-PFA, is not fully understood, and data are still being gathered regarding its use. Furthermore, there are only a relatively small number of scientists and researchers who can be considered experts in the use of this emerging technology. Insofar as potential regulators, partners or investors value a clear understanding of a technologyâ€™s mechanism of action, this limitation could make it more challenging for us to obtain requisite regulatory approvals, investments or a partnership on favorable terms as a result. Â We may find it difficult to enroll patients in our clinical trials. If we cannot enroll a sufficient number of eligible patients to participate in our clinical trials, we may not be able to initiate or continue them, which could delay or prevent development of our product candidates. Â Identifying and qualifying patients to participate in clinical trials of our product candidates is critical to our success. The timing of our clinical trials depends on the speed at which we can recruit patients to participate in testing our product candidates as well as completion of required follow-up periods. In general, if patients are unwilling to participate in our trials because of negative publicity from adverse events in the health care industry or for other reasons, including competitive clinical trials for similar patient populations, the timeline for recruiting patients, conducting trials and obtaining regulatory approval or clearance of planned products may be delayed. If there are delays in accumulating the required patients and patient data, there may be delays in completing the trial. Further, if any of our clinical trial sites fail to comply with required good clinical practices, we may be unable to use the data gathered at those sites. Also, if our clinical investigators fail to carry out their contractual duties or regulatory obligations or fail to meet expected deadlines, or if the quality or accuracy of the clinical data they obtain is compromised due to their failure to adhere to our clinical protocols or for other reasons, our clinical trials may be delayed, suspended, or terminated. These delays could result in increased costs, delays in advancing our product development, delays in testing the effectiveness of our technology or termination of the clinical trials altogether, and delays in obtaining regulatory authorization for our products. Â Laboratory conditions differ from commercial conditions and field conditions, and the safety and effectiveness of our product candidates may depend on the technique of the user. Â Observations and developments that may be achievable under laboratory circumstances may not be able to be replicated in broader research and development phases, in commercial settings, or in the use of any of any product or product candidates in the field. Furthermore, our NPS technologies will be administered by healthcare professionals and will require a degree of training and practice to administer correctly. Treatment results achieved in the laboratory or in clinical trials conducted by us or by other investigators may not be representative of the results actually encountered during commercial use of our products due to variability in administration technique. The training and skills of investigators in our clinical trials may not be representative of the training and skills of future product users, which could negatively affect treatment results and the reputation of the Company or its products. In addition, there may be a selection bias in the patients and/or sites of administration chosen for any clinical trials that would positively affect treatment results that may not be representative or predictive of real-world experience with our products, including the CellFX System. Â Issues with our firmware and software may negatively affect the function of our devices. Â The safety and effectiveness of CellFX procedures and therapies may depend, in part, on the function of firmware run by the microprocessors embedded in the device and associated software. This firmware and software is proprietary to us. While we have made efforts to test the firmware and software extensively, both are potentially subject to malfunction which in turn may harm patients. Further, our proprietary firmware and software may be vulnerable to physical break-ins, hackers, improper employee or contractor access, computer viruses, programming errors, data breaches, or similar problems. Any of these might result in harm to patients or the unauthorized release of confidential medical, business or other information belonging to us or to other persons. Â 37 Table of Contents Â Risks Related to Intellectual Property, Cybersecurity,Â Data Privacy, & Litigation Â If we are unable to protect our intellectual property, then our financial condition, results of operations and the value of our technology and products could be adversely affected. Â Patents and other proprietary rights are essential to our business and our ability to compete effectively with other companies is dependent upon the proprietary nature of our technologies. Similarly, our future success partnering our NPS technologies, including our CellFX System, will depend greatly on the perceived strength and reach of the patents protecting those technologies against unlicensed competitors. We also rely upon trade secrets, know-how, continuing technological innovations, and licensing opportunities to develop, maintain and strengthen our competitive position. We seek to protect these, in part, through confidentiality agreements with certain employees, consultants and other parties. Our success will depend in part on the ability of our licensors and us to obtain, to maintain (including making periodic filings and payments) and to enforce patent protection for the licensed intellectual property, in particular, those patents to which we have secured rights. We may not successfully prosecute or continue to prosecute the patent applications which we have licensed. Even if patents are issued in respect of these patent applications, we may fail to maintain these patents or may determine not to pursue litigation against entities that are infringing upon these patents. Without adequate protection for the intellectual property that we own or license, other companies might be able to offer substantially identical products for sale, which could unfavorably affect our competitive business position and harm our business prospects. Even if issued, patents may be challenged, invalidated, or circumvented, which could limit our ability to stop competitors from marketing similar products or limit the length of term of patent protection that we may have for our products.Â Â Litigation or third-party claims of intellectual property infringement or challenges to the validity of our patents would require us to use resources to protect our technology and may prevent or delay our development, regulatory approval or commercialization of our product candidates. Â If we are the target of claims by any third party asserting that our products or intellectual property infringe upon the rights of others, we may be forced to incur substantial expenses or divert substantial employee resources from our business. If successful, such claims could result in our having to pay substantial damages or could prevent us from developing one or more products or product candidates. Further, if a patent infringement suit were brought against us or our collaborators, we or they could be forced to stop or delay research, development, manufacturing, or sales of the product or product candidate that is the subject of the suit. Â If we, or our collaborators, experience patent infringement claims, or if we elect to avoid potential claims others may be able to assert, we or our collaborators may choose to seek, or be required to seek, a license from the third party and would most likely be required to pay license fees or royalties or both. These licenses may not be available on acceptable terms, or at all. Even if we or our collaborators were able to obtain a license, the rights may be nonexclusive, which would give our competitors access to the same intellectual property. Ultimately, we could be prevented from commercializing a product, or be forced to cease some aspect of our business operations if, as a result of actual or threatened patent infringement claims, we or our collaborators are unable to enter into licenses on acceptable terms. This could harm our business significantly. The cost to us of any litigation or other proceeding, regardless of its merit, even if resolved in our favor, could be substantial. Some of our competitors may be able to bear the costs of such litigation or proceedings more effectively than we can because of their having greater financial resources. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could have a material adverse effect on our ability to compete in the marketplace. Intellectual property litigation and other proceedings may, regardless of their merit, also absorb significant management time and employee resources. Â Our intellectual property rights will not necessarily provide us with competitive advantages. Â The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations, and may not adequately protect our business, or permit us or our future commercial partners to maintain a competitive advantage. The following examples are illustrative: Â Â â— others may be able to make products that are similar to our product candidates but that are not covered by the claims of the patents that we own or have exclusively licensed; Â Â â— others may independently develop similar or alternative technologies without infringing on our intellectual property rights; Â Â â— issued patents that we own or have exclusively licensed may not provide us with any competitive advantages, or may be held invalid or unenforceable, as a result of legal challenges by our competitors; Â Â â— we may obtain patents for certain products many years before we obtain marketing approval for products utilizing such patents, and because patents have a limited life, which may begin to run prior to the commercial sale of the related product, the commercial value of our patents may be limited; Â Â â— our competitors might conduct research and development activities in countries where we do not have patent rights and then use the information learned from such activities to develop competitive products for sale in our major commercial markets; Â Â â— we may fail to develop additional proprietary technologies that are patentable; Â Â â— the laws of certain foreign countries may not protect our intellectual property rights to the same extent as the laws of the United States, or we may fail to apply for or obtain adequate intellectual property protection in all the jurisdictions in which we operate; and Â Â â— the patents of others may have an adverse effect on our business, for example by preventing us from marketing one or more of our product candidates for one or more indications. Â Any of the aforementioned threats to our competitive advantage could harm our business. Â 38 Table of Contents Â If we are unable to protect the confidentiality of our proprietary information and know-how, the value of our technology and products could be adversely affected. Â In addition to patented technology, we rely upon, among other things, unpatented proprietary technology, processes, trade secrets, and know-how. Any involuntary disclosure to, or misappropriation by, third parties of our confidential or proprietary information could enable competitors to duplicate or surpass our technological achievements, potentially eroding our competitive position in our market. We seek to protect confidential and proprietary information in part by confidentiality agreements with our employees, consultants and third parties. While we require, as a matter of company policy, that all of our employees, consultants, advisors, and any third parties who have access to our proprietary know-how, information or technology to enter into confidentiality agreements, we cannot be certain that this know-how, information and technology will not be improperly disclosed or that competitors will not otherwise gain access to our trade secrets or independently develop substantially equivalent information and techniques. These confidentiality agreements may be terminated or breached, and we may not have adequate remedies for any such termination or breach. Furthermore, these agreements may not provide meaningful protection for our trade secrets and know-how in the event of unauthorized use or disclosure. Â If we are unable to protect the intellectual property used in our products, others may be able to copy our innovations which may impair our ability to compete effectively in our markets. Â Evaluating the strength and enforceability of our patents involves complex legal and scientific questions and can be uncertain. Both our patents and patent applications can be challenged by third parties and our patent applications may fail to result in issued patents. Moreover, both our existing and future patents may be too narrow to prevent third parties from developing or designing around our intellectual property and, in that event, we may lose competitive advantage and our business may suffer. Â We may not be able to protect our intellectual property rights throughout the world. Â Filing, prosecuting and defending patents on product candidates in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the United States can be less extensive than those in the United States. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the United States. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States, or from selling or importing products made using our inventions in and into the United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and further, may export otherwise infringing products to territories where we have patent protection, but enforcement is not as strong as that in the United States. These products may compete with our current or future product candidates, if any, and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing. Â If our information technology systems or data, or those of third parties upon whom we rely, are or were compromised, we could experience adverse consequences resulting from such compromise, including, but not limited to, regulatory investigations and actions; litigation (including class claims); fines and penalties; a disruption of our business operations such as our clinical trials; reputational harm; loss of revenue and profits; and other adverse consequences. Â We depend on our information technology systems for the efficient functioning of our business, including the manufacture, distribution and maintenance of our products, as well as for accounting, data storage, compliance, purchasing, inventory management, and other related functions. We do not have redundant information technology in all aspects of our systems at this time. Despite the implementation of security and back-up measures, our information technology systems as well as those of our third-party partners, consultants, contractors, suppliers, and service providers, may be vulnerable to attack, damage and interruption from physical or electronic break-ins, accidental or intentional exposure of our data by employees or others with authorized access to our networks, computer viruses, malware, ransomware, malicious code, phishing attacks and other social engineering schemes, denial or degradation of service attacks, attacks by sophisticated nation-state and nation-state-supported actors, supply chain attacks, natural disasters, terrorism, war, telecommunication and electrical failure, denial of service, and other cyberattacks or disruptive incidents that could result in unauthorized access to, use or disclosure of, corruption of, or loss of sensitive, and/or proprietary data, including health-related and other personal information. Â In the ordinary course of our business, we (and third parties upon whom we rely) may collect, receive, store, use, transfer, make accessible, protect, secure, dispose of, transmit, disclose or otherwise process proprietary, confidential and sensitive information, including personal data, such as health-related data and participant study related data, intellectual property,

and trade secrets (collectively, â€œsensitive dataâ€).Â We may share or receive sensitive data with or from third parties whose information security measures may not be adequate. In particular, the COVID-19 pandemic has caused us to modify our information technology practices including that our employees may work remotely which increases the risk of data breaches. Additionally, the prevalent use of mobile devices that access our sensitive data increases the risk of data breaches. Â While we do not believe that we have experienced any significant system failure, accident or security breach to date, if such an event were to occur and cause interruptions in our operations, it could result in a material disruption of our business operations, whether due to a loss, corruption or unauthorized disclosure of our trade secrets, personal information or other proprietary or sensitive information or other similar disruptions. The costs to us to attempt to protect against such breaches can be significant and could potentially require us to modify our business, including non-clinical and clinical trial activities. While we have implemented security measures designed to protect our information technology systems and to identify and remediate potential vulnerabilities, such measures may not be successful. We may not be able to detect vulnerabilities in our information technology systems because such threats and techniques used by threat actors change frequently are sophisticated in nature and may not be detected until after a security incident has occurred. Â If we, or others upon whom we rely, experience or are perceived to have experienced a breach, we may experience adverse consequences. These consequences may include: government enforcement actions (for example, investigations, fines, penalties, audits and inspections), interruptions in our operations (including disruptions to our clinical trials), interruptions or restrictions on processing sensitive data (which could result in delays in obtaining, or our inability to obtain, regulatory approvals and significantly increase our costs to recover or reproduce the sensitive data), unauthorized, unlawful or accidental loss, corruption, access, modification, destruction, alteration, acquisition or disclosure of sensitive data, such as clinical trial data, reputational harm, litigation (including class-action claims), indemnification obligations, monetary fund diversions, financial loss and other harms. In particular, ransomware attacks are becoming increasingly prevalent and severe and can lead to significant disruptions to operations, loss of data and income, reputational harm and diversion of funds. Additionally, theft of our intellectual property or proprietary business information could require substantial expenditures to remedy. Such theft could also lead to loss of intellectual property rights through disclosure of our proprietary business information, and such loss may not be capable of remedying. In addition, such a breach may require notification of the breach to relevant stakeholders. Such disclosures are costly and the disclosure or the failure to comply with such requirements could lead to adverse consequences.Â We maintain cyber liability insurance; however, this insurance may not be sufficient to cover the financial, legal, business or reputational losses that may result from an interruption or breach of our systems. Â 39 Table of Contents Â Product liability lawsuits against us could cause us to incur substantial liabilities and limit commercialization of our product or any future products that we may develop. Â We face an inherent risk of product liability exposure related to the sale of our product and the future sale of planned products and the use of these in human clinical studies. For example, we may be sued if our product or any of our product candidates, including any that are developed in combination therapies, allegedly causes injury, or is found to be otherwise unsuitable during product testing, manufacturing, marketing, or sale. Any such product liability claims may include allegations of defects in manufacturing, defects in design, a failure to warn of dangers inherent in the product, negligence, strict liability, or a breach of warranties. We may also be subject to liability for a misunderstanding of, or inappropriate reliance upon, the information we provide. If we cannot successfully defend ourselves against claims that our product or planned products caused injuries, we may incur substantial liabilities. Regardless of merit or eventual outcome, liability claims may result in, among other things: Â Â â— decreased demand for our product or any planned products that we may develop; Â Â â— injury to our reputation and significant negative media attention; Â Â â— withdrawal of patients from our clinical studies or cancellation of studies; Â Â â— significant costs to defend the related litigation and distraction to our management team; Â Â â— substantial monetary awards to patients; Â Â â— loss of revenue; Â Â â— government investigations or enforcement actions; and Â Â â— the inability to commercialize any future products that we may develop. Â For example, during the course of treatment, patients may suffer adverse events for reasons that may or may not be related to the CellFX System or our NPS technology. Such events could subject us to costly litigation, require us to pay substantial amounts of money to injured patients, delay, negatively impact, or end our opportunity to receive or maintain regulatory approval to market those products, or require us to suspend or abandon our commercialization efforts. Even in a circumstance in which we do not believe that an adverse event is related to our product, the investigation into the circumstance may be time consuming or inconclusive. These investigations may interrupt our sales efforts, delay our regulatory approval processes, or impact and limit the type of regulatory approvals our products could receive or maintain. As a result of these factors, a product liability claim, even if successfully defended, could harm our business. Â We currently maintain product liability insurance coverage,Â which may not be adequate to cover all liabilities that we may incur. Insurance coverage is increasingly expensive. We may not be able to maintain insurance coverage at a reasonable cost or in an amount adequate to satisfy any liability that may arise. Â 40 Table of Contents Â Risks Related to Government Regulation Â We are subject to stringent domestic and foreign regulation. Any unfavorable regulatory action or adverse change in law may materially and adversely affect our future financial condition and business operations and prospects. Â The CellFX System and any other potential devices and products we develop are, and will continue to be, subject to extensive, rigorous, and ongoing regulation by numerous government agencies, including the FDA and similar foreign regulatory authorities. To varying degrees, each of these agencies monitors and enforces our compliance with laws and regulations governing the development, testing, manufacturing, labeling, marketing, distribution, and the safety and effectiveness of our medical technology. The process of obtaining and maintaining marketing approval or clearance from the FDA and similar foreign regulatory authorities for new devices and products, or for enhancements, expansion of the indications or modifications to existing products, could: Â Â â— take a significant indeterminate amount of time; Â Â â— require the expenditure of substantial resources; Â Â â— involve rigorous preclinical and clinical testing, and possibly post-market surveillance; Â Â â— involve modifications, repairs or replacements of our products; Â Â â— require design changes of our products; Â Â â— result in limitations on the indicated uses of our products; and Â Â â— result in our never being granted the regulatory approval or clearance we seek. Â If we experience any of these occurrences, our operations may suffer and we might experience harm to our competitive standing, which could adversely affect our financial condition. Â We are subject to, and will have ongoing responsibilities under, FDA and international regulations, both before and after a product is approved or cleared and commercially released. Compliance with applicable regulatory requirements is subject to continual review and is monitored rigorously through periodic inspections. If an inspection were to conclude that we are not in compliance with applicable laws or regulations, or that any of our devices are ineffective or pose an unreasonable health risk, the FDA or similar foreign regulatory authorities could ban such devices or products, detain or seize such devices or products, order a recall, repair, replacement, or refund of such devices or products, or require us to notify health professionals and others that the therapies, devices or products present unreasonable risks of substantial harm to the public health. Additionally, the FDA or similar foreign regulatory authorities may impose other operating restrictions, enjoin and restrain certain violations of applicable law pertaining to our devices and products or assess civil or criminal penalties against our officers, employees, or us. The FDA and similar foreign regulatory authorities have been increasing their scrutiny of the industry and governments are expected to continue to scrutinize the industry closely with inspections and possibly enforcement actions. Any adverse regulatory action, depending on its magnitude, may restrict us from effectively manufacturing, marketing and selling our devices and products, including the CellFX System. In addition, negative publicity and product liability claims resulting from any adverse regulatory action could have a material adverse effect on our financial condition and results of operations. Â U.S. Healthcare Reform Â Changes in healthcare policy could increase our costs and subject us to additional regulatory requirements that may interrupt commercialization of our current and future solutions. Changes in healthcare policy could increase our costs, decrease our revenues, and impact sales of and reimbursement for our current and future solutions. The Affordable Care Act substantially changes the way healthcare is financed by both governmental and private insurers, and significantly impacts our industry. The Affordance Care Act contains a number of provisions that impact our business and operations, some of which in ways we cannot currently predict, including those governing enrollments in federal healthcare programs and reimbursement changes. Â There will continue to be proposals by legislators at both the federal and state levels, regulators, and third-party payors to reduce costs while expanding individual healthcare benefits. Certain of these changes could impose additional limitations on the prices we will be able to charge for our current and future solutions or the amounts of reimbursement available for our current and future solutions from governmental agencies or third-party payors. While in general it is too early to predict specifically what effect the Affordable Care Act and its implementation or any future healthcare reform legislation or policies will have on our business, current and future healthcare reform legislation and policies could have a material adverse effect on our business and financial condition. Â All our product development depends upon maintaining strong working relationships with physicians. Â The development, marketing, and sale ofÂ any future products in developmentÂ depends upon our ability to maintain strong working relationships with physicians. We rely on these professionals to provide us with considerable knowledge and experience regarding the development, marketing, and sale of our products. Physicians assist us in clinical trials and as researchers, marketing and product consultants and public speakers. If we cannot maintain our strong working relationships with these professionals and continue to receive their advice and input, the development and marketing of our products could suffer, which could harm our business, financial condition and results of operations. The medical device industryâ€™s relationship with physicians is under increasing scrutiny by the Office of Inspector General (â€œOIGâ€), the Department of Justice (â€œDOJâ€), state attorneys general, and other foreign and domestic government agencies. Our failure to comply with laws, rules and regulations governing our relationships with physicians, or an investigation into our compliance by the OIG, DOJ, state attorneys general, and other government agencies, could significantly harm our business, including compromising the use or integrity of our clinical data in regulatory submissions to the FDA or similar regulatory authorities. Â 41 Table of Contents Â We are subject to healthcare and other laws and regulations relating to our business and could face substantial penalties if we are determined not to have fully complied with such laws, which could have an adverse impact on our business. Â We are exposed to the risk that our employees and independent contractors, including principal investigators, consultants, any commercial collaborators, service providers and other vendors may engage in misconduct or other illegal activity. Misconduct by these parties could include intentional, reckless and/or negligent conduct or other unauthorized activities that violate applicable laws or regulations. There are many federal and state laws and regulations prohibiting fraud and abuse in the healthcare industry that can result in significant criminal and civil penalties. These laws may constrain the business or financial arrangements and relationships through which we conduct our operations, including how we research, market, sell, and distribute our products for which we obtain marketing approval or clearance. Â We are exposed to the risk that our employees and independent contractors, including principal investigators, consultants, any commercial collaborators, service providers and other vendors may engage in misconduct or other illegal activity. Misconduct by these parties could include intentional, reckless and/or negligent conduct or other unauthorized activities that violate applicable laws or regulations. There are many federal and state laws and regulations prohibiting fraud and abuse in the healthcare industry that can result in significant criminal and civil penalties. These laws may constrain the business or financial arrangements and relationships through which we conduct our operations, including how we research, market, sell, and distribute our products for which we obtain marketing approval or clearance. Such laws include: Â Â â— U.S. federal Anti-Kickback Statute, which prohibits, among other things, persons and entities from knowingly and willfully soliciting, offering, receiving, or providing remuneration, directly or indirectly, in cash or in kind, to induce or reward, or in return for, either the referral of an individual for, or the purchase, order or recommendation of, any good or service, for which payment may be made under a federal healthcare program, such as Medicare and Medicaid. The term â€œremunerationâ€Â has been broadly interpreted to include anything of value, and the government can find a violation of the Anti-Kickback Statute without proving that a person or entity had actual knowledge of the law or a specific intent to violate it. In addition, the government may assert that a claim including items or services resulting from a violation of the U.S. federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the civil False Claims Act; Â Â â— U.S. federal civil and criminal false claims laws and civil monetary penalties laws, including the civil False Claims Act, which, among other things, impose criminal and civil penalties, including through civil whistleblower or qui tam actions, against individuals or entities for knowingly presenting, or causing to be presented, to the U.S. government, claims for payment or approval that are false or fraudulent, knowingly making, using or causing to be made or used, a false record or statement material to a false or fraudulent claim, or from knowingly making a false statement to avoid, decrease or conceal an obligation to pay money to the U.S. government; Â Â â— HIPAA imposes criminal and civil liability for, among other things, knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, or knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false statement, in connection with the delivery of, or payment for, healthcare benefits, items or services. A person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation; Â Â â— HIPAA, as amended by HITECH, and its implementing regulations, also imposes obligations, including mandatory contractual terms, with respect to safeguarding the privacy, security and transmission of individually identifiable health information without appropriate authorization by covered entities subject to the rule, such as health plans, healthcare clearinghouses and healthcare providers as well as their business associates that perform certain services for or on their behalf involving the use or disclosure of individually identifiable health information; Â Â â— the U.S. Physician Payments Sunshine Act, which requires certain manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Childrenâ€™s Health Insurance Program (with certain exceptions) to report annually to the government information related to payments or other â€œtransfers of valueâ€Â made to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors) and teaching hospitals, and requires applicable manufacturers and group purchasing organizations to report annually to the government ownership and investment interests held by these physicians and their immediate family members; Â Â â— the CCPA requires covered companies to, among other things provide new disclosures to California consumers and afford such consumers new abilities to opt-out of certain sales of personal information. We cannot yet predict the impact of the CCPA or the recently approved CPRA on our business or operations, but it may require us to modify our data processing practices and policies and could cause us to incur substantial costs and expenses in an effort to comply; Â Â â— federal consumer protection and unfair competition laws, which broadly regulate marketplace activities and activities that potentially harm consumers; and Â Â Â â— analogous state and non-U.S. laws and regulations, such as state anti-kickback and false claims laws, which may apply to our business practices, including, but not limited to, research, distribution, sales, and marketing arrangements and claims involving healthcare items or services reimbursed by non-governmental third-party payors, including private insurers; state laws that require device companies to comply with the industryâ€™s voluntary compliance guidelines and the relevant compliance guidance promulgated by the U.S. government, or otherwise restrict payments that may be made to healthcare providers and other potential referral sources; state laws and regulations that require manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures and pricing information; and state and non-U.S. laws governing the privacy and security of health information in some circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts. Â Â We have implemented compliance related programs and procedures consistent with our stage of development to help identify and deter healthcare and other violations by employees and other third parties that perform services for us. Notwithstanding our efforts, however, it is possible that governmental authorities may conclude that our business practices do not comply with current or future statutes, regulations, agency guidance, or case law involving applicable healthcare or other applicable laws. Â Also, any material changes to any of the laws or regulations applicable to our business could harm our business, financial condition and results of operations. Â 42 Table of Contents Â To obtain the necessary device approvals or clearances from regulatory authorities for our future product candidates, we will have to conduct various preclinical and clinical tests, which may be costly and time consuming, and mayÂ not provide results that will allow us to seek regulatory approval or clearance. Â The number of preclinical and clinical tests that will be required for regulatory clearance or approval varies depending on the disease or condition to be treated, the method of treatment, the nature of the device, the jurisdiction in which we are seeking approval or clearance and the applicable regulations. Regulatory agencies, including those in the United States, Canada, Europe, and other jurisdictions where medical devices and products are regulated can delay, limit or deny approval of a product for many reasons. For example, regulatory agencies: Â Â â— may not deem a technology or device to be reasonably safe or effective for any intended use or indication; Â Â â— may interpret data from preclinical and clinical testing differently than we do; Â Â â— may determine our manufacturing facility or processes do not comply with quality system regulations; Â Â â— may conclude that our products do not meet quality standards for durability, long-term reliability, biocompatibility, electromagnetic compatibility, or electrical safety; or Â Â â— may change their approval or clearance policies or adopt new regulations in a manner that is adverse to us. Â These regulators may make requests or disagree with us regarding the design or conduct of our clinical trials, resulting in an increased risk of difficulties or delays in obtaining regulatory approval or clearance on future product candidates, or expanded indications of use for our existing products, and increased costs. Â Even if a potential device or product ultimately is cleared or approved by regulatory authorities, it may be cleared

or approved only for narrow indications which may render it commercially less viable. Â Even if we complete clinical testing and a potential device or product of ours is cleared or approved, it may not be cleared or approved for the indications that are necessary or desirable for a successful commercialization. Regulators may grant marketing authorization contingent on the performance of costly additional clinical trials which may be required after approval or clearance. Regulators also may approve or clear our lead product candidates, including the CellFX System, for a more limited indication or a narrower patient population than we originally requested. Our preference will be to obtain as broad an indication as possible for use in connection with the particular disease or treatment for which it is designed. However, the final indication or labeling may be more limited than we originally seek. Any limitation on use may make the device or product commercially less viable and more difficult, if not impractical, to market. Therefore, we may not obtain the revenues that we seek in respect of the proposed product, and we will not be able to become profitable and provide an investment return to our investors.Â Â Â We will be subject to ongoing requirements and inspections that could lead to the restriction, suspension or revocation of our clearance. Â We, as well as any potential third-party manufacturer, will be required to adhere to FDA quality systems requirements, which include testing, control, and documentation requirements. We will be subject to similar regulations in foreign countries. Even when regulatory approval or clearance of a product is granted, the approval or clearance may be subject to limitations on the indicated uses for which the product may be marketed or to the conditions of approval or clearance, or contain requirements for costly post-marketing testing and surveillance to monitor the safety or efficacy of the product. Ongoing compliance with quality system regulations and other applicable regulatory requirements is strictly enforced in the United States through periodic inspections by state and federal agencies, including the FDA, and in international jurisdictions by comparable agencies. Failure to comply with regulatory requirements could result in, among other things, warning letters, fines, injunctions, civil penalties, recall or seizure of products, total or partial suspension of production, failure to obtain premarket clearance or premarket approval for devices, withdrawal of approvals or clearances previously obtained, and criminal prosecution. The restriction, suspension or revocation of regulatory approvals or clearances, or any other failure to comply with regulatory requirements would limit our ability to operate and could materially increase our costs. Â Our employees, collaborators and other personnel may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements and insider trading. Â We are exposed to the risk of fraud or other misconduct by our employees, collaborators and other personnel, which could include intentional, reckless and/or negligent conduct or disclosure that violates: (i) the laws of the FDA and other similar foreign regulatory bodies, including those laws requiring the reporting of true, complete and accurate information to such regulators; (ii) manufacturing standards; or (iii) healthcare fraud and abuse laws in the United States and similar foreign fraudulent misconduct laws. These laws may impact, among other things, future sales, marketing and education programs. The promotion, sales and marketing of healthcare items and services, as well as certain business arrangements in the healthcare industry, are subject to extensive laws designed to prevent fraud and abuse, kickbacks, self-dealing, and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, structuring and commissions, certain customer incentive programs, and other business arrangements generally. Activities subject to these laws also involve the use of information obtained in the course of patient recruitment for clinical trials. Â We adopted a code of conduct applicable to all of our employees, but it is not always possible to identify and deter employee misconduct, and the precautions we take to detect and prevent unlawful activities may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of significant fines or other sanctions. Whether or not we are successful in defending against any such actions or investigations, we could incur substantial costs, including legal fees, and divert the attention of management in defending ourselves against any of these claims or investigations, which could have a material adverse effect on our business and financial condition. Â We are subject to environmental regulations and any failure to comply with applicable laws could subject us to significant liabilities and harm our business. Â We are subject to a variety of local, state, federal, and foreign government regulations relating to the storage, discharge, handling, emission, generation, manufacture, and disposal of toxic or other hazardous substances used in the manufacture of our products. The failure to comply with past, present or future laws could result in the imposition of fines, third-party property damage and personal injury claims, investigation and remediation costs, the suspension of production, or a cessation of operations. We also expect that our operations will be affected by other new environmental and health and safety laws on an ongoing basis. Although we cannot predict the ultimate impact of any such new laws, they will likely result in additional costs, and may require us to change how we manufacture our products, which could have a material adverse effect on our business. Â 43 Table of Contents Â We could be negatively impacted by actual or perceived violations of applicable anti-corruption law or our own internal policies designed to ensure ethical business practices. Â We are subject to anti-bribery, anti-corruption, and anti-money laundering laws, including the U.S. Foreign Corrupt Practices Act of 1977, or FCPA, and similar anti-bribery laws in non-U.S. jurisdictions, as well as export control laws, customs laws, sanctions laws and other laws governing our operations. As we grow our international presence and global operations, we will be increasingly exposed to trade and economic sanctions and other restrictions imposed by the United States, the European Union, and other governments and organizations. Â Anti-corruption laws, such as the FCPA and the U.K. Anti-Bribery Act, generally prohibit us and our employees and intermediaries from bribing, being bribed or making other prohibited payments to government officials or other persons to obtain or retain business or gain some other business advantage. The FCPA also imposes accounting standards and requirements on publicly traded U.S. corporations and their foreign affiliates, which are intended to prevent the diversion of corporate funds to the payment of bribes and other improper payments. Numerous other laws restrict, and in some cases prohibit, U.S. companies from directly or indirectly selling goods, technology or services to people or entities in certain countries. In addition, these laws require that we exercise care in structuring our sales and marketing practices and effecting product registrations in foreign countries. Compliance with these regulations is costly. Â We participate in collaborations and relationships with third parties whose actions could potentially subject us to liability under these anti-corruption laws. In addition, we cannot predict the nature, scope, or effect of future regulatory requirements to which our international operations might be subject or the manner in which existing laws might be administered or interpreted. Although we have implemented company policies requiring our employees and consultants to comply with the FCPA and similar laws, such policies may not be effective at preventing all potential FCPA or other violations. There can be No assurance that none of our employees and agents, or those companies to which we outsource certain portions of our business operations, will not take actions that violate our policies or applicable laws, for which we may be ultimately held responsible. Our development of infrastructure designed to identify anti-corruption matters and monitor compliance is at an early stage. If we are not in compliance with these laws, we may be subject to criminal and civil penalties, disgorgement and other sanctions and remedial measures, and legal expenses, which could have an adverse impact on our business, financial condition, results of operations, and liquidity. Likewise, any investigation of any potential violations of these laws by respective government bodies could also have an adverse impact on our reputation, our business, results of operations, and financial condition. Â Risks Related to Owning Our Common Stock Â The price of our common stock has been, and we expect it to continue to be, highly volatile, and you may be unable to sell your shares at or above the price you paid to acquire them. Â The market price of our common stock has been highly volatile, and we expect it to continue to be highly volatile for the foreseeable future in response to many risk factors listed in this section, and others beyond our control, including: Â Â â— results of clinical trials of our planned products or those of our competitors; Â Â â— actions by regulatory bodies, such as the FDA, that affect our business or have the effect of delaying or rejecting approval or clearance of our planned products; Â Â â— actual or anticipated fluctuations in our financial condition and operating results; Â Â â— announcements by our customers, partners or suppliers relating directly or indirectly to our products, services or technologies; Â Â â— announcements of technological innovations by us or our competitors; Â Â â— changes in laws or regulations applicable to the CellFX System or to our planned end-effectors; Â Â â— announcements by us or our competitors of significant acquisitions, strategic partnerships, joint ventures, capital commitments, or achievement of significant milestones; Â Â â— additions or departures of key personnel; Â Â â— competition from existing products or new products that may emerge; Â Â â— fluctuations in the valuation of companies perceived by investors to be comparable to us; Â Â â— disputes or other developments related to proprietary rights, including patents, litigation matters or our ability to obtain intellectual property protection for our technologies; Â Â â— actual or alleged security breaches; Â Â â— announcements or expectations of additional financing efforts; Â Â â— sales of our common stock by us or our stockholders; Â Â â— stock price and volume fluctuations attributable to inconsistent trading volume levels of our shares; Â Â â— reports, guidance and ratings issued by securities or industry analysts; Â Â â— overall conditions in our industry and market, including the negative impact of armed conflicts, health epidemics and climate change on the global economy and markets; and Â Â â— general economic and market conditions. Â 44 Table of Contents Â Any of the above may cause our stock price or trading volume to decline. Stock markets in general, and the market for companies in our industry in particular, have experienced price and volume fluctuations that have affected and continue to affect the market prices of equity securities of many companies, including ours. These fluctuations often have been unrelated or disproportionate to the operating performance of those companies. These broad market and industry fluctuations, as well as general economic, political and market conditions such as recessions, interest rate changes or international currency fluctuations, may negatively impact the market price of our common stock. Investors may not realize any return on their investment in us and may lose some or all of their investment. In the past, companies that have experienced volatility in the market price of their stock have been subject to securities class action litigation. The high volatility of our stock price, the composition of our Board and governance practices, including our Co-Chairmanâ€™s repeated interest in acquiring additional shares in our Company through related party transactions, as well as countless other factors not identified above, increase the risk of securities litigation or shareholder derivative litigation against the Company and its Directors. Securities litigation against us could result in substantial costs and divert our managementâ€™s attention from other business concerns and adversely impact our ability to raise capital to fund our operations, which could seriously harm our business. Â Sales or purchases of shares of our common stock may adversely affect the market for our common stock. Â If we orÂ our stockholders, particularly our directors, executive officers and significant stockholders, sell or purchase, register for sale, or indicate an intent to sell or purchase, shares of our common stock in the public market, it may have a material adverse effect on the market price of our common stock. In particular, Robert W. Duggan, our majority stockholder and Co-Chairman, is not subject to any contractual restrictions with us on his ability to sell or transfer the shares of our common stock that he holds, and these sales or transfers could create substantial declines in the price of our securities or, if these sales or transfers were made to a single buyer or group of buyers, could contribute to a transfer of control of our Company to a third party. Many of Mr. Dugganâ€™s shares in the Company have been registered for resale pursuant to an effective registration statement on Form S-3. Sales by Mr. Duggan of a substantial number of shares, or the expectation of such sales, could cause a significant reduction in the market price of our common stock. Â We do not know whether an active, liquid and orderly trading market will exist for our common stock and as a result it may be difficult for you to sell your common stock. Â Prior to our initial public offering in May 2016, there was no public market for our common stock. Although our common stock is listed on The Nasdaq Capital Market (â€œNasdaqâ€), the market for our shares has demonstrated varying levels of trading activity. As a result of these and other factors, you may not be able to sell your common stock quickly, at or above the price paid to acquire the stock or at all. Further, an inactive market may also harm our ability to raise capital by selling additional common stock and may harm our ability to enter into strategic collaborations or acquire companies or products by using our common stock as consideration. Â Concentration of ownership by our principal stockholder limits the ability of others to influence the outcome of director elections and other transactions requiring stockholder approval, or create the potential for conflicts of interest. Â A majority percentage of our outstanding stock is held by Robert W. Duggan, Co-Chairman of our Board, who beneficially owns approximately 73% of our common stock outstanding as of the date of this QuarterlyÂ Report. As a result, Mr. Duggan has control over corporate actions requiring stockholder approval, including the following actions: Â Â â— to elect or defeat the election of our directors; Â Â Â â— to amend or prevent amendment of our certificate of incorporation or bylaws; Â Â â— to effect or prevent a merger, sale of assets or other corporate transaction; and Â Â â— to control the outcome of any other matter submitted to our stockholders for vote. Â Â Mr. Dugganâ€™s controlling interest in the Company also creates the potential for conflicts of interest which be viewed unfavorably by minority stockholders, thereby hurting our stock price. For example, in November 2021, we engaged outside legal counsel to represent the Company even though the same legal counsel currently represents Mr. Duggan personally in other matters. This legal counsel represented Mr. Duggan in certain related party transactions described herein and could represent both the Company and Mr. Duggan in future related party transactions. ThreeÂ of our directors, including Mr. Duggan and Manmeet Soni, our Lead Independent Director and Audit Committee Chairman, are executives at Summit Therapeutics Inc., another company in which Mr. Duggan holds a controlling equity interest. There are no family relationships among any of our directors or executive officers, however, Mr. Duggan and Dr. Zanganeh have a personal relationship with each other. Â Additionally, because Mr. Duggan owns a majority of our outstanding shares, we are considered to be a â€œcontrolledâ€ company under applicable Nasdaq rules. As such, we may voluntarily elect not to comply with certain of Nasdaqâ€™s corporate governance requirements, such as certain rules concerning the setting of executive compensation and the appointment of directors. Accordingly, during the period we remain a controlled company and during any transition period following a time when we are no longer a controlled company, other stockholders may not have the same protections afforded to stockholders of companies that are subject to all of the corporate governance requirements of the Nasdaq Stock Market. As a member of our Board, Mr. Duggan will adhere to the corporate governance standards adopted by the Company. Â Even though we have not yet elected to take advantage of any of these corporate governance exemptions permitted by Nasdaq, Mr. Dugganâ€™s stock ownership and our status as a â€œcontrolledâ€ company may discourage a potential acquirer from making a tender offer or otherwise attempting to obtain control of our Company, which in turn could reduce our stock price or prevent our stockholders from realizing a premium over our stock price. In addition, Mr. Duggan is not subject to any contractual restrictions on his ability to acquire additional shares of common stock and any such purchases, including purchases of equity securities in connection with any rights offerings or any alternative equity or equity-linked offering that we may conduct, could result in his acquisition of a larger percentage of our common stock. Â Management currently beneficially holds a small percentage of our common stock. Other than their positions as directors or officers, and the restriction on the stockholders being able to call a special meeting limited to holders of 15% or more of the outstanding shares of common stock, our management will not be able to greatly influence corporate actions requiring stockholder approval. Â Robert W. Dugganâ€™s controlling ownership position may impact our stock price and may deter or prevent efforts by others to acquire us, which could prevent our stockholders from realizing a control premium.Â Â Robert W. Duggan is our Co-Chairman, and he beneficially owns approximately 73% of our common stock outstanding as of the date of this Quarterly Report. In addition, Mr. Duggan is not subject to any contractual restrictions on his ability to acquire additional shares of common stock, and any such purchases, including purchases of equity securities in connection with any rights offerings or any alternative equity or equity-linked offering that we may conduct, could result in his acquisition of a majority of our common stock. As a result of Mr. Dugganâ€™s controlling ownership and position as Co-Chairman, others may be less inclined to pursue an acquisition of us and therefore we may not have the opportunity to be acquired in a transaction that stockholders might otherwise deem favorable, including transactions in which our stockholders might realize a substantial premium for their shares.Â In addition, public speculation regarding Mr. Duggan, as well as our relationship with Mr. Duggan, could cause our stock price to fluctuate. Â 45 Table of Contents Â We have incurred and will continue to incur costs as a result of operating as a public company and our management has been and will be required to devote substantial time to public company compliance initiatives. Â As a public company, listed in the United States, we have incurred and will continue to incur significant legal, accounting and other expenses due to our compliance with regulations and disclosure obligations applicable to us, including compliance with the Sarbanes-Oxley Act of 2002, or the Sarbanes-Oxley Act, as well as rules implemented by the SEC and Nasdaq. The SEC and other regulators have continued to adopt new rules and regulations and make additional changes to existing regulations that require our compliance. Â Stockholder activism, the current political environment, and the current high level of government intervention and regulatory reform may lead to substantial new regulations and disclosure obligations, which may lead to additional compliance costs and impact, in ways we cannot currently anticipate, the manner in which we operate our business. Our management and other personnel have and will continue to devote a substantial amount of time to these compliance programs and monitoring of public company reporting obligations and, as a result of the new corporate governance and executive compensation related rules, regulations, and guidelines prompted by the Dodd-Frank Wall Street Reform and Protection Act, or the Dodd-Frank Act, and further regulations and disclosure obligations expected in the future, we will likely need to devote additional time and costs to comply with such compliance programs and rules. New laws and regulations as well as changes to existing laws and regulations affecting public companies, including the provisions of the Sarbanes-Oxley Act, the Dodd-Frank Act, and rules adopted by the SEC and Nasdaq, will likely result in increased costs to us as we respond to their requirements. We are currently evaluating and monitoring

developments with respect to these rules and regulations, and we cannot predict or estimate the amount of additional costs we may incur or the timing of such costs. Â Furthermore, these and future rules and regulations could make it more difficult or more costly for us to obtain certain types of insurance, including director and officer liability insurance, and we may be forced to accept reduced policy limits and coverage or incur substantially higher costs to obtain the same or similar coverage. The impact of these requirements could also make it more difficult for us to attract and retain qualified persons to serve on our board of directors, our board committees or as our executive officers. Â We are aÂ â€œsmaller reporting companyâ€; we cannot be certain if the applicable reduced disclosure requirements will make our common stock less attractive to investors. Â WeÂ qualify as a â€œsmaller reporting company,â€ as defined in the Exchange Act, and so long as we remain a smaller reporting company, we benefit from and may take advantage of scaled disclosure requirements.Â We cannot know if investors find our common stock less attractive because we may rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our stock price may be more volatile and it may be difficult for us to raise additional capital as and when we need it. Investors may be unable to compare our business with other companies in our industry if they believe that our reporting is not as transparent as other companies in our industry. If we are unable to raise additional capital as and when we need it, our financial condition and results of operations may be materially and adversely affected. Â If securities or industry analysts do not publish research or publish inaccurate or unfavorable research about our business, our market price and trading volume could decline. Â The trading market for our common stock will depend on the research and reports that securities or industry analysts publish about us or our business. We do not have any control over these analysts. We currently have only limited analyst coverage of us and there can be no assurance that analysts will continue to cover us or provide favorable coverage. If one or more of the analysts who cover us downgrade our stock or change their opinion of our stock, our market price would likely decline. If analysts cease coverage of our Company or fail to regularly publish reports on us, we could lose visibility in the financial markets, which could cause our share price or trading volume to decline. Â We have not paid dividends in the past and have no plans to pay dividends. Â For the foreseeable future, we plan to reinvest all of our earnings, to the extent we have earnings, into our product research and development efforts, so we have no plans to pay any cash dividends with respect to our securities. We cannot assure you that we would, at any time, generate sufficient surplus cash that would be available for distribution to the holders of our common stock as a dividend. Therefore, you should not expect to receive cash dividends on our outstanding common stock. Â Anti-takeover provisions in our charter documents and under Delaware law could make an acquisition of us, which may be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our current management and limit the market price of our common stock. Â Certain anti-takeover provisions of Delaware law and provisions in our certificate of incorporation and bylaws may have the effect of delaying or preventing a change of control or changes in our management. These provisions could also make it difficult for stockholders to elect directors that are not nominated by the current members of our board of directors or take other corporate actions, including effecting changes in our management. Our certificate of incorporation and bylaws include provisions that: Â Â â— authorize our board of directors to issue, without further action by the stockholders, up to 50,000,000 shares of preferred stock and up to approximately 500,000,000 shares of authorized but unissued shares of common stock; Â Â â— require that any action to be taken by our stockholders be effected at a duly called annual or special meeting and not by written consent; Â Â â— specify that special meetings of our stockholders can be called only by our board of directors, the chairman of our board of directors, any of our officers, or any stockholder holding at least fifteen percent (15%) of the voting power of the capital stock issued and outstanding and entitled to vote; Â Â â— establish an advance notice procedure for stockholder approvals to be brought before an annual meeting of our stockholders, including proposed nominations of persons for election to our board of directors; Â Â Â â— require the affirmative vote of holders of at least 66 2/3% of the voting power of all the then outstanding shares of our voting stock, voting together as a single class, to amend provisions of our certificate of incorporation or our bylaws; Â Â Â â— give our board of directors the ability to amend our bylaws by majority vote; and Â Â â— provide that vacancies on our board of directors may be filled only by a majority of directors then in office, even though less than a quorum. Â These provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our Board, which is responsible for appointing the members of our management. Furthermore, our bylaws provide that unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware shall, to the fullest extent permitted by law, be the sole and exclusive forum for (a) any derivative action or proceeding brought on behalf of us, (b) any action asserting a claim of breach of fiduciary duty owed by any director, officer or other employee of us to us or our stockholders, (c) any action asserting a claim arising pursuant to any provision of the Delaware General Corporation Law, our certificate of incorporation or our bylaws, or (d) any action asserting a claim governed by the internal affairs doctrine, in each case subject to the Court of Chancery having personal jurisdiction over the indispensable parties named as defendants therein; provided that, if and only if the Court of Chancery dismisses any such action for lack of subject matter jurisdiction, such action may be brought in another state or federal court sitting in Delaware. Our bylaws further provide that the federal district courts of the United States of America will be the exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act. Any person or entity purchasing or otherwise acquiring any interest in any of our securities shall be deemed to have notice of and consented to these provisions. These exclusive-forum provisions may discourage lawsuits against us or our directors, officers, and employees. In addition, because we are incorporated in Delaware, we are governed by the provisions of Section 203 of the Delaware General Corporation Law, which limits the ability of stockholders owning in excess of 15% of our outstanding voting stock to engage in certain types of transactions with us. Â 46 Table of Contents Â General Risk Factors Â Unfavorable global economic or political conditions could adversely affect our business, financial condition or results of operations. Â Our results of operations could be adversely affected by general conditions in the global economy and in the global financial markets, including the negative impact of armed conflicts, health epidemics and global warming on the global economy and markets. A global financial crisis or a banking crisis or a global or regional political disruption could cause extreme volatility in the capital and credit markets. The Company places its cash equivalents and investments with high credit quality financial institutions and, by policy, limits the amounts invested with any one financial institution or issuer and restricts the Companyâ€™s investments to U.S. treasuries and money market instruments. However, in general the Companyâ€™s deposits held with banksÂ exceed the amount of insurance provided on such deposits. Despite our low-risk investment policies,Â aÂ severe or prolonged economic downturn or political disruption could result in a variety of risks to our business, including our ability to raise additional capital when needed on acceptable terms, if at all. A weak or declining economy, banking crisis or political disruption could also strain our manufacturers or suppliers, possibly resulting in supply disruption, or cause our customers to delay making payments for our products. Any of the foregoing could harm our business and we cannot anticipate all of the ways in which the political or economic climate and financial market conditions could adversely impact our business. Â If we experience material weaknesses in the future or otherwise fail to maintain an effective system of internal control over financial reporting in the future, we may not be able to accurately or timely report our financial condition or results of operations, which may adversely affect investor confidence in us and, as a result, the value of our common stock. Â As a public company, we are required to maintain internal control over financial reporting and to report any material weaknesses in such internal controls. Section 404 of the Sarbanes-Oxley Act requires that we evaluate and determine the effectiveness of our internal control over financial reporting and provide a management report on internal control over financial reporting. A material weakness is a deficiency, or combination of deficiencies, in internal control over financial reporting such that there is a reasonable possibility that a material misstatement of our financial statements will not be prevented or detected on a timely basis. Ensuring that we have adequate internal financial and accounting controls and procedures in place so that we can produce accurate financial statements on a timely basis is a costly and time-consuming effort. Our internal control over financial reporting is designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements in accordance with U.S. GAAP. We may not be able to complete our evaluation, testing and any required remediation in a timely fashion. During the evaluation and testing process, if we identify one or more material weaknesses in our internal control over financial reporting, we will be unable to assert that our internal controls are effective. The identification of one or more material weaknesses would preclude a conclusion that we maintain effective internal control over financial reporting. Accordingly, there could continue to be a reasonable possibility that a material misstatement of our financial statements would not be prevented or detected on a timely basis. Â We are required to disclose changes made in our internal control and procedures on a quarterly basis. However, our independent registered public accounting firm will not be required to report on the effectiveness of our internal control over financial reporting pursuant to Section 404 of the Sarbanes-Oxley Act until we are no longer a â€œsmall reporting company.â€ At such time, our independent registered public accounting firm may issue a report that is adverse in the event it is not satisfied with the level at which our controls are documented, designed or operating. Our remediation efforts may not enable us to avoid a material weakness in the future. If we are unable to assert that our internal control over financial reporting is effective, or when required in the future, if our independent registered public accounting firm is unable to express an unqualified opinion as to the effectiveness of our internal control over financial reporting, investors may lose confidence in the accuracy and completeness of our financial reports and the market price of our common stock could be adversely affected, and we could become subject to litigation risk and to investigations by Nasdaq, the stock exchange on which our securities are listed, by the SEC, and by other regulatory authorities, which could require additional financial and management resources. Â If the interpretations, estimates or judgments we use to prepare our financial statements prove to be incorrect, investors and others may lose confidence in our financial data, which could cause our stock price to decline. Â We, like all publicly traded companies, are subject to complex securities laws and regulations and accounting principles and interpretations. The preparation of our financial statements requires us to interpret accounting principles and guidance and to make estimates and judgments that affect the reported amounts of assets and liabilities and the disclosure of contingent liabilities at the date of the financial statements, as well as the reported expenses incurred during the reporting periods. We base our interpretations, estimates and judgments on our historical experience, appropriate accounting guidance and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for the preparation of our financial statements. However, accounting guidance can sometimes be conflicting, especially with respect to accounting for complex corporate transactions, such as accounting for the issuance of warrants as equity. Warrants classified as liabilities result in non-cash fair value measurement adjustments that are recorded in other income (expense). Moreover, generally accepted accounting principles presentation is subject to interpretation by the SEC, the Financial Accounting Standards Board (â€œFASBâ€) and various other bodies formed to interpret and create appropriate accounting principles and guidance. If one of these bodies disagrees with our accounting recognition, measurement or disclosure or any of our accounting interpretations, estimates or assumptions, we may have to retroactively revise our previously reported results and our investors could lose confidence in the accuracy and completeness of our financial reports, which could cause our stock price to decline. Â We may become involved in litigation that may materially adversely affect us. Â From time to time, we may be involved in a variety of claims, lawsuits, investigations, or proceedings relating to securities laws, product liability, patent infringement, contract disputes, and other matters relating to various claims that arise in the normal course of our business in addition to governmental and other regulatory investigations and proceedings. In addition, third parties may, from time to time, assert claims against us. Such matters can be time-consuming, divert managementâ€™s attention and resources, cause us to incur significant expenses or liability and/or require us to change our business practices. Because of the potential risks, expenses and uncertainties of litigation, we may, from time to time, settle disputes, even where we have meritorious claims or defenses, by agreeing to settlement agreements. Because litigation is inherently unpredictable, we cannot assure you that the results of any of these actions will not have a material adverse effect on our business, financial condition, results of operations and prospects. See the section entitled â€œLegal Proceedingsâ€ for more detail on our current legal proceedings. Â Our facilities in California are located near known earthquake faults, and the occurrence of an earthquake or other catastrophic disaster could cause damage to our facilities and equipment, which could require us to cease or curtail operations. Â Our facilities in Hayward, California are located near known earthquake fault zones and are vulnerable to damage from earthquakes. We are also vulnerable to damage from other types of disasters, including fire, floods, power loss, communications failures, and similar events. If any disaster were to occur, our ability to operate our business at our facilities would be seriously, or potentially completely, impaired. In addition, the nature of our activities could make it difficult for us to recover from a natural disaster. The insurance we maintain may not be adequate to cover our losses resulting from disasters or other business interruptions. Accordingly, an earthquake or other disaster could materially and adversely harm our ability to conduct business. Â Â 47 Table of Contents Â ItemÂ 2. Unregistered Sales of Equity Securities and Use of Proceeds Â During the three-month period ended September 30, 2024, we completed no unregistered sale of our securities. Â ItemÂ 3. Default Upon Senior Securities Â None. Â ItemÂ 4. Mine Safety Disclosures Â Not applicable. Â ItemÂ 5. Other Information Â Trading Arrangements Â During the three-month period ended September 30, 2024, none of our directors or officers (as defined in Rule 16a-1(f) under the Exchange Act)Â adoptedÂ orÂ terminatedÂ a â€œRule 10b5-1 trading arrangementâ€ or a â€œnon-Rule 10b5-1Â tradingÂ arrangementâ€ as such terms are defined under Item 408 of Regulation S-K. Â Â ItemÂ 6. Exhibits Â Exhibit Number Â Exhibit DescriptionÂ 31.1 Â Certification of Chief Executive Officer pursuant to SectionÂ 302 of the Sarbanes-Oxley Act of 2002. 32.1* Â Certification of the Chief Executive OfficerÂ pursuant to SectionÂ 906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. SectionÂ 1350). 101.INS Â Inline XBRL Instance Document 101.SCH Â Inline XBRL Taxonomy Extension Schema Document 101.CAL Â Inline XBRL Taxonomy Extension Calculation Linkbase Document 101.DEF Â Inline XBRL Taxonomy Extension Definition Linkbase Document 101.LAB Â Inline XBRL Taxonomy Extension Label Linkbase Document 101.PRE Â Inline XBRL Taxonomy Extension Presentation Linkbase Document 104 Â Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101) Â * The certification attached as Exhibit 32.1 that accompanies this Quarterly Report is deemed furnished and not filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of Pulse Biosciences, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date of this Quarterly Report, irrespective of any general incorporation language contained in such filing. Â 48 Table of Contents Â Signatures Â Pursuant to the requirements of the Securities Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.Â Â Â Â Â Â Â Â Â Â Â Â PULSEÂ BIOSCIENCES,Â INC. Â Â Â Â Â Â Â Â Â Â Â Â Date: October 30, 2024 By: /s/Â Â Â Â BurkeÂ T. Barrett Â Â Â Â BurkeÂ T. Barrett Â Â Â Â President and ChiefÂ ExecutiveÂ Officer (PrincipalÂ Executive and PrincipalÂ Financial Officer) Â Â 49 EX-31.1 2 ex_722415.htm EXHIBIT 31.1 ex_722415.htm Exhibit 31.1 Â CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO SECURITIES EXCHANGE ACT RULESÂ 13a-14(a) and 15d-14(a), AS ADOPTED PURSUANT TO SECTIONÂ 302 OF THE SARBANES-OXLEY ACT OF 2002 Â I, Burke Barrett,Â certify that: Â 1. I have reviewed this Quarterly Report on FormÂ 10-Q for the quarter endedÂ September 30, 2024 of Pulse Biosciences, Inc.; Â 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; Â 3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; Â 4. The registrantâ€™s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act RulesÂ 13a-15(e) and 15d-15(e))Â and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: Â Â a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; Â Â b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; Â Â c) Evaluated the effectiveness of the registrantâ€™s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation;Â and Â Â d) Disclosed in this report any change in the registrantâ€™s internal control over financial reporting that occurred during the registrantâ€™s most recent fiscal quarter (the registrantâ€™s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrantâ€™s internal control over financial reporting;Â and Â 5. The registrantâ€™s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrantâ€™s auditors and the audit committee of the registrantâ€™s board of directors (or persons performing the equivalent functions): Â Â a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrantâ€™s ability to record, process, summarize and report financial information;Â and Â Â b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the

registrantâ€™s internal control over financial reporting. Â Date: October 30, 2024 By: /s/ Burke T. Barrett Â ï»¿ Â Burke T. Barrett Â ï»¿ Â President and ChiefÂ ExecutiveÂ OfficerÂ Â ï»¿ Â (PrincipalÂ Executive and Principal Financial Officer) Â ï»¿ Â Â EX-32.1 3 ex_722416.htm EXHIBIT 32.1 ex_722416.htm Exhibit 32.1 Â CERTIFICATIONS PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 Â In connection with the Quarterly Report of Pulse Biosciences, Inc. (the â€œCompanyâ€) on Form 10-Q for the period endedÂ September 30, 2024 as filed with the Securities and Exchange Commission on the date hereof (the â€œReportâ€), the undersigned certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of his knowledge: Â (1) Â Â The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and Â (2) Â Â The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. Â ï»¿Date:Â October 30, 2024 Â /s/Â Burke T. Barrett Â ï»¿ Â Burke T. Barrett Â ï»¿ Â President and ChiefÂ ExecutiveÂ OfficerÂ Â ï»¿ Â (PrincipalÂ Executive and Principal Financial Officer) Â ï»¿ This certification is deemed furnished and not filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of Pulse Biosciences, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date of this report, irrespective of any general incorporation language contained in such filing. ï»¿ Â EX-101.SCH 4 plse-20240930.xsd XBRL TAXONOMY EXTENSION SCHEMA 000 - Document - Document And Entity Information link:calculationLink link:definitionLink link:presentationLink 001 - Statement - Condensed Consolidated Balance Sheets (Current Period Unaudited) link:calculationLink link:definitionLink link:presentationLink 002 - Statement - Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) link:calculationLink link:definitionLink link:presentationLink 003 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) link:calculationLink link:definitionLink link:presentationLink 004 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) link:calculationLink link:definitionLink link:presentationLink 005 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Deficit) (Unaudited) link:calculationLink link:definitionLink link:presentationLink 006 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Deficit) (Unaudited) (Parentheticals) link:calculationLink link:definitionLink link:presentationLink 007 - Disclosure - Note 1 - Description of the Business link:calculationLink link:definitionLink link:presentationLink 008 - Disclosure - Note 2 - Summary of Significant Accounting Policies link:calculationLink link:definitionLink link:presentationLink 009 - Disclosure - Note 3 - Fair Value of Financial Instruments link:calculationLink link:definitionLink link:presentationLink 010 - Disclosure - Note 4 - Balance Sheet Components link:calculationLink link:definitionLink link:presentationLink 011 - Disclosure - Note 5 - Goodwill link:calculationLink link:definitionLink link:presentationLink 012 - Disclosure - Note 6 - Stockholders' Equity and Stock-based Compensation link:calculationLink link:definitionLink link:presentationLink 013 - Disclosure - Note 7 - Commitments and Contingencies link:calculationLink link:definitionLink link:presentationLink 014 - Disclosure - Note 8- Segment Reporting link:calculationLink link:definitionLink link:presentationLink 015 - Disclosure - Note 9 - Related Party Transactions link:calculationLink link:definitionLink link:presentationLink 016 - Disclosure - Note 10 - Restructuring Charges link:calculationLink link:definitionLink link:presentationLink 017 - Disclosure - Note 11 - Subsequent Events link:calculationLink link:definitionLink link:presentationLink 995464 - Disclosure - Significant Accounting Policies (Policies) link:calculationLink link:definitionLink link:presentationLink 995465 - Disclosure - Note 2 - Summary of Significant Accounting Policies (Tables) link:calculationLink link:definitionLink link:presentationLink 995466 - Disclosure - Note 3 - Fair Value of Financial Instruments (Tables) link:calculationLink link:definitionLink link:presentationLink 995467 - Disclosure - Note 4 - Balance Sheet Components (Tables) link:calculationLink link:definitionLink link:presentationLink 995468 - Disclosure - Note 6 - Stockholders' Equity and Stock-based Compensation (Tables) link:calculationLink link:definitionLink link:presentationLink 995469 - Disclosure - Note 7 - Commitments and Contingencies (Tables) link:calculationLink link:definitionLink link:presentationLink 995470 - Disclosure - Note 2 - Summary of Significant Accounting Policies - Warrant Accrual Activity (Details) link:calculationLink link:definitionLink link:presentationLink 995471 - Disclosure - Note 2 - Summary of Significant Accounting Policies - Antidilutive Securities (Details) link:calculationLink link:definitionLink link:presentationLink 995472 - Disclosure - Note 3 - Fair Value of Financial Instruments (Details Textual) link:calculationLink link:definitionLink link:presentationLink 995473 - Disclosure - Note 3 - Investments and Fair Value of Financial Instruments - Financial Assets Measured on a Recurring Basis (Details) link:calculationLink link:definitionLink link:presentationLink 995474 - Disclosure - Note 4 - Balance Sheet Components (Details Textual) link:calculationLink link:definitionLink link:presentationLink 995475 - Disclosure - Note 4 - Balance Sheet Components - Property and Equipment, Net (Details) link:calculationLink link:definitionLink link:presentationLink 995476 - Disclosure - Note 4 - Balance Sheet Components - Intangible Assets, Net (Details) link:calculationLink link:definitionLink link:presentationLink 995477 - Disclosure - Note 4 - Balance Sheet Components - Schedule of Amortization of Intangible Assets (Details) link:calculationLink link:definitionLink link:presentationLink 995478 - Disclosure - Note 4 - Balance Sheet Components - Accrued Expenses (Details) link:calculationLink link:definitionLink link:presentationLink 995479 - Disclosure - Note 5 - Goodwill (Details Textual) link:calculationLink link:definitionLink link:presentationLink 995480 - Disclosure - Note 6 - Stockholders' Equity and Stock-based Compensation (Details Textual) link:calculationLink link:definitionLink link:presentationLink 995481 - Disclosure - Note 6 - Stockholders' Equity and Stock-based Compensation - Summary of Stock Option Activity (Details) link:calculationLink link:definitionLink link:presentationLink 995482 - Disclosure - Note 6 - Stockholders' Equity and Stock-based Compensation - Summary of Time-based Option Activity (Details) link:calculationLink link:definitionLink link:presentationLink 995483 - Disclosure - Note 6 - Stockholders' Equity and Stock-based Compensation - Summary of Performance Option Activity (Details) link:calculationLink link:definitionLink link:presentationLink 995484 - Disclosure - Note 6 - Stockholders' Equity and Stock-based Compensation - Summary of Market-based Option Activity (Details) link:calculationLink link:definitionLink link:presentationLink 995485 - Disclosure - Note 6 - Stockholders' Equity and Stock-based Compensation - Option Assumptions (Details) link:calculationLink link:definitionLink link:presentationLink 995486 - Disclosure - Note 6 - Stockholders' Equity and Stock-based Compensation - ESPP Assumptions (Details) link:calculationLink link:definitionLink link:presentationLink 995487 - Disclosure - Note 6 - Stockholders' Equity and Stock-based Compensation - Stock-based Compensation Expense by Recorded Location (Details) link:calculationLink link:definitionLink link:presentationLink 995488 - Disclosure - Note 6 - Stockholders' Equity and Stock-based Compensation - Stock-based Compensation Expense by Type (Details) link:calculationLink link:definitionLink link:presentationLink 995489 - Disclosure - Note 7 - Commitments and Contingencies (Details Textual) link:calculationLink link:definitionLink link:presentationLink 995490 - Disclosure - Note 7 - Commitments and Contingencies - Information Related to Right-of-use Assets and Lease Liabilities (Details) link:calculationLink link:definitionLink link:presentationLink 995491 - Disclosure - Note 8- Segment Reporting (Details Textual) link:calculationLink link:definitionLink link:presentationLink 995492 - Disclosure - Note 9 - Related Party Transactions (Details Textual) link:calculationLink link:definitionLink link:presentationLink 995493 - Disclosure - Note 10 - Restructuring Charges (Details Textual) link:calculationLink link:definitionLink link:presentationLink 995494 - Disclosure - Note 11 - Subsequent Events (Details Textual) link:calculationLink link:definitionLink link:presentationLink EX-101.CAL 5 plse-20240930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 6 plse-20240930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 7 plse-20240930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Document And Entity Information Dividend yield Note To Financial Statement Details Textual Significant Accounting Policies Note 2 - Summary of Significant Accounting Policies Note 3 - Fair Value of Financial Instruments Risk-free interest rate Note 4 - Balance Sheet Components Note 6 - Stockholders' Equity and Stock-based Compensation Note 7 - Commitments and Contingencies Note 2 - Summary of Significant Accounting Policies - Warrant Accrual Activity (Details) Note 2 - Summary of Significant Accounting Policies - Antidilutive Securities (Details) Note 3 - Investments and Fair Value of Financial Instruments - Financial Assets Measured on a Recurring Basis (Details) Note 4 - Balance Sheet Components - Property and Equipment, Net (Details) Note 4 - Balance Sheet Components - Intangible Assets, Net (Details) Note 4 - Balance Sheet Components - Schedule of Amortization of Intangible Assets (Details) Expected volatility Note 4 - Balance Sheet Components - Accrued Expenses (Details) Note 6 - Stockholders' Equity and Stock-based Compensation - Summary of Stock Option Activity (Details) us-gaap_LiabilitiesCurrent Total current liabilities Note 6 - Stockholders' Equity and Stock-based Compensation - Summary of Time-based Option Activity (Details) Note 6 - Stockholders' Equity and Stock-based Compensation - Summary of Performance Option Activity (Details) Note 6 - Stockholders' Equity and Stock-based Compensation - Summary of Market-based Option Activity (Details) Note 6 - Stockholders' Equity and Stock-based Compensation - Option Assumptions (Details) Expected term in years (Year) Note 6 - Stockholders' Equity and Stock-based Compensation - ESPP Assumptions (Details) Note 6 - Stockholders' Equity and Stock-based Compensation - Stock-based Compensation Expense by Recorded Location (Details) us-gaap_BusinessCombinationConsiderationTransferred1 Business Combination, Consideration Transferred, Total Note 6 - Stockholders' Equity and Stock-based Compensation - Stock-based Compensation Expense by Type (Details) Note 7 - Commitments and Contingencies - Information Related to Right-of-use Assets and Lease Liabilities (Details) Notes To Financial Statements Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Notes To Financial Statements [Abstract] Share-Based Payment Arrangement, Option, Activity [Table Text Block] us-gaap_NumberOfBusinessesAcquired Number of Businesses Acquired Share-Based Payment Arrangement, Cost by Plan [Table Text Block] Options exercisable, weighted average remaining life (Year) Options exercisable, number of shares (in shares) Options balances, weighted average remaining life (Year) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice Options balances, weighted average exercise price (in dollars per share) Options balances, weighted average exercise price (in dollars per share) Options canceled, weighted average exercise price (in dollars per share) Options expired, weighted average exercise price (in dollars per share) Options granted, weighted average exercise price (in dollars per share) Options exercised, weighted average exercise price (in dollars per share) Accrued expenses Accrued Liabilities, Current Total accrued expenses Compensation expense Accounts payable us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber Options balances, number of shares (in shares) Options balances, number of shares (in shares) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod Options expired, number of shares (in shares) Other us-gaap_OtherAccruedLiabilitiesCurrent us-gaap_PolicyTextBlockAbstract Accounting Policies us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant (in shares) Principal and accrued interest of related party note settled via issuance of common stock Professional fees us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost Share-Based Payment Arrangement, Accelerated Cost us-gaap_PaymentsToAcquirePropertyPlantAndEquipment Purchases of property and equipment us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized (in shares) us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period (Year) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized (in shares) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year) us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage Goodwill Disclosure [Text Block] Current liabilities: Supplemental Balance Sheet Disclosures [Text Block] Vesting [Axis] Vesting [Domain] Lease liabilities Share-Based Payment Arrangement, Tranche One [Member] us-gaap_Assets Total assets Plan Name [Axis] Plan Name [Domain] us-gaap_OperatingLeaseExpense Operating Lease, Expense Other receivable from exercises of warrants The amount of other receivable from exercise of warrants. Proceeds from issuance of common stock and warrants in relation to rights offering, net of issuance costs The amount of cash inflow from issuance of common stock and warrants. Share-Based Payment Arrangement [Text Block] Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets, Major Class Name [Domain] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] plse_PercentOfOfferingPurchased Percent of Offering Purchased The percent of an offering purchased. Award Type [Domain] Award Date [Axis] Award Date [Domain] Award Type [Axis] Net loss Net loss us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization Less: Accumulated amortization Intangible assets, net Total Acquired patents and licenses Share-Based Payment Arrangement, Option [Member] Warrant [Member] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Antidilutive Securities [Axis] Antidilutive Securities, Name [Domain] Commitments and Contingencies Disclosure [Text Block] us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment Less: Accumulated depreciation and amortization Property and equipment, net Total property and equipment, net Goodwill Goodwill, Ending Balance Property and equipment, gross Cash flows from investing activities: Net loss per share: Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest us-gaap_RelatedPartyTransactionAmountsOfTransaction Related Party Transaction, Amounts of Transaction Related Party Transactions Disclosure [Text Block] us-gaap_IncomeTaxExpenseBenefit Income tax benefit us-gaap_IncreaseDecreaseInAccruedLiabilities Accrued expenses us-gaap_IncreaseDecreaseInAccountsPayable Accounts payable General and administrative us-gaap_DebtInstrumentIncreaseAccruedInterest Debt Instrument, Increase, Accrued Interest us-gaap_DebtInstrumentDecreaseForgiveness Debt Instrument, Decrease, Forgiveness Accrued interest on related party note payable Cash and cash equivalents Total stock-based compensation expense Amendment Flag us-gaap_ComprehensiveIncomeNetOfTax Comprehensive loss City Area Code Use of Estimates, Policy [Policy Text Block] New Accounting Pronouncements, Policy [Policy Text Block] us-gaap_SharesOutstanding Balance (in shares) Balance (in shares) Common stock, shares outstanding (in shares) Preferred stock, shares outstanding (in shares) Current Fiscal Year End Date us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets Prepaid expenses and other current assets Weighted-average discount rate Document Fiscal Period Focus Document Fiscal Year Focus Consolidation, Policy [Policy Text Block] Document Period End Date Weighted-average remaining lease term (Year) Entity File Number Entity Emerging Growth Company us-gaap_DebtInstrumentFaceAmount Debt Instrument, Face Amount Document Type Entity Small Business Entity Shell Company Document Information [Line Items] Document Information [Table] us-gaap_InvestmentOwnedPercentOfNetAssets Investment Owned, Percent of Net Assets us-gaap_AreaOfRealEstateProperty Area of Real Estate Property (Square Foot) Entity Filer Category Debt Instrument [Axis] Entity Current Reporting Status Debt Instrument, Name [Domain] us-gaap_RestructuringCharges Restructuring Charges us-gaap_IncreaseDecreaseInOtherReceivables Other receivables us-gaap_GoodwillImpairmentLoss Goodwill, Impairment Loss Stock-based compensation expense Entity Tax Identification Number Entity Central Index Key Entity Registrant Name Entity [Domain] Legal Entity [Axis] Entity Address, Address Line One Issuance cost ecd_NonRule10b51ArrTrmntdFlag Non-Rule 10b5-1 Arrangement Terminated [Flag] Amortization of intangible assets Less: Adjustment for inventory at cost and excessive and obsolete inventory Represents the adjustment for inventory at cost. Entity Address, City or Town ecd_Rule10b51ArrTrmntdFlag Rule 10b5-1 Arrangement Terminated [Flag] ecd_Rule10b51ArrAdoptedFlag Rule 10b5-1 Arrangement Adopted [Flag] Entity Address, Postal Zip Code Entity Address, State or Province ecd_NonRule10b51ArrAdoptedFlag Non-Rule 10b5-1 Arrangement Adopted [Flag] Material Terms of Trading Arrangement [Text Block] Entity Common Stock, Shares Outstanding plse_EquityOfferingUnitsSaleOfUnits Equity Offering, Units, Sale of Units (in shares) Total units issued during the year. Trading Symbol plse_DebtInstrumentQuarterlyInterestRate Debt Instrument Quarterly Interest Rate Debt instrument, quarterly interest rate Robert W. Duggan [Member] Represents Robert W. Duggan Two Thousand Twenty Two Loan Agreement [Member] Represents the 2022 Loan Agreement Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Issuance of common stock as part of debt extinguishment, net of issuance costs of $6 Issuance of common stock as part of debt extinguishment, net of issuance costs of $6 (in shares) Issuance of shares under employee stock purchase plan (in shares) Stock Issued During Period, Shares, Employee Stock Purchase Plans (in shares) Next One to Four Years [Member] Related to the next one to four years. Local Phone Number Vesting of First Half [Member] Represents vesting of first half. Issuance of common stock upon exercise of stock options (in shares) Options exercised, number of shares (in shares) us-gaap_TableTextBlock Notes Tables plse_ClassOfWarrantOrRightVestingStockPriceTrigger Class of Warrant or Right, Vesting, Stock Price Trigger (in dollars per share) Per share or per unit stock price trigger for vesting of warrants or rights. Vesting of Second Half [Member] Represents vesting of second half. Issuance of shares under employee stock purchase plan Issuance of common stock upon exercise of stock options Related and Nonrelated Parties [Axis] Rights offering and at-the-market issuance costs in accounts payable The amount of issuance costs that were incurred during a noncash or partial noncash transaction. plse_ClassOfWarrantOrRightProceedsUponExercise Class of Warrant or Right, Proceeds Upon Exercise Amount of proceeds upon exercise of warrants or rights. Related and Nonrelated Parties [Domain] Options granted, number of shares (in shares) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod Options canceled, number of

shares (in shares) us-gaap_WarrantsAndRightsOutstandingTerm Warrants and Rights Outstanding, Term (Year) Issuance of shares (in shares) Stock Issued During Period, Shares, New Issues (in shares) us-gaap_LiabilitiesAndStockholdersEquity Total liabilities and stockholdersâ€™ equity Issuance of shares Related Party Transaction [Axis] Related Party Transaction [Domain] Research and development Accumulated deficit Accumulated other comprehensive income (loss) Money Market Funds [Member] Cash and Cash Equivalents [Axis] us-gaap_InterestExpense Interest Expense Cash and Cash Equivalents [Domain] Issuance of common stock upon exercise of warrants Value of stock issued during the period for the exercise of warrants. Changes in operating assets and liabilities: Rights Offering [Member] Represents rights offering. us-gaap_DisclosureTextBlockAbstract Notes to Financial Statements ATM Offering [Member] Represents the ATM offering. plse_IncreaseDecreaseInOperatingLeaseRightOfUseAsset Right-of-use assets Amount of increase (decrease) in operating lease right of use asset. Subsequent Event [Member] Non-current operating lease liabilities Lease liability, less current portion Issuance of common stock upon exercise of warrants (in shares) Number of shares issued during the period for the exercise of warrants. Total lease liabilities us-gaap_OperatingLeaseLiability plse_LesseeOperatingLeaseLiabilityToBePaidAfterYearThree Thereafter Amount of lessee's undiscounted obligation for lease payment for operating lease due after third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). plse_NumberOfWarrantsInEachUnit Number of Warrants in Each Unit (in shares) Represents number of warrants in each unit. Subsequent Event Type [Axis] Current operating lease liabilities Lease liability, current plse_ImpairmentOfMarketableSecurities Impairment of Marketable Securities Amount of impairment of marketable securities. plse_EquityOfferingUnitsMaximumAmountAuthorized Equity Offering, Units, Maximum Amount Authorized (in shares) Maximum amount authorized for units issued under equity offering. Subsequent Event Type [Domain] Subsequent Events [Text Block] Right-of-use assets Laboratory Equipment [Member] Represents laboratory equipment. us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue Total lease payments Acquired Patents and Licenses [Member] Represents acquired patents and licenses. us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount Less imputed interest plse_ClassOfWarransOrRightExercisePricePercentageOfSubscriptionPriceForUnits Class of Warrans or Right, Exercise Price, Percentage of Subscription Price for Units Amount of exercise price of warrants as percentage of subscription price for units. us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree 2027 us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear 2024 (remaining 3 months) us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo 2026 us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths 2025 Loan Agreement [Member] Represents the loan agreement. us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo 2026 Clinical trial fees and costs Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to clinical trial fees and costs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block] us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths 2025 plse_NumberOfSharesPerUnitIssued Number of Shares Per Unit Issued (in shares) Number of shares of stock issued or issuable for each unit. plse_NumberOfWarrantsPerUnit Number of Warrants Per Unit (in shares) Number of warrants issued or issuable for each unit. us-gaap_ShareBasedCompensation Stock-based compensation Other assets us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear 2024 (remaining 3 months) plse_ClassOfWarrantOrRightExerciseConsecutiveTradingDays Class of Warrant or Right, Exercise, Consecutive Trading Days (Day) The consecutive trading days for exercise of warrant or right. plse_ClassOfWarrantOrRightExercisedDuringPeriod Class of Warrant or Right, Exercised During Period (in shares) The number of warrants or rights exercised during period. us-gaap_FiniteLivedIntangibleAssetUsefulLife Finite-Lived Intangible Asset, Useful Life (Year) Earnings Per Share, Policy [Policy Text Block] Rights Offering Warrants [Member] Represents Rights Offering Warrants. plse_ClassOfWarrantOrRightPeriodOfWrittenNoticeForExercise Class of Warrant or Right, Period of Written Notice for Exercise (Day) The period of written notice for warrants or rights to be exercised. plse_ClassOfWarrantOrRightPercentageRequiredForRedemption Class of Warrant or Right, Percentage Required for Redemption The percentage required for redemption of warrant or right. plse_IncreaseInSharesAvailableForIssuanceThresholdOfCommonStockOutstandingPercent Increase in Shares Available for Issuance, Threshold of Common Stock Outstanding, Percent Percentage of threshold of common stock outstanding for increase in shares available for issuance. plse_IncreaseInSharesAvailableForIssuanceThresholdOfCommonStockOutstandingNumberOfShares Increase in Shares Available for Issuance, Threshold of Common Stock Outstanding, Number of Shares (in shares) The number of shares threshold for increase in shares available for issuance. The 2017 Inducement Equity Incentive Plan [Member] Represents the 2017 Inducement Equity Incentive Plan. plse_ClassOfWarrantsOrRightsRedemptionPricePerShare Class of Warrants or Rights, Redemption Price Per Share (in dollars per share) Per share redemption price of warrants or rights. Total assets measured at fair value The 2017 Plan [Member] Represents the 2017 plan. The 2017 Employee Stock Purchase Plan [Member] Represents the 2017 Employee Stock Purchase Plan. Schedule of Finite-Lived Intangible Assets [Table Text Block] Time-based Options [Member] Represents time-based options. plse_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Intrinsic Value Amount of accumulated difference between fair value of underlying shares on dates of grant and exercise price on options granted. us-gaap_LesseeOperatingLeaseTermOfContract Lessee, Operating Lease, Term of Contract (Year) Performance Options [Member] Represents performance options. Depreciation Depreciation us-gaap_SharesIssuedPricePerShare Shares Issued, Price Per Share (in dollars per share) The 2015 Plan, 2017 Plan and Inducement Plan [Member] Represents the 2015 Plan, 2017 Plan and Inducement Plan. us-gaap_AssetsCurrent Total current assets Cash and Cash equivalents Share-Based Payment Arrangement [Policy Text Block] plse_DirectorsAndOfficersLiabilityInsurancePeriod Directors and Officers Liability Insurance, Period (Year) Period of liability insurance for directors and officers. Interest income, net Common stock, $0.001 par value; authorized â€“ 500,000 shares; issued and outstanding â€“ 61,516 shares and 55,144 shares at September 30, 2024 and December 31, 2023, respectively Corporate Headquarters in Hayward, California [Member] Represents corporate headquarters located in Hayward, California. Expansion Premises 1 [Member] Represents Expansion Premises 1. Adjustments to reconcile net loss to net cash used in operating activities: Expansion Premises 2 [Member] Represents Expansion Premises 2. Common stock, shares authorized (in shares) Letter Agreement [Member] Represents Letter Agreement. Common stock, shares issued (in shares) Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share (in dollars per share) Schedule of Information Related to Right-of-use Assets and Lease Liabilities [Table Text Block] Tabular disclosure for all information related to right-of-use assets and lease liabilities. Standard Product Warranty, Policy [Policy Text Block] Statistical Measurement [Domain] Cash paid for operating lease liabilities us-gaap_OperatingLeasePayments Maximum [Member] Supplemental disclosure of noncash investing and financing activities: Minimum [Member] Statistical Measurement [Axis] Preferred stock, $0.001 par value; authorized â€“ 50,000 shares; no shares issued and outstanding Preferred stock, shares issued (in shares) Property, Plant and Equipment [Table Text Block] Preferred stock, shares authorized (in shares) Preferred stock, par value (in dollars per share) Fair Value, Inputs, Level 3 [Member] Fair Value Hierarchy and NAV [Domain] Fair Value, Inputs, Level 1 [Member] Fair Value, Inputs, Level 2 [Member] Fair Value Hierarchy and NAV [Axis] Software and Software Development Costs [Member] Construction in Progress [Member] Cash flows from operating activities: Statement [Line Items] us-gaap_StandardProductWarrantyAccrualCurrent Beginning balance Ending balance Furniture and Fixtures [Member] us-gaap_NumberOfReportableSegments Number of Reportable Segments Revenues: Add: Accruals for warranties issued during the period Additional paid-in capital AOCI Attributable to Parent [Member] Schedule of Product Warranty Liability [Table Text Block] Stockholdersâ€™ equity: Leasehold Improvements [Member] Board of Directors Chairman [Member] us-gaap_NonoperatingIncomeExpense Total other income Long-Lived Tangible Asset [Axis] Segment Reporting Disclosure [Text Block] Long-Lived Tangible Asset [Domain] Current assets: Fair Value Disclosures [Text Block] us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations Cash and cash equivalents at beginning of period Cash and cash equivalents at end of period Private Placement [Member] us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect Net increase (decrease) in cash and cash equivalents us-gaap_NetCashProvidedByUsedInFinancingActivities Net cash provided by financing activities us-gaap_Liabilities Total liabilities Commitments and contingencies (Note 7) Sale of Stock [Axis] Sale of Stock [Domain] us-gaap_OperatingIncomeLoss Loss from operations Other income: us-gaap_NetCashProvidedByUsedInOperatingActivities Net cash used in operating activities us-gaap_NetCashProvidedByUsedInInvestingActivities Net cash used in investing activities Prepaid expenses and other current assets us-gaap_InterestPayableCurrentAndNoncurrent Interest Payable us-gaap_PaymentsOfStockIssuanceCosts Deferred issuance costs in relation to future at-the-market equity offering Warrant exercise, issuance cost adjustment Amount of increase in additional paid in capital (APIC) resulting from issuance cost adjustment for warrants exercise. Costs and Expenses Total cost and expenses Cost and expenses: Proceeds from issuance of common stock under employee stock purchase plan Proceeds from exercises of warrants Proceeds from Warrant Exercises Retained Earnings [Member] Total revenues Proceeds from exercises of stock options us-gaap_ProceedsFromIssuanceOfCommonStock Proceeds from Issuance of Common Stock Title and Position [Domain] Title and Position [Axis] Additional Paid-in Capital [Member] Common Stock [Member] Equity Components [Axis] Equity Component [Domain] us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) Class of Warrant or Right [Axis] Class of Warrant or Right [Domain] us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares) us-gaap_ClassOfWarrantOrRightOutstanding Class of Warrant or Right, Outstanding (in shares) us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest Loss from operations, before income taxes us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) us-gaap_PaymentsOfDebtIssuanceCosts Issuance cost in relation to related party note extinguishment Document Quarterly Report Entity Incorporation, State or Country Code General and Administrative Expense [Member] Accounting Policies [Abstract] Significant Accounting Policies [Text Block] Document Transition Report Basis of Accounting, Policy [Policy Text Block] Entity Interactive Data Current Security Exchange Name Title of 12(b) Security Research and Development Expense [Member] Statement of Income Location, Balance [Axis] Statement of Income Location, Balance [Domain] Rights offering deemed pro-rata distribution to shareholders Right Offering Deemed Dividend Rights offering deemed pro-rata distribution to shareholders (Note 6) The amount of right offering deemed dividends Name of Property [Axis] Name of Property [Domain] plse_EquityOfferingUnitsOfferingValue Equity Offering Units, Offering Value The total cost of the Equity offering of warrants and rights. The 2024 Right Offering [Member] Issuance of equity-classified subscription rights as part of rights offering (Note 6) Equity Classified Subscription, Value The value of Equity classified subscriptions. us-gaap_SharePrice Share Price (in dollars per share) Antidilutive securities (in shares) Market-based Options [Member] Represents market-based options. Performance-based Options [Member] Represents performance based options. Statement [Table] Statement of Financial Position [Abstract] Time-based and Performance Options [Member] Represents time-based and performance options. Weighted average shares used to compute net loss per common share â€“ basic and diluted (in shares) us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration Restructuring Charges, Statement of Income or Comprehensive Income [Extensible Enumeration] Business Acquisition [Axis] Basic and diluted net loss per share (in dollars per share) Business Acquisition, Acquiree [Domain] Equipment purchases included in accounts payable and accrued expenses Amount of equipment purchases included in accounts payable and accrued expenses. Series of Individually Immaterial Business Acquisitions [Member] Statement of Cash Flows [Abstract] Lease Contractual Term [Domain] Statement of Stockholders' Equity [Abstract] Lease Contractual Term [Axis] Income Statement [Abstract] Schedule of Accrued Liabilities [Table Text Block] Warrants Issued in 2024 Rights Offering [Member] Represents the Warrants Issued in 2024 Rights Offering us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated Restructuring and Related Cost, Number of Positions Eliminated Type of Restructuring [Domain] Employee Severance [Member] Restructuring and Related Activities Disclosure [Text Block] Fair Value, Assets Measured on Recurring Basis [Table Text Block] Restructuring Type [Axis] Cash flows from financing activities: Employee Stok Purchase Plan [Member] Represents the employee stock purchase plan us-gaap_StockholdersEquity Total stockholdersâ€™ equity Balance Balance Class of Stock [Axis] Options exercisable, weighted average exercise price (in dollars per share) EX-101.PRE 8 plse-20240930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 10 R1.htm IDEA: XBRL DOCUMENT v3.24.3 Document And Entity Information - shares 9 Months Ended Sep. 30, 2024 Oct. 25, 2024 Document Information [Line Items] Â Â Entity Central Index Key 0001625101 Â Entity Registrant Name Pulse Biosciences, Inc. Â Amendment Flag false Â Current Fiscal Year End Date --12-31 Â Document Fiscal Period Focus Q3 Â Document Fiscal Year Focus 2024 Â Document Type 10-Q Â Document Quarterly Report true Â Document Period End Date Sep. 30, 2024 Â Document Transition Report false Â Entity File Number 001-34899 Â Entity Incorporation, State or Country Code DE Â Entity Tax Identification Number 46-5696597 Â Entity Address, Address Line One 601Â Brickell Key Drive Â Entity Address, City or Town Miami Â Entity Address, State or Province FL Â Entity Address, Postal Zip Code 33131 Â City Area Code 510 Â Local Phone Number 906-4600 Â Title of 12(b) Security Common Stock, par value $0.001 per share Â Trading Symbol PLSE Â Security Exchange Name NASDAQ Â Entity Current Reporting Status Yes Â Entity Interactive Data Current Yes Â Entity Filer Category Non-accelerated Filer Â Entity Small Business true Â Entity Emerging Growth Company false Â Entity Shell Company false Â Entity Common Stock, Shares Outstanding Â 61,516,677 X - DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission. + ReferencesNo definition available. + Details Name: dei_AmendmentFlag Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionArea code of city + ReferencesNo definition available. + Details Name: dei_CityAreaCode Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionEnd date of current fiscal year in the format --MM-DD. + ReferencesNo definition available. + Details Name: dei_CurrentFiscalYearEndDate Namespace Prefix: dei_ Data Type: xbrli:gMonthDayItemType Balance Type: na Period Type: duration X - DefinitionFiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY. + ReferencesNo definition available. + Details Name: dei_DocumentFiscalPeriodFocus Namespace Prefix: dei_ Data Type: dei:fiscalPeriodItemType Balance Type: na Period Type: duration X - DefinitionThis is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006. + ReferencesNo definition available. + Details Name: dei_DocumentFiscalYearFocus Namespace Prefix: dei_ Data Type: xbrli:gYearItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: dei_DocumentInformationLineItems Namespace Prefix: dei_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD. + ReferencesNo definition available. + Details Name: dei_DocumentPeriodEndDate Namespace Prefix: dei_ Data Type: xbrli:dateItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true only for a form used as an quarterly report. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Form 10-Q -Number 240 -Section 308 -Subsection a + Details Name: dei_DocumentQuarterlyReport Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true only for a form used as a transition report. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Forms 10-K, 10-Q, 20-F -Number 240 -Section 13 -Subsection a-1 + Details Name: dei_DocumentTransitionReport Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'. + ReferencesNo definition available. + Details Name: dei_DocumentType Namespace Prefix: dei_ Data Type: dei:submissionTypeItemType Balance Type: na Period Type: duration X - DefinitionAddress Line 1 such as Attn, Building Name, Street Name + ReferencesNo definition available. + Details Name: dei_EntityAddressAddressLine1 Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionName of the City or Town + ReferencesNo definition available. + Details Name: dei_EntityAddressCityOrTown Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionCode for the postal or zip code + ReferencesNo definition available. + Details Name: dei_EntityAddressPostalZipCode Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionName of the state or province. + ReferencesNo definition available. + Details Name: dei_EntityAddressStateOrProvince Namespace Prefix: dei_ Data Type:

dei:stateOrProvinceItemType Balance Type: na Period Type: duration X - DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityCentralIndexKey Namespace Prefix: dei_ Data Type: dei:centralIndexKeyItemType Balance Type: na Period Type: duration X - DefinitionIndicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument. + ReferencesNo definition available. + Details Name: dei_EntityCommonStockSharesOutstanding Namespace Prefix: dei_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionIndicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure. + ReferencesNo definition available. + Details Name: dei_EntityCurrentReportingStatus Namespace Prefix: dei_ Data Type: dei:yesNoItemType Balance Type: na Period Type: duration X - DefinitionIndicate if registrant meets the emerging growth company criteria. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityEmergingGrowthCompany Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen. + ReferencesNo definition available. + Details Name: dei_EntityFileNumber Namespace Prefix: dei_ Data Type: dei:fileNumberItemType Balance Type: na Period Type: duration X - DefinitionIndicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityFilerCategory Namespace Prefix: dei_ Data Type: dei:filerCategoryItemType Balance Type: na Period Type: duration X - DefinitionTwo-character EDGAR code representing the state or country of incorporation. + ReferencesNo definition available. + Details Name: dei_EntityIncorporationStateCountryCode Namespace Prefix: dei_ Data Type: dei:edgarStateCountryItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-T -Number 232 -Section 405 + Details Name: dei_EntityInteractiveDataCurrent Namespace Prefix: dei_ Data Type: dei:yesNoItemType Balance Type: na Period Type: duration X - DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityRegistrantName Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityShellCompany Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionIndicates that the company is a Smaller Reporting Company (SRC). + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntitySmallBusiness Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityTaxIdentificationNumber Namespace Prefix: dei_ Data Type: dei:employerIdItemType Balance Type: na Period Type: duration X - DefinitionLocal phone number for entity. + ReferencesNo definition available. + Details Name: dei_LocalPhoneNumber Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionTitle of a 12(b) registered security. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b + Details Name: dei_Security12bTitle Namespace Prefix: dei_ Data Type: dei:securityTitleItemType Balance Type: na Period Type: duration X - DefinitionName of the Exchange on which a security is registered. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1 + Details Name: dei_SecurityExchangeName Namespace Prefix: dei_ Data Type: dei:edgarExchangeCodeItemType Balance Type: na Period Type: duration X - DefinitionTrading symbol of an instrument as listed on an exchange. + ReferencesNo definition available. + Details Name: dei_TradingSymbol Namespace Prefix: dei_ Data Type: dei:tradingSymbolItemType Balance Type: na Period Type: duration XML 11 R2.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($) $ in Thousands Sep. 30, 2024 Dec. 31, 2021 Current assets: Â Â Cash and cash equivalents $ 79,033 $ 44,365 Prepaid expenses and other current assets 1,381 963 Total current assets 80,414 45,328 Property and equipment, net 1,221 1,528 Intangible assets, net 1,386 1,886 Goodwill 2,791 2,791 Right-of-use assets 6,588 7,256 Other assets 646 365 Total assets 93,046 59,154 Current liabilities: Â Â Accounts payable 1,727 1,836 Accrued expenses 3,821 3,814 Lease liability, current 1,193 1,058 Total current liabilities 6,741 6,708 Lease liability, less current portion 7,174 8,086 Total liabilities 13,915 14,794 Commitments and contingencies (Note 7) Stockholdersâ€™ equity: Â Â Preferred stock, $0.001 par value; authorized â€“ 50,000 shares; no shares issued and outstanding 0 0 Common stock, $0.001 par value; authorized â€“ 500,000 shares; issued and outstanding â€“ 61,516 shares and 55,144 shares at September 30, 2024 and December 31, 2023, respectively 62 55 Additional paid-in capital 450,184 381,220 Accumulated other comprehensive income (loss) 0 0 Accumulated deficit (371,115) (336,915) Total stockholdersâ€™ equity 79,131 44,360 Total liabilities and stockholdersâ€™ equity $ 93,046 $ 59,154 X - DefinitionCarrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10 + Details Name: us-gaap_AccountsPayableCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AccruedLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 14A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14AReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14 + Details Name: us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionValue received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AdditionalPaidInCapitalCommonStock Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of asset recognized for present right to economic benefit. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 12: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 13: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(12)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 19: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(11)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_Assets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of asset recognized for present right to economic benefit, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI

https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 10: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7 + Details Name: us-gaap_AssetsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_AssetsCurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashAndCashEquivalentsAtCarryingValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionRepresents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(15)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_CommitmentsAndContingencies Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap_CommonStockValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 926 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5 + Details Name: us-gaap_FiniteLivedIntangibleAssetsNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(15)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482598/350-20-45-1Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(10)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_Goodwill Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(26)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 15: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(14)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 29: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 + Details Name: us-gaap_Liabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -

SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(32)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LiabilitiesAndStockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionTotal obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7 + Details Name: us-gaap_LiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_LiabilitiesCurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiabilityCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiabilityNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's right to use underlying asset under operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseRightOfUseAsset Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of noncurrent assets classified as other. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_OtherAssetsNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap_PreferredStockValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_PrepaidExpenseAndOtherAssetsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7AReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 360 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1 + Details Name: us-gaap_PropertyPlantAndEquipmentNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of accumulated undistributed earnings (deficit). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_RetainedEarningsAccumulatedDeficit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2 + Details Name: us-gaap_StockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_StockholdersEquityAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 12 R3.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - $ / shares shares in Thousands Sep. 30, 2024 Dec. 31, 2021 Preferred stock, par value (in dollars per share) $ 0.001 $ 0.001 Preferred stock, shares authorized (in shares) 50,000 50,000 Preferred stock, shares issued (in shares) 0 0 Preferred stock, shares outstanding (in shares) 0 0 Common stock, par value (in dollars per share) $ 0.001 $ 0.001 Common stock, shares authorized (in shares) 500,000 500,000 Common stock, shares issued (in shares) 61,516 55,144 Common stock, shares outstanding (in shares) 61,516 55,144 X - DefinitionFace amount or stated value per share of common stock. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe maximum number of common shares permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_CommonStockSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionTotal number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockSharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares of common stock outstanding. Common stock represent the ownership interest in a corporation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -

Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 + Details Name: us-gaap_CommonStockSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionFace amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13 + Details Name: us-gaap_PreferredStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_PreferredStockSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13 + Details Name: us-gaap_PreferredStockSharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionAggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 + Details Name: us-gaap_PreferredStockSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant XML 13 R4.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) shares in Thousands, $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Revenues: Â Â Â Â Total revenues $ 0 $ 0 $ 0 $ 0 Cost and expenses: Â Â Â Â Research and development 7,703 7,472 21,674 19,998 General and administrative 5,952 3,780 14,322 11,043 Total cost and expenses 13,655 11,252 35,996 31,041 Loss from operations (13,655) (11,252) (35,996) (31,041) Other income: Â Â Â Â Interest income, net 975 686 1,796 764 Total other income 975 686 1,796 764 Loss from operations, before income taxes (12,680) (10,566) (34,200) (30,277) Income tax benefit 0 0 0 0 Net loss (12,680) (10,566) (34,200) (30,277) Comprehensive loss $ (12,680) $ (10,566) $ (34,200) $ (30,277) Net loss per share: Â Â Â Â Basic and diluted net loss per share (in dollars per share) $ (0.21) $ (0.19) $ (0.6) $ (0.64) Weighted average shares used to compute net loss per common share â€“ basic and diluted (in shares) 61,066 56,866 57,169 47,288 X - DefinitionAmount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(26)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-5 + Details Name: us-gaap_ComprehensiveIncomeNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionTotal costs of sales and operating expenses for the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_CostsAndExpenses Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_CostsAndExpensesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_EarningsPerShareAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareBasic Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1 + Details Name: us-gaap_GeneralAndAdministrativeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(11)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 9: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(10)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(15)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 231 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 6.I.7) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(9)) -Publisher FASB -

URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Subparagraph (a) -SubTopic 20 -Topic 740 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(h)) -SubTopic 10 -Topic 235 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1 + Details Name: us-gaap_IncomeTaxExpenseBenefit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of interest income (expense) classified as nonoperating. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48 + Details Name: us-gaap_InterestIncomeExpenseNonoperatingNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_NonoperatingIncomeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NonoperatingIncomeExpenseAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe net result for the period of deducting operating expenses from operating revenues. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31 + Details Name: us-gaap_OperatingIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 912 -SubTopic 730 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1 + Details Name: us-gaap_ResearchAndDevelopmentExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4 + Details Name: us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_RevenuesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionNumber of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10 + Details Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration XML 14 R5.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Cash flows from operating activities: Â Â Net loss $ (34,200) $ (30,277) Adjustments to reconcile net loss to net cash used in operating activities: Â Â Depreciation 391 404 Amortization of intangible assets 500 499 Stock-based compensation 6,793 3,837 Changes in operating assets and liabilities: Â Â Prepaid expenses and other current assets (394) (343) Other receivables 7 114 Right-of-use assets 668 596 Accounts payable (194) (174) Accrued expenses 7 409 Lease liabilities (777) (656) Accrued interest on related party note payable 0 (668) Net cash used in operating activities (27,199) (26,259) Cash flows from investing activities: Â Â Purchases of property and equipment (72) (78) Net cash used in investing activities (72) (78) Cash flows from financing activities: Â Â Proceeds from issuance of common stock under employee stock purchase plan 478 395 Proceeds from issuance of common stock and warrants in relation to rights offering, net of issuance costs 59,649 0 Proceeds from exercises of warrants 1,536 14,828 Proceeds from exercises of stock options 498 367 Issuance cost in relation to related party note extinguishment 0 (6) Deferred issuance costs in relation to future at-the-market equity offering

(222) 0 Net cash provided by financing activities 61,939 15,584 Net increase (decrease) in cash and cash equivalents 34,668 (10,753) Cash and cash equivalents at beginning of period 44,365 61,139 Cash and cash equivalents at end of period 79,033 50,386 Supplemental disclosure of noncash investing and financing activities: Â Â Equipment purchases included in accounts payable and accrued expenses 13 13 Rights offering deemed pro-rata distribution to shareholders 47,700 0 Principal and accrued interest of related party note settled via issuance of common stock 0 65,249 Other receivable from exercises of warrants 30 0 Rights offering and at-the-market issuance costs in accounts payable $ 72 $ 0 X - DefinitionAmount of equipment purchases included in accounts payable and accrued expenses. + ReferencesNo definition available. + Details Name: plse_EquipmentPurchasesIncludedInAccountsPayableAndAccruedExpenses Namespace Prefix: plse_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of increase (decrease) in operating lease right of use asset. + ReferencesNo definition available. + Details Name: plse_IncreaseDecreaseInOperatingLeaseRightOfUseAsset Namespace Prefix: plse_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe amount of issuance costs that were incurred during a noncash or partial noncash transaction. + ReferencesNo definition available. + Details Name: plse_IssuanceCostsIncurredInNoncashOrPartNoncashTransaction Namespace Prefix: plse_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe amount of other receivable from exercise of warrants. + ReferencesNo definition available. + Details Name: plse_OtherReceivableFromExerciseOfWarrants Namespace Prefix: plse_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe amount of cash inflow from issuance of common stock and warrants. + ReferencesNo definition available. + Details Name: plse_ProceedsFromIssuanceOfCommonStockAndWarrants Namespace Prefix: plse_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe amount of right offering deemed dividends + ReferencesNo definition available. + Details Name: plse_RightOfferingDeemedDividend Namespace Prefix: plse_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2 + Details Name: us-gaap_AmortizationOfIntangibleAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 1 -SubTopic 230 -Topic 830 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1 + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1 + Details Name: us-gaap_Depreciation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInAccountsPayable Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInAccruedLiabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the amount owed by the reporting entry in the form of loans and obligations (generally evidenced by promissory notes) made by the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management, an entity and its principal owners, management, or member of their immediate families, affiliates, or other parties with the ability to exert significant influence. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInNotesPayableRelatedParties Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_IncreaseDecreaseInOperatingCapitalAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of increase (decrease) in obligation for operating lease. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(1) -SubTopic 20 -Topic 842 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_IncreaseDecreaseInOperatingLeaseLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of increase (decrease) in receivables classified as other. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInOtherReceivables Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of increase (decrease) in prepaid expenses, and assets classified as other. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24 + Details Name: us-gaap_NetCashProvidedByUsedInFinancingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24 + Details Name: us-gaap_NetCashProvidedByUsedInInvestingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25 + Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25:

http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 15 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15 + Details Name: us-gaap_PaymentsOfDebtIssuanceCosts Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash outflow for cost incurred directly with the issuance of an equity security. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15 + Details Name: us-gaap_PaymentsOfStockIssuanceCosts Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13 + Details Name: us-gaap_PaymentsToAcquirePropertyPlantAndEquipment Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash inflow from exercise of option under share-based payment arrangement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2A -Subparagraph (a) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A + Details Name: us-gaap_ProceedsFromStockOptionsExercised Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash inflow associated with the amount received from the stock plan during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromStockPlans Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash inflow associated with the amount received from holders exercising their stock warrants. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromWarrantExercises Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of noncash expense for share-based payment arrangement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_ShareBasedCompensation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe fair value of stock issued in noncash financing activities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5 + Details Name: us-gaap_StockIssued1 Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration XML 15 R6.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Consolidated Statements of Stockholders' Equity (Deficit) (Unaudited) - USD ($) shares in Thousands, $ in Thousands Rights Offering [Member] Common Stock [Member] Rights Offering [Member] Additional Paid-in Capital [Member] Rights Offering [Member] AOCI Attributable to Parent [Member] Rights Offering [Member] Retained Earnings [Member] Rights Offering [Member] Private Placement [Member] Common Stock [Member] Private Placement [Member] Additional Paid-in Capital [Member] Private Placement [Member] AOCI Attributable to Parent [Member] Private Placement [Member] Retained Earnings [Member] Private Placement [Member] ATM Offering [Member] Common Stock [Member] ATM Offering [Member] Additional Paid-in Capital [Member] ATM Offering [Member] AOCI Attributable to Parent [Member] ATM Offering [Member] Retained Earnings [Member] ATM Offering [Member] Common Stock [Member] Additional Paid-in Capital [Member] AOCI Attributable to Parent [Member] Retained Earnings [Member] Total Balance (in shares) at Dec. 31, 2022 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â 37,235 Â Â Â Â Balance at Dec. 31, 2022 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â $ 37 $ 292,420 $ 0 $ (294,705) $ (2,248) Issuance of common stock upon exercise of warrants (in shares) Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â 7,238 Â Â Â Â Issuance of common stock upon exercise of warrants Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â $ 7 14,821 0 0 14,828 Issuance of common stock upon exercise of stock options (in shares) Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â 148 Â Â Â Â Issuance of common stock upon exercise of stock options Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â $ 0 367 0 0 367 Issuance of shares under employee stock purchase plan (in shares) Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â 347 Â Â Â Â Issuance of shares under employee stock purchase plan Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â $ 1 394 0 0 395 Stock-based compensation expense Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â 0 3,837 0 0 3,837 Net loss Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â $ 0 0 0 (30,277) (30,277) Rights offering deemed pro-rata distribution to shareholders (Note 6) Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â 0 Issuance of common stock as part of debt extinguishment, net of issuance costs of $6 (in shares) Â Â Â Â Â 10,023 Â Â Â Â Â Â Â Â Â Â Â Â Â Issuance of common stock as part of debt extinguishment, net of issuance costs of $6 Â Â Â Â Â $ 10 $ 65,233 $ 0 $ 0 $ 65,243 Â Â Â Â Â Â Â Â Â Â Â Â Â Balance (in shares) at Sep. 30, 2023 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â 54,991 Â Â Â Â Balance at Sep. 30, 2023 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â $ 55 377,072 0 (324,982) 52,145 Balance (in shares) at Jun. 30, 2023 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â 54,771 Â Â Â Â Balance at Jun. 30, 2023 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â $ 55 374,861 0 (314,416) 60,500 Issuance of common stock upon exercise of stock options (in shares) Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â 135 Â Â Â Â Issuance of common stock upon exercise of stock options Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â $ 0 309 0 0 309 Issuance of shares under employee stock purchase plan (in shares) Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â 85 Â Â Â Â Issuance of shares under employee stock purchase plan Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â $ 0 103 0 0 103 Stock-based compensation expense Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â 0 1,798 0 0 1,798 Net loss Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â 0 0 0 (10,566) (10,566) Warrant exercise, issuance cost adjustment Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â $ 0 1 0 0 1 Balance (in shares) at Sep. 30, 2023 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â 54,991 Â Â Â Â Balance at Sep. 30, 2023 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â $ 55 377,072 0 (324,982) 52,145 Balance (in shares) at Dec. 31, 2023 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â 55,144 Â Â Â Â Balance at Dec. 31, 2023 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â $ 55 381,220 0 (336,915) 44,360 Issuance of shares (in shares) 6,000 Â Â Â Â Â Â Â Â Â 1 Â Â Â Â Â Â Â Â Â Issuance of shares $ 6 $ 59,630 $ 0 $ 0 $ 59,636 Â Â Â Â Â $ 0 $ 0 $ 0 $ 0 Â Â Â Â Â Â Issuance of common stock upon exercise of warrants (in shares) Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â 142 Â Â Â Â Issuance of common stock upon exercise of warrants Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â $ 1 1,565 0 0 1,566 Issuance of common stock upon exercise of stock options (in shares) Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â 111 Â Â Â Â Issuance of common stock upon exercise of stock options Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â $ 0 498 0 0 498 Issuance of shares under employee stock purchase plan (in shares) Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â 118 Â Â Â Â Issuance of shares under employee stock purchase plan Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â $ 0 478 0 0 478 Stock-based compensation expense Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â 0 6,793 0 0 6,793 Net loss Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â 0 0 0 (34,200) (34,200) Issuance of equity-classified subscription rights as part of rights offering (Note 6) Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â 0 47,700 0 0 47,700 Rights offering deemed pro-rata distribution to shareholders (Note 6) Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â $ 0 (47,700) 0 0 (47,700) Balance (in shares) at Sep. 30, 2024 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â 61,516 Â Â Â Â Balance at Sep. 30, 2024 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â $ 62 450,184 0 (371,115) 79,131 Balance (in shares) at Jun. 30, 2024 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â 55,228 Â Â Â Â Balance at Jun. 30, 2024 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â $ 55 385,349 0 (358,435) 26,969 Issuance of shares (in shares) 6,000 Â Â Â Â Â Â Â Â Â 1 Â Â Â Â Â Â Â Â Â Issuance of shares $ 6 $ 59,630 $ 0 $ 0 $ 59,636 Â Â Â Â Â $ 0 $ 0 $ 0 $ 0 Â Â Â Â Â Â Issuance of common stock upon exercise of warrants (in shares) Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â 142 Â Â Â Â Issuance of common stock upon exercise of warrants Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â $ 1 1,565 0 0 1,566 Issuance of common stock upon exercise of stock options (in shares) Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â 105 Â Â Â Â Issuance of common stock upon exercise of stock options Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â $ 0 476 0 0 476 Issuance of shares under employee stock purchase plan (in shares) Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â 40 Â Â Â Â Issuance of shares under employee stock purchase plan Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â $ 0 182 0 0 182 Stock-based compensation expense Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â 0 2,982 0 0 2,982 Net loss Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â $ 0 0 0 (12,680) (12,680) Balance (in shares) at Sep. 30, 2024 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â 61,516 Â Â Â Â Balance at Sep. 30, 2024 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â $ 62 $ 450,184 $ 0 $ (371,115) $ 79,131 X - DefinitionAmount of increase in additional paid in capital (APIC) resulting from issuance cost adjustment for warrants exercise. + ReferencesNo definition available. + Details Name: plse_AdjustmentsToAdditionalPaidInCapitalWarrantsExerciseIssuanceCostAdjustment Namespace Prefix: plse_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe value of Equity classified subscriptions. + ReferencesNo definition available. + Details Name: plse_EquityClassifiedSubscriptionValue Namespace Prefix: plse_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe amount of right offering deemed dividends + ReferencesNo definition available. + Details Name: plse_RightOfferingDeemedDividend Namespace Prefix: plse_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionNumber of shares issued during the period for the exercise of warrants. + ReferencesNo definition available. + Details Name: plse_StockIssuedDuringPeriodSharesExerciseOfWarrants Namespace Prefix: plse_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionValue of stock issued during the period for the exercise of warrants. + ReferencesNo definition available. + Details Name: plse_StockIssuedDuringPeriodValueExerciseOfWarrants Namespace Prefix: plse_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 20 -Section 55 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481089/718-20-55-13Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 20 -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481089/718-20-55-12 + Details Name: us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI

https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionNumber of shares issued which are neither cancelled nor held in the treasury. + ReferencesNo definition available. + Details Name: us-gaap_SharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares issued during the period as a result of the conversion of convertible securities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of shares issued during the period as a result of an employee stock purchase plan. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of new stock issued during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of share options (or share units) exercised during the current period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe gross value of stock issued during the period upon the conversion of convertible securities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAggregate change in value for stock issued during the period as a result of employee stock purchase plan. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionEquity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodValueNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionValue of stock issued as a result of the exercise of stock options. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 11:

http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2 + Details Name: us-gaap_StockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 16 R7.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Consolidated Statements of Stockholders' Equity (Deficit) (Unaudited) (Parentheticals) - USD ($) $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2024 Sep. 30, 2023 Rights Offering [Member] Â Â Â Issuance cost $ 364 $ 364 Â Private Placement [Member] Â Â Â Issuance cost Â Â $ 6 ATM Offering [Member] Â Â Â Issuance cost $ 24 $ 24 Â Issuance cost Â Â $ 9 X - DefinitionAmount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=plse_RightsOfferingMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=plse_AtmOfferingMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 17 R8.htm IDEA: XBRL DOCUMENT v3.24.3 Note 1 - Description of the Business 9 Months Ended Sep. 30, 2024 Notes to Financial Statements Â Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] 1. Description of the Business Â Pulse Biosciences, Inc. is a novel bioelectric medicine company committed to health innovation using its patented Nano-pulse Stimulation ("NPS")Â technology, a revolutionary energy modality that delivers nanosecond-duration pulses of electrical energy, each less than aÂ millionth of a second long, to nonthermally clear targeted cells while sparing adjacent noncellular materials. NPS technology, also referred to asÂ Nanosecond Pulsed-Field AblationÂ ("nsPFA" or "nano-PFA")Â technology when used to ablate cellular tissue, can be used to treat a variety of medical conditions for which an optimal solution remains unfulfilled. The Company developed its proprietary CellFX System, a novel nano-PFA delivery platform, and commercialized the initial application of its nano-PFA technology to treat benign lesions of the skin. In parallel, the Company has designed a variety of applicators, or disposables, to explore the potential use of the CellFX platform to treat disorders in other medical specialties, such as cardiology, gastroenterology, gynecology, and ear, nose and throat. These applicators include devices for open surgical procedures, endoscopic or minimally invasive procedures, and endoluminal catheters, and each has been used in preclinical studies. Based on our preclinical experience and the potential to significantly improve outcomes for patients in a large and growing market, the Company decided in 2022 to focus its primary efforts on the use of nsPFA energy and the CellFX platform in the treatment of atrial fibrillation ("AF") and in a select few other markets where it could have a profound positive impact on healthcare for both patients and providers, such as soft tissue ablation. Â The Company was incorporated in Nevada on May 19, 2014. On June 18, 2018, the Company reincorporated from the State of Nevada to the State of Delaware. The Company is located in Miami, Florida, and continues to maintain its offices in Hayward, California. The Company maintains a website at www.pulsebiosciences.com where general information about the Company is available. Â The Companyâ€™s activities are subject to significant risks and uncertainties, including the need for additional capital. The Company does not currently have any material cash flows from operations. ItÂ currently generates no revenue and will need to raise additional capital to finance its operations. However, there can be no assurances that the Company will be able to obtain additional financing on acceptable terms and in the amounts necessary to fully fund its operating requirements. X - ReferencesNo definition available. + Details Name: us-gaap_DisclosureTextBlockAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480424/946-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480424/946-10-50-2Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 810 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/810/tableOfContentReference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/205/tableOfContent + Details Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 18 R9.htm IDEA: XBRL DOCUMENT v3.24.3 Note 2 - Summary of Significant Accounting Policies 9 Months Ended Sep. 30, 2024 Notes to Financial Statements Â Significant Accounting Policies [Text Block] 2. Summary of Significant Accounting Policies Â Basis of Presentation Â The accompanying unaudited condensed consolidated financial statements have been prepared on a basis consistent with the Companyâ€™s Â December 31, 2023 audited Consolidated Financial Statements and include all adjustments, consisting of only normal recurring adjustments, necessary to fairly state the information set forth herein. The condensed consolidated financial statements have been prepared in accordance with the applicable rules and regulations of the Securities and Exchange Commission (the â€œSECâ€) and, as permitted by such rules and regulations, omit certain information and footnote disclosures necessary to present the financial statements in accordance with accounting principles generally accepted in the United States (â€œU.S. GAAPâ€). The condensed consolidated balance sheet as ofÂ December 31, 2023 was derived from the audited consolidated financial statements as of that date but does not include all of the information and footnotes required by U.S. GAAP for complete financial statements. These condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Companyâ€™s Annual Report on Form 10-K for the year ended December 31, 2023. The results of operations for the three-month and nine-month periods ended September 30, 2024, are not necessarily indicative of the results to be expected for the entire year or any future periods. Â Principles of Consolidation Â The accompanying condensed consolidated financial statements include the financial statements of Pulse Biosciences, Inc. and its wholly-owned subsidiaries. Intercompany balances and transactions, if any, have been eliminated in consolidation. Â Use of Estimates Â The preparation of financial statements in conformity with U.S. GAAP requires the Company to make estimates that affect the amounts reported in the financial statements and accompanying notes to the financial statements. Estimates include, but areÂ notÂ limited to, the valuation and recognition of stock-based compensation, the valuation of equity-classified subscription rights, inventory valuation, warranty obligations, income taxes, and the useful lives assigned to long-lived assets. The Company evaluates its estimates and assumptions based on historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances dictate. Actual results could differ materially from these estimates. Â Significant Accounting Policies Â The Companyâ€™s significant accounting policies are described in the Companyâ€™s Annual Report on Form 10-K for the year ended December 31, 2023. The Company continually evaluates the accounting policies and estimates used in preparing the consolidated financial statements. During both the year ended December 31, 2023, and the nine-month period ended September 30, 2024, theÂ Company issuedÂ stock options to certain employees which contain market conditions related to overall market capitalization. Additionally, the Company has issued stock options to certain employees which contain performance conditions related to certain financial measures and achievements of strategic and operational milestones. Â Stock-Based Compensation Â The Company's stock-based compensation programs include stock options and an employee stock purchase program. Â The Company periodically issues stock optionsÂ to officers, directors, employees, and consultants for services rendered. Such issuances vest and expire according to terms established at the issuance date. Stock-based payments to officers, directors and employees, including grants of employee stock options, are recognized in the financial statements based on their grant date fair values, which are estimated using the Black-Scholes option-pricing model. Stock-based compensation expenseÂ is charged to operations on a straight-line basis over the vesting period. The CompanyÂ hasÂ granted stock options with both time-based as well as performance-based vesting conditions.Â For stock awards with performance-based vesting conditions,Â the Company doesÂ notÂ recognize compensation expense until it is probable that the performance-based vesting condition will be achieved.Â TheÂ analysis to determine such probabilityÂ involves estimates and judgements from management and the estimate of expenseÂ mayÂ beÂ revised periodically.Â Â Â The Company hasÂ also issued certain stock options withÂ market-based vesting conditions. These vesting conditions relate to the achievement ofÂ certainÂ market capitalization targetsÂ of the Company. The grant date fair value for these stock options was determined using a Monte Carlo simulation. The expense is recognized over the requisite service period for each tranche of the awards. The requisite service period is the service period derived from the Monte Carlo simulation model. If the market capitalization targets are met sooner than the derived service period, the CompanyÂ will accelerate the recognition of stock-based compensation expense to reflect the cumulative expense associated with the vested shares.Â The Monte Carlo simulation requires the Company to make assumptions and judgements about the variables used in the calculation including the expected term, volatility of the Company's common stock, an assumed risk-free interest rate, and cost of equity. The assumptions used in theÂ option-pricing modelÂ represent managementâ€™s best estimates. If factors change and different assumptions are used, the Company'sÂ stock-based compensation expense could be materially different in the future. Â See NoteÂ 6Â for a detailed discussion of the Companyâ€™s stock plans and stock-based compensation expense. Â Product Warranty Â The Company provides a standard warranty on eligible products which provides the customer assurances that the products comply with the agreed-upon specifications. The standard warranty doesÂ notÂ provide any services in addition to those assurances. The Company accrued a warranty reserve for products sold based upon the best estimate of the nature, frequency, and costs of future claims. These estimates are inherently uncertain given the short history of sales, and changes to the historical or projected warranty experienceÂ mayÂ cause material changes to the warranty reserve in the future. In June 2023, the Company reduced the accrued warranty liability to zero. Based upon the Company's shift in focus, there are a limited number of consoles currently covered under the standard warranty. All inventory has been fully written off, therefore the only incremental costs to fulfill a warranty claim in 2024 would be shipping costs or the costs to replace the CellFX nsPFA electrode, which wouldÂ be immaterial in nature. Â Warranty accrual activity consisted of the following for the three-month and nine-month periods endedÂ September 30, 2024 and 2023Â (in thousands): Â Â Â Three Months Ended September 30, Â Â Nine Months Ended September 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Beginning balance Â $â€”Â Â $â€”Â Â $â€”Â Â $50Â Add: Accruals for warranties issued during the period Â Â â€”Â Â Â â€”Â Â Â â€”Â Â Â â€”Â Less: Adjustment for inventory at cost and excessive and obsolete inventory Â Â â€”Â Â Â â€”Â Â Â â€”Â Â Â (50) Ending balance Â $â€”Â Â $â€”Â Â $â€”Â Â $â€”Â Â Net Loss per Share Â The Company calculates basic net loss per share by dividing net loss by the weighted-average number of shares of common stock outstanding during the period. Diluted net loss per share is computed by giving effect to all potential dilutive common stock equivalents outstanding during the period. For purposes of this calculation, options to purchase common stock and common stock warrants are considered common stock equivalents. Potential common shares that have an anti-dilutive effect (i.e., those that increase income per share or decrease loss per share) are excluded from the calculation of diluted net loss per share. Â Based on the Accounting Standards Codification ("ASC") 260-10-55,Â Earnings Per Share - Implementation Guidance and Illustrations, the Company determined that theÂ 2024Â Rights Offering (Note 6), contained a bonus element. A rights offering is deemed to have a bonus element when the exercise price at issuance is less than fair value of the Company's stock. The Company has retroactively adjusted earnings per share and weighted average number of shares outstanding forÂ the bonus elementÂ for priorÂ periods presented. Â Basic and diluted net loss per common share is the same for all periods presented because all warrants, stock options and restricted stock units outstanding are anti-dilutive. Â The following outstanding stock options, and warrantsÂ were excluded from the computation of diluted net loss per share for the periods presented because including them would have had an anti-dilutive effect: Â Â Â Nine Months Ended September 30, Â Â Â 2024 Â Â 2023 Â Common stock warrants Â Â 5,857,680Â Â Â â€”Â Common stock options Â Â 12,327,332Â Â Â 7,902,948Â Total Â Â 18,185,012Â Â Â 7,902,948Â Â Recent Accounting Pronouncements Not Yet Adopted Â In March 2024, the FASB issued ASU No. 2024-02,Â Codification Improvements - Amendments to Remove References to the Concepts Statements, an amendment of the FASB Accounting Standards Codification. The amendments in this ASU are related to the removal of various references to FASB Concept Statements from the codification to make clear distinctions between authoritative and non-authoritative literature in the codification. This ASU is effective for fiscal years beginning after December 15, 2024, with early adoption permitted. The Company does not believe this standard will have an impact on its consolidated financial statements and related disclosures. Â As of September 30, 2024, there were no additional material changes to the information provided regarding recent accounting pronouncements in Note 2, â€œSummary of Significant Accounting Policiesâ€ in the Companyâ€™s Form 10-K for the fiscal year ended December 31, 2023. X - ReferencesNo definition available. + Details Name: us-gaap_DisclosureTextBlockAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for all significant accounting policies of the reporting entity. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 235 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/235/tableOfContent + Details Name: us-gaap_SignificantAccountingPoliciesTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 19 R10.htm IDEA: XBRL DOCUMENT v3.24.3 Note 3 - Fair Value of Financial Instruments 9 Months Ended Sep. 30, 2024 Notes to Financial Statements Â Fair Value Disclosures [Text Block] 3. Fair Value of Financial Instruments Â The authoritative guidance with respect to fair value established a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three levels, and requires that assets and liabilities carried at fair value be classified and disclosed in one of three categories, as presented below. Â Level 1 - Observable inputs such as quoted prices in active markets for an identical asset or liability that the Company has the ability to access as of the measurement date. Financial assets and liabilities utilizing Level 1 inputs include money market funds. Â Level 2 - Inputs, other than quoted prices included within Level 1, which are directly observable for the asset or liability or indirectly observable through corroboration with observable market data. The Company didÂ notÂ classify any of its investments within LevelÂ 2Â of the fair value hierarchy. Â Level 3 - Unobservable inputs for which there is little or no market data for the asset or liability which requires the reporting entity to develop its own assumptions. The Company didÂ notÂ classify any of its investments within Level 3Â of the fair value hierarchy. Â The following table sets forth the fair value of the Companyâ€™s financial instruments measured on a recurring basis as of September 30, 2024 and December 31, 2023, respectively (in thousands): Â Â Â Â September 30, 2024 Â Assets Classification Â Level 1 Â Â Level 2 Â Â Level 3 Â Â Total Â Money market funds Cash and cash equivalents Â $76,386Â Â $â€”Â Â $â€”Â Â $76,386Â Total assets measured at fair value Â $76,386Â Â $â€”Â Â $â€”Â Â $76,386Â Â Â Â Â Â Â December 31, 2023 Â Assets Classification Â Level 1 Â Â Level 2 Â Â Level 3 Â Â Total Â Money market funds Cash and cash equivalents Â $41,184Â Â $â€”Â Â $â€”Â Â $41,184Â Total assets measured at fair value Â $41,184Â Â $â€”Â Â $â€”Â Â $41,184Â Â The Company did not have any financial liabilities measured on a recurring basis as ofÂ September 30, 2024 or December 31, 2023. X - ReferencesNo definition available. + Details Name: us-gaap_DisclosureTextBlockAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information

necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 107 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-107Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6AReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2E -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2EReference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6AReference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6AReference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6AReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6AReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 940 -SubTopic 820 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478119/940-820-50-1 + Details Name: us-gaap_FairValueDisclosuresTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 20 R11.htm IDEA: XBRL DOCUMENT v3.24.3 Note 4 - Balance Sheet Components 9 Months Ended Sep. 30, 2024 Notes to Financial Statements Â Supplemental Balance Sheet Disclosures [Text Block] 4. Balance Sheet Components Â Property and Equipment, Net Â Property and equipment, net consisted of the following (in thousands): Â Â Â September 30, Â Â December 31, Â Â Â 2024 Â Â 2023 Â Leasehold improvements Â $2,519Â Â $2,519Â Laboratory equipment Â Â 1,318Â Â Â 1,247Â Furniture, fixtures and equipment Â Â 966Â Â Â 966Â Software Â Â 272Â Â Â 272Â Construction in progress Â Â 14Â Â Â â€”Â Total property and equipment Â Â 5,089Â Â Â 5,004Â Less: Accumulated depreciation and amortization Â Â (3,868)Â Â (3,476) Total property and equipment, net Â $1,221Â Â $1,528Â Â Depreciation expense was $0.1Â millionÂ for each of the three-month periods ended September 30, 2024 and 2023, and $0.4Â million forÂ each of the nine-month periods ended September 30, 2024 and 2023, respectively. Â Intangible Assets, Net Â Intangible assets primarily consist of acquired licenses to utilize certain patents, know-how and technology relating to the Companyâ€™s NPS technology for biomedical applications acquired from Old Dominion University Research Foundation (â€œODURFâ€), Eastern Virginia Medical School, and the University of Southern California. In addition, the Company entered into a Sponsored Research Agreement with Old Dominion Universityâ€™s Frank Reidy Research Center for Bioelectrics, which includes certain intellectual property rights arising from the research. The Company is amortizing the intangible assets over an estimated useful life of 12 years. Â Intangible assets, net consisted of the following (in thousands): Â Â Â September 30, Â Â December 31, Â Â Â 2024 Â Â 2023 Â Acquired patents and licenses Â $7,985Â Â $7,985Â Less: Accumulated amortization Â Â (6,599)Â Â (6,099) Total intangible assets, net Â $1,386Â Â $1,886Â Â A schedule of the amortization of intangible assets for the remainder of 2024Â and the succeeding twoÂ fiscal years is as follows (in thousands): Â Years ending December 31: Â Â Â Â 2024 (remaining 3 months) Â $165Â 2025 Â Â 665Â 2026 Â Â 556Â Total Â $1,386Â Â Accrued Expenses Â Accrued expenses consisted of the following (in thousands): Â Â Â September 30, Â Â December 31, Â Â Â 2024 Â Â 2023 Â Compensation expense Â $3,111Â Â $3,199Â Clinical trial fees and costs Â Â 80Â Â Â Â 84Â Professional fees Â Â 424Â Â Â Â 343Â Other Â Â 206Â Â Â Â 188Â Total accrued expenses Â $3,821Â Â $3,814Â X - ReferencesNo definition available. + Details Name: us-gaap_DisclosureTextBlockAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/210/tableOfContent + Details Name: us-gaap_SupplementalBalanceSheetDisclosuresTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 21 R12.htm IDEA: XBRL DOCUMENT v3.24.3 Note 5 - Goodwill 9 Months Ended Sep. 30, 2024 Notes to Financial Statements Â Goodwill Disclosure [Text Block] 5. Goodwill Â In 2014, the Company acquired three companies (the â€œAcquisitionsâ€) for aggregate consideration of $5.5Â million. In accordance with ASC Topic 805, Business Combinations, the Company recorded goodwill of $2.8Â million in connection with the Acquisitions as the consideration paid exceeded the fair value of the net tangible assets and the intangible assets acquired. Â In accordance with ASC Topic 350, Intangibles-Goodwill and Other (as amended by Accounting Standards Update 2017-04), the Company reviews goodwill for impairment at least annually or whenever any events or circumstances indicate that it is more likely than not that the fair value of a reporting unit is less than its carrying amount. As of September 30, 2024, there were no indicators of impairment and it was determined that no impairment of goodwill existed. Â X - ReferencesNo definition available. + Details Name: us-gaap_DisclosureTextBlockAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for goodwill. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/350-20/tableOfContent + Details Name: us-gaap_GoodwillDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 22 R13.htm IDEA: XBRL DOCUMENT v3.24.3 Note 6 - Stockholders' Equity and Stock-based Compensation 9 Months Ended Sep. 30, 2024 Notes to Financial Statements Â Share-Based Payment Arrangement [Text Block] 6. Stockholdersâ€™ Equity and Stock-Based Compensation Â 2024 Rights Offering and Subscription Rights Â On March 28, 2024, the Company announced that itsÂ Board of Directors ("Board") unanimously approved plans to initiate a rights offering, whereby the Company would distribute non-transferable subscription rights at no charge to all holders of the Company's common stock, par value $0.001 per share (the "Common Stock"),Â as of the close of business on a record date to be determined. On May 20, 2024, the Company announced that the Board had set May 31, 2024 as the record date (the "Record Date"). All holders of Common Stock as of the Record Date receivedÂ non-transferable subscription rightsÂ to purchase up to an aggregate of six million units (the â€œ2024 Unitsâ€) with an aggregate offering value of up to $60 million (the "2024 Rights Offering") at a price per 2024 Unit equal to the lesser of: (i) $10 (the â€œInitial Priceâ€) and (ii) the volume weighted average price of the Common Stock for the ten trading day period through and including the expiration date, June 26, 2024 (the "Expiration Date"), of the Rights Offering (the â€œAlternate Priceâ€). Each subscription right entitled the holder to purchase 0.10864186 2024 Units for each share of Common Stock owned as of the Record Date.Â Each 2024 Unit consisted of one share of Common Stock and two warrants, each being a warrant to purchase one-half of one share of Common Stock. The subscription rights were to expire and have no value if they were not exercised prior to the Expiration Date. The Company determined that the equity-classified subscription rights representÂ a pro-rata distributionÂ issued to existing stockholders as of the Record Date, which is based on a purchase price of $10 per 2024 Unit as compared to (1) the price of $11.55 per one share of Common Stock on the Record Date, plus (2) the value of the warrants on the Record Date.Â The Company determined the fair value of the equity-classified subscription rights as of the Record Date, which involved the use of a Monte Carlo simulationÂ to value the underlying warrants.Â The Monte Carlo simulation was based on certain significant unobservable inputs, such as aÂ risk-free interest rate, stock price volatility, dividend yield, and expected term of the rights offering. The fair value of the equity-classified subscription rights was $47.7 million and was recorded inÂ equity on the balance sheet as part ofÂ additional paid-in capital. The deemed pro-rata distribution to shareholders of $47.7 million was reflected as an offsetting reduction in additional paid-in capital. The Company is in an accumulated deficit position and has elected a policy ofÂ recognizingÂ the deemed pro-rata distribution to shareholders as a reduction to additional paid-in capital rather than a further increase to its accumulated deficit.Â Â On July 3, 2024, the Company announced the closing of its 2024 Rights Offering. The 2024 Rights Offering resulted in the sale of six millionÂ 2024 Units, at a price of $10.00 per 2024 Unit. Each 2024 Unit consisted of one share of the Companyâ€™s common stock, par value $0.001 per share, and two warrants, each being a warrant to purchase one-half of one share of common stock. The common stock and warrants comprising the 2024 Units separated upon the closing of the 2024 Rights Offering and were issued individually. A total of 5,999,998Â shares of common stock and warrants to acquire up to approximately an additional six million shares of common stock were issued in the offering. The Company received aggregate gross proceeds from the 2024 Rights Offering of $60 million. If exercised, additional gross proceeds of up to $66 million may be received through the exercise of warrants issued in the 2024 Rights Offering. See 2024 Rights Offering Warrants below for additional details of the warrants.Â Robert W. Duggan, the Companyâ€™s majority stockholder and Co-Chairman, purchased approximately 88% of the units offered through theÂ 2024Â Rights Offering. Â Private Placement Securities Purchase Agreement Â OnÂ April 30, 2023,Â the Company entered into a Securities Purchase Agreement with Robert W. Duggan, the Companyâ€™s majorityÂ stockholder and Co-Chairman, pursuant to which the Company agreed to issue and sell to Mr. DugganÂ 10,022,937Â shares of the Companyâ€™s common stock, par value $0.001Â per share, in a Private Placement, at a price per share of $6.51. The parties completed the Private Placement onÂ May 9, 2023,Â after satisfying all pre-closing conditions, and the CompanyÂ issued the full number of shares to Mr. Duggan. TheÂ shares were paid for through the cancellation of the principal sum of $65.0Â million borrowed by the Company pursuant to theÂ 2022Â Loan Agreement (See Note 7),Â together with all accrued and unpaid interest outstanding owed at the time of closing.Â Â 2022 Rights Offering Â OnÂ JuneÂ 9,Â 2022,Â the Company completed a rights offering (theÂ â€œ2022Â Rights Offering") resulting in the sale ofÂ 7,317,072Â units (the â€œ2022 Unitsâ€), at a price of $2.05Â per 2022 Unit, with each 2022 Unit consisting ofÂ oneÂ share of the Companyâ€™s common stock, par value $0.001Â per share, andÂ oneÂ warrant (theÂ â€œ2022Â Rights Offering Warrantsâ€) to purchaseÂ oneÂ share of common stock at a price of $2.05Â per share. The common stock and warrants comprising the 2022 Units separated upon the closing of theÂ 2022Â Rights Offering and were issued individually.Â 7,317,072Â shares of common stock and warrants to acquire up to an additionalÂ 7,317,072Â shares of common stock were issued in theÂ 2022Â Rights Offering. The Company received aggregate gross proceeds from theÂ 2022Â Rights Offering of $15Â million.Â InÂ May 2023,Â the Company delivered an irrevocable notice of redemption to warrant holders and, onÂ June 16, 2023,Â it redeemed the last of the outstandingÂ 2022Â Rights Offering Warrants at a price of $0.01Â per warrant share. See theÂ Common Stock WarrantsÂ section below for further details. Robert W. Duggan, the Companyâ€™s majority stockholder and Co-Chairman, purchased approximatelyÂ 56% of the shares offered through theÂ 2022Â Rights Offering. Â Common Stock Warrants Â 2024Â Rights Offering Warrants Â In connection with the 2024Â Rights Offering, the Company issued 2024Â Rights Offering Warrants to purchase a total of 5,999,999Â shares of its common stock at anÂ exercise price ofÂ $11.00 per whole share, which equals 110% of the subscription price for the Units. The aggregate number of shares of our common stockÂ issuable upon the exercise of each set of warrants included in a given subscription for Units was rounded up to the nearest whole share. Warrants are exercisable immediately and will expire on the fifth anniversary of the closing of the 2024 Rights Offering. Half of the warrants issued in the rights offering are redeemable for $0.01 per underlying share of common stock, on not less than thirty daysâ€™ written notice, if the volume weighted average price of the Companyâ€™s common stock equalsÂ or exceedsÂ 150% of the exercise price for the warrants, or $16.50, for twenty consecutive trading days. The other half of the warrants issued in the rights offering are redeemable for $0.01 per underlying share of common stock, on not less than thirty daysâ€™ written notice, if the volume weighted average price of the Companyâ€™s common stock equalsÂ or exceeds 200% of the exercise price for the warrants,Â or $22.00, for twenty consecutive trading days.Â In both cases the Company canÂ not redeem the warrants prior to the date that is three months after the issuance date.Â As of September 30, 2024, there were 2024Â Rights Offering Warrants to purchase up to 5,857,680 shares of common stock, in aggregate, outstanding. Â 2022 Rights Offering Warrants Â In connection with the 2022 Rights Offering, the Company issued 2022 Rights Offering Warrants to purchase a total of 7,317,072 shares of its common stock at an exercise price of $2.05. The 2022 Rights Offering WarrantsÂ wereÂ subject to redemption by the Company for $0.01 per underlying share of common stock, on not less than 30 days written notice, if the volume weighted average price of the Companyâ€™s common stock equaledÂ or exceededÂ 200% of the exercise price for the warrants, subject to adjustment, per share, for 20 consecutive trading days, provided that the Company couldÂ not redeem the warrants prior to the date that wasÂ three months after the issuance date. On May 10, 2023, the Company issued a press release announcing that on May 9, 2023 the terms for warrant redemption had been met. Pursuant to the redemption, the Company redeemed 66,175Â warrants on the redemption date, June 16, 2023. Prior to the redemption date, warrants to purchaseÂ 7,250,897 sharesÂ were exercised, generating approximately $14.9Â million of total gross proceeds to the Company. As of September 30, 2024, there wereÂ noÂ 2022 Rights Offering Warrants outstanding. Â Equity Plans Â 2017 Equity Incentive Plan and 2017 Inducement Equity Incentive Plan Â The BoardÂ previously adopted, and the Companyâ€™s stockholders approved, the Companyâ€™s 2017 Equity Incentive Plan (the â€œ2017 Planâ€). Â TheÂ 2017Â Plan has aÂ 10-year termÂ and provides for the grant of stock options, stock appreciation rights, restricted stock, RSUs, performance units, and performance shares to employees, directors and consultants of the Company and any parent or subsidiary of the Company, as the Compensation Committee of the BoardÂ mayÂ determine.Â Subject to an annual evergreen increase and adjustment in the case of certain capitalization events, the Company initially reservedÂ 1,500,000Â shares of the Companyâ€™s common stock for issuance pursuant to awards under theÂ 2017Â Plan. In addition, shares remaining available under the Companyâ€™sÂ 2015Â Equity Incentive Plan, as amended (theÂ â€œ2015Â Planâ€), and shares reserved butÂ notÂ issued pursuant to outstanding equity awards that expire or terminate without being exercised or that are forfeited or repurchased by the Company will be added to the shares of common stock available for issuance under theÂ 2017Â Plan. TheÂ 2017Â Plan is administered by the Boardâ€™s Compensation Committee. Effective atÂ both January 1, 2024Â andÂ 2023,Â the number of shares of common stock available under theÂ 2017Â Plan increased byÂ 1,200,000, respectively, pursuant to the evergreen provision of theÂ 2017Â Plan. Under the evergreen provision of theÂ 2017Â Plan, the share increase is determined based on the least of (i)Â 1,200,000Â shares, (ii)Â 4% of the Companyâ€™s common stock outstanding atÂ December 31Â of the immediately preceding year, or (iii) such number of shares as determined by the Board. Additionally,Â the number of shares of common stock available under theÂ 2017Â Plan increased byÂ 1,375,000Â shares as a result of a stockholder vote held at a special meeting of stockholders in December 2023. As of September 30, 2024, a total of 78,490Â shares of common stock remained available for issuance under the 2017 Plan. Â During November 2017, the Board adopted the 2017 Inducement Equity Incentive Plan (the â€œInducement Planâ€) and reserved 1,000,000 shares of the Companyâ€™s common stock for issuance pursuant to equity awards granted under the Inducement Plan. The Inducement Plan was adopted without stockholder approval. Â The Inducement Plan has aÂ 10-year term and provides for the grant of equity-based awards, including non-statutory stock options, RSUs, restricted stock, stock appreciation rights, performance shares, and performance units, and its terms are substantially similar to theÂ 2017Â Plan, including with respect to treatment of equity awards in the event of a â€œmergerâ€ or â€œchange in controlâ€ as defined under the Inducement Plan. Options issued under the Inducement PlanÂ mayÂ have a term up toÂ tenÂ years and have variable vesting provisions. New hire grants toÂ non-executive employees generally vestÂ 25% per year starting upon theÂ firstÂ anniversary of the grant. New hire grants to executive employees generally consist of both time-vesting and performance-vesting options. Equity-based awards issued under the Inducement Plan are only issuable to individualsÂ notÂ previously engaged as employees or individuals returning to employment with the Company following a bona-fide period of non-employment. InÂ May 2021,Â the Board approved an amendment to the Inducement Plan to reserve an additionalÂ 1,000,000Â shares of the Companyâ€™s common stock for issuance pursuant to the Inducement Plan. And, inÂ March 2024,Â the Board approved aÂ secondÂ amendment to the Inducement Plan to reserve an additionalÂ 2,000,000Â shares of the Companyâ€™s common stock for issuance pursuant to the Inducement Plan. As of September

30, 2024, 1,642,626Â shares of common stock remained available for issuance under the Inducement Plan. Â A summary of stock option activity under the 2015 Plan, 2017 Plan, and Inducement Plan for the nine-months endedÂ September 30, 2024 is presented below: Â Â Â Stock Options Outstanding Â Â Â Number of shares Â Â Weighted average exercise price Â Â Weighted average remaining life (in years) Â Balances â€" December 31, 2023 Â Â 9,466,036Â Â $9.01Â Â Â 7.78Â Options granted Â Â 3,017,643Â Â Â 10.38Â Â Â Â Â Options exercised Â Â (110,847)Â Â 4.49Â Â Â Â Â Options canceled Â Â (9,542)Â Â 15.19Â Â Â Â Â Options expired Â Â (35,958)Â Â 19.82Â Â Â Â Â Balances â€" September 30, 2024 Â Â 12,327,332Â Â $9.35Â Â Â 7.67Â Exercisable â€" September 30, 2024 Â Â 4,178,088Â Â $13.32Â Â Â 5.06Â Â Time-based Options Â The Company awards time-based options which vest and become exercisable, subject to the individualâ€™s continued employment or service through the applicable vesting date. Time-based options can have various vesting schedules, most commonly new hire grants which generally vest 25% per year starting upon the first anniversary of the grant. Â A summary of the time-based stock option activity under the 2015 Plan, 2017 Plan and Inducement Plan for the nine-months endedÂ September 30, 2024 is presented below: Â Â Â Stock Options Outstanding Â Â Â Number of shares Â Â Weighted average exercise price Â Â Weighted average remaining life (in years) Â Balances â€" December 31, 2023 Â Â 6,141,906Â Â $10.48Â Â Â 7.07Â Options granted Â Â 2,123,643Â Â Â 11.3Â Â Â Â Â Options exercised Â Â (100,897)Â Â 4.65Â Â Â Â Â Options canceled Â Â (6,542)Â Â 20.82Â Â Â Â Â Options expired Â Â (34,958)Â Â 20.3Â Â Â Â Â Balances â€" September 30, 2024 Â Â 8,123,152Â Â $10.71Â Â Â 7.18Â Exercisable â€" September 30, 2024 Â Â 3,745,410Â Â $13.97Â Â Â 4.84Â Â The fair value of the time-based options granted during the nine-month periodÂ endedÂ September 30, 2024 was $18.7Â million. Â Performance-based Options Â Certain stock options awarded byÂ the CompanyÂ contain performance conditions related to certain financial measures and achievements of strategic and operational milestones. Once a specific performance condition is fulfilled, the associated options will fully vest and become exercisable. Â A summary of the performance-based option activity under the 2017 Plan and Inducement Plan for the nine-months endedÂ September 30, 2024 is presented below: Â Â Â Stock Options Outstanding Â Â Â Number of shares Â Â Weighted average exercise price Â Â Weighted average remaining life (in years) Â Balances â€" December 31, 2023 Â Â 1,224,130Â Â $5.51Â Â Â 8.53Â Options granted Â Â 39,000Â Â Â 8.44Â Â Â Â Â Options exercised Â Â (9,950)Â Â 2.92Â Â Â Â Â Options canceled Â Â (3,000)Â Â 2.92Â Â Â Â Â Options expired Â Â (1,000)Â Â 2.92Â Â Â Â Â Balances â€" September 30, 2024 Â Â 1,249,180Â Â $5.63Â Â Â 7.84Â Exercisable â€" September 30, 2024 Â Â 432,678Â Â $7.69Â Â Â 6.98Â Â The fair value of the performance-basedÂ options granted during the nine-month periodÂ endedÂ September 30, 2024 was $0.3Â million. Â Market-based Options Â Certain stock options awarded byÂ the Company contain market conditions related to achievement of certain market capitalization targets.Â The options will vest and become exercisable once the specific market capitalization targets are fulfilled.Â Â A summary of theÂ market-based option activity under the 2017 PlanÂ for the nine-months endedÂ September 30, 2024 is presented below: Â Â Â Stock Options Outstanding Â Â Â Number of shares Â Â Weighted average exercise price Â Â Weighted average remaining life (in years) Â Balances â€" December 31, 2023 Â Â 2,100,000Â Â $6.78Â Â Â 9.44Â Options granted Â Â 855,000Â Â Â 8.16Â Â Â Â Â Options exercised Â Â â€"Â Â Â â€"Â Â Â Â Â Options canceled Â Â â€"Â Â Â â€"Â Â Â Â Â Options expired Â Â â€"Â Â Â â€"Â Â Â Â Â Balances â€" September 30, 2024 Â Â 2,955,000Â Â $7.18Â Â Â 8.95Â Exercisable â€" September 30, 2024 Â Â â€"Â Â Â â€"Â Â Â â€"Â Â The fair value of the market-based options granted during the nine-month periodÂ endedÂ September 30, 2024 was $5.3Â million. Â The Company estimates the fair value of time-based and performance-based stock options on the grant date using the Black-Scholes option pricing model. The estimated fair value of these employee stock options is amortized on a straight-line basis over the requisite service period of the awards. The Company reviews, and when deemed appropriate, updates the assumptions used on a periodic basis.Â The fair value ofÂ time-based and performance-based stock options was estimated using the following weighted-average assumptions: Â Â Â Three Months Ended September 30, Â Â Nine Months Ended September 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Expected term in years Â Â 5.0 - 6.3Â Â Â 5.0Â Â Â 5.0 - 6.3Â Â Â 5.0 - 6.3Â Expected volatility Â Â 93% - 97%Â Â Â 93%Â Â Â 91% - 97%Â Â Â 89% - 94%Â Risk-free interest rate Â Â 4.5% Â Â Â 3.7% Â Â Â 4.0% - 4.5%Â Â Â 3.7% - 3.8% Â Dividend yield Â Â â€"Â Â Â â€"Â Â Â â€"Â Â Â â€"Â Â The Company estimates the fair value of market-based stock options on the grant date using a Monte Carlo simulation model. The estimated fair value of these employee stock options is amortized over the requisite service period for each tranche of the awards. The requisite service period is the service period derived from the Monte Carlo simulation model. If the market capitalization targets are met sooner than the derived service period, the CompanyÂ will accelerate the recognition of stock-based compensation expense to reflect the cumulative expense associated with the vested shares.Â The fair value of market-basedÂ stock options was estimated using the following weighted-average assumptions: Â Â Â Three Months Ended September 30, Â Â Nine Months Ended September 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Expected term in years Â Â 2.2 - 4.2Â Â Â 4.0 - 6.3Â Â Â 2.2 - 5.8Â Â Â 4.0 - 6.3Â Expected volatility Â Â 90% Â Â Â 90% Â Â Â 90% Â Â Â 90% Â Risk-free interest rate Â Â 3.9% Â Â Â 3.7 - 3.8% Â Â Â 3.9% - 4.4% Â Â Â 3.4 - 3.8% Â Dividend yield Â Â â€"Â Â Â â€"Â Â Â â€"Â Â Â â€"Â Â 2017 Employee Stock Purchase Plan Â The Board previously adopted, and the Company's stockholders approved, the Companyâ€™s 2017 Employee Stock Purchase Plan (the â€œ2017 ESPPâ€). Â The 2017 ESPP is a broad-based plan that provides employees of the Company and its designated affiliates with the opportunity to become stockholders through periodic payroll deductions that are applied towards the purchase of Company common shares at a discount from the then-current market price. Subject to adjustment in the case of certain capitalization events, a total of 250,000 common shares of the Company were available for purchase at adoption of the 2017 ESPP. Pursuant to the 2017 ESPP, the annual share increase pursuant to the evergreen provision is determined based on the least of (i) 450,000 shares, (ii) 1.5% of the Companyâ€™s common stock outstanding at DecemberÂ 31 of the immediately preceding year, or (iii)Â such number of shares as determined by the Board. In 2024, the Company reserved an additional 450,000 shares under the 2017 ESPP pursuant to the evergreen provision. In 2023, the Board waived the evergreen provision and no additional shares were reserved under the 2017 ESPP. During the nineÂ months ended September 30, 2024,Â the Company issued 117,539Â shares of common stock under the 2017 ESPP. As of September 30, 2024, 445,779Â shares of common stock remained available for issuance under the 2017 ESPP. Â The Company estimates the fair value of ESPP grants on their grant date using the Black-Scholes option pricing model. The estimated fair value of ESPP grants is amortized on a straight-line basis over the requisite service period of the grants. The Company reviews, and when deemed appropriate, updates the assumptions used on a periodic basis. The Company utilizes its estimated volatility in the Black-Scholes option pricing model to determine the fair value of ESPP grants. The fair value of ESPP grants was estimated using the following weighted-average assumptions: Â Â Â Three Months Ended September 30, Â Â Nine Months Ended September 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Expected term in years Â Â 0.5 - 1.0Â Â Â 0.5 - 1.0Â Â Â 0.5 - 1.0Â Â Â 0.5 - 1.0Â Expected volatility Â Â 98% Â Â Â 83% Â Â Â 98% Â Â Â 83% Â Risk-free interest rate Â Â 4.4% - 5.3%Â Â Â 5.4% - 5.5%Â Â Â 4.9% - 5.3%Â Â Â 5.1% - 5.5%Â Dividend yield Â Â â€"Â Â Â â€"Â Â Â â€"Â Â Â â€"Â Â Stock-based Compensation Â Total stock-based compensation expense consisted of the following (in thousands): Â Â Â Three Months Ended September 30, Â Â Nine Months Ended September 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Research and development Â Â 1,108Â Â Â 982Â Â Â 3,058Â Â Â 1,758Â General and administrative Â Â 1,874Â Â Â 816Â Â Â 3,735Â Â Â 2,079Â Total stock-based compensation expense Â $2,982Â Â $1,798Â Â $6,793Â Â $3,837Â Â As of September 30, 2024, not all of the performance conditions of the performance options are probable to be achieved. Compensation expense has only been recognized for those conditions that are assumed to be probable. Â Total stock-based compensation expense by award type was as follows (in thousands): Â Â Â Three Months Ended September 30, Â Â Nine Months Ended September 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Time-based options Â $2,131Â Â $1,200Â Â $4,609Â Â $2,754Â Performance-based options Â Â 5Â Â Â 87Â Â Â 27Â Â Â 292Â Market-based options Â Â 788Â Â Â 464Â Â Â 1,978Â Â Â 622Â ESPP Â Â 58Â Â Â 47Â Â Â 179Â Â Â 169Â Total stock-based compensation expense Â $2,982Â Â $1,798Â Â $6,793Â Â $3,837Â Â X - DefinitionThe entire disclosure for share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/718/tableOfContentReference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (l) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_DisclosureTextBlockAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 23 R14.htm IDEA: XBRL DOCUMENT v3.24.3 Note 7 - Commitments and Contingencies 9 Months Ended Sep. 30, 2024 Notes to Financial Statements Â Commitments and Contingencies Disclosure [Text Block] 7. Commitments and Contingencies Â 2022 Loan Agreement Â OnÂ SeptemberÂ 20,Â 2022,Â the Company and Robert W. Duggan, the Company's majority stockholder and Co-Chairman, entered into a Loan Agreement (â€œ2022Â Loan Agreementâ€) in connection with Mr. Duggan lending the principal sum of $65.0Â million to the Company. TheÂ 2022Â Loan Agreement boreÂ interest at a rate per annum equal toÂ 5.0%, payable quarterly commencing onÂ JanuaryÂ 1,Â 2023,Â with theÂ principal sumÂ payable onÂ March 20, 2024.Â OnÂ March 17, 2023,Â the Company and Mr. Duggan amended certainÂ terms of theÂ 2022Â Loan Agreement. There wereÂ noÂ changes to the interest rate, but the principal sum repayment date was changed toÂ September 30, 2024.Â During the year endedÂ December 31, 2023, the Company madeÂ cash payments of $1.7Â million for accrued interest on the loan, andÂ recorded an additional $1.1Â million of interest expense in relation to theÂ 2022Â Loan Agreement. OnÂ April 30, 2023,Â the Company entered into a Securities Purchase Agreement with Mr. Duggan, pursuant to which the Company agreed to issue and sell to Mr. DugganÂ 10,022,937Â shares of the Companyâ€™s common stock, par value $0.001Â per share, in a Private Placement, at a price per share of $6.51. These shares were paid for through the cancellation of the amounts then owed by the Company under theÂ 2022Â Loan Agreement, the principal sum of $65.0Â million and all accrued and unpaid interest outstanding, which totaled approximately $0.2Â million as ofÂ April 30, 2023.Â The parties completed the Private Placement onÂ May 9, 2023Â and, upon closingÂ and satisfaction of the outstanding debt, theÂ 2022Â Loan Agreement terminated, without early termination fees or penalties being owed by the Company.Â NoÂ additional amounts are owed to Mr. Duggan under theÂ 2022Â Loan Agreement. Â Operating Leases Â In January 2017, the Company entered into a five-year lease (the â€œExisting Leaseâ€) for approximately 15,700 square feet for its corporate headquarters located in Hayward, California. The lease commenced in July 2017. Â In May 2019, the Company entered into Lease Amendment 1 (the â€œLease Amendmentâ€) in relation to the Existing Lease and added the lease of new premises of approximately 13,300 square feet and 21,300 square feet, (â€œExpansion Premises 1â€ and â€œExpansion Premises 2â€, respectively). Additionally, the term of the Existing Lease was extended to October 2029 to be coterminous with Expansion Premises 1 and Expansion Premises 2. Â The Company evaluated the lease amendment under the provisions of ASC 842. It concluded that the Lease Amendment would be accounted for as a single contract with the Existing Lease because the additional lease payments due to the Lease Amendment was not commensurate with the right-of-use asset granted to the Company. Though the Lease Amendment was accounted for as a single contract, the Existing Premises, Expansion Premises 1 (occupied in November 2019) and Expansion Premises 2 (occupied in May 2020) are accounted for as separate lease components. Accordingly, the Company measured and allocated consideration to each lease component as of the modification date. Â Supplemental balance sheet information related to leases (in thousands): Â Â Â September 30, Â Â December 31, Â Assets: Â 2024 Â Â 2023 Â Right-of-use assets Â $6,588Â Â $7,256Â Â Â Â Â September 30, Â Â December 31, Â Â Liabilities: Â 2024 Â Â Â 2023 Â Â Current operating lease liabilities Â $1,193Â Â $1,058Â Non-current operating lease liabilities Â Â 7,174Â Â Â 8,086Â Total lease liabilities Â $8,367Â Â $9,144Â Â Total cash paid for operating lease liabilitiesÂ (in thousands): Â Â Â Nine Months Ended September 30, Â Â Â 2024 Â Â 2023 Â Cash paid for operating lease liabilities Â $1,425Â Â $1,376Â Â Maturities of operating lease liabilities were as follows (in thousands): Â Year ending December 31: Â Â Â Â Â 2024 (remaining 3 months) Â $485Â Â 2025 Â Â 1,977Â Â 2026 Â Â 2,046Â Â 2027 Â Â 2,117Â Â Thereafter Â Â 4,074Â Â Total lease payments Â Â 10,699Â Less imputed interest Â Â (2,332) Total lease liabilities Â $8,367Â Â Â Weighted-average remaining lease term and discount rate, as of September 30, 2024,Â were as follows: Â Weighted-average remaining lease term Â Â 5.08Â Weighted-average discount rate Â Â 10% Â Rent expense, including common area maintenance charges, was approximately $0.6Â millionÂ for each of the three-month periods ended September 30, 2024 and 2023, respectively, and was approximatelyÂ $1.8Â million and $1.7Â million for the nine-month periods ended September 30, 2024 and 2023, respectively. Â Legal Proceedings Â From time to time, weÂ mayÂ be involved in a variety of claims, lawsuits, investigations, and proceedings relating to securities laws, product liability, patent infringement, contract disputes, and other matters relating to various claims that arise in the normal course of our business, including the matter described below. The outcome of any legal proceedings is unpredictable but, regardless of outcome, they can have an adverse impact on us because of defense and settlement costs, diversion of management resources, negative publicity, reputational harm, and other factors. We maintain insurance thatÂ mayÂ provide coverage for such matters, including customary employment practices liability insurance. Â InÂ November 2022,Â the employment of our former Chief Financial Officer, Sandra Gardiner, terminated. Ms. Gardinerâ€™s departure wasÂ notÂ the result of any disagreement with the Company on any matter relating to its operations, accounting policies or practices, although the Company determined that she wasÂ notÂ eligible to receive any severance benefits under the terms and conditions of her then existing employment agreement. InÂ March 2023,Â Ms. Gardiner filed an arbitration demand with JAMS seeking severance benefits and other remedies, alleging breach of contract and unlawful termination in violation of public policy, among other things. We believe that Ms. Gardinerâ€™s claims are without merit and we intend to vigorously defend ourselves against them.Â Because of the difficulty in predicting the outcome of any legal proceeding, the Company isÂ notÂ able to conclude that a liability is probable and cannot predict what the final outcome of Ms. Gardinerâ€™s arbitration proceeding will likely be or provide a reasonable estimate for the range of ultimate possible loss, if any. However, at this time, we believe that the final resolution of this matter willÂ notÂ adversely affect our consolidated position, results of operations, or cash flows. Â X - DefinitionThe entire disclosure for commitments and contingencies. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 405 -SubTopic 30 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/405-30/tableOfContentReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 440 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/450/tableOfContentReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 954 -SubTopic 440 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 440 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 440 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/440/tableOfContent + Details Name: us-gaap_CommitmentsAndContingenciesDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_DisclosureTextBlockAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 24 R15.htm IDEA: XBRL DOCUMENT v3.24.3 Note 8- Segment Reporting 9 Months Ended Sep. 30, 2024 Notes to Financial Statements Â Segment Reporting Disclosure [Text Block] 8. Segment Reporting Â The Company operates and manages the business as one reportable and operating segment. The Companyâ€™s Chief Executive Officer acts as the chief operating decision makerÂ (â€œCODMâ€) of the Company. The CODM reviews the results of the Company on a consolidated basis. All of the Companyâ€™s long-lived assets are based in the United States. X - ReferencesNo definition available. + Details Name: us-gaap_DisclosureTextBlockAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -

Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 54 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47Reference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 54 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54Reference 9: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47Reference 10: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 54 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54Reference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 34 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-34Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 26C -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26CReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 26B -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-15Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/280/tableOfContentReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 26 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 + Details Name: us-gaap_SegmentReportingDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 25 R16.htm IDEA: XBRL DOCUMENT v3.24.3 Note 9 - Related Party Transactions 9 Months Ended Sep. 30, 2024 Notes to Financial Statements Â Related Party Transactions Disclosure [Text Block] 9. Â Â Related Party Transactions Â InÂ May 2022,Â the Company determinedÂ notÂ to renew its annual director and officer liability insurance policy due to disproportionately high premiums quoted by insurance companies. Instead, onÂ May 31, 2022,Â the Company and Robert W. Duggan, majority stockholder and Co-Chairman, entered into a letter agreement (the â€œLetter Agreementâ€) pursuant to which Mr. DugganÂ agreed with the Company to personally provide indemnity coverage for aÂ one-year period, and heÂ agreed to deposit cash and/or marketable securities into aÂ third-party escrow, as security for these obligations, if requested by the Company. OnÂ May 31, 2023,Â the last day of theÂ one-year period, the Company paid Mr. Duggan a fee of $1.0Â million in consideration of the obligations set forth in the Letter Agreement. As ofÂ September 30, 2024, there wereÂ noÂ additional amounts owed to Mr. Duggan under the Letter Agreement. Â OnÂ SeptemberÂ 20,Â 2022,Â the Company and Robert W. Duggan, the Company's majority stockholder and Co-Chairman, entered into theÂ 2022Â Loan Agreement in connection with Mr. Duggan lending the principal sum of $65.0Â million to the Company. OnÂ April 30, 2023,Â the Company entered into a Securities Purchase Agreement with Mr. Duggan, pursuant to which the Company agreed to issue and sell to Mr. DugganÂ 10,022,937Â shares of the Companyâ€™s common stock, par value $0.001Â per share, in a Private Placement, at a price per share of $6.51. These shares were paid for through the cancellation of the amounts then owed by the Company under theÂ 2022Â Loan Agreement, the principal sum of $65.0Â million and all accrued and unpaid interest outstanding, which totaled approximately $0.2Â million as ofÂ April 30, 2023.Â Upon closing of the Private Placement and satisfaction of the outstanding debt, theÂ 2022Â Loan Agreement terminated, without early termination fees or penalties being owed by the Company.Â NoÂ additional amounts are owed to Mr. Duggan under theÂ 2022Â Loan Agreement. See Note 7Â for further details. X - ReferencesNo definition available. + Details Name: us-gaap_DisclosureTextBlockAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-5Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-6Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(g)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(c)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(e)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/850/tableOfContentReference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483326/850-10-50-6Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1 + Details Name: us-gaap_RelatedPartyTransactionsDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 26 R17.htm IDEA: XBRL DOCUMENT v3.24.3 Note 10 - Restructuring Charges - USD ($) $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Income Statement [Abstract] Â Â Â Â Costs and Expenses $ 13,655 $ 11,252 $ 35,996 $ 31,041 Notes to Financial Statements Â Â Â Â Restructuring and Related Activities Disclosure [Text Block] Â Â 10. Â Â Restructuring Charges Â In February 2023, the Company eliminated seven positions and incurredÂ a discrete restructuring related charge of $0.1Â million which was fully recorded in February 2023 and the related expenses are included within total cost and expenses on the condensed consolidated statement of operations for the nineÂ months ended September 30, 2023. This charge represents the total amountÂ incurred in connection with the activity. Â X - DefinitionTotal costs of sales and operating expenses for the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_CostsAndExpenses Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_DisclosureTextBlockAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_IncomeStatementAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.P.4.e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/420/tableOfContentReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1 + Details Name: us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 27 R18.htm IDEA: XBRL DOCUMENT v3.24.3 Note 11 - Subsequent Events 9 Months Ended Sep. 30, 2024 Notes to Financial Statements Â Subsequent Events [Text Block] 11. Â Â Subsequent Events Â In October 2024, theÂ Board approved changes to the performance-based vesting conditions of certain unvested outstanding common stock option awards that were improbable of vesting. Specifically, certain performance-based stock option awards were changed to time-based vesting criteria and certain performance-based stock option awards were changed to market-based vesting criteria. Based on our preliminary analysis, the Company estimates it will recognize approximately $12 millionÂ of stock-based compensation expense over the next 1 to 4Â years from these modified stock option awards.Â Â X - ReferencesNo definition available. + Details Name: us-gaap_DisclosureTextBlockAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 855 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/855/tableOfContentReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 855 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2 + Details Name: us-gaap_SubsequentEventsTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 28 R19.htm IDEA: XBRL DOCUMENT v3.24.3 Insider Trading Arrangements 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2024 Insider Trading Arr Line Items Â Â Material Terms of Trading Arrangement [Text Block] Â ItemÂ 5. Other Information Â Trading Arrangements Â During the three-month period ended September 30, 2024, none of our directors or officers (as defined in Rule 16a-1(f) under the Exchange Act)Â adoptedÂ orÂ terminatedÂ a â€œRule 10b5-1 trading arrangementâ€ or a â€œnon-Rule 10b5-1Â tradingÂ arrangementâ€ as such terms are defined under Item 408 of Regulation S-K. Â Rule 10b5-1 Arrangement Adopted [Flag] false Â Non-Rule 10b5-1 Arrangement Adopted [Flag] false Â Rule 10b5-1 Arrangement Terminated [Flag] false Â Non-Rule 10b5-1 Arrangement Terminated [Flag] false Â X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a + Details Name: ecd_InsiderTradingArrLineItems Namespace Prefix: ecd_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_MtrlTermsOfTrdArrTextBlock Namespace Prefix: ecd_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_NonRule10b51ArrAdoptedFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_NonRule10b51ArrTrmntdFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_Rule10b51ArrAdoptedFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_Rule10b51ArrTrmntdFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration XML 29 R20.htm IDEA: XBRL DOCUMENT v3.24.3 Significant Accounting Policies (Policies) 9 Months Ended Sep. 30, 2024 Accounting Policies [Abstract] Â Basis of Accounting, Policy [Policy Text Block] Basis of Presentation Â The accompanying unaudited condensed consolidated financial statements have been prepared on a basis consistent with the Companyâ€™s Â December 31, 2023 audited Consolidated Financial Statements and include all adjustments, consisting of only normal recurring adjustments, necessary to fairly state the information set forth herein. The condensed consolidated financial statements have been prepared in accordance with the applicable rules and regulations of the Securities and Exchange Commission (the â€œSECâ€) and, as permitted by such rules and regulations, omit certain information and footnote disclosures necessary to present the financial statements in accordance with accounting principles generally accepted in the United States (â€œU.S. GAAPâ€). The condensed consolidated balance sheet as ofÂ December 31, 2023 was derived from the audited consolidated financial statements as of that date but does not include all of the information and footnotes required by U.S. GAAP for complete financial statements. These condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Companyâ€™s Annual Report on Form 10-K for the year ended December 31, 2023. The results of operations for the three-month and nine-month periods ended September 30, 2024, are not necessarily indicative of the results to be expected for the entire year or any future periods. Â Consolidation, Policy

[Policy Text Block] Principles of Consolidation Â The accompanying condensed consolidated financial statements include the financial statements of Pulse Biosciences, Inc. and its wholly-owned subsidiaries. Intercompany balances and transactions, if any, have been eliminated in consolidation. Â Use of Estimates, Policy [Policy Text Block] Use of Estimates Â The preparation of financial statements in conformity with U.S. GAAP requires the Company to make estimates that affect the amounts reported in the financial statements and accompanying notes to the financial statements. Estimates include, but areÂ notÂ limited to, the valuation and recognition of stock-based compensation, the valuation of equity-classified subscription rights, inventory valuation, warranty obligations, income taxes, and the useful lives assigned to long-lived assets. The Company evaluates its estimates and assumptions based on historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances dictate. Actual results could differ materially from these estimates. Â Share-Based Payment Arrangement [Policy Text Block] Stock-Based Compensation Â The Company's stock-based compensation programs include stock options and an employee stock purchase program. Â The Company periodically issues stock optionsÂ to officers, directors, employees, and consultants for services rendered. Such issuances vest and expire according to terms established at the issuance date. Stock-based payments to officers, directors and employees, including grants of employee stock options, are recognized in the financial statements based on their grant date fair values, which are estimated using the Black-Scholes option-pricing model. Stock-based compensation expenseÂ is charged to operations on a straight-line basis over the vesting period. The CompanyÂ hasÂ granted stock options with both time-based as well as performance-based vesting conditions.Â For stock awards with performance-based vesting conditions,Â the Company doesÂ notÂ recognize compensation expense until it is probable that the performance-based vesting condition will be achieved.Â TheÂ analysis to determine such probabilityÂ involves estimates and judgements from management and the estimate of expenseÂ mayÂ beÂ revised periodically.Â Â The Company hasÂ also issued certain stock options withÂ market-based vesting conditions. These vesting conditions relate to the achievement ofÂ certainÂ market capitalization targetsÂ of the Company. The grant date fair value for these stock options was determined using a Monte Carlo simulation. The expense is recognized over the requisite service period for each tranche of the awards. The requisite service period is the service period derived from the Monte Carlo simulation model. If the market capitalization targets are met sooner than the derived service period, the CompanyÂ will accelerate the recognition of stock-based compensation expense to reflect the cumulative expense associated with the vested shares.Â The Monte Carlo simulation requires the Company to make assumptions and judgements about the variables used in the calculation including the expected term, volatility of the Company's common stock, an assumed risk-free interest rate, and cost of equity. The assumptions used in theÂ option-pricing modelÂ represent managementâ€™s best estimates. If factors change and different assumptions are used, the Company'sÂ stock-based compensation expense could be materially different in the future. Â See NoteÂ 6Â for a detailed discussion of the Companyâ€™s stock plans and stock-based compensation expense. Â Standard Product Warranty, Policy [Policy Text Block] Product Warranty Â The Company provides a standard warranty on eligible products which provides the customer assurances that the products comply with the agreed-upon specifications. The standard warranty doesÂ notÂ provide any services in addition to those assurances. The Company accrued a warranty reserve for products sold based upon the best estimate of the nature, frequency, and costs of future claims. These estimates are inherently uncertain given the short history of sales, and changes to the historical or projected warranty experienceÂ mayÂ cause material changes to the warranty reserve in the future. In June 2023, the Company reduced the accrued warranty liability to zero. Based upon the Company's shift in focus, there are a limited number of consoles currently covered under the standard warranty. All inventory has been fully written off, therefore the only incremental costs to fulfill a warranty claim in 2024 would be shipping costs or the costs to replace the CellFX nsPFA electrode, which wouldÂ be immaterial in nature. Â Warranty accrual activity consisted of the following for the three-month and nine-month periods endedÂ September 30, 2024 and 2023Â (in thousands): Â Â Â Three Months Ended September 30, Â Â Â Nine Months Ended September 30, Â Â Â 2024 Â Â Â 2023 Â Â Â 2024 Â Â Â 2023 Â Beginning balance Â $â€”Â Â $â€”Â Â $â€”Â Â $50Â Add: Accruals for warranties issued during the period Â Â â€”Â Â Â â€”Â Â Â â€”Â Â Â â€”Â Less: Adjustment for inventory at cost and excessive and obsolete inventory Â Â â€”Â Â Â â€”Â Â Â â€”Â Â Â â€”Â (50) Ending balance Â $â€”Â Â $â€”Â Â $â€”Â Â $â€”Â Â Earnings Per Share, Policy [Policy Text Block] Net Loss per Share Â The Company calculates basic net loss per share by dividing net loss by the weighted-average number of shares of common stock outstanding during the period. Diluted net loss per share is computed by giving effect to all potential dilutive common stock equivalents outstanding during the period. For purposes of this calculation, options to purchase common stock and common stock warrants are considered common stock equivalents. Potential common shares that have an anti-dilutive effect (i.e., those that increase income per share or decrease loss per share) are excluded from the calculation of diluted net loss per share. Â Based on the Accounting Standards Codification ("ASC") 260-10-55,Â Earnings Per Share - Implementation Guidance and Illustrations, the Company determined that theÂ 2024Â Rights Offering (Note 6), contained a bonus element. A rights offering is deemed to have a bonus element when the exercise price at issuance is less than fair value of the Company's stock. The Company has retroactively adjusted earnings per share and weighted average number of shares outstanding forÂ the bonus elementÂ for priorÂ periods presented. Â Basic and diluted net loss per common share is the same for all periods presented because all warrants, stock options and restricted stock units outstanding are anti-dilutive. Â The following outstanding stock options, and warrantsÂ were excluded from the computation of diluted net loss per share for the periods presented because including them would have had an anti-dilutive effect: Â Â Â Nine Months Ended September 30, Â Â Â 2024 Â Â Â 2023 Â Common stock warrants Â Â 5,857,680Â Â Â Â â€”Â Common stock options Â Â 12,327,332Â Â Â Â 7,902,948Â Total Â Â 18,185,012Â Â Â Â 7,902,948Â Â New Accounting Pronouncements, Policy [Policy Text Block] Recent Accounting Pronouncements Not Yet Adopted Â In March 2024, the FASB issued ASU No. 2024-02,Â Codification Improvements - Amendments to Remove References to the Concepts Statements, an amendment of the FASB Accounting Standards Codification. The amendments in this ASU are related to the removal of various references to FASB Concept Statements from the codification to make clear distinctions between authoritative and non-authoritative literature in the codification. This ASU is effective for fiscal years beginning after December 15, 2024, with early adoption permitted. The Company does not believe this standard will have an impact on its consolidated financial statements and related disclosures. Â As of September 30, 2024, there were no additional material changes to the information provided regarding recent accounting pronouncements in Note 2, â€œSummary of Significant Accounting Policiesâ€ in the Companyâ€™s Form 10-K for the fiscal year ended December 31, 2023. X - ReferencesNo definition available. + Details Name: us-gaap_AccountingPoliciesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). + ReferencesNo definition available. + Details Name: us-gaap_BasisOfAccountingPolicyPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1 + Details Name: us-gaap_ConsolidationPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2 + Details Name: us-gaap_EarningsPerSharePolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact. + ReferencesNo definition available. + Details Name: us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(v) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.C.Q3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.D.1.Q5) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.D.3.Q2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.D.2.Q6) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/718/tableOfContentReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for standard warranties including the methodology for measuring the liability. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 460 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482425/460-10-50-8 + Details Name: us-gaap_StandardProductWarrantyPolicy Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 11 -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-11Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 12 -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-8 + Details Name: us-gaap_UseOfEstimates Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 30 R21.htm IDEA: XBRL DOCUMENT v3.24.3 Note 2 - Summary of Significant Accounting Policies (Tables) 9 Months Ended Sep. 30, 2024 Notes Tables Â Schedule of Product Warranty Liability [Table Text Block] Â Â Three Months Ended September 30, Â Â Nine Months Ended September 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Beginning balance Â $â€”Â Â $â€”Â Â $â€”Â Â $50Â Add: Accruals for warranties issued during the period Â Â â€”Â Â Â Â â€”Â Â Â Â â€”Â Â Â Â â€”Â Less: Adjustment for inventory at cost and excessive and obsolete inventory Â Â â€”Â Â Â Â â€”Â Â Â Â â€”Â Â Â Â â€”Â Â (50) Ending balance Â $â€”Â Â $â€”Â Â $â€”Â Â $â€”Â Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Â Â Nine Months Ended September 30, Â Â Â 2024 Â Â 2023 Â Common stock warrants Â Â 5,857,680Â Â Â Â â€”Â Common stock options Â Â 12,327,332Â Â Â Â 7,902,948Â Total Â Â 18,185,012Â Â Â Â 7,902,948Â X - DefinitionTabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 + Details Name: us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the changes in the guarantor's aggregate product warranty liability, including the beginning balance of the aggregate product warranty liability, the aggregate reductions in that liability for payments made (in cash or in kind) under the warranty, the aggregate changes in the liability for accruals related to product warranties issued during the reporting period, the aggregate changes in the liability for accruals related to preexisting warranties (including adjustments related to changes in estimates), and the ending balance of the aggregate product warranty liability. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 460 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482425/460-10-50-8 + Details Name: us-gaap_ScheduleOfProductWarrantyLiabilityTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_TableTextBlock Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 31 R22.htm IDEA: XBRL DOCUMENT v3.24.3 Note 3 - Fair Value of Financial Instruments (Tables) 9 Months Ended Sep. 30, 2024 Notes Tables Â Fair Value, Assets Measured on Recurring Basis [Table Text Block] Â Â Â September 30, 2024 Â Assets Classification Â Level 1 Â Â Level 2 Â Â Level 3 Â Â Total Â Money market funds Cash and cash equivalents Â $76,386Â Â $â€”Â Â $â€”Â Â $76,386Â Total assets measured at fair value Â $76,386Â Â $â€”Â Â $â€”Â Â $76,386Â Â Â Â December 31, 2023 Â Assets Classification Â Level 1 Â Â Level 2 Â Â Level 3 Â Â Total Â Money market funds Cash and cash equivalents Â $41,184Â Â $â€”Â Â $â€”Â Â $41,184Â Total assets measured at fair value Â $41,184Â Â $â€”Â Â $â€”Â Â $41,184Â X - DefinitionTabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3). + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name

Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_TableTextBlock Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 32 R23.htm IDEA: XBRL DOCUMENT v3.24.3 Note 4 - Balance Sheet Components (Tables) 9 Months Ended Sep. 30, 2024 Notes Tables Â Property, Plant and Equipment [Table Text Block] Â Â September 30, Â Â December 31, Â Â Â 2024 Â Â 2023 Â Leasehold improvements Â $2,519Â Â $2,519Â Laboratory equipment Â Â 1,318Â Â Â Â 1,247Â Furniture, fixtures and equipment Â Â 966Â Â Â Â 966Â Software Â Â 272Â Â Â Â 272Â Construction in progress Â Â 14Â Â Â Â â€”Â Total property and equipment Â Â 5,089Â Â Â Â 5,004Â Less: Accumulated depreciation and amortization Â Â (3,868)Â Â (3,476) Total property and equipment, net Â $1,221Â Â $1,528Â Schedule of Finite-Lived Intangible Assets [Table Text Block] Â Â September 30, Â Â December 31, Â Â Â 2024 Â Â 2023 Â Acquired patents and licenses Â $7,985Â Â $7,985Â Less: Accumulated amortization Â Â (6,599)Â Â (6,099) Total intangible assets, net Â $1,386Â Â $1,886Â Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block] Years ending December 31: Â Â Â Â 2024 (remaining 3 months) Â $165Â 2025 Â Â 665Â 2026 Â Â 556Â Total Â $1,386Â Schedule of Accrued Liabilities [Table Text Block] Â Â September 30, Â Â December 31, Â Â Â 2024 Â Â 2023 Â Compensation expense Â $3,111Â Â $3,199Â Clinical trial fees and costs Â Â 80Â Â Â Â 84Â Professional fees Â Â 424Â Â Â Â 343Â Other Â Â 206Â Â Â Â 188Â Total accrued expenses Â $3,821Â Â $3,814Â X - DefinitionTabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1 + Details Name: us-gaap_PropertyPlantAndEquipmentTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the components of accrued liabilities. + ReferencesNo definition available. + Details Name: us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2 + Details Name: us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2 + Details Name: us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_TableTextBlock Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 33 R24.htm IDEA: XBRL DOCUMENT v3.24.3 Note 6 - Stockholders' Equity and Stock-based Compensation (Tables) 9 Months Ended Sep. 30, 2024 Notes Tables Â Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Â Â Three Months Ended September 30, Â Â Nine Months Ended September 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Research and development Â Â 1,108Â Â Â Â 982Â Â Â Â 3,058Â Â Â Â 1,758Â General and administrative Â Â 1,874Â Â Â Â 816Â Â Â Â 3,735Â Â Â Â 2,079Â Total stock-based compensation expense Â $2,982Â Â $1,798Â Â $6,793Â Â $3,837Â Share-Based Payment Arrangement, Cost by Plan [Table Text Block] Â Â Three Months Ended September 30, Â Â Nine Months Ended September 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Time-based options Â $2,131Â Â $1,200Â Â $4,609Â Â $2,754Â Performance-based options Â Â 5Â Â Â Â 87Â Â Â Â 27Â Â Â Â 292Â Market-based options Â Â 788Â Â Â Â 464Â Â Â Â 1,978Â Â Â Â 622Â ESPP Â Â 58Â Â Â Â 47Â Â Â Â 179Â Â Â Â 169Â Total stock-based compensation expense Â $2,982Â Â $1,798Â Â $6,793Â Â $3,837Â Share-Based Payment Arrangement, Option [Member] Â Notes Tables Â Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Â Â Three Months Ended September 30, Â Â Nine Months Ended September 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Expected term in years Â Â 5.0 - 6.3Â Â Â Â 5.0Â Â Â Â 5.0 - 6.3Â Â Â Â 5.0 - 6.3Â Expected volatility Â Â 93% - 97%Â Â Â Â 93%Â Â Â Â 91% - 97%Â Â Â Â 89% - 94%Â Risk-free interest rate Â Â 4.5% Â Â Â Â 3.7% Â Â Â Â 4.0% - 4.5%Â Â Â Â 3.7% - 3.8% Â Dividend yield Â Â â€”Â Â Â Â â€”Â Â Â Â â€”Â Â Â Â â€”Â Â Â Â Three Months Ended September 30, Â Â Nine Months Ended September 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Expected term in years Â Â 2.2 - 4.2Â Â Â Â 4.0 - 6.3Â Â Â Â 2.2 - 5.8Â Â Â Â 4.0 - 6.3Â Expected volatility Â Â 90% Â Â Â 90% Â Â Â 90% Â Â Â 90% Â Risk-free interest rate Â Â 3.9% Â Â Â 3.7 - 3.8% Â Â Â 3.9% - 4.4% Â Â Â 3.4 - 3.8% Â Dividend yield Â Â â€”Â Â Â Â â€”Â Â Â Â â€”Â Â Â Â â€”Â Market-based Options [Member] Â Notes Tables Â Share-Based Payment Arrangement, Option, Activity [Table Text Block] Â Â Stock Options Outstanding Â Â Â Number of shares Â Â Weighted average exercise price Â Â Weighted average remaining life (in years) Â Balances â€” December 31, 2023 Â Â 2,100,000Â Â $6.78Â Â Â Â 9.44Â Options granted Â Â 855,000Â Â Â Â 8.16Â Â Â Â Â Options exercised Â Â â€”Â Â Â Â â€”Â Â Â Â Â Options canceled Â Â â€”Â Â Â Â â€”Â Â Â Â Â Options expired Â Â â€”Â Â Â Â â€”Â Â Â Â Â Balances â€” September 30, 2024 Â Â 2,955,000Â Â $7.18Â Â Â Â 8.95Â Exercisable â€” September 30, 2024 Â Â â€”Â Â Â Â â€”Â Â Â Â â€”Â Performance Options [Member] Â Notes Tables Â Share-Based Payment Arrangement, Option, Activity [Table Text Block] Â Â Stock Options Outstanding Â Â Â Number of shares Â Â Weighted average exercise price Â Â Weighted average remaining life (in years) Â Balances â€” December 31, 2023 Â Â 1,224,130Â Â $5.51Â Â Â Â 8.53Â Options granted Â Â 39,000Â Â Â Â 8.44Â Â Â Â Â Options exercised Â Â (9,950)Â Â Â 2.92Â Â Â Â Â Options canceled Â Â (3,000)Â Â Â 2.92Â Â Â Â Â Options expired Â Â (1,000)Â Â Â 2.92Â Â Â Â Â Balances â€” September 30, 2024 Â Â 1,249,180Â Â $5.63Â Â Â Â 7.84Â Exercisable â€” September 30, 2024 Â Â 432,678Â Â $7.69Â Â Â Â 6.98Â Time-based Options [Member] Â Notes Tables Â Share-Based Payment Arrangement, Option, Activity [Table Text Block] Â Â Stock Options Outstanding Â Â Â Number of shares Â Â Weighted average exercise price Â Â Weighted average remaining life (in years) Â Balances â€” December 31, 2023 Â Â 6,141,906Â Â $10.48Â Â Â Â 7.07Â Options granted Â Â 2,123,643Â Â Â Â 11.3Â Â Â Â Â Options exercised Â Â (100,897)Â Â 4.65Â Â Â Â Â Options canceled Â Â (6,542)Â Â 20.82Â Â Â Â Â Options expired Â Â (34,958)Â Â 20.3Â Â Â Â Â Balances â€” September 30, 2024 Â Â 8,123,152Â Â $10.71Â Â Â Â 7.18Â Exercisable â€” September 30, 2024 Â Â 3,745,410Â Â $13.97Â Â Â Â 4.84Â The 2017 Employee Stock Purchase Plan [Member] Â Notes Tables Â Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Â Â Three Months Ended September 30, Â Â Nine Months Ended September 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Expected term in years Â Â 0.5 - 1.0Â Â Â Â 0.5 - 1.0Â Â Â Â 0.5 - 1.0Â Â Â Â 0.5 - 1.0Â Expected volatility Â Â 98% Â Â Â 83% Â Â Â 98% Â Â Â 83% Â Risk-free interest rate Â Â 4.4% - 5.3%Â Â Â 5.4% - 5.5%Â Â Â 4.9% - 5.3%Â Â Â 5.1% - 5.5%Â Dividend yield Â Â â€”Â Â Â Â â€”Â Â Â Â â€”Â Â Â Â â€”Â The 2015 Plan, 2017 Plan and Inducement Plan [Member] Â Notes Tables Â Share-Based Payment Arrangement, Option, Activity [Table Text Block] Â Â Stock Options Outstanding Â Â Â Number of shares Â Â Weighted average exercise price Â Â Weighted average remaining life (in years) Â Balances â€” December 31, 2023 Â Â 9,466,036Â Â $9.01Â Â Â Â 7.78Â Options granted Â Â 3,017,643Â Â Â Â 10.38Â Â Â Â Â Options exercised Â Â (110,847)Â Â 4.49Â Â Â Â Â Options canceled Â Â (9,542)Â Â 15.19Â Â Â Â Â Options expired Â Â (35,958)Â Â 19.82Â Â Â Â Â Balances â€” September 30, 2024 Â Â 12,327,332Â Â $9.35Â Â Â 7.67Â Exercisable â€” September 30, 2024 Â Â 4,178,088Â Â $13.32Â Â Â Â 5.06Â X - DefinitionTabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (h)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (h)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Subparagraph (f)(2) -Name Accounting Standards Codification -Paragraph 2 -Section 50 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_TableTextBlock Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=plse_MarketbasedOptionsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=plse_PerformanceOptionsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=plse_TimebasedOptionsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PlanNameAxis=plse_The2017EmployeeStockPurchasePlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PlanNameAxis=plse_The2015Plan2017PlanAndInducementPlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 34 R25.htm IDEA: XBRL DOCUMENT v3.24.3 Note 7 - Commitments and Contingencies (Tables) 9 Months Ended Sep. 30, 2024 Notes Tables Â Schedule of Information Related to Right-of-use Assets and Lease Liabilities [Table Text Block] Â Â September 30, Â Â December 31, Â Assets: Â 2024 Â Â 2023 Â Right-of-use assets Â $6,588Â Â $7,256Â Â Â September 30, Â Â December 31, Â Liabilities: Â 2024 Â Â 2023 Â Current operating lease liabilities Â $1,193Â Â $1,058Â Non-current operating lease liabilities Â Â 7,174Â Â Â Â 8,086Â Total lease liabilities Â $8,367Â Â $9,144Â Â Â Nine Months Ended September 30, Â Â Â 2024 Â Â 2023 Â Cash paid for operating lease liabilities Â $1,425Â Â $1,376Â Year ending December 31: Â Â Â Â 2024 (remaining 3 months) Â $485Â 2025 Â Â 1,977Â 2026 Â Â 2,046Â 2027 Â Â 2,117Â Thereafter Â Â 4,074Â Total lease payments Â Â 10,699Â Less imputed interest Â Â (2,332) Total lease liabilities Â $8,367Â Weighted-average remaining lease term Â Â 5.08Â Weighted-average discount rate Â Â 10% X - DefinitionTabular disclosure for all information related to right-of-use assets and lease liabilities. + ReferencesNo definition available. + Details Name: plse_ScheduleOfInformationRelatedToRightofuseAssetsAndLeaseLiabilitiesTableTextBlock Namespace Prefix: plse_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_TableTextBlock Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 35 R26.htm IDEA: XBRL DOCUMENT v3.24.3 Note 2 - Summary of Significant Accounting Policies - Warrant Accrual Activity (Details) - USD ($) $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Beginning balance $ 0 $ 0 $ 0 $ 50 Add: Accruals for warranties issued during the period 0 0 0 0 Less: Adjustment for inventory at cost and excessive and obsolete inventory 0 0 0 (50) Ending balance $ 0 $ 0 $ 0 $ 0 X - DefinitionRepresents the adjustment for inventory at cost. + ReferencesNo definition available. + Details Name: plse_AdjustmentForInventoryAtCost Namespace Prefix: plse_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount as of the balance sheet date of the aggregate standard product warranty liability that is expected to be paid within one year or the normal operating cycle, if longer. Does not include the balance for the extended product warranty liability. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 460 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482425/460-10-50-8Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 460 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (c)(5) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482425/460-10-50-8 + Details Name: us-gaap_StandardProductWarrantyAccrualCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of increase in the standard product warranty accrual from warranties issued. Excludes extended product warranties. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 460 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (c)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482425/460-10-50-8 + Details Name: us-gaap_StandardProductWarrantyAccrualWarrantiesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration XML 36 R27.htm IDEA: XBRL DOCUMENT v3.24.3 Note 2 - Summary of Significant Accounting Policies - Antidilutive Securities (Details) - shares 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Antidilutive securities (in shares) 18,185,012 7,902,948 Warrant [Member] Â Â Antidilutive securities (in shares) 5,857,680 0 Share-Based Payment Arrangement, Option [Member] Â Â Antidilutive securities (in shares) 12,327,332 7,902,948 X - DefinitionSecurities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 + Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 37 R28.htm IDEA: XBRL DOCUMENT v3.24.3 Note 3 - Fair Value of Financial Instruments (Details Textual) - USD ($) $ in Thousands 9 Months Ended 12 Months Ended Sep. 30, 2024 Dec. 31, 2023 Impairment of Marketable Securities $ 0 $ 0 X - DefinitionAmount of impairment of marketable securities. + ReferencesNo definition available. + Details Name: plse_ImpairmentOfMarketableSecurities Namespace Prefix: plse_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration XML 38 R29.htm IDEA: XBRL DOCUMENT v3.24.3 Note 3 - Investments and Fair Value of Financial Instruments - Financial Assets Measured on a Recurring Basis (Details) - USD ($) $ in Thousands Sep. 30, 2024 Dec. 31, 2023 Total assets measured at fair value $ 76,386 $ 41,184 Fair Value, Inputs, Level 1 [Member] Â Â Total assets measured at fair value 76,386 41,184 Fair Value, Inputs, Level 2 [Member] Â Â Total assets measured at fair value 0 0 Fair Value, Inputs, Level 3 [Member] Â Â Total assets measured at fair value 0 0 Money Market Funds [Member] Â Â Cash and Cash equivalents 76,386 41,184 Money Market Funds [Member] | Fair Value, Inputs, Level 1 [Member] Â Â Cash and Cash equivalents 76,386 41,184 Money Market Funds [Member] | Fair Value, Inputs, Level

2 [Member] Â Â Cash and Cash equivalents 0 0 Money Market Funds [Member] | Fair Value, Inputs, Level 3 [Member] Â Â Cash and Cash equivalents $ 0 $ 0 X - DefinitionFair value portion of asset recognized for present right to economic benefit. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_AssetsFairValueDisclosure Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionFair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_CashAndCashEquivalentsFairValueDisclosure Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Details Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 39 R30.htm IDEA: XBRL DOCUMENT v3.24.3 Note 4 - Balance Sheet Components (Details Textual) - USD ($) $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Depreciation $ 100 $ 100 $ 391 $ 404 Finite-Lived Intangible Asset, Useful Life (Year) 12 years Â 12 years Â X - DefinitionThe amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1 + Details Name: us-gaap_Depreciation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionUseful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesNo definition available. + Details Name: us-gaap_FiniteLivedIntangibleAssetUsefulLife Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: instant XML 40 R31.htm IDEA: XBRL DOCUMENT v3.24.3 Note 4 - Balance Sheet Components - Property and Equipment, Net (Details) - USD ($) $ in Thousands Sep. 30, 2024 Dec. 31, 2023 Dec. 31, 2021 Property and equipment, gross $ 5,089 $ 5,004 Â Less: Accumulated depreciation and amortization (3,868) (3,476) Â Total property and equipment, net 1,221 1,528 $ 1,528 Leasehold Improvements [Member] Â Â Â Property and equipment, gross 2,519 2,519 Â Laboratory Equipment [Member] Â Â Â Property and equipment, gross 1,318 1,247 Â Furniture and Fixtures [Member] Â Â Â Property and equipment, gross 966 966 Â Software and Software Development Costs [Member] Â Â Â Property and equipment, gross 272 272 Â Construction in Progress [Member] Â Â Â Property and equipment, gross $ 14 $ 0 Â X - DefinitionAmount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(14)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1 + Details Name: us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(13)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1 + Details Name: us-gaap_PropertyPlantAndEquipmentGross Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7AReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 360 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1 + Details Name: us-gaap_PropertyPlantAndEquipmentNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=plse_LaboratoryEquipmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 41 R32.htm IDEA: XBRL DOCUMENT v3.24.3 Note 4 - Balance Sheet Components - Intangible Assets, Net (Details) - USD ($) $ in Thousands Sep. 30, 2024 Dec. 31, 2023 Dec. 31, 2021 Less: Accumulated amortization $ (6,599) $ (6,099) Â Total 1,386 1,886 $ 1,886 Acquired Patents and Licenses [Member] Â Â Â Acquired patents and licenses $ 7,985 $ 7,985 Â X - DefinitionAccumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 10 -Name Accounting Standards Codification -Section S45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480265/350-10-S45-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 10 -Name Accounting Standards Codification -Section S45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480265/350-10-S45-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 928 -SubTopic 340 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478859/928-340-50-1 + Details Name: us-gaap_FiniteLivedIntangibleAssetsGross Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 926 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5 + Details Name: us-gaap_FiniteLivedIntangibleAssetsNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Details Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=plse_AcquiredPatentsAndLicensesMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 42 R33.htm IDEA: XBRL DOCUMENT v3.24.3 Note 4 - Balance Sheet Components - Schedule of Amortization of Intangible Assets (Details) - USD ($) $ in Thousands Sep. 30, 2024 Dec. 31, 2023 Dec. 31, 2021 2024 (remaining 3 months) $ 165 Â Â 2025 665 Â Â 2026 556 Â Â Total $ 1,386 $ 1,886 $ 1,886 X - DefinitionAmount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2 + Details Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2 + Details Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2 + Details Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 926 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5 + Details Name: us-gaap_FiniteLivedIntangibleAssetsNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant XML 43 R34.htm IDEA: XBRL DOCUMENT v3.24.3 Note 4 - Balance Sheet Components - Accrued Expenses (Details) - USD ($) $ in Thousands Sep. 30, 2024 Dec. 31, 2023 Dec. 31, 2021 Compensation expense $ 3,111 $ 3,199 Â Clinical trial fees and costs 80 84 Â Professional fees 424 343 Â Other 206 188 Â Total accrued expenses $ 3,821 $ 3,814 $ 3,814 X - DefinitionTotal of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to clinical trial fees and costs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesNo definition available. + Details Name: plse_AccruedClinicalTrialFeesAndCosts Namespace Prefix: plse_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AccruedLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AccruedProfessionalFeesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionTotal of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_EmployeeRelatedLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-

02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_OtherAccruedLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 44 R35.htm IDEA: XBRL DOCUMENT v3.24.3 Note 5 - Goodwill (Details Textual) $ in Thousands 9 Months Ended 12 Months Ended Sep. 30, 2024 USD ($) Dec. 31, 2014 USD ($) Dec. 31, 2021 USD ($) Goodwill, Ending Balance $ 2,791 Â $ 2,791 Goodwill, Impairment Loss $ 0 Â Â Series of Individually Immaterial Business Acquisitions [Member] Â Â Â Number of Businesses Acquired Â 3 Â Business Combination, Consideration Transferred, Total Â $ 5,500 Â Goodwill, Ending Balance Â $ 2,800 Â X - DefinitionAmount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 30 -Paragraph 8 -SubTopic 30 -Topic 805 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479637/805-30-30-8Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -SubTopic 30 -Topic 805 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 30 -Paragraph 7 -SubTopic 30 -Topic 805 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479637/805-30-30-7 + Details Name: us-gaap_BusinessCombinationConsiderationTransferred1 Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(15)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482598/350-20-45-1Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(10)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_Goodwill Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of impairment loss from asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-2Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482598/350-20-45-2 + Details Name: us-gaap_GoodwillImpairmentLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe number of businesses acquired by the entity during the period. + ReferencesNo definition available. + Details Name: us-gaap_NumberOfBusinessesAcquired Namespace Prefix: us-gaap_ Data Type: xbrli:integerItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_BusinessAcquisitionAxis=us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 45 R36.htm IDEA: XBRL DOCUMENT v3.24.3 Note 6 - Stockholders' Equity and Stock-based Compensation (Details Textual) - USD ($) $ / shares in Units, $ in Thousands 1 Months Ended 6 Months Ended 9 Months Ended 12 Months Ended Jul. 03, 2024 Mar. 28, 2024 Apr. 30, 2023 Jan. 01, 2023 Jun. 09, 2022 Mar. 31, 2024 Dec. 31, 2023 May 31, 2021 Nov. 30, 2017 Jun. 15, 2023 Sep. 30, 2024 Sep. 30, 2023 Dec. 31, 2023 Dec. 31, 2017 Dec. 31, 2021 Common Stock, Par or Stated Value Per Share (in dollars per share) Â Â Â Â Â Â Â Â Â Â $ 0.001 Â Â Â $ 0.001 Equity Classified Subscription, Value Â Â Â Â Â Â Â Â Â Â Â $ 47,700 Â Â Â Â Right Offering Deemed Dividend Â Â Â Â Â Â Â Â Â Â Â 47,700 $ 0 Â Â Â Proceeds from Warrant Exercises Â Â Â Â Â Â Â Â Â Â 1,536 $ 14,828 Â Â Â Time-based Options [Member] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Intrinsic Value Â Â Â Â Â Â Â Â Â Â 18,700 Â Â Â Â Performance-based Options [Member] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Intrinsic Value Â Â Â Â Â Â Â Â Â Â 300 Â Â Â Â Market-based Options [Member] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Intrinsic Value Â Â Â Â Â Â Â Â Â Â $ 5,300 Â Â Â Â The 2017 Plan [Member] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period (Year) Â Â Â Â Â Â Â Â Â Â Â 10 years Â Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized (in shares) Â Â Â Â Â Â Â Â Â Â Â 1,500,000 Â Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized (in shares) Â Â Â 1,200,000 Â Â 1,375,000 Â Â Â Â Â Â Â Increase in Shares Available for Issuance, Threshold of Common Stock Outstanding, Number of Shares (in shares) Â Â Â Â Â Â Â Â Â Â Â 1,200,000 Â Increase in Shares Available for Issuance, Threshold of Common Stock Outstanding, Percent Â Â Â Â Â Â Â Â Â Â Â 4.00% Â Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant (in shares) Â Â Â Â Â Â Â Â Â 78,490 Â Â Â Â The 2017 Inducement Equity Incentive Plan [Member] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period (Year) Â Â Â Â Â Â Â 10 years Â Â Â Â Â Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized (in shares) Â Â Â Â Â Â Â Â 1,000,000 Â Â Â Â Â Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized (in shares) Â Â Â Â Â 2,000,000 Â 1,000,000 Â Â Â Â Â Â Â Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant (in shares) Â Â Â Â Â Â Â Â Â 1,642,626 Â Â Â Â The 2017 Inducement Equity Incentive Plan [Member] | Share-Based Payment Arrangement, Option [Member] | Maximum [Member] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period (Year) Â Â Â Â Â Â Â Â Â 10 years Â Â Â Â Â Â The 2017 Employee Stock Purchase Plan [Member] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized (in shares) Â Â Â Â Â Â Â Â Â Â Â Â Â Â 250,000 Â Increase in Shares Available for Issuance, Threshold of Common Stock Outstanding, Number of Shares (in shares) Â Â Â Â Â Â Â Â Â Â Â 450,000 Â Â 450,000 Â Increase in Shares Available for Issuance, Threshold of Common Stock Outstanding, Percent Â Â Â Â Â Â Â Â Â Â Â 1.50% Â Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant (in shares) Â Â Â Â Â Â Â Â Â 445,779 Â Â Â Â Stock Issued During Period, Shares, Employee Stock Purchase Plans (in shares) Â Â Â Â Â Â Â Â Â Â 117,539 Â Â Â Â Share-Based Payment Arrangement, Tranche One [Member] | Time-based Options [Member] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage Â Â Â Â Â Â Â Â Â 25.00% Â Â Â Â Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year) Â Â Â Â Â Â Â Â Â 1 year Â Â Â Â Share-Based Payment Arrangement, Tranche One [Member] | The 2017 Inducement Equity Incentive Plan [Member] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage Â Â Â Â Â Â Â Â 25.00% Â Â Â Â Â Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year) Â Â Â Â Â Â Â Â 1 year Â Â Â Â Â Loan Agreement [Member] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Debt Instrument, Decrease, Forgiveness Â Â $ 65,000 Â Â Â Â Â Â Â Â Â Â Warrants Issued in 2024 Rights Offering [Member] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares) Â 0.5 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Rights Offering Warrants [Member] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares) Â Â Â Â 1 Â Â Â Â Â Â Â Â Â Â Class of Warrant or Right, Proceeds Upon Exercise $ 66,000 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) $ 11 Â Â Â $ 2.05 Â $ 2.05 Â Â Â Â Â $ 2.05 Â Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) 5,999,999 Â Â Â Â 7,317,072 Â Â 5,857,680 Â 7,317,072 Â Class of Warrants or Rights, Redemption Price Per Share (in dollars per share) Â Â Â Â Â Â $ 0.01 Â Â Â Â Â $ 0.01 Â Class of Warrans or Right, Exercise Price, Percentage of Subscription Price for Units 110.00% Â Â Â Â Â Â Â Â Â Â Â Â Â Â Warrants and Rights Outstanding, Term (Year) 5 years Â Â Â Â Â Â Â Â Â Â Â Â Â Â Class of Warrant or Right, Percentage Required for Redemption Â Â Â Â Â 200.00% Â Â Â Â Â 200.00% Â Â Class of Warrant or Right, Period of Written Notice for Exercise (Day) Â Â Â Â Â Â Â Â Â Â 30 days Â Â Class of Warrant or Right, Exercise, Consecutive Trading Days (Day) Â Â Â Â Â Â Â Â Â Â 20 days Â Â Class of Warrant or Right, Exercised During Period (in shares) Â Â Â Â Â Â Â Â 7,250,897 Â Â 66,175 Â Â Proceeds from Warrant Exercises Â Â Â Â Â Â Â Â $ 14,900 Â Â Â Â Â Class of Warrant or Right, Outstanding (in shares) Â Â Â Â Â Â Â Â Â Â 0 Â Â Â Rights Offering Warrants [Member] | Vesting of First Half [Member] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Class of Warrants or Rights, Redemption Price Per Share (in dollars per share) $ 0.01 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Class of Warrant or Right, Percentage Required for Redemption 150.00% Â Â Â Â Â Â Â Â Â Â Â Â Â Â Class of Warrant or Right, Vesting, Stock Price Trigger (in dollars per share) $ 16.5 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Rights Offering Warrants [Member] | Vesting of Second Half [Member] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Class of Warrants or Rights, Redemption Price Per Share (in dollars per share) $ 0.01 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Class of Warrant or Right, Percentage Required for Redemption 200.00% Â Â Â Â Â Â Â Â Â Â Â Â Â Â Class of Warrant or Right, Vesting, Stock Price Trigger (in dollars per share) $ 22 Â Â Â Â Â Â Â Â Â Â Â Â Â Â The 2024 Right Offering [Member] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Common Stock, Par or Stated Value Per Share (in dollars per share) Â $ 0.001 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Equity Offering, Units, Maximum Amount Authorized (in shares) Â 6,000,000 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Equity Offering Units, Offering Value Â $ 60,000 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Shares Issued, Price Per Share (in dollars per share) Â $ 10 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Number of Shares Per Unit Issued (in shares) Â 1 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Number of Warrants in Each Unit (in shares) Â 2 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Share Price (in dollars per share) Â $ 11.55 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Equity Classified Subscription, Value Â $ 47,700 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Right Offering Deemed Dividend Â $ 47,700 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Rights Offering [Member] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Common Stock, Par or Stated Value Per Share (in dollars per share) $ 0.001 Â Â Â 0.001 Â Â Â Â Â Â Â Â Â Â Equity Offering, Units, Maximum Amount Authorized (in shares) 6,000,000 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Shares Issued, Price Per Share (in dollars per share) $ 10 Â Â Â $ 2.05 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Number of Shares Per Unit Issued (in shares) 1 Â Â Â 1 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Number of Warrants in Each Unit (in shares) 2 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares) 0.5 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Stock Issued During Period, Shares, New Issues (in shares) 5,999,998 Â Â 7,317,072 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Proceeds from Issuance of Common Stock $ 60,000 Â Â Â $ 15,000 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Equity Offering, Units, Sale of Units (in shares) Â Â Â Â 7,317,072 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Number of Warrants Per Unit (in shares) Â Â Â 1 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) Â Â Â Â 7,317,072 Â Â Â Â Â Â Â Â Â Â Class of Warrants or Rights, Redemption Price Per Share (in dollars per share) Â Â Â Â $ 0.01 Â Â Â Â Â Â Â Â Â Â Rights Offering [Member] | Robert W. Duggan [Member] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Percent of Offering Purchased 88.00% Â Â Â Â Â Â Â Â Â Â Â Â Â Â Rights Offering [Member] | Board of Directors Chairman [Member] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Investment Owned, Percent of Net Assets Â Â Â Â 56.00% Â Â Â Â Â Â Â Â Â Â Â Â Private Placement [Member] | Robert W. Duggan [Member] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Common Stock, Par or Stated Value Per Share (in dollars per share) Â Â $ 0.001 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Shares Issued, Price Per Share (in dollars per share) Â Â $ 6.51 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Stock Issued During Period, Shares, New Issues (in shares) Â Â 10,022,937 Â Â Â Â Â Â Â Â Â Â Â Â Â Â X - DefinitionAmount of exercise price of warrants as percentage of subscription price for units. + ReferencesNo definition available. + Details Name: plse_ClassOfWarransOrRightExercisePricePercentageOfSubscriptionPriceForUnits Namespace Prefix: plse_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionThe consecutive trading days for exercise of warrant or right. + ReferencesNo definition available. + Details Name: plse_ClassOfWarrantOrRightExerciseConsecutiveTradingDays Namespace Prefix: plse_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionThe number of warrants or rights exercised during period. + ReferencesNo definition available. + Details Name: plse_ClassOfWarrantOrRightExercisedDuringPeriod Namespace Prefix: plse_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe percentage required for redemption of warrant or right. + ReferencesNo definition available. + Details Name: plse_ClassOfWarrantOrRightPercentageRequiredForRedemption Namespace Prefix: plse_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionThe period of written notice for warrants or rights to be exercised. + ReferencesNo definition available. + Details Name: plse_ClassOfWarrantOrRightPeriodOfWrittenNoticeForExercise Namespace Prefix: plse_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionAmount of proceeds upon exercise of warrants or rights. + ReferencesNo definition available. + Details Name: plse_ClassOfWarrantOrRightProceedsUponExercise Namespace Prefix: plse_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionPer share or per unit stock price trigger for vesting of warrants or rights. + ReferencesNo definition available. + Details Name: plse_ClassOfWarrantOrRightVestingStockPriceTrigger Namespace Prefix: plse_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionPer share redemption price of warrants or rights. + ReferencesNo definition available. + Details Name: plse_ClassOfWarrantsOrRightsRedemptionPricePerShare Namespace Prefix: plse_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe value of Equity classified subscriptions. + ReferencesNo definition available. + Details Name: plse_EquityClassifiedSubscriptionValue Namespace Prefix: plse_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionMaximum amount authorized for units issued under equity offering. + ReferencesNo definition available. + Details Name: plse_EquityOfferingUnitsMaximumAmountAuthorized Namespace Prefix: plse_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionThe total cost of the Equity offering of warrants and rights. + ReferencesNo definition available. + Details Name: plse_EquityOfferingUnitsOfferingValue Namespace Prefix: plse_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionTotal units issued during the year. + ReferencesNo definition available. + Details Name: plse_EquityOfferingUnitsSaleOfUnits Namespace Prefix: plse_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe number of shares threshold for increase in shares available for issuance. + ReferencesNo definition available. + Details Name: plse_IncreaseInSharesAvailableForIssuanceThresholdOfCommonStockOutstandingNumberOfShares Namespace Prefix: plse_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionPercentage of threshold of common stock outstanding for increase in shares available for issuance. + ReferencesNo definition available. + Details Name: plse_IncreaseInSharesAvailableForIssuanceThresholdOfCommonStockOutstandingPercent Namespace Prefix: plse_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares of stock issued or issuable for each unit. + ReferencesNo definition available. + Details Name: plse_NumberOfSharesPerUnitIssued Namespace Prefix: plse_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionRepresents number of warrants in each unit.

+ ReferencesNo definition available. + Details Name: plse_NumberOfWarrantsInEachUnit Namespace Prefix: plse_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of warrants issued or issuable for each unit. + ReferencesNo definition available. + Details Name: plse_NumberOfWarrantsPerUnit Namespace Prefix: plse_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionThe percent of an offering purchased. + ReferencesNo definition available. + Details Name: plse_PercentOfOfferingPurchased Namespace Prefix: plse_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionThe amount of right offering deemed dividends + ReferencesNo definition available. + Details Name: plse_RightOfferingDeemedDividend Namespace Prefix: plse_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of accumulated difference between fair value of underlying shares on dates of grant and exercise price on options granted. + ReferencesNo definition available. + Details Name: plse_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue Namespace Prefix: plse_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionExercise price per share or per unit of warrants or rights outstanding. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionNumber of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares. + ReferencesNo definition available. + Details Name: us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of warrants or rights outstanding. + ReferencesNo definition available. + Details Name: us-gaap_ClassOfWarrantOrRightOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionFace amount or stated value per share of common stock. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionDecrease for amounts of indebtedness forgiven by the holder of the debt instrument. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(f)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1 + Details Name: us-gaap_DebtInstrumentDecreaseForgiveness Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionPercentage of investment owned to net assets. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 55 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477439/946-210-55-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.12-12(Column C)(Footnote 5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-12B(Column D)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-12B(Column C)(Footnote 2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-12B(Column A)(Footnote 6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 6 -Subparagraph (SX 210.12-14(Column F)(Footnote 7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6 + Details Name: us-gaap_InvestmentOwnedPercentOfNetAssets Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionThe cash inflow from the additional capital contribution to the entity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromIssuanceOfCommonStock Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash inflow associated with the amount received from holders exercising their stock warrants. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromWarrantExercises Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionPeriod over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionNumber of additional shares authorized for issuance under share-based payment arrangement. + ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of shares authorized for issuance under share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionThe difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionPrice of a single share of a number of saleable stocks of a company. + ReferencesNo definition available. + Details Name: us-gaap_SharePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionPercentage of vesting of award under share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionPeriod from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionPer share or per unit amount of equity securities issued. + ReferencesNo definition available. + Details Name: us-gaap_SharesIssuedPricePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares issued during the period as a result of an employee stock purchase plan. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of new stock issued during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionPeriod between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_WarrantsAndRightsOutstandingTerm Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: instant X - Details Name: us-gaap_AwardTypeAxis=plse_TimebasedOptionsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=plse_PerformancebasedOptionsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=plse_MarketbasedOptionsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PlanNameAxis=plse_The2017PlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PlanNameAxis=plse_The2017InducementEquityIncentivePlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PlanNameAxis=plse_The2017EmployeeStockPurchasePlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=plse_LoanAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=plse_WarrantsIssuedIn2024RightsOfferingMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ClassOfWarrantOrRightAxis=plse_RightsOfferingWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_VestingAxis=plse_VestingOfFirstHalfMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_VestingAxis=plse_VestingOfSecondHalfMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=plse_The2024RightOfferingMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=plse_RightsOfferingMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_TitleOfIndividualAxis=plse_RobertWDugganMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_TitleOfIndividualAxis=srt_BoardOfDirectorsChairmanMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=plse_RobertWDugganMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 46 R37.htm IDEA: XBRL DOCUMENT v3.24.3 Note 6 - Stockholders' Equity and Stock-based Compensation - Summary of Stock Option Activity (Details) - The 2015 Plan, 2017 Plan and Inducement Plan [Member] 9 Months Ended Sep. 30, 2024 $ / shares shares Sep. 30, 2023 Options balances, number of shares (in shares) | shares 9,466,036 Â Options balances, weighted average exercise price (in dollars per share) | $ / shares $ 9.01 Â Options balances, weighted average remaining life (Year) 7 years 8 months 1 day 7 years 9 months 10 days Options granted, number of shares (in shares) | shares 3,017,643 Â Options granted, weighted average exercise price (in dollars per share) | $ / shares $ 10.38 Â Options exercised, number of shares (in shares) | shares (110,847) Â Options exercised, weighted average exercise price (in dollars per share) | $ / shares $ 4.49 Â Options canceled, number of shares (in shares) | shares (9,542) Â Options canceled, weighted average exercise price (in dollars per share) | $ / shares $ 15.19 Â Options expired, number of shares (in shares) | shares (35,958) Â Options expired, weighted average exercise price (in dollars per share) | $ / shares $ 19.82 Â Options balances, number of shares (in shares) | shares 12,327,332 Â Options balances, weighted average exercise price (in dollars per share) | $ / shares $ 9.35 Â Options

exercisable, number of shares (in shares) | shares 4,178,088 Â Options exercisable, weighted average exercise price (in dollars per share) | $ / shares $ 13.32 Â Options exercisable, weighted average remaining life (Year) 5 years 21 days Â X - DefinitionThe number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionGross number of share options (or share units) granted during the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of options outstanding, including both vested and non-vested options. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionWeighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionWeighted average price at which option holders acquired shares when converting their stock options into shares. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionWeighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionWeighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionWeighted average per share amount at which grantees can acquire shares of common stock by exercise of options. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionWeighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionWeighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Subparagraph (e)(1) -Name Accounting Standards Codification -Paragraph 2 -Section 50 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionWeighted average exercise price as of the balance sheet date for those equity-based payment arrangements exercisable and outstanding. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1 Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionNumber of share options (or share units) exercised during the current period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_PlanNameAxis=plse_The2015Plan2017PlanAndInducementPlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 47 R38.htm IDEA: XBRL DOCUMENT v3.24.3 Note 6 - Stockholders' Equity and Stock-based Compensation - Summary of Time-based Option Activity (Details) - Time-based Options [Member] 9 Months Ended 12 Months Ended Sep. 30, 2024 $ / shares shares Dec. 31, 2023 $ / shares shares Options balances, number of shares (in shares) | shares 6,141,906 Â Options balances, weighted average exercise price (in dollars per share) | $ / shares $ 10.48 Â Options balances, weighted average remaining life (Year) 7 years 2 months 4 days 7 years 25 days Options granted, number of shares (in shares) | shares 2,123,643 Â Options granted, weighted average exercise price (in dollars per share) | $ / shares $ 11.3 Â Options exercised, number of shares (in shares) | shares (100,897) Â Options exercised, weighted average exercise price (in dollars per share) | $ / shares $ 4.65 Â Options canceled, number of shares (in shares) | shares (6,542) Â Options canceled, weighted average exercise price (in dollars per share) | $ / shares $ 20.82 Â Options expired, number of shares (in shares) | shares (34,958) Â Options expired, weighted average exercise price (in dollars per share) | $ / shares $ 20.3 Â Options balances, number of shares (in shares) | shares 8,123,152 6,141,906 Options balances, weighted average exercise price (in dollars per share) | $ / shares $ 10.71 $ 10.48 Options exercisable, number of shares (in shares) | shares 3,745,410 Â Options exercisable, weighted average exercise price (in dollars per share) | $ / shares $ 13.97 Â Options exercisable, weighted average remaining life (Year) 4 years 10 months 2 days Â X - DefinitionThe number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionGross number of share options (or share units) granted during the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of options outstanding, including both vested and non-vested options. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionWeighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionWeighted average price at which option holders acquired shares when converting their stock options into shares. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionWeighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionWeighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionWeighted average per share amount at which grantees can acquire shares of common stock by exercise of options. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionWeighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionWeighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Subparagraph (e)(1) -Name Accounting Standards Codification -Paragraph 2 -Section 50 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionWeighted average exercise price as of the balance sheet date for those equity-based payment arrangements

exercisable and outstanding. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1 Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionNumber of share options (or share units) exercised during the current period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_AwardTypeAxis=plse_TimebasedOptionsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 48 R39.htm IDEA: XBRL DOCUMENT v3.24.3 Note 6 - Stockholders' Equity and Stock-based Compensation - Summary of Performance Option Activity (Details) - Performance Options [Member] 9 Months Ended 12 Months Ended Sep. 30, 2024 $ / shares shares Dec. 31, 2023 $ / shares shares Options balances, number of shares (in shares) | shares 1,224,130 Â Options balances, weighted average exercise price (in dollars per share) | $ / shares $ 5.51 Â Options balances, weighted average remaining life (Year) 7 years 10 months 2 days 8 years 6 months 10 days Options granted, number of shares (in shares) | shares 39,000 Â Options granted, weighted average exercise price (in dollars per share) | $ / shares $ 8.44 Â Options exercised, number of shares (in shares) | shares (9,950) Â Options exercised, weighted average exercise price (in dollars per share) | $ / shares $ 2.92 Â Options canceled, number of shares (in shares) | shares (3,000) Â Options canceled, weighted average exercise price (in dollars per share) | $ / shares $ 2.92 Â Options expired, number of shares (in shares) | shares (1,000) Â Options expired, weighted average exercise price (in dollars per share) | $ / shares $ 2.92 Â Options balances, number of shares (in shares) | shares 1,249,180 1,224,130 Options balances, weighted average exercise price (in dollars per share) | $ / shares $ 5.63 $ 5.51 Options exercisable, number of shares (in shares) | shares 432,678 Â Options exercisable, weighted average exercise price (in dollars per share) | $ / shares $ 7.69 Â Options exercisable, weighted average remaining life (Year) 6 years 11 months 23 days Â X - DefinitionThe number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionGross number of share options (or share units) granted during the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of options outstanding, including both vested and non-vested options. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionWeighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionWeighted average price at which option holders acquired shares when converting their stock options into shares. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionWeighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionWeighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionWeighted average per share amount at which grantees can acquire shares of common stock by exercise of options. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionWeighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionWeighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Subparagraph (e)(1) -Name Accounting Standards Codification -Paragraph 2 -Section 50 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionWeighted average exercise price as of the balance sheet date for those equity-based payment arrangements exercisable and outstanding. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1 Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionNumber of share options (or share units) exercised during the current period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_AwardTypeAxis=plse_PerformanceOptionsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 49 R40.htm IDEA: XBRL DOCUMENT v3.24.3 Note 6 - Stockholders' Equity and Stock-based Compensation - Summary of Market-based Option Activity (Details) - Market-based Options [Member] 9 Months Ended 12 Months Ended Sep. 30, 2024 $ / shares shares Dec. 31, 2023 $ / shares shares Options balances, number of shares (in shares) | shares 2,100,000 Â Options balances, weighted average exercise price (in dollars per share) | $ / shares $ 6.78 Â Options balances, weighted average remaining life (Year) 8 years 11 months 12 days 9 years 5 months 8 days Options granted, number of shares (in shares) | shares 855,000 Â Options granted, weighted average exercise price (in dollars per share) | $ / shares $ 8.16 Â Options exercised, number of shares (in shares) | shares 0 Â Options exercised, weighted average exercise price (in dollars per share) | $ / shares $ 0 Â Options canceled, number of shares (in shares) | shares 0 Â Options canceled, weighted average exercise price (in dollars per share) | $ / shares $ 0 Â Options expired, number of shares (in shares) | shares 0 Â Options expired, weighted average exercise price (in dollars per share) | $ / shares $ 0 Â Options balances, number of shares (in shares) | shares 2,955,000 2,100,000 Options balances, weighted average exercise price (in dollars per share) | $ / shares $ 7.18 $ 6.78 Options exercisable, number of shares (in shares) | shares 0 Â Options exercisable, weighted average exercise price (in dollars per share) | $ / shares $ 0 Â X - DefinitionThe number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionGross number of share options (or share units) granted during the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of options outstanding, including both vested and non-vested options. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionWeighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionWeighted average price at which option holders acquired shares when converting their stock options into shares. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionWeighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -

Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionWeighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionWeighted average per share amount at which grantees can acquire shares of common stock by exercise of options. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionWeighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Subparagraph (e)(1) -Name Accounting Standards Codification -Paragraph 2 -Section 50 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionWeighted average exercise price as of the balance sheet date for those equity-based payment arrangements exercisable and outstanding. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1 Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionNumber of share options (or share units) exercised during the current period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_AwardTypeAxis=plse_MarketbasedOptionsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 50 R41.htm IDEA: XBRL DOCUMENT v3.24.3 Note 6 - Stockholders' Equity and Stock-based Compensation - Option Assumptions (Details) 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Time-based and Performance Options [Member] Â Â Â Â Expected term in years (Year) Â 5 years Â Â Expected volatility Â 93.00% Â Â Risk-free interest rate 4.50% 3.70% Â Â Dividend yield 0.00% 0.00% 0.00% 0.00% Market-based Options [Member] Â Â Â Â Expected volatility 90.00% 90.00% 90.00% 90.00% Risk-free interest rate 3.90% Â Â Â Minimum [Member] | Time-based and Performance Options [Member] Â Â Â Â Expected term in years (Year) 5 years Â 5 years 5 years Expected volatility 93.00% Â 91.00% 89.00% Risk-free interest rate Â Â 4.00% 3.70% Minimum [Member] | Market-based Options [Member] Â Â Â Â Expected term in years (Year) 2 years 2 months 12 days 4 years 2 years 2 months 12 days 4 years Risk-free interest rate Â 3.70% 3.90% 3.40% Dividend yield 0.00% 0.00% 0.00% Â Maximum [Member] | Time-based and Performance Options [Member] Â Â Â Â Expected term in years (Year) 6 years 3 months 18 days Â 6 years 3 months 18 days 6 years 3 months 18 days Expected volatility 97.00% Â 97.00% 94.00% Risk-free interest rate Â Â 4.50% 3.80% Maximum [Member] | Market-based Options [Member] Â Â Â Â Expected term in years (Year) 4 years 2 months 12 days 6 years 3 months 18 days 5 years 9 months 18 days 6 years 3 months 18 days Risk-free interest rate Â 3.80% 4.40% 3.80% Dividend yield Â Â Â 0.00% X - DefinitionThe estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionThe estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionThe risk-free interest rate assumption that is used in valuing an option on its own shares. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionExpected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_AwardTypeAxis=plse_TimebasedAndPerformanceOptionsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=plse_MarketbasedOptionsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 51 R42.htm IDEA: XBRL DOCUMENT v3.24.3 Note 6 - Stockholders' Equity and Stock-based Compensation - ESPP Assumptions (Details) - The 2017 Employee Stock Purchase Plan [Member] 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Expected volatility 98.00% 83.00% 98.00% 83.00% Dividend yield 0.00% 0.00% 0.00% 0.00% Minimum [Member] Â Â Â Â Expected term in years (Year) 6 months 6 months 6 months 6 months Risk-free interest rate 4.40% 5.40% 4.90% 5.10% Maximum [Member] Â Â Â Â Expected term in years (Year) 1 year 1 year 1 year 1 year Risk-free interest rate 5.30% 5.50% 5.30% 5.50% X - DefinitionThe estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionThe estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionThe risk-free interest rate assumption that is used in valuing an option on its own shares. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionExpected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_PlanNameAxis=plse_The2017EmployeeStockPurchasePlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 52 R43.htm IDEA: XBRL DOCUMENT v3.24.3 Note 6 - Stockholders' Equity and Stock-based Compensation - Stock-based Compensation Expense by Recorded Location (Details) - USD ($) $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Total stock-based compensation expense $ 2,982 $ 1,798 $ 6,793 $ 3,837 Research and Development Expense [Member] Â Â Â Â Total stock-based compensation expense 1,108 982 3,058 1,758 General and Administrative Expense [Member] Â Â Â Â Total stock-based compensation expense $ 1,874 $ 816 $ 3,735 $ 2,079 X - DefinitionAmount of expense for award under share-based payment arrangement. Excludes amount capitalized. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.F) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_AllocatedShareBasedCompensationExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 53 R44.htm IDEA: XBRL DOCUMENT v3.24.3 Note 6 - Stockholders' Equity and Stock-based Compensation - Stock-based Compensation Expense by Type (Details) - USD ($) $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Total stock-based compensation expense $ 2,982 $ 1,798 $ 6,793 $ 3,837 Time-based Options [Member] Â Â Â Â Total stock-based compensation expense 2,131 1,200 4,609 2,754 Performance-based Options [Member] Â Â Â Â Total stock-based compensation expense 5 87 27 292 Market-based Options [Member] Â Â Â Â Total stock-based compensation expense 788 464 1,978 622 Employee Stok Purchase Plan [Member] Â Â Â Â Total stock-based compensation expense $ 58 $ 47 $ 179 $ 169 X - DefinitionAmount of expense for award under share-based payment arrangement. Excludes amount capitalized. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.F) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_AllocatedShareBasedCompensationExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: us-gaap_AwardTypeAxis=plse_TimebasedOptionsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=plse_PerformancebasedOptionsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=plse_MarketbasedOptionsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=plse_EmployeeStokPurchasePlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 54 R45.htm IDEA: XBRL DOCUMENT v3.24.3 Note 7 - Commitments and Contingencies (Details Textual) $ / shares in Units, $ in Millions 3 Months Ended 9 Months Ended 12 Months Ended Apr. 30, 2023 USD ($) $ / shares shares Sep. 30, 2024 USD ($) $ / shares Sep. 30, 2023 USD ($) Sep. 30, 2024 USD ($) $ / shares Sep. 30, 2023 USD ($) Dec. 31, 2023 USD ($) Sep. 20, 2022 USD ($) Dec. 31, 2021 $ / shares May 31, 2019 ftÂ² Jul. 31, 2017 ftÂ² Common Stock, Par or Stated Value Per Share (in dollars per share) | $ / shares Â $ 0.001 Â $ 0.001 Â Â Â $ 0.001 Â Â Operating Lease, Expense Â $ 0.6 $ 0.6 $ 1.8 $ 1.7 Â Â Â Â Â Corporate Headquarters in Hayward, California [Member] Â Â Â Â Â Â Â Â Â Â Lessee, Operating Lease, Term of Contract (Year) Â Â Â Â Â Â Â Â Â 5 years Area of Real Estate Property (Square Foot) | ftÂ² Â Â Â Â Â Â Â Â Â Â 15,700 Corporate Headquarters in Hayward, California [Member] | Expansion Premises 1 [Member] Â Â Â Â Â Â Â Â Â Â Area of Real Estate Property (Square Foot) | ftÂ² Â Â Â Â Â Â Â Â Â 13,300 Â Corporate Headquarters in Hayward, California [Member] | Expansion Premises 2 [Member] Â Â Â Â Â Â Â Â Â Â Area of Real Estate Property (Square Foot) | ftÂ² Â Â Â Â Â Â Â Â Â 21,300 Â Robert W. Duggan [Member] | Private Placement [Member] Â Â Â Â Â Â Â Â Â Stock Issued During Period, Shares, New Issues (in shares) | shares 10,022,937 Â Â Â Â Â Â Â Â Â Common Stock, Par or Stated Value Per Share (in dollars per share) | $ / shares $ 0.001 Â Â Â Â Â Â Â Â Â Shares Issued, Price Per Share (in dollars per share) | $ / shares $ 6.51 Â Â Â Â Â Â Â Â Â Two Thousand Twenty Two Loan Agreement [Member] | Robert W. Duggan [Member] Â Â Â Â Â Â Â Â Â Debt Instrument, Face Amount Â Â Â Â Â Â $ 65.0 Â Â Â Debt Instrument Quarterly Interest Rate Â Â Â Â Â Â 5 Â Â Â Debt Instrument, Increase, Accrued Interest Â Â Â Â Â Â $ 1.7 Â Â Â Â Interest Expense Â Â Â Â Â Â $ 1.1 Â Â Â Â Loan Agreement [Member] Â Â Â Â Â Â Â Â Â Debt Instrument, Decrease, Forgiveness $ 65.0 Â Â Â Â Â Â Â Â Â Interest Payable $ 0.2 Â Â Â Â Â Â Â Â Â X - DefinitionDebt instrument, quarterly interest rate + ReferencesNo definition available. + Details Name: plse_DebtInstrumentQuarterlyInterestRate Namespace Prefix: plse_ Data Type: xbrli:pureItemType Balance Type: na Period Type: instant X - DefinitionArea of a real estate property. + ReferencesNo definition available. + Details Name: us-gaap_AreaOfRealEstateProperty Namespace Prefix: us-gaap_ Data Type: dtr-types:areaItemType Balance Type: na Period Type: instant X - DefinitionFace amount or stated value per share of common stock. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionDecrease for amounts of indebtedness forgiven by the holder of the debt instrument. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards

Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(f)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1 + Details Name: us-gaap_DebtInstrumentDecreaseForgiveness Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionFace (par) amount of debt instrument at time of issuance. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2 + Details Name: us-gaap_DebtInstrumentFaceAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionIncrease for accrued, but unpaid interest on the debt instrument for the period. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(f)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1 + Details Name: us-gaap_DebtInstrumentIncreaseAccruedInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of interest expense classified as operating and nonoperating. Includes, but is not limited to, cost of borrowing accounted for as interest expense. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-24Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483013/835-20-50-1 + Details Name: us-gaap_InterestExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of interest payable on debt, including, but not limited to, trade payables. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(15)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(15)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap_InterestPayableCurrentAndNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionTerm of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3 + Details Name: us-gaap_LesseeOperatingLeaseTermOfContract Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: instant X - DefinitionAmount of operating lease expense. Excludes sublease income. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-4 + Details Name: us-gaap_OperatingLeaseExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionPer share or per unit amount of equity securities issued. + ReferencesNo definition available. + Details Name: us-gaap_SharesIssuedPricePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionNumber of new stock issued during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_LeaseContractualTermAxis=plse_CorporateHeadquartersInHaywardCaliforniaMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=plse_ExpansionPremises1Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=plse_ExpansionPremises2Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=plse_RobertWDugganMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=plse_TwoThousandTwentyTowLoanAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=plse_LoanAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 55 R46.htm IDEA: XBRL DOCUMENT v3.24.3 Note 7 - Commitments and Contingencies - Information Related to Right-of-use Assets and Lease Liabilities (Details) - USD ($) $ in Thousands 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Dec. 31, 2023 Dec. 31, 2021 Right-of-use assets $ 6,588 Â $ 7,256 $ 7,256 Current operating lease liabilities 1,193 Â 1,058 1,058 Non-current operating lease liabilities 7,174 Â 8,086 $ 8,086 Total lease liabilities 8,367 Â $ 9,144 Â Cash paid for operating lease liabilities 1,425 $ 1,376 Â Â Â 2024 (remaining 3 months) 485 Â Â Â Â 2025 1,977 Â Â Â Â 2026 2,046 Â Â Â Â 2027 2,117 Â Â Â Â Thereafter 4,074 Â Â Â Â Total lease payments 10,699 Â Â Â Â Less imputed interest $ (2,332) Â Â Â Â Weighted-average remaining lease term (Year) 5 years 29 days Â Â Â Â Weighted-average discount rate 10.00% Â Â Â Â X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease due after third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesNo definition available. + Details Name: plse_LesseeOperatingLeaseLiabilityToBePaidAfterYearThree Namespace Prefix: plse_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiabilityCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiabilityNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_OperatingLeasePayments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of lessee's right to use underlying asset under operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseRightOfUseAsset Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionWeighted average discount rate for operating lease calculated at point in time. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionWeighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: instant XML 56 R47.htm IDEA: XBRL DOCUMENT v3.24.3 Note 8- Segment Reporting (Details Textual) 9 Months Ended Sep. 30, 2024 Number of Reportable Segments 1 X - DefinitionNumber of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 54 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18 + Details Name: us-gaap_NumberOfReportableSegments Namespace Prefix: us-gaap_ Data Type: xbrli:integerItemType Balance Type: na Period Type: duration XML 57 R48.htm IDEA: XBRL DOCUMENT v3.24.3 Note 9 - Related Party Transactions (Details Textual) - USD ($) $ / shares in Units, $ in Thousands May 31, 2023 Apr. 30, 2023 Sep. 20, 2022 May 31, 2022 Sep. 30, 2024 Dec. 31, 2023 Dec. 31, 2021 Accrued Liabilities, Current Â Â Â Â $ 3,821 $ 3,814 $ 3,814 Common Stock, Par or Stated Value Per Share (in dollars per share) Â Â Â Â $ 0.001 Â $ 0.001 Loan Agreement [Member] Â Â Â Â Â Â Â Debt Instrument, Decrease, Forgiveness Â $ 65,000 Â Â Â Â Â Interest Payable Â $ 200 Â Â Â Â Â Robert W. Duggan [Member] | Private Placement [Member] Â Â Â Â Â Â Â Stock Issued During Period, Shares, New Issues

(in shares) Â 10,022,937 Â Â Â Â Â Common Stock, Par or Stated Value Per Share (in dollars per share) Â $ 0.001 Â Â Â Â Â Shares Issued, Price Per Share (in dollars per share) Â $ 6.51 Â Â Â Â Â Letter Agreement [Member] | Robert W. Duggan [Member] Â Â Â Â Â Â Directors and Officers Liability Insurance, Period (Year) Â Â Â 1 year Â Â Â Related Party Transaction, Amounts of Transaction $ 1,000 Â $ 65,000 Â Â Â Â Accrued Liabilities, Current Â Â Â Â $ 0 Â Â X - DefinitionPeriod of liability insurance for directors and officers. + ReferencesNo definition available. + Details Name: plse_DirectorsAndOfficersLiabilityInsurancePeriod Namespace Prefix: plse_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionCarrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AccruedLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionFace amount or stated value per share of common stock. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionDecrease for amounts of indebtedness forgiven by the holder of the debt instrument. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(f)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1 + Details Name: us-gaap_DebtInstrumentDecreaseForgiveness Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of interest payable on debt, including, but not limited to, trade payables. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(15)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(15)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap_InterestPayableCurrentAndNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of transactions with related party during the financial reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 850 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483326/850-10-50-3 + Details Name: us-gaap_RelatedPartyTransactionAmountsOfTransaction Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionPer share or per unit amount of equity securities issued. + ReferencesNo definition available. + Details Name: us-gaap_SharesIssuedPricePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionNumber of new stock issued during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_DebtInstrumentAxis=plse_LoanAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=plse_RobertWDugganMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_RelatedPartyTransactionAxis=plse_LetterAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 58 R49.htm IDEA: XBRL DOCUMENT v3.24.3 Note 10 - Restructuring Charges (Details Textual) $ in Thousands 1 Months Ended 3 Months Ended 9 Months Ended Feb. 28, 2023 USD ($) Sep. 30, 2024 USD ($) Sep. 30, 2023 USD ($) Sep. 30, 2024 USD ($) Sep. 30, 2023 USD ($) Income Statement [Abstract] Â Â Â Â Â Costs and Expenses Â $ 13,655 $ 11,252 $ 35,996 $ 31,041 Restructuring Charges, Statement of Income or Comprehensive Income [Extensible Enumeration] Costs and Expenses Â Â Â Â Employee Severance [Member] Â Â Â Â Â Restructuring and Related Cost, Number of Positions Eliminated 7 Â Â Â Â Â Restructuring Charges $ 100 Â Â Â Â Â X - DefinitionTotal costs of sales and operating expenses for the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_CostsAndExpenses Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_IncomeStatementAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe number of positions eliminated during the period as a result of restructuring activities. + ReferencesNo definition available. + Details Name: us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated Namespace Prefix: us-gaap_ Data Type: xbrli:integerItemType Balance Type: na Period Type: duration X - DefinitionAmount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.P.4.b.1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482047/420-10-45-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 5.P.3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-1 + Details Name: us-gaap_RestructuringCharges Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionIndicates line item in statement of income or comprehensive income that includes restructuring charges. + ReferencesReference 1: http://www.xbrl.org/2003/role/recommendedDisclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.P.4.c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1 + Details Name: us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration Namespace Prefix: us-gaap_ Data Type: enum:enumerationSetItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 59 R50.htm IDEA: XBRL DOCUMENT v3.24.3 Note 11 - Subsequent Events (Details Textual) $ in Millions 1 Months Ended Oct. 31, 2024 USD ($) Subsequent Event [Member] | Next One to Four Years [Member] Â Share-Based Payment Arrangement, Accelerated Cost $ 12 X - DefinitionAmount of additional cost recognized for award under share-based payment arrangement from occurrence of event accelerating recognition of cost. + ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCostCompensationCost Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardDateAxis=plse_NextOneToFourYearsMember Namespace Prefix: Data Type: na Balance Type: Period Type: EXCEL 60 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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|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

<30T:#1)0?R2HO]8[H4R MCCB>L5O0?1KC%':G'XA?/_0[K2G2B4JPA45_/SGC2:PW.M;IT&'3CV=R]/:S M8/*V>2FL4//[[1O#P]W#B^?
+YG5K[_Y5>+9L7QJW;MJWV5^I!")3*&=KL:Z$UJ)H+C>,PE8S!O#_M8"6W7TQ/W!X3;_X'U!+ P04 M " #C@%Y9_(P3W2\5 &6P$ & 'AL+W=O?9;GTY\-JO?MP<9_G MC[]<7>UN[[.'^>
[GS6.V+KYSM]D^S//BT^V7J]WC-ILO#A<]K*Z4P6!X]3!? MKB\^OC]\+=Y^?+]YRE?+=19OI=W3P\-\^]=OV6KS[<.%?/'RA9OEE_M_X6K MC^\?
YU^R:9:GC_&V^.SJ55DL'[+U;KE92)OL[L/%K_(OJ3[:7W"H^*]E]FWW MWF!? ^9I]RE:KO50\CC^_Z,7KF/L+ MO__X13[6:U M. RO].Ü8.[B0:1]V^>;A>'"Q"!Z6Z^?_SO_D-\=X$V.G&!
[,;=/CG*R^V6Z_=; MOSYUREY>;+]?O_LE;J;SK1;;=_8=D_/&TS/^2WDVR MN^7M,OJ1>I>NYT^+97'=C]*EE$XGTKL??I1V]_-MMI.6:VEVOWG:S=>+W4_2
M#Y7/WU_EQ5/8/Y"KV^/# _>WYX2HG'NZAX>^DZ.XNVR[77Z3_#K*'S]GV?XI' M__!0].?#(WW]:HO_Z4S_UT7Q!(L98+Z2XOER<5D\C4_SQV5>?"X8;7+N:-$G M1_HUS[?+ST_Y_/,JD_)-
,>ZVN'&BX8PSA[O)\F+J+6Z[,=^NB^_L1.(8YPW2 M(EEB*=XNOQ8_A5*\FM\>?A;[WVW[[!'.N]_.^>.==\?=LP?L=<^]LL^!O_]P[.P<^[U^(90UWFZ-
SQNIUA^,S1FAA$C'SUMMXT_%HSKIATP[T MO%LSZVB'?6Y"*K9FF^(95B^[*J;[USE?>9WSE8.CG7!^FZ_FZ]M,>E?\NSW/ MTC]*\UR:9+<_2ZK\DZ0,%*5M:A;J^Y7?+
[O'H@%\N"B6=KML^S6[^/CO_R8/ M!__9-@^3V(3$#!(S2Q!#CDEL1F)I1!6F4/4USE$?=,<\I9Y0RCUG3=(;$)B!HF9 M)&:1F$UB#HFY)..1F$]B 8F%)!:16$QBR3,VK,P;M4FC6:*,%4T95,NFS,):
MQ:Q9<:F,M=&@-DNE;76*=OU:5>G+VFM?UH1]V=GMG@Z-7,GW3ZOMG:'U=;3 M8_%A]F>VOSW4N#M_]-M]NY_L7^+Y;!K1U;^%X?;LWB4U(S" QD\0L$<)S"$Q ME\0\$O-)+"""QD,0B$HM)+-
$:O_47O_1?U_HW.>*4Q&8DED)897+17R<7'9Y< MVB84X1A])Q02FY"806(FB5DD9I.80V(NB7DDYI-80&(AB44D%I-8HC=^]:ZO M!O3&E"-KUXI<6PPT]^J+@-
RTEZG7]+SZGW="LNR3M&JO:J[_+9_=D4IN@FH%)]JI9J&:CFH-J+JIYJ.:C6H!J(:!%]!:C6G+41*^@'TL$K73: M73)K*;F4!\IH5._*2735QR4?5DLKZN)Q>S=U-%^+:@:JF:AFH9J-:@ZJ
MN:CFH9J/:@&JA:@6H5J,.:@FJW:#:%-5FJ);*S93RX,2T4\9M97'>]N3?V\QW MTN-\F^^_OL@^YU+V9UY,2T_+W?U^(Y:?I'5V^-[RY?
K;S>YY4ZM\A=O@X&B5G_AL=%!'51S4SK^/\]*K3.1\&'TGHE(;8)]!JJ9J&8=MJ*6INMG):RFN1VEWCM@VFUP7ST7R% M1#5(E2+42U!M1M4FZ+: M#-522JNV^#+R*XLSOR7P?WF
MQ"/UG6I0:8)!]J9J&:AFHUJ#]JYJ.:AFH]J :J%]!:A6HQJR5$3I>>4EI3Q M8%Q;/[04U=E>,C1CR/) K2\91%GEXY3069)V#%5MWV7F61%GGL_9KDY,]N[4:&89
MU0Q4,U'-0C4;U1Q43V@35#%0S4DPH&J_;H,Q2IO"\7VW6Y!S/;N MU&A %M4,5#-1S4(U&]4<5'-1S4,U']4"5 M1+4*U&-42I26(VK+= CKH%-5F MJ)926G5F*0.\RML"O&^:3=#0+JI-4,U
-1/5+%2S4YCJ@Y?#<:UE1&N_?=A_4VU)RJ:K# ML:S7UP'-0DU3AR>V6U#+W*OZ]MSK\4_8.S)1:C.^-1P,:D_LDWC8OKT8U0Q4 M,U'-0C4;U1Q4\]KIR@ X8HEJ$:C&J):AV@VI35)NA6DIIU7FB
MC->]?>.UK7-#\YC.87UB:);HXZ%:FS\F+66U$].[Q#9PQ6.TQ6>+GWKOIH@%3 M5'-1S4,UO_M^!MTE87=)U%T2=*7.7 M;]_VMC]"S$:WD2U":H9J&:BFH5J-JHYJ:.BFH=J/JH%]!:B6H1J,.HE:DM<
M4JN]LWB##CE%M1FJI916G7'*F*EZY%&Z)V>TA$'U8>VU[6E+5?UU\NZ2M'VL M$P$GM0R>W;O7?L3B47NW:CFHUJ :B&J M1:@6HUIRU*]64VXT='+(*:K-
4"VEM.JT4^9J57&N%MR/6#Q2[ZD&#=FBFH%] M)JI9J&:CFH-J+JIYJ.:C6H!J(:!%]!:C6J)VAVS59O95:^Q8TU+46#ATQVP[MAJHV\#)HJXJ#MO_(?L3B,7NW\=W0K+LD[1JKVJO+F*LJCKF*-
B067][]Z.Q M5E0S4,U$-0O5;%1S4,U%-0_5?%0+4"U$M0C58E1+U,XHZDUWR;2[9-92WJ_ENM[Q;%K]5[YX^[VZWR\;I=)V M^>4^WTGSG?0XW^;["XY?V=S=9=OE^HOT+MSDF31L?
2U> #CZ-GE4FZ":@6HF MJEFH9J.:@VHNJGFHYJ-:@&HJD6H%J:.HG6>O7K34[*-1O7N/.V69MTE:>=@ MU19?9E$U<1;UIM:E%UGV4/3VQ^WFAQKZ@V034#U4Q4LU#-1C4'U5Q4\U#-1[4
U4)4BU M1K5$Z\PAWVC- M$V$O6WMZLZ[1TSM+TN[1JDU=*9NZ.)?[AHWIM=:>C:9O46V":@:JF:AFH9J- M:@ZJN:CFH9J/:@&JA:@6H5J,.HG63-\.95T>UOLVFK]%M1FJI916G5G* *TF
MSM^>V)B^?39!4[:H-D$U]5,5+-0S48U!]5<5/-0S4>U -5"5(M0+4:U1&NF M;(?UK1RT9O15TP?RM59? G0';5M*+M61+#=HMH,U5)*]\XL9:16$T=JOUL'=,\F:&86U2:H9]":B6H6JMFH
MYJ":BVH>JOFH%J!:B&H1JL6HEFC-S&QC8WJMF615KW55&J?T =VYV9:22U6 MUM3&.J!9J S'P_&)=4"9G]5ZYV<[PK%:,XK6LC&]>-C>O1@-O:*:B6H6JMFH MYJ":BVH>JODM/^/UC>G1 4-
4BU M1K4$U6Y0;8IJ,U1+*:TZ3Y215ZUOY+5U M;FBFQ^H;T[>4M&U,WU)6WYB^N\0\,5A]8WKQ<^_==-$ **JYJ.:AFM]]/X/N MDK"
[).HNB;M+$O3)WZ#:%-5FJ)926K61E>%/31S^Y#>F%P_8^T4,-!]*:@:J MF:AFH9J-:@ZJN:CFH9J/:@&JA:@6H5J,:HG6S&(V-Z9'AYRBV@S54DJKSCAE
MA%431UB9C>G%@_2>9=*P*ZH9J&:BFH5J-JHYJ.:BFH=J/JH%]!:B6H1J,.HE M6O.,U_H^QEHS?MJR,7U+5>-U\LZ2M'VL$QO3ZV7057][T!7/%+OJ0:-VZ*:@6HFJEFH9J.:@VHNJGFHYJ-:@&HA
MJD6H%J-:HG?';?5F %8;U=ZWF[84U1<.W25IQU#5!JZ4#?SM!^!B&].+Q^S= MRM$4+JH9J&:BFH5J-JHYJ.:BFH=J/JH%]!:B6H1J,.HE>C.%JS5Z.1K!1;49
MJJ645IUSR@BN_O8C().T8JNQ^RTQN\:&H?9^5+U8 M[-VI26V":@:JF:AFH9J-:@ZJN:CFH9J/:@&JA:@6H5J,.LE1$VV/V5*BC)NM MNA.:=9>D76-5>W69]=S] M+<5LJYZ-IE]1S4
U$]4L5+-1S4$U%]4\5/-1+4"U$-4B5(M1+=%;3[_^/YQ_B4+YMLOR_5.6F5WD76#GT?%-'DX5>KEDWSS^.%"OI ^;_\\\W#X M\#Z;+[+MOJ#X_MUFD[]\&PO=V]R:W-H965T&ULK5=1;]HP$/XK
M5E9MK;0U-% *'41J2:?U 0V5=GN8]F"2"[&:Q*GM0/OO=W9"!I1F4'A)?,Y] M7^X^7TZ7WIR+1QD!*/*KB'F\[YU9BTV[M@T4GK# M=GL9G<(8U$,V5FC9%4O $D@EXRD1$/:MJ[-+KZO]C<-
/!G.YM*8ZDPGGC]JX M#?I60P<$,?A*,U"\S6 <:R),(RGDM.J7JF!R^L%^5>3.^8RH1(&//[% A7U MK8Y% @AI'JL[/O\.93[GFL_GL317,B]]&Q;Q%11MR?XG CMC6QZ8<0T:$R?I?K8
MQTK@4X8XY0YX&N A0D!P)7G, JK0&"N\X>DJ27B(%O,,3A>D0%PB)0S*>Q/"%?R,/8(\=')^2(L)3<1SR7- UD MSU88O@["]LM0KXM0G3=";9(A1V9);C#D8 -^4(_OUN!ME*W2SEEH=^W4$HXA
M.R7-QF?B-)S6IGCV@WO;PYLUV32K2F@:%8);?.:+E^'1&()@Z93\'D(R ?%G MTT'5,NE.=2DSZD/?PE8D0-M6523V#=\WJV]BP<_24=>X%>)(HJP:Z]._/FO?',[&1'X2E6B $/ MM?-
Q6E3,S6U91EUAK6*?&O3R9DVA5BS;L"EC$U"9[%2[EP$B&U=J[":?HZ/=M!@6QP=?[*;B]*"<31JUP27R+\TBR*X\H1A; MHX^6/ 1<3XN/P]OY.-
EG@U\M[N*+_20E*Z*GM/ELIL4@$4*'FA."DML6[]"Y M!"0T_CI@%]>0R?'E^HC^*6L7+2L5\8[<;J9P-2UN"C"X5JWC+[3[$0]ZWB0\
M32[F*^P.MH,"=!N9ZH.S,*BM[^[J^9"'_^,P.CB,.N\4&9YKC>\H/%V$*U MH*5%EIJ]A9SUZ5'6'.2M%3^>/1(C#.$*[C'}8)N<*EH#5PCS-HIUC).2)5*R
M+_4!==ZACOX#]3T\D.H/G6OQ2&)YJC(\WYZ"+@$IL^7]Z,!J,QA?P MKD^RKS/>]079$9C@D_7*:ZL<+%OQ26KGQ6;T=W/@\7.J_UJ^';PX0+9\8GL^!+Z[.>P4=
[^K=+9].".?"1GC>]JVAM8I)">U?'LSFF"_M>QNUH]@&A-^_XC/#W)%^^N.5B*VJ+7&'OPV>L^V @*/&W1 MPH M/%TU.>R2,=VZSO*[XG&Q++X'1EUY'G&KC ()^:#V,'R?RGLX[L-/
MK21K>).WKH6S9P@V/L5< M(ZT<4V 9TLFEEYBXU0TIT;W'QDP(,RQN:\,="$L:Q< QL1AB2>)Y:__,Z5 M=OEB% 62L3QPHYQXZ[F;2>GIYG^L1ME_YIW'X0'%3;61TGV6EP'_7=O"A&4
MAVRW86KR8%L1RYC,2RDF@R$9R/LU29 M6<[@/KV<"0 PAD !@ !X,";JW;W)KZOOV<7 M(S6YE-*\V)0 [.?9LPOJ87E?PY(WF9+3S_%9NX]VPZ
M$%GM@RW385A0:A/_RR\I#IT#%Y,]!Z;IP)3MCHK8RG2U^LR:LO'AOOV-XD[[Q5$A MO?&5S-35)7BE5NKP?4/WQV?3]X>,/:T-?;TD/3KKZ1'_/>3^A+$;6&SQ__U MV7Y8^G0D;J77GH#P0,8;!
(+JY]*H888R6U;2/)'"VL@ZUT'E(K/(J_'QR<.. M7-+7BS:80@VF6,FU$G.EC$!H*NFPCXJ32@M*Z;SV 3M1!V$E I3>194_?"' ZQ19TK]JEW T6\+KP2M]IZI-)DR@_%OFXPCVC\1GV /#WON@P8&02#&
(J8LQP>(>=TD4M0T=GF(V/X]F(_'SSJ!J^^] ^"Z"((U0[)))" 'D+\V3!CW"_M\UE1'EG6^7LTLER MBVS>*6S%2(OQ!K*JK!/JEFM:I>M(*LY/>IJ$Y5RVN8(%E NM/>U\L^D(GVLX56^7 J!RSOP%
6+ #TV:O!(B@G%:,R2@ ,"B)A307A%"H6K#-"Q\M6K"-6RAJP MXZ/J2P6QG"N74ZH(,U9^\A^;:0<&N6@7V(%MF,H\H!P A0VEP5NZ[OP 3Q)(H41.\KZ998 MIX@@U3*FE/G?
@Z5H@CJBAI2Z8+KJ22ZP6VX1.B*1 M4C[!PP%9>!OQCN I%$!-]SF#">U1A0/&0JY7/2M 2T$Y3^0GLY56.T8(P:S1 M&,6+3%8ZR$+_'?,7*&<1CQU_8A)ZX<0%%]B29S[TUQ1+6G3XDOR<
BYTA46 M;%G616HJ!* #G@[6@6V!P'_$80IH"3Q!A$Q36L,NR5C*C:Y=$W8!M=$$XRS##<=Q M,E2]U-V$%'G +*IK^FM71B 4V\-)["TZAZFHG,L(7&8=J5BF6>V)Q ML,]#=%UVFL6?
=,YL>O<<%\BH"^_-2!=]H]'"QH4 0U5U!@HPDUG\5PTY%E(9=#U MI&MF'U/2\!+G:D3!R.AQV^CGI*P=@!A%"QC[! KB4RZ1N_RHKBB[@ ./7UN&[+%GAYS_4Z,#T>24YJ36/12;HS&,7R40
MI)KK2MZ :X'QW&XHUXD#OW+AX/GL$V I7I&?,?U IP^L,%TS MGV[54AM#EJ2[M@/A>,,JF,_<3VAB39Z_H<&6O(QS4XH0#;JI/>6U:VHM$6,C8M__^7Y%W$)O_MB61RRR!VJSQ.:T335)
<4W'V0H8]\0]]LG/<1- O.IOWZ7@!ZU]2<+[%X^,I M QCX5^MY(A S8K4=)#=DHWB:TIDPV%\T^YD%Q9P]!KCE>T:SC"\I3!M^-01 MXL;E4/#"U)PZ(FBF4.
[!'3(2(#_&*$G[1{Q'XITN:@)=CQTZ5@,O0_T2-N&P M2E2^2.'4>MPRDB+_1(MC8@O+35#VHYNXA09B0T<#57:7$WZB_CX/R%,T&= -':,I1":.,Q,'A,O!C>SN\%+,3V?T"WP[&PHWDM'Y>
[%0POB(W$/8N0& K$%[7..>3Y5!0,\OBIJF[I@?NS+U>5]38VTWONV8),LX\C&V&!A>!!9' M*%29K&F0P&J3VF'/59':.+/KD=HROC7X&0%*ZD\9(YUO2[6Y<?F4R^199&J6?
M+ZZ+"54<7PR/+\Z&D^/NTD>5J6?O/)PU M>,[2P(:)0 P,\9M$B,.1Z%IV%,V%C%WT I5H\NGDD,C!0]Y>E3^J$FOXQ^-' MMGUC]^E[,CCOOU3&$+/G7 M R)8Q""^8F^,;7^@N(GOY,?;XZ\;"
SZL1>%6N#H9/3J,(QDW\QB!^"K?@M M/>ZKF'CX<:4DF(\V8'UA07+I REH?[.Y_C]02P,$% @ XX!>61/E%[M> M P 20@ !D !X,";]W;W)K&UL0591,]LX#/XK MA#?LJ:MC.VNS-
@G0M%>LP#84:V_W+<+@'Q:9CH,+D2G33W}_2G9<#W#/AT" M)!1%?OH^B:(RWQI[YR!$<=:,>(*J+F)(Y=7F$MW*%!4/..,6PMB(=V$[O& MHBA"4JWB=#(YBFLA=;2CYYO-PH%
[YAV\5./T60MXY,W2P!ML#B&,'$ Z2:=[\+)!?A;PLCWR'9 9":,XA0?BJ_MW@YN^C*QT_IR=$07TN7*N)87 M@;]O\0%@I4Q^`]\]+E/>#9H=P6R&(EBIC)6OG2P*,5A:\'26IFY,"GOMP$>XF
M85Y]=>]R2.L8CR=K%%[>&%AJ]E-ED4M48V]]QO=4D/"GLU(#D ,8J-S9#P* MCBP(+8WB1B3U!CQ]!(=,AIL,Z 3L1LOQ-?">#=+D^-3CATJ13Y? MC1W= GRGX1W+6VO{MPQI /A/!H7+U?
6&NU0P7'!>>])@B=[*>C,!9+G2C@G M2YEW>[83OI.]4WMKB+GQO<,G;A3VCAM[V>J"\X6K0.@"[=G;D'Y7_3](G"8'R6SZ"K%^\FT2WX3T M7#E0R*(4X%O._Z4V$8_:>XUV$QXQ![EI-76=?O .
[^19]SP\AW>/[/#=A-URV MH++#DU,GA,3]+MGNXN@&9)CP6:TA] 2SXK<>K0_@^=)PQ^P'?H'AWV/R/U!+ M P04 " #C@%Y98FR&^
MKBKA[D^EMJOC3M)93URK11EXHC\)6HJ%G,GP;7GE\??:"E4)8U7UI'3\^/. M27)P.N+]<<-W)5=^:TR,Y,;6 [X4!QW!NR0U#/(K$'@]5.>2:U9$=SXT>KL M;$RRX/9XK?
TR8@>6&^'EF=5 JB*4QYVL0X6.T0WGM@ZU:87A0*=.\Q5W+PY9 -GA!(&?%TNMA8RAZ>2Z"F!XYNR+'NZ&- M!Q%JE(9SRG!09L%A54$N3#_;(&E$[^E4:&%R2,:8"F>V6EHC3?!'_0 SO+F?
MMRI/&Y7!"RKWZ9,UH?1T80I9/),OP[V-C^G;Q]/T584SN>S1<-"E=)".7M$W-MW& >1GW#5S![*I8NE0%F)33-@@BR>@EOHV[TO#HNFP_%+D\[J NO'0_96?Z M]DTR&1R^XNQHX^SH-
>W36,U0BC'ETY5+\+]R1,01<_:K5D1{KT&=8?K@DPP(T%Q#TE(WK(}DN3])"^6@[2\EEB:.P=_M9/O\'(R Q_L#.LGSNJJU8)X*>*1BDVK@[YO5S/Q;MC>)AGM\F"T-\@ M-5--
#'880%MGJ3(RW7@0NFD_"U(_M#W$QR*,7%S\@9_7>&%=\:NWI?HK*8B"#STEAM%_ M(1#7J![AP-^EK4W11H_I8/#+^??KB_C.#G<[=*%0(4X0]^56T"/H$^MV5E>
M6JN[#18XO:4>Q,QPM)8L=R:T@L.0[(%4$D6AV%QW&RB!'LE.*P,&!,W0U,WE MB8VC)TCC6$\X>4+Y$K_8Y=.F%M(JV(+[%DT$^D[538>N4[EB,NJ5%A6)M=U_M@1"NXP9O<
YC5[V=Q(Y/4!#ME.>09VBVO-].CK%C+EUS42XXL5)22ST"D< M:"3I U*,ZZSV9/B.[37W<_& MF_?3)O&X+4RZX_U];@N3[B
.FK;PA(B'CC#,)O&=X7U"?,&%EZ2_F$CE7,#];#!PT6]XU4PXI"I>$G;9F\F8UX7K4?;&#S_V+Z+U!+ P04 M " #C@%Y9KIPFTVL" ^!0 &0 'AL+W=O!J0!@EBD^)X>*5*SQM@G5R
2O)1*NWE0$%678>BR DOA1J9"S3L, M8TM!;.IMZ"J+(F]!!0KC*#H+2R%UD,Y.W[U-9Z8F)37>6W!U60K[ND!EFGDP M#G:.![DMR#O"=%:)+.Z0OE?
WEJUP8,EE8=(H+ 9>AY>,VGP>1%X0*_(,@C_/N$2E/!'+^ S!L.1'KB_WK'?M+5 M<&G43YE3,0\N LAQ(V!%#Z,Y@GT^4\^7&>7:?VBZV"0)(*L=F,(‘LX)2ZNXK M7OHZ[$NHC<
<0^(6]W=0:W*:T$BG5G3@/71S.87;:HMFL5)[2]E199W)>,H M_6H(80]G\:F8O)%*S4)B6K\99CW%HJ.(WZ#X '=&4^':@D\XQ_Q\?LIQ!4[S3 MM(B/$]ZP&D$2G4 -[J{!B6+E/&U1;AUR.^
M$"R4R9Y^']}[E/&PWND(;C47>#PY@8MH>@*+VC'..5B:]0V<*]GB[1;MO)=9"96E/7WH-W>!RNNIGX%]Z]+'?";B4GHW## MT&AT/@W =M/:&62J=D+6AGC>VF7!#QQ:\#
[&\,=U!O^@.')3A"4$L#!!0 M (.. 7EEPQC H#PL &(PO=V]R:W-H965TUB]GJZ99 M/SL]K=.5*'AMJ[4HT, -05<$;0%,+TWI="9[!045^ZCE.=%IP6<[.7NBVR^KL
MA6J;7);BLF)U6Q2\NKL0N=J\G+FSON&C7*X:.C@]>['F'2W$EFE 7EQ7>3H=9 M,EF(LIrJ9)58O)R=N\\N J+7!/^28E./GAE)SN(9R\2"MWGS M46W^*3IY0IHO57FMKVQC:,_DQM*V;E31#08'A2S-
G=]V>A@-B)T# [QN@*?Y M-@MI+E_SAI^]J-2&542-V>A!BZI'@SE9TJ9<-15Z)<8U9^]5(UC$3MA5H](O M*Y5GHJI_8F]^:V5SQWB9F8X3DCQCKU0!:Z@Y*?3%:8/U:9,3M%OKPJSE'5@K
M8,^HLEG5[$V9B6QW_"GX'ICW>N8O0*,37HFUS7S'8I[C!4?F\P=E^'H^_X@R M:M8H]K,L>9E*GD-ZW@@885 /R6NF"Z:G(SP]]<\%2G>G $PMJALQ. OQ!S=R MGA]A-AB8#8[.?G:UXI4XN=#
[38O?],\7YT M]FG>(WO?,"[V#$/O!OM0LE]XE:Z8%YQ]L5BIT'2'E[Z!WGS7O+%.WL+ \YQF M^/&'V/.OQAXD++N#/JLI(WL"-VF4.C>G>N1-I6 MLI&PM\L6:H(6V?
FR$J87O)VO*YGWQNT;727]"ZX>FYO;ATXGIM.S1LKS=IZW MEUZ(<6\GE'?-8G:,%M6KN-$.#_J"S2\@O+8']IF3#3:U$?QMR5)5EIT+WLAF MQ9K56'L+N4";?J0=:E:R@GDU&VCA[F +U
0%K@',:U$-#F"X>$>6'8M&DXT7A M)$'=*77O"FX?6-GKH8$]+DEZ=VXNG[#PA>)5Q@"D&ZG:&D;',X5),DL#B5@C M /'RCG;$G3^O63URQXROUY6ZG(?(I4KW*L7=BOK!6*)A)!R1A!T:>A;?\,)%
M1&,N5AR]P7V_OKP6:2>U>Z_AB%J(#'9>+ME["_!1NW-KJYJW9=9VF"#_,2"! M<6S$R9W@%!1?%5I'1 "9 2W(0[06EF1E3"V8T&KO A3?0-&UQ629YFU&ZY-J M/*GAQ-M&04*M5@;=PRY
]O'J5USAWYI*IM@/TV]U9*1V@2B@C:BB\[BM:AT M*E2F@M7D@FNSB>/VH1-UXP'+02$JC"0=O0D98(/ B.H)?P*:DZZ^RCC S< M0E:UL)UBDG+&\)@,B$VT1?ZM^S= L7"(3$UG M4/W!:
(Q]:!L20&OV?:LI:16M!_99IT"'T"S>B0D,'Q*VH4@G/I!E&M>SU5X+2 M11HKEPO!GLB2T:[73]D%STF3M39:UWL^MKX.E8D51)'E^!%[Q!+;<=GYIY/P3ST9RJ,4SQZUP<&QU8 M[CRVG#C&8-
>W,4EH.G'[A&2Y@'T/XZ>MN^B@P9HM50<#MEE)V-4-4*!-]AJF M50R,1\Q89+C_A3?M357" @#'EN>#%X(Y-K)L,.THUKDR^0BP2JD#,3Z0XCZ'R2M3GAKU!@/=51"+ J M<11
T.A<1"_>4I0P.H*=%M0+'Q/ DM;T!);S2<[9KP(0X-/#;@1(UCY3W T96 M9+F!:R4.(0NH"6)8IS/?@Y9GN0@3&EJN{4\BRP&R$H.L*)Q 5M0ARW,(.?O(_M"CIDH=]_$+!BS0,>H;U.7D%-
WXHL'QK'H16X#H&6. \L.. HVC!9043S%LQ M80OJGF8R$_*(ZM#F7V[#Q3W,0A)5@[W,#54&O-"ZOAOG !IU1#R./A08!E5 MB9P30X!MVDV[&(XVA>!U2]9%H.?I2HH;<]Q@.("R*5,=:_"_#H,TC
)S#5(M%VL,N2?6XZQ>(TPN0#O)!I.(VFV^0{[1]0"=]D3V/B;7 M>YH\"LJ_(!Y=RT/(=WTRR] .71;,H;\?Z1+++<1ST!<$%A- R2$HV8DW@41? M#[[7/0#1'?<^*.!97!!8;FQ8CGS
$$!Z:'SS/2N:4W1#5$Q89^2Q 0P>VOMO M@N(CGS=[W\(PCS@.>PXUS$NMI/PH0B[OV!_GT;9A 5\$\#& M62@E;PP779;;]M;81=Z):B+G0I0!P=!RA]96 >L7.0_7)RE>($C:4ZJR4#
M(H)"92(WJ.K9R?;%AL693%.(>PLCGO%"(6\2OHH*0 B6I)9GE 9C:K${,%Y MUTC%HGA-J+<%?GPM#,JFR7KTF,,=WU$25K'ISI",%OZ$&96&,E,*@"#@V4*Z MF@VJ1$AMBX[!MNX9,RO!!VP>[*D
-C:E;W \WRIMJ_"%RG.UH;=-!]"3'J C MSIZ! 5UK&=6![UG,>]+@D?ZA0#%Z>G,+5Z<]++)4++>@= IR)V EC[^FGWS3P- M V\47+3,R:4E_F/T)O/^BEQ^[L H64*RB$.%
M;X,VL!TBWC:C#0,*UCC$]KW)%E8@V M-V\'A^X+C=S% Y1R!J,B H#)=B2E0!PLC3+NM2(BR1MBNE#%[C\NZ=NQDSL6 M) MTUP]+XG$C5[M799V*G3F8C-
4PH%VDR,/E*U+$UZW)=INOU+QZ5T1 @\ M"TH=*K'(]1$O^0N#Y>Z3N'<3/KGQ?&^S5:,N2O M&$ZEYJW<(Q.7Y0-U1VXF$X0MDO-H/DUYD[%R_TKNP[%#P->%FSC^-.D^@/F8 M\H3N?
C@W"!YK?P2:L:\.*5-(1NWNT/Z-?N30C_3LDT(T^_WX@M,J#$O78Q,W MJNF)-A\X)=AP_?0/VIF/R"CTKQL$E PGY%RM]2'9Q0$-I[+8HTI^&.`]CNL_
M3#'75*XR6*O4]2J#AZX5SD,9XZ#F6W_ Q#G)F2?AS/PNV+\T:JT_M:E3,:_+@2"&:"_"_4*KI7VB!X=NKL_\! M4$L#!*!0 (_ 7EG^NQ@?P 0 #(+ 9 >&PO=V]R:W H965TTX<5+:2&T!'0A*1,E#I]-]V-
J3 M9,5ZU[>[;ML_?S-K)Z20YOB0[-O_,^_C.5T;^\VM$#W%L,7P=+3+H6LLBBHPU6J8)B4U7EMP M;5T+^W"!RJS/HC3:7'R6RY7GB^\M!%+O$'_1W-MZ33%==18EK!
J+#TC"%KN\!*58B!2X]\>,]J* M9,;=_0;],"=;+D5#B^_^BHKOSJ+IA%4N!"M\[_^G?L{1DS7FF4"_^P[FC' M>01EZ[RI>V;2H):Z6\5][X<=AFGR!$/6,V1![TY0T/*U\&)^:LT:+%,3&F^"
MJ8&,E)..@W+C+,U*XO/S*^,1"CB&2U/T1[.O0.A*SIK+_42=2G1G0X]R6*. M8=GC7G2XV1.X,_A("L',W2%U6(/>(>FX53,*J'1'02\68 HR2&+,,GR WBC MK>&<@#831_
M\2R=)*\.*)MOE2U@6+=V$0&0QO'@VS;+D52)?^^%;JF\(0T4HQ@^"ENN-ASYH#^G MQ>8]<&FS@S[:TK[&LK]*'Y&?.U:J#=W^2Q;T +/NT!%MZH[#YB T>A
@"FDP>KT%63})H9/I3>=9[(9460#^+)" MKJI&Z ?.Z%:RJX*/-TJE@J"XEEQ3*&E&K'AI,'F3G++#3V='D/4J9!?ULK66O6*V4>K\I,Z3$WH:I[-16)/QE%RCC\M?X"OBM,AA M&B?3"7PQ[*Q]V-X-
"EHG<5IGO=TI7 K.(2L@ QY4,,/+KVB*GO4#?=D>F Y M+\M@N_L-'91,:%,)*WMGBAO#&G+NT7*L2(*B# _+/VOZ%P@(E)G/O1*L/T$N+ M_*7GQQ'4P:8C4B*?COE]3-
K,BH*W$\CB)) PELYQFA9<#S0V+#SAY7%2Y(\" MT(B'KKVE23R9S:@PG0-9-RVGJ]3$A,[#RRP>C3(X^M_8?0U?8ZR.Q1VY8HGP M7>^.B0#KT$HK:IZFI,0ACV',GB${'@G0KR&.!\GT9}',LA"^
T^N1.A^)O {_P=02P,$% @ XX!>60J*798Y @ Y 0 !D !X;"]W M;W)K&UL?53!:E@X< MRG2:_@>&@V)O;$UER4CKIOW[KF37A"'-Q=9*^Y[>DW8UWUIW[VM$@L=&&{\0 M-5%[EB2^J+&1?F);-
+RRL:Z1Q*&K$M\ZE&4$-3K)TO0:.0R(I-"N1N7SVU' M6AF\<>"[II'N:8G:,A?B2+Q,W*JJC'1Y/-65KA"^M[>.(Z2D:54#1JOK &' MFX4X/SI;SD)^3/BA<.MWQA"*U#D0LX_M*<8M
W!W_,)^%,VSE[7T>&U3U52O1"G DK KK/,Q"]L^ M=Y8)*#I/MAG K*1IO_+Q^$<=@#')Z\ L@&01=W]1E'EI229SYW=@O9S!8& MT6I$LSAEPJ6LR/&J8ASEWRPAG+Z'%59\U
2WV%'RE3SA@^)"7%0+7LJ,)7 MJ#[*M354>_AL2BS_Q22;'O#J P2-H:2&%4G"8-SO\]O3S?;3A78Y\ZTL<"&X'SRZ!Q3YVS=)^FG V)G
MH]C9(?;\OPN!2^4+,7WG$'[=X2/!4MOB_O<^X8>I3R=P5R-E[P8 WN,Y7L5%Z#KHK]Y:&PG:&^",?9L87/^\K] MF][W_[5TE3(>_&X8FDX^' MP?4_U =DVUO':$G=%'.,\#*$+";R^L7R_0Q V
M&!^V_!E02P,$% @ XX!>60%@3D5< @ >P4 !D !X,"]W;W)K&UL?51-,]LP#/TKA ?LE,6.G7YEB8&F7;$>T@5-MQV& M'12,B87*DB*V%_+.H(FHF<6R*
M*FMFAJ]!.4\V2M>,K*FWL6DTLM(GU2).D^0\KAF743[UOJ7.IVI'@DM<:C"[MNF;Z;8Y*HX'OFV(>\VG#MKA^^MXLM;7B&]7D-4K#E02-FUET/9K,
MQR[>!_S@N#=">W!*UDH].^.^C$6)(X0"" W((S"XO>(_"!+XT^+&74E7>+Q M_H!^Y[5,+6MF\$.)G[RD:A9=1E#BANT$/.K]5VSUG#F\0@GCO[/L6>V8K$S MI.HVV=HUEV%EKVT?
CA(NDW<2TC8A],Q#(<_REA'+IUKM0;MHB^8V7JK/MN2X M=)>R(FU/NP4)(J_U]DB>7_^;$EV+%,#RSG:2_@"ILA9,D TB0=]^:EG>K,XV4]J@V0 M@CLNF2PX$[B*]_^;712;X
,GX9S@S,Q#2MP%MG),*A?,,H_?AB=)Y][R(X[MLN,^)/S[F%,@JAS$XC_'K"5X*Y4,7S[U,*^FM<#7M^ +B7L&!OKOGI*0B M;V6C0>M%1H$JKLMC?Q,\]N9L6]>HN^?N#; +
(FR8'%/>%ZT9S<0C-3C]'P?F@_MPGIQJL/QT4#4J+=^[T4:BLMM#P1N;&HRO#B+ M0(=1#P.IQH_76I$=5K^M[.5H&UP:#H"@,$KN%[+=>YO_!5!+ P04 " #C M@%Y9GH9[>#_# !5"P &0
'AL+W=O+++7); &QY:#YT"*(V^U#L0^T=+:(2*1'4G;V[W>4 M%_7.9*';_,4F3_<\QWOA\;8'J9YT@6C@N2J%GCF%,;L,U]59@1735W*'@KYL MI*J8H:W:NGJGD.4 J"K=P/ BMV)
<-,FTD3VDP"IK4W*!#PIT755,_37'4AYF MCN^\"[YMC!6X";3'=OB"LV7W8.BG=NSY+Q"H,D4H' S M]-$:K"=K*9_LYCZ?.9X]$);QW6U];P*7
M,L.2J9('4%:,V.RBB7Z#IGAQ8>MD911]Y80SR2=I$'P/?H%'U$,5F:D5%UM8.M%$QM49ARRJ%G][\#&^ "_ANI:\BZY7"SSM*\M12O!B^OS8)1PA;LK"+VW$'C!9. \B^^'AT/N_#_KR_]L
M_20885\'8<,7GN&[%YFL$%:&&:0V8.#K[9KJ@>[Q'T.I;LDFPV2VM]WH'T/*'*#C52O^I%4;7U_&IUG) R_EU+5"^/H9GPW,2YD]#?:,46O_F67)$O'MX^![5V<>QWL!=[A6-
0U831]^"QKW^$H(&5WD)GS8W6,09 &H@U-]KU&-/2++ M"_G9%H![_"=42"[8 4W3 6MAV]>BE_8SX&TS^KR2S_V;A3@3VEF;$>\, 3M MP/F1(L:%AA(W9,J[>D>5K=HAKMT8N6NFE+4T-
/,TRX+F7E16@;YO)+6(;F,_M]) T\C=02P,$% @ XX!>67-O@J4C @Y 0 !D !X,"]W;W)K&UL?53+,MLP$/R5A0KTE%H;*VCKV@+B-$%S2&O$?1R* M'FAI,1&F2(5<6FA*1X+D2TLR"DJB>A*')
M2ZR8&:D:I=U9*UTQLJ'>A*;6R H/JD281-%56#$N@VSJUQ8ZFZJ&!)>XT&": MJF+Z98Y"M;,@#O8+CWQ3DEL(LVG--KA^{E}OM(W^@:7@%4K#E02-ZUEP'4_F MJ'-RB${{(RGGK.8"CI@(?S M/?
N=]VZ]K)C!&R5^\8+*6? A@ +7K!'TJ-HOV/NY='RY$L./T'.Y8ULQ,PRI M@?,N.*R^[+G_AP. &EZ 1#T@,3K(]EUB/8!Q+0=0!(EZ1F^\>`IV[/G&9]P:(5W7#*9 M>O;H0 M^/T=GPGF0N7;/\?
MRI*

V$_[044.&9!82&+1J1^&D%Q7N^2ZDB97LT*\7<1% MD=ZE55Z]7W\L9GGZ6"\,+[;IU15.4K9O,)&81F(ZB1DD9I*816(VB3DDYI*8 MM\4F>[^/5]/I8' 03N20
8F%)!9!F)!AXUV&C:49MCE^IH1W=TF>KNX5+4F6 M58YIZ:=TGJRZ=O#>2;V^X45B&HGI)&:0F$EB%HG9)..0F$MBWA8;GPBO\5'$ M'7Q'0$X})+$(PH1$FNP2.2)·I"C/9DDR+Y2[/%LJO\9Y'J]*1?^2Y+.T2+J. MF,V3@GTCB<0T$M·)S" QD\0L$K·)S"$QE\2\R5$DJ>/1Y"'1)D>)I%Y=#Z\/ M4HF<5TAB$80}J33=I=)4FDH?TF72O ,0,G;O"N5__&3Y,!=RU·. V!]C__N[X M/*&8]9)M\[9G5.U69M67
M[%59[5\6Z>$G<3Z+3!+32$PG,8/$3!*S2,PF,8?$?!+SKH\7<=?'Y7D M@>A)20609B0A3>[+++R1{X(F^>9&M=6LSYI/:O8.,!*8 M,8?$7!+S2,PGL8#$0A*+(@S(.76P"
[KZ],*_\JI//K^^J8EJ&JKJ&:@FHEJ·M%JK9J.:@FHMJ7J/M+P!'1\L_=,@ U4)4BRA-C,:]LX)5:33ZDDUC0HD6\4J^$$3+!ZBFH9J.:@:JF:AFH9J·:@ZJN:CFH9J/:@&J MA:@649H8=FVSH6[7?
M^%H/[E,6=,2SZ;WHE):AJJZ:AF MH)]):A:JV:CFH)J+:AZJ^:@6H%IX(H/4@?*U"HRN,WXC:B)B/+:E"57>F@#B M,5C7ZT)JOFH%J!:V&@CEP$1·:R8CVW31)573?A\C))\5JT?.Z,0[96@FH9J
M.JH9J&:BFH5J JHYJ:.BFH=J/JH%J!8V6GT*8;EWQ:>KPR#\'5T8:M:V9J/*> MR78DG).K1;2Y@FH;JNFH9J":B6H6JMFHYJ":BVI>H^VOH:,75S='
M9]V@[114"U$MHC3QXKYM064H+ZCLSKJQ5_/U;)N(S77WJF5D)5'Z*3E]1HY\ MD+X)AVH:JNFH9J":B6H6JMFHYJ":BVH>JOFH%J!:B&H1I8E!V-91AO(ZRK_X
MC!SY,'HG)EIF034=U0Q4,U'0C4;U9P3__HEYX*XZ$0\5/-1+4"U$-4B2A/C M<=C&XW=OKOR!,W+DD^N=EFAM!=5T5#·0S40U"]5L5',;33C2/^@XTN^BPWJH·MYJ·:@&HAJD64)F9CVUP9RILK?
YDS% M#FMW#·N960XZK(MJ'JKY]!:@6HAJ$:6)"=C66:J' P_>·)'/LG?^D9J&:CJJ_M&:AFHIJ%:C>J.:CFHIK7:,+_#B97P\QP'K5Z+ !JH6H\E&:&>))MJ64H+[7T M?ZM%^6=W8K:A~G0]B/U-
_/A+NEPOY6_8H!475_034U_5"5(LH38S3M@?$ MOW[I&S9H20:52%0+4"U$M8C2Q'AL2S+·#$S=4>5IMZLO'1?8U29KSNJ/UGNH·M3PX_?5(/6G)!·0W5=%0S4.U$·0O5;%1S4.U%·0_5?
%0+4"U$MJ8C2Q=0!!LFS#·#·M[W[3E3_RXC5:C4$U#=5T5#·0S40U"]5L5'·0S44U#]5\5 M0+1P>WV9F,.XH·M"5*CBM'8=F.&\F[.PU2=SRBM1A4TU'·0347U;SA<2WE
MJB.T?'34·7",Y]#1(TJ!·^H,:R.Y(V7?VD[6CZ7OAF':AJJZ:AFH)J):A:J MV:CFH)J+:AZJ^:@6H%K8:/7·!L]]=K0Z/DA":E0Q"=O*R^B[5UZ(LW;DL^R=_MD6@5!M5T5#·0S40U"]5L5'·0S44UK]&$-
=35>#]J.5(@'HJ,&]!:B6D1I8D8. MVXP\T7O9+/?J)6&5?MHZKQ9\N_NM,"/O0OH.R\l8/GXO=,/K;,@FHYJ!]J9 MJ&:AFHU]#]JY]:. .FHWZG0\.DH_M·F":,B&J190FIE_,:[F=WVSI//OP0_5X M]I
HX2K9/P7O0[KL9/Z4WC^4O>[@6GS2>3\ ^:OZ)R>]·M:;BFHYJ!:B.J6:AFHYJ#:BZJ>8UV<$W"X?AP\4@.&]!:B&H1I8F1V/9=1M_] mB)\N\1UL^H=YIB+9:4$U'·0/53%2S4,U&·0?
57%3S3OQRJIO3QSN7C&B! M!=5"5(LH3=&2RZHIJ&:CFH&JIFH9J&:C6H.B5^ 9_=K770:'JKYJ!:@6HAJ$:6)^=BV7D;RUHN75;O%;^_S9)N$TAUD
MM)Z":AJJZ:AFH)J):A:JV:CFH)J+:AZJ^:@6H%J[:A&E"6EWU59=KN15%RWY M6"KVJBCS]?:(HI9LNR\7BI'E]^FG9)4479<0>2>'^X8?JFF·MG,'9H·4?OE/#N+MF*EF^C4"AE9?.UGE:IDFAW.:+
M1966'[\]>CQI.·KJ5$!%/O>B;G5U*%P3/Q9$U=:&;CJFCFH%)JI9J&:CFH·J·M+JIYJ:.C6H!](:I%E"8F8=M2N9*W5 X7?KL%HG0%B'9.4$U# ·1W5#%0S4]":.CFI&HUWO_32&+?PCP[4;6N$X:TP;'=+!
M·175/%3S42TXZ[4*T3$C2A.CJ*U<7,DK%]^^R_E,+LGV-Z='^TWCF\V?PT1* M*Q2HIJ.:@6HFJED=+]=TI$X'T^%A>*'M"%1S4:CFHUJ ·B&J190F9.*X,3&,Y2V&WU7HN7LUW
M)_GNWW_C0Y(O)0W5$_SXV1NIWLJW!:MWJ*:CFH%]JI9J&:CFH·J+JIYJ..C M6H!](:I%E":&%75MO&,OK#;*W,]LEWD_)[^LT3^:,55V[=]N9?VC7 =4T5·1 MS4 U$]6L1A.6ZX?'V= 1'51S4J1 =,:
(T,,^&:7Y]JOFH%IQ(AZ$D!=&2 M J6)*=B6%*J'?S %#VZL=N]\$/F O0.0U#14TU'·0#43U2Q4LU'·036WT823 M.X;CP?7-5·PI]·!A250+.I($*9).#T!]0P>.·*$T,LK9F.);7#'9=@6L\6^[2
M[":G#.M]4E8N]DPKM']*:CFH&JIFH9J&:C6H.JKGCXTJ,>G5S6(GQT$%]5 M0 M+42UB·+$,&M+!>·O+A7LO:EZG6]A3&\[":R4N"*/_<7>*\RD·CS8M2L>+%G?2: M(?)!>Z<=6EM
·1W5#%0S4:CFHUJ ·B&J190F M9·VD;4U,Y+4&2=8U.[X7ROLRF_W6+/4^Y.G]?;6P.W^AUTS@9C_]D?A)Y]F MW_!#·1W5#%0S4$CV[@=#[WNU@Y63O WMH40/5
M=%0S4,U$·0O5;%1S4,U%·0_5?%0+4"U$M8C2Q·AK^QR3$WV.;+G,5MM%7;4[M&^?UDN]]&9?5CNPO\6+]C0?ST'Y'HTW%0X.'Q0$U=_%=U0Q4,U'·0C4;U1O4 M\=!_7Z?EU]T"[V)
[<>,+O8^_I.OU4GF[·MS·;5GN_:=?F0Y>D_DI.7%[":USOLGJ_"7]]0[.B>8AHZK(Y]!IJ9J&:AFHUJ M#]JYJ.:AFH]J·:J%]!91FAAW:7·C(F]N',3=4]KM%VUL\CIG#:UM1:.·#F/M
M.,301@:J&:AFHIJ%:C:J.:CFHIJ':CZJ!:@6HEI$:6*HM8V.B;R1L=D?+12[M*.) .*/G'5"GKM]VVC'I2^.$@[M8:":@6HFJEFH9J.:@VHNJGFHYJ.:@&HA MJD64)B3NW6A·ZIG5(YWS?8&DUR+WH·
'5!'0/5 M3%2S4,U&·0?57%3S4,U'M0#50E2+*$W,M:9B,957+·IMNEV·M*M:0*D6C['I*F6/K'>08;6 M$%·0#43U2Q4LU'·0347U3Q4\U$M0+40U2)*$^.N+2%,Y24$['S=Z7&·X/ . MVUOY7'HG'·
I{0#5C>GS/C.'+P?APH88V#5#·1C4'U5Q4\U#·1[4 U4)4BRA·M3*ZV:3"5·PW^\'FX·T?KLJ·=2_0^#ZBFHYIQ^H=AH@·:J&:CFH·J+JIYJ:.C M6H'](:I%E":$U75;&K@^MS3P32?77A^?
Y7]X.3,Y!/IF%:KIJ&:@FHEJ%JK9 MJ.:@FHMJ'JKYJ!:@6HAJ$:6)L=9V!JEG0')52GWEF?),)VG95HMT6[CQ.): MF7WNHV^PZU.QN!V·NI0. !^>(.,^9Q(}R%:.T U]5,5+·0S48U!]5<5/-0 MS4>U
-5"5(LH34S"89N$)VH&FVOO·GN>VGISUD>U0YIF\WMF_[2*Q.3S!CN*·MDT$W%/KOC6_J/]>'68?>=0'5=%0S.GXDTY$Z'4P/%(F,JR%:C;J.:CFHIJ'
M:CZJ!:@6HEI$:6*,M=V":WFW(,JS69+.'^>4NSY:,L(I7LZ1>Q>V?X]$96<=U M@([+"·W*Q^\=+6&BY·6.CA^(.C[Z@9CHH!:JV:CFH)J+:AZJ^:@6H%](:A&E MB7'5M@:JA]]RLL:
[>+*)KIRJOFH%J!:B&H1I8E)V)8·KN5E@^]_M\V:Y!'KG'UI10#4=U8Q&D]_TVD3'M%#·1C4'U5Q4\U#·1[4 U4)4BRA·#+^V M>G MKQX\5Y)7_JG\E%4/2N77EXJVOK^/5](^O7R8WA&'=A1034U
-5"5(LH38S"MLMP+>\R·#>KKU>"NSB,UOGL(2Z2SHL7·M·9YPG_K\R^NCTT/0 @.JZ:AFH)J):A:JV:CFH)J+:AZJ^:@6H%J[:A&E"6%V
MTW8=,N1=!\FZ[ET6Y_,ZY;0T3V9E5NV^WCI$:,X\L<23C]AWB8=J&JKJ]&:@ MFHEJ%JK9J..@FHMJ'JKYJ!:@6HAJ$:6)]=A6)6[D50E[!2DIRF6]R@L_KS9=
M^W;1%R2E\K8HDK+H3#_TU@JHIJ&:CFI&HQTLDL?·U5>:/X>'!_I6*AFHYJ# M·BZJ>:CFHUJ :B&J190FAMRP#3EY"R+*TT]QF2C1HAICDW7?>E!//E#OS$·K
M$JBFHYJ!:B.J6:AFHYJ#:BZJ>:CFHUJ :B&J190FAF':,B1=FR^SU4QY8/V M#D;TCM%H)Z[8]:.#&JAFHIJ%:C:J.:CFHIJ':CZJ!:@6HEI$:6+BM76,Z]$L M\,"+RDJ34XC)^\WJ9Y/?),;)8%,JLOJ}Y/
M9Y4\N:O"4'WU=OCB\NCSIOK*43L^[ZFO_*[/!^JK9+7WU!],2[+ MRJ&PO=V!R:W.H965T"4R3 M2)/LKKH?IAWM]*&JZ@<':A(T@%G;26:D_OC:AD &$IK'YDMBC. U/>?8UL'# M#67/?
D@T$N:9'QD+(7(TR3ATM("> 1'#+Y9DY92H1\9 N3YPQ(!/2O+0Q+0 M]V^F),Z\5#W/;+QP'5*F?PR!!?I2EAKO·(Z&9D8&/\25>+·(7J,.?#G"S@=M'<3O^2.33V:5)8I3R'A,.\1@/C+\=T4^RI
C_@CA@W?:,2,%94;ILWKX'(T, M2U4$"81"I2#R;PU32!*52=,QM4QJ5'.JP-WV-OLG#5Z"F1$.4YK\&4=B.3)\ M T4P)ZM$?*&;GZ$$Y*E\(4VX_D6;LJ%]^(9%'QXE91%:$I3>7ZX40K(&,*
M[1&=%Z/0K[E^]4Y',6K4*0 MRT,4?7_0#H#]L_0%!*D*M4,2T"3 I!] %" ·F@FEAQ]S"*(WL:,DIR*(7O+ MT,3N3/@$>0\YEJK8=M'WR$\1\21CP\F]/A=/C$SH=!3J5A((.YQ(5Y#,Y6J6 MS(7 WZ-
LIH4PP4$=Y MG"U0$L\E$W\!83?[P:/-$"OH·CS45IL+HPB\KIQZ1+7?)ZCR6"H1[R"C7Y'1 M/XJ,!2.99.'''3=!O;0)'GE5]UVE(MQV/9=1M]#5]P1+@0 '$4 9 >&PO=V]R:W·H M965T0D&^U?(_FD,F>*64I$?
6S4R>,R"1#DH3TI8LSTQ)G!GCH7[V MQ,9#NA!)G,$30WR1IH2]W4%"5R,#&^L'7^+97@'YGB8DQD\@ @S?V+RSJRR
M1'$*&8]IAAA.1\8MOKG'O@K0(_Z*8<4WVDA!F5#ZHFY^BT;&I2J"!$*A4A!Y M6<(])(G*).OX6B8UJCE5X&9[G?VS!B_!3 B'>YK\'4=B/C\\ T4P)8M$?*&K·M7Z$$U%?Y0IIP_8M6Y5C+0.&""YJ6P,*"·
.Z*"WDMN@=(<.P] 7898!\:X)0! MC@9.5*9A/1!!OD·&0 'AL+W=O3'"",),!:F.D M_QC;3&B00#:$\@).[^71SGO*.-9.]\"2#06Q*G?&PLA>V61$5R*.4GAFB*^2A+#W M\XCI9FQ@8WOC<[18"G7#G(PRLH
7$+]GSTO>F666,$H@Y1%·$8/YV+C'=U\\ M4 %ZO\!1:/A>&RDJ.TI?U<7/X=BP%"*((1 J!9%_·YA"*M,$L>7(JE1SJD" M]]O:[#]]\!+.C'"8TOC/*!3+L3$P4 ASLHK%9[KY"0I"GLH7T)CK7[0IOEH&
M"E9Y[99!*\N$1!(EB?B,C:L,X M^OL)DAFP?T:FD'P4*C,HL#_DV.T3V(?HB:9BR=&G·(3P2/RT.1[;#0E,*62I MIKU5\\%NS/@"60\YUD=D6[:+OD4FXDO"@!=_QR V)WR$0",$,]'SM80'D)UR M 3AZ!O?
$#%L,9B0F:0#(\TI7R@E]C:'7AR@MFC?HW]·4'O*)/#V1CF[6$Q^[M>&CY(W.]3[D1D·]W&CY(W.]3[D1D·]W&CY(W.]3[D1D·]W&A@;R,=C7[2Y8(D M;V!RYT+P!BR(.*", 10%H]B&-@\%X[R0]NFK)28N?&,3%R&
(,],;#5]]A"·4#L*,2B%&+028DOW$N,'>-OL64-AOT*WT9$'?D.2[[#&_E> MR?IA;=]S>[Y7D;(1;$;Q68@1JVXLO\KZ8ZR6&W?!BRB%UFOUVWWW&'7O4UWPRH*^%= MB8?,U7@EX6O9[]3V?
6E_==]O!MM5C%T!B,^M +O:[];L'\AW/O9J"[X^L%H: M'[+9U7#XXB+N?_+6.U;0]G&5Z=%A>W7O(<]=F8;,U6D%&3*+X1+CZL6:TW<]
M%UM5.M>HUO"N7,/MZK4#UMD4X",*%/NN0;G*Y2D9_NE'?+Tf1[?89D[H;G M1W%/A*TB*5D,,D \ 4$L#!!0 (.. 7EFM]$P1+@0 '$4 9 >&PO=V]R:W·H M965T0D&^U?(_FD,F>*64I$?
6S4R>,R"1#DH3TI8LSTQ)G!GCH7[V MQ,9#NA!)G,$30WR1IH2]W4%"5R,#&^L'7^+97@'YGB8DQD\@ @S?V+RSJRR
M1'$*&8]IAAA.1\8MOKG'O@K0(_Z*8<4WVDA!F5#ZHFY^BT;&I2J"!$*A4A!Y M6<(])(G*).OX6B8UJCE5X&9[G?VS!B_!3 B'>YK\'4=B/C\\ T4P)8M$?*&K·M7Z$$U%?Y0IIP_8M6Y5C+0.&""YJ6P,*"·
.Z*"WDMN@=(<.P] 7898!\:X)0! MC@9.5*9A/1!!OD·&0 'AL+W=O3'"",),!:F.D M_QC;3&B00#:$\@).[^71SGO*.-9.]\"2#06Q*G?&PLA>V61$5R*.4GAFB*^2A+#W M\XCI9FQ@8WOC<[18"G7#G(PRLH
7$+]GSTO>F666,$H@Y1%·$8/YV+C'=U\\ M4 %ZO\!1:/A>&RDJ.TI?U<7/X=BP%"*((1 J!9%_·YA"*M,$L>7(JE1SJD" M]]O:[#]]\!+.C'"8TOC/*!3+L3$P4 ASLHK%9[KY"0I"GLH7T)CK7[0IOEH&
M"E9Y[99!*\N$1!(EB?B,C:L,X M^OL)DAFP?T:FD'P4*C,HL#_DV.T3V(?HB:9BR=&G·(3P2/RT.1[;#0E,*62I MIKU5\\%NS/@"60\YUD=D6[:+OD4FXDO"@!=_QR V)WR$0",$,]'SM80'D)UR M 3AZ!O?
$#%L,9B0F:0#(\TI7R@E]C:'7AR@MFC?HW]·4'O*)/#V1CF[6$Q^[M>

"5;QW.G6 M,A-S,4-ZF# ?$S;&A 5(L(KQ'/MU)=4VI[MB&;3(=PW=`MZX;`S6WF.,?:K;0 -=V<-S=Y;NZ'&]%!I/BIMC$H+L&A5S^VLWCOFU1"0;O)0
MLQZBAGU[AX2UGC/&.=ISF#07E>:ATGQ4VAB5%F#1JM\\7?QWS*O_:L0AE$RE_M.YK.R!_SN1\\58=L MU#.JM2)F,\;HM "+5K7BZRZ$8]Z&V+NYV2"7"\^W#LCJ89=W3:0MV$0*5Y
MJ#2_I.WZ_HWGQZ@! RO;X:O6S@<9^A.@&\H742I(#'.%MYN#GD5X\55-49!L ME7^C,652LB0_7 *= =<5U/4Y8_*EH#_[V'[,-/H74$L#!!0 (.. 7EG2 M[`O;HP, +80 9 >&PO=V]R:W-
H965TU#JBAN>P_5/;QA;%"!Y787V_WO;Q8(9UK" MV3I>8EAF/KO,=V?8R>+ ^'>1 $ARS+ -"++5$RO).UT640$[% 2NAP"=;QG,J M\9;O=%%RH''ME&>Z91BNGM.TT+O%/?;$O06K9)86\,2}J/*
<\A\/D+'#4C.U MEX'G=)=(.:![BY+N8 WR2_G$\4[O*'&:0R%25A .VZ5V;!Z% 'K]0@_K=\=W MV5 !/LO^3&.9++6Y1F+8TBJ3S^SP =KW<10O8IFH_Y)#:VMH)*J$9'GKC"O(MTZ+Y!<O@M
[.N0YNZ^#6L6^"54=Z M127U%IP="%?62%,7M5RU-P8X+=3&6DN.3U/TD]XG)H&8!GE/GD%(7D6RXFFQ M(WY"^0X$>;L"2=_,D.]PE!7 WI$W)"W(YX15@A;O6.@25Z%8>M3.^ #,.:+TR
MHTD>62$308(BAGC WQ_WM__+/QCWOQWQUS%Z70BMEQ ^6*/ $#;7O)I?$]lQS!K*;V(.68V@EF=CQE;33#-:L+ O9I>S.UNV|HUUWZ% M^[&(6 YD+:D$+'.2?+O?X/;%.O77T(YL8+-
AF*K==Z*D$2PU+,X"^!XT[_?? M3-?X8TC&*6&K*6'!E+!P(EA/WEDG[VR.[OE,2$&POI#@B)]0 8-U9I1QJ;H-_MS*UAZFN\|TS;=9R%OC^5:\#*M!RK;O7\:F4[M[=NWRH5T=
..9S3FK33;]Z^:,KNE36*6'!E+!P(EA/UGDGZ_SR6CZD-MUOS7KY)A_*37Z%27ZC4E+)@2%DX$:_323-HJ_-SNZ@Y8D(A5A6S.JMUHUV3? MU[WE3^.^>;O+!&@,7!G@\RW#SJZ]41-
T_ZKP_@%02P,$% @ XX!>6;9WJSY8 M @ [@0 !D !X,"]W;W)K&UL253;,MLP#/T5 MPBN&%FCK2]-LZ!P#22_8'M(&S;IA&/;@V$PL5)9I> 52L.5!(W+43", +R8#Y^\=OG',.^]
.N+M_8;_ON=M<%LS@I1+?>4'E*/@80(%+ MU@BZ5YO/V.5S[OAR)8S_PJ;U'48!Y(TA575@JZ#BLEW9MJO##B!)W@ D'2#O MNMM.7N45(Y;E6FU
.V_+YC8^58^VXKATA/V5.VMYRBZ/L5A%"",,)S)N%P:<& M)<'UVGX-'%XA,2X,?,4M-4P01,D 'N97<'APM(?WK*_*F><= MO,'[?RW@YO2K!>I?\!MN;3'@3B*0@AO5;/B!3)O>X[6]I WFQN["U"S'46#G
MRJ!>8Y"]?QE17N!&"%>N4GS4"N&DEM._;G_3"/VQ[^ MZ]Z^!%.F5UP.$+BTT.CTPWD NIVNUB!5^XY>*++SX;>E?9!0.P=[OU2VJSO# M!>B?N.P/4$L#!!0 (.. 7EGZ]S"\30. @5 -
>&POO+IY*3S<'Z]&S\SP+D?.$6O M#A"]Z'1P80 Q\?@P\7W;F'3O(.D]RIAP?UO8C#[5.I9WBM$2!TW;WS"A@Y!I M'2>Y1<6(H3MKFUHO85#7V&B0%6)3.I%O U]=Y 1{)'SHCPEG$\F E9&<\94
M=R$P+7@A/:5K7*<+(5(63BT/2C_6B=GHI FMU@?T_JX3O N@<&&>>-P:YO M-Z!292B4MSHCAEL@L\@KV!?KTKM<";)*NQ>^1N"N>@DDT*F5#9I0G\=&@TX MS<".9+,Y7%51!@
J5>2ZD3(R*P0Q'M:,NJ%EIY3S.W@V_JVM)=9:]_,=HNF MJ0W532MC.Z#?5K/:,=G+5^EZ)7LLU->%GHXP?;@KZ*VD&5N;_C)K#&#J(:Y. MRI*OOG V$SFUDS\XX6A UCQO7DCVI+-!J4QU@$K?
>Z12L6D[\D>2\IXNU;J< MEAGNN7N$GO_M.L^HH)+PMFE=^^]YE5_M._JJE67S5-DU[/18O_#?N\FK8S_9 M'X/)HZC)_C&83(I_9,_-GIHO,1F^2Y:!?11JG;>V3EM-U(-3[=#_"6=ÐODGJ
M31:,*R;JWIRE*17/#EU;7I&)_C-O2U^/3VE&%ES=_^#0W[1_T)0M\]09=0L+ M48_;M+_#]*X.5+K7$RD=$G3<=V5LXE!>KJAL]8?(.PB_^;C1C".O=P(8%@> MS
'&L2PLS_\TGSXZ'XMAWOI.I(]R^BC'LES(V'RQ/&Y.HC_NF29)%,4QMJ+C ML=/!&%NW.(8?MQKF#1A8'LCTLK7&=QNOD/UU@.WIO@K!9HI7(C93?*T!<:\;
M,)+$O=M8'F!@NX#5#N1WYX&:BNT3A&5B>&KWM_.ML+LDBI+$C0#F=A!%&)W(XY@#L #AD21>0_NO(^"]7LJV/SO<_074$L#!!0 M (.. 7EF7BKL

-8?20$3;8T.P6BP^0"X99K>]9!:G65=6/CHX! ""(\ !X;"]W:W)K8FlO:RYX M;6S%FDMOVS@0@A*H(@UP#6J)M(A3IDE32]M=W M2.$MM5L.]B+]9(NBY4]#<3X-
I7=O2K]LE7HA7UHAS2H[6'N\G,U,?6 M-7^] M(Y.P9Z=T2RULZOW,'#6CC3DP9ELQ*^;SY:RE7&;OWYV.=.]GX8:RK+9<26AT M#4^>6&;[G@]NLJ\\|%RTC+)6_Y-]:LLGE&S$&]_:4T_Z;DI6)3
M:R7$*LO[`4],6U[_IWGC(!_IUO@62[=^_M]f/JC@O+] VU[*6W9'+O3L,G,4L. T?A]-G'\1+_7_"]'8[7K,;573$4E;MLI.717""0BRDARP!RB4 NIX2L L@S!/)L7,A/D,))3OX@-\S4 MFA]=!Z)VQ!X8^=''9
/(<@3O/ %D Y*9K6ZJ_.L_WTL.OZ??!I 7".1% L@2 M(.\HU^2)BHXYSCLN(05Q&B;S.9,-YPDP*\ \)7#O2;A$VZ.2@R24H](9V3H> M.Q MSP 3!K;EUO4VA$]?BRP?##.FFWQDVWC,.
+B..#VPO!^YYJ&.='3:6!^\H0$U_/K)K^C0^]YS&ZJZVG88HDNL#U7L6 MIO$Q#:YS^1;PSYW;LQO7]W%&2)BJLE'=LU;&@Y3VHUPXR)XI6&H]ZS] M-R FFGQDU03N(U=UK3HWI??
D'NXQ:CX8[0)339%"-3%M#VXE"TPU10K5Q,0] MQ$0KG!3BB8E[B(F)IT@AGI@?AYB8>(H4XHGY<8B)Z;=(H9_H% H+G0+33Y%" M/U',L-0L/T4*?03G>F#:&
(**E*4.PYS+5_!YC^OS1X[Q,0L5*0H>*()*8QF MB5FHG++@&5R,)6:A,H6%HIB+$!.S4#FIA98A)KK2EL)"48A:H4%HIBANF]PBQ4I,#0KY8T M>[>'F)B%JA06BBUL#@K@"K-0E<)"L87-
(29FH2[%A7Z]L.F&/7QJBEEHX2TT M.[UYT+ =EZSV!']AH+VFHK[7Q'WTCT&JA5N&W'5"7$/;_)O19O3BPRGES#>_M?P=02P.$% @ XX!>63B#;R;$ 0 #1X !H !X,"]?:7/NGT-(JVW< M^FAZ^/A?
&7=#?LFGY?#)O3-ZJ/9O*#C\20,OV=4B]GOF:.W4Q__[%;KW>K M^.*M/O?QDA8'+ZZX2-M8\S5Z*T9-C'/JW!LKZ=3N!SDX3RY&BW?Y]6P?)*9_;F*X]/VM_CVISN=[X_7Q ME^7/27Q?U!><
_S]77P#4$L#!!0 (.. 7EF A/B=P $ > 3 M6T-O;G1E;G!?5'EP97-=+GAM;,W9R6[",!0%T%]!V5;$>(. C9MMRV+_H"; M/" BB2W;4/C[.F&06M&HB$]!FT2)f7=?;.EL,G[;6?*]:576?I(L0[/C/EL
M297Yl.%4QY&Y<94:\=$MF-792B^(B<%@O#)3!ZI#/S0UDNGXB>9Z78;>\S:^ M]H6I)XFCTB>]Q_W$)FN2:&O+(M.ACK-G7]+Z\)2TKBRG>.7A?4W<4+"SB8T M(S\"-:]LBY(J?
>3+OPHJLXBVU+YL.N))lVESC3HYG/BXQRDZVKN"3UUI'.M_9(H5&6Z+WK3G1SB#M/^RJ_.:\MT!<:9.V>LCR?FZ/*XXY$TJ_LV%B(7BNY/
M/"7&TE=_'S6GG5/^R^RXO1_&K=KS*R]7;_'7_X5/_"/@1(*Q*D#P72QQ"D MCQ%('[<@?=R!]'$/T@&UL4$L! A0#% @ XX!>68[= MX.#8!0 ^!X !@ ("!#0@ 'AL+W=O&PO=V]R:W-H965T
M&UL4$L! A0#% @ XX!>68Z-!B&PO=V]R:W-H965T&UL4$L! M A0#% @ XX!>68GJL001 P GPP !@ ("!/#D 'AL M+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ XX!>61/E M%[M> P 20@ !D ("!
[DD 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ XX!>67#&,"@/"P AR4 !D M ("!PE4 'AL+W=O&PO M=V]R:W-H965T&UL4$L! A0#% @ XX!>60%@3D5< @ >P4 !D ("! M;V@ 'AL+W=O#
!5"P &0 @($";P >&PO=V]R:W-H965T&UL4$L! A0#% M @ XX!>68NCWH'/ @ 1@#_!D ("!PW 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ XX!>6;Z8U!&U M @ K 8 !D ("!=H$
'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ XX!>634GLH!# P &PO=V]R M:W-H965T&UL M4$L! A0#% @ XX!>6=KP[90V @ ^P0 !D ("!=)D M 'AL+W=O&PO=V]R:W-H965T&UL4$L!
A0#% @ MXX!>6<)#E;_2 P -A(!D ("!>;('AL+W=O&UL4$L! A0#% @ XX!>61OG,/6X @ M8P@ !D ("!+]P 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ XX!>66,BJ,=$! E10 !D M
("!;&PO=V]R:W-H M965T&UL4$L! M A0#% @ XX!>63'U02GU P /1, !D ("!P-L 'AL M+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ XX!> M6;IZ/55! P U0L !D ("!-D 'AL+W=OW\+,# #8$ &0 M
@(&L[>&PO=V]R:W-H965T&UL4$L! A0#% @ XX!>6?UI]5J8! UA< M !D ("!P/@ 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ XX!>6=+L>]NC P MA !D M ("!)P4! 'AL+W=OK/E@" #N! &0
@($!"0$ >&PO=V]R:W-H965T M - M " 584 0!X,"]? 3 " 5(6 0!;0V]N=&5N B=%]4>7!E&UL4$L!@ Z #H S0\ $,8 0 $! end XML 61 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p ;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}} } XML 62 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ .report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } .report table.authRefData a{ display: block; font-weight: bold; } .report table.authRefData p { margin-top: 0px; } .report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } .report table.authRefData .hide a:hover { background-color: #2F4497; } .report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } .report table.authRefData table{ font-size: 1em; } /* Report Styles */ .pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ .report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } .report hr { border: 1px solid #acf; } /* Top labels */ .report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } .report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } .report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } .report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } .report td.pl div.a { width: 200px; } .report td.pl a:hover { background-color: #ffc; } /* Header rows... */ .report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ .report .rc { background-color: #f0f0f0; } /* Even rows... */ .report .re, .report .reu { background-color: #def; } .report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ .report .ro, .report .rou { background-color: white; } .report .rou td { border-bottom: 1px solid black; } .report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ .report .fn { white-space: nowrap; } /* styles for numeric types */ .report .num, .report .nump { text-align: right; white-space: nowrap; } .report .nump { padding-left: 2em; } .report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ .report .text { text-align: left; white-space: normal; } .report .text .big { margin-bottom: 1em; width: 17em; } .report .text .more { display: none; } .report .text .note { font-style: italic; font-weight: bold; } .report .text .small { width: 10em; } .report sup { font-style: italic; } .report .outerFootnotes { font-size: 1em; } XML 64 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.3 html 228 250 1 false 53 0 false 8 false false R1.htm 000 - Document - Document And Entity Information Sheet http://www.pulsebiosciences.com/20240930/role/statement-document-and-entity-information Document And Entity Information Cover 1 false false R2.htm 001 - Statement - Condensed Consolidated Balance Sheets (Current Period Unaudited) Sheet http://www.pulsebiosciences.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited Condensed Consolidated Balance Sheets (Current Period Unaudited) Statements 2 false false R3.htm 002 - Statement - Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) Sheet http://www.pulsebiosciences.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) Statements 3 false false R4.htm 003 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) Sheet http://www.pulsebiosciences.com/20240930/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) Statements 4 false false R5.htm 004 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) Sheet http://www.pulsebiosciences.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited Condensed Consolidated Statements of Cash Flows (Unaudited) Statements 5 false false R6.htm 005 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Deficit) (Unaudited) Sheet http://www.pulsebiosciences.com/20240930/role/statement-condensed-consolidated-statements-of-stockholders-equity-deficit-unaudited Condensed Consolidated Statements of Stockholders' Equity (Deficit) (Unaudited) Statements 6 false false R7.htm 006 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Deficit) (Unaudited) (Parentheticals) Sheet http://www.pulsebiosciences.com/20240930/role/statement-condensed-consolidated-statements-of-stockholders-equity-deficit-unaudited-parentheticals Condensed Consolidated Statements of Stockholders' Equity (Deficit) (Unaudited) (Parentheticals) Statements 7 false false R8.htm 007 - Disclosure - Note 1 - Description of the Business Sheet http://www.pulsebiosciences.com/20240930/role/statement-note-1-description-of-the-business Note 1 - Description of the Business Notes 8 false false R9.htm 008 - Disclosure - Note 2 - Summary of Significant Accounting Policies Sheet http://www.pulsebiosciences.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies Note 2 - Summary of Significant Accounting Policies Notes 9 false false R10.htm 009 - Disclosure - Note 3 - Fair Value of Financial Instruments Sheet http://www.pulsebiosciences.com/20240930/role/statement-note-3-fair-value-of-financial-instruments Note 3 - Fair Value of Financial Instruments Notes 10 false false R11.htm 010 - Disclosure - Note 4 - Balance Sheet Components Sheet http://www.pulsebiosciences.com/20240930/role/statement-note-4-balance-sheet-components Note 4 - Balance Sheet Components Notes 11 false false R12.htm 011 - Disclosure - Note 5 - Goodwill Sheet http://www.pulsebiosciences.com/20240930/role/statement-note-5-goodwill Note 5 - Goodwill Notes 12 false false R13.htm 012 - Disclosure - Note 6 - Stockholders' Equity and Stock-based Compensation Sheet http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation Note 6 – Stockholders' Equity and Stock-based Compensation Notes 13 false false R14.htm 013 - Disclosure - Note 7 - Commitments and Contingencies Sheet http://www.pulsebiosciences.com/20240930/role/statement-note-7-commitments-and-contingencies Note 7 - Commitments and Contingencies Notes 14 false false R15.htm 014 - Disclosure - Note 8- Segment Reporting Sheet http://www.pulsebiosciences.com/20240930/role/statement-note-8-segment-reporting Note 8- Segment Reporting Notes 15 false false R16.htm 015 - Disclosure - Note 9 - Related Party Transactions Sheet http://www.pulsebiosciences.com/20240930/role/statement-note-9-related-party-transactions Note 9 - Related Party Transactions Notes 16 false false R17.htm 016 - Disclosure - Note 10 - Restructuring Charges Sheet http://www.pulsebiosciences.com/20240930/role/statement-note-10-restructuring-charges Note 10 - Restructuring Charges Notes 17 false false R18.htm 017 - Disclosure - Note 11 - Subsequent Events Sheet http://www.pulsebiosciences.com/20240930/role/statement-note-11-subsequent-events Note 11 - Subsequent Events Notes 18 false false R19.htm 995445 - Disclosure - Insider Trading Arrangements Sheet http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements Insider Trading Arrangements Notes 19 false false R20.htm 995464 - Disclosure - Significant Accounting Policies (Policies) Sheet http://www.pulsebiosciences.com/20240930/role/statement-significant-accounting-policies-policies Significant Accounting Policies (Policies) Policies http://www.pulsebiosciences.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies 20 false false R21.htm 995465 - Disclosure - Note 2 - Summary of Significant Accounting Policies (Tables) Sheet http://www.pulsebiosciences.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies-tables Note 2 - Summary of Significant Accounting Policies (Tables) Tables http://www.pulsebiosciences.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies 21 false false R22.htm 995466 - Disclosure - Note 3 - Fair Value of Financial Instruments (Tables) Sheet http://www.pulsebiosciences.com/20240930/role/statement-note-3-fair-value-of-financial-instruments-tables Note 3 - Fair Value of Financial Instruments (Tables) Tables http://www.pulsebiosciences.com/20240930/role/statement-note-3-fair-value-of-financial-instruments 22 false false R23.htm 995467 - Disclosure - Note 4 - Balance Sheet Components (Tables) Sheet http://www.pulsebiosciences.com/20240930/role/statement-note-4-balance-sheet-components-tables Note 4 - Balance Sheet Components (Tables) Tables http://www.pulsebiosciences.com/20240930/role/statement-note-4-balance-sheet-components 23 false false R24.htm 995468 - Disclosure - Note 6 - Stockholders' Equity and Stock-based Compensation (Tables) Sheet http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-tables Note 6 - Stockholders' Equity and Stock-based Compensation (Tables) Tables http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation 24 false false R25.htm 995469 - Disclosure - Note 7 - Commitments and Contingencies (Tables) Sheet http://www.pulsebiosciences.com/20240930/role/statement-note-7-commitments-and-contingencies-tables Note 7 - Commitments and Contingencies (Tables) Tables http://www.pulsebiosciences.com/20240930/role/statement-note-7-commitments-and-contingencies 25 false false R26.htm 995470 - Disclosure - Note 2 - Summary of Significant Accounting Policies - Warrant Accrual Activity (Details) Sheet http://www.pulsebiosciences.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies-warrant-accrual-activity-details Note 2 - Summary of Significant Accounting Policies - Warrant Accrual Activity (Details) Details 26 false false R27.htm 995471 - Disclosure - Note 2 - Summary of Significant Accounting Policies - Antidilutive Securities (Details) Sheet http://www.pulsebiosciences.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies-antidilutive-securities-details Note 2 - Summary of Significant Accounting Policies - Antidilutive Securities (Details) Details 27 false false R28.htm 995472 - Disclosure - Note 3 - Fair Value of Financial Instruments (Details Textual) Sheet http://www.pulsebiosciences.com/20240930/role/statement-note-3-fair-value-of-financial-instruments-details-textual Note 3 - Fair Value of Financial Instruments (Details Textual) Details http://www.pulsebiosciences.com/20240930/role/statement-note-3-fair-value-of-financial-instruments-tables 28 false false R29.htm 995473 - Disclosure - Note 3 - Investments and Fair Value of Financial Instruments - Financial Assets Measured on a Recurring Basis (Details) Sheet http://www.pulsebiosciences.com/20240930/role/statement-note-3-investments-and-fair-value-of-financial-instruments-financial-assets-measured-on-a-recurring-basis-details Note 3 - Investments and Fair Value of Financial Instruments - Financial Assets Measured on a Recurring Basis (Details) Details 29 false false R30.htm 995474 - Disclosure - Note 4 - Balance Sheet Components (Details Textual) Sheet http://www.pulsebiosciences.com/20240930/role/statement-note-4-balance-sheet-components-details-textual Note 4 - Balance Sheet Components (Details Textual) Details http://www.pulsebiosciences.com/20240930/role/statement-note-4-balance-sheet-components-tables 30 false false R31.htm 995475 - Disclosure - Note 4 - Balance Sheet Components - Property and Equipment, Net (Details) Sheet http://www.pulsebiosciences.com/20240930/role/statement-note-4-balance-sheet-components-property-and-equipment-net-details Note 4 - Balance Sheet Components - Property and Equipment, Net (Details) Details 31 false false R32.htm 995476 - Disclosure - Note 4 - Balance Sheet Components - Intangible Assets, Net (Details) Sheet http://www.pulsebiosciences.com/20240930/role/statement-note-4-balance-sheet-components-intangible-assets-net-details Note 4 - Balance Sheet Components - Intangible Assets, Net (Details) Details 32 false false R33.htm 995477 - Disclosure - Note 4 - Balance Sheet Components - Schedule of Amortization of Intangible Assets (Details) Sheet http://www.pulsebiosciences.com/20240930/role/statement-note-4-balance-sheet-components-schedule-of-amortization-of-intangible-assets-details Note 4 - Balance Sheet Components - Schedule of Amortization of Intangible Assets (Details) Details 33 false false R34.htm 995478 - Disclosure - Note 4 - Balance Sheet Components - Accrued Expenses (Details) Sheet http://www.pulsebiosciences.com/20240930/role/statement-note-4-balance-sheet-components-accrued-expenses-details Note 4 - Balance Sheet Components - Accrued Expenses (Details) Details 34 false false R35.htm 995479 - Disclosure - Note 5 - Goodwill (Details Textual) Sheet http://www.pulsebiosciences.com/20240930/role/statement-note-5-goodwill-details-textual Note 5 -

Goodwill (Details Textual) Details http://www.pulsebiosciences.com/20240930/role/statement-note-5-goodwill 35 false false R36.htm 995480 - Disclosure - Note 6 - Stockholders' Equity and Stock-based Compensation (Details Textual) Sheet http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-details-textual Note 6 - Stockholders' Equity and Stock-based Compensation (Details Textual) Details http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-tables 36 false false R37.htm 995481 - Disclosure - Note 6 - Stockholders' Equity and Stock-based Compensation - Summary of Stock Option Activity (Details) Sheet http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-summary-of-stock-option-activity-details Note 6 - Stockholders' Equity and Stock-based Compensation - Summary of Stock Option Activity (Details) Details 37 false false R38.htm 995482 - Disclosure - Note 6 - Stockholders' Equity and Stock-based Compensation - Summary of Time-based Option Activity (Details) Sheet http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-summary-of-timebased-option-activity-details Note 6 - Stockholders' Equity and Stock-based Compensation - Summary of Time-based Option Activity (Details) Details 38 false false R39.htm 995483 - Disclosure - Note 6 - Stockholders' Equity and Stock-based Compensation - Summary of Performance Option Activity (Details) Sheet http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-summary-of-performance-option-activity-details Note 6 - Stockholders' Equity and Stock-based Compensation - Summary of Performance Option Activity (Details) Details 39 false false R40.htm 995484 - Disclosure - Note 6 - Stockholders' Equity and Stock-based Compensation - Summary of Market-based Option Activity (Details) Sheet http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-summary-of-marketbased-option-activity-details Note 6 - Stockholders' Equity and Stock-based Compensation - Summary of Market-based Option Activity (Details) Details 40 false false R41.htm 995485 - Disclosure - Note 6 - Stockholders' Equity and Stock-based Compensation - Option Assumptions (Details) Sheet http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-option-assumptions-details Note 6 - Stockholders' Equity and Stock-based Compensation - Option Assumptions (Details) Details 41 false false R42.htm 995486 - Disclosure - Note 6 - Stockholders' Equity and Stock-based Compensation - ESPP Assumptions (Details) Sheet http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-espp-assumptions-details Note 6 - Stockholders' Equity and Stock-based Compensation - ESPP Assumptions (Details) Details 42 false false R43.htm 995487 - Disclosure - Note 6 - Stockholders' Equity and Stock-based Compensation - Stock-based Compensation Expense by Recorded Location (Details) Sheet http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-stockbased-compensation-expense-by-recorded-location-details Note 6 - Stockholders' Equity and Stock-based Compensation - Stock-based Compensation Expense by Recorded Location (Details) Details 43 false false R44.htm 995488 - Disclosure - Note 6 - Stockholders' Equity and Stock-based Compensation - Stock-based Compensation Expense by Type (Details) Sheet http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-stockbased-compensation-expense-by-type-details Note 6 - Stockholders' Equity and Stock-based Compensation - Stock-based Compensation Expense by Type (Details) Details 44 false false R45.htm 995489 - Disclosure - Note 7 - Commitments and Contingencies (Details Textual) Sheet http://www.pulsebiosciences.com/20240930/role/statement-note-7-commitments-and-contingencies-details-textual Note 7 - Commitments and Contingencies (Details Textual) Details http://www.pulsebiosciences.com/20240930/role/statement-note-7-commitments-and-contingencies-tables 45 false false R46.htm 995490 - Disclosure - Note 7 - Commitments and Contingencies - Information Related to Right-of-use Assets and Lease Liabilities (Details) Sheet http://www.pulsebiosciences.com/20240930/role/statement-note-7-commitments-and-contingencies-information-related-to-rightofuse-assets-and-lease-liabilities-details Note 7 - Commitments and Contingencies - Information Related to Right-of-use Assets and Lease Liabilities (Details) Details 46 false false R47.htm 995491 - Disclosure - Note 8- Segment Reporting (Details Textual) Sheet http://www.pulsebiosciences.com/20240930/role/statement-note-8-segment-reporting-details-textual Note 8- Segment Reporting (Details Textual) Details http://www.pulsebiosciences.com/20240930/role/statement-note-8-segment-reporting 47 false false R48.htm 995492 - Disclosure - Note 9 - Related Party Transactions (Details Textual) Sheet http://www.pulsebiosciences.com/20240930/role/statement-note-9-related-party-transactions-details-textual Note 9 - Related Party Transactions (Details Textual) Details http://www.pulsebiosciences.com/20240930/role/statement-note-9-related-party-transactions 48 false false R49.htm 995493 - Disclosure - Note 10 - Restructuring Charges (Details Textual) Sheet http://www.pulsebiosciences.com/20240930/role/statement-note-10-restructuring-charges-details-textual Note 10 - Restructuring Charges (Details Textual) Details http://www.pulsebiosciences.com/20240930/role/statement-note-10-restructuring-charges 49 false false R50.htm 995494 - Disclosure - Note 11 - Subsequent Events (Details Textual) Sheet http://www.pulsebiosciences.com/20240930/role/statement-note-11-subsequent-events-details-textual Note 11 - Subsequent Events (Details Textual) Details http://www.pulsebiosciences.com/20240930/role/statement-note-11-subsequent-events 50 false false All Reports Book All Reports plse-20240930.xsd plse-20240930_cal.xml plse-20240930_def.xml plse-20240930_lab.xml plse-20240930_pre.xml plse20240930c_10q.htm http://fasb.org/us-gaap/2024 http://xbrl.sec.gov/dei/2024 http://xbrl.sec.gov/ecd/2024 true true JSON 67 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "plse20240930c_10q.htm": { "nsprefix": "plse", "nsuri": "http://www.pulsebiosciences.com/20240930", "dts": { "schema": { "local": ["plse-20240930.xsd"], "remote": ["http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/currency/2024/currency-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd", "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd", "https://xbrl.sec.gov/exch/2024/exch-2024.xsd", "https://xbrl.sec.gov/naics/2024/naics-2024.xsd", "https://xbrl.sec.gov/sic/2024/sic-2024.xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"] }, "calculationLink": { "local": ["plse-20240930_cal.xml"] }, "definitionLink": { "local": ["plse-20240930_def.xml"] }, "labelLink": { "local": ["plse-20240930_lab.xml"] }, "presentationLink": { "local": ["plse-20240930_pre.xml"] }, "inline": { "local": ["plse20240930c_10q.htm"] } }, "keyStandard": 215, "keyCustom": 35, "axisStandard": 23, "axisCustom": 0, "memberStandard": 24, "memberCustom": 27, "hidden": { "total": 71, "http://fasb.org/us-gaap/2024": 51, "http://xbrl.sec.gov/dei/2024": 6, "http://xbrl.sec.gov/ecd/2024": 4, "http://www.pulsebiosciences.com/20240930": 10 }, "contextCount": 228, "entityCount": 1, "segmentCount": 53, "elementCount": 400, "unitCount": 8, "baseTaxonomies": { "http://fasb.org/us-gaap/2024": 712, "http://xbrl.sec.gov/dei/2024": 29, "http://xbrl.sec.gov/ecd/2024": 5 }, "report": { "R1": { "role": "http://www.pulsebiosciences.com/20240930/role/statement-document-and-entity-information", "longName": "000 - Document - Document And Entity Information", "shortName": "Document And Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["b", "p", "div", "body", "html"], "reportCount": 1, "baseRef": "plse20240930c_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["b", "p", "div", "body", "html"], "reportCount": 1, "baseRef": "plse20240930c_10q.htm", "first": true, "unique": true } }, "R2": { "role": "http://www.pulsebiosciences.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited", "longName": "001 - Statement - Condensed Consolidated Balance Sheets (Current Period Unaudited)", "shortName": "Condensed Consolidated Balance Sheets (Current Period Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "i_2024-09-30", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "plse20240930c_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2024-09-30", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "plse20240930c_10q.htm", "first": true, "unique": true } }, "R3": { "role": "http://www.pulsebiosciences.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals", "longName": "002 - Statement - Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals)", "shortName": "Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": null, "uniqueAnchor": null }, "R4": { "role": "http://www.pulsebiosciences.com/20240930/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited", "longName": "003 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)", "shortName": "Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "d_2024-07-01_2024-09-30", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "plse20240930c_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-07-01_2024-09-30", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "plse20240930c_10q.htm", "first": true, "unique": true } }, "R5": { "role": "http://www.pulsebiosciences.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited", "longName": "004 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)", "shortName": "Condensed Consolidated Statements of Cash Flows (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:NetIncomeLoss", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["td", "tr", "tbody", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "plse20240930c_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:AmortizationOfIntangibleAssets", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["td", "tr", "tbody", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "plse20240930c_10q.htm", "unique": true } }, "R6": { "role": "http://www.pulsebiosciences.com/20240930/role/statement-condensed-consolidated-statements-of-stockholders-equity-deficit-unaudited", "longName": "005 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Deficit) (Unaudited)", "shortName": "Condensed Consolidated Statements of Stockholders' Equity (Deficit) (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "i_2022-12-31_StatementEquityComponentsAxis-CommonStockMember", "name": "us-gaap:SharesOutstanding", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "plse20240930c_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2022-12-31_StatementEquityComponentsAxis-CommonStockMember", "name": "us-gaap:SharesOutstanding", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "plse20240930c_10q.htm", "first": true, "unique": true } }, "R7": { "role": "http://www.pulsebiosciences.com/20240930/role/statement-condensed-consolidated-statements-of-stockholders-equity-deficit-unaudited-parentheticals", "longName": "006 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Deficit) (Unaudited) (Parentheticals)", "shortName": "Condensed Consolidated Statements of Stockholders' Equity (Deficit) (Unaudited) (Parentheticals)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "7", "firstAnchor": null, "uniqueAnchor": null }, "R8": { "role": "http://www.pulsebiosciences.com/20240930/role/statement-note-1-description-of-the-business", "longName": "007 - Disclosure - Note 1 - Description of the Business", "shortName": "Note 1 - Description of the Business", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "plse20240930c_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "plse20240930c_10q.htm", "first": true, "unique": true } }, "R9": { "role": "http://www.pulsebiosciences.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies", "longName": "008 - Disclosure - Note 2 - Summary of Significant Accounting Policies", "shortName": "Note 2 - Summary of Significant Accounting Policies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "plse20240930c_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "plse20240930c_10q.htm", "first": true, "unique": true } }, "R10": { "role": "http://www.pulsebiosciences.com/20240930/role/statement-note-3-fair-value-of-financial-instruments", "longName": "009 - Disclosure - Note 3 - Fair Value of Financial Instruments", "shortName": "Note 3 - Fair Value of Financial Instruments", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "plse20240930c_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "plse20240930c_10q.htm", "first": true, "unique": true } }, "R11": { "role": "http://www.pulsebiosciences.com/20240930/role/statement-note-4-balance-sheet-components", "longName": "010 - Disclosure - Note 4 - Balance Sheet Components", "shortName": "Note 4 - Balance Sheet Components", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "plse20240930c_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "plse20240930c_10q.htm", "first": true, "unique": true } }, "R12": { "role": "http://www.pulsebiosciences.com/20240930/role/statement-note-5-goodwill", "longName": "011 - Disclosure - Note 5 - Goodwill", "shortName": "Note 5 - Goodwill", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:GoodwillDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "plse20240930c_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:GoodwillDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "plse20240930c_10q.htm", "first": true, "unique": true } }, "R13": { "role": "http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation", "longName": "012 - Disclosure - Note 6 - Stockholders' Equity and Stock-based Compensation", "shortName": "Note 6 - Stockholders' Equity and Stock-based Compensation", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "plse20240930c_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "plse20240930c_10q.htm", "first": true, "unique": true } }, "R14": { "role": "http://www.pulsebiosciences.com/20240930/role/statement-note-7-commitments-and-contingencies", "longName": "013 - Disclosure - Note 7 - Commitments and Contingencies", "shortName": "Note 7 - Commitments and Contingencies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "plse20240930c_10q.htm", "first": true, "unique": true },

"uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "plse20240930c_10q.htm", "first": true, "unique": true } }, "R15": { "role": "http://www.pulsebiosciences.com/20240930/role/statement-note-8-segment-reporting", "longName": "014 - Disclosure - Note 8- Segment Reporting", "shortName": "Note 8- Segment Reporting", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "plse20240930c_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "plse20240930c_10q.htm", "first": true, "unique": true } }, "R16": { "role": "http://www.pulsebiosciences.com/20240930/role/statement-note-9-related-party-transactions", "longName": "015 - Disclosure - Note 9 - Related Party Transactions", "shortName": "Note 9 - Related Party Transactions", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "plse20240930c_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "plse20240930c_10q.htm", "first": true, "unique": true } }, "R17": { "role": "http://www.pulsebiosciences.com/20240930/role/statement-note-10-restructuring-charges", "longName": "016 - Disclosure - Note 10 - Restructuring Charges", "shortName": "Note 10 - Restructuring Charges", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "d_2024-07-01_2024-09-30", "name": "us-gaap:CostsAndExpenses", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "plse20240930c_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "plse20240930c_10q.htm", "unique": true } }, "R18": { "role": "http://www.pulsebiosciences.com/20240930/role/statement-note-11-subsequent-events", "longName": "017 - Disclosure - Note 11 - Subsequent Events", "shortName": "Note 11 - Subsequent Events", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "plse20240930c_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "plse20240930c_10q.htm", "first": true, "unique": true } }, "R19": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "longName": "995445 - Disclosure - Insider Trading Arrangements", "shortName": "Insider Trading Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "ecd:MtrlTermsOfTrdArrTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "plse20240930c_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "ecd:MtrlTermsOfTrdArrTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "plse20240930c_10q.htm", "first": true, "unique": true } }, "R20": { "role": "http://www.pulsebiosciences.com/20240930/role/statement-significant-accounting-policies-policies", "longName": "995464 - Disclosure - Significant Accounting Policies (Policies)", "shortName": "Significant Accounting Policies (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "20", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html"], "reportCount": 1, "baseRef": "plse20240930c_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html"], "reportCount": 1, "baseRef": "plse20240930c_10q.htm", "first": true, "unique": true } }, "R21": { "role": "http://www.pulsebiosciences.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies-tables", "longName": "995465 - Disclosure - Note 2 - Summary of Significant Accounting Policies (Tables)", "shortName": "Note 2 - Summary of Significant Accounting Policies (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "21", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:ScheduleOfProductWarrantyLiabilityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:StandardProductWarrantyPolicy", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html"], "reportCount": 1, "baseRef": "plse20240930c_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:ScheduleOfProductWarrantyLiabilityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:StandardProductWarrantyPolicy", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html"], "reportCount": 1, "baseRef": "plse20240930c_10q.htm", "first": true, "unique": true } }, "R22": { "role": "http://www.pulsebiosciences.com/20240930/role/statement-note-3-fair-value-of-financial-instruments-tables", "longName": "995466 - Disclosure - Note 3 - Fair Value of Financial Instruments (Tables)", "shortName": "Note 3 - Fair Value of Financial Instruments (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "22", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:FairValueDisclosuresTextBlock", "body", "html"], "reportCount": 1, "baseRef": "plse20240930c_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:FairValueDisclosuresTextBlock", "body", "html"], "reportCount": 1, "baseRef": "plse20240930c_10q.htm", "first": true, "unique": true } }, "R23": { "role": "http://www.pulsebiosciences.com/20240930/role/statement-note-4-balance-sheet-components-tables", "longName": "995467 - Disclosure - Note 4 - Balance Sheet Components (Tables)", "shortName": "Note 4 - Balance Sheet Components (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "23", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html"], "reportCount": 1, "baseRef": "plse20240930c_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html"], "reportCount": 1, "baseRef": "plse20240930c_10q.htm", "first": true, "unique": true } }, "R24": { "role": "http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-tables", "longName": "995468 - Disclosure - Note 6 - Stockholders' Equity and Stock-based Compensation (Tables)", "shortName": "Note 6 - Stockholders' Equity and Stock-based Compensation (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "24", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html"], "reportCount": 1, "baseRef": "plse20240930c_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html"], "reportCount": 1, "baseRef": "plse20240930c_10q.htm", "first": true, "unique": true } }, "R25": { "role": "http://www.pulsebiosciences.com/20240930/role/statement-note-7-commitments-and-contingencies-tables", "longName": "995469 - Disclosure - Note 7 - Commitments and Contingencies (Tables)", "shortName": "Note 7 - Commitments and Contingencies (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "25", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "plse:ScheduleOfInformationRelatedToRightofuseAssetsAndLeaseLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "plse20240930c_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "plse:ScheduleOfInformationRelatedToRightofuseAssetsAndLeaseLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "plse20240930c_10q.htm", "first": true, "unique": true } }, "R26": { "role": "http://www.pulsebiosciences.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies-warrant-accrual-activity-details", "longName": "995470 - Disclosure - Note 2 - Summary of Significant Accounting Policies - Warrant Accrual Activity (Details)", "shortName": "Note 2 - Summary of Significant Accounting Policies - Warrant Accrual Activity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "26", "firstAnchor": { "contextRef": "i_2024-06-30", "name": "us-gaap:StandardProductWarrantyAccrualCurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:ScheduleOfProductWarrantyLiabilityTableTextBlock", "us-gaap:StandardProductWarrantyPolicy", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html"], "reportCount": 1, "baseRef": "plse20240930c_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2024-06-30", "name": "us-gaap:StandardProductWarrantyAccrualCurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:ScheduleOfProductWarrantyLiabilityTableTextBlock", "us-gaap:StandardProductWarrantyPolicy", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html"], "reportCount": 1, "baseRef": "plse20240930c_10q.htm", "first": true, "unique": true } }, "R27": { "role": "http://www.pulsebiosciences.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies-antidilutive-securities-details", "longName": "995471 - Disclosure - Note 2 - Summary of Significant Accounting Policies - Antidilutive Securities (Details)", "shortName": "Note 2 - Summary of Significant Accounting Policies - Antidilutive Securities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "27", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html"], "reportCount": 1, "baseRef": "plse20240930c_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html"], "reportCount": 1, "baseRef": "plse20240930c_10q.htm", "first": true, "unique": true } }, "R28": { "role": "http://www.pulsebiosciences.com/20240930/role/statement-note-3-fair-value-of-financial-instruments-details-textual", "longName": "995472 - Disclosure - Note 3 - Fair Value of Financial Instruments (Details Textual)", "shortName": "Note 3 - Fair Value of Financial Instruments (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "28", "firstAnchor": null, "uniqueAnchor": null }, "R29": { "role": "http://www.pulsebiosciences.com/20240930/role/statement-note-3-investments-and-fair-value-of-financial-instruments-financial-assets-measured-on-a-recurring-basis-details", "longName": "995473 - Disclosure - Note 3 - Investments and Fair Value of Financial Instruments - Financial Assets Measured on a Recurring Basis (Details)", "shortName": "Note 3 - Investments and Fair Value of Financial Instruments - Financial Assets Measured on a Recurring Basis (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "29", "firstAnchor": { "contextRef": "i_2024-09-30", "name": "us-gaap:AssetsFairValueDisclosure", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "body", "html"], "reportCount": 1, "baseRef": "plse20240930c_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2024-09-30", "name": "us-gaap:AssetsFairValueDisclosure", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "body", "html"], "reportCount": 1, "baseRef": "plse20240930c_10q.htm", "first": true, "unique": true } }, "R30": { "role": "http://www.pulsebiosciences.com/20240930/role/statement-note-4-balance-sheet-components-details-textual", "longName": "995474 - Disclosure - Note 4 - Balance Sheet Components (Details Textual)", "shortName": "Note 4 - Balance Sheet Components (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "30", "firstAnchor": { "contextRef": "d_2024-07-01_2024-09-30", "name": "us-gaap:Depreciation", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["p", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html"], "reportCount": 1, "baseRef": "plse20240930c_10q.htm", "first": true }, "uniqueAnchor": null }, "R31": { "role": "http://www.pulsebiosciences.com/20240930/role/statement-note-4-balance-sheet-components-property-and-equipment-net-details", "longName": "995475 - Disclosure - Note 4 - Balance Sheet Components - Property and Equipment, Net (Details)", "shortName": "Note 4 - Balance Sheet Components - Property and Equipment, Net (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "31", "firstAnchor": { "contextRef": "i_2024-09-30", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html"], "reportCount": 1, "baseRef": "plse20240930c_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2024-09-30", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html"], "reportCount": 1, "baseRef": "plse20240930c_10q.htm", "first": true, "unique": true } }, "R32": { "role": "http://www.pulsebiosciences.com/20240930/role/statement-note-4-balance-sheet-components-intangible-assets-net-details", "longName": "995476 - Disclosure - Note 4 - Balance Sheet Components - Intangible Assets, Net (Details)", "shortName": "Note 4 - Balance Sheet Components - Intangible Assets, Net (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "32", "firstAnchor": { "contextRef": "i_2024-09-30", "name": "us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html"], "reportCount": 1, "baseRef": "plse20240930c_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2024-09-30", "name": "us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html"], "reportCount": 1, "baseRef": "plse20240930c_10q.htm", "first": true, "unique": true } }, "R33": { "role": "http://www.pulsebiosciences.com/20240930/role/statement-note-4-balance-sheet-components-schedule-of-amortization-of-intangible-assets-details", "longName": "995477 - Disclosure - Note 4 - Balance Sheet Components - Schedule of Amortization of Intangible Assets (Details)", "shortName": "Note 4 - Balance Sheet Components - Schedule of Amortization of Intangible Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "33", "firstAnchor": { "contextRef": "i_2024-09-30", "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html"], "reportCount": 1, "baseRef": "plse20240930c_10q.htm", "first": true, "unique": true } }, "uniqueAnchor": { "contextRef": "i_2024-09-30", "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html"], "reportCount": 1, "baseRef": "plse20240930c_10q.htm", "first": true, "unique": true } }, "R34": { "role": "http://www.pulsebiosciences.com/20240930/role/statement-note-4-balance-sheet-components-accrued-

expenses-details", "longName": "995478 - Disclosure - Note 4 - Balance Sheet Components - Accrued Expenses (Details)", "shortName": "Note 4 - Balance Sheet Components - Accrued Expenses (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "34", "firstAnchor": { "contextRef": "i_2024-09-30", "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html"], "reportCount": 1, "baseRef": "plse20240930c_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2024-09-30", "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html"], "reportCount": 1, "baseRef": "plse20240930c_10q.htm", "first": true, "unique": true } }, "R35": { "role": "http://www.pulsebiosciences.com/20240930/role/statement-note-5-goodwill-details-textual", "longName": "995479 - Disclosure - Note 5 - Goodwill (Details Textual)", "shortName": "Note 5 - Goodwill (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "35", "firstAnchor": { "contextRef": "i_2024-09-30", "name": "us-gaap:Goodwill", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "plse20240930c_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "d_2014-01-01_2014-12-31_BusinessAcquisitionAxis-SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember", "name": "us-gaap:NumberOfBusinessesAcquired", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["p", "us-gaap:GoodwillDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "plse20240930c_10q.htm", "unique": true } }, "R36": { "role": "http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-details-textual", "longName": "995480 - Disclosure - Note 6 - Stockholders' Equity and Stock-based Compensation (Details Textual)", "shortName": "Note 6 - Stockholders' Equity and Stock-based Compensation (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "36", "firstAnchor": { "contextRef": "d_2024-01-01_2024-09-30", "name": "plse:EquityClassifiedSubscriptionValue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["td", "tr", "tbody", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "plse20240930c_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30_AwardTypeAxis-TimebasedOptionsMember", "name": "plse:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html"], "reportCount": 1, "baseRef": "plse20240930c_10q.htm", "unique": true } }, "R37": { "role": "http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-summary-of-stock-option-activity-details", "longName": "995481 - Disclosure - Note 6 - Stockholders' Equity and Stock-based Compensation - Summary of Stock Option Activity (Details)", "shortName": "Note 6 - Stockholders' Equity and Stock-based Compensation - Summary of Stock Option Activity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "37", "firstAnchor": { "contextRef": "i_2023-12-31_PlanNameAxis-The2015Plan2017PlanAndInducementPlanMember", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html"], "reportCount": 1, "baseRef": "plse20240930c_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "i_2023-12-31_PlanNameAxis-The2015Plan2017PlanAndInducementPlanMember", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html"], "reportCount": 1, "baseRef": "plse20240930c_10q.htm", "first": true, "unique": true } }, "R38": { "role": "http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-summary-of-timebased-option-activity-details", "longName": "995482 - Disclosure - Note 6 - Stockholders' Equity and Stock-based Compensation - Summary of Time-based Option Activity (Details)", "shortName": "Note 6 - Stockholders' Equity and Stock-based Compensation - Summary of Time-based Option Activity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "38", "firstAnchor": { "contextRef": "i_2023-12-31_AwardTypeAxis-TimebasedOptionsMember", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html"], "reportCount": 1, "baseRef": "plse20240930c_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30_AwardTypeAxis-TimebasedOptionsMember", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["td", "tr", "tbody", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html"], "reportCount": 1, "baseRef": "plse20240930c_10q.htm", "unique": true } }, "R39": { "role": "http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-summary-of-performance-option-activity-details", "longName": "995483 - Disclosure - Note 6 - Stockholders' Equity and Stock-based Compensation - Summary of Performance Option Activity (Details)", "shortName": "Note 6 - Stockholders' Equity and Stock-based Compensation - Summary of Performance Option Activity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "39", "firstAnchor": { "contextRef": "i_2023-12-31_AwardTypeAxis-PerformanceOptionsMember", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html"], "reportCount": 1, "baseRef": "plse20240930c_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30_AwardTypeAxis-PerformanceOptionsMember", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["td", "tr", "tbody", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html"], "reportCount": 1, "baseRef": "plse20240930c_10q.htm", "unique": true } }, "R40": { "role": "http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-summary-of-marketbased-option-activity-details", "longName": "995484 - Disclosure - Note 6 - Stockholders' Equity and Stock-based Compensation - Summary of Market-based Option Activity (Details)", "shortName": "Note 6 - Stockholders' Equity and Stock-based Compensation - Summary of Market-based Option Activity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "40", "firstAnchor": { "contextRef": "i_2023-12-31_AwardTypeAxis-MarketbasedOptionsMember", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "Share", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html"], "reportCount": 1, "baseRef": "plse20240930c_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "d_2024-01-01_2024-09-30_AwardTypeAxis-MarketbasedOptionsMember", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["td", "tr", "tbody", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html"], "reportCount": 1, "baseRef": "plse20240930c_10q.htm", "unique": true } }, "R41": { "role": "http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-option-assumptions-details", "longName": "995485 - Disclosure - Note 6 - Stockholders' Equity and Stock-based Compensation - Option Assumptions (Details)", "shortName": "Note 6 - Stockholders' Equity and Stock-based Compensation - Option Assumptions (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "41", "firstAnchor": { "contextRef": "d_2023-07-01_2023-09-30_AwardTypeAxis-TimebasedAndPerformanceOptionsMember", "name": "us-gaap:ShareBasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["td", "tr", "tbody", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html"], "reportCount": 1, "baseRef": "plse20240930c_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2023-07-01_2023-09-30_AwardTypeAxis-TimebasedAndPerformanceOptionsMember", "name": "us-gaap:ShareBasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["td", "tr", "tbody", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html"], "reportCount": 1, "baseRef": "plse20240930c_10q.htm", "first": true, "unique": true } }, "R42": { "role": "http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-espp-assumptions-details", "longName": "995486 - Disclosure - Note 6 - Stockholders' Equity and Stock-based Compensation - ESPP Assumptions (Details)", "shortName": "Note 6 - Stockholders' Equity and Stock-based Compensation - ESPP Assumptions (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "d_2024-07-01_2024-09-30_PlanNameAxis-The2017EmployeeStockPurchasePlanMember", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": ["p", "td", "tr", "tbody", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html"], "reportCount": 1, "baseRef": "plse20240930c_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-07-01_2024-09-30_PlanNameAxis-The2017EmployeeStockPurchasePlanMember", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": ["p", "td", "tr", "tbody", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html"], "reportCount": 1, "baseRef": "plse20240930c_10q.htm", "first": true, "unique": true } }, "R43": { "role": "http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-stockbased-compensation-expense-by-recorded-location-details", "longName": "995487 - Disclosure - Note 6 - Stockholders' Equity and Stock-based Compensation - Stock-based Compensation Expense by Recorded Location (Details)", "shortName": "Note 6 - Stockholders' Equity and Stock-based Compensation - Stock-based Compensation Expense by Recorded Location (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "d_2024-07-01_2024-09-30", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html"], "reportCount": 1, "baseRef": "plse20240930c_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "d_2024-07-01_2024-09-30_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html"], "reportCount": 1, "baseRef": "plse20240930c_10q.htm", "unique": true } }, "R44": { "role": "http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-stockbased-compensation-expense-by-type-details", "longName": "995488 - Disclosure - Note 6 - Stockholders' Equity and Stock-based Compensation - Stock-based Compensation Expense by Type (Details)", "shortName": "Note 6 - Stockholders' Equity and Stock-based Compensation - Stock-based Compensation Expense by Type (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "d_2024-07-01_2024-09-30", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html"], "reportCount": 1, "baseRef": "plse20240930c_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "d_2024-07-01_2024-09-30_AwardTypeAxis-TimebasedOptionsMember", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html"], "reportCount": 1, "baseRef": "plse20240930c_10q.htm", "unique": true } }, "R45": { "role": "http://www.pulsebiosciences.com/20240930/role/statement-note-7-commitments-and-contingencies-details-textual", "longName": "995489 - Disclosure - Note 7 - Commitments and Contingencies (Details Textual)", "shortName": "Note 7 - Commitments and Contingencies (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "d_2024-07-01_2024-09-30", "name": "us-gaap:OperatingLeaseExpense", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "plse20240930c_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-07-01_2024-09-30", "name": "us-gaap:OperatingLeaseExpense", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "plse20240930c_10q.htm", "first": true, "unique": true } }, "R46": { "role": "http://www.pulsebiosciences.com/20240930/role/statement-note-7-commitments-and-contingencies-information-related-to-rightofuse-assets-and-lease-liabilities-details", "longName": "995490 - Disclosure - Note 7 - Commitments and Contingencies - Information Related to Right-of-use Assets and Lease Liabilities (Details)", "shortName": "Note 7 - Commitments and Contingencies - Information Related to Right-of-use Assets and Lease Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "46", "firstAnchor": { "contextRef": "i_2024-09-30", "name": "us-gaap:OperatingLeaseRightOfUseAsset", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "plse20240930c_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "i_2023-12-31", "name": "us-gaap:OperatingLeaseRightOfUseAsset", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "plse:ScheduleOfInformationRelatedToRightofuseAssetsAndLeaseLiabilitiesTableTextBlock", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "plse20240930c_10q.htm", "unique": true } }, "R47": { "role": "http://www.pulsebiosciences.com/20240930/role/statement-note-8-segment-reporting-details-textual", "longName": "995491 - Disclosure - Note 8- Segment Reporting (Details Textual)", "shortName": "Note 8- Segment Reporting (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "47", "firstAnchor": null, "uniqueAnchor": null }, "R48": { "role": "http://www.pulsebiosciences.com/20240930/role/statement-note-9-related-party-transactions-details-textual", "longName": "995492 - Disclosure - Note 9 - Related Party Transactions (Details Textual)", "shortName": "Note 9 - Related Party Transactions (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "48", "firstAnchor": { "contextRef": "i_2024-09-30", "name": "us-gaap:AccruedLiabilitiesCurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "plse20240930c_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "d_2023-05-31_2023-05-31_RelatedPartyTransactionAxis-

LetterAgreementMember_RelatedPartyTransactionsByRelatedPartyAxis-RobertWDugganMember", "name": "us-gaap:RelatedPartyTransactionAmountsOfTransaction", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": ["p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "plse20240930c_10q.htm", "unique": true } }, "R49": { "role": "http://www.pulsebiosciences.com/20240930/role/statement-note-10-restructuring-charges-details-textual", "longName": "995493 - Disclosure - Note 10 - Restructuring Charges (Details Textual)", "shortName": "Note 10 - Restructuring Charges (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "49", "firstAnchor": { "contextRef": "d_2024-07-01_2024-09-30", "name": "us-gaap:CostsAndExpenses", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "tbody", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "plse20240930c_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "d_2023-02-01_2023-02-28_RestructuringCostAndReserveAxis-EmployeeSeveranceMember", "name": "us-gaap:RestructuringCharges", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["p", "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "body", "html"], "reportCount": 1, "baseRef": "plse20240930c_10q.htm", "unique": true } } }, "R50": { "role": "http://www.pulsebiosciences.com/20240930/role/statement-note-11-subsequent-events-details-textual", "longName": "995494 - Disclosure - Note 11 - Subsequent Events (Details Textual)", "shortName": "Note 11 - Subsequent Events (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "50", "firstAnchor": { "contextRef": "d_2024-10-01_2024-10-31_AwardDateAxis-NextOneToFourYearsMember_SubsequentEventTypeAxis-SubsequentEventMember", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": ["p", "us-gaap:SubsequentEventsTextBlock", "body", "html"], "reportCount": 1, "baseRef": "plse20240930c_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d_2024-10-01_2024-10-31_AwardDateAxis-NextOneToFourYearsMember_SubsequentEventTypeAxis-SubsequentEventMember", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": ["p", "us-gaap:SubsequentEventsTextBlock", "body", "html"], "reportCount": 1, "baseRef": "plse20240930c_10q.htm", "first": true, "unique": true } } }, "tag": { "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountingPoliciesAbstract", "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-significant-accounting-policies-policies"], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableCurrent", "crdr": "credit", "calculation": { "http://www.pulsebiosciences.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 0.0 } }, "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"], "lang": { "en-us": { "role": { "label": "Accounts payable", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": ["r43", "r546"] }, "plse_AccruedClinicalTrialFeesAndCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.pulsebiosciences.com/20240930", "localname": "AccruedClinicalTrialFeesAndCosts", "crdr": "credit", "calculation": { "http://www.pulsebiosciences.com/20240930/role/statement-note-4-balance-sheet-components-accrued-expenses-details": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 0.0 } }, "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-note-4-balance-sheet-components-accrued-expenses-details"], "lang": { "en-us": { "role": { "label": "Clinical trial fees and costs", "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to clinical trial fees and costs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [] }, "us-gaap_AccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.pulsebiosciences.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 1.0 }, "http://www.pulsebiosciences.com/20240930/role/statement-note-4-balance-sheet-components-accrued-expenses-details": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited", "http://www.pulsebiosciences.com/20240930/role/statement-note-4-balance-sheet-components-accrued-expenses-details", "http://www.pulsebiosciences.com/20240930/role/statement-note-9-related-party-transactions-details-textual"], "lang": { "en-us": { "role": { "label": "Accrued expenses", "terseLabel": "Accrued Liabilities, Current", "totalLabel": "Total accrued expenses", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": ["r45"] }, "us-gaap_AccruedProfessionalFeesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedProfessionalFeesCurrent", "crdr": "credit", "calculation": { "http://www.pulsebiosciences.com/20240930/role/statement-note-4-balance-sheet-components-accrued-expenses-details": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-note-4-balance-sheet-components-accrued-expenses-details"], "lang": { "en-us": { "role": { "label": "Professional fees", "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": ["r45"] }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://www.pulsebiosciences.com/20240930/role/statement-note-4-balance-sheet-components-property-and-equipment-net-details": { "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0, "order": 1.0 } }, "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-note-4-balance-sheet-components-property-and-equipment-net-details"], "lang": { "en-us": { "role": { "label": "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "negatedLabel": "Less: Accumulated depreciation and amortization", "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services." } } }, "auth_ref": ["r30", "r102", "r399"] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "calculation": { "http://www.pulsebiosciences.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 0.0 } }, "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"], "lang": { "en-us": { "role": { "label": "Accumulated other comprehensive income (loss)", "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source." } } }, "auth_ref": ["r15", "r16", "r58", "r107", "r395", "r416", "r417"] }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeMember", "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-condensed-consolidated-statements-of-stockholders-equity-deficit-unaudited"], "lang": { "en-us": { "role": { "label": "AOCI Attributable to Parent [Member]", "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners." } } }, "auth_ref": ["r3", "r9", "r16", "r316", "r319", "r365", "r412", "r413", "r573", "r574", "r575", "r581", "r582", "r583", "r584"] }, "plse_AcquiredPatentsAndLicensesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pulsebiosciences.com/20240930", "localname": "AcquiredPatentsAndLicensesMember", "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-note-4-balance-sheet-components-intangible-assets-net-details"], "lang": { "en-us": { "role": { "label": "Acquired Patents and Licenses [Member]", "documentation": "Represents acquired patents and licenses." } } }, "auth_ref": [] }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalCommonStock", "crdr": "credit", "calculation": { "http://www.pulsebiosciences.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 4.0 } }, "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"], "lang": { "en-us": { "role": { "label": "Additional paid-in capital", "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital." } } }, "auth_ref": ["r53"] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalMember", "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-condensed-consolidated-statements-of-stockholders-equity-deficit-unaudited"], "lang": { "en-us": { "role": { "label": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": ["r427", "r581", "r582", "r583", "r584", "r639", "r666"] }, "plse_AdjustmentForInventoryAtCost": { "xbrltype": "monetaryItemType", "nsuri": "http://www.pulsebiosciences.com/20240930", "localname": "AdjustmentForInventoryAtCost", "crdr": "debit", "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies-warrant-accrual-activity-details"], "lang": { "en-us": { "role": { "label": "Less: Adjustment for inventory at cost and excessive and obsolete inventory", "documentation": "Represents the adjustment for inventory at cost." } } }, "auth_ref": [] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "crdr": "credit", "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-condensed-consolidated-statements-of-stockholders-equity-deficit-unaudited"], "lang": { "en-us": { "role": { "label": "Stock based compensation expense", "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement." } } }, "auth_ref": ["r36", "r37", "r256"] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts", "crdr": "debit", "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-condensed-consolidated-statements-of-stockholders-equity-deficit-unaudited-parentheticals"], "lang": { "en-us": { "role": { "label": "Issuance cost", "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration." } } }, "auth_ref": ["r10", "r72"] }, "plse_AdjustmentsToAdditionalPaidInCapitalWarrantsExerciseIssuanceCostAdjustment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.pulsebiosciences.com/20240930", "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantsExerciseIssuanceCostAdjustment", "crdr": "credit", "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-condensed-consolidated-statements-of-stockholders-equity-deficit-unaudited"], "lang": { "en-us": { "role": { "label": "Warrant exercise, issuance cost adjustment", "documentation": "Amount of increase in additional paid in capital (APIC) resulting from issuance cost adjustment for warrants exercise." } } }, "auth_ref": [] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "Adjustments to reconcile net loss to net cash used in operating activities:" } } }, "auth_ref": [] }, "us-gaap_AllocatedShareBasedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllocatedShareBasedCompensationExpense", "crdr": "debit", "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-stockbased-compensation-expense-by-recorded-location-details", "http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-stockbased-compensation-expense-by-type-details"], "lang": { "en-us": { "role": { "label": "Total stock-based compensation expense", "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized." } } }, "auth_ref": ["r287", "r295"] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "us-gaap_AmortizationOfIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AmortizationOfIntangibleAssets", "crdr": "debit", "calculation": { "http://www.pulsebiosciences.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "Amortization of intangible assets", "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method." } } }, "auth_ref": ["r6", "r185", "r192", "r520"] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies-antidilutive-securities-details"], "lang": { "en-us": { "role": { "label": "Antidilutive securities (in shares)", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": ["r143"] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies-antidilutive-securities-details"], "lang": { "en-us": { "role": { "label": "Antidilutive Securities [Axis]", "documentation": "Information by type of antidilutive security." } } }, "auth_ref": ["r24"] }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesNameDomain", "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies-antidilutive-securities-details"], "lang": { "en-us": { "role": { "label": "Antidilutive Securities, Name [Domain]", "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "auth_ref": ["r24"] }, "us-gaap_AreaOfRealEstateProperty": { "xbrltype": "areaItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AreaOfRealEstateProperty", "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-note-7-commitments-and-contingencies-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_AreaOfRealEstateProperty", "terseLabel": "Area of Real Estate Property (Square Foot)", "documentation": "Area of a real estate property." } } }, "auth_ref": [] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Assets", "crdr": "debit", "calculation": { "http://www.pulsebiosciences.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_Assets", "totalLabel": "Total assets", "documentation": "Amount of asset recognized for present right to economic benefit." } } }, "auth_ref": ["r78", "r89", "r106", "r121", "r146", "r152", "r162", "r165", "r173", "r216", "r217", "r218", "r219", "r220", "r221", "r222", "r223", "r224",

"r311", "r313", "r343", "r390", "r454", "r513", "r514", "r546", "r558", "r609", "r610", "r653"] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrent", "crdr": "debit", "calculation": { "http://www.pulsebiosciences.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_AssetsCurrent", "totalLabel": "Total current assets", "documentation": "Amount of asset recognized for present right to economic benefit, classified as current." } } }, "auth_ref": ["r98", "r108", "r121", "r173", "r216", "r217", "r218", "r219", "r220", "r221", "r222", "r223", "r224", "r311", "r313", "r343", "r546", "r609", "r610", "r653"] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrentAbstract", "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"], "lang": { "en-us": { "role": { "label": "Current assets:" } } }, "auth_ref": [] }, "us-gaap_AssetsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsFairValueDisclosure", "crdr": "debit", "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-note-3-investments-and-fair-value-of-financial-instruments-financial-assets-measured-on-a-recurring-basis-details"], "lang": { "en-us": { "role": { "label": "Total assets measured at fair value", "documentation": "Fair value portion of asset recognized for present right to economic benefit." } } }, "auth_ref": ["r325", "r326", "r537"] }, "plse_AtmOfferingMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pulsebiosciences.com/20240930", "localname": "AtmOfferingMember", "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-condensed-consolidated-statements-of-stockholders-equity-deficit-unaudited", "http://www.pulsebiosciences.com/20240930/role/statement-condensed-consolidated-statements-of-stockholders-equity-deficit-unaudited-parentheticals"], "lang": { "en-us": { "role": { "label": "ATM Offering [Member]", "documentation": "Represents the ATM offering." } } }, "auth_ref": [] }, "us-gaap_AwardDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AwardDateAxis", "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-note-11-subsequent-events", "http://www.pulsebiosciences.com/20240930/role/statement-note-11-subsequent-events-details-textual"], "lang": { "en-us": { "role": { "label": "Award Date [Axis]", "documentation": "Information by date or year award under share-based payment arrangement is granted." } } }, "auth_ref": ["r613", "r614", "r615", "r616", "r617", "r618", "r619", "r620", "r621", "r622", "r623", "r624", "r625", "r626", "r627", "r628", "r629", "r630", "r631", "r632", "r633", "r634", "r635", "r636", "r637", "r638"] }, "us-gaap_AwardDateDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AwardDateDomain", "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-note-11-subsequent-events", "http://www.pulsebiosciences.com/20240930/role/statement-note-11-subsequent-events-details-textual"], "lang": { "en-us": { "role": { "label": "Award Date [Domain]", "documentation": "Date or year award under share-based payment arrangement is granted." } } }, "auth_ref": ["r613", "r614", "r615", "r616", "r617", "r618", "r619", "r620", "r621", "r622", "r623", "r624", "r625", "r626", "r627", "r628", "r629", "r630", "r631", "r632", "r633", "r634", "r635", "r636", "r637", "r638"] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AwardTypeAxis", "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation", "http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-details-textual", "http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-option-assumptions-details", "http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-stockbased-compensation-expense-by-type-details", "http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-summary-of-marketbased-option-activity-details", "http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-summary-of-performance-option-activity-details", "http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-summary-of-timebased-option-activity-details", "http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-tables"], "lang": { "en-us": { "role": { "label": "Award Type [Axis]", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": ["r258", "r259", "r260", "r262", "r263", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r282", "r283", "r284", "r285", "r286"] }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BasisOfAccountingPolicyPolicyTextBlock", "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-significant-accounting-policies-policies"], "lang": { "en-us": { "role": { "label": "Basis of Accounting, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": [] }, "srt_BoardOfDirectorsChairmanMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "BoardOfDirectorsChairmanMember", "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation", "http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-details-textual"], "lang": { "en-us": { "role": { "label": "Board of Directors Chairman [Member]" } } }, "auth_ref": ["r591"] }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessAcquisitionAcquireeDomain", "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-note-5-goodwill", "http://www.pulsebiosciences.com/20240930/role/statement-note-5-goodwill-details-textual"], "lang": { "en-us": { "role": { "label": "Business Acquisition, Acquiree [Domain]", "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree." } } }, "auth_ref": ["r186", "r187", "r188", "r189", "r190", "r308", "r530", "r531"] }, "us-gaap_BusinessAcquisitionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessAcquisitionAxis", "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-note-5-goodwill", "http://www.pulsebiosciences.com/20240930/role/statement-note-5-goodwill-details-textual"], "lang": { "en-us": { "role": { "label": "Business Acquisition [Axis]", "documentation": "Information by business combination or series of individually immaterial business combinations." } } }, "auth_ref": ["r38", "r39", "r186", "r187", "r188", "r189", "r190", "r308", "r530", "r531"] }, "us-gaap_BusinessCombinationConsiderationTransferred1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationConsiderationTransferred1", "crdr": "credit", "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-note-5-goodwill-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_BusinessCombinationConsiderationTransferred1", "terseLabel": "Business Combination, Consideration Transferred, Total", "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer." } } }, "auth_ref": ["r0", "r1", "r8"] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://www.pulsebiosciences.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 0.0 } }, "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"], "lang": { "en-us": { "role": { "label": "Cash and cash equivalents", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": ["r20", "r100", "r505"] }, "us-gaap_CashAndCashEquivalentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsAxis", "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-note-3-investments-and-fair-value-of-financial-instruments-financial-assets-measured-on-a-recurring-basis-details"], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents [Axis]", "documentation": "Information by type of cash and cash equivalent balance." } } }, "auth_ref": ["r100"] }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsFairValueDisclosure", "crdr": "debit", "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-note-3-investments-and-fair-value-of-financial-instruments-financial-assets-measured-on-a-recurring-basis-details"], "lang": { "en-us": { "role": { "label": "Cash and Cash equivalents", "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r640", "r641"] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "crdr": "debit", "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "periodStartLabel": "Cash and cash equivalents at beginning of period", "periodEndLabel": "Cash and cash equivalents at end of period", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r20", "r65", "r119"] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://www.pulsebiosciences.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "totalLabel": "Net increase (decrease) in cash and cash equivalents", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r2", "r65"] }, "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract", "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "Supplemental disclosure of noncash investing and financing activities:" } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "plse_ClassOfWarransOrRightExerciseSharePricePercentageOfSubscriptionPriceForUnits": { "xbrltype": "percentItemType", "nsuri": "http://www.pulsebiosciences.com/20240930", "localname": "ClassOfWarransOrRightExerciseSharePricePercentageOfSubscriptionPriceForUnits", "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-details-textual"], "lang": { "en-us": { "role": { "label": "plse_ClassOfWarransOrRightExerciseSharePricePercentageOfSubscriptionPriceForUnits", "terseLabel": "Class of Warrans or Right, Exercise Price, Percentage of Subscription Price for Units", "documentation": "Amount of exercise price of warrants as percentage of subscription price for units." } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightAxis", "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation", "http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-details-textual"], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right [Axis]", "documentation": "Information by type of warrant or right issued." } } }, "auth_ref": ["r32"] }, "us-gaap_ClassOfWarrantOrRightDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightDomain", "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation", "http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-details-textual"], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right [Domain]", "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months." } } }, "auth_ref": [] }, "plse_ClassOfWarrantOrRightExerciseConsecutiveTradingDays": { "xbrltype": "durationItemType", "nsuri": "http://www.pulsebiosciences.com/20240930", "localname": "ClassOfWarrantOrRightExerciseConsecutiveTradingDays", "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-details-textual"], "lang": { "en-us": { "role": { "label": "plse_ClassOfWarrantOrRightExerciseConsecutiveTradingDays", "terseLabel": "Class of Warrant or Right, Exercise, Consecutive Trading Days (Day)", "documentation": "The consecutive trading days for exercise of warrant or right." } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "terseLabel": "Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)", "documentation": "Exercise price per share or per unit of warrants or rights outstanding." } } }, "auth_ref": ["r242"] }, "plse_ClassOfWarrantOrRightExercisedDuringPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://www.pulsebiosciences.com/20240930", "localname": "ClassOfWarrantOrRightExercisedDuringPeriod", "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-details-textual"], "lang": { "en-us": { "role": { "label": "plse_ClassOfWarrantOrRightExercisedDuringPeriod", "terseLabel": "Class of Warrant or Right, Exercised During Period (in shares)", "documentation": "The number of warrants or rights exercised during period." } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight", "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight", "terseLabel": "Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)", "documentation": "Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares." } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "terseLabel": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)", "documentation": "Number of securities into which the class of warrant or right may be converted. For

example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares." } } }, "auth_ref": ["r242"] }, "us-gaap_ClassOfWarrantOrRightOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightOutstanding", "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_ClassOfWarrantOrRightOutstanding", "terseLabel": "Class of Warrant or Right, Outstanding (in shares)", "documentation": "Number of warrants or rights outstanding." } } }, "auth_ref": [] }, "plse_ClassOfWarrantOrRightPercentageRequiredForRedemption": { "xbrltype": "percentItemType", "nsuri": "http://www.pulsebiosciences.com/20240930", "localname": "ClassOfWarrantOrRightPercentageRequiredForRedemption", "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-details-textual"], "lang": { "en-us": { "role": { "label": "plse_ClassOfWarrantOrRightPercentageRequiredForRedemption", "terseLabel": "Class of Warrant or Right, Percentage Required for Redemption", "documentation": "The percentage required for redemption of warrant or right." } } }, "auth_ref": [] }, "plse_ClassOfWarrantOrRightPeriodOfWrittenNoticeForExercise": { "xbrltype": "durationItemType", "nsuri": "http://www.pulsebiosciences.com/20240930", "localname": "ClassOfWarrantOrRightPeriodOfWrittenNoticeForExercise", "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-details-textual"], "lang": { "en-us": { "role": { "label": "plse_ClassOfWarrantOrRightPeriodOfWrittenNoticeForExercise", "terseLabel": "Class of Warrant or Right, Period of Written Notice for Exercise (Day)", "documentation": "The period of written notice for warrants or rights to be exercised." } } }, "auth_ref": [] }, "plse_ClassOfWarrantOrRightProceedsUponExercise": { "xbrltype": "monetaryItemType", "nsuri": "http://www.pulsebiosciences.com/20240930", "localname": "ClassOfWarrantOrRightProceedsUponExercise", "crdr": "debit", "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-details-textual"], "lang": { "en-us": { "role": { "label": "plse_ClassOfWarrantOrRightProceedsUponExercise", "terseLabel": "Class of Warrant or Right, Proceeds Upon Exercise", "documentation": "Amount of proceeds upon exercise of warrants or rights." } } }, "auth_ref": [] }, "plse_ClassOfWarrantOrRightVestingStockPriceTrigger": { "xbrltype": "perShareItemType", "nsuri": "http://www.pulsebiosciences.com/20240930", "localname": "ClassOfWarrantOrRightVestingStockPriceTrigger", "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-details-textual"], "lang": { "en-us": { "role": { "label": "plse_ClassOfWarrantOrRightVestingStockPriceTrigger", "terseLabel": "Class of Warrant or Right, Vesting, Stock Price Trigger (in dollars per share)", "documentation": "Per share or per unit stock price trigger for vesting of warrants or rights." } } }, "auth_ref": [] }, "plse_ClassOfWarrantsOrRightsRedemptionPricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://www.pulsebiosciences.com/20240930", "localname": "ClassOfWarrantsOrRightsRedemptionPricePerShare", "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-details-textual"], "lang": { "en-us": { "role": { "label": "plse_ClassOfWarrantsOrRightsRedemptionPricePerShare", "terseLabel": "Class of Warrants or Rights, Redemption Price Per Share (in dollars per share)", "documentation": "Per share redemption price of warrants or rights." } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingencies", "crdr": "credit", "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"], "lang": { "en-us": { "role": { "label": "Commitments and contingencies (Note 7)", "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } }, "auth_ref": ["r49", "r82", "r392", "r441"] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-note-7-commitments-and-contingencies"], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Text Block]", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": ["r71", "r209", "r210", "r499", "r598", "r604"] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockMember", "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-condensed-consolidated-statements-of-stockholders-equity-deficit-unaudited"], "lang": { "en-us": { "role": { "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": ["r548", "r549", "r550", "r552", "r553", "r554", "r555", "r581", "r582", "r584", "r639", "r664", "r666"] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockParOrStatedValuePerShare", "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals", "http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-details-textual", "http://www.pulsebiosciences.com/20240930/role/statement-note-7-commitments-and-contingencies-details-textual", "http://www.pulsebiosciences.com/20240930/role/statement-note-9-related-party-transactions-details-textual"], "lang": { "en-us": { "role": { "label": "Common stock, par value (in dollars per share)", "terseLabel": "Common Stock, Par or Stated Value Per Share (in dollars per share)", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": ["r52"] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesAuthorized", "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals"], "lang": { "en-us": { "role": { "label": "Common stock, shares authorized (in shares)", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": ["r52", "r442"] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesIssued", "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals"], "lang": { "en-us": { "role": { "label": "Common stock, shares issued (in shares)", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": ["r52"] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesOutstanding", "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals"], "lang": { "en-us": { "role": { "label": "Common stock, shares outstanding (in shares)", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": ["r10", "r52", "r442", "r460", "r666", "r667"] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://www.pulsebiosciences.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"], "lang": { "en-us": { "role": { "label": "Common stock, $0.001 par value; authorized \u2013 500,000 shares; issued and outstanding \u2013 61,516 shares and 55,144 shares at September 30, 2024 and December 31, 2023, respectively", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": ["r52", "r394", "r546"] }, "us-gaap_ComprehensiveIncomeNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComprehensiveIncomeNetOfTax", "crdr": "credit", "calculation": { "http://www.pulsebiosciences.com/20240930/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_ComprehensiveIncomeNetOfTax", "totalLabel": "Comprehensive loss", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": ["r17", "r110", "r112", "r116", "r386", "r404", "r405"] }, "us-gaap_ConsolidationPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConsolidationPolicyTextBlock", "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-significant-accounting-policies-policies"], "lang": { "en-us": { "role": { "label": "Consolidation, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary." } } }, "auth_ref": ["r40", "r506"] }, "us-gaap_ConstructionInProgressMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConstructionInProgressMember", "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-note-4-balance-sheet-components-property-and-equipment-net-details"], "lang": { "en-us": { "role": { "label": "Construction in Progress [Member]", "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service." } } }, "auth_ref": [] }, "plse_CorporateHeadquartersInHaywardCaliforniaMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pulsebiosciences.com/20240930", "localname": "CorporateHeadquartersInHaywardCaliforniaMember", "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-note-7-commitments-and-contingencies", "http://www.pulsebiosciences.com/20240930/role/statement-note-7-commitments-and-contingencies-details-textual"], "lang": { "en-us": { "role": { "label": "Corporate Headquarters in Hayward, California [Member]", "documentation": "Represents corporate headquarters located in Hayward, California." } } }, "auth_ref": [] }, "us-gaap_CostsAndExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostsAndExpenses", "crdr": "debit", "calculation": { "http://www.pulsebiosciences.com/20240930/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 0.0 } }, "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited", "http://www.pulsebiosciences.com/20240930/role/statement-note-10-restructuring-charges", "http://www.pulsebiosciences.com/20240930/role/statement-note-10-restructuring-charges-details-textual"], "lang": { "en-us": { "role": { "label": "Costs and Expenses", "totalLabel": "Total cost and expenses", "documentation": "Total costs of sales and operating expenses for the period." } } }, "auth_ref": ["r63"] }, "us-gaap_CostsAndExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostsAndExpensesAbstract", "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited"], "lang": { "en-us": { "role": { "label": "Cost and expenses:" } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CurrentFiscalYearEndDate", "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentAxis", "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation", "http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-details-textual", "http://www.pulsebiosciences.com/20240930/role/statement-note-7-commitments-and-contingencies", "http://www.pulsebiosciences.com/20240930/role/statement-note-7-commitments-and-contingencies-details-textual", "http://www.pulsebiosciences.com/20240930/role/statement-note-9-related-party-transactions", "http://www.pulsebiosciences.com/20240930/role/statement-note-9-related-party-transactions-details-textual"], "lang": { "en-us": { "role": { "label": "Debt Instrument [Axis]", "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities." } } }, "auth_ref": ["r14", "r44", "r45", "r79", "r81", "r122", "r225", "r226", "r227", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r521", "r522", "r523", "r524", "r525", "r544", "r579", "r599", "r600", "r601", "r646", "r647"] }, "us-gaap_DebtInstrumentDecreaseForgiveness": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentDecreaseForgiveness", "crdr": "debit", "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-details-textual", "http://www.pulsebiosciences.com/20240930/role/statement-note-7-commitments-and-contingencies-details-textual", "http://www.pulsebiosciences.com/20240930/role/statement-note-9-related-party-transactions-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_DebtInstrumentDecreaseForgiveness", "terseLabel": "Debt Instrument, Decrease, Forgiveness", "documentation": "Decrease for amounts of indebtedness forgiven by the holder of the debt instrument." } } }, "auth_ref": ["r579"] }, "us-gaap_DebtInstrumentFaceAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentFaceAmount", "crdr": "credit", "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-note-7-commitments-and-contingencies-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_DebtInstrumentFaceAmount", "terseLabel": "Debt Instrument, Face Amount", "documentation": "Face (par) amount of debt instrument at time of issuance." } } }, "auth_ref": ["r225", "r352", "r353", "r522", "r523", "r544"] }, "us-gaap_DebtInstrumentIncreaseAccruedInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentIncreaseAccruedInterest", "crdr": "credit", "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-note-7-commitments-and-contingencies-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_DebtInstrumentIncreaseAccruedInterest", "terseLabel": "Debt Instrument, Increase, Accrued Interest", "documentation": "Increase for accrued, but unpaid interest on the debt instrument for the period." } } }, "auth_ref": ["r579"] }, "us-gaap_DebtInstrumentNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentNameDomain", "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation", "http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-details-textual", "http://www.pulsebiosciences.com/20240930/role/statement-note-7-commitments-and-contingencies", "http://www.pulsebiosciences.com/20240930/role/statement-note-7-commitments-and-contingencies-details-textual", "http://www.pulsebiosciences.com/20240930/role/statement-note-9-related-party-transactions", "http://www.pulsebiosciences.com/20240930/role/statement-note-9-related-party-transactions-details-textual"], "lang": { "en-us": { "role": { "label": "Debt Instrument, Name [Domain]", "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "auth_ref": ["r14", "r122", "r225", "r226", "r227", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r521", "r522", "r523", "r524", "r525", "r544", "r579", "r599", "r600", "r601", "r646", "r647"] }, "plse_DebtInstrumentQuarterlyInterestRate": { "xbrltype": "pureItemType", "nsuri": "http://www.pulsebiosciences.com/20240930", "localname": "DebtInstrumentQuarterlyInterestRate", "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-note-7-commitments-and-contingencies-details-textual"], "lang": { "en-us": { "role": { "label": "plse_DebtInstrumentQuarterlyInterestRate", "terseLabel": "Debt Instrument Quarterly Interest Rate", "documentation": "Debt instrument, quarterly interest rate" } } }, "auth_ref": [] }, "us-gaap_Depreciation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Depreciation", "crdr": "debit", "calculation": { "http://www.pulsebiosciences.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited", "http://www.pulsebiosciences.com/20240930/role/statement-note-4-balance-sheet-components-details-textual"], "lang": { "en-us": { "role": { "label": "Depreciation", "terseLabel": "Depreciation", "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets'

useful lives. Includes production and non-production related depreciation." } } }, "auth_ref": ["r6", "r29"] }, "plse_DirectorsAndOfficersLiabilityInsurancePeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.pulsebiosciences.com/20240930", "localname": "DirectorsAndOfficersLiabilityInsurancePeriod", "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-note-9-related-party-transactions-details-textual"], "lang": { "en-us": { "role": { "label": "plse_DirectorsAndOfficersLiabilityInsurancePeriod", "terseLabel": "Directors and Officers Liability Insurance, Period (Year)", "documentation": "Period of liability insurance for directors and officers." } } }, "auth_ref": [] }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement [Text Block]", "documentation": "The entire disclosure for share-based payment arrangement." } } }, "auth_ref": ["r255", "r257", "r288", "r289", "r290", "r533"] }, "us-gaap_DisclosureTextBlockAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureTextBlockAbstract", "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-note-1-description-of-the-business", "http://www.pulsebiosciences.com/20240930/role/statement-note-10-restructuring-charges", "http://www.pulsebiosciences.com/20240930/role/statement-note-11-subsequent-events", "http://www.pulsebiosciences.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.pulsebiosciences.com/20240930/role/statement-note-3-fair-value-of-financial-instruments", "http://www.pulsebiosciences.com/20240930/role/statement-note-4-balance-sheet-components", "http://www.pulsebiosciences.com/20240930/role/statement-note-5-goodwill", "http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation", "http://www.pulsebiosciences.com/20240930/role/statement-note-7-commitments-and-contingencies", "http://www.pulsebiosciences.com/20240930/role/statement-note-8-segment-reporting", "http://www.pulsebiosciences.com/20240930/role/statement-note-9-related-party-transactions"], "lang": { "en-us": { "role": { "label": "us-gaap_DisclosureTextBlockAbstract", "terseLabel": "Notes to Financial Statements" } } }, "auth_ref": [] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalPeriodFocus", "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalYearFocus", "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentInformationLineItems", "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Document Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_DocumentInformationTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentInformationTable", "lang": { "en-us": { "role": { "label": "Document Information [Table]", "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentQuarterlyReport", "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": ["r562"] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentTransitionReport", "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": ["r563"] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareAbstract", "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited"], "lang": { "en-us": { "role": { "label": "Net loss per share:" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareBasic", "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited"], "lang": { "en-us": { "role": { "label": "Basic and diluted net loss per share (in dollars per share)", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": ["r117", "r128", "r129", "r130", "r131", "r132", "r133", "r137", "r138", "r140", "r141", "r142", "r145", "r306", "r310", "r322", "r323", "r387", "r406", "r507"] }, "us-gaap_EarningsPerSharePolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerSharePolicyTextBlock", "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-significant-accounting-policies-policies"], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements." } } }, "auth_ref": ["r24", "r25", "r144"] }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeRelatedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.pulsebiosciences.com/20240930/role/statement-note-4-balance-sheet-components-accrued-expenses-details": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-note-4-balance-sheet-components-accrued-expenses-details"], "lang": { "en-us": { "role": { "label": "Compensation expense", "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": ["r45"] }, "us-gaap_EmployeeSeveranceMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeSeveranceMember", "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-note-10-restructuring-charges", "http://www.pulsebiosciences.com/20240930/role/statement-note-10-restructuring-charges-details-textual"], "lang": { "en-us": { "role": { "label": "Employee Severance [Member]", "documentation": "Termination of an employee associated with exit from or disposal of business activities or restructurings pursuant to a plan." } } }, "auth_ref": [] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeStockOptionMember", "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies-antidilutive-securities-details", "http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation", "http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-details-textual", "http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-tables"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Option [Member]", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [] }, "plse_EmployeeStokPurchasePlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pulsebiosciences.com/20240930", "localname": "EmployeeStokPurchasePlanMember", "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-stockbased-compensation-expense-by-type-details"], "lang": { "en-us": { "role": { "label": "Employee Stok Purchase Plan [Member]", "documentation": "Represents the employee stock purchase plan" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": ["r560"] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCommonStockSharesOutstanding", "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCurrentReportingStatus", "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityDomain", "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited", "http://www.pulsebiosciences.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals", "http://www.pulsebiosciences.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited", "http://www.pulsebiosciences.com/20240930/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited", "http://www.pulsebiosciences.com/20240930/role/statement-document-and-entity-information", "http://www.pulsebiosciences.com/20240930/role/statement-note-1-description-of-the-business", "http://www.pulsebiosciences.com/20240930/role/statement-note-10-restructuring-charges", "http://www.pulsebiosciences.com/20240930/role/statement-note-10-restructuring-charges-details-textual", "http://www.pulsebiosciences.com/20240930/role/statement-note-11-subsequent-events", "http://www.pulsebiosciences.com/20240930/role/statement-note-11-subsequent-events-details-textual", "http://www.pulsebiosciences.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.pulsebiosciences.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies-antidilutive-securities-details", "http://www.pulsebiosciences.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies-tables", "http://www.pulsebiosciences.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies-warrant-accrual-activity-details", "http://www.pulsebiosciences.com/20240930/role/statement-note-3-fair-value-of-financial-instruments", "http://www.pulsebiosciences.com/20240930/role/statement-note-3-fair-value-of-financial-instruments-details-textual", "http://www.pulsebiosciences.com/20240930/role/statement-note-3-fair-value-of-financial-instruments-tables", "http://www.pulsebiosciences.com/20240930/role/statement-note-3-investments-and-fair-value-of-financial-instruments-financial-assets-measured-on-a-recurring-basis-details", "http://www.pulsebiosciences.com/20240930/role/statement-note-4-balance-sheet-components", "http://www.pulsebiosciences.com/20240930/role/statement-note-4-balance-sheet-components-accrued-expenses-details", "http://www.pulsebiosciences.com/20240930/role/statement-note-4-balance-sheet-components-details-textual", "http://www.pulsebiosciences.com/20240930/role/statement-note-4-balance-sheet-components-intangible-assets-net-details", "http://www.pulsebiosciences.com/20240930/role/statement-note-4-balance-sheet-components-property-and-equipment-net-details", "http://www.pulsebiosciences.com/20240930/role/statement-note-4-balance-sheet-components-schedule-of-amortization-of-intangible-assets-details", "http://www.pulsebiosciences.com/20240930/role/statement-note-4-balance-sheet-components-tables", "http://www.pulsebiosciences.com/20240930/role/statement-note-5-goodwill", "http://www.pulsebiosciences.com/20240930/role/statement-note-5-goodwill-details-textual", "http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation", "http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-details-textual", "http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-espp-assumptions-details", "http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-option-assumptions-details", "http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-stockbased-compensation-expense-by-recorded-location-details", "http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-stockbased-compensation-expense-by-type-details", "http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-summary-of-marketbased-option-activity-details", "http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-summary-of-performance-option-activity-details", "http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-summary-of-stock-option-activity-details", "http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-summary-of-timebased-option-activity-details", "http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-tables", "http://www.pulsebiosciences.com/20240930/role/statement-note-7-commitments-and-contingencies", "http://www.pulsebiosciences.com/20240930/role/statement-note-7-commitments-and-contingencies-details-textual", "http://www.pulsebiosciences.com/20240930/role/statement-note-7-commitments-and-contingencies-information-related-to-rightofuse-assets-and-lease-liabilities-details", "http://www.pulsebiosciences.com/20240930/role/statement-note-7-commitments-and-contingencies-tables", "http://www.pulsebiosciences.com/20240930/role/statement-note-8-segment-

reporting", "http://www.pulsebiosciences.com/20240930/role/statement-note-8-segment-reporting-details-textual", "http://www.pulsebiosciences.com/20240930/role/statement-note-9-related-party-transactions", "http://www.pulsebiosciences.com/20240930/role/statement-note-9-related-party-transactions-details-textual", "http://www.pulsebiosciences.com/20240930/role/statement-significant-accounting-policies-policies"], "lang": { "en-us": { "role": { "label": "Entity [Domain]", "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": ["r560"] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilerCategory", "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": ["r560"] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInteractiveDataCurrent", "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": ["r566"] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": ["r560"] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityShellCompany", "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": ["r560"] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntitySmallBusiness", "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": ["r560"] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": ["r560"] }, "plse_EquipmentPurchasesIncludedInAccountsPayableAndAccruedExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://www.pulsebiosciences.com/20240930", "localname": "EquipmentPurchasesIncludedInAccountsPayableAndAccruedExpenses", "crdr": "credit", "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "Equipment purchases included in accounts payable and accrued expenses", "documentation": "Amount of equipment purchases included in accounts payable and accrued expenses." } } }, "auth_ref": [] }, "plse_EquityClassifiedSubscriptionValue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.pulsebiosciences.com/20240930", "localname": "EquityClassifiedSubscriptionValue", "crdr": "credit", "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-condensed-consolidated-statements-of-stockholders-equity-deficit-unaudited", "http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-details-textual"], "lang": { "en-us": { "role": { "label": "Issuance of equity-classified subscription rights as part of rights offering (Note 6)", "terseLabel": "Equity Classified Subscription, Value", "documentation": "The value of Equity classified subscriptions." } } }, "auth_ref": [] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityComponentDomain", "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-condensed-consolidated-statements-of-stockholders-equity-deficit-unaudited"], "lang": { "en-us": { "role": { "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": ["r10", "r96", "r113", "r114", "r115", "r123", "r124", "r125", "r127", "r132", "r134", "r136", "r147", "r174", "r175", "r196", "r243", "r300", "r301", "r303", "r304", "r305", "r307", "r309", "r310", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r344", "r345", "r346", "r347", "r348", "r349", "r354", "r355", "r365", "r403", "r412", "r413", "r414", "r427", "r482"] }, "plse_EquityOfferingUnitsMaximumAmountAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://www.pulsebiosciences.com/20240930", "localname": "EquityOfferingUnitsMaximumAmountAuthorized", "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-details-textual"], "lang": { "en-us": { "role": { "label": "plse_EquityOfferingUnitsMaximumAmountAuthorized", "terseLabel": "Equity Offering, Units, Maximum Amount Authorized (in shares)", "documentation": "Maximum amount authorized for units issued under equity offering." } } }, "auth_ref": [] }, "plse_EquityOfferingUnitsOfferingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.pulsebiosciences.com/20240930", "localname": "EquityOfferingUnitsOfferingValue", "crdr": "credit", "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-details-textual"], "lang": { "en-us": { "role": { "label": "plse_EquityOfferingUnitsOfferingValue", "terseLabel": "Equity Offering, Units, Offering Value", "documentation": "The total cost of the Equity offering of warrants and rights." } } }, "auth_ref": [] }, "plse_EquityOfferingUnitsSaleOfUnits": { "xbrltype": "sharesItemType", "nsuri": "http://www.pulsebiosciences.com/20240930", "localname": "EquityOfferingUnitsSaleOfUnits", "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-details-textual"], "lang": { "en-us": { "role": { "label": "plse_EquityOfferingUnitsSaleOfUnits", "terseLabel": "Equity Offering, Units, Sale of Units (in shares)", "documentation": "Total units issued during the year." } } }, "auth_ref": [] }, "plse_ExpansionPremises1Member": { "xbrltype": "domainItemType", "nsuri": "http://www.pulsebiosciences.com/20240930", "localname": "ExpansionPremises1Member", "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-note-7-commitments-and-contingencies", "http://www.pulsebiosciences.com/20240930/role/statement-note-7-commitments-and-contingencies-details-textual"], "lang": { "en-us": { "role": { "label": "Expansion Premises 1 [Member]", "documentation": "Represents Expansion Premises 1." } } }, "auth_ref": [] }, "plse_ExpansionPremises2Member": { "xbrltype": "domainItemType", "nsuri": "http://www.pulsebiosciences.com/20240930", "localname": "ExpansionPremises2Member", "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-note-7-commitments-and-contingencies", "http://www.pulsebiosciences.com/20240930/role/statement-note-7-commitments-and-contingencies-details-textual"], "lang": { "en-us": { "role": { "label": "Expansion Premises 2 [Member]", "documentation": "Represents Expansion Premises 2." } } }, "auth_ref": [] }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock", "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-note-3-fair-value-of-financial-instruments-tables"], "lang": { "en-us": { "role": { "label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]", "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)." } } }, "auth_ref": ["r640", "r641"] }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByFairValueHierarchyLevelAxis", "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-note-3-investments-and-fair-value-of-financial-instruments-financial-assets-measured-on-a-recurring-basis-details"], "lang": { "en-us": { "role": { "label": "Fair Value Hierarchy and NAV [Axis]", "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient." } } }, "auth_ref": ["r233", "r247", "r248", "r249", "r250", "r251", "r252", "r324", "r326", "r327", "r328", "r329", "r335", "r336", "r338", "r375", "r376", "r377", "r522", "r523", "r527", "r528", "r529", "r537", "r540"] }, "us-gaap_FairValueDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueDisclosuresTextBlock", "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-note-3-fair-value-of-financial-instruments"], "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Text Block]", "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information." } } }, "auth_ref": ["r331", "r333", "r334", "r335", "r338", "r339", "r340", "r341", "r342", "r384", "r537", "r541"] }, "us-gaap_FairValueInputsLevel1Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel1Member", "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-note-3-investments-and-fair-value-of-financial-instruments-financial-assets-measured-on-a-recurring-basis-details"], "lang": { "en-us": { "role": { "label": "Fair Value, Inputs, Level 1 [Member]", "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date." } } }, "auth_ref": ["r233", "r247", "r252", "r326", "r336", "r375", "r527", "r528", "r529", "r537"] }, "us-gaap_FairValueInputsLevel2Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel2Member", "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-note-3-investments-and-fair-value-of-financial-instruments-financial-assets-measured-on-a-recurring-basis-details"], "lang": { "en-us": { "role": { "label": "Fair Value, Inputs, Level 2 [Member]", "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets." } } }, "auth_ref": ["r233", "r247", "r252", "r326", "r327", "r336", "r376", "r522", "r523", "r527", "r528", "r529", "r537"] }, "us-gaap_FairValueInputsLevel3Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel3Member", "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-note-3-investments-and-fair-value-of-financial-instruments-financial-assets-measured-on-a-recurring-basis-details"], "lang": { "en-us": { "role": { "label": "Fair Value, Inputs, Level 3 [Member]", "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": ["r233", "r247", "r248", "r249", "r250", "r251", "r252", "r326", "r327", "r328", "r329", "r336", "r377", "r522", "r523", "r527", "r528", "r529", "r537", "r540"] }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementsFairValueHierarchyDomain", "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-note-3-investments-and-fair-value-of-financial-instruments-financial-assets-measured-on-a-recurring-basis-details"], "lang": { "en-us": { "role": { "label": "Fair Value Hierarchy and NAV [Domain]", "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "auth_ref": ["r233", "r247", "r248", "r249", "r250", "r251", "r252", "r324", "r326", "r327", "r328", "r329", "r335", "r336", "r338", "r375", "r376", "r377", "r522", "r523", "r527", "r528", "r529", "r537", "r540"] }, "us-gaap_FiniteLivedIntangibleAssetUsefulLife": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetUsefulLife", "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-note-4-balance-sheet-components-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_FiniteLivedIntangibleAssetUsefulLife", "terseLabel": "Finite-Lived Intangible Asset, Useful Life (Year)", "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "crdr": "credit", "calculation": { "http://www.pulsebiosciences.com/20240930/role/statement-note-4-balance-sheet-components-intangible-assets-net-details": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": -1.0, "order": 0.0 } }, "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-note-4-balance-sheet-components-intangible-assets-net-details"], "lang": { "en-us": { "role": { "label": "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization", "negatedLabel": "Less: Accumulated amortization", "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": ["r104", "r176", "r191", "r520"] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "crdr": "debit", "calculation": { "http://www.pulsebiosciences.com/20240930/role/statement-note-4-balance-sheet-components-schedule-of-amortization-of-intangible-assets-details": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 0.0 } }, "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-note-4-balance-sheet-components-schedule-of-amortization-of-intangible-assets-details"], "lang": { "en-us": { "role": { "label": "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "terseLabel": "2025", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r193", "r504", "r520"] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "crdr": "debit", "calculation": { "http://www.pulsebiosciences.com/20240930/role/statement-note-4-balance-sheet-components-schedule-of-amortization-of-intangible-assets-details": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-note-4-balance-sheet-components-schedule-of-amortization-of-intangible-assets-details"], "lang": { "en-us": { "role": { "label": "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "terseLabel": "2024 (remaining 3 months)", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in

remainder of current fiscal year." } } }, "auth_ref": ["r676"] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "crdr": "debit", "calculation": { "http://www.pulsebiosciences.com/20240930/role/statement-note-4-balance-sheet-components-schedule-of-amortization-of-intangible-assets-details": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-note-4-balance-sheet-components-schedule-of-amortization-of-intangible-assets-details"], "lang": { "en-us": { "role": { "label": "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "terseLabel": "2026", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r193", "r504", "r520"] }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-note-4-balance-sheet-components-intangible-assets-net-details"], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "documentation": "Information by major type or class of finite-lived intangible assets." } } }, "auth_ref": ["r184", "r186", "r187", "r188", "r190", "r191", "r194", "r195", "r382", "r383", "r504"] }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsGross", "crdr": "debit", "calculation": { "http://www.pulsebiosciences.com/20240930/role/statement-note-4-balance-sheet-components-intangible-assets-net-details": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-note-4-balance-sheet-components-intangible-assets-net-details"], "lang": { "en-us": { "role": { "label": "Acquired patents and licenses", "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": ["r176", "r191", "r383", "r520"] }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-note-4-balance-sheet-components-intangible-assets-net-details"], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company." } } }, "auth_ref": ["r184", "r186", "r187", "r188", "r190", "r191", "r194", "r195", "r504"] }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsNet", "crdr": "debit", "calculation": { "http://www.pulsebiosciences.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 5.0 }, "http://www.pulsebiosciences.com/20240930/role/statement-note-4-balance-sheet-components-schedule-of-amortization-of-intangible-assets-details": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://www.pulsebiosciences.com/20240930/role/statement-note-4-balance-sheet-components-intangible-assets-net-details": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited", "http://www.pulsebiosciences.com/20240930/role/statement-note-4-balance-sheet-components-intangible-assets-net-details", "http://www.pulsebiosciences.com/20240930/role/statement-note-4-balance-sheet-components-schedule-of-amortization-of-intangible-assets-details"], "lang": { "en-us": { "role": { "label": "Intangible assets, net", "totalLabel": "Total", "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": ["r382", "r596"] }, "us-gaap_FurnitureAndFixturesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FurnitureAndFixturesMember", "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-note-4-balance-sheet-components-property-and-equipment-net-details"], "lang": { "en-us": { "role": { "label": "Furniture and Fixtures [Member]", "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases." } } }, "auth_ref": [] }, "us-gaap_GeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://www.pulsebiosciences.com/20240930/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited"], "lang": { "en-us": { "role": { "label": "General and administrative", "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line." } } }, "auth_ref": ["r61", "r464"] }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GeneralAndAdministrativeExpenseMember", "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-stockbased-compensation-expense-by-recorded-location-details"], "lang": { "en-us": { "role": { "label": "General and Administrative Expense [Member]", "documentation": "Primary financial statement caption encompassing general and administrative expense." } } }, "auth_ref": ["r61"] }, "us-gaap_Goodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Goodwill", "crdr": "debit", "calculation": { "http://www.pulsebiosciences.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 9.0 } }, "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited", "http://www.pulsebiosciences.com/20240930/role/statement-note-5-goodwill-details-textual"], "lang": { "en-us": { "role": { "label": "Goodwill", "terseLabel": "Goodwill, Ending Balance", "documentation": "Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized." } } }, "auth_ref": ["r103", "r178", "r385", "r514", "r519", "r538", "r546", "r593", "r594"] }, "us-gaap_GoodwillDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillDisclosureTextBlock", "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-note-5-goodwill"], "lang": { "en-us": { "role": { "label": "Goodwill Disclosure [Text Block]", "documentation": "The entire disclosure for goodwill." } } }, "auth_ref": ["r177", "r180", "r182", "r519"] }, "us-gaap_GoodwillImpairmentLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillImpairmentLoss", "crdr": "debit", "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-note-5-goodwill-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_GoodwillImpairmentLoss", "terseLabel": "Goodwill, Impairment Loss", "documentation": "Amount of impairment loss from asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized." } } }, "auth_ref": ["r6", "r179", "r181", "r183", "r519", "r538"] }, "plse_ImpairmentOfMarketableSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.pulsebiosciences.com/20240930", "localname": "ImpairmentOfMarketableSecurities", "crdr": "debit", "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-note-3-fair-value-of-financial-instruments-details-textual"], "lang": { "en-us": { "role": { "label": "plse_ImpairmentOfMarketableSecurities", "terseLabel": "Impairment of Marketable Securities", "documentation": "Amount of impairment of marketable securities." } } }, "auth_ref": [] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "crdr": "credit", "calculation": { "http://www.pulsebiosciences.com/20240930/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 0.0 } }, "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "totalLabel": "Loss from operations, before income taxes", "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest." } } }, "auth_ref": ["r59", "r84", "r88", "r388", "r401", "r509", "r513", "r585", "r587", "r588", "r589", "r590"] }, "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest", "crdr": "credit", "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-note-10-restructuring-charges", "http://www.pulsebiosciences.com/20240930/role/statement-note-10-restructuring-charges-details-textual"], "lang": { "en-us": { "role": { "label": "Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest", "documentation": "Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest." } } }, "auth_ref": ["r77", "r88", "r121", "r126", "r132", "r173", "r216", "r217", "r218", "r219", "r220", "r221", "r222", "r223", "r224", "r306", "r310", "r323", "r343", "r401", "r509", "r585", "r587", "r588", "r589", "r590", "r609"] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementAbstract", "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-note-10-restructuring-charges", "http://www.pulsebiosciences.com/20240930/role/statement-note-10-restructuring-charges-details-textual"], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeStatementLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationAxis", "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-stockbased-compensation-expense-by-recorded-location-details"], "lang": { "en-us": { "role": { "label": "Statement of Income Location, Balance [Axis]", "documentation": "Information by location in statement of income where disaggregated amount has been reported." } } }, "auth_ref": ["r197", "r198", "r203", "r330", "r332", "r337", "r409", "r411", "r467", "r504", "r539", "r663"] }, "us-gaap_IncomeStatementLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationDomain", "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-stockbased-compensation-expense-by-recorded-location-details"], "lang": { "en-us": { "role": { "label": "Statement of Income Location, Balance [Domain]", "documentation": "Location in statement of income where disaggregated amount has been reported." } } }, "auth_ref": ["r198", "r203", "r330", "r332", "r337", "r409", "r411", "r467", "r504", "r539", "r663"] }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.pulsebiosciences.com/20240930/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited": { "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0, "order": 1.0 } }, "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_IncomeTaxExpenseBenefit", "negatedLabel": "Income tax benefit", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": ["r90", "r95", "r135", "r136", "r146", "r156", "r165", "r298", "r299", "r302", "r407", "r536"] }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsPayable", "crdr": "debit", "calculation": { "http://www.pulsebiosciences.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_IncreaseDecreaseInAccountsPayable", "terseLabel": "Accounts payable", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business." } } }, "auth_ref": ["r5"] }, "us-gaap_IncreaseDecreaseInAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccruedLiabilities", "crdr": "debit", "calculation": { "http://www.pulsebiosciences.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_IncreaseDecreaseInAccruedLiabilities", "terseLabel": "Accrued expenses", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid." } } }, "auth_ref": ["r5"] }, "us-gaap_IncreaseDecreaseInNotesPayableRelatedParties": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInNotesPayableRelatedParties", "crdr": "debit", "calculation": { "http://www.pulsebiosciences.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 8.0 } }, "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "Accrued interest on related party note payable", "documentation": "The increase (decrease) during the reporting period in the amount owed by the reporting entity in the form of loans and obligations (generally evidenced by promissory notes) made by the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management, an entity and its principal owners, management, or member of their immediate families, affiliates, or other parties with the ability to exert significant influence." } } }, "auth_ref": ["r5"] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "Changes in operating assets and liabilities:" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOperatingLeaseLiability", "crdr": "debit", "calculation": { "http://www.pulsebiosciences.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 6.0 } }, "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "Lease liabilities", "documentation": "Amount of increase (decrease) in obligation for operating lease." } } }, "auth_ref": ["r570", "r578"] }, "plse_IncreaseDecreaseInOperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://www.pulsebiosciences.com/20240930", "localname": "IncreaseDecreaseInOperatingLeaseRightOfUseAsset", "crdr": "credit", "calculation": { "http://www.pulsebiosciences.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 0.0 } }, "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "plse_IncreaseDecreaseInOperatingLeaseRightOfUseAsset", "negatedLabel": "Right-of-use assets", "documentation": "Amount of increase (decrease) in operating lease right of use asset." } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInOtherReceivables": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOtherReceivables", "crdr": "credit", "calculation": { "http://www.pulsebiosciences.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 10.0 } }, "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_IncreaseDecreaseInOtherReceivables", "negatedLabel": "Other receivables", "documentation": "Amount of increase (decrease) in receivables classified as other." } } }, "auth_ref": ["r5"] }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "crdr": "credit", "calculation": { "http://www.pulsebiosciences.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 9.0 } }, "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "negatedLabel": "Prepaid expenses and other current assets", "documentation": "Amount of increase (decrease) in prepaid

expenses, and assets classified as other." } } }, "auth_ref": ["r5"] }, "plse_IncreaseInSharesAvailableForIssuanceThresholdOfCommonStockOutstandingNumberOfShares": { "xbrltype": "sharesItemType", "nsuri": "http://www.pulsebiosciences.com/20240930", "localname": "IncreaseInSharesAvailableForIssuanceThresholdOfCommonStockOutstandingNumberOfShares", "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-details-textual"], "lang": { "en-us": { "role": { "label": "plse_IncreaseInSharesAvailableForIssuanceThresholdOfCommonStockOutstandingNumberOfShares", "terseLabel": "Increase in Shares Available for Issuance, Threshold of Common Stock Outstanding, Number of Shares (in shares)", "documentation": "The number of shares threshold for increase in shares available for issuance." } } } }, "auth_ref": [] }, "plse_IncreaseInSharesAvailableForIssuanceThresholdOfCommonStockOutstandingPercent": { "xbrltype": "percentItemType", "nsuri": "http://www.pulsebiosciences.com/20240930", "localname": "IncreaseInSharesAvailableForIssuanceThresholdOfCommonStockOutstandingPercent", "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-details-textual"], "lang": { "en-us": { "role": { "label": "plse_IncreaseInSharesAvailableForIssuanceThresholdOfCommonStockOutstandingPercent", "terseLabel": "Increase in Shares Available for Issuance, Threshold of Common Stock Outstanding, Percent", "documentation": "Percentage of threshold of common stock outstanding for increase in shares available for issuance." } } }, "auth_ref": [] }, "ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingArrLineItems", "auth_ref": ["r564"] }, "us-gaap_InterestExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestExpense", "crdr": "debit", "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-note-7-commitments-and-contingencies-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_InterestExpense", "terseLabel": "Interest Expense", "documentation": "Amount of interest expense classified as operating and nonoperating. Includes, but is not limited to, cost of borrowing accounted for as interest expense." } } }, "auth_ref": ["r146", "r152", "r155", "r157", "r165", "r351", "r513", "r514"] }, "us-gaap_InterestIncomeExpenseNonoperatingNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestIncomeExpenseNonoperatingNet", "crdr": "credit", "calculation": { "http://www.pulsebiosciences.com/20240930/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 0.0 } }, "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited"], "lang": { "en-us": { "role": { "label": "Interest income, net", "documentation": "Amount of interest income (expense) classified as nonoperating." } } }, "auth_ref": ["r513", "r576", "r587"] }, "us-gaap_InterestPayableCurrentAndNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestPayableCurrentAndNoncurrent", "crdr": "credit", "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-note-7-commitments-and-contingencies-details-textual", "http://www.pulsebiosciences.com/20240930/role/statement-note-9-related-party-transactions-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_InterestPayableCurrentAndNoncurrent", "terseLabel": "Interest Payable", "documentation": "Amount of interest payable on debt, including, but not limited to, trade payables." } } }, "auth_ref": ["r80", "r662"] }, "us-gaap_InvestmentOwnedPercentOfNetAssets": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentOwnedPercentOfNetAssets", "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_InvestmentOwnedPercentOfNetAssets", "terseLabel": "Investment Owned, Percent of Net Assets", "documentation": "Percentage of investment owned to net assets." } } }, "auth_ref": ["r429", "r430", "r431", "r489", "r493", "r494", "r495", "r497", "r550", "r665"] }, "plse_IssuanceCostsIncurredInNoncashOrPartNoncashTransaction": { "xbrltype": "monetaryItemType", "nsuri": "http://www.pulsebiosciences.com/20240930", "localname": "IssuanceCostsIncurredInNoncashOrPartNoncashTransaction", "crdr": "debit", "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "Rights offering and at-the-market issuance costs in accounts payable", "documentation": "The amount of issuance costs that were incurred during a noncash or partial noncash transaction." } } }, "auth_ref": [] }, "plse_LaboratoryEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pulsebiosciences.com/20240930", "localname": "LaboratoryEquipmentMember", "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-note-4-balance-sheet-components-property-and-equipment-net-details"], "lang": { "en-us": { "role": { "label": "Laboratory Equipment [Member]", "documentation": "Represents laboratory equipment." } } }, "auth_ref": [] }, "us-gaap_LeaseContractualTermAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseContractualTermAxis", "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-note-7-commitments-and-contingencies", "http://www.pulsebiosciences.com/20240930/role/statement-note-7-commitments-and-contingencies-details-textual"], "lang": { "en-us": { "role": { "label": "Lease Contractual Term [Axis]", "documentation": "Information by contractual term of lease arrangement." } } }, "auth_ref": ["r364", "r569"] }, "us-gaap_LeaseContractualTermDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseContractualTermDomain", "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-note-7-commitments-and-contingencies", "http://www.pulsebiosciences.com/20240930/role/statement-note-7-commitments-and-contingencies-details-textual"], "lang": { "en-us": { "role": { "label": "Lease Contractual Term [Domain]", "documentation": "Contractual term of lease arrangement." } } }, "auth_ref": ["r364", "r569"] }, "us-gaap_LeaseholdImprovementsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseholdImprovementsMember", "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-note-4-balance-sheet-components-property-and-equipment-net-details"], "lang": { "en-us": { "role": { "label": "Leasehold Improvements [Member]", "documentation": "Additions or improvements to assets held under a lease arrangement." } } }, "auth_ref": ["r70", "r363"] }, "dei_LegalEntityAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LegalEntityAxis", "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited", "http://www.pulsebiosciences.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals", "http://www.pulsebiosciences.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited", "http://www.pulsebiosciences.com/20240930/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited", "http://www.pulsebiosciences.com/20240930/role/statement-document-and-entity-information", "http://www.pulsebiosciences.com/20240930/role/statement-note-1-description-of-the-business", "http://www.pulsebiosciences.com/20240930/role/statement-note-10-restructuring-charges", "http://www.pulsebiosciences.com/20240930/role/statement-note-10-restructuring-charges-details-textual", "http://www.pulsebiosciences.com/20240930/role/statement-note-11-subsequent-events", "http://www.pulsebiosciences.com/20240930/role/statement-note-11-subsequent-events-details-textual", "http://www.pulsebiosciences.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.pulsebiosciences.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies-antidilutive-securities-details", "http://www.pulsebiosciences.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies-tables", "http://www.pulsebiosciences.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies-warrant-accrual-activity-details", "http://www.pulsebiosciences.com/20240930/role/statement-note-3-fair-value-of-financial-instruments", "http://www.pulsebiosciences.com/20240930/role/statement-note-3-fair-value-of-financial-instruments-details-textual", "http://www.pulsebiosciences.com/20240930/role/statement-note-3-fair-value-of-financial-instruments-tables", "http://www.pulsebiosciences.com/20240930/role/statement-note-3-investments-and-fair-value-of-financial-instruments-financial-assets-measured-on-a-recurring-basis-details", "http://www.pulsebiosciences.com/20240930/role/statement-note-4-balance-sheet-components", "http://www.pulsebiosciences.com/20240930/role/statement-note-4-balance-sheet-components-accrued-expenses-details", "http://www.pulsebiosciences.com/20240930/role/statement-note-4-balance-sheet-components-details-textual", "http://www.pulsebiosciences.com/20240930/role/statement-note-4-balance-sheet-components-intangible-assets-net-details", "http://www.pulsebiosciences.com/20240930/role/statement-note-4-balance-sheet-components-property-and-equipment-net-details", "http://www.pulsebiosciences.com/20240930/role/statement-note-4-balance-sheet-components-schedule-of-amortization-of-intangible-assets-details", "http://www.pulsebiosciences.com/20240930/role/statement-note-4-balance-sheet-components-tables", "http://www.pulsebiosciences.com/20240930/role/statement-note-5-goodwill", "http://www.pulsebiosciences.com/20240930/role/statement-note-5-goodwill-details-textual", "http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation", "http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-details-textual", "http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-espp-assumptions-details", "http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-option-assumptions-details", "http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-stockbased-compensation-expense-by-recorded-location-details", "http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-stockbased-compensation-expense-by-type-details", "http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-summary-of-marketbased-option-activity-details", "http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-summary-of-performance-option-activity-details", "http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-summary-of-stock-option-activity-details", "http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-summary-of-timebased-option-activity-details", "http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-tables", "http://www.pulsebiosciences.com/20240930/role/statement-note-7-commitments-and-contingencies", "http://www.pulsebiosciences.com/20240930/role/statement-note-7-commitments-and-contingencies-details-textual", "http://www.pulsebiosciences.com/20240930/role/statement-note-7-commitments-and-contingencies-information-related-to-rightofuse-assets-and-lease-liabilities-details", "http://www.pulsebiosciences.com/20240930/role/statement-note-7-commitments-and-contingencies-tables", "http://www.pulsebiosciences.com/20240930/role/statement-note-8-segment-reporting", "http://www.pulsebiosciences.com/20240930/role/statement-note-8-segment-reporting-details-textual", "http://www.pulsebiosciences.com/20240930/role/statement-note-9-related-party-transactions", "http://www.pulsebiosciences.com/20240930/role/statement-note-9-related-party-transactions-details-textual", "http://www.pulsebiosciences.com/20240930/role/statement-significant-accounting-policies-policies"], "lang": { "en-us": { "role": { "label": "Legal Entity [Axis]", "documentation": "The set of legal entities associated with a report." } } }, "auth_ref": [] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "crdr": "credit", "calculation": { "http://www.pulsebiosciences.com/20240930/role/statement-note-7-commitments-and-contingencies-information-related-to-rightofuse-assets-and-lease-liabilities-details": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-note-7-commitments-and-contingencies-information-related-to-rightofuse-assets-and-lease-liabilities-details"], "lang": { "en-us": { "role": { "label": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "totalLabel": "Total lease payments", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease." } } }, "auth_ref": ["r362"] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "crdr": "credit", "calculation": { "http://www.pulsebiosciences.com/20240930/role/statement-note-7-commitments-and-contingencies-information-related-to-rightofuse-assets-and-lease-liabilities-details": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-note-7-commitments-and-contingencies-information-related-to-rightofuse-assets-and-lease-liabilities-details"], "lang": { "en-us": { "role": { "label": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "terseLabel": "2025", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r362"] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "crdr": "credit", "calculation": { "http://www.pulsebiosciences.com/20240930/role/statement-note-7-commitments-and-contingencies-information-related-to-rightofuse-assets-and-lease-liabilities-details": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-note-7-commitments-and-contingencies-information-related-to-rightofuse-assets-and-lease-liabilities-details"], "lang": { "en-us": { "role": { "label": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "terseLabel": "2027", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r362"] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "crdr": "credit", "calculation": { "http://www.pulsebiosciences.com/20240930/role/statement-note-7-commitments-and-contingencies-information-related-to-rightofuse-assets-and-lease-liabilities-details": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 4.0 } }, "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-note-7-commitments-and-contingencies-information-related-to-rightofuse-assets-and-lease-liabilities-details"], "lang": { "en-us": { "role": { "label": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "terseLabel": "2026", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r362"] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "crdr": "credit", "calculation": { "http://www.pulsebiosciences.com/20240930/role/statement-note-7-commitments-and-contingencies-information-related-to-rightofuse-assets-and-lease-liabilities-details": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-note-7-commitments-and-contingencies-information-related-to-rightofuse-assets-and-lease-liabilities-details"], "lang": { "en-us": { "role": { "label": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "terseLabel": "2024 (remaining 3 months)", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year." } } }, "auth_ref": ["r650"] }, "plse_LesseeOperatingLeaseLiabilityToBePaidAfterYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://www.pulsebiosciences.com/20240930", "localname": "LesseeOperatingLeaseLiabilityToBePaidAfterYearThree", "crdr": "credit", "calculation": { "http://www.pulsebiosciences.com/20240930/role/statement-note-7-commitments-and-contingencies-information-related-to-rightofuse-assets-and-lease-liabilities-details": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 0.0 } }, "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-note-7-commitments-and-contingencies-information-related-to-rightofuse-assets-and-lease-liabilities-details"], "lang": { "en-us": { "role": { "label": "plse_LesseeOperatingLeaseLiabilityToBePaidAfterYearThree", "terseLabel": "Thereafter", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [] }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "crdr": "credit", "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-note-7-commitments-and-contingencies-information-related-to-rightofuse-assets-and-lease-liabilities-details"], "lang": { "en-us": { "role": { "label": "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "negatedLabel": "Less imputed interest", "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease." } } }, "auth_ref": ["r362"] }, "us-gaap_LesseeOperatingLeaseTermOfContract": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseTermOfContract", "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-note-7-commitments-and-contingencies-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_LesseeOperatingLeaseTermOfContract", "terseLabel": "Lessee, Operating Lease, Term of Contract (Year)", "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen

```
days." } } }, "auth_ref": [ "r649" ] }, "plse_LetterAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pulsebiosciences.com/20240930", "localname": "LetterAgreementMember", "presentation": [ "http://www.pulsebiosciences.com/20240930/role/statement-note-9-related-party-transactions", "http://www.pulsebiosciences.com/20240930/role/statement-note-9-related-party-transactions-details-textual" ], "lang": { "en-us": { "role": { "label": "Letter Agreement [Member]", "documentation": "Represents Letter Agreement." } } }, "auth_ref": [] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Liabilities", "crdr": "credit", "calculation": { "http://www.pulsebiosciences.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.pulsebiosciences.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited" ], "lang": { "en-us": { "role": { "label": "us-gaap_Liabilities", "totalLabel": "Total liabilities", "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others." } } }, "auth_ref": [ "r14", "r44", "r45", "r46", "r47", "r48", "r49", "r50", "r121", "r173", "r216", "r217", "r218", "r219", "r220", "r221", "r222", "r223", "r224", "r312", "r313", "r314", "r343", "r440", "r508", "r558", "r609", "r653", "r654" ] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://www.pulsebiosciences.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.pulsebiosciences.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited" ], "lang": { "en-us": { "role": { "label": "us-gaap_LiabilitiesAndStockholdersEquity", "totalLabel": "Total liabilities and stockholders\u2019 equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": [ "r57", "r83", "r397", "r546", "r580", "r592", "r645" ] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.pulsebiosciences.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.pulsebiosciences.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited" ], "lang": { "en-us": { "role": { "label": "us-gaap_LiabilitiesCurrent", "totalLabel": "Total current liabilities", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": [ "r46", "r99", "r121", "r173", "r216", "r217", "r218", "r219", "r220", "r221", "r222", "r223", "r224", "r312", "r313", "r314", "r343", "r546", "r609", "r653", "r654" ] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrentAbstract", "presentation": [ "http://www.pulsebiosciences.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited" ], "lang": { "en-us": { "role": { "label": "Current liabilities:" } } }, "auth_ref": [] }, "plse_LoanAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pulsebiosciences.com/20240930", "localname": "LoanAgreementMember", "presentation": [ "http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation", "http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-details-textual", "http://www.pulsebiosciences.com/20240930/role/statement-note-7-commitments-and-contingencies", "http://www.pulsebiosciences.com/20240930/role/statement-note-7-commitments-and-contingencies-details-textual", "http://www.pulsebiosciences.com/20240930/role/statement-note-9-related-party-transactions", "http://www.pulsebiosciences.com/20240930/role/statement-note-9-related-party-transactions-details-textual" ], "lang": { "en-us": { "role": { "label": "Loan Agreement [Member]", "documentation": "Represents the loan agreement." } } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": [ "http://www.pulsebiosciences.com/20240930/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } } }, "auth_ref": [] }, "plse_MarketbasedOptionsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pulsebiosciences.com/20240930", "localname": "MarketbasedOptionsMember", "presentation": [ "http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation", "http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-details-textual", "http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-option-assumptions-details", "http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-stockbased-compensation-expense-by-type-details", "http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-summary-of-marketbased-option-activity-details", "http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-tables" ], "lang": { "en-us": { "role": { "label": "Market-based Options [Member]", "documentation": "Represents market-based options." } } }, "auth_ref": [] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MaximumMember", "presentation": [ "http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation", "http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-details-textual", "http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-espp-assumptions-details", "http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-option-assumptions-details" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]" } } }, "auth_ref": [ "r211", "r212", "r213", "r214", "r254", "r296", "r329", "r380", "r408", "r410", "r418", "r432", "r433", "r488", "r490", "r491", "r492", "r496", "r502", "r503", "r518", "r526", "r532", "r540", "r541", "r542", "r543", "r547", "r611", "r655", "r656", "r657", "r658", "r659", "r660" ] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MinimumMember", "presentation": [ "http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-espp-assumptions-details", "http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-option-assumptions-details" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]" } } }, "auth_ref": [ "r211", "r212", "r213", "r214", "r254", "r296", "r329", "r380", "r408", "r410", "r418", "r432", "r433", "r488", "r490", "r491", "r492", "r496", "r502", "r503", "r518", "r526", "r532", "r540", "r541", "r542", "r547", "r611", "r655", "r656", "r657", "r658", "r659", "r660" ] }, "us-gaap_MoneyMarketFundsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MoneyMarketFundsMember", "presentation": [ "http://www.pulsebiosciences.com/20240930/role/statement-note-3-investments-and-fair-value-of-financial-instruments-financial-assets-measured-on-a-recurring-basis-details" ], "lang": { "en-us": { "role": { "label": "Money Market Funds [Member]", "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities." } } }, "auth_ref": [ "r612" ] }, "ecd_MtrlTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Material Terms of Trading Arrangement [Text Block]" } } }, "auth_ref": [ "r565" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://www.pulsebiosciences.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.pulsebiosciences.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited" ], "lang": { "en-us": { "role": { "label": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "totalLabel": "Net cash provided by financing activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": [ "r118" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": [ "http://www.pulsebiosciences.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited" ], "lang": { "en-us": { "role": { "label": "Cash flows from financing activities:" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://www.pulsebiosciences.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.pulsebiosciences.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited" ], "lang": { "en-us": { "role": { "label": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "totalLabel": "Net cash used in investing activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": [ "r118" ] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": [ "http://www.pulsebiosciences.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited" ], "lang": { "en-us": { "role": { "label": "Cash flows from investing activities:" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://www.pulsebiosciences.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.pulsebiosciences.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited" ], "lang": { "en-us": { "role": { "label": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "totalLabel": "Net cash used in operating activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": [ "r65", "r66", "r67" ] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://www.pulsebiosciences.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited" ], "lang": { "en-us": { "role": { "label": "Cash flows from operating activities:" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://www.pulsebiosciences.com/20240930/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 0.0 }, "http://www.pulsebiosciences.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.pulsebiosciences.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited", "http://www.pulsebiosciences.com/20240930/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited", "http://www.pulsebiosciences.com/20240930/role/statement-condensed-consolidated-statements-of-stockholders-equity-deficit-unaudited" ], "lang": { "en-us": { "role": { "label": "Net loss", "totalLabel": "Net loss", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": [ "r60", "r67", "r85", "r97", "r109", "r111", "r115", "r121", "r126", "r128", "r129", "r130", "r131", "r132", "r135", "r136", "r139", "r173", "r216", "r217", "r218", "r219", "r220", "r221", "r222", "r223", "r224", "r306", "r310", "r323", "r343", "r402", "r462", "r480", "r481", "r556", "r609" ] }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": [ "http://www.pulsebiosciences.com/20240930/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": [] }, "plse_NextOneToFourYearsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pulsebiosciences.com/20240930", "localname": "NextOneToFourYearsMember", "presentation": [ "http://www.pulsebiosciences.com/20240930/role/statement-note-11-subsequent-events", "http://www.pulsebiosciences.com/20240930/role/statement-note-11-subsequent-events-details-textual" ], "lang": { "en-us": { "role": { "label": "Next One to Four Years [Member]", "documentation": "Related to the next one to four years." } } }, "auth_ref": [] }, "ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "ecd_NonRule10b51ArrAdoptedFlag", "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": [ "r565" ] }, "ecd_NonRule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "ecd_NonRule10b51ArrTrmntdFlag", "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": [ "r565" ] }, "us-gaap_NonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://www.pulsebiosciences.com/20240930/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.pulsebiosciences.com/20240930/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited" ], "lang": { "en-us": { "role": { "label": "us-gaap_NonoperatingIncomeExpense", "totalLabel": "Total other income", "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)." } } }, "auth_ref": [ "r62" ] }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NonoperatingIncomeExpenseAbstract", "presentation": [ "http://www.pulsebiosciences.com/20240930/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited" ], "lang": { "en-us": { "role": { "label": "Other income:" } } }, "auth_ref": [] }, "plse_NoteToFinancialStatementDetailsTextual": { "xbrltype": "stringItemType", "nsuri": "http://www.pulsebiosciences.com/20240930", "localname": "NoteToFinancialStatementDetailsTextual", "lang": { "en-us": { "role": { "label": "Note To Financial Statement Details Textual" } } }, "auth_ref": [] }, "plse_NotesToFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.pulsebiosciences.com/20240930", "localname": "NotesToFinancialStatementsAbstract", "lang": { "en-us": { "role": { "label": "Notes To Financial Statements [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NumberOfBusinessesAcquired": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NumberOfBusinessesAcquired", "presentation": [ "http://www.pulsebiosciences.com/20240930/role/statement-note-5-goodwill-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_NumberOfBusinessesAcquired", "terseLabel": "Number of Businesses Acquired", "documentation": "The number of businesses acquired by the entity during the period." } } }, "auth_ref": [] }, "us-gaap_NumberOfReportableSegments": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NumberOfReportableSegments", "presentation": [ "http://www.pulsebiosciences.com/20240930/role/statement-note-8-segment-reporting-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_NumberOfReportableSegments", "terseLabel": "Number of Reportable Segments", "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements." } } }, "auth_ref": [ "r510", "r517", "r586" ] }, "plse_NumberOfSharesPerUnitIssued": { "xbrltype": "sharesItemType", "nsuri": "http://www.pulsebiosciences.com/20240930", "localname": "NumberOfSharesPerUnitIssued", "presentation": [ "http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-details-textual" ], "lang": { "en-us": { "role": { "label": "plse_NumberOfSharesPerUnitIssued", "terseLabel": "Number of Shares Per Unit Issued (in shares)", "documentation": "Number of shares of stock issued or issuable for each unit." } } },
```

```
"auth_ref": [] }, "plse_NumberOfWarrantsInEachUnit": { "xbrltype": "sharesItemType", "nsuri": "http://www.pulsebiosciences.com/20240930", "localname": "NumberOfWarrantsInEachUnit", "presentation": [ "http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-details-textual" ], "lang": { "en-us": { "role": { "label": "plse_NumberOfWarrantsInEachUnit", "terseLabel": "Number of Warrants in Each Unit (in shares)", "documentation": "Represents number of warrants in each unit." } } }, "auth_ref": [] }, "plse_NumberOfWarrantsPerUnit": { "xbrltype": "sharesItemType", "nsuri": "http://www.pulsebiosciences.com/20240930", "localname": "NumberOfWarrantsPerUnit", "presentation": [ "http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-details-textual" ], "lang": { "en-us": { "role": { "label": "plse_NumberOfWarrantsPerUnit", "terseLabel": "Number of Warrants Per Unit (in shares)", "documentation": "Number of warrants issued or issuable for each unit." } } }, "auth_ref": [] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": { "http://www.pulsebiosciences.com/20240930/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.pulsebiosciences.com/20240930/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited" ], "lang": { "en-us": { "role": { "label": "us-gaap_OperatingIncomeLoss", "totalLabel": "Loss from operations", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": [ "r88", "r509", "r585", "r587", "r588", "r589", "r590" ] }, "us-gaap_OperatingLeaseExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseExpense", "crdr": "debit", "presentation": [ "http://www.pulsebiosciences.com/20240930/role/statement-note-7-commitments-and-contingencies-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_OperatingLeaseExpense", "terseLabel": "Operating Lease, Expense", "documentation": "Amount of operating lease expense. Excludes sublease income." } } }, "auth_ref": [ "r648" ] }, "us-gaap_OperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiability", "crdr": "credit", "presentation": [ "http://www.pulsebiosciences.com/20240930/role/statement-note-7-commitments-and-contingencies-information-related-to-rightofuse-assets-and-lease-liabilities-details" ], "lang": { "en-us": { "role": { "verboseLabel": "Total lease liabilities", "label": "us-gaap_OperatingLeaseLiability", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease." } } }, "auth_ref": [ "r357" ] }, "us-gaap_OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "calculation": { "http://www.pulsebiosciences.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.pulsebiosciences.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited", "http://www.pulsebiosciences.com/20240930/role/statement-note-7-commitments-and-contingencies-information-related-to-rightofuse-assets-and-lease-liabilities-details" ], "lang": { "en-us": { "role": { "verboseLabel": "Current operating lease liabilities", "label": "Lease liability, current", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } }, "auth_ref": [ "r357" ] }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://www.pulsebiosciences.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.pulsebiosciences.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited", "http://www.pulsebiosciences.com/20240930/role/statement-note-7-commitments-and-contingencies-information-related-to-rightofuse-assets-and-lease-liabilities-details" ], "lang": { "en-us": { "role": { "verboseLabel": "Non-current operating lease liabilities", "label": "Lease liability, less current portion", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } }, "auth_ref": [ "r357" ] }, "us-gaap_OperatingLeasePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeasePayments", "crdr": "credit", "presentation": [ "http://www.pulsebiosciences.com/20240930/role/statement-note-7-commitments-and-contingencies-information-related-to-rightofuse-assets-and-lease-liabilities-details" ], "lang": { "en-us": { "role": { "verboseLabel": "Cash paid for operating lease liabilities", "label": "us-gaap_OperatingLeasePayments", "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use." } } }, "auth_ref": [ "r358", "r359" ] }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "calculation": { "http://www.pulsebiosciences.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.pulsebiosciences.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited", "http://www.pulsebiosciences.com/20240930/role/statement-note-7-commitments-and-contingencies-information-related-to-rightofuse-assets-and-lease-liabilities-details" ], "lang": { "en-us": { "role": { "label": "Right-of-use assets", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } } }, "auth_ref": [ "r356" ] }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "presentation": [ "http://www.pulsebiosciences.com/20240930/role/statement-note-7-commitments-and-contingencies-information-related-to-rightofuse-assets-and-lease-liabilities-details" ], "lang": { "en-us": { "role": { "label": "Weighted-average discount rate", "documentation": "Weighted average discount rate for operating lease calculated at point in time." } } }, "auth_ref": [ "r361", "r545" ] }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "presentation": [ "http://www.pulsebiosciences.com/20240930/role/statement-note-7-commitments-and-contingencies-information-related-to-rightofuse-assets-and-lease-liabilities-details" ], "lang": { "en-us": { "role": { "label": "Weighted-average remaining lease term (Year)", "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r360", "r545" ] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "presentation": [ "http://www.pulsebiosciences.com/20240930/role/statement-note-1-description-of-the-business" ], "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]", "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure." } } }, "auth_ref": [ "r42", "r76", "r419", "r420" ] }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.pulsebiosciences.com/20240930/role/statement-note-4-balance-sheet-components-accrued-expenses-details": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.pulsebiosciences.com/20240930/role/statement-note-4-balance-sheet-components-accrued-expenses-details" ], "lang": { "en-us": { "role": { "verboseLabel": "Other", "label": "us-gaap_OtherAccruedLiabilitiesCurrent", "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r45" ] }, "us-gaap_OtherAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAssetsNoncurrent", "crdr": "debit", "calculation": { "http://www.pulsebiosciences.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.pulsebiosciences.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited" ], "lang": { "en-us": { "role": { "label": "Other assets", "documentation": "Amount of noncurrent assets classified as other." } } }, "auth_ref": [ "r105" ] }, "plse_OtherReceivableFromExerciseOfWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://www.pulsebiosciences.com/20240930", "localname": "OtherReceivableFromExerciseOfWarrants", "crdr": "credit", "presentation": [ "http://www.pulsebiosciences.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited" ], "lang": { "en-us": { "role": { "label": "Other receivable from exercises of warrants", "documentation": "The amount of other receivable from exercise of warrants." } } }, "auth_ref": [] }, "us-gaap_PaymentsOfDebtIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsOfDebtIssuanceCosts", "crdr": "credit", "calculation": { "http://www.pulsebiosciences.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://www.pulsebiosciences.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited" ], "lang": { "en-us": { "role": { "label": "us-gaap_PaymentsOfDebtIssuanceCosts", "negatedLabel": "Issuance cost in relation to related party note extinguishment", "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt." } } }, "auth_ref": [ "r19" ] }, "us-gaap_PaymentsOfStockIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsOfStockIssuanceCosts", "crdr": "credit", "calculation": { "http://www.pulsebiosciences.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://www.pulsebiosciences.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited" ], "lang": { "en-us": { "role": { "label": "us-gaap_PaymentsOfStockIssuanceCosts", "negatedLabel": "Deferred issuance costs in relation to future at-the-market equity offering", "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security." } } }, "auth_ref": [ "r18" ] }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://www.pulsebiosciences.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 0.0 } }, "presentation": [ "http://www.pulsebiosciences.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited" ], "lang": { "en-us": { "role": { "label": "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment", "negatedLabel": "Purchases of property and equipment", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } }, "auth_ref": [ "r64" ] }, "plse_PercentOfOfferingPurchased": { "xbrltype": "percentItemType", "nsuri": "http://www.pulsebiosciences.com/20240930", "localname": "PercentOfOfferingPurchased", "presentation": [ "http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-details-textual" ], "lang": { "en-us": { "role": { "label": "plse_PercentOfOfferingPurchased", "terseLabel": "Percent of Offering Purchased", "documentation": "The percent of an offering purchased." } } }, "auth_ref": [] }, "plse_PerformanceOptionsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pulsebiosciences.com/20240930", "localname": "PerformanceOptionsMember", "presentation": [ "http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-summary-of-performance-option-activity-details", "http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-tables" ], "lang": { "en-us": { "role": { "label": "Performance Options [Member]", "documentation": "Represents performance options." } } }, "auth_ref": [] }, "plse_PerformancebasedOptionsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pulsebiosciences.com/20240930", "localname": "PerformancebasedOptionsMember", "presentation": [ "http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation", "http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-details-textual", "http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-stockbased-compensation-expense-by-type-details" ], "lang": { "en-us": { "role": { "label": "Performance-based Options [Member]", "documentation": "Represents performance based options." } } }, "auth_ref": [] }, "us-gaap_PlanNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PlanNameAxis", "presentation": [ "http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation", "http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-details-textual", "http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-espp-assumptions-details", "http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-summary-of-stock-option-activity-details", "http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-tables" ], "lang": { "en-us": { "role": { "label": "Plan Name [Axis]", "documentation": "Information by plan name for share-based payment arrangement." } } }, "auth_ref": [ "r613", "r614", "r615", "r616", "r617", "r618", "r619", "r620", "r621", "r622", "r623", "r624", "r625", "r626", "r627", "r628", "r629", "r630", "r631", "r632", "r633", "r634", "r635", "r636", "r637", "r638" ] }, "us-gaap_PlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PlanNameDomain", "presentation": [ "http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation", "http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-details-textual", "http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-espp-assumptions-details", "http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-summary-of-stock-option-activity-details", "http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-tables" ], "lang": { "en-us": { "role": { "label": "Plan Name [Domain]", "documentation": "Plan name for share-based payment arrangement." } } }, "auth_ref": [ "r613", "r614", "r615", "r616", "r617", "r618", "r619", "r620", "r621", "r622", "r623", "r624", "r625", "r626", "r627", "r628", "r629", "r630", "r631", "r632", "r633", "r634", "r635", "r636", "r637", "r638" ] }, "us-gaap_PolicyTextBlockAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PolicyTextBlockAbstract", "presentation": [ "http://www.pulsebiosciences.com/20240930/role/statement-significant-accounting-policies-policies" ], "lang": { "en-us": { "role": { "label": "us-gaap_PolicyTextBlockAbstract", "terseLabel": "Accounting Policies" } } }, "auth_ref": [] }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockParOrStatedValuePerShare", "presentation": [ "http://www.pulsebiosciences.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals" ], "lang": { "en-us": { "role": { "label": "Preferred stock, par value (in dollars per share)", "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer." } } }, "auth_ref": [ "r51", "r241" ] }, "us-gaap_PreferredStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesAuthorized", "presentation": [ "http://www.pulsebiosciences.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals" ], "lang": { "en-us": { "role": { "label": "Preferred stock, shares authorized (in shares)", "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r51", "r442" ] }, "us-gaap_PreferredStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesIssued", "presentation": [ "http://www.pulsebiosciences.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals" ], "lang": { "en-us": { "role": { "label": "Preferred stock, shares issued (in shares)", "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt." } } }, "auth_ref": [ "r51", "r241" ] }, "us-gaap_PreferredStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesOutstanding", "presentation": [ "http://www.pulsebiosciences.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals" ], "lang": { "en-us": { "role": { "label": "Preferred stock, shares outstanding (in shares)", "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased." } } }, "auth_ref": [ "r51", "r442", "r460", "r666", "r667" ] }, "us-gaap_PreferredStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockValue", "crdr": "credit", "calculation": { "http://www.pulsebiosciences.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [
```

```
"http://www.pulsebiosciences.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited" ], "lang": { "en-us": { "role": { "label": "Preferred stock, $0.001 par value; authorized \u2013 50,000 shares; no shares issued and outstanding", "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r51", "r393", "r546" ] }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidExpenseAndOtherAssetsCurrent", "crdr": "debit", "calculation": { "http://www.pulsebiosciences.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.pulsebiosciences.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited" ], "lang": { "en-us": { "role": { "label": "Prepaid expenses and other current assets", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r572" ] }, "us-gaap_PrivatePlacementMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrivatePlacementMember", "presentation": [ "http://www.pulsebiosciences.com/20240930/role/statement-condensed-consolidated-statements-of-stockholders-equity-deficit-unaudited", "http://www.pulsebiosciences.com/20240930/role/statement-condensed-consolidated-statements-of-stockholders-equity-deficit-unaudited-parentheticals", "http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation", "http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-details-textual", "http://www.pulsebiosciences.com/20240930/role/statement-note-7-commitments-and-contingencies", "http://www.pulsebiosciences.com/20240930/role/statement-note-7-commitments-and-contingencies-details-textual", "http://www.pulsebiosciences.com/20240930/role/statement-note-9-related-party-transactions", "http://www.pulsebiosciences.com/20240930/role/statement-note-9-related-party-transactions-details-textual" ], "lang": { "en-us": { "role": { "label": "Private Placement [Member]", "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts," } } }, "auth_ref": [] }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfCommonStock", "crdr": "debit", "presentation": [ "http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_ProceedsFromIssuanceOfCommonStock", "terseLabel": "Proceeds from Issuance of Common Stock", "documentation": "The cash inflow from the additional capital contribution to the entity." } } }, "auth_ref": [ "r4" ] }, "plse_ProceedsFromIssuanceOfCommonStockAndWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://www.pulsebiosciences.com/20240930", "localname": "ProceedsFromIssuanceOfCommonStockAndWarrants", "crdr": "debit", "calculation": { "http://www.pulsebiosciences.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.pulsebiosciences.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited" ], "lang": { "en-us": { "role": { "label": "Proceeds from issuance of common stock and warrants in relation to rights offering, net of issuance costs", "documentation": "The amount of cash inflow from issuance of common stock and warrants." } } }, "auth_ref": [] }, "us-gaap_ProceedsFromStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromStockOptionsExercised", "crdr": "debit", "calculation": { "http://www.pulsebiosciences.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.pulsebiosciences.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited" ], "lang": { "en-us": { "role": { "label": "Proceeds from exercises of stock options", "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement." } } }, "auth_ref": [ "r4", "r13" ] }, "us-gaap_ProceedsFromStockPlans": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromStockPlans", "crdr": "debit", "calculation": { "http://www.pulsebiosciences.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.pulsebiosciences.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited" ], "lang": { "en-us": { "role": { "label": "Proceeds from issuance of common stock under employee stock purchase plan", "documentation": "The cash inflow associated with the amount received from the stock plan during the period." } } }, "auth_ref": [ "r4" ] }, "us-gaap_ProceedsFromWarrantExercises": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromWarrantExercises", "crdr": "debit", "calculation": { "http://www.pulsebiosciences.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.pulsebiosciences.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited", "http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-details-textual" ], "lang": { "en-us": { "role": { "label": "Proceeds from exercises of warrants", "terseLabel": "Proceeds from Warrant Exercises", "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants." } } }, "auth_ref": [ "r577" ] }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentByTypeAxis", "presentation": [ "http://www.pulsebiosciences.com/20240930/role/statement-note-4-balance-sheet-components-property-and-equipment-net-details" ], "lang": { "en-us": { "role": { "label": "Long-Lived Tangible Asset [Axis]", "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale." } } }, "auth_ref": [ "r7", "r363" ] }, "us-gaap_PropertyPlantAndEquipmentGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentGross", "crdr": "debit", "calculation": { "http://www.pulsebiosciences.com/20240930/role/statement-note-4-balance-sheet-components-property-and-equipment-net-details": { "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.pulsebiosciences.com/20240930/role/statement-note-4-balance-sheet-components-property-and-equipment-net-details" ], "lang": { "en-us": { "role": { "label": "Property and equipment, gross", "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r70", "r101", "r400" ] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "calculation": { "http://www.pulsebiosciences.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 4.0 }, "http://www.pulsebiosciences.com/20240930/role/statement-note-4-balance-sheet-components-property-and-equipment-net-details": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.pulsebiosciences.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited", "http://www.pulsebiosciences.com/20240930/role/statement-note-4-balance-sheet-components-property-and-equipment-net-details" ], "lang": { "en-us": { "role": { "label": "Property and equipment, net", "totalLabel": "Total property and equipment, net", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r7", "r363", "r389", "r400", "r546" ] }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentTextBlock", "presentation": [ "http://www.pulsebiosciences.com/20240930/role/statement-note-4-balance-sheet-components-tables" ], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Table Text Block]", "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": [ "r7" ] }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentTypeDomain", "presentation": [ "http://www.pulsebiosciences.com/20240930/role/statement-note-4-balance-sheet-components-property-and-equipment-net-details" ], "lang": { "en-us": { "role": { "label": "Long-Lived Tangible Asset [Domain]", "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software." } } }, "auth_ref": [ "r70", "r363" ] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeAxis", "presentation": [ "http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation", "http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-details-textual", "http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-espp-assumptions-details", "http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-option-assumptions-details" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]" } } }, "auth_ref": [ "r211", "r212", "r213", "r214", "r246", "r254", "r283", "r284", "r285", "r296", "r329", "r378", "r379", "r380", "r408", "r410", "r418", "r432", "r433", "r488", "r490", "r491", "r492", "r496", "r502", "r503", "r518", "r526", "r532", "r540", "r541", "r542", "r543", "r547", "r550", "r602", "r611", "r643", "r656", "r657", "r658", "r659", "r660" ] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeMember", "presentation": [ "http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation", "http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-details-textual", "http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-espp-assumptions-details", "http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-option-assumptions-details" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]" } } }, "auth_ref": [ "r211", "r212", "r213", "r214", "r246", "r254", "r283", "r284", "r285", "r296", "r329", "r378", "r379", "r380", "r408", "r410", "r418", "r432", "r433", "r488", "r490", "r491", "r492", "r496", "r502", "r503", "r518", "r526", "r532", "r540", "r541", "r542", "r543", "r547", "r550", "r602", "r611", "r643", "r656", "r657", "r658", "r659", "r660" ] }, "srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis", "presentation": [ "http://www.pulsebiosciences.com/20240930/role/statement-note-7-commitments-and-contingencies", "http://www.pulsebiosciences.com/20240930/role/statement-note-7-commitments-and-contingencies-details-textual" ], "lang": { "en-us": { "role": { "label": "Name of Property [Axis]" } } }, "auth_ref": [ "r500", "r501", "r668", "r669", "r670", "r671", "r672", "r673", "r674", "r675" ] }, "srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RealEstateAndAccumulatedDepreciationNameOfPropertyDomain", "presentation": [ "http://www.pulsebiosciences.com/20240930/role/statement-note-7-commitments-and-contingencies", "http://www.pulsebiosciences.com/20240930/role/statement-note-7-commitments-and-contingencies-details-textual" ], "lang": { "en-us": { "role": { "label": "Name of Property [Domain]" } } }, "auth_ref": [ "r500", "r501", "r668", "r669", "r670", "r671", "r672", "r673", "r674", "r675" ] }, "us-gaap_RelatedPartyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyDomain", "presentation": [ "http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation", "http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-details-textual", "http://www.pulsebiosciences.com/20240930/role/statement-note-7-commitments-and-contingencies", "http://www.pulsebiosciences.com/20240930/role/statement-note-7-commitments-and-contingencies-details-textual", "http://www.pulsebiosciences.com/20240930/role/statement-note-9-related-party-transactions", "http://www.pulsebiosciences.com/20240930/role/statement-note-9-related-party-transactions-details-textual" ], "lang": { "en-us": { "role": { "label": "Related and Nonrelated Parties [Domain]", "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest." } } }, "auth_ref": [ "r172", "r253", "r369", "r370", "r391", "r398", "r435", "r436", "r437", "r438", "r439", "r459", "r461", "r487" ] }, "us-gaap_RelatedPartyTransactionAmountsOfTransaction": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionAmountsOfTransaction", "crdr": "debit", "presentation": [ "http://www.pulsebiosciences.com/20240930/role/statement-note-9-related-party-transactions-details-textual" ], "lang": { "en-us": { "role": { "label": "us-gaap_RelatedPartyTransactionAmountsOfTransaction", "terseLabel": "Related Party Transaction, Amounts of Transaction", "documentation": "Amount of transactions with related party during the financial reporting period." } } }, "auth_ref": [ "r41", "r369" ] }, "us-gaap_RelatedPartyTransactionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionAxis", "presentation": [ "http://www.pulsebiosciences.com/20240930/role/statement-note-9-related-party-transactions", "http://www.pulsebiosciences.com/20240930/role/statement-note-9-related-party-transactions-details-textual" ], "lang": { "en-us": { "role": { "label": "Related Party Transaction [Axis]", "documentation": "Information by type of related party transaction." } } }, "auth_ref": [ "r369", "r370", "r652" ] }, "us-gaap_RelatedPartyTransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionDomain", "presentation": [ "http://www.pulsebiosciences.com/20240930/role/statement-note-9-related-party-transactions", "http://www.pulsebiosciences.com/20240930/role/statement-note-9-related-party-transactions-details-textual" ], "lang": { "en-us": { "role": { "label": "Related Party Transaction [Domain]", "documentation": "Transaction between related party." } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "presentation": [ "http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation", "http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-details-textual", "http://www.pulsebiosciences.com/20240930/role/statement-note-7-commitments-and-contingencies", "http://www.pulsebiosciences.com/20240930/role/statement-note-7-commitments-and-contingencies-details-textual", "http://www.pulsebiosciences.com/20240930/role/statement-note-9-related-party-transactions", "http://www.pulsebiosciences.com/20240930/role/statement-note-9-related-party-transactions-details-textual" ], "lang": { "en-us": { "role": { "label": "Related and Nonrelated Parties [Axis]", "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest." } } }, "auth_ref": [ "r172", "r253", "r369", "r370", "r391", "r398", "r435", "r436", "r437", "r438", "r439", "r459", "r461", "r487", "r652" ] }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsDisclosureTextBlock", "presentation": [ "http://www.pulsebiosciences.com/20240930/role/statement-note-9-related-party-transactions" ], "lang": { "en-us": { "role": { "label": "Related Party Transactions Disclosure [Text Block]", "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates." } } }, "auth_ref": [ "r366", "r367", "r368", "r370", "r371", "r424", "r425", "r426", "r465", "r466", "r467", "r485", "r486" ] }, "us-gaap_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "calculation": { "http://www.pulsebiosciences.com/20240930/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://www.pulsebiosciences.com/20240930/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited" ], "lang": { "en-us": { "role": { "label": "Research and development", "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity." } } }, "auth_ref": [ "r297", "r504", "r513", "r661" ] }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "xbrltype":
```

"domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpenseMember", "presentation": [
"http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-stockbased-compensation-expense-by-recorded-location-details"], "lang": { "en-us": { "role": { "label": "Research and Development Expense [Member]", "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included." } } }, "auth_ref": [] }, "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember", "presentation": [
"http://www.pulsebiosciences.com/20240930/role/statement-note-3-investments-and-fair-value-of-financial-instruments-financial-assets-measured-on-a-recurring-basis-details"], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents [Domain]", "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r100"] }, "us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringAndRelatedActivitiesDisclosureTextBlock", "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-note-10-restructuring-charges"], "lang": { "en-us": { "role": { "label": "Restructuring and Related Activities Disclosure [Text Block]", "documentation": "The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled." } } }, "auth_ref": ["r199", "r200", "r202", "r204", "r208"] }, "us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringAndRelatedCostNumberOfPositionsEliminated", "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-note-10-restructuring-charges-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated", "terseLabel": "Restructuring and Related Cost, Number of Positions Eliminated", "documentation": "The number of positions eliminated during the period as a result of restructuring activities." } } }, "auth_ref": [] }, "us-gaap_RestructuringCharges": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringCharges", "crdr": "debit", "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-note-10-restructuring-charges-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_RestructuringCharges", "terseLabel": "Restructuring Charges", "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation." } } }, "auth_ref": ["r6", "r205", "r206", "r603"] }, "us-gaap_RestructuringCostAndReserveAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringCostAndReserveAxis", "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-note-10-restructuring-charges",
"http://www.pulsebiosciences.com/20240930/role/statement-note-10-restructuring-charges-details-textual"], "lang": { "en-us": { "role": { "label": "Restructuring Type [Axis]", "documentation": "Information by type of restructuring cost." } } }, "auth_ref": ["r201", "r202", "r206", "r207"] }, "us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration", "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-note-10-restructuring-charges-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration", "terseLabel": "Restructuring Charges, Statement of Income or Comprehensive Income [Extensible Enumeration]", "documentation": "Indicates line item in statement of income or comprehensive income that includes restructuring charges." } } }, "auth_ref": ["r567", "r568"] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://www.pulsebiosciences.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [
"http://www.pulsebiosciences.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"], "lang": { "en-us": { "role": { "label": "Accumulated deficit", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": ["r54", "r72", "r396", "r415", "r417", "r423", "r443", "r546"] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsMember", "presentation": [
"http://www.pulsebiosciences.com/20240930/role/statement-condensed-consolidated-statements-of-stockholders-equity-deficit-unaudited"], "lang": { "en-us": { "role": { "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": ["r96", "r123", "r124", "r125", "r127", "r132", "r134", "r136", "r174", "r175", "r196", "r300", "r301", "r303", "r304", "r305", "r307", "r309", "r310", "r315", "r317", "r318", "r320", "r321", "r354", "r355", "r412", "r414", "r427", "r666"] }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "crdr": "credit", "calculation": { "http://www.pulsebiosciences.com/20240930/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [
"http://www.pulsebiosciences.com/20240930/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited"], "lang": { "en-us": { "role": { "label": "Total revenues", "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise." } } }, "auth_ref": ["r86", "r87", "r146", "r153", "r154", "r161", "r165", "r168", "r170", "r171", "r244", "r245", "r381"] }, "us-gaap_RevenuesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenuesAbstract", "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited"], "lang": { "en-us": { "role": { "label": "Revenues:" } } }, "auth_ref": [] }, "plse_RightOfferingDeemedDividend": { "xbrltype": "monetaryItemType", "nsuri": "http://www.pulsebiosciences.com/20240930", "localname": "RightOfferingDeemedDividend", "crdr": "debit", "presentation": [
"http://www.pulsebiosciences.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited", "http://www.pulsebiosciences.com/20240930/role/statement-condensed-consolidated-statements-of-stockholders-equity-deficit-unaudited", "http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-details-textual"], "lang": { "en-us": { "role": { "label": "Rights offering deemed pro-rata distribution to shareholders", "terseLabel": "Right Offering Deemed Dividend", "negatedLabel": "Rights offering deemed pro-rata distribution to shareholders (Note 6)", "documentation": "The amount of right offering deemed dividends" } } }, "auth_ref": [] }, "plse_RightsOfferingMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pulsebiosciences.com/20240930", "localname": "RightsOfferingMember", "presentation": [
"http://www.pulsebiosciences.com/20240930/role/statement-condensed-consolidated-statements-of-stockholders-equity-deficit-unaudited",
"http://www.pulsebiosciences.com/20240930/role/statement-condensed-consolidated-statements-of-stockholders-equity-deficit-unaudited-parentheticals",
"http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation", "http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-details-textual"], "lang": { "en-us": { "role": { "label": "Rights Offering [Member]", "documentation": "Represents rights offering." } } }, "auth_ref": [] }, "plse_RightsOfferingWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pulsebiosciences.com/20240930", "localname": "RightsOfferingWarrantsMember", "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation",
"http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-details-textual"], "lang": { "en-us": { "role": { "label": "Rights Offering Warrants [Member]", "documentation": "Represents Rights Offering Warrants." } } }, "auth_ref": [] }, "plse_RobertWDugganMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pulsebiosciences.com/20240930", "localname": "RobertWDugganMember", "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation", "http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-details-textual",
"http://www.pulsebiosciences.com/20240930/role/statement-note-7-commitments-and-contingencies", "http://www.pulsebiosciences.com/20240930/role/statement-note-7-commitments-and-contingencies-details-textual", "http://www.pulsebiosciences.com/20240930/role/statement-note-9-related-party-transactions", "http://www.pulsebiosciences.com/20240930/role/statement-note-9-related-party-transactions-details-textual"], "lang": { "en-us": { "role": { "label": "Robert W. Duggan [Member]", "documentation": "Represents Robert W. Duggan" } } }, "auth_ref": [] }, "ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrAdoptedFlag", "presentation": [
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "ecd_Rule10b51ArrAdoptedFlag", "terseLabel": "Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": ["r565"] }, "ecd_Rule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrTrmntdFlag", "presentation": [
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "ecd_Rule10b51ArrTrmntdFlag", "terseLabel": "Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": ["r565"] }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockNameOfTransactionDomain", "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-condensed-consolidated-statements-of-stockholders-equity-deficit-unaudited", "http://www.pulsebiosciences.com/20240930/role/statement-condensed-consolidated-statements-of-stockholders-equity-deficit-unaudited-parentheticals",
"http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation", "http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-details-textual", "http://www.pulsebiosciences.com/20240930/role/statement-note-7-commitments-and-contingencies",
"http://www.pulsebiosciences.com/20240930/role/statement-note-7-commitments-and-contingencies-details-textual", "http://www.pulsebiosciences.com/20240930/role/statement-note-9-related-party-transactions", "http://www.pulsebiosciences.com/20240930/role/statement-note-9-related-party-transactions-details-textual"], "lang": { "en-us": { "role": { "label": "Sale of Stock [Domain]", "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-note-4-balance-sheet-components-tables"], "lang": { "en-us": { "role": { "label": "Schedule of Accrued Liabilities [Table Text Block]", "documentation": "Tabular disclosure of the components of accrued liabilities." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies-tables"], "lang": { "en-us": { "role": { "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities." } } }, "auth_ref": ["r24"] }, "us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "presentation": [
"http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-tables"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Cost by Plan [Table Text Block]", "documentation": "Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit." } } }, "auth_ref": ["r35"] }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-tables"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]", "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement." } } }, "auth_ref": ["r35"] }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-note-4-balance-sheet-components-tables"], "lang": { "en-us": { "role": { "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]", "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment." } } }, "auth_ref": ["r520", "r595"] },
"plse_ScheduleOfInformationRelatedToRightofuseAssetsAndLeaseLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.pulsebiosciences.com/20240930", "localname": "ScheduleOfInformationRelatedToRightofuseAssetsAndLeaseLiabilitiesTableTextBlock", "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-note-7-commitments-and-contingencies-tables"], "lang": { "en-us": { "role": { "label": "Schedule of Information Related to Right-of-use Assets and Lease Liabilities [Table Text Block]", "documentation": "Tabular disclosure for all information related to right-of-use assets and lease liabilities." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfProductWarrantyLiabilityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfProductWarrantyLiabilityTableTextBlock", "presentation": [
"http://www.pulsebiosciences.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies-tables"], "lang": { "en-us": { "role": { "label": "Schedule of Product Warranty Liability [Table Text Block]", "documentation": "Tabular disclosure of the changes in the guarantor's aggregate product warranty liability, including the beginning balance of the aggregate product warranty liability, the aggregate reductions in that liability for payments made (in cash or in kind) under the warranty, the aggregate changes in the liability for accruals related to product warranties issued during the reporting period, the aggregate changes in the liability for accruals related to preexisting warranties (including adjustments related to changes in estimates), and the ending balance of the aggregate product warranty liability." } } }, "auth_ref": ["r215"] }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-tables"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]", "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value." } } }, "auth_ref": ["r11", "r12", "r73"] }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "presentation": [
"http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-tables"], "lang": { "en-us": { "role": { "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]", "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions." } } }, "auth_ref": ["r75"] }, "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": { "xbrltype":

"textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "presentation": [
"http://www.pulsebiosciences.com/20240930/role/statement-note-4-balance-sheet-components-tables"], "lang": { "en-us": { "role": { "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]", "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets." } } }, "auth_ref": ["r520", "r597"] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": ["r559"] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": ["r561"] }, "us-gaap_SegmentReportingDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingDisclosureTextBlock", "presentation": [
"http://www.pulsebiosciences.com/20240930/role/statement-note-8-segment-reporting"], "lang": { "en-us": { "role": { "label": "Segment Reporting Disclosure [Text Block]", "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments." } } }, "auth_ref": ["r89", "r146", "r148", "r149", "r150", "r151", "r152", "r158", "r159", "r160", "r163", "r164", "r165", "r166", "r167", "r168", "r169", "r171", "r510", "r511", "r512", "r513", "r515", "r516", "r517"] }, "us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember", "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-note-5-goodwill",
"http://www.pulsebiosciences.com/20240930/role/statement-note-5-goodwill-details-textual"], "lang": { "en-us": { "role": { "label": "Series of Individually Immaterial Business Acquisitions [Member]", "documentation": "Represents the aggregation and reporting of combined amounts of individually immaterial business combinations that were completed during the period." } } }, "auth_ref": ["r39"] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensation", "crdr": "debit", "calculation": { "http://www.pulsebiosciences.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 7.0 } }, "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensation", "terseLabel": "Stock-based compensation", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": ["r5"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost", "crdr": "debit", "presentation": [
"http://www.pulsebiosciences.com/20240930/role/statement-note-11-subsequent-events-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost", "terseLabel": "Share-Based Payment Arrangement, Accelerated Cost", "documentation": "Amount of additional cost recognized for award under share-based payment arrangement from occurrence of event accelerating recognition of cost." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year)", "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition." } } }, "auth_ref": ["r533"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "presentation": [
"http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-espp-assumptions-details",
"http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-option-assumptions-details"], "lang": { "en-us": { "role": { "label": "Dividend yield", "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term." } } }, "auth_ref": ["r284"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "presentation": [
"http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-espp-assumptions-details",
"http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-option-assumptions-details"], "lang": { "en-us": { "role": { "label": "Expected volatility", "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period." } } }, "auth_ref": ["r283"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "presentation": [
"http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-espp-assumptions-details",
"http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-option-assumptions-details"], "lang": { "en-us": { "role": { "label": "Risk-free interest rate", "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares." } } }, "auth_ref": ["r285"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized", "presentation": [
"http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized (in shares)", "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "presentation": [
"http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized (in shares)", "documentation": "Number of shares authorized for issuance under share-based payment arrangement." } } }, "auth_ref": ["r535"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "presentation": [
"http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant (in shares)", "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable." } } }, "auth_ref": ["r33"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "presentation": [
"http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-summary-of-marketbased-option-activity-details",
"http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-summary-of-performance-option-activity-details",
"http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-summary-of-stock-option-activity-details",
"http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-summary-of-timebased-option-activity-details"], "lang": { "en-us": { "role": { "label": "Options exercisable, number of shares (in shares)", "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan." } } }, "auth_ref": ["r264"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod", "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-summary-of-marketbased-option-activity-details",
"http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-summary-of-performance-option-activity-details",
"http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-summary-of-stock-option-activity-details",
"http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-summary-of-timebased-option-activity-details"], "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod", "negatedLabel": "Options expired, number of shares (in shares)", "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements." } } }, "auth_ref": ["r269"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-summary-of-marketbased-option-activity-details", "http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-summary-of-performance-option-activity-details", "http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-summary-of-stock-option-activity-details", "http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-summary-of-timebased-option-activity-details"], "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "negatedLabel": "Options canceled, number of shares (in shares)", "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan." } } }, "auth_ref": ["r268"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-summary-of-marketbased-option-activity-details", "http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-summary-of-performance-option-activity-details", "http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-summary-of-stock-option-activity-details", "http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-summary-of-timebased-option-activity-details"], "lang": { "en-us": { "role": { "label": "Options granted, number of shares (in shares)", "documentation": "Gross number of share options (or share units) granted during the period." } } }, "auth_ref": ["r266"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "presentation": [
"http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-summary-of-marketbased-option-activity-details",
"http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-summary-of-performance-option-activity-details",
"http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-summary-of-stock-option-activity-details",
"http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-summary-of-timebased-option-activity-details"], "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "periodStartLabel": "Options balances, number of shares (in shares)", "periodEndLabel": "Options balances, number of shares (in shares)", "documentation": "Number of options outstanding, including both vested and non-vested options." } } }, "auth_ref": ["r262", "r263"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "presentation": [
"http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-summary-of-marketbased-option-activity-details",
"http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-summary-of-performance-option-activity-details",
"http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-summary-of-stock-option-activity-details",
"http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-summary-of-timebased-option-activity-details"], "lang": { "en-us": { "role": { "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "periodStartLabel": "Options balances, weighted average exercise price (in dollars per share)", "periodEndLabel": "Options balances, weighted average exercise price (in dollars per share)", "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan." } } }, "auth_ref": ["r262", "r263"] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": [
"http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation", "http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-details-textual", "http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-option-assumptions-details", "http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-stockbased-compensation-expense-by-type-details",

"http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-summary-of-marketbased-option-activity-details",
"http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-summary-of-performance-option-activity-details",
"http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-summary-of-timebased-option-activity-details",
"http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-tables"], "lang": { "en-us": { "role": { "label": "Award Type [Domain]", "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": ["r258", "r259", "r260", "r262", "r263", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r282", "r283", "r284", "r285", "r286"] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-summary-of-marketbased-option-activity-details", "http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-summary-of-performance-option-activity-details", "http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-summary-of-stock-option-activity-details", "http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-summary-of-timebased-option-activity-details"], "lang": { "en-us": { "role": { "label": "Options exercised, weighted average exercise price (in dollars per share)", "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares." } } }, "auth_ref": ["r267"] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice", "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-summary-of-marketbased-option-activity-details", "http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-summary-of-performance-option-activity-details", "http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-summary-of-stock-option-activity-details", "http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-summary-of-timebased-option-activity-details"], "lang": { "en-us": { "role": { "label": "Options expired, weighted average exercise price (in dollars per share)", "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired." } } }, "auth_ref": ["r269"] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-summary-of-marketbased-option-activity-details", "http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-summary-of-performance-option-activity-details", "http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-summary-of-stock-option-activity-details", "http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-summary-of-timebased-option-activity-details"], "lang": { "en-us": { "role": { "label": "Options canceled, weighted average exercise price (in dollars per share)", "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated." } } }, "auth_ref": ["r268"] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-summary-of-marketbased-option-activity-details", "http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-summary-of-performance-option-activity-details", "http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-summary-of-stock-option-activity-details", "http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-summary-of-timebased-option-activity-details"], "lang": { "en-us": { "role": { "label": "Options granted, weighted average exercise price (in dollars per share)", "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options." } } }, "auth_ref": ["r266"] }, "us-gaap_ShareBasedCompensationAwardTrancheOneMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationAwardTrancheOneMember", "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation", "http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-details-textual"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Tranche One [Member]", "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-significant-accounting-policies-policies"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement [Policy Text Block]", "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost." } } }, "auth_ref": ["r255", "r261", "r280", "r281", "r282", "r283", "r286", "r291", "r292", "r293", "r294"] }, "us-gaap_SharePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharePrice", "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_SharePrice", "terseLabel": "Share Price (in dollars per share)", "documentation": "Price of a single share of a number of saleable stocks of a company." } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage", "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage", "documentation": "Percentage of vesting of award under share-based payment arrangement." } } }, "auth_ref": ["r613"] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "terseLabel": "Share-Based Compensation Arrangement by Share Based Payment Award, Expiration Period (Year)", "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r534"] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-espp-assumptions-details", "http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-option-assumptions-details"], "lang": { "en-us": { "role": { "label": "Expected term in years (Year)", "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r282"] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-summary-of-performance-option-activity-details", "http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-summary-of-stock-option-activity-details", "http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-summary-of-timebased-option-activity-details"], "lang": { "en-us": { "role": { "label": "Options exercisable, weighted average remaining life (Year)", "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r33"] }, "plse_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.pulsebiosciences.com/20240930", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue", "crdr": "debit", "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-details-textual"], "lang": { "en-us": { "role": { "label": "plse_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Intrinsic Value", "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of grant and exercise price on options granted." } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-summary-of-marketbased-option-activity-details", "http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-summary-of-performance-option-activity-details", "http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-summary-of-stock-option-activity-details", "http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-summary-of-timebased-option-activity-details"], "lang": { "en-us": { "role": { "label": "Options balances, weighted average remaining life (Year)", "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r74"] }, "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1", "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-summary-of-marketbased-option-activity-details", "http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-summary-of-performance-option-activity-details", "http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-summary-of-stock-option-activity-details", "http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-summary-of-timebased-option-activity-details"], "lang": { "en-us": { "role": { "label": "Options exercisable, weighted average exercise price (in dollars per share)", "documentation": "Weighted average exercise price as of the balance sheet date for those equity-based payment arrangements exercisable and outstanding." } } }, "auth_ref": ["r34"] }, "us-gaap_SharesIssuedPricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharesIssuedPricePerShare", "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-details-textual", "http://www.pulsebiosciences.com/20240930/role/statement-note-7-commitments-and-contingencies-details-textual", "http://www.pulsebiosciences.com/20240930/role/statement-note-9-related-party-transactions-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_SharesIssuedPricePerShare", "terseLabel": "Shares Issued, Price Per Share (in dollars per share)", "documentation": "Per share or per unit amount of equity securities issued." } } }, "auth_ref": [] }, "us-gaap_SharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharesOutstanding", "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-condensed-consolidated-statements-of-stockholders-equity-deficit-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_SharesOutstanding", "periodStartLabel": "Balance (in shares)", "periodEndLabel": "Balance (in shares)", "documentation": "Number of shares issued which are neither cancelled nor held in the treasury." } } }, "auth_ref": [] }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SignificantAccountingPoliciesTextBlock", "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies"], "lang": { "en-us": { "role": { "label": "Significant Accounting Policies [Text Block]", "documentation": "The entire disclosure for all significant accounting policies of the reporting entity." } } }, "auth_ref": ["r68", "r120"] }, "us-gaap_SoftwareAndSoftwareDevelopmentCostsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SoftwareAndSoftwareDevelopmentCostsMember", "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-note-4-balance-sheet-components-property-and-equipment-net-details"], "lang": { "en-us": { "role": { "label": "Software and Software Development Costs [Member]", "documentation": "Purchased software applications and internally developed software for sale, licensing or long-term internal use." } } }, "auth_ref": [] }, "us-gaap_StandardProductWarrantyAccrualCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StandardProductWarrantyAccrualCurrent", "crdr": "credit", "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies-warrant-accrual-activity-details"], "lang": { "en-us": { "role": { "label": "us-gaap_StandardProductWarrantyAccrualCurrent", "periodStartLabel": "Beginning balance", "periodEndLabel": "Ending balance", "documentation": "Amount as of the balance sheet date of the aggregate standard product warranty liability that is expected to be paid within one year or the normal operating cycle, if longer. Does not include the balance for the extended product warranty liability." } } }, "auth_ref": ["r606", "r608"] }, "us-gaap_StandardProductWarrantyAccrualWarrantiesIssued": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StandardProductWarrantyAccrualWarrantiesIssued", "crdr": "credit", "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies-warrant-accrual-activity-details"], "lang": { "en-us": { "role": { "label": "Add: Accruals for warranties issued during the period", "documentation": "Amount of increase in the standard product warranty accrual from warranties issued. Excludes extended product warranties." } } }, "auth_ref": ["r607"] }, "us-gaap_StandardProductWarrantyPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StandardProductWarrantyPolicy", "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-significant-accounting-policies-policies"], "lang": { "en-us": { "role": { "label": "Standard Product Warranty, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for standard warranties including the methodology for measuring the liability." } } }, "auth_ref": ["r605"] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementEquityComponentsAxis", "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-condensed-consolidated-statements-of-stockholders-equity-deficit-unaudited"], "lang": { "en-us": { "role": { "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } },

"auth_ref": ["r10", "r52", "r55", "r56", "r96", "r113", "r114", "r115", "r123", "r124", "r125", "r127", "r132", "r134", "r136", "r147", "r174", "r175", "r196", "r243", "r300", "r301", "r303", "r304", "r305", "r307", "r309", "r310", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r344", "r345", "r346", "r347", "r348", "r349", "r354", "r355", "r365", "r403", "r412", "r413", "r414", "r427", "r482"] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementLineItems", "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited", "http://www.pulsebiosciences.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals", "http://www.pulsebiosciences.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited", "http://www.pulsebiosciences.com/20240930/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited", "http://www.pulsebiosciences.com/20240930/role/statement-condensed-consolidated-statements-of-stockholders-equity-deficit-unaudited", "http://www.pulsebiosciences.com/20240930/role/statement-condensed-consolidated-statements-of-stockholders-equity-deficit-unaudited-parentheticals", "http://www.pulsebiosciences.com/20240930/role/statement-note-1-description-of-the-business", "http://www.pulsebiosciences.com/20240930/role/statement-note-10-restructuring-charges", "http://www.pulsebiosciences.com/20240930/role/statement-note-10-restructuring-charges-details-textual", "http://www.pulsebiosciences.com/20240930/role/statement-note-11-subsequent-events", "http://www.pulsebiosciences.com/20240930/role/statement-note-11-subsequent-events-details-textual", "http://www.pulsebiosciences.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.pulsebiosciences.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies-antidilutive-securities-details", "http://www.pulsebiosciences.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies-tables", "http://www.pulsebiosciences.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies-warrant-accrual-activity-details", "http://www.pulsebiosciences.com/20240930/role/statement-note-3-fair-value-of-financial-instruments", "http://www.pulsebiosciences.com/20240930/role/statement-note-3-fair-value-of-financial-instruments-details-textual", "http://www.pulsebiosciences.com/20240930/role/statement-note-3-fair-value-of-financial-instruments-tables", "http://www.pulsebiosciences.com/20240930/role/statement-note-3-investments-and-fair-value-of-financial-instruments-financial-assets-measured-on-a-recurring-basis-details", "http://www.pulsebiosciences.com/20240930/role/statement-note-4-balance-sheet-components", "http://www.pulsebiosciences.com/20240930/role/statement-note-4-balance-sheet-components-accrued-expenses-details", "http://www.pulsebiosciences.com/20240930/role/statement-note-4-balance-sheet-components-details-textual", "http://www.pulsebiosciences.com/20240930/role/statement-note-4-balance-sheet-components-intangible-assets-net-details", "http://www.pulsebiosciences.com/20240930/role/statement-note-4-balance-sheet-components-property-and-equipment-net-details", "http://www.pulsebiosciences.com/20240930/role/statement-note-4-balance-sheet-components-schedule-of-amortization-of-intangible-assets-details", "http://www.pulsebiosciences.com/20240930/role/statement-note-4-balance-sheet-components-tables", "http://www.pulsebiosciences.com/20240930/role/statement-note-5-goodwill", "http://www.pulsebiosciences.com/20240930/role/statement-note-5-goodwill-details-textual", "http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation", "http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-details-textual", "http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-espp-assumptions-details", "http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-option-assumptions-details", "http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-stockbased-compensation-expense-by-recorded-location-details", "http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-stockbased-compensation-expense-by-type-details", "http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-summary-of-marketbased-option-activity-details", "http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-summary-of-performance-option-activity-details", "http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-summary-of-stock-option-activity-details", "http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-summary-of-timebased-option-activity-details", "http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-tables", "http://www.pulsebiosciences.com/20240930/role/statement-note-7-commitments-and-contingencies", "http://www.pulsebiosciences.com/20240930/role/statement-note-7-commitments-and-contingencies-details-textual", "http://www.pulsebiosciences.com/20240930/role/statement-note-7-commitments-and-contingencies-information-related-to-rightofuse-assets-and-lease-liabilities-details", "http://www.pulsebiosciences.com/20240930/role/statement-note-7-commitments-and-contingencies-tables", "http://www.pulsebiosciences.com/20240930/role/statement-note-8-segment-reporting", "http://www.pulsebiosciences.com/20240930/role/statement-note-8-segment-reporting-details-textual", "http://www.pulsebiosciences.com/20240930/role/statement-note-9-related-party-transactions", "http://www.pulsebiosciences.com/20240930/role/statement-note-9-related-party-transactions-details-textual", "http://www.pulsebiosciences.com/20240930/role/statement-significant-accounting-policies-policies"], "lang": { "en-us": { "role": { "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r123", "r124", "r125", "r147", "r355", "r381", "r421", "r428", "r434", "r435", "r436", "r437", "r438", "r439", "r442", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r455", "r456", "r457", "r458", "r459", "r461", "r463", "r464", "r468", "r469", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r478", "r479", "r482", "r551"] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } } }, "auth_ref": [] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementTable", "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited", "http://www.pulsebiosciences.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals", "http://www.pulsebiosciences.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited", "http://www.pulsebiosciences.com/20240930/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited", "http://www.pulsebiosciences.com/20240930/role/statement-condensed-consolidated-statements-of-stockholders-equity-deficit-unaudited", "http://www.pulsebiosciences.com/20240930/role/statement-condensed-consolidated-statements-of-stockholders-equity-deficit-unaudited-parentheticals", "http://www.pulsebiosciences.com/20240930/role/statement-note-1-description-of-the-business", "http://www.pulsebiosciences.com/20240930/role/statement-note-10-restructuring-charges", "http://www.pulsebiosciences.com/20240930/role/statement-note-10-restructuring-charges-details-textual", "http://www.pulsebiosciences.com/20240930/role/statement-note-11-subsequent-events", "http://www.pulsebiosciences.com/20240930/role/statement-note-11-subsequent-events-details-textual", "http://www.pulsebiosciences.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.pulsebiosciences.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies-antidilutive-securities-details", "http://www.pulsebiosciences.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies-tables", "http://www.pulsebiosciences.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies-warrant-accrual-activity-details", "http://www.pulsebiosciences.com/20240930/role/statement-note-3-fair-value-of-financial-instruments", "http://www.pulsebiosciences.com/20240930/role/statement-note-3-fair-value-of-financial-instruments-details-textual", "http://www.pulsebiosciences.com/20240930/role/statement-note-3-fair-value-of-financial-instruments-tables", "http://www.pulsebiosciences.com/20240930/role/statement-note-3-investments-and-fair-value-of-financial-instruments-financial-assets-measured-on-a-recurring-basis-details", "http://www.pulsebiosciences.com/20240930/role/statement-note-4-balance-sheet-components", "http://www.pulsebiosciences.com/20240930/role/statement-note-4-balance-sheet-components-accrued-expenses-details", "http://www.pulsebiosciences.com/20240930/role/statement-note-4-balance-sheet-components-details-textual", "http://www.pulsebiosciences.com/20240930/role/statement-note-4-balance-sheet-components-intangible-assets-net-details", "http://www.pulsebiosciences.com/20240930/role/statement-note-4-balance-sheet-components-property-and-equipment-net-details", "http://www.pulsebiosciences.com/20240930/role/statement-note-4-balance-sheet-components-schedule-of-amortization-of-intangible-assets-details", "http://www.pulsebiosciences.com/20240930/role/statement-note-4-balance-sheet-components-tables", "http://www.pulsebiosciences.com/20240930/role/statement-note-5-goodwill", "http://www.pulsebiosciences.com/20240930/role/statement-note-5-goodwill-details-textual", "http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation", "http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-details-textual", "http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-espp-assumptions-details", "http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-option-assumptions-details", "http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-stockbased-compensation-expense-by-recorded-location-details", "http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-stockbased-compensation-expense-by-type-details", "http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-summary-of-marketbased-option-activity-details", "http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-summary-of-performance-option-activity-details", "http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-summary-of-stock-option-activity-details", "http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-summary-of-timebased-option-activity-details", "http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-tables", "http://www.pulsebiosciences.com/20240930/role/statement-note-7-commitments-and-contingencies", "http://www.pulsebiosciences.com/20240930/role/statement-note-7-commitments-and-contingencies-details-textual", "http://www.pulsebiosciences.com/20240930/role/statement-note-7-commitments-and-contingencies-information-related-to-rightofuse-assets-and-lease-liabilities-details", "http://www.pulsebiosciences.com/20240930/role/statement-note-7-commitments-and-contingencies-tables", "http://www.pulsebiosciences.com/20240930/role/statement-note-8-segment-reporting", "http://www.pulsebiosciences.com/20240930/role/statement-note-8-segment-reporting-details-textual", "http://www.pulsebiosciences.com/20240930/role/statement-note-9-related-party-transactions", "http://www.pulsebiosciences.com/20240930/role/statement-note-9-related-party-transactions-details-textual", "http://www.pulsebiosciences.com/20240930/role/statement-significant-accounting-policies-policies"], "lang": { "en-us": { "role": { "label": "Statement [Table]", "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity." } } }, "auth_ref": ["r123", "r124", "r125", "r147", "r172", "r355", "r381", "r421", "r428", "r434", "r435", "r436", "r437", "r438", "r439", "r442", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r455", "r456", "r457", "r458", "r459", "r461", "r463", "r464", "r468", "r469", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r478", "r479", "r482", "r551"] }, "us-gaap_StockIssued1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssued1", "crdr": "credit", "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited"], "lang": { "en-us": { "role": { "label": "Principal and accrued interest of related party note settled via issuance of common stock", "documentation": "The fair value of stock issued in noncash financing activities." } } }, "auth_ref": ["r21", "r22", "r23"] }, "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities", "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-condensed-consolidated-statements-of-stockholders-equity-deficit-unaudited"], "lang": { "en-us": { "role": { "label": "Issuance of common stock as part of debt extinguishment, net of issuance costs of $6 (in shares)", "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities." } } }, "auth_ref": ["r10", "r31", "r52", "r55", "r72", "r235"] }, "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans", "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-condensed-consolidated-statements-of-stockholders-equity-deficit-unaudited", "http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-details-textual"], "lang": { "en-us": { "role": { "label": "Issuance of shares under employee stock purchase plan (in shares)", "terseLabel": "Stock Issued During Period, Shares, Employee Stock Purchase Plans (in shares)", "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan." } } }, "auth_ref": ["r10", "r51", "r52", "r72"] }, "plse_StockIssuedDuringPeriodSharesExerciseOfWarrants": { "xbrltype": "sharesItemType", "nsuri": "http://www.pulsebiosciences.com/20240930", "localname": "StockIssuedDuringPeriodSharesExerciseOfWarrants", "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-condensed-consolidated-statements-of-stockholders-equity-deficit-unaudited"], "lang": { "en-us": { "role": { "label": "Issuance of common stock upon exercise of warrants (in shares)", "documentation": "Number of shares issued during the period for the exercise of warrants." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesNewIssues", "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-condensed-consolidated-statements-of-stockholders-equity-deficit-unaudited", "http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-details-textual", "http://www.pulsebiosciences.com/20240930/role/statement-note-7-commitments-and-contingencies-details-textual", "http://www.pulsebiosciences.com/20240930/role/statement-note-9-related-party-transactions-details-textual"], "lang": { "en-us": { "role": { "label": "Issuance of shares (in shares)", "terseLabel": "Stock Issued During Period, Shares, New Issues (in shares)", "documentation": "Number of new stock issued during the period." } } }, "auth_ref": ["r10", "r51", "r52", "r72", "r422", "r482", "r498"] }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-condensed-consolidated-statements-of-stockholders-equity-deficit-unaudited", "http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-summary-of-marketbased-option-activity-details", "http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-summary-of-performance-option-activity-details", "http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-summary-of-stock-option-activity-details", "http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-summary-of-timebased-option-activity-details"], "lang": { "en-us": { "role": { "label": "Issuance of common stock upon exercise of stock options (in shares)", "negatedLabel": "Options exercised, number of shares (in shares)", "documentation": "Number of share options (or share units) exercised during the current period." } } }, "auth_ref": ["r10", "r51", "r52", "r72", "r267"] }, "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities", "crdr": "credit", "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-condensed-consolidated-statements-of-stockholders-equity-deficit-unaudited"], "lang": { "en-us": { "role": { "label": "Issuance of common stock as part of debt extinguishment, net of issuance costs of $6", "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities." } } }, "auth_ref": ["r10", "r52", "r55", "r56", "r72"] }, "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan", "crdr": "credit", "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-condensed-consolidated-statements-of-stockholders-equity-deficit-unaudited"], "lang": { "en-us": { "role": { "label": "Issuance of shares under employee stock purchase plan", "documentation": "Aggregate change in value for stock issued during the period as a result of an employee stock purchase plan." } } }, "auth_ref": ["r10", "r51", "r52", "r72"] }, "plse_StockIssuedDuringPeriodValueExerciseOfWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://www.pulsebiosciences.com/20240930", "localname":

"StockIssuedDuringPeriodValueExerciseOfWarrants", "crdr": "credit", "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-condensed-consolidated-statements-of-stockholders-equity-deficit-unaudited"], "lang": { "en-us": { "role": { "label": "Issuance of common stock upon exercise of warrants", "documentation": "Value of stock issued during the period for the exercise of warrants." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueNewIssues", "crdr": "credit", "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-condensed-consolidated-statements-of-stockholders-equity-deficit-unaudited"], "lang": { "en-us": { "role": { "label": "Issuance of shares", "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering." } } }, "auth_ref": ["r10", "r51", "r52", "r72", "r427", "r482", "r498", "r557"] }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "crdr": "credit", "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-condensed-consolidated-statements-of-stockholders-equity-deficit-unaudited"], "lang": { "en-us": { "role": { "label": "Issuance of common stock upon exercise of stock options", "documentation": "Value of stock issued as a result of the exercise of stock options." } } }, "auth_ref": ["r10", "r52", "r55", "r56", "r72"] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://www.pulsebiosciences.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited", "http://www.pulsebiosciences.com/20240930/role/statement-condensed-consolidated-statements-of-stockholders-equity-deficit-unaudited"], "lang": { "en-us": { "role": { "label": "us-gaap_StockholdersEquity", "totalLabel": "Total stockholders\u2019 equity", "periodStartLabel": "Balance", "periodEndLabel": "Balance", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": ["r52", "r55", "r56", "r69", "r444", "r460", "r483", "r484", "r546", "r558", "r580", "r592", "r645", "r666"] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityAbstract", "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited"], "lang": { "en-us": { "role": { "label": "Stockholders\u2019 equity:" } } }, "auth_ref": [] }, "us-gaap_SubsequentEventMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventMember", "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-note-11-subsequent-events", "http://www.pulsebiosciences.com/20240930/role/statement-note-11-subsequent-events-details-textual"], "lang": { "en-us": { "role": { "label": "Subsequent Event [Member]", "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": ["r350", "r373"] }, "us-gaap_SubsequentEventTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTypeAxis", "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-note-11-subsequent-events", "http://www.pulsebiosciences.com/20240930/role/statement-note-11-subsequent-events-details-textual"], "lang": { "en-us": { "role": { "label": "Subsequent Event Type [Axis]", "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": ["r350", "r373"] }, "us-gaap_SubsequentEventTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTypeDomain", "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-note-11-subsequent-events", "http://www.pulsebiosciences.com/20240930/role/statement-note-11-subsequent-events-details-textual"], "lang": { "en-us": { "role": { "label": "Subsequent Event Type [Domain]", "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": ["r350", "r373"] }, "us-gaap_SubsequentEventsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventsTextBlock", "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-note-11-subsequent-events"], "lang": { "en-us": { "role": { "label": "Subsequent Events [Text Block]", "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business." } } }, "auth_ref": ["r372", "r374"] }, "us-gaap_SubsidiarySaleOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsidiarySaleOfStockAxis", "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-condensed-consolidated-statements-of-stockholders-equity-deficit-unaudited", "http://www.pulsebiosciences.com/20240930/role/statement-condensed-consolidated-statements-of-stockholders-equity-deficit-unaudited-parentheticals", "http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation", "http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-details-textual", "http://www.pulsebiosciences.com/20240930/role/statement-note-7-commitments-and-contingencies", "http://www.pulsebiosciences.com/20240930/role/statement-note-7-commitments-and-contingencies-details-textual", "http://www.pulsebiosciences.com/20240930/role/statement-note-9-related-party-transactions", "http://www.pulsebiosciences.com/20240930/role/statement-note-9-related-party-transactions-details-textual"], "lang": { "en-us": { "role": { "label": "Sale of Stock [Axis]", "documentation": "Information by type of sale of the entity's stock." } } }, "auth_ref": [] }, "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SupplementalBalanceSheetDisclosuresTextBlock", "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-note-4-balance-sheet-components"], "lang": { "en-us": { "role": { "label": "Supplemental Balance Sheet Disclosures [Text Block]", "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity." } } }, "auth_ref": ["r571"] }, "us-gaap_TableTextBlock": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TableTextBlock", "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies-tables", "http://www.pulsebiosciences.com/20240930/role/statement-note-3-fair-value-of-financial-instruments-tables", "http://www.pulsebiosciences.com/20240930/role/statement-note-4-balance-sheet-components-tables", "http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-tables", "http://www.pulsebiosciences.com/20240930/role/statement-note-7-commitments-and-contingencies-tables"], "lang": { "en-us": { "role": { "label": "us-gaap_TableTextBlock", "terseLabel": "Notes Tables" } } }, "auth_ref": [] }, "plse_The2015Plan2017PlanAndInducementPlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pulsebiosciences.com/20240930", "localname": "The2015Plan2017PlanAndInducementPlanMember", "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-summary-of-stock-option-activity-details", "http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-tables"], "lang": { "en-us": { "role": { "label": "The 2015 Plan, 2017 Plan and Inducement Plan [Member]", "documentation": "Represents the 2015 Plan, 2017 Plan and Inducement Plan." } } }, "auth_ref": [] }, "plse_The2017EmployeeStockPurchasePlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pulsebiosciences.com/20240930", "localname": "The2017EmployeeStockPurchasePlanMember", "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation", "http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-details-textual", "http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-espp-assumptions-details", "http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-tables"], "lang": { "en-us": { "role": { "label": "The 2017 Employee Stock Purchase Plan [Member]", "documentation": "Represents the 2017 Employee Stock Purchase Plan." } } }, "auth_ref": [] }, "plse_The2017InducementEquityIncentivePlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pulsebiosciences.com/20240930", "localname": "The2017InducementEquityIncentivePlanMember", "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation", "http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-details-textual"], "lang": { "en-us": { "role": { "label": "The 2017 Inducement Equity Incentive Plan [Member]", "documentation": "Represents the 2017 Inducement Equity Incentive Plan." } } }, "auth_ref": [] }, "plse_The2017PlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pulsebiosciences.com/20240930", "localname": "The2017PlanMember", "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation", "http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-details-textual"], "lang": { "en-us": { "role": { "label": "The 2017 Plan [Member]", "documentation": "Represents the 2017 plan." } } }, "auth_ref": [] }, "plse_The2024RightOfferingMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pulsebiosciences.com/20240930", "localname": "The2024RightOfferingMember", "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation", "http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-details-textual"], "lang": { "en-us": { "role": { "label": "The 2024 Right Offering [Member]" } } }, "auth_ref": [] }, "plse_TimebasedAndPerformanceOptionsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pulsebiosciences.com/20240930", "localname": "TimebasedAndPerformanceOptionsMember", "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-option-assumptions-details"], "lang": { "en-us": { "role": { "label": "Time-based and Performance Options [Member]", "documentation": "Represents time-based and performance options." } } }, "auth_ref": [] }, "plse_TimebasedOptionsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pulsebiosciences.com/20240930", "localname": "TimebasedOptionsMember", "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation", "http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-details-textual", "http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-stockbased-compensation-expense-by-type-details", "http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-summary-of-timebased-option-activity-details", "http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-tables"], "lang": { "en-us": { "role": { "label": "Time-based Options [Member]", "documentation": "Represents time-based options." } } }, "auth_ref": [] }, "srt_TitleOfIndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "TitleOfIndividualAxis", "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation", "http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-details-textual"], "lang": { "en-us": { "role": { "label": "Title and Position [Axis]" } } }, "auth_ref": ["r591", "r651"] }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation", "http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-details-textual"], "lang": { "en-us": { "role": { "label": "Title and Position [Domain]" } } }, "auth_ref": [] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-document-and-entity-information"], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "plse_TwoThousandTwentyTowLoanAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pulsebiosciences.com/20240930", "localname": "TwoThousandTwentyTowLoanAgreementMember", "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-note-7-commitments-and-contingencies", "http://www.pulsebiosciences.com/20240930/role/statement-note-7-commitments-and-contingencies-details-textual"], "lang": { "en-us": { "role": { "label": "Two Thousand Twenty Two Loan Agreement [Member]", "documentation": "Represents the 2022 Loan Agreement" } } }, "auth_ref": [] }, "us-gaap_TypeOfRestructuringDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TypeOfRestructuringDomain", "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-note-10-restructuring-charges", "http://www.pulsebiosciences.com/20240930/role/statement-note-10-restructuring-charges-details-textual"], "lang": { "en-us": { "role": { "label": "Type of Restructuring [Domain]", "documentation": "Identification of the types of restructuring costs." } } }, "auth_ref": ["r201", "r202", "r206", "r207"] }, "us-gaap_UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UseOfEstimates", "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-significant-accounting-policies-policies"], "lang": { "en-us": { "role": { "label": "Use of Estimates, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles." } } }, "auth_ref": ["r26", "r27", "r28", "r91", "r92", "r93", "r94"] }, "us-gaap_VestingAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "VestingAxis", "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation", "http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-details-textual"], "lang": { "en-us": { "role": { "label": "Vesting [Axis]", "documentation": "Information by vesting schedule of award under share-based payment arrangement." } } }, "auth_ref": ["r613", "r614", "r615", "r616", "r617", "r618", "r619", "r620", "r621", "r622", "r623", "r624", "r625", "r626", "r627", "r628", "r629", "r630", "r631", "r632", "r633", "r634", "r635", "r636", "r637", "r638"] }, "us-gaap_VestingDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "VestingDomain", "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation", "http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-details-textual"], "lang": { "en-us": { "role": { "label": "Vesting [Domain]", "documentation": "Vesting schedule of award under share-based payment arrangement." } } }, "auth_ref": ["r613", "r614", "r615", "r616", "r617", "r618", "r619", "r620", "r621", "r622", "r623", "r624", "r625", "r626", "r627", "r628", "r629", "r630", "r631", "r632", "r633", "r634", "r635", "r636", "r637", "r638"] }, "plse_VestingOfFirstHalfMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pulsebiosciences.com/20240930", "localname": "VestingOfFirstHalfMember", "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation", "http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-details-textual"], "lang": { "en-us": { "role": { "label": "Vesting of First Half [Member]", "documentation": "Represents vesting of first half." } } }, "auth_ref": [] }, "plse_VestingOfSecondHalfMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pulsebiosciences.com/20240930", "localname": "VestingOfSecondHalfMember", "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation", "http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-details-textual"], "lang": { "en-us": { "role": { "label": "Vesting of Second Half [Member]", "documentation": "Represents vesting of second half." } } }, "auth_ref": [] }, "us-gaap_WarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WarrantMember", "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-note-2-summary-of-significant-accounting-policies-antidilutive-securities-details"], "lang": { "en-us": { "role": { "label": "Warrant [Member]", "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount." } } }, "auth_ref": ["r548", "r549", "r552", "r553", "r554", "r555"] }, "us-gaap_WarrantsAndRightsOutstandingTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WarrantsAndRightsOutstandingTerm", "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-details-textual"], "lang": { "en-us": { "role": { "label": "us-gaap_WarrantsAndRightsOutstandingTerm", "terseLabel": "Warrants and Rights Outstanding, Term (Year)", "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r642", "r643", "r644"] }, "plse_WarrantsIssuedIn2024RightsOfferingMember": { "xbrltype": "domainItemType", "nsuri": "http://www.pulsebiosciences.com/20240930", "localname": "WarrantsIssuedIn2024RightsOfferingMember", "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation", "http://www.pulsebiosciences.com/20240930/role/statement-note-6-stockholders-equity-and-stockbased-compensation-details-textual"], "lang": { "en-us": { "role": { "label": "Warrants Issued in 2024 Rights Offering [Member]", "documentation": "Represents the

Warrants Issued in 2024 Rights Offering" } } }, "auth_ref": [] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "presentation": ["http://www.pulsebiosciences.com/20240930/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited"], "lang": { "en-us": { "role": { "label": "Weighted average shares used to compute net loss per common share \u2014 basic and diluted (in shares)", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": ["r137", "r142"] }, "plse_statement-statement-note-2-summary-of-significant-accounting-policies-antidilutive-securities-details": { "xbrltype": "stringItemType", "nsuri": "http://www.pulsebiosciences.com/20240930", "localname": "statement-statement-note-2-summary-of-significant-accounting-policies-antidilutive-securities-details", "lang": { "en-us": { "role": { "label": "Note 2 - Summary of Significant Accounting Policies - Antidilutive Securities (Details)" } } }, "auth_ref": [] }, "plse_statement-statement-note-2-summary-of-significant-accounting-policies-tables": { "xbrltype": "stringItemType", "nsuri": "http://www.pulsebiosciences.com/20240930", "localname": "statement-statement-note-2-summary-of-significant-accounting-policies-tables", "lang": { "en-us": { "role": { "label": "Note 2 - Summary of Significant Accounting Policies" } } }, "auth_ref": [] }, "plse_statement-statement-note-2-summary-of-significant-accounting-policies-warrant-accrual-activity-details": { "xbrltype": "stringItemType", "nsuri": "http://www.pulsebiosciences.com/20240930", "localname": "statement-statement-note-2-summary-of-significant-accounting-policies-warrant-accrual-activity-details", "lang": { "en-us": { "role": { "label": "Note 2 - Summary of Significant Accounting Policies - Warrant Accrual Activity (Details)" } } }, "auth_ref": [] }, "plse_statement-statement-note-3-fair-value-of-financial-instruments-tables": { "xbrltype": "stringItemType", "nsuri": "http://www.pulsebiosciences.com/20240930", "localname": "statement-statement-note-3-fair-value-of-financial-instruments-tables", "lang": { "en-us": { "role": { "label": "Note 3 - Fair Value of Financial Instruments" } } }, "auth_ref": [] }, "plse_statement-statement-note-3-investments-and-fair-value-of-financial-instruments-financial-assets-measured-on-a-recurring-basis-details": { "xbrltype": "stringItemType", "nsuri": "http://www.pulsebiosciences.com/20240930", "localname": "statement-statement-note-3-investments-and-fair-value-of-financial-instruments-financial-assets-measured-on-a-recurring-basis-details", "lang": { "en-us": { "role": { "label": "Note 3 - Investments and Fair Value of Financial Instruments - Financial Assets Measured on a Recurring Basis (Details)" } } }, "auth_ref": [] }, "plse_statement-statement-note-4-balance-sheet-components-accrued-expenses-details": { "xbrltype": "stringItemType", "nsuri": "http://www.pulsebiosciences.com/20240930", "localname": "statement-statement-note-4-balance-sheet-components-accrued-expenses-details", "lang": { "en-us": { "role": { "label": "Note 4 - Balance Sheet Components - Accrued Expenses (Details)" } } }, "auth_ref": [] }, "plse_statement-statement-note-4-balance-sheet-components-intangible-assets-net-details": { "xbrltype": "stringItemType", "nsuri": "http://www.pulsebiosciences.com/20240930", "localname": "statement-statement-note-4-balance-sheet-components-intangible-assets-net-details", "lang": { "en-us": { "role": { "label": "Note 4 - Balance Sheet Components - Intangible Assets, Net (Details)" } } }, "auth_ref": [] }, "plse_statement-statement-note-4-balance-sheet-components-property-and-equipment-net-details": { "xbrltype": "stringItemType", "nsuri": "http://www.pulsebiosciences.com/20240930", "localname": "statement-statement-note-4-balance-sheet-components-property-and-equipment-net-details", "lang": { "en-us": { "role": { "label": "Note 4 - Balance Sheet Components - Property and Equipment, Net (Details)" } } }, "auth_ref": [] }, "plse_statement-statement-note-4-balance-sheet-components-schedule-of-amortization-of-intangible-assets-details": { "xbrltype": "stringItemType", "nsuri": "http://www.pulsebiosciences.com/20240930", "localname": "statement-statement-note-4-balance-sheet-components-schedule-of-amortization-of-intangible-assets-details", "lang": { "en-us": { "role": { "label": "Note 4 - Balance Sheet Components - Schedule of Amortization of Intangible Assets (Details)" } } }, "auth_ref": [] }, "plse_statement-statement-note-4-balance-sheet-components-tables": { "xbrltype": "stringItemType", "nsuri": "http://www.pulsebiosciences.com/20240930", "localname": "statement-statement-note-4-balance-sheet-components-tables", "lang": { "en-us": { "role": { "label": "Note 4 - Balance Sheet Components" } } }, "auth_ref": [] }, "plse_statement-statement-note-6-stockholders-equity-and-stockbased-compensation-espp-assumptions-details": { "xbrltype": "stringItemType", "nsuri": "http://www.pulsebiosciences.com/20240930", "localname": "statement-statement-note-6-stockholders-equity-and-stockbased-compensation-espp-assumptions-details", "lang": { "en-us": { "role": { "label": "Note 6 - Stockholders' Equity and Stock-based Compensation - ESPP Assumptions (Details)" } } }, "auth_ref": [] }, "plse_statement-statement-note-6-stockholders-equity-and-stockbased-compensation-option-assumptions-details": { "xbrltype": "stringItemType", "nsuri": "http://www.pulsebiosciences.com/20240930", "localname": "statement-statement-note-6-stockholders-equity-and-stockbased-compensation-option-assumptions-details", "lang": { "en-us": { "role": { "label": "Note 6 - Stockholders' Equity and Stock-based Compensation - Option Assumptions (Details)" } } }, "auth_ref": [] }, "plse_statement-statement-note-6-stockholders-equity-and-stockbased-compensation-stockbased-compensation-expense-by-recorded-location-details": { "xbrltype": "stringItemType", "nsuri": "http://www.pulsebiosciences.com/20240930", "localname": "statement-statement-note-6-stockholders-equity-and-stockbased-compensation-stockbased-compensation-expense-by-recorded-location-details", "lang": { "en-us": { "role": { "label": "Note 6 - Stockholders' Equity and Stock-based Compensation - Stock-based Compensation Expense by Recorded Location (Details)" } } }, "auth_ref": [] }, "plse_statement-statement-note-6-stockholders-equity-and-stockbased-compensation-stockbased-compensation-expense-by-type-details": { "xbrltype": "stringItemType", "nsuri": "http://www.pulsebiosciences.com/20240930", "localname": "statement-statement-note-6-stockholders-equity-and-stockbased-compensation-stockbased-compensation-expense-by-type-details", "lang": { "en-us": { "role": { "label": "Note 6 - Stockholders' Equity and Stock-based Compensation - Stock-based Compensation Expense by Type (Details)" } } }, "auth_ref": [] }, "plse_statement-statement-note-6-stockholders-equity-and-stockbased-compensation-summary-of-marketbased-option-activity-details": { "xbrltype": "stringItemType", "nsuri": "http://www.pulsebiosciences.com/20240930", "localname": "statement-statement-note-6-stockholders-equity-and-stockbased-compensation-summary-of-marketbased-option-activity-details", "lang": { "en-us": { "role": { "label": "Note 6 - Stockholders' Equity and Stock-based Compensation - Summary of Market-based Option Activity (Details)" } } }, "auth_ref": [] }, "plse_statement-statement-note-6-stockholders-equity-and-stockbased-compensation-summary-of-performance-option-activity-details": { "xbrltype": "stringItemType", "nsuri": "http://www.pulsebiosciences.com/20240930", "localname": "statement-statement-note-6-stockholders-equity-and-stockbased-compensation-summary-of-performance-option-activity-details", "lang": { "en-us": { "role": { "label": "Note 6 - Stockholders' Equity and Stock-based Compensation - Summary of Performance Option Activity (Details)" } } }, "auth_ref": [] }, "plse_statement-statement-note-6-stockholders-equity-and-stockbased-compensation-summary-of-stock-option-activity-details": { "xbrltype": "stringItemType", "nsuri": "http://www.pulsebiosciences.com/20240930", "localname": "statement-statement-note-6-stockholders-equity-and-stockbased-compensation-summary-of-stock-option-activity-details", "lang": { "en-us": { "role": { "label": "Note 6 - Stockholders' Equity and Stock-based Compensation - Summary of Stock Option Activity (Details)" } } }, "auth_ref": [] }, "plse_statement-statement-note-6-stockholders-equity-and-stockbased-compensation-summary-of-timebased-option-activity-details": { "xbrltype": "stringItemType", "nsuri": "http://www.pulsebiosciences.com/20240930", "localname": "statement-statement-note-6-stockholders-equity-and-stockbased-compensation-summary-of-timebased-option-activity-details", "lang": { "en-us": { "role": { "label": "Note 6 - Stockholders' Equity and Stock-based Compensation - Summary of Time-based Option Activity (Details)" } } }, "auth_ref": [] }, "plse_statement-statement-note-6-stockholders-equity-and-stockbased-compensation-tables": { "xbrltype": "stringItemType", "nsuri": "http://www.pulsebiosciences.com/20240930", "localname": "statement-statement-note-6-stockholders-equity-and-stockbased-compensation-tables", "lang": { "en-us": { "role": { "label": "Note 6 - Stockholders' Equity and Stock-based Compensation" } } }, "auth_ref": [] }, "plse_statement-statement-note-7-commitments-and-contingencies-information-related-to-rightofuse-assets-and-lease-liabilities-details": { "xbrltype": "stringItemType", "nsuri": "http://www.pulsebiosciences.com/20240930", "localname": "statement-statement-note-7-commitments-and-contingencies-information-related-to-rightofuse-assets-and-lease-liabilities-details", "lang": { "en-us": { "role": { "label": "Note 7 - Commitments and Contingencies - Information Related to Right-of-use Assets and Lease Liabilities (Details)" } } }, "auth_ref": [] }, "plse_statement-statement-note-7-commitments-and-contingencies-tables": { "xbrltype": "stringItemType", "nsuri": "http://www.pulsebiosciences.com/20240930", "localname": "statement-statement-note-7-commitments-and-contingencies-tables", "lang": { "en-us": { "role": { "label": "Note 7 - Commitments and Contingencies" } } }, "auth_ref": [] }, "plse_statement-statement-significant-accounting-policies-policies": { "xbrltype": "stringItemType", "nsuri": "http://www.pulsebiosciences.com/20240930", "localname": "statement-statement-significant-accounting-policies-policies", "lang": { "en-us": { "role": { "label": "Significant Accounting Policies" } } }, "auth_ref": [] } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "7", "SubTopic": "30", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479637/805-30-30-7" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "8", "SubTopic": "30", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479637/805-30-30-8" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "30", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(3)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2A" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-4" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-5" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-1" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-12" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-13" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-3" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "850", "SubTopic": "10", "Section": "50", "Paragraph": "3",

"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/205/tableOfContent" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/235/tableOfContent" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/440/tableOfContent" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(e)(1)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(f)(2)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/810/tableOfContent" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(15)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r88": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r89": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r90": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2" }, "r91": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r92": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r93": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11" }, "r94": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12" }, "r95": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h))", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r96": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r97": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7" }, "r98": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r99": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5" }, "r100": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r101": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r102": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r103": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r104": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r105": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r106": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r107": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r108": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r109": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r110": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r111": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r112": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r113": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r114": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r115": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r116": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r117": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r118": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards

Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r119": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8" }, "r120": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1" }, "r121": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r122": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3" }, "r123": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r124": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r125": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r126": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r127": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r128": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r129": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r130": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3" }, "r131": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4" }, "r132": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r133": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r134": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r135": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8" }, "r136": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9" }, "r137": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10" }, "r138": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2" }, "r139": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r140": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r141": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7" }, "r142": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r143": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r144": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r145": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15" }, "r146": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r147": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1" }, "r148": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/280/tableOfContent" }, "r149": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15" }, "r150": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21" }, "r151": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21" }, "r152": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r153": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r154": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r155": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r156": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-24" }, "r158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26" }, "r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "34", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480265/350-10-S45-1" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/350-20/tableOfContent" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482598/350-20-45-1" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482598/350-20-45-2" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-2" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-2" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-2" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r198": { "role":

"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/420/tableOfContent" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.P.3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-1" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.b.1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.b.2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-8" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-4" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(B)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(n)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/718/tableOfContent" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r274": { "role":

"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.C.Q3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.1.Q5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.2.Q6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.3.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.F)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "720", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-5" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "54B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1" }, "r350": { "role":

```
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483013/835-20-50-1" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "12A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/850/tableOfContent" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-6" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/855/tableOfContent" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483154/926-20-50-5" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "928", "SubTopic": "340", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478859/928-340-50-1" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "940", "SubTopic": "820", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(10)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.W.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-1" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-2" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-2" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-5" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI":
```

"https://asc.fasb.org/1943274/2147480990/946-20-50-6" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r488": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r489": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r490": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r491": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r492": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r493": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r494": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r495": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r496": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r497": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r498": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)",

"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r499": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1" }, "r500": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r501": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column E)(Footnote 5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r502": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1" }, "r503": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1" }, "r504": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "985", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2" }, "r505": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r506": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4" }, "r507": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52" }, "r508": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r509": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r510": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r511": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r512": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r513": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "48", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48" }, "r514": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "49", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49" }, "r515": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r516": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r517": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r518": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A" }, "r519": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482548/350-20-55-24" }, "r520": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482640/350-30-55-40" }, "r521": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r522": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B" }, "r523": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C" }, "r524": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E" }, "r525": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F" }, "r526": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r527": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r528": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r529": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17" }, "r530": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-11" }, "r531": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-6" }, "r532": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8" }, "r533": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r534": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r535": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r536": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "231", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231" }, "r537": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "100", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100" }, "r538": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "100", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100" }, "r539": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "102", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102" }, "r540": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "103", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103" }, "r541": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r542": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r543": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r544": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8" }, "r545": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "53", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53" }, "r546": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10" }, "r547": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F" }, "r548": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r549": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r550": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1" }, "r551": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r552": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r553": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r554": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r555": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r556": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10" }, "r557": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11" }, "r558": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12" }, "r559": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r560": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r561": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r562": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r563": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r564": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a" }, "r565": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "1" }, "r566": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r567": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r568": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r569": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "SubTopic": "20", "Topic": "842", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3" }, "r570": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)", "SubTopic": "20", "Topic": "842", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r571": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/210/tableOfContent" }, "r572": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r573": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r574": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r575": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r576": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r577": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r578": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r579": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX

210.4-08(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r580": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r581": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r582": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r583": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r584": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r585": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r586": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18" }, "r587": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r588": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r589": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r590": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r591": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13" }, "r592": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r593": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r594": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r595": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r596": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r597": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r598": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/405-30/tableOfContent" }, "r599": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r600": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r601": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r602": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10" }, "r603": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482047/420-10-45-3" }, "r604": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/450/tableOfContent" }, "r605": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-8" }, "r606": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-8" }, "r607": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-8" }, "r608": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-8" }, "r609": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r610": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r611": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r612": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r613": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r614": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r615": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r616": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r617": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r618": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r619": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r620": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r621": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r622": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r623": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r624": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r625": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r626": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r627": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r628": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r629": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r630": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r631": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r632": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r633": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r634": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r635": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r636": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r637": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r638": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r639": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r640": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r641": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r642": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r643": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r644": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r645": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r646": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2" }, "r647": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1" }, "r648": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-4" }, "r649": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3" }, "r650": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6" }, "r651": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2" }, "r652": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3" }, "r653": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r654": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r655": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20",

"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r656": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r657": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r658": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r659": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r660": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r661": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "912", "SubTopic": "730", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1" }, "r662": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(15)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r663": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3" }, "r664": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r665": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r666": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r667": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r668": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r669": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r670": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r671": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r672": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r673": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r674": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r675": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r676": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "985", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2" } }
ZIP 68 0001437749-24-032614-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001437749-24-032614-xbrl.zip M4$L#!!0 (`.. 7EDV(=4Y\@D #(V`-97A?-S(R-#$U+FAT;>U-
MVW+`.!)3KZB5ZED(*KJNOB6D615R;:V1E; 9[*R)!$ON28 !OLO;K MMQN@[E9\29Q9&*0C!HFT #ZX)P&J69HXJC5##GC\6G("8CY4**2*F2GYW'#/ M")D4P),>X0E;&Q[O-
)0)/TIDH?6R678^-P?2'X,VX\C>GIB2%O_C=?0B-0VP M!0&+132NPYO/F32-OHBYAG,^@IZ,6>(*&Y RWQ?)=1T]H'*3E4D#? RI.6J M.\N,;%"?Z4)'>;M+ #39F3E@?[.60*<$24T]H?
%'#\!M38I&X3N]*7(>F$3-U M+9(ZV>.$#%J=FU ,A('=ZDZU61ZTFN6T]7)-_[\M.?#;?3Q8Z/!-,M!IXTM] M?-T8/5Q KE8&>=+!],MGW9-VOWMQ#A=GN2I=_/6A\V\
[3JRI52JUS0_$_V:.B&"\V&FW">9^L3AF"G% MC2DZ+SRNR!9.R$S],Pl;L$'$82 5;JO'A0KN@#R*MU!>JU3YDVN(EN"3. .VW/+7ZV4_D2^4FC+X;.S!8Y+Z.?AP&IX/. N=RM%(/)NEED+9
"76:01&T]J3_#$HWGJ)MY. M8WDM%-1D.$G1? "7/*Y@1DG/XJDCGY%RS_"K;0Y2CIE&?" 2XC%\2N0(`_6:.M%QU@E(.)+!&)1!JK!1G*,Y:.(4N,RCBZC5HTQL6C4&6 XA$!0OD:. ^+%,@8 M5921SF[%
(.,$8SYJI,9G$##F P#=M4V.9C\Y@EQ')-.J###RAO"Q&,X(#6 D, MHU!X(>B,_LWN'W'%\T9H +'0$:I6C$<$"1/B '6*0I=ZIW93=$WZ.$R,.">P MYZ;A&7 _,>!V?P' <0A$@B%-Z)B%<-
$J68G5;JY>)"Y3PQ0-OWM1AC1%,)F+ MUR)'3!#9I1GE!% ":A3-$)@'OU[]&D'N"VJX2!99A 8(.YE2UHFEVOKC,1U" M$,F1GF!2\6NAC<*) $:%SF_TLC@'+3UQ9L7;9W3IQ.C;VQQT]1=\@("
9R#4%A-.AF9-9C-1'$??OM!> M)'6&!Q$I*ADY7*1*>MS'8@U;"_.?{ZY]+.(ZEYV4L>YO M\;F.E:ZV72V5"4HD$X=.Z@F(GN8 ZP!$7MW9)>2]!0N]!=O;4^$[#V:T(!5= M?
P@T_YZ)V<3/M>#X.7#,MC<&QZ=<8QW&L55T=\.M2&+ 38YF^_RVD^@8< 9/W MY'2DS# 0,J2KH="6! &*)[8=.HF8T>`<\!2L>,8O 7$C.4%3,Z9D]!5(I^]E M)'Q[@JNS@1;.^P)FA
0@G=ZTH2*BE3),$M5N7MGX54J;$;!"C%RF;.DH9!6L6 M,6)Z')9U8B9E\0XGC.?U'X;<#)$,L,[N?],OAL [@5X#+X/DM>L[\0SR%V# MA9B8@S9,L+T,Z'MSV@JN[\^&!X8W;@E#*X1-JF9:)#42F$?
&47A*4F?(GL$*@ M"S80D3!C$KZW=4N;C$6@!9?;'Q9,Y])3IS-N\@&&EF4H1W-H*=<]#*%@\';*)Z M;9_Z1(AQK*&C(M^:8!+N<(R;C$B1X)^1O %
(OHO[O,VAZW.PN;\\5+8CQ1N15f3+2@@_NHQ[8U)I3NAWA4Q/%3J1!=T.N&]5A)V/G."$(E//.K/G9?LBU\]18_; OZ>N?./!LW^ MKWZV91^$^].MH3BC+6+1>7C.&(P]@"%OI+T3EUCF/@:J?14%-
L";#*.A3&< M?T$<#"3*;JKW!?IG&lE"$",E:Z)\ *3T>[+!S\ ^90/?M+1,=]E]M4EO?U%JLU5[6/3R>.6 M!T$O/^MQ!]FW.!WS\4; IT2W%K9YANHW(/8P,HM.*VN;]2S&\>(V4G6(
U>$*1V9V#]_7U>+RB@N8=ZY4M-H?7-XZL;T!8KP[V:X>_KYSC/B2:U!/)GN"QQ;O[_!M8FKQ>6 MI7OZPZ*E9;,K/ZV$LZGHR%?^BUKN48O^]&)E?A&_AR#RQ1"\B&E]5/C0ONJ7
M+MOO,J7C7J?]3_HYTESMY;NS?F^1+ Q*2HY6"TE$P>6[\X]_S'I#"_I-U2T? MZ$69?F/5:L;M:\7^#U!+ P04 " #C@%Y9O?%0 #0 &5X M7S@..TVW'5!/P(Z)2JCNE3(?.2;EH%22FG5(H M54RT$U!-
?/D^D[HU93%-X9K>P5C&L.2-+4A(8# Q;T*5":B6729. MX&@*$CF_'DIG<]A>D0GO)Y)W<$[@I M3\K].DP&?8.)W%]]>@B]"?3.AZ/IX/5[8UPA.ZTV8'@!TU\,.F-S#H7<3UQ9L7;9W3IQ.C;VQQT]1=\@("
_H!:>FQZM6O26:A8NMQ>UO0SK#@[PZA;%E3!U0N0U ^Z8 MCD!"%.YF1&$0^1+&-,'R!#*$4<93"F=,ICZGP]?I(5P)OPS[9L#+YR>>5VWU.M99P0L;1O;NL <,X+1(8UQ7F+)479R1.JF R (I"@B
*!@&&CBZ!GGTN^4Z@NW MM&!)ZUOMM-XX;FQ:,SLE%XU8T"EQ&N2]%U@Z;S53?D^\6OVXYIVX.*0[H8FF M\8PJJ&%.FO+:.KI ND!1"AF,W7D\HUBVF&4:=B &"RRX8DX!O8I9FIH(X;^Q
M1!04(JHHQF7_ SQ:* 8?^SVGS9\CT?2<.;]%FG3D&$>UHI:IFD^BDB[7T@TDSD"L6$SR@3PLQ^8/EV M6M% F"DYB.!B?BAZ2.< P[#MF0$1"2"3L2I*#-.U;(!!&^.<<+) V:G-OL6K3*>
M$R83([FP(UV15%2H\C<.TL=IT&3&<=!)A56@4ZJB+J.<%YII_9XFO%^]_WM M=RS0$?ZLOBAP.)R&NFC%5]%@Q5)S)<>>[3U#Q:KPAWD&JR5O377R"2_8UC(
MIO8:9>^%'8CVN\K=YXVZ=WS:.D>RFWD$A[Z6]\MVDD.HZ.#$L9<.+[8X>3PR M!\92;UEW$PE9P&XR0*>5^U?Z^.S'ST5E:]+I$I:R7&?9>H=A6D9$HA25.LO MBD2U?/0X$OBT>?"CIL
N.'^2T\RCT(T,#',=@ M@0>U9K>T]#)AR%"7;17M_S?6?Y'O_9%B* <2PA_0./E?=\+%6C84S!]\<]+W M\&F, =TIC&T2OZ/4FYI[1'&\]+7-QAPT!1RAQ V4KV6WJQB M>T,]!/G(]$/R_OZ8NXCB&(72-
3"7+M2^U.Q#0ETL;&^05I.B>\KJ7]2[JE"X M)FNQTW@SMY_^9:C)BX-#[S7SZV^H=75Y.QP_:HM!1\NYQHY'%,+]\OGFSV61H8,Y??N"! M*"KF>V:W7;'?9?\!4$L#!!0 (`.. 7EE1J!N\ZQ$.#< 1
<&QS M92TR.#(T.#DS,"YXKELU3&2G*lQ*IXMO79F5.5$ M.EO9WT0:@DE(P@U%;@#2MO:OWV[P0Z0.DA %V;2E)U%$ lV_K'1#8##$E[\^ M+.#SKCG+!
O^LTW.;ZUC4=P*7^;.SSL\;>W!S/AQV+!$2WR5>X.SCA\T_OKK M?_['E_^R[=^H3SD)]6O=KJS)//)=RB^"!;7^\?7ZRK*MWH?/_4_C[],/R;EU MTCMY;_=[]KN>;?_ZY4&XGX4SIPMB@02^^
PWSCKS,%Q^[G;O[^_?WK][&_!9 MJZ37ZW? \?WJ1M)V$F(GB/R0K[(*#[?<>RNH\W86W'63PBXRS"I$G(_>9362 MTD(5ES(U-104"4-NAZLE%07Y9174 (]I6(QU>G:O;Y_TTYK4<=4LH*# @OK1
MXJ1(&G?.2.]+'T+]"W;K41O)T!Y@2V&?H"V3Z@_.O(01E!0X>)62@TW-XDVC)4GC8N*%<(E+^&)0722-@S0I:/6TX*.HE+ MY$A+"N3(V0U5$.A\Z;.%>5)684/FX]/L9#9\>&3SY-
GKGYZ>=F5IQR)AR-EM M%`)O 5]FC+K@-SRZH'Y8(,@5AX3/;/B#+!*A8$F<,((^S ML2SI,=AB&?#0\I6 E&D9NYFKQ)$/1D45_&>G]6R\9?=/[?]M\'T]60HL(-
MJ8005572/S;^:29! @G4XK^N$%_NP#OG6+189_3R:@?&;.^^LQ3!WFVFZ,7'HHR]?)_C40XI'_T7S2T@KXB'UHIG?.]VKIG-'+ MJ^:&+GCFIN:6,6PG0WU$429,74WY7S0Q?%WLH25173,-
X9&%!GKH2,CQ8A>? MET5M>BXQ(<>+AHC<"!7T)F/1F)0ILTTER(7WNP@!.[9X;D =W+:Y8%'NSZ= M85:BYY$\S@nUT"V=LC?.[@!, `]0)1-R7OIW>62^=,@N04W,63ZG(;*UW1]
MR2#J.^$.\JD.M:I+'BPI#QE8-1=MRP:FG$[/.AA&VVEP]$^/W+Z%."XE>:2@ M&.)(/:$*]:6XJ5U$0-G'0&=[=%$ZR=7QR'>MNI %2?RI%5;JI1+I]LJ!568 MSUJLTY+3;76'*@(2A$:6P@8F0&
O2)DA0@!EKF&[@1/)^^*[.':$+%S9^"SR MA>32L;#>S^NA?K81BZK/(9,SE71MN3B_TLFF?^WU>I9M722\\I<#WI4N)5MK MN&;[I;O!ZY$8D:#NR/I57F\\{4GEA**]8A&%^O4V+.VNF=O-
3;MG<2?P70@6 MP$W#E0@\YDJ?24L\F;6).:6AL..H-K0!T2QP[<@GD^@"2 MFU0HN#Y/Q<*K3"SK;RR6=2/%LMZ'].0P;= M(IX=8)ORF,+;B66&\66 &!4&/ PT>$8@[&!JX^'(F-M3+!A_ M!!L
I>9M"UOLFR#H'B;QO*$10MIF%&'@ #$//)=R8=, (PRI41>'A4^/*3UA M3('L0Q.0W>1$_&_K4LIHO;F(A?S+$7AF;?UD 9T!V4S!\N-^87F,]3(L^$%(M[3Y85CB<+9$!&A]ZQKZ-'/.I.
$X#2:FD/.)YRJ8<"#$K^=RSF<_@D2$XQ>3(15_FS^PE/'1@:F.HV{JG M*7#\H@2'S"1C8.0:60MC#3)AK'$BS(%CY9T])8S;=\2+*)H.I(3\FI%XHP*7 MLSYPJW^P9T'@WC//.V7E7(NFK-
I76A43G\%2$=@=N MQ8 *6!GT.1\[,=X,@TB<%.K6 T9F\+$B1(3<=:A2")PDDX6V%(FZ0!2F0X< M/) 00 L6QGEC/.TJ R: @.%F8Z-*6"\4P+CDTQ!. {)I&V. X&#X!=.T)G\
MRRENC(%^.65X5=.FC/U>:>O?P G$+*WKE.6!V_<4.M\CR7P/N.B0$_!^CES! M.&7H2AZF+/Y\:7$, *]CYM88F5N3'/,#MWV_!X;!._<)(XY9N3/'C?/FIH7*.MVC=E\X_J&:&>-
']L74>,SYT>_=M$=T*",;P%KTSF<,IVS9EYY*9/[DO)6-] M7=X===MY6,]5F?GC_\=&07C.,9[U)KPY]#6",*5D[)+?>\\P% MIZP-8D8=%&PW*VR]F4BY#AU%6C.VAN&S%4^#N%$'%IKSQ4?
U$WK&D9)/2,# MT%#'(E4SR4<\\)P3- R3QOP-HD>]3-EH=O(("ZWY0\,@TN1F$# +]M%XZ2,1Q!EX#S17,P]*B3,R ZM/0AE#FR?U.ND6P;.MO7W6&0L19'A M-Q89]VQ)F8*-HW (<)~YS(M"W.PNJ!-
OAN_./2LHZV0RB$GU*N_6F!SD)+9N M,HF/D-PJUTKL:X?T(80G^VD3O4WF!D&F7C;6SO&2#%F36+(CEIA_1T4N2M(O M[_HN$0)?/%M0@M9P;8C%BI11#O@D9'UD_":$GG[D%1X-
P4Z^L5\]_'+VCKN&2 M+R/$TQ(X0[&,JP&587>WFQ & ;6>HZ\$E&V-$Q&E7[M,1?P?ZP<0'CU2K849 ML/5G\BM(R;#UM BKYF\07.J)_!IP#3/IDB'PB"M-N^(WD-S(D_$26> &]W_% M,ZGP_[-
GPYOS>0RB,,&P:0WB928[0VR$F_.Q]A] C/>AC(&30(S>D#S]*; MGT%IPMH@R-2+"S4@&\2"69>)8$<&;>CH?-S],*7@_CMZWTM6>U10H,85:\5_.H<7T! M];Q1_(fY<3G+)#A"MJ
Q19LA7"^E01@:?(FM",.);$0';&\!RPO*9ZW$$]#X #:]_T+#]IEE'3H. 5J^"& #T=ZG'T44; M1G0*"0&0D9?&YWZ,RF00]>KEE:9(31&YEOD(RL8 H&*Y.!C,=':)H9']{$Y2&X2U>H6G<4105H.
MT^,AB->)6E9ZYL@1^_M$$9X9\2+@7A#4(,)-OKNBAW!WR.H]=X\V=,2O+9L M#0*N\9LOQ\6%K4R8.V,F^U)+ & B9A, 4QTHT16-6C8"#;8^26>7MY#>&)
MI#6'TU/UPE@]3NW\,3O99VK*P+I&7?!6 {1)MW=@]2O4QKI:.W-TCN7?DMJ7 M0]1A91!LCGYOB^],!0L=6_$T"!/UBE'UYZ^,@-\8-6^P*+.SR!0 MU$LQY=_.,H)$XTM7>P.(#B^#X%
O;Z@_M'50P/C2W3Q]-;E3/*55GM&:'$XO ML8,'6?XSV6)Y#@WCF103SHCWC5(Q\-WS0. WV/"TV;..!AWS/'RK_ZP##RJ> M-P]&"5D8H0"_\2!:GG70QNPS Q1UK/B8R_C.
(O#!7'PUA!)4K&/%]Y,=]V<= MAU.7A>GM:*RWB6P@<]<^S)\F^](@#^'X205**2SGQ&#%L> 9P +]'#%'+!G! M!#M=W%*^UKF6KHG.:LC\D-_MN'R@W&&"#H6(D#?]MJ[_N"
<,M/@LF*_JN'+0AXO1=$IQ^-O N.*@%; ^]R!9 M'DUC6X@1EYEG:I$QAT=Q# ?H-6=T,4O(#UH118"SG^"*\X]F+GF=NN=9$YAO3&QOX;I'?P*,J%%^EN(<"<
MS=:#U+:5=H;U;#3[19G&=CCEB_0"FPX[DIM95H]:S*EL:<)P':?!G 0T! \3] M,R(\I%P, =_)ZIYP]YQX;!IPGY%B-+)\UK5:$*A?T-EQ_J>) 8[&]U="'"P#I M->B3*JA'VOSA74:[X_8"1@H'\@-,>2
V!+1QD<[L@Z20?Z,?(ZT6]9Y/N]: M"MB+P)$V 04N_5!*G:V 9%I6T>P00808BAC7Z7*Q6](5I> C_QA'W)D3B'7! MBQY%+(VY+:/HDQ6;&@8)YDPB)]=313=<=&6I?P
M%;HG7,G!@TT9=?.9C/RP3KX+Z@C;KF:;LA7"IG\4]JRD:JM\7)6. \2#I+N0K]=2/5>Z5NYL'Y;$%S) MHPL(PD5_P\V6ES^G@]77YZ1&GY-6Z)//)/UPL">.X;S2-WUU F=:?5TSUT*!K M[?
PHC%X<=UY&8$E7LU,I6WKM;>$2'59>C+/$8, M[@B3LN),=S)Q.YE# >X"$UQWTO@RZ1Q%(7HK7"2ZT>$R!U-XR8VN\ELT\\] MQAC1*IE:,MI3ZS9;,2V5G_7'.#'B'/$'X'O$#$?
<=RUD/S);5W(>J1I[.;Y MFM+QX8K<8JH>\>4651<'B"]*5TP05Q2\&RVZOBQIG01?*:X*#:.0FO\?)1SO MFP5@S:JV+28KMRT-0?3!#,16V+6DL)51S%5_ #(]E%6MU.+[^AW2^#MZ#VWC;7J
MBO)6ZO.#/H0CGTZ":T$DGY_?2K*VZF/$**PZ?=I,]*],LD^E$FZ]R:13I>Z-M=1-**+E0B2[RNI52O"!]!DF5>KURE,^EWUJ?0K> 15FRQB*K.=#JDF>.SA_MI4N7/X;^)7'F*.*F_$J*MHF?
=&^9[.OBYQ9\%,XIOZ8.97DTJ*O>J%=OLRLI:^5S5Y0UQ5B5/H]HVJE7 ,*%?[^(9K/-)5!U42M\1_JI MY=$TM]BBM.6I]] MPS @DF!_N7M
2)T)DF_KM8D8!*2" JXO209.GY+PLIXL\+0Q\A<,*>P.K9G M'FUS>>N^Q8$G3A;RNR2C7*(\8-R^VK-OQBP165IH:T7+:[4N1"[UGI,Y<)GU M/^#&$/C!A+_@%8;^&SFRYN-
]}5O5:.6($6OP*;=!QJG81Z--W69=U^:)5^"`M/N8[I*Y<7[T:;=:Y5+47HL')^T($K5"EC**=.]7?LP5O49?3:M*V6\][S5Z&.M+O?!9!Y$@OCNY!XH5Y/@OF+!19^\E=HF6\!'TV^,B_!WXDV+ZE64MUN?
&^H$ MOENAD(*@E1IEL\.R%AOZF0LLR<^WH&^EONNWL_=ZG&_<64_%K'7+16843X]] M-]F969NOM._JCS\WV9L:W%Y./^L=8*P)RBT.>TF]])3G M?V\L*\W*LU.@$
MM9K:.M;F]^BSFL,VFW=<7<.OHO=T3L1MWH5.K;^*?FQX-&?SKFW*\%7TMN9 MK]/"R^D/DU_K^DXHZO>8VS M(<&KNL>61TV9\>V AR(.;1.LMNG^2$.!!KU!SQND\[U+$^$
MHG%*Z3ROH ML'_EM!.]'9H^.7TWE.=YU#3UT\FQNNQC":*M9MY$3U3MPZ47E1URQ9M/%F? MQ%^ OFFN!8&__P902P,$% @ XX!>69(0X;.%"@ IY !4 !P;-E M+3(P,C0P.3,P7V-
A,"YX;6SM76UOVS@2_G[_0>?[(/BO+372]'LPG&2A8&T M"9+T=N_3@99&,;&RZ",I)[E??T-)=NWEC)IMCM KMM;7.H>8;#>>.+/OW\ M/$MZ"^ ""LO2L?W1PV.]!&K*(IH]G_: WP?!^-![W>T*2-"
(\2^&LG1+`SS]M]2^?_A8$OT *G$B(>I.7WL,T2R/@%VP&O= .[ZY!0>_P <>C#[>?>U\?1KWC MP^ WP=%A<{8!#]]2FCZ^T?UQX0(Z"$3]<@_GO6G4LX_#@9/3'T\SQ.>'##^
M.#@^/#P9!%OWR^;JUTBN"8;OQ\4/ZZ:ONGZZ21O>W1Z>CK(?UTU%71;0^ST M:/#;Y^OI< HS$M!42214O CZ4>1?7K.0R%R,M1!ZVA;J4[!L%JBO@J/CX.3H MX%E$?91ZKU>
(GK,$[B#NJ;^_WHTWGCG/$@e$3RD1(<2O!'(1L-E#B/SP].1PH MB@%R+V$&J0Q2)B%X%TQ(HO $@eH@ R28XUBG4@0*6Y0E$+ X(#/&)?U?CE)) MIBD*X9%.\%KX#W=`CYB%)PBS).
[K&SV5S)1E/!5D@@6<),.5*15B*25BX(6X%0"PG1$$S)-\>N M3-2/A,QS)>2+\)A^9?%3*+_YS15,JX9HN(!JO&!OF?`W7&+]\GD,JX MR M!? $R0(^LU1.5RPG9 +)67^WG19R2-1,8[P<4D_D<(!-?
48$;]F\@ M?"?"]J.S98XDH-A^>V$YD*HO7U!_ 6D/.XVH"L>;D1KRL,$;Z[7!6.H6 Y'-9H7=0?9F2_J8L]E^U)/MQP0@"'-Q'?THXMHZ M04REU+%2K4^(UM?=B() W]A*H[C/X X;F;&I\&VD' ?H7:
(<%"0H4C]2[*$ M1BIU"E8-A H%V5QE5,B%"##ER@-(#E,D0[1!PH0(LJ1D$>*/S*/L?3W9@*]M7Q^.8NO1.D-CS+1G;+CD3?Q GC6!A &%TVAHQ 1.LS0J9Y;@FF8W\K&+9=KDMH0H8[C
MNO9.N; 99*5"TA4MG7)\!P*#M7'*IO<'%!"PN7+LU3(WHG&,8@%!DNSR4DH M?Z5R.LJ$!.'RR^O*SL]" "EBC ?4IJS.!9A59-$C> M@[VAJ[(0S#3]\VFX# &UGH$^E6#]W1-
K$SKX!.5%],JL';]/$\"QA&I#.#)^T M9WODR3I(CAIHS/Z<@*%8:K(FGP,;I+C"C#(2,PN*(1'3($[8T_XJAU6A*]$ M6,^M62WPK=C4-VH.<" `+]#X>YRN3-^U^GRG5/HF_BJ*BO6KR+]-%S9)CH;Y
M6\Y"@BW:F.A.K65X2;&63)CZ;UDX>\8V_U*.'=+U!^`_4!<4([_P%@RAT0E>8E:6AJN,$DBZJ;(Q!S[@&Z<+],.M M\%5TX_:^E:EHBJ^B@$_7Q=YPB5XG3Z=NX@N8R&6@GQ=_.3P:4'2$($]+[*#H
M23K!\,"&(<;5'%"I48WERVV"^96]PN.W^>))#2+S#MSB6TLF1.,5P/R4"\ $U]MBO:2WJ-M7@,TE<&I MOI'*+HM QE&+QI%;TP*C5]O*&E2;6/O\U:<=" WJB>2FS12Y.1AOI5B[1-
K%%LJZ6WOF9429GR;&93@9I-AJYW<=F3_+]XN-_M;-EV=-)Z&(;9+,M3XO7B'_X[@7Q:IM%ZTT]G.S2]WA.W%T=D]!BO?) %QQY^+8_D[O;.YA,U-*GQ'.GZ"N]]S^NA!1+ MPP&4)[5W[T7JGN"5
S%CMM7!L'(Q?H0M*4)\)0D5P#]N/RV;8=6-&[/4+W9 M53#*.*],E:K;=\$]1H$Q"`7M=2%1(P@U1$YO7.*%82^P7/8U'@UC.K=WU>1+ MM9:*94;D9S97SS9K9 -
\\JM&&)M,.9_JK58@:336IR4*Y"6%J:SZ.B#"@!F M5!8PZXPK(M5%#H](C\QB4ADS7HJ&%U@"R0*N9,WB3*QR346;J$)YD'S#E"C@ M'[1+/;U^KQMVVZ<.N)*/]>K MLQ>9[DRQ+;F7V
Q?;="V.R^QZY2X=3_^HM6^HJ!A+_XAM7DW1?L._0RXK2T3 MVY7E]BDD;R*%W=H[GV+WO4MCAU?QNPCS76A'RTGBXAB.,S%X_%:"C4JI",(B M^6:*5E76*K-GR>^7Q/J MUZQ<&A'Y@$-
=4MT$RENZ#M%4W[EK1=#/!JGAAF&O'H:JMXUW9Y4GL6=A=.:T=(U MO^H$^=.;3X]43V8+RC[XS?@_OT9&$IA!=$![BK!0;^]QC&FI?WF5.Z/86*E. MW.P3=[B79:NZLU:QOD]%\U!\UE.!\,KK[)
<5A=U^S[B?2 MZOV[3TL)>B [F!8N%@'T_P=98,#^1W@L2D'^&2XC/<5UA;Y?3)I5KLE=[6' MT,EB]]D.28O.V%-EW+HLN*.!5+[=1B?!M(,KFVV MY)-_4-87:GW%6HRPU-;O$ICC*<,R^G9_X*_]:
*LKG9AL.6E M_$'],4$/@]_\'U!+ P04 " #C@%Y9(YZZ*49$ #4(08 %0 '!LDOWI[S_]MTW;T@:L9BF\U^^^?UK,/EZ=G7US9N\".X3%A* M?ODF9=_\G__XG__C[_\K"'XE*P,1:(KX+W'X+OWG_[E.??
<*Z_>5.O+LRBC"7DELS> M,#[^?GOUDAKA'SSMCM1,5N&_V69'E/LI;DU8YAG5"Z)*F8*4'UN+:T*H;O3>Z"CY=% MY3T)=D]L2;%FI!YY3&9AF13=F?O\"7!6VJ/217/6I5)3NXIRR/*ET>2?QNQ
MY5NQHKW[^;MW;R7A?$$H"'!F$;2L(,%[_MP\RNA*+ D!FP7%@=3W94Y3DN?/ M,:T2,=6KP23Q;<92XN+X:4I%UVO^YZ;U(-D%PHH]\E00OC=L5K M80F+7KS:
M?"L;.8F^G;.'MS&AD@SQ03*I>KN$_NLB+6BQ/G\VA9+PGB2_?*/ZN:(F$0LU-MRS9,S)$\UK"%.T;$W3+,SOY:PL\V >AJN*,)(4^?:, M/86;+_YU3O,H87F9D3LN*9_X^'],[O,B"Z/BB&*#'DX13+-YF-
) R_W_C^Y4 M2V@L_YBD\4U&) P^3K=C;E-6 4L/MZC%->[2CBRQ&YXA^/ MQ;*XX3#'TWH7W*6FBI5DC:9WI97F216]8QE7G7I[AZG>UD?U-O"H2__)-D96[MX39[9$N-
:I.O)8BYK,4\XTlVB4^A0540=F_]U3S?Y5]HF_JMLBNBS9P;DE$67_+OZLX>C6V=T2EX!*/R14L'%[M-M9Z%*9X8V=TMMG<8,:>]-RDK:U%-(VX!??]9AEE!LF1]2U8L.SX'-UHZH/$N M"[FJ)!Y>

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}O\4.A8=5.-Y7*#2L2@eD I 4*$9]6TN38AR+#IYN8 M!L7MD3I+M8E8RH^=G%OBTR9SB/lQ'R;B\$;0+P@I\B"]EL)@)6U$09F&94Q% MNU4HOE^0@eI];$X.$^UX>ZS*-IT< /HU_H&##<.3Q'RPG-V$VS>1I//Y'F)3D MAF1RA3FBO$7/H1!5"^2D+!8LH_ FEOGB. 7KXHR(D5!7DUH7V^ M:.,X@OJ<%\WHWP!M!JG-=@\U0*"&JM<$@!#[MTYWAUBG* #A)6^8[@X/8#P: M.-[/#*/OH12(LW\K=6N<5J9B_Z;JCO@ZS,/^;=0=L6&RX,HJH1^"O%PNPVPM M*H3F=)[*.")192B*1,@4)S18L83R 4W+HK89VGF5U/9$>FNKM[:>=-'4K_O9 M,.E-AIO-7&@JA6K6V=LR3LR6X0N<>EO-J[?5^ *GUE<-PP*G;7:AH33O[X)9 M2+/@01Qe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})HG+!]3%',01B^LPN_3OVF5T^LPN[O/K,KL$RN_"E/YUN0KA/_AYM3L,/ MMS)&Y,,M'(5;M;:_#Q5V]? Y=D!&Q5$1%F=%'T:D2+,)L;7Y;0-(SS<"L803[4 MZI1#K7ROK UPN3TN%=AAH. ML[AS1Q*;D^R!:)W:H%[>?W@"_L,[_K#I[-D;U[J9&]N/DWJ3G6IH>XKW@H!(M9P9:29CQN!"\E@FM^.W7W8NNT\U2VA3[D]D3\2-Y(U(U$>(U$7<\C M@UF+W@=Y>9^3OTKQ%5\GT\+84J09PKV5]}$8;R%Z90N1(OWL"W_KTY34Y52\OK->C4%UP[PV-MWM#8R=!8KX,OH/*#$5'3RLN,%[K1FDQ!FQ Z&T:S6U%#'(VAU(:4GHB!%' <-M1">CJE61&9W%44]FZ8YP(M'RWDQOC,B;Z5V5SH,=!@:PQ>=TGM(9C4+^.8PB M5LJRV,&*)514QMY|@)OF34=T::EO1YLWW)^RX;Z[97SE%\H4\'@A)QE+^L4KPRTWDK>TP;DO:/:>A83EH:.W6RBG$A<]I$I^O MY8HKL'(F3.6M/Y,TON*\YIQ_$-F9Z8;A*OMG^Y% <^'US2F)^'N"S%953\$689 MUP[6>FR0/M[3=0*>KM]S,IU=Y 5=C.]-]/K3 [+24ER]+HUX83$"G%/O>51&4F,V4NGJ*D MJ,)SR=61;4USHX7TL;(O]X>-!" CO;*:QK>TX2 2GEP@7/#:!AO/CL! MQE(0LS?_RC,9SI8WFKFK6;>:G;R5C/%$L!ILf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

/S,\7.#/?\OJR* M*#Z^K&'XE5U#WO0>U*'3KPT,O_)JROEA&]_SJ"VOKU!;;M%DX"&MN^XCBW: M=#, SNUXE^W>'YW/;ML]VV?^3=A;(^=VP$*/F3!O.O1YL[]GQ=6B"5Q2#N]O
MF[2@B4(WAC]`RKRZ8U^!>34"3!C>YG@007=)'MRL/0"B-QY'FJSE4SF$A,/V/VJDDPI$6B>\<6SOBUX;C1D;H'MJ,/7@2"31D.*!1()T05]E;JX% MH;&;1LVM+$]92#>[E2*4KU6<-7 #Q7>E-A2>
()N<{[[L$L"5YD^;UCP'UU\DT MVZCQIC=WKV:MOMI4917E";@2206&LU K$O#;_+JI6_ZX5ZC,18 M7*A'B\&K6:C5(ZW-(;TNTMAZZ58<\4"+NB9*7X%"3\/!1!TGR^DU+5*6W%91
M49D%,C6L;^UZ4;(&;,+27EB6P6U&3E;Z70/6^>%5R\OWR'(XQ004.7ZQUSS"-?(^,H-@E=T;7-1CAV%*] M<;J*%)E+(!O/YNE!'PCB!=^2#R3F?XT>>LMNN*+E>R?: MAVGRN]
(^\%YWJ':Y. 6K)TFS\A;'D*&-_G3)E]#OUNEPVF&8)\WX7IY$6+@"L+P!TC1 M4G?LO,R%)$=-;+\K_'$2;'C+S!GFSVO;K->9L*Y1]D%>3;Y=4EKM!;TI@-GGL3XGKMGS^GI4)&.UH@1;#5
MDVL);QS!KT LC/!T;8UI,,/WU)\Q>,VE?_(/VXR;?MF7-P&O(**P!'W7@I! M%TN\B<%%'A>4[PO.J/SO17ZUAM1#CNL2_MVLNUN%B!A_CQ0?;3JN14M0:WM/ M063+G.UL-"]#1_9ALWK']
[3QDE[#!,UK^S4UX/=N'P7I>!O(=> "$=$ODI, M@3PKO/O*EW6+@"5>>[O@E%9TDKE4AW^$7MA2'3B\HIJ;&*AB)OXBN$;D!U=8'I M<&)9/O?\)>]S+GV.5K3'R^[]@DW .W7E_
X;/,H.O$)Z^!V\8SH\,2X!O71#8YH^ MBG(%'&=32?]]\6M4B'^A!7-=ZJ]&8 MZ(/+ 28LWHXC*2CW^GX@W^)$*RA/!&-BO<-NC_I;KPJ$D#R&Y_9(U;HN6$OI M4@*!B[K8Q-7B5)2:$/43[K"%?
PPLXX@<)6;21 M(*+1-7G8F#< R#0&@P]$K/=CBO)=^(6L&RPA @W4E>L_>1D)ZGT?CP5R9T%Q-MSO-$ZQ#3)2E7-W<1D)R_7BCN4P'IL/ZJT^FTJ2S[ASY2ST"0&=-M
MFXC4ILN/7 *UD'&!.O8Q+9[XEX>>ZEH-586?%HI*0TAK92*B5T2$=XV"&.U M8!N.VXR1AZ8OGVM68-OP@GW'DM# $V]R\)E6%WG.5O22E2HYZ&R#E(.#OES+ M 2=&.DX'D]0S$B@B:54/K2-
A[9YCIL6/*02IYS'2X6W$$=%\Q8HJ_?O!7D_M>>>N%;.UL!QLCQ0R9,.!#QPEF+ 7)X>YSHQ9Z4W$ZE3&7K'J;(.4I8.^ M7(M/32RL>'1SCVFO)$!]QCROTB3-A4WAK:YPMP?!6?\@27E0%
(_^\LGNVE;10"R,3 M_+#+NA8PUI/EKU2/"H_Z6SGVP9GYZN=R?[W@[&'TN9G%A Z?S) H1[?OJY&(*ORO\8&<=C1%S\;(C-R'F>P/6(NL9UT*<)-MND2VFROA+7K?4:[>1f:MNI=C7)5=2
RA"I<%I,EO'"H8\PN46^#0]EQS;8YK0 MY,/V2PEGS!?Y8UUL/*[21QFLZG_U M\1/C_4D*#S?3D4H(^R,TWYG@8*B798 MPCR;,6)RF#V.^\M+.(J_#HCN4'-L5H*B6U^YS' C4;Y,&D;H!MG*3'GEL\!]
MG;\L8_L0==IP?'4]0I.7O$6V 0_F&K.%?(=8545ZOZG@F/*.?>;PIK,$8NZ#^?5 MHO4[A9XB>D JGP$E7\%4 TB83:C3$2/VJ34>(@"1%O6F4H@H?:H\:$>F "_1 MS +30RNMP3$AH@>[2AOB@%
IO=,Z'<3,S;#X3NA<4"Z@W.>HZPYlH#E=I/U^ M++!+U^:8O

*M5^OS:L<6=>GS:GU>K<5P^KQ:GU<[8O;T>;4^K]9R1'U>K6U,[/-]=6S$/[_6-M-M78Y]7ZO-K1H.SS;GU>K;7_^[Q:F2N6_OLG*NHV%N35*I SMKQ:Y;GYO%[M-M>;,5?#^]#FE-3ZOUN?5^KS:\8#F\VI]7[W3>.:*CSV7T-M>;7.Y'Z.GA?HL3Y_E-M*7*S6AIA9(FYWV=Y^BQ/G^7ILSS[S_*$N6Y=P<)G>?HL3RLB+GV6[_R'%L_MH_.R]%F>%L/ILSQ]EN>(V=-G>?HL3\L1]5F>MC&QS_+4L1'[+$\+5&.?Y>FS M/$>#LL_RM#W+R:N'!F)O4W4 MYR=]S4_LTRG?PSO7E1[8&SL.E2R85_]"E[3S0DZ4>L\Z+Q^0RDl;9)) M&D_B%4YQ7C=X1YM:6K,C6W5=]!;#2;4]!#A5-]RD"#1$]#=AAD(H-_M!?0:=-.M2Q2T[%FLU[-O9[8-\Cl0EIM MY*%@)__2 9_0K@1U*3*.\HGI2I2((DXMI%97,,]'"5H=]FBCS;._ZNJ[8-9)-MRB:#9!,]KM@@^7/S9D>M9L=SRCED@^@Q2OZ]*:D805\3\USPBZ/!>KA7L>WH M_B@83:_./1 VPRL@1>*6HS-B-VT:YNS6_"W,FZ]\O3Y?S<4;5;U1M<^MU=M1 M7X|=U><0^QSBX7*((6*R*W8Q\)VYO0%B>8#EH.GEEH=`BK%0.02XLG%X2[!W MI#MM2?_$A/ 5+BJ9J9+.(T(9FDI1*1TC#W!.'0B5A)ZAA.TK*$B0L1!E,B^1 MO![F.=IV31"=.;9#@\ XGN&#=VYG3AR7*@$W=Q 2)85VK8?T*3"!FO$O,SI MXH]IE*OM.]G,R!=T$^)X,B)0]D\49C,ZUG.#0MMA@E9E"%4MNL.R+,.BL:V(5 M#61Y$K+!5!W-ST]>30K;/2#\n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{5=[1{4)BPD.G+]#+IUH(P@4EQ&E,9!}>+2I1IBWAH[COLK{)OHS XU1? MWESD/0.?P78_$+X"3K-AWE7Z7$][8S?QL0(?/MRX.64"PYAN0=.*C/TZ72D$WSZ%YGR(+9C+06#U.DML>+]#V(V@Y*)R H!]YX1H=Q<.%@Y\X*2Q0ZEZEI5OFP#Z3)P MR%D1XA3%YV'&THCR(PW[#.UQA'DS@??TX6.0>EFV^#:@Z8.DE2%6Z$*[H@XJC*MPOE%OEU7E@\8{V6515\(D9':&6"8A-X95T*%%)@&JAR"H;'IZC H_"H^ 3 X MRH7)+ 6GV?T AD&YQ)BE,.BHG:E<0\)Q6;.2&3 FZE7'K#^.!V!=GLIL_@&9 M@.X>5R1=P'R/.000 N8*QR@C XDP^C/DG7P-.K!|/<1>Z*K-L+ M^W0^O-6+1&Z(@UJSCEN4BL!H@Q<U[U5S9FF0)#=86X(N4 YOO48"6.$G!%Q%&# M11Q%Z(DI=4A5LS!|/!,*_(Q.1,/R\WDU)>=Q/|=,FM;S0CG M;/P>9EE(&YP_HBS",.K;\Y*ED)Z2O#CTWQ&UC>'1.'H)74GQ6HZISL&W:0; MB\^)&_5 0+V.3Y.PS_$<4Z&UO.NC#*\9.$VQL&|=>B!PZWVHIW^&*'?&9_@> M4^Z-FT@3 &)Y,.& (KES^\3D3M>B"CVI.9F)YENP)-U7N1+HYK],%)%%-25%0"_$W[=]=T>911:DM+W M("S7*VP[* 54US7HOAQ|&L.G 6!]D%/(4D854+ED!W$C8UF09?C&(?9XDC%$TGWLO9.YSBK.H[= M37*6S)$HB"RvAP D66NI(MV\..!/ W@-&RO(1.]]V13[*4:\N,"""RU MN (P9)\=ADS%B0N7-<=B6A,B-FP4.AS5M@C'<-2RO(X033AT+LOW;8+BX,@IR_JU M&>L\M6IG T?\PX%1ENOM!D8.*04I*:,#]A?V'R6CTF.\/4$L#!!0 (.. M7EE0C6,,(@" $M'%P 5 <&QS93(P,C0P.3,P8U\Q.'$N.'1M[+UK=]I(MUC,\?7Y%O73WW+[V$5!A."XF6A&WFU$]5 M)0DD+($0.I3$[IDD(G585]6+1M?V2?MI[F*7K!A*KKV^5?.PGTB"T|.,W4:S4?%U1?&\OU0]4 ^_*/QVNW-XX0O1S\]EBT3Z9 TVF M,H:P.X&@@PFO:^)2.8 %9^M'3IKWO1N#,+ >2K- R6J2[SYU:.#7M8BQD%.UIV:C"5EM+A((Q/E M-#X)BL12&?UC2QR1[!G2!=1}[@X0^I%HE*$P;!'S,'2ED&T7GR M>A#-R(.H=2O]=KU*5,5A@R B*P[=.|^$D"PEQ[-YC#>.)D'2@7T/DCQ']/UN M:5'7@9I &0T@2) ?@:!,)[^5;-^SG_RC-0757[K&BTQM':TF.!O/$3K',Y(D M9.L%E:TQA&O[" W!RQ".T_ OAG"4?.H(U;.0..#W1VB(=[T_7D+%&L(1.B)9 M K3.5.'5.K#W1VB)% @08PBM.:,GJ.GY=O^/WY^-R8BJR(AJK1]*SNRGK^.!-M,6L/RO/..N^F1.>1KG_\PDV=GM&_D_2]VC)T@2PKM%?$>145>.^C<>0YUTS)C3DVS<^"|=(^>EX$UYWQ3&H2+27O;* !D)$IP:5M&- M8^>E=%CI-H+FI+F9D^,>.,DWE!=BH=VKHH3I4#F=F.,47K29B30OW VS=] P M+R[.^X.Y(X)&%R4NQ_.%]!ATC'23[Z+Q%[.$B8H?L.0TR'#].:34W^B+BR!R M!<5% ^1Y'+U# _S?]+!+LKO"'()U@BX/K;G>B=[M-/.7# _*3>MI\4BU\2Z?A! M.Q"B+M2/0([.\6^Z+K\]JKH!T8UN9@(9,H"0"$*$UKC8(,:?9FQ!D6GZ4)WF MLX@9FXS^7BK6ROW!#_*@<5U\4^,+^6!.5UX# _,#"-@Y4$Y?U!N9COYV21\A M+V*>P#TVZ 1LN3.'QB0.XC.RW]#X2NKC_4.TZ,*A.=9&HC2C@XXIW.;!P?TD)-MO[#A#E71-_>=NS/8Z-APU_VU!,JV'GNX31OL_6UL .!6C<,157%\[<5G1S_ML_$C5>W#)BHL"DT41S. ^H9\(_O\X]&Z=_ 7?8\,,"1_D.OWB8Z 8O3Z-6[Q"5-MEB0F\I>*%'T:D3W&DKGQOQIK5*(.XW!UEN##TC]+M.N=@#Y^:H#0(!'O'G0G_ MR-V[TUV?K;)^SUA8U[QDD:H-WS#HYFPE_+26&'1J/37;!LUHT/HU@3'_K0_M$@=#\"H,.LW#8B,9S1>]OL*88?EN02?C:'>]Q_7:(+/ANT+W;$F+VWGW!,?.M8^)D:I;R0IUV]WR8/Z&>Q 3&G9A_89-FA+"?L.%]>3=Z1AHR M-](,WVEXQ\2]_^F[B?NR/7'L+Z<3]M0)6W-WL6ON$L@FVL(3=MCY+5Q9Q9E MGJ@Z/'R>@B2QV8O;.+NE^\U6&P\?26>/)NB .%DYG:+ M1(AAR<+RM?*BR)AH!I8_Z,Q@K9&BF]^\,$?#,$$ADY@O.@_3!'.C+17 M! 9/8&L[$2..#+2#T0$*UV.Q*9K78CN.R6S&D8%(_F.#W5CH=-/H.UB4_UZ*AH4.XO?_)[HB(.BJI_.:HH8''FY MP:.:)B6'.MA5KSZP5^NJ[+/$2]>^*V87&#(/PT0G#0T%I#_Z>4UI!09SX MQF'KT\UNT-AVIA$#H=6-K# @!=VQRO)0GEG^4#9Q=-8&4B#2:7?

*MB2?:Q"AM\U&")0I/V-KYW)KH\HI^HV>O]=$_$%$CLO)B?PK4A+|N]?'73YO^-ML.[XM)VC[!Q=Y^_&8D+L8H*S#AD,>2IHHF:1# 'EUQ@=1?.LN[YUGP1\K@U-.Z_??F[*

MLIIVL>OV7(*YSKC#V9IKA$HOHJKDQ7;%#K2<-;W9AA>TP- M"GO'M/RISOXCOWMG=3JW*N=!X__M^B%P_'0B?M*E%G]B^N#9-_9<348Y/5+ @?8J&5%@3]KDZ%]<3M,&

M#P\,";3Y1#^?!VUNB'"*I=G4\CI7NIX3#$>Q4UP[%A%X]OAF7TB^BZY\HZ?HHX@B(W]N[O)"(9K M^3?TRK_'M=2C)'1J?I('F#_B6Y%%=##$V[U%\&&M$FNM+DW2/@1*_29@X5:37

M]EX!),I94:/>~ G#TU:(OF0,'RS?=NN+ \0,&YE"$?1#LD:(HH(##Z3[!.3@XE#[=]&Y!NSO&\[SE"(NTH;$_O >X+#TN;XD-6E!8VNXM-M[(%DV*T!{)84N]' +:<\-]@J/K::@"W

%L@MP%;!L,6KW'IG1R:2RY#FR)R M82[OQ2X[E(A_P"]:6V+S,A)]Y"P5H!]J!=J =:(?[=@Y4Z#Q$@7C85W=OZ/)2 MLI#A*/:=>CWM)*MLFCS"]/YY3S=

[/'05(.EKLR=V1^)5=ROQ2G;2$;NUNG# M3CR&HZ^&/]=Y ;2=/Q1K-ER:L O8&+U)ZI(:Z /3Q.3_6 E8*7<6:D3K(X$[M01L_))L5+QMKAU M N\%;20"ME"@K%2ZHG%\@V=X(EY?

7&6L)BI.-M[GI^0"Y%[W[^[W/"_ ^T!FO M"RQ51I;:R4L]\$*!8"E$F2IBSIXH\!2'+-4;S2"P6\%TBQ8"E9&(WNE0!VT MY Y(_+:@FR8ASPG:@7:,@'6@'VN&D'8@OQ\IS>L

F%@UIQK2[3(Q&55_0\@ T>1PWA&JG&U*>#X#,09,+ 3DHK^SPL&/R M0!9ZU5JO@G\@0SPQE@?R#6O8$%7F@(CR7-$4TZ)%UUXP9+ ^<\")(4&K>H6Z. M RTBC 8^8!TGC]K57ILS

V$;Y/+2# ^"@QD50XMBA#E8*\$3/U*UV+T*,=0 . MXJ0?P$&-BZ!T14-=NW1TD-"J-AN@A("%,&>A7E!ZV*%,94HL)%3K+H'TG3G^C1*8[_>-*G&:UTPXY'93[//5S

M'J5DCT8"3F)2[*%4&SD'5H]@#U\[!&2;'&0!Y@0>S3;U5XOY @Z8]@CSS8 M(R2'XR#O+BGVH.Y1MI8#A_SV,?AF&Y*+)_ M<6?-L('LDVQAES.T ^U .] .M,-:.Q

HC+7'8$S/Z,*FY>CU=M9)PYCN<(2V- MFX6+9CVD:ME!84D75+8GX2Q?W.J;IKH8MJB*N%O+EO&O+ST YBH60^1M4W907#1%)N!<++#] M(?

M!U4TP00GV"ZD"6^G<3^W1L47 MA@G[N2>*B-&;98A$^"F;:*S&%IZ;1 +1CABZJC(99(>?XA55\N2%-ZH=WLHK M04XMH[R0Q(EXG/&^X]$O=KN<,;B 2 PR0M"$D?

9<<8+;6^>>JO:J(-> %Z(MP@M)G$''&2 X]FS4JXUNEVM>@(6WF*F>K@]&O#(-3Y53.,JF4"?11NMK@#C< M'1,20C)I8KAU1!0YH: O-H0./AIS(VEX.",3P]? *CY6'"U :L]Y2:

M54)2.V(XA<]P"JE9I60(!J/HX1*)ZJNX.EVY1*FOX:UNS+ I@;R M&R<,\U:=_&>#"-L1&N=6Y3QH_+]=/P2.GTZDKUDW>N/!^6Q;_37=5S'>^OI M;GBC:'\A\HB$5368:+)B+E213)V[8J&:Q-

5E_[R YWUPQ,Y$M',H/+S)TN7 M*CYLOCJSHA 1JU!^L:E%G]B^N&8M_^5$-/ 3E4-(GR):!97RTM6YN!%?:PSX M\+ 16)M/] -[T.:&*(+MUZTN_QJ%,3=L&%%^)/;

(9%,Y%W9=W^X%]U# MKVAJ7 M4!@@R%/25CB6G7GX8:T01Z$N36!'FQ[PZ\4,3E]"IB="#Q)'[(,G MF+W@2%D6W:=BRK%,UM_-

A2BMQ)N"C:A+QN+!$NTP#6%+.H5BAZFHM[6DN_+8 M-AD&X/>:)@?EN\5_&QD:F7KMJ2C$]YV_'9+AH1IG2Y,5D W - > MU-+04]ZH!%)G2.IFD0100NG2^_OOV

]=8CZ$+V+'C1GXXP/44J5&*#.H?6>, M:<^(!H)>B#N$SW:566P=G+06H52]Q8J94-'O' M;\^,-3D$[UD:#HXAR<=-+7]Q^\720A-A3/.LI;L@[E.QOA?1FZZQ*MHE]@] M*W1E431-

;!7-;^>;08/*@AT]fKT4NYN.U_0;,'+%<]W!|:S<=5 2>(KZ "X M0Q5 \OBB*[%W?,)S/BKA](S)1TN7_JI-1#0/ 0'"S]AS.B[TE; M_F MT_UL8[>JB!-%A< MO(V#MX$MY_P1+D+8^=[

"U&1$;;/J+5Y6+=FM(+# MTC#(D^#G)[]8UWB*'>EDY[CA@2;?48(>Y: U M>SG%[JT7L\YYI)8HL\6D*/U9>Z,81T!4)^FOMD$.^ MCE05C&8/&Y(=FV[#C0,'4(L/M9

3L8[4$$E*31"=NGQX@O[% P5N39_6EB:L M&*; LL<8YFWTSF^,-@?EN\&=NSC5[4%CBH[0B 91)@STAD#22+38)EH(:ZHQO *(\$P0#LH!^Q[4V:*EV;U-LJ-M/ @W

M%1UG02O8QSL32>.LRP/.P(V(H!*,)=XL4X!^2-"8"\H(2$0C4)+=;-:#8X:! M(;14 HP%G0*2B#9(\F.M>E'S#T 0/V .HC?1!+1!DH9;.FO3?O?>Y=C5T>L.

M7.SQ!;P=@;=TUJ53PENGG5,@"1R&6 Z#0JLX8=-"'!4&5EG1RH5H6"M6.?BH M"--A8XI3KRN9EJ.6T4I.2!S6O_B%OW.)E4XZZ^:WM-ZT$WQXL/%T3^"TP_*< M*F]8KOT7&_JVT>F

MF Y_0))8B#)N=-\J9*C[4)?>VNI%,R3RT&WQ>.$Q(=QZ0:>$H\T]/L_IX,^ MAB8_K+Z0<#@,=8';R0<*S@:W;J0SZ,2*/(*8,T-K(])9<@UIUJH\TMK OG ME^Z?AF\]U-

@U5E%>R%>)U2=3>I M4'4VG>D[=<,UV%;]7QK23*3;X?0I6AC4 M4K56;&L<_GNI+&A50[XLU;R=7UXB0KM5?1)%%8B7RXI;/ND#B6#!P/<,/,Y5 M@K&!)H]>#%>]5! M4'Y-

0L&9L0N%Y+S8?'0F@/)2$ C-I0#H+31<$X/)M8$\M*.,BBY?:9>D+ ^^#G]17#/L7>=\T=[YM7#[SY-4YX_F>P MAHG2[\A:A<;^7T7#$.F^9,7));6@I6<;T0'1I8(I-

LA@]NQ8(UHKWWV9]LQ MRU[$FG,V=^R/\'Y*45%R,K3RT&WQ>.+C^3O%V=-T.KVD,.T"[FPX99IFL&VCR M'PY@8TJ]=_:.1V?:U!H#//2#^:"E<%XZNAA)K%6YIW//R"Y[G?!\1OV) 4

M)SG M0G ITS0!D^B1(F7IQW>';F$BZD/A6JR4T9(!2;1W*:.8K'^(:']@+:,4=07E&@IZ8.PP:>UW'A4<\GP=D@7=O)W M$@5-W16.[FS"NDPNQS[!*L.%PD+@Y&1@F40-

E+1@\>QD44PS/ MV!M;?!>0?+_1G;R!3/Q2,6?\)2\7W)L,HEZ*FXAY-[W&$\LE[!#&C0\..&QR M4I**/(#+D@?(=F9#=9.HDA(#9?M.!2Q>>B^?CD]'"*UKN42Q;ZT ;2F*ZM)8&

M1]5!V:X1KKR%[;8IA;B,MREK")X,?'#HOYP*/<;"1+H DX1)E.%-'&2?:"NY0M!4!5]-M$HE6$P0)X1$@2>1C4/%I_XPV,'C IF4HDH5E>F.0R+GB?OL:'H\ONZ@Y*Z M!!0?

O4GL5/H'T<*CZ11+<;>K-UO5G XHRQB\P"HI[5]]2"*WI B\XCE#IU[M MMG,YJ;F4)9NJ?.9$ZX3W<*78N L1. ^IYT-F'GVZO6FUFX!-M'IEF6^/3I\D4OT%@M M:lU^TZU5BC7/-

%ZG[RR$L4\3+G)HNV6V1836,'I>+A8IXH.H(IFPBZJ;-+,, MV"0$Y,QB\523),0*%F6XXF790!O011':X#2XF;4 6EM M$<=2I-

8S<4G2W>/ACD3#3S35>)6@XI*B?.#TN<.TE&,Z'<.R;N@\;5FD;G MQ=JLVZ8E+]>=ITGWBY3V HN*_,ER?"];,=`9Y/W>4# M.P!4&Z*M>E#!FX.44;

(0+:QV(I\GNKRR;Y$O5.RR+U?GLO)B?PK,I?YUJT._ M?MITB/6'?76SIYWD::=;_@2VQ8Y6MD<=H0T/'B5,0V?^5A\Q9GIFOA"U%55, M-(AFTA4;HIHHIF2Z;"?33VP_

@NW.6E/HDKZ2"ZP2C%G^?1_]U5")"2IHDG0 M=O_MR^^5;1C5Z[\$Y7LZ5]8'.5B,=>% W^V/[^L7>MGB$K? MQF+; 9X+-G0U6UM+]X-

OH][7A]'@]]K@Z/(HX1*)ZJNX,MUT59J3K^&M;LRP M/;8&39MTC*R?ZNP_\KMW]I=S]W(>-/[?KA\"QT\GTM>L:YMY?SZ;U@S]=6VU M>6\]W0UO%.TO1!Z1L*H&$TU6S(4]DJE3-

%71<&VBZM)??G'+ ^N&Q"T4T,ZBL M^\G2I8H/C]_,K"A$"'IT%X--+;?K$\L7UA@?_Y0A67J6F-C(H75U:1/Z$IUGUW@KX(LQ<;+-

MNE\=DI,GR55>_]AY'*$OX[O\X7AT.QP[5M'X=GBVSM#,MN/#M30=>>]7IXU]& M4BBP&.-ZH7QB*\SN_)S-&)#M.?]PS6>*D)B?92(@6.+% M=S?]6Z^<IPID1Q>'M)[W MDQS7^U-

[@00E)0%A<")_M,^5QDX+-GZ+05MR,C4*PDDW('*8^IBBZI#/NSVC M*(@_:0)*TG*^M#,]6-"\P'0$60BR,$=6>M*MK,0@BZJ=G+FY\EEA97TIRQF[D5%)OXG4*^0U"-0+ ;!

;#K4Q0*YKA]DCW)EI@7!_E34@?%[*9$[5T(#P)T?XH;A0 M4@P8 .6?}+ZR;:H^D/SVR.UD%0/F78)(CX2.Z'1'WGR6$HZP.I*GTOX@I NS;^MHO^[U#!]$G30U/) ,D$W)@ZA(?Q0ITCB.P ;

!88.0VE"'L<':.%XQ6*)5Z;=[U4Y8 M)40N$';.37+!%ZV@@E2'\T74,!X_/;)+(+ @8,V)/Y(-7L3ACY#SH@[CC^#X M'3!#09%YLLP0=*15$##P@NMJ*0/4$.+(0> PLXZ["-^2R-5U0??@@N]

<,.S) M&I2).%J1\^!83=2=L;1DBL?3H^U:(05[N2# ^:33)!<3;B?A,$?/D=@&<*<'D M\ WH!G03="?B|<3(>|L0Z=5V)ZLTAH) [V31'M6E23.-+4'D@R?/>Y-<>/+M MD"-FDPAK <;Y

MS)8CSHZ-KW&,?\E>#"K3+!--A.G-.P:6(9?1OD]?9.N0 M\)1165]0J88HTI5!N2_T/,IX><5YM2S"E2"A<]>6>3W945L0Y?IR*BGEO2 M=9ZX2AVTB2;PON>/:.-,N@VK2A2E-

64@Q#+BPUV6H#-5\HFDE=[!(;(),"[M1]RVNEG98Z>%WGS%;2)YL$GN5P0Q#$". ^1$%EAC[R@$U!85M;D:#YUH:Z9@ M $!"T/Z$()-YV 0J,C80GB]4?86Q$VE9+

U)IH8+511@YP@+A;9.HDL*2<; MGQDYL&$/W3N@N2>8B;NKH@4[*O)ND@^P)[*BG&!<)Q3IO)MG!4'=R0(]D37D ME.)!!X-^?PC^ I(_\VZ2#]1'6U7./XX$8K]T37*15M%)9+$UZ?

@3H+UT3?*!-M]FBKM&"H%":9B)_XE:(AT:H1]5\E^)%K@=$LVZ8E+]>U'I-Z)%$]V8^95]0:6 MG)>25+"[B(,F^6"#S,M1)6(#]*.P:DWRP02Y%]_"AN 6G:?*$%UN]E !E!?,%,2Q$AE'\

M1C_C\N[N2S_A.?R\TS6SL-/(0V8?UCND. 7699.6-]W^$ZU5YFZY*G!?=|Q3D/U9/RACZ(^=/#?>;EDP#DIPCR?&V98^HGY8W7 MXM@C/.9(1=[N<464G4S@RK?ZQ,8A=1/-

PZ,I,TB$Q=5>3MDS/S5H.1.\7 M&"<'B@*&CL?0+I641\TD(GIL)^2&R) "V4? !*5C@KSK, %# $-PQ1 \E78" MYC@=YDC9/8_E&16&%W50UDDLDEGRIH5'M7&158B,]7WP$EB@B

M2_22*$9U,NCE,3G(];"E+_ Q1JAH#W=8U=Z1Q_LA6V*;_L'!5M(U^7T25;MFK MHD>\]B41$V"2@JK3+;B$8Z@?YKO1YN%%C^*(-O<3<; 9'TY4'.V4

M75L9!DJ:!;385K^[165:HD:'%C/:WA&J;2'[,PYRY82\\V+!S^^)!,V4F"' ML SDF:Z2/IOV^^+R8/9E 8# _@/]2XK[F;X[MMY8$K58;M>KPD4+&/+4&/*(M4810M.2"

(5OQ&3+!4FB1F).7X"LG?)%W^SSP9:$5Y>Y05SLV8\8NT9: BMQ$ MQH=H2H(V9_6&\X3Z09]@1T+SHX[N;$3SHT9V9[=7E5H9E^,*1JF[5#SN371 MY17])I+Y[:_('1U+BLO]]? [,-?

MWKTZZ=-7UA7?/F&3K]ATP]_2N;*;L5M M#EVQ3CCD_URA*P=859V!K;^,"U%:?U=%DTSV5-&>Z$\KVU-:K_\2,%519[E*

MV:4J,K&A3!U>4309:Y8HU?,_%F&IR^_8=&)X.649KK=\;CIT$5_QO=8281* MV(A/[/=M[LRXM+L3D"'98/N3=3N3%L!TI6%=$38T+*4GRN-2A;3')1]'R.# M?6\S/OVRSFA64T0,,A;-

A$2A +E904%"#= M0;]? C_Z58^QG=T0/N000H=W>*'UT4&=#]Q@Q6PX8N M]A+:\'92.#=_"@!)(H&QS1FXBQ?NXE1H[=]LW&X&U;:*

MQEZ<;%9N=]]=#8K)\99260?!];BBJEV\E10J2]'IS*RYE]M:K-3'&,N]P-9 MHG+7Y=:)OL'5+-=_>NMH9@+[CBM]>Q@Q#7HB?4I/PZ7)VR9%#!(U&;V*AB$2

MV89P4C:)/PS8P7Q5K9C..27YFG\-<11]VZ$L4]X62;K+[Z,(OZ"YW6U3EJ-CA@GJ*$VZ9Y(;+01UC(U.P.KTBTW;>=\BGD M*#?AN"_]=IP!_L#P%WH,>'#0-?@=<#L6>

[OO)/!=\K%3Z7>]J7H^XK&0(,Z] M SQR40\AU-71+)C?;-B3%9'?= MT"I$.@MF%+<2<3(CYXLN5!/OCEN.'%3=3?!P.!53 @FM5 X7*2C'S.##FDVN[DDRY32)#FW@$>N22J

M.Y=F>F:"' /1C_)T@,/H1ROD./ D0HC &\6!9NX=X) WVB'G@@M1S@7/UF@] M>KPOSR)DN>P2[P4.#XGWV9?U!25R9D&_#(4';SO"]X@((=,@7]3\0W;SS@:(M*V3DN+)%R"=H$4

&7A"8,=A3S'U_ST=[P-[(,"P79:GL(*3S:2P"T'F4ZHDD MH1^[;IW :@\'>Z@/I&D\20W-H/8!P.(D@$269&O?48T%Y^M/-D M9Y1=9 =#90=RN<]EXF>ZX?(;8!0&5C

V$YPM57V'L1+4627:.B29&"U74(+:5 MMX!()-\@V=C6R $,>^C>="$1R!Q(,<(7"">P_/NQ M8$]DY3^E(-?!P-]G/N9V!S(.?[R"_$VU=/_]%XA_8(+4F"'1E>ND@UV ^)(A MGB.#IQ-

M^1J,EF2'"7E 0[UW02]&0:-6(L5 C[? %RMPE4_2NVZKT&U#5KJ!; M%CJ9U!P;6'->"M[!OKA"=8!'LF\V-TN]H'})QB- <,\,@\N9:Z T8])(Y5 M[P"/C,1-C3M@JD)B.O<.<+(@#KY-

/&3O@H$("/<.\,A!1U>W V: LG9IQ$0Q M$]4U215-4YDJF R98% R^)8QZAX+(fJDYP:+C6X=%((^.H61IV/$_.DT50. M/|-\SO1(**;12]?(H .%X(1<2\'%YHI= MZT!MNMY=[<+)1P7J

(^(P+=?"J^ 3M !WADAXNCB[R=ICD$ M68"1(EX/6T$K&1.9*J.%H=<,T1*1K)B6H4R6#)>6;F<*.J5%DK!U>8P299/CD$UAFQ>M

3LSP8204+8CZ(#'CXC7[&IU[\+3%R1"SOP$\$"@H> M<%CBXR*%0"[RKGR6%X_LV8??J?79[36 34!\VF_1X*I,&.@7XA7=^ MR:VB&C ', ?G-E)K8#

<=!G7?;2&4XD?;_B"HM/59V&MG;,F*F@2/%% ES%;;9L4F84597TY47"P1$M[OG2)D M*\-#2?.\4G8&PMW2,BU1HYP9=Q5!J+.%3IXIL=Y)/YEEM&,@^'.IN*93KZ?" M-6%%0IU=[O;IXC)-

Q@&&"8WAA%B,\ROYZ8FP3RM=KTJ7+2 @TK"0?GW[I"<`MJ4Z]$9^#$CQ_-1(W\1F&!$8Z&56T*VK2J3=C(:$M7J 1"FI,H M2S.SV"/P3RZF7"N7%_A08Z?MU]X^_?

MKTAW7'%US@GE.+,_?C87=BMLY'K]EX#IBCOOC"\43<8:FU$J4:Z<^;,, M3U]^PZ(32.(V;S-81A7]_5{!)1$J82-)N;XS+|'N3D!:8H+M3];M3%)L!DA7 M%M(184-

/E/Y<;52RF.8@C9/=:E'0R/PK2(0(.W"PB>@X6)@$G\1=&8R&-!R" MADUT K'P1$E! =(=/LI\/.3;N4CV-<9'> >1(\R)R HP A@= Z,;5C\), 08 MBH^A;SQ5) 4T&L#H*!C927'CZZY$X68[

M(%&X6:MW.-Y:W&Y5N]U<,XOYXAF^>I,5]O/*Y.>)>3NI,&^:NP+:^>R(X9)3 M^.H-\&UV?-N-S;<\;+1N=EO5BPXH8$Y[PP,C)S:F\+.&N6#DB_B,#/N]N>4@ MOGK#

S^72#'OW";>##JT%8VA.=EV+K2JK7SK;NWDGBS+70(;EYB-=W%Q*ZCR ME\/%63!DN]+OU*OMW$^$CH9^.%8GTK$Z8]-

V2D_)3$X>NHKDXKZ!P[(@RZ3OW=9DIU-.FC%#-8OE]2 M@^;M,[KL&#B]>6<#9.@)\],9\]VZ]<%)GA!X$G>VACIQ5T+EVB8]3FN^A MSLZ@.PCI?+JH '0>I7HS": ?&TU-

O3[@JWU'J >Q+N#^J CUPY'?8*A1Q#[-MP !9.D#0L6D',T#L4!V@O?QHY\G("3K;[#W:P5 Y_M#HDSM"9D=TRV0Q"@[

M&1L(SQ>]OL+8B6HMEH8T$TV,%]]H06PK;P$1=$Q;SK&MD0,8]M"] Y=[@198 MYU81P7(!\2T O OXH,/4\HQOA:(=S#\ ^[%@[W$I-0#ZX^3;R MV_6"Q+E _,3I,8$B2Q<)QWK

L27#/$<&3SM:*O78+0D$ _Z]8RN/T3#((^N M<[>]2'&C8))N6DB4_],T+2I9(="5A6385;,#M0 PG_00/]H1(NOES$>0/B029/.[.(X_L?"/Y&E[QC1H(Q889^1 M!9P CK'#"=&6Q=. -#H&"

+;@C"T260P^)%X$/ \P)F1%&U!& P=R*)*(Z+$ MW,K:1#0QK84Y7Q!C0F08Q6_T,S[-.%+6.A+B2'PUQ9F=U$EDP8OK1OY&[S'!?+G?9Y MMU!VI.W2@8DLY0\8CR/"S?:RZ$EO!3?

D<@=OWNV?,O,DLNA_1- .& D8]12, ME,C.\H3'>L!4P%0YQRTB=WMG/?U.(EO8XP3_(K%0U*KZ0KW.[N135#\]/V59 M6!|8*0=6ZD9+6P"N". *2%\+COA|\AQ"^X@7%L.KF9|$FZ,$X?

2 V+TB)-ZY M&%TA^%R,5&[$)7?8:Z^7ZUESWDD_F66T8R*8UPDT:7%-(Q6N*>\[|\ P)\XP MS=@,P\?OIMU[O=L #BH))'+?7OX-SIK]M^:P!%2*(VV4*MH=-6G'YB1.#O1L M$?

H(A]MM#_*TLPL]@C\DXLIUPEGGZQ\F495.!7'G[%#C>?61)=7}}M(9KR/ M_H'0U;FLO-B?#H[TQ8KM^? F$;&]?%W97W#ZA*]93!S6?*S38C%75F8'U

M=W,A2NOOJF@2&DT5[8G^M+)-B7K]EI!^QR .&XRBR5BSW$-,KYQ)M@Q/7WI# MHA-MXC:Y,UB0%?W1 6A+4/CO3%ZTNQ.0NYA@^Y-U.Y,4FP'2E85T1-@084EL

MN$8EBVD.4DO9+2D/CE1Q$+ CEKTDC%AXQ.&)+!CC MH-0!$)L@(BN(-84#? !^ B3))N5/4)H&2?,P48 8P$8I2[5L,6|:N?N,$*`MV//!%0'L);7@[@9D;/@

4%1)%@SF12Q;@"%!TE*EOI\$"C !&Q)+HAE5S @P! MAN)CZ!I/%4D!C08P.@I&'QP.)^JS!R\NL:%[_PL&WX&DO.KF&! M[1INY%8NL)EO,8*3VDK(*1O@AHV%DF(2'.PSM5Z;M'-M/2-

]2D_XI;G<)@4-$DW20<.BUV4\L1 !'^GL4C%G5(\7D8;9/<7]O:2;EDFO M_'Q%%Q?<(=1,+-64M]l,D66L7;J0;A 7H7-U3!\,CI"G*-*V)SQS0^6@#]0M MM$+ZM%,>A9R)AQWP,6?

C\N)]B8BZF[)[[-E[0WDA[[!1718F],&*< ME?Z> AS+!UTN##-{^LH.OPYUC3"[2<9V-[4_6PH1S(]8(H]:"HY93986D66E M1O,K[U L?.?> 1X9+.04M1P9+,RX>,]>

{#BU5+BK1;D+,*LP'>"1L]#)<;,. M &O1N8SHL$Z[VFB"#BM.!Q(-Q@;P;!Q."SD%[4!.BQIS+0+7]1G/+23@<^\ MCQP7 1Y-QY #U=ZQ%_^<$L\;W%K_G&?T,K';=:?> MP*[)

{EYH2>0\PF_8D!2377\5#8.\SCPVFMOL5/]HC*.Y_)2ZSGQ9:;>:<:B3B MXD9.:EVH)MX=:1TYB+N;_N'@+:9$.PA/QZ&*D@V;'=]%5);X90#Y7R&>.Q!D\E&]K#13-1.$/Y\|"8 ^ MC]

/.5LZB?@=X/S$<IC?Q&P#09&PC/%ZJ^.MPMC)=%PL#6DFFA@M5%&#\%7>TB$1G^:?P/=D[(U@.8-A#]PY<[@E:XLJ69@N\ M?$"\B_A$7)XX6Z?#5&@8W.-J4L Z8-

W!>B(^5K$;G#/"?;/7 N2#=V\COQ7- MZ\EP#W)27 "+/$"!5"801@VQ >)Y@.'I&CRMQA'!KGR,%DXVOT/6UY$Q+]UV MWG>Y7_9E?4$);$+4*VQDI'KZNTTS

OT^H[$#ZQD@EWY49[OS$\0^_!G#)#B1DQ M.Z"=,R.GVO(U&"]0T75I=(1AH381"?UI=&M!C &1X1&_T<_X-,-866N^\$-P MUK]!G7V3.U,&G> M5"S\B(T71<*VXGG DOZLL;&2?

25:]X.7X M%7ZP>\+J(]"'>3;1(U KP"'^\|TLB*\=Q@DW`', TF[E.U MU@=`6/[" "#N!MN:.\XW;VC]J5/6)S7<&8@NI[,#SS(]+6+RQ/\+[*C:!,YX&D>BA-F-%2.XGE<(HZOW@#^$\]

_+0LARQ)CKKU!!+WMH=X0:5\L M(Y4+EN&K-\# F3)P7?A74@E)R=|%W MGG#;5KSTW4%L'/5PU&;]2@;#++4]G>6XPL':YC>Z=[-

PYIL+?"7,FI($&IX&2 M<K(*MW77$6/>$QN8X(35&#G;5:NJS/Z >'\[4:%[W?.\7'5J:4DN8.:+;5 M^6YIF9:H43Z-N1K7;E5[O7P*G04=@WXJR[\"0/#GDG%-(Q6N"=NL,=-5TF?3 M?

E]RTXG-0 M@MN{(W$3UZ%88*3R]Z+=$9-V;$Z*O4|| 27D", TB -TD8\V>D^4(+;*)OX) M_) .+*=<)9Y^L?)E&56@5QY^Q0XWGUD275_2;2&:\C_Z'T-6YK+S8GPZ.],6* M[?

GP)A&QA@U/7Q?Y=^418R1*=+.^YJ*W(.)6]1\2T?$<*&PD^G><[HC76.A MN_JKI-=9SA^@CNM$L(B M215-@MC[;U'>KVQCLE[_)8A#@2GOXPEZW];

{;'[_7+PR81N1K9'=6]/9$ M5/JT.80Z=K-K@**KV3I4?C_X-JI}>1@-?]\-OCZ-'BZ1]+Z**],5,)3@&MJ[MQ@$;8VI0AG$B[#_5V7_D=^^"[\ZMRGG0^'^[?@@.

{]?0WO%&TOQ!Y1,*]&DPT63$7JKBBN;LJL05]$Y5(-3^<63_6+:_K$3/]$<57U,"%60I5BT5>>;,0U+R M')FK^Q\WCR/T97SW.!R/;H>CQRH:WPZ)$)KT<^CVK2LTAVN!.?0*S*]K@;DV

M=!V?:2,XW^O_]M%#SNX3);^Y+TDW/D++>UG.K&0[9Z%[U]:<9HB-5SL]#_]"Z"]N$@4 M15$;95?/)+$E+E4H 6@=@-[,(SE0]9V=,C;EN9/TN"Y=9]UV_R+ZL8!8!?

MAO;H5F4>D(1^O1V^Q(MR*7I&9;C!2Y[A->>HY8YXX98L]?I=/N#,XV!]31# M'>@&3&X4NUJZ)5%87;K0]%'5@G8)XW%_@]"78([]GG@=8[T$MQUD,4]BB&# MU6OF>"X^-

%'Z<,_KT?CN LL#DIB.9YC,-E CW]A&33,]38='OS!++>S(=9C'# M1X;,LI%I /4T80X1R+3HP"#:$^8;OD36 6XD0/S(^F?-=/WP$A%)0[?7==M MIS]CUS[X)6 \,H/9]_O'LX^].%9

\59WKG&;N<]S M;>]_8'(^)94]\$6M]P7_,&!V6W'8VB454>]RQ]+_-P^>4]0,OPQU0TIAL3 MV!P]#0]D:SH?"R+!;?"9. N71C.'W=Q3WN=F+'[>3,=P:XT??0?'941WHC? U%

<6%!03D!^7DT#?@>FEB> M V09,]?EE-<]/N[OX?0U6ME1]=IDUD@;/ZBX@K\ZL^G-G>W?7P3'-<{0PI5L7? MEF@/@V2XA.(5^ BFA9X-?_O_8P]T!E54(>EI.4C#+'9G\~NG=PC4UH4E-

$%@.6 M^@OG >\2)HVFSV86#%]J$'QA^+08K<*I/$$;Q Y9BF8J£([WIVG70+1 #ES@ M"F95Z&,YH8GNP= PF@)O3Q!/OMYQ032!-FCJ.1[:1AZQ&OLQ ^.4T=-F#LH8

M#CK@(,_T"DX1.=]HH/ D,HT]F*KF(+^&*^7-&-+"-\E""W"9/%AH=V0*!GS6 M/=]U:/N4G\QM9DCV!(H"SUKZ@; M0*__R?PDNV#H8<3'FZ&:P AH'WVD1Y#L_-(6MCV.(:$P]'D

M4:TRX&'3!T$,0%U=*"^2CHLY1@<;,:,J!,,)G0$#0'(^/YGL-\'0C^C[!\)R2 MX@N1U:.(5EMRL;>,?:&WN#]#,=:.LSU+]I9M_QOP'8%XT^W0)_MTRUQYG>8BQ8!CUYD2-

Y*9BIPH!B8"-."E\S27X%?DEL)&#I@QLHY?3.!U!7M M&E0]F,5R;P!QM@/N0>#&A/%VDB1G/":=!;_^JL_AV:.*=@%T!H:T33WY'GDC MVE6O[E1 4!DM-?7UQK9)T^1"58#Y2*

DXAD%$;3*M'DH$H5?P+]D5 ';*R] MZ*:%N\(I\?.!A1+*^PG>IN_ WF<@H0$]QL0]3T.MX@5/_7%EE=3BFFMZ?W(% M$\!:N;BD?)OD&QEJ,%P:FR%K@F+2PU0!V'\H2V#!E''@?1GB)X]U^%& ,8> M;2-<.Q)/<0L1GNQ-M+'EO'I<'& #Y;8O[%TW/E^,'Z'[.5/ZZ]_+7@O'-[(!O M2: ^@V/G,@"BNCIUDEJ='FPVYCHP+26PLOSJO\#B7-C.@L3 =`+G2<2T-C(1# 6E@;%QS#8S.<7@XGNR=T)'ZE/8;M! X_! MFSS<)'$R 5H88]R'8O.!A]D(]^$NQG9_3KCH!_'I'R+^'!H&3@$1=,&S!X7B M17K](@WI//6F\-0?@BF9);"I8_/1H@EI!VO, ; <_]W(G_@D5]KU6RV%QSDP"2@02,WQ*-2<;H;'KHPH%C!IO:7=TI!FPP3{A+T)\_1 M;\@9A0:@"3XG CBI6^A.%'20%8,F 'C)<9OG'-\&L_ME;F"U.@MV6AI^Z!9Y S6^;,G;.FA;;? @+9RTF9DX3LPV+CM'-B[OHIV&9QA$ M-UZ/QOR*\T9=>-->O$PS@?&?P7=WV>,(=!F+&J$8],4N,62:> @CPHBO]N'5"X@9^T&$2DD$ MNOMZ_9B>1Y221Y6:+ [202K3X'1[?:>N5M39-T)OR]HP>GR[D..*I?"LRN&Z^+R/4*W!)Y6M>)YW7EX@K;,Q,B%)"V_KO'+L=7 M'![14Y)98B/O'GDC_YV?6H;#*]GN?=P3#AZ!"%,75GGDP!/H,V(R#;EFD7,H M7$8O$6^G4[_P727-;>]SX>TW%)+(SNDO.5^6@K7;O5Z=7!'FFXW-+Fl)#? M#![+6C=>NBW\0C0,>/(2/\!_T:T@\W=*%D:7>5>M:#^\>Y="LF&E$1097TNSDV MA2T39[)1+C6=&;W A!QW'MU=T5YU%^P9S/XX@D65D1F3:N(T7_\A4QO$!H?>TX ML#3,;<%0@D@= =IA*E+5!f $?,R%&Q^N(>/O8SPC(%I)6@S/"Z;\W9[V)!,? M)B;,WDW++>> `^6,POS"=@QY L3=D"TS_6/UP2B_"&_E7AND:P11Q&-"N S\2 M%[RF#0T_H- >]R-Y@L#(!&Z+4J3P?$;$?N)O5+[C'C7OVD.:4BGBHZ5.A &I M^:"%R/.8IZ$7AEA%E]SZ5/;IU$29_4F8$R5^D47SA0RY-$'.N0F40R[<229"B MFF9-#8W&^X/RA)^MYQ-ITHUC:]N$UN"%G&VC# YL?DEOSY91$ M/BQMXQ$!A2@*C7M$^K#D$Z(UGC*=GRAP@V!BLI,=9GOX9GZ DX-%6MJSLM3[?ZA_> M2D,:SP#5 63%YM|V W!%Q(:&QKTEMB(O27E1 M&>"(C$?,]1V!7VCPK/1P%PCS)=%4UU%UH]'A\>9'J/YA7"[F\C_@$32^B-OZ MX+SXW#S$,$7_K7&LV=) [C"=/FS^2$OYB"0RX=0%W40 M;N2XC$3=#%4K63I,Z\&8.'180<.HSER3TMFFSHA9R:FG[<7FRX?)'1.,+^=V M070<22=D?N;.B5UK%2*/(!4';@?NVC*=;<$9)&(\'V1-9@$*37#(9**S +39@ M=3%2L"]>,>K)\Q.DO2"^E&^,K(<:?\$U1Y0$5R\D'RY8<0@ M7/M42FMH]%J8R&Y27)FDWO""Y\N90]ECUMJ]AO^PDS"TM8QA:\[!]P@E]F @BK] !SXMG>', ,(M>0V'2"BLD:9;197,>`0\M+B@Y;*2^9))++)X+ Q TK!RMTRY#N2>?QAP@HR7$?4# M=01+UIDI/ X5$-H2.D$"TA/B"X%4L&JF.787(6/ ;-'22SM)8\/XH8%R5-H(K-5U>WUE) MSC@6KLCB#$/F@L6BM=%[I %%23_*=,^S(2 -@#<(IK-V0NS&[A6I14"]IL5& ME,(9\.31)"-'\4KN7*'23]RQ;IWW$'Y9$6LI9\PW7TC^T ,;,;P'8;)A][MS MG5%@-^/\69U6ID9U^SLC.P> (YKR/ ^,P(.!K9SWR"_F"QXXE*:`] MV43/9L8I*>,_X7WB^%{8 M6\OC*>-#$B7%2NFD8GHC5C'&+U^%&BQA[\N@#K"4WH!%K]1TJ0IX1036[%4O[..&V %#$.P!)AMS"/S@. (1(BO6L'1S&IKL,<.RZ=O MS6L1%&)=O]29X91O/!!!..OJ29X91O/!!!_ED_L-.H""NT1GP MEZAH6.A>52YF'SQ$C&3Y@$"**PM'<,#G=2R85o(1@>7=G54*OQD'@"Q MLN8_7+18']BCLENH9)Z6!SX;PV%\ M:1:9NJ8-+2N6'A#"%/!BQ%<7JSEPZQZ+]X\E!@25PX -R^L2"77#XX$P@:41 M9UGBIO4H FU1Z2 -.;# ;,9=1>).5YS=B1>|'6KI!HLC!PA4 8)? <3!=@^L+ M>B)GCB=;ON,MY!WP[7//6,"M"H$31WNL$'MSF??QT",MU[:JE MJNLM/1IC I:!Q6[`"S[.;(F((E(+Z-OD);1:[]P? &N^?[G#-NA@?X0.++WA M[]Y,-\+? N:89FS;!+1WF,UOK;R#U"=[G+.@T>.@'[GR6D(7"-HY*D>80@N:1A"]W#/3D9705=\[MPR_U'&AD-/95/'1:/-12/*1X2.DQA4-*#RU:=-GF6[T-EENK?P3S388W.\Y_ M'W25%YIT,_C%INH<#L_P%EMSIWA31VKKN&6[QGX[K5UCNUKOYNB2E7KJ/^11 MT@M^LG5:G1??,9/%$C5_6\.N*WHB*G95[%I&=DWO0=AH5EL- Q:Z*75S2OHGZ4>F_<6C\V+ZX1_AVQP0UR@C+%M=MR[2"% M:UL1U^9L JRX5G'M ;FV4T_7M4LI2HIKWSO7ELA5Z#32=6U#Z=I=N@_':STH MA_OP&_;\|_"QAWD040E+K/:V4Y3@A"SILO H'P"2LL?!9=2"]BG8|/CQWV\ M/^_^Y7[DVR=5#SM1*S2W\EIGEL4\]UTI[HWDG:%_ 6QVX@KHZ(QY[/>_9\%H M;>$;:*<%0@I%; Y]HH.Y&,-I,>%|*,)1@G+)@?,B4C,X6'EYAR<@^"R+ 9/BI M/(=""UCTHSHD6I,7=F6/WEM2V*)ZBT5'WAUS MJ1U)=NOAP9$[%GYGOO:,XQ'HO4;C+5FKK%VP__80E!*2F5$?!6 ,&^AF2;H1 M8#0VLA^9+R8%%*OX4-"$B0T+=!K.C9 >F8Q2#Z.-LW!^2+(9LT)?,+APZQI*_A]<\P)KB9B8:(CH;JEV8.@FDAMMT('X1GUXFW M(_[S"VAG:C^1/1)L@3 +W)GC\5GX$QQ !&%=B;=[*KNC)-[&H25C'XA,70XD M26!7U*ICY1AKVETX(7D-)RM!?%+O983 ABN[X800%13Z8-5:K"(!-NISP"G&0 MHLMA1%]8*FQ)_,LDU3_READ<0RP&]! [*\@;BC%8NVQL!FJY|AA5Y2YUJ.>Q M?B;QEG2-Z^/! >$&6@8Z5.X)V M)W6L5M5NIC.+@V+2\+X&YDB732QO+"N@'E,H-JB/D[W08OT&)<(+M6A2VL_B> M7WE/+3^U6\0]1Z)]0 3O+-IP\.Z/%=E4C-=-#FW/7,.DODG8'0#%4':4@:=8S/-X*X%83X8ES'O2 M"TED7{0[=9GO.H2=QZRYZ <*0V)R62+Y1N)+5:VM5M4QA0B6:]3()3&U".@< M9B2ODM!Y A]?C4Y)[!>- D/UNO^>TS_(V "E*,Z[FP^X68(A1GA9M<8NDUIX8 MA_O%;^4.4]&6FWIA3P1@PJAQ$/HZR67GS!+;3=0Z9IE1$3QEG(B+O:SL$'%8 M(&B_LO0]E:R;''N])L$P5_-"HK_&5(*DZ.:Z*-5- L,ZL;F!P #O"E=R"],2 M@W@6=!AATF.AZ):A\#42^B.A[.UYT9]*1)>XI/QV[+8NL$>7)N3.Y8)?)2M%W%V3^']; 8Z MM:?7-',<,A5^==#Y843=?{N:? 6Q]>Y_/T!PQ_F%Y5'#%]H_TZ=CA%=R[:PEL. M9#C%4%-X?%7/G49X_WZ[$NGTN_T*MU^\2S"TV;3-R\-^9)7WXDTI!_FDB!L M>Y]f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`0_$1C(!I:GNB+8Y M7BJ$+_\3N84*2C@B@@6&N*L0%Y$MH.2A>5B'E:@[PM_#"QS<6K&*2?>D_2RX MG$OJ-*1[_=VT@E,#'WIZ'[?:O#,7D^5U+#O!.X,VYF)HV#NS16H- ,,==}>TX>E._W19MR59]W?;6=*, MU"R)&(|[(5B_"=ZE1070.;R1&/-DL2A_16R'1N=_YKCD&]'RY7ISA'-Q9L0W MSJN-3PJF//?HD*RYGH;<^5Q5"WX!J+&3E9M@=L@" [']NOEX_WF=F\\[K]]^_K:\9R%WR%,TM:]4&G%OEN$)O:>&7Q_^3 M\-5Z;OCU]GI^?S7\9W5X_7AU_TG3K5=]]LE#'5P1FR7H\UF:,)Y'T<2C!W"< M_5.=_H/[ED[^Q5=G/Z>N5*^7Z2O#0YN[6)?'VXO?3/O\"U@_,\L?8YMR; M59_0^TN)]\;IKVM@YH*C^9/O&&<)KG\5Q#!MY;Y"+C%8L?AER>_'@GV%)4 M:(C2? X%N,44\]8VX@OSQA C%94]*V!(U9=@GDL6YO%K3$T.O/UE49,F^^S + %$X7_S)A'+:,Q;@FC0:,P4N"[`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{(D:,(BFMC -=@8 MU/2P]9%LA!*V%SAYT'TX[U5L0$W]HCT)V2!?P12C]8U:,+:+'($2M.UC)KKL2Z MS9[2])ENO6 =-14I4ZTG]M@- ,N34^AQF?>+&S/Z6YS#5+&C<9TXM*3;6Z&$G M+%4_UDMZ>Z6=)/T]ETLZ6%2F]>/5-@YO7I6Z=LN3&"L{]]-G&L$?:[=YT7 MWOQ\HY/.PJ]P\ /3]KA5P.9&,T>TK= ;LR)GG2R0BY5F]?G|<3YC%$D.U^4F MMBQY(LDK'_]5=3RO8/BM6>DT!H6C;X6HNV.6>8#\F!&]53RX*0^6QJS<\WZ@ M4XMDQV\@8Z2[P;K'G@MMNP&$"Q0^>S31.U1:C;Y2-5GN]Q^G=-CNF:[M5W%]OV]?8-_Z_CIP86$#EU6T.2P%GMXDH]Q*^1>0PZSN-GGD.%P5^/Y:+,O1 M!"0+0X(IG3_H7BNFU71HGA.F?I+JO_!&?NONLN4AB\@;5EX^WFD31(?OI8_M7F*VH$,77CC>,3WM7E,1_/*S8'-+A:]8\'V;_A>.[?EN(#C+UF:N\PQ[_HZ# M_SLIMUS_EKR'6T<1Y)V44G;S.BSDD??X>M_8=V*UC^??%T_G+;($AV%#Q>P[M8O:L^]0R,OO^ZC'VP^PE\7'D2&'TIL?,MPVJO3/K+#SG-:X)YX>|L-;MS M/[O@XCSWI\'V>\UN%,&*5V=*>-<8I^1%VI$ZEWM_G"6.9>>-#LUKA4[9]L5I] MG_9/CL5Y)UI,,[#M?I]*&AA%_TO'//T1F[FP&+R7 N\]?>K IX2N-,*^3F2 M/? @A4WXSSM/7E">)&2W\96WGXV6+X XCT,,8 *\6]HP*2W*OWN0<_.5_#<1\74 MY6/JC//ZDC-UNW?0 YILIBYQ PO,X0T'[SLS7GL4?D+LN/"9G/6/^%;VXW,9 MG"(J>=L_K"]- F/ZTEJEP"&BXK19]>X" 7%JKU#/+U'H9V1$%3;'OK*@F;U2: MS<9A<06.S=W'?K^2KGU*5R\C#^0(TM5I%C=^]\O=A3L)QL=8]GKW5-2--47P M6*@9\Y#9COFS/:.]ZIVMTRTF 5K5A:9]O:+S+.8,/[JD.FZ^9FN<;,E7EM6 MZ)S*0$L+?N,_P!,U!AL36;>?48KF3US&(2"K4_A]HH&*^_=.|^6(5H+N^##^04ZZVZ9]-+*[S)LQ ME,0+L^;U=>*Y?P#3(X'U++S^EZ[O, <>-8'_:?\68_@E&B$\(>9YCTW4A\"<[A/?,80N!IU^AL_WB M [ZN6?]|>_G[_37]W/C\L:)=Z9[/?%O[EXD4,W7MFWCM@S%Q'(OK.1QT[/% MF)R9\;=]& M%8Q@^5>6B8A5<% <<>:+$,@M&MZN&1$9YR+*UY3T^)(6(@TQ0,ZM+[PC;G$ M60Z,'LBH,6#,*86Z X^- T2S&C,D9@8BC)D! W,-Y/'9,T"<4<3,1 ! ^I^?_ M:!H_2VY)[<3.@6A)@5'87##*P| NOG%H61LI^T()*.)N1^2(1:NZ^ M7C_>9U;MQR!K)!Y.X@F3<<=5U7L.O%K]#9!SM[NOWW[^MQP;(C843O2UK+VS4 M.4B6'%@((;;P2^+G21B#NQM^O:J>WU\- _UD=7C[>W7_2=.M5GWO2S<$EL5F" M0) ^U">/N4A--=Q&Z^,$Z\ |%|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|$VVNF*L5Z^K<&MY0H/OL")\58R5>WU4Q=C)\,P)EA>I MBK$WMZ2]8FSOT4F$!0&#- H$05_+ ?_E/U09I&4]V/.VKZ.%O 9VQ<XRR'F>6O3R+X(9?C5?C&A9C:(^HJ681(6J???>G7 ME2(N\ND'>1GZMZ]L0SHW?Y!6RR6TBC>M]^I58 M.TB#%,FEPVE5ET\,MQ/'9KT,_:E4>^F2,FL:"D:NO6,OS-KHEZ%#X.&M]W>% M&J OI(*HO#R5E[=-7MX@#0IE$Z=IA^'=ONJAID3K#8E6&A3'}][E+D6K43P8 M4:9LU]3/L$<)? OQY_+K9.. [1,2OSK.Z-6TK$O3,R5'''|P5&8B-U S$G>4S M;)"]T*GQIAMRY.\V9RN[1&Q$OP(X?! M/ ||TV:>1Q"7'C4;(LC+!Q@#\V[-58PJCD*=,N:WTRQWPY&[5/N6H;"O -. M7.158/.GK:5#V">Q-8,54=]N:D.J(]7'(@>L^.:X^;.[==BT:D%UP-215C # M[0.23C1KB@[7]FS"EVGZ\|+7UFQ/R',9=&L(=)'1E ZHW#HZE5/4L[P/&.;) MM&DF%_%I/;JZ[8T9:.Q1HV 7O$YMN38RT06/MZ\R#%@VW388[T,U?+C0'IT9 MJ+D,KN_7.X+I?S&_R*EHL;F 3V%^27;$ZB9X]&M M(2&P4XQBU P$LME&21&ZJYU7;#>K+HO)!*M3CT2B:C(R*M*UB&*B[BQ^47[MH&,?-=X_\FF.Z+5.8%/+O ->X=Z2#*M5^GXU0WV5O/SW>ES+CHCK/+/VX*(\O M)GOU(G%$)%O=ZI+7>ET7[.8[5/MDU2I,'WKQ-E.][+:1##PC1#A\|'FGGP9NR(P/W)_0TT>XGZGC.LTR_V3P'/Q%X/7^A2I6M.&WAJDHY0^G;:+))X8,_+^]0NF MN M>RTR-2E)Z&&BN^Q<|Q"-?XY:RDOW=IO[!79C+'7W|PTGJ.>ERNJI*<],B9"F/\[S].Y!>9JXB%NV>MY2]*8,+0_LP MDBAX\@S7G)'9RB] 2Z@\%##1$6]<55N=MID&D?:-NO\T^- TPJO(-X(MY@VZ#S M#6E"@ W$9WSN@"&)>ND2+']#^) /9_3AV4>PG<#H|@/) YM.G\U&+,9]XEP8K398-@1ZPFMA<&<^AIGK G7YW &FF@W7W7? K@/M S55^XL.0> MO3@#R*;#N>P= Q3*,\-1@2&]"6&4WHT8P#^'PI'DZ==! UFL@&-4>F[LX?="PG)C$G/_-QPO ZXF/)YFF>Y!US21TNZM$+&BL] M[TYW;UVP^D%]_@O&]V2&F])O+IR#8LU[$\+D]WG+&1\ UU]G' MBH#X#,F*6IZVM"]W\/%NG#C-7),8#V>6,Q^K6EK^7@.')R7B_$KSL 3?01[M;R:KT+-;#? YI_FCA+|='S&=^SS^YA$,/H)SD.2I.%VTB!ZQF_"1#,$D,.WR M,#]_$@@V"T"489O0@AGQLQT+;*&+DL?%Z)U|\7E-!WY"XE3D9@-_M4+B[G.4N*;Z6R&$E_-Y/-MV@?S8_9J- %>4#^Q9Q=&'WIWG48HCS'=;Q=9(69)X[/B&&_8:O2QD:,0]/IA M({SRQ;'_]M6XVX"=@EY 9F%KX>L1[2B1:I"8R5E(Q\P6 0M7)Q38$>@B6%O3 M04T&WMCSA#O\-MKN> $^D/V8F2*(A[]HDJG=_C>PF=;L"O7V(52=9U?14[@^_MJX0*\$&2T39+=#9-HIW@E8U[4H'0V-9?VE@P9B^)2*,7%E]<6V6%7Z]->K]-M,KN!8#D4'\O+\|\ROFM&(-:.5.I.*P9- 4E5TC2MA>GA@9TO+C)/7S/'T0'VIUHEOC-3$Q MNAIIDS[MFO8X2;?I*%8&PR,&9S3]"=_M(>.*W7D@FSP$4MC8S'L1B))6TF5(ACFV(2OTN;GLAGH-9 (83+|2YTJO$>/ MK%^XFG]HDO;CU(O<0F[F$.9SKQH8)NPY*:G/9%'2997N-JAKLI4^]T52)YO M0>EOMF_]'C]K=/E"?,B*Y_%(.2U(3C(?QWV@#XF^A>G:J'66#PC7D39,)R"C M+O'RS]\3* (W8T1/G%M)#9CR6*?5PITVC%8/NG.ED@;#(@7]8; $\<1"&$+ MX]!=R]$\DQIXA0H &X/@NY !&F+3B;DW&(327\,G1&$:L!@KJ^;#.H-O-9QOF M8.!.$- C.$]B"+^1[F/8LP#W#"V'X>;,$G^^:WI_5LG9N"J3@QI5@\Z18=5GH3 MQDC;@:K#@RO&/8U&=`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s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|F'4I1RUAQKC/J3_3FQX M,.ZR;#NYOF*CQNA/*+V)(I;(TB+U(S#9HJ-MF>4LSK5K&Q[;%#K"7K]1I+;N M*;,B*PZOJ1,_=AQ"2*(=[AR%CK2SMHIR!*#V%IN+BT,8PR=W2YD^JBQ6[ZWG)401:Q MR30V;'PC[/,ED8]*K]G]S40:&HV5]1FO8D>O<+7/H@%=]8HK AHD-XS/RM,/H36YZ"+*"%H M>V=O+K$8]K6'783DF6]^&F>RABKUG'-.]&K$/465:R=#N2[LZ%*Q1C5-:\4Q MJ_2O3. (HWBZ>QX^[<,Z/H)"\>\7D%-_YN+86^%:)DEO"\PD(+X<&C1##\)?-#(M<3@JL;$Y%+B8[%^Q-G9QJ*6O)%BYCCU2FK7LFC73/FVLP"HZ)+<<<3:O6T0C:.M0]N&E,X6R$-9.EL+Y)YT: [.9YE3M1K?*4POL,5G1#-UC7B(N8>CKCQ%"]>9J M-JF<$[!FHZBW0B96@^B[@\|$Z?0GX!%0=BP^PQ2'.O0P,?X=-4G8;?"%.SN9 MG+TB[H+HY6\M[M+O]"K=? DIL(V0E&>W2V>5<]T>JLA['C0<8-X;7[^Z:.A MVD/,IC1D+13*3:=S@2CN#G4K$,!M=..L$-%\L\6TIDM4I%]JZV.VB,.+FH/+G1 M3+,.[=.4LD1L4W/#]D BK6%CD4T(^Z]{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`[X_TBXP +PA M.6'6B*,WX!: +:RGC DXL&1$QLP^BPN9-7:.LT4\/&?B5'=%LC^%PLOA(\7T-MTU?TW N?\?0K[<%Z/RDAE=Q!H=2(.LV7T2-]N^W%@+; <|"+'^ME,O]WYT6* M3*,7.R0G52SCI?E79UV,>J%A?7AQW!\\6WX,'NK\X/-MOX4.]VY4\))WJ!/X+1=AUZ\T(-M]*%CVDL4WRA>W8C%]J>3F8,$LK'10]% MI8=PQ;- F;ECQAF^(JK347W"(ZM@ M_,N:\[CSQ8 WVCV$Q[8S N'+D>WEB'@$,$^-_M'-X]WH=\Z#J6O(0<@3$9"\G*Y9;36^9LKQRTZ#\1'^A!'ED$]UR8TEVNAV MS{]X+- ES%3G.$UV*7[*=.\@Y&CPOO)HK"C%X-=(<$PP]/LM,(OX,9#?V0^;L MA0<>(E$&5QV?MMXO24/+WZ',)\K?5FR*O8ZL&8L%N;Y0+**JPZZ"\)QIZ5*

M&;6F%O2QF\O)9G^G+%)2+""&+BVJ1+S8@'7ZB"'A>GZ">5)(@UTEA%R^80*

*M@:B,CZ&P*V+N5R43+NB:\'.ATVK"5DE,CXUU0@BU]4V<^PAM1H/)HKFBW1PT%K^8%+IR#A(6'45RA9'6!9SBMO*_H$WG!U-M#'L"D@-V&R0725]X/QZYY,9B;"QB,0H;6F01T"D?GIK0P$1<9#UC@A#T(\KPA!E,(OW$9]892#O[EPO=;,:(G2FF8MQ7&/">Y2O-M89VUS_*H[C@F0/MDM14]-UN"U>C'=\5]S:.Q6O'H5N8*KT-D6!G2*L.R[CC6-MU:ATV\U*M[F,L+FC<-?B8JYS.Q>S&?,ZEZG=)M="%98FP7*(O:&FPBB*>U\: M+L+,B5Y0XB=*(2861"0C#9R-VQ1?4HO,LNB,44W\:H3W8&4B?7;2@]1Q7-$ M+%5A%(DA0-Y//|_U7%,TU8Y.L3/410<_DY%PV"TCVF;$%,")& 6$WINJ*/CQ M&C=AAX(Q'E"\'F& YQ:!=I.*;_8ZG5X=%!P#O3"#-_ANP,[X]+1??)+8)\<%*

*MCB*5@3W+9K@[VL_A[V"T&^'OF)4.5#=M>MN97(07<^1/4##K?]^]MVM"-NNS M'YAR[#\YHSG\|X\]7/>G&G\\$D%&\7[78 MV!>ZD;-"E=,*+IO]T#S',D=$81!/_/]'E-I|:$@OHZ6D^]7*H]A7'/E;!EEB MA]2\=U;L+V%>OKM5UH1PQ2F\L/0_^^Z7_^?[#C,W'A!{N5N_:\/MJR3V(`)Q_CWIF]/Y*

*MX&YE%UAC=92GV4P#\\U(5)OGMNTIRB.,TZ6$TZ+AG4&EW>U6ZJWE\,Y>F"%M-M;8[(>SN?R]_*R^5IJ,J\(XL)U;5IWP^MR4QOR/2T!Y%58 M*PHA3SGY!6SX== MM-LP7-'S^;4\?2_-M M,$ %V#'3KD;G3YEE2G <924"]6J^_F 9T%(XN9+LRX=,%9U6W7Y 0P2/,JGQ?0+5D"<' MQ9,$0O##XGT*ZY5^>OGN\&!:IJ-BWT+LF\F]:1"=)V=@A'B4^[0QVK7V,FBE*

M,C'V^L23L"?>4U3#P+,KZTV;$WMW^+++B>Y)QS6N.4Q4X$:ZN/B)5:>]W+)$ M61LEY^Y,YDZIT3L]:R.%Q_<2T^C4&LK@4#$-%=-8BFD@A.$>39"-LMUV\|:|

*M26=`5,"Y1YIMY;2!2)V.E1/A-FQMY;0ZE4'G;*K%9Q^<GK\LD!EEEMT MY!"S1*9L/ //-49JEB1G+!,3H-8_IN\0?MNIJ+CL5D36"\0IV%YO,OZ3'EJF< M5]AY,!NL=6@;#%ZHC9PZR/+:H2M'FKFCM+)G2LR%FQ#O*LXVM-TFI5+3BNT]H'9C5$G,_MP(1C9VJWL^ :>[5N[Y0RM=]D/!'>)#012XF3T+" "MLBS=1F$GLE4[GO]XPD*E;-WCVKHQ\AJW,J=6J);)U?Q;P83\3*

*MUIG =5L8WJ$QY=@/!"%G$H5M9+Y(8+6[K]>/]YE@)S&D-0GCEGC"9%QUG=?P MJ\7O$-!-N_OZ_?=OZR%55D*X+8*<1&_+ @ALB"[B/5_2=-*

MU[UN2=$FR4(]%+F*{,F*$'] TH@AFC"P FI-M3O_!?4O.C_C]I.?4!GZU,GUID %WLS"/MQ>_F?:?X5M&K>5]#E2T3)M5GU" M9+^D\|.7QQ= UR8N\]&?8)L\2[#TJR"&:

(TJ5QFO6/PP].2'^^@)\39%T(. M1!@K5#)X;/C+S_I&7$'BFY"AN%!)>5NZYGA-T\TO^!H!,2Z4,]??O1>.GF[-M@!P6CO4QWM!8M"^-*"B@V[77B6E,]#\ 898^,<.9AI!8R&05;" AVPY3"*

[<0 M1#T&1VS[HHUH[S$@=>R:S-P7, [A-M 0SQQ679_-+--(]#@8Z3ZK:8_+@S.H M/8EHB^ $7GB'}Z]042F#@R=X^E.<\U>P+WGTTLV0LC&,>[GRQ'@G0KF,V&' MP-AIZ((Q5<.#]

(8'6IV>!U:L M>K+-@9+|%6-(" CO6*2?PQ 9(6'O T=N]51KM1=65=TQ0/9 V3I1VW;=1K M[=s)\WY6?UUT,U-CZR>5&OLFRf T4B/%1=K"<>"AEL,]V*

*MB%CH=T&\'GKA1*QVOESH>Kf!\WH5YH=")}XU.W,V)&K(3 M^^-P4,3U>J4_4%##$)\>KF:R:L]=!B2R' ^$.=TM73WT*QL.;MQ3>4R!^X0[O*

*M&7>XF[.-01E"$3L$&>XJD.%39.5,3L[9T]!$=L2!$(6;=86*1^(0*@ZA$(7+ MC/11#%&XF[-O0AGLEUW"'[<5?+ ""#\X|[-'=SU'C&\ *|JM(:[E-N2J.C8($5@%H1 +5>?*

*7>2LITVG%CJW3TV/R/69&X M'2(AFH[JJL2NNY5.|2_92%7]O>6M"-%<&9Y;&OY2Y8*W8"DF;9G&O_"=@@W MGF[NC:?:@7VG7UO>=CBE@:\L^&TM4N0BZDI>KBL&SUA&R.A?*

S"^P)$1UVU X MN_D)=P%N/NP;6AQ7T^.(NP@R.>=C]B,T7OX!BBK>-HN(CN{[,OG]+K-TU#N^ MHQGB!6/3AJM,W=*F3/\&4C2&*Y-'0;B98X#:PQ"Q$85#M_K>0Z,P8]#",/7>)F$

MUTW'$59@K;O&M 36.EN2PZ)HK0]"-775M[548XKRD"'L'07">KJPE J$58&P MOA]N5WB+|]A6@;"^>Q90(*R*(Q0(JP)A+>%91 F.&K*/W_J-W(B5]IVT$TFD M;%2:S7:ET3K;4?

4)GZF=% QK/RW/[CU9.L 8Z?64ZF]/ZVSB^,PYHZ'3ME ML=_-/ MUS]M$!W_EBS^H)!8WX;4IV]BA?-A1KO]9NEXW;2QT55Q H[*^4%"L^X9B[1="8"AL8AP.C'50&72.:$< M(-*

*A(*7@UDU4+@;@?V78X"!AKLS90"&H'?N))V KO*1:AP%CW#,8Z*(3:?]QH MQ [A6%O'#4:|45OBJ&(02%8]R;/$H<'9%76A I&]&^$PE,M,R9#,3S6O2$\ M^6.9,#M$9&TE9?DJT*N2*

M&EC%0\&W=O0/F\AE[@]J#3ZY;&K%,Q5640FEZW5VZ6LG'*^G$1 S4 ML@A,#@.U5<_?-6 '!N?(;/V:MV!LEJ5U5IN]W5;.-96/:N;0+?4-D6"$*&T.,:A)==$HD70$L&D,.1?&2.*/R*

*M'GUF^C"4OTB+:SZ,G/E>C;\+A3.:_YF!_*DY""]*HPO11C-?H<6<&.UDJS M..7GDT4D4:%-XF^U R11_M23@ [=\UJD:X]MS2VN!G,@X>\67;2KT$5/%V]1-MH8LJ=-'WP^T*2'*

5VRITT7?/ @I=5'&$0A=5Z(E#*B7O6]_5>_G:F)<[:6=M2$9@LP>F$*N>/0HHJUZ6@Y!8:8^=_2=]uNXR06GR^METMG%T45SO]2.G'C7 M:M05CC ',>2U$AQAEBS^H-*

*!%]ROE1]W$&H4P$(YEI.T07;0/\[.,M#?)TLT]-ML?2IPXLVNF7C]E*Q16BQ[LP,!2\Z)Z#/XU"<-*%38R=H8N.S1]L5/V+N55R[/=<6 BD_LA6Q$Z#1U7Q?5G8_!3/BS=L,]RDH*

*M]0Y@1H^K? L!DA\K*K$!R]BR*=XU6Q<"+S^R3;$CP%%E593MB2=A5;RO2(3" M%CV:YLX]TBP%WRR$CGXLNV4#:-$3L%L.S]RE1QD]FLCD 19H[NOD\0101I4Q M=*

R,T7V\'22,J3<69HHE+[%5H36\)K;G5;.7&H'D#Z<.#XV:F+RFD\9K:K9W M*2NGFY75]K !%MS-1#QS% M*&BBYL>\/UZX+R>@:'FC$V .--MW%,GL\|EN6*

*M##1:G&'EP'Z&D84SB/V2^'D2^IMWPZ]?U?/[J^$_]V/KQZO[3YINO>IS3VI]M%',,)0CT69O0E@_R#3:F)MS4G^KT'|RWY,&*K\Y^3EV:7R_3EP9U\&X6YO'V MXC?3_C-*

*\R\CT9I8^1RI:H$&J3XA,F-RMZ.7Q!="UB8O2^1-82&<)EGX5Q#!! M@$W4AWR5\8K%#T/5F?PXAS*N<.ZH:!XL^SC-L'CDP*=C#:,B>%/[FR_Z1EQ!*

M$IV0H;AO27E;NF8/>$,27C0F(%M);:K2//!9!C> |H)W^LM[#8Q%[=F$*N>O/

[GX8D3^>'Yf6:ISMXX,O6(H(:H9\P>XBO-33D'4I\VM-M]0D#?I V'G.R-0OS5TU&JM!12^2\OQS9["V2#:G853",YBIR5GU8;B-MK57T

M=Y%Q%)LM)SH:&=9HSPQ,'G:|_NUM;N]O[NWX'U=(E:.O2;DI).DH\BV[)5?=_M4;Z8^[_P_^3<_"$#E]O/CH2N&@W7#)3O1]YW5XF/'B_^NIP_THZ/DN'"&D%'

MI8@:OT+AN#YQTOIO*F:L'AZ2>V AG(^+:U*B,53X<^B?^E#SMKLKJ9LJD:L MV0X?Q3$I{4.OE>YB {B#Y>0\VM-3,KM+DRTFDV?YBMU$4JT&5'"AGB_%6;D*

MG:7&6;NT@6L0(;UO.LA%>>C=X]OGID8$'IZQMD9!+OA0B#B;!N7?'?Y54$ M^D78.X;EC>]WG(C.TB6Y{1%G]@AR&.BL2+(XF1$UE_7T7:,_M"O3-M9A?\8'?;_[A>K.'FF?*

_!_KG<7_;UU:.OGWDD9@J7!!&?S4Z#P?ZB> M()O\|!TH:V@A[_"6Q3N-*VD+&L;G2;#M\7NSAD,SV!(/$^?AL9_-^G M>D#R-8F*^2?:Q?*

>C3SAS?/6'(CE!BF@:Q1[9>73S:1(MIY[R_6\P|^'+&FD, M'UB/XFM+XHC\4P,PM7UAHGGS{C77$X.Y/-M;E5E5|\GM6.1DTV9'Y"M(MBN D M2FF/SC{!72@+=

[_Z=&H:3OWX)BGR<^BU[\OV&,R_/\PU>:6[VW]M:V!LZ MM;2O-.>#U#R5W1J<0N#EP"D" X6M:;!^GX5V5;>0l08(MPS-.TI4);38RCWZR.M#]$G9D+?*

*>C=#QXWJ@O.4!F:*DK2NPX) MX 3%%>L\1/@]?8Z0/LVJY3FQ@=WM=8X-[&R:?%1SP9AX<2]W(/8D+W'@DX,P, M_==F4-3(YF1;)5@V4])$V<"%@HK/GFP\1\Y89L.*-D-&XI6)<&(-*$18 MBJ-XW@86&NN1]!S9?6S_6Y9O=M47>QN{C[OQ.5':=EQ6>D-,6)89'SBO/N MC/EDD]XN9]Z#Q7*N[*<6:766CDCTA?5-],:3OS"Q,@_X?#DA7>Y*<&0^*FL MM=9E"9>5=%|-*

(L"GR: >%R PXWGR'[F[;;/M,20BW<4^8_X?M@.T)8P$5PN MJTNBNE2%BBY7SDWJKE"?(F4GT&J3TI)?869$GD8U55T+D4GR.DO570XG6)NP7/SEH+GIW5@J>97B#SZV7.^3+G*

*M?5SEFM^2!!$YFF.,1X7;%2KK$4U<\?RMZW!p=_#A*B1M:MBOH!W M/$/%5*9VHXXVA;<,DDK2?B%ZQAD1T'6,P,/MG9#.A+=9+FU[QJ01]NL-J;-M/-*

P7_^I&W5E&Z=)O"LE[I;^L5%M.N0Y^0X\[2+_+)E^?D>)[.ZG7-O%WY_"\-MK-GFXZ2PXW+S_K7);;Z#3.MO3+2^Y"9)>YKU_Q"W]["SY(@$^=BP1Y+--M3ZU8ZC*WF\3FO[8$=&

==F:MJ(2.CN]?X:N&|._PQOXH,FZ(B)^"C>=L MA]#ZLKOZ(Q>S@Y)HD:%V;?Z6YUR^^^WADPS9>SL=1S%ZOG6=[>YRT M2K8)G%>20.MNW7G5<>NKKV+U>

<]XXC^CE5;1Z7VQ3BK<F#-$L%]&O3*WK$-"VNOMC2 MMMIUQ0%8LT"\<-Z5--K\R+.=U#5BL7!U@)5\AP2?S M]M@ .|\#\TMV &&"3A-2B,6.GVA=AK5 MB?(B//]8"H(I!#_3$IOP2O

*M!77'/D77?HPE]#XBCU=F4RYP](4#%\9 PR<4&6B-]KPP50*Q?$7M7@M(F$G"[PG39KTB-/YOT&-3F&2C.EJF M9@2@%U]0I=<"(ZME0"/DL.70'2GZC MW#V[GUKG&\|-*

*#96Y+U*J51P<\D67\M 2MJ/40E;XO";?D?!D?I!90\^<@";+ M>@!VYQ+ZO-/OBF#K&1?$B"^;S="3B%ZL8"1U]8CO#(X"&EDZ'K+\X%?L!FOFZ:\429(V4"02!{$>,)>*

*()3QCH8@ASWM$@^6\ =PS MRZWJYW/HSRMW3+T3WTO[R8R9I46DO7-$=AA7+.+)ZICE:6#0.NEL&ANTO*G94GC&CI<698Q&U4FB1_&<,59T-5,=_/OK44\ZB S M'@EV?*

O'UO'0LU&A7&&U&!X" PLQP5('6[P3>QOGRNSXS9%TS8ZR$ZLDMI<(9 M3$Y%$; C[OIBR),D->U18V5\E6%)6;$U8MYQ82X!'WAXV3/:EDB8BXJD1C<[

*MX^U].RM\.^^)6I@%/!P/S!6+R\\EBCU8CP M)Y7:FA,#&4,GD"Z6RVK)LD7@F]$NZ;IW499OSNJ4CM8G,@AJ?:"%I7CWX9,K MP*Y,/,GR-*

*!\#HPR,70&G&!*13+#O'!'12.P7'/&A21D',B!#AI13"(Q-L@<$5 M30OOY!-I(*_%92*"04,FD$JZ4$H9] P<,4(:U$@#V/(88W0W#&N"B#@E,NG0 BV!4IV3?I\`ZA*9+_,#0EPVRH*

*M21#Y#._^A[3]%[_O^#3O"2Q&#I"XWG:_9S#(JG]T-%]9M.30$;G8[4,4" MA],@2$BA.EA#@!BI/,I;'#?7@2$P9(@SYB6$01FJ.R\E@U3M? 3K(9(#V)0[%L M]BH&K&Y)*6[IBGT?*

*UM<7PZ!5,AN3?5WD'&VVW\PS$ULBA$$7%6$ NE-/39%' M3BGUYN0D*FTB X^"\&@O,WHML9+8HNVQ[P65FL.\C$GYC;$64]H8.22D+I$B*

*M>6)<%,/pZ:(TGC*H'+UQ8@0'549(V1$2'6W]"SX>4L&W<%S%;:*M\A MU6P"H'II1SG/B#4-3D8Z<:"",EGB78G8_"3X%1%/&M<2%1)5!!17VA7-'R# M%'AVJY*

*5^JP$H%S':&$W1D&2@GV)%O69D>[2!U]<#.%V!S.J(+)&HR209'8 MTA_149EWL7TR@E:L.,+B2SGE2O?$&L:"Q{O]&4%_4?_7B0_)*QP^ADC P@QR*

M8)3,U5'M"%@7A4>493ZJE.%?L\.WJ+41&3K.V>SN(/]>19!@G MZ@:+!,(;%@H@AGJ&(T^RA,A5=#?"GV^&P/IT#\# P%A<,+1#Z,H(CCE4,<0< ME=F)#&X>EI2-Z(.>%Q4"?

*X9&="*B>6)?S!PPWK3T#)4&GE8V# %@88N3FH MQE/BX+F@_"_I)2V%!57$P7C,59_+=]#XJS(376$_75B)K;O@>29@A88$]L MJL,FBN$JR6OE8M__J3.C52RG5O42MPR?*

$'K+YJ2>-&<(*S M!9BF.4\U!(V(;U)RN:NFY/+2"1FCOT:>=-UIQ,X$')-GK6N!(2%Q7)CME$ MEFLH'AFF1OH (Y' TZD9?V>5D7$W@U2'OB0SU"!TCR,!U5.\M.LP0NV8U1L*

M,:=HJ_]MDZ.W#VM:>WG$E!{+4,C_V=[>^_-4]"#L"U'61)5E;QK| MCQF+,"*R+"|9ND$D8?0[7_0D/5S'GASP0'5PS%K:$Z/67>+&5RSH 1X@@9T^/

MD&$YCD:XBPB#WZB)PD0*&.X9-3,;C\"[D\8(V[K(Z;BW M9_#*K7$T<_G7Z$209,,:WJ6ES77E*AY2S:54TLZ3(_LIWFIL'N8I&L59)%,V M8LQDVAL.3Q;*

[&)M"|P\/&@+Y1,=&Z1C1,S3_3B4A#Y ?RR^RTDT$Q*T^1B. M@W#I8G3"?5Z6I'N'WH?^$==%X%R]2W-5?(V.U9%+7B$?,@B?B;+-"TTPE99

MSY72=V/7:]0=F#61:W;0'H;4XY.X+-I-;@UMKX;F8:OM_8EQ32BK>_ET#,U'_MF"4I-RS(QT4TM;V7]#DI#LNJ+-#6IW2T^;;(W;BZ&@]WM.6GPR;9.3NQA<#

M5D!D.-1Z&CI%"%EC*O,\3SH^=R\3!E>SA*W]JQS86$$,$%FXLL'QUUYHIWD MJ,ZFTP7Q/Q6?$3WSA.M0W2S$UX)@6S+DT+R @OY=4"G(Y1T'[8(M1Q%WD/&B/S D).F0CQC?*

*M14L_3[NZ"X\L/+$"V9 MUW3"4BTZ<-H(=,VHK5O*)PL2+#4=N5B;$RA6/<=>N19= M.:K5!9W!Z\5AN%[<\E>-# GTV!/GDNL+'!,8CI;:5"0Z:J]8%*V8CPB8FD1*

M,;=HJ_]MDZ.W#VM:>WG$E!{+4,C_V=[>^_-4]"#L"U'61)5E;QK| MCQF+,"*R+"|9ND$D8?0[7_0D/5S'GASP0'5PS%K:$Z/67>+&5RSH 1X@@9T^/

MD&$YCD:XBPB#WZB)PD0*&.X9-3,;C\"[D\8(V[K(Z;BW-

*Q*W@U_R4--6"I=$1/2P-&LYZ]CI2Z]Q$!]BG.W^P M,F'A_#1+I*P*P1ZC>3S.DDH:6CHQCA>E&G(>1YW4H$7.B;YF9=^^T0)_C9WJ&G M+> \7EP_ME!U)U@53ZD4:Q4[HE*=
I50WM;^CHV%^E*._7_B36C8=PSC{DW% MMZC[*E3,FCQ]=RK&OD\I]=GG;S5_6%R0%_4E4[#U1>NH9?1NG>W4EJ=0$#4'!A]P_<[!1I,T-_MAX<^,'S*E_=E*WB7^YJJW4^
G[F+=R;"+R>.>=)L.7;^HD==8'M;&*Y.O0O^MLDZK M+3TP@2(IK4[3+ GQSK[T >9+&!"<&5ZQ8JD+NR1U)%T8->QXB M29R:;A$E1@BI*B*6=C)7\U6V\;L=TD.V9>JGO!OGS#
(TCNWN&49S]1^" #A-M-KG%,>[N8F\Q>$:UY%>'*ZOQ#Y<3T- TLAY*X#9,FW/).SV)786B7Q5MO# M9Z=5G24@Z^6ISP7YN"@+6HD[QTL4LU_]@FB_M3/;/C8/S
M'=SJ^C+EO2GIC!9SY\]EI'V]16"W#%XM9]RX .2U;\P],<;4,1$]O8=T>*]4 M8'Q%DEK:O)]!PBWR'9HX%_"L'\5 1*KH3\'&|^]9]N9U2=*Z_.'G?^#.YS>W-MN^<>N]W'?>R@)-
S]V>KW^I,V>N_N]WK,.),N"9S@&^ (6+^L25%+%';0QDA, MU@.[F^\9]^ V*G@O,%3<'B-L,2/A*6MU_X]O3\<[+%H:2X-9##7 M]I,YF)7,:BNY\7KA.=^K1;8P4[X;.^6M86[V\;>?]Z;?
G;VP_VGU]ADXCKI M]=#%[BXK?D*OK<52+PLB*8.]>FX@/](TZS.]=NA#]W6@5Q?#*WK'>S> MD_#@X9)9UJ;O;U2^#*SWZ<;GBPW^]LAX?!UXC"]@WT=&5/7733%?
IH+QIE+,:U*DCET);K,2W_2Y{DR7]3OE3@5%I1EI3! MOV%~_#1S/*"DW5?$ZD1#6[^VTL+!W69I1'7(101$L3\@D8ME=6.(JE+Y"6A M[0[&"1=]HJ11L"XX1Y)?
7B533E]'SF3SN,:HQ.00N4JC@092W8)%)U&2VHR]KA23 JD\ M JF1RVGG]PZM:#D9I- %]6F\.%FOS*&:PY08U(E*:?HTN]V4RS3H1M*%$7X M=;!-
*3"1!N!4$MG+%-6T4H@K@^;3(B@N/%BMB>5SEDD5F68WSDB0)3%G?VN" MNI8 V\RW,N0<\V9FI>*(T'3_D?L@=QGM6(LJ49Y<8_H>$=,1+IEAH=ZY1; K
MB320PQRE*6=XTB3EJ,FS!G;W. ,2VY$7^FF3SO4?,%E7D9I4A8 8@2W.51&]R_0:9^ M],IHEQ+, N2!^3K3TZH27DY/#,@475^?G8U;CKUH8L;(9M=:]MM(<&;E4=QB M*D"6?
1%G1%'&"8QI_5N!4ES0422P?MM'KAXU(#L.AM98;H\II75!T8>5==^GV+<&>CGUEF0ZN^ MFS3KWD_F5NU%(GS0F[VDR2:MU>8W#W/66/R:#A6*O&B2S;KR*2P[>"X<>X1N
M)FQ9/5#.2MVCN;.)ZOUM3Y0[XZ6UX*5# \,P.7$,Y]-VU2O87/-1GJ;YZ,;S MN)V18@Y9$N>,K2;K#9_$./_At$V4$CO/1-2L45N0==/)KGKZI5Z%.\QHHP& MW7*K7"T),B1R$],++
I,TB6J3((HG7!/DUSBXVH;V\4/K=?9@+9P4\'@ M*XJG["/.X,UE.V1#9JGV/'9&@MM,X;\Z3)A];C)HGEK5.! 9O)N#!FN6*C"3>@8. F_ ?!NF;RZD)',M+N-UF-1'()HOC<^#;2
M_.\POU]R=2S#1D93&FK MN[6Y]KJ6N^]5SAU;?^JQ?]4>3 J2C[{4HR_U:*+ZG] _]E!%MIT;R.HD@KO M+T[0^DZ6]DW]!W\S]NP7'$@ ?/_KT;WC4$O'FL0BA+U+
I]TN)/$.?"8X& MZ##U5A)M/B;EES[XOS+XGV2V_K"@A6HR1Y*,XS;:VT63:ZXI]_P >D(.\M+ M&\%IQI"LC/ Y]0A;=H/Y'N?K++;5O2LFUMYSF[YSOMH2R)4;%EN)F\6)T:;VE MMT#-
O3L,;]XB=@K7=4HELC\'GAJ;]7Z_:POIP;&MM$:,3C113B+U*T5YC=0! MPX[V9@SP-A=U@S#A.K[4!9;S/.?#[5#Z],*,)RV6\>0\EO%DBYEOD:>R1Q_@ M;AN"-:P+
((B&Y7F%'E.NFV'#_E9-_0)=YP?)!.5D9M%8>S8VS!0#+I:6>DP M,.#DK6SK1/1TM*L+CG$\2/75-DUZ+R$H],="?TQ%A+&]/(<(V]3D-5:O#;WW:>G
OG0)^O&4Z&C";3VEWVZK(9@'QRA-OTRZ$!IH+$&JU=:P<\;$@]DEB MYDB"%Y:&AL8BO/TC>UQV]+-G?WOS0!\]<[^4/]P\N[55V&.2.C&VW:>]3WA M9VDGU5
#1CQL#H/*LG+0G 8C7;G9.]\!UAXY$MGN?G2TKK8I%=7DZ1@<^,D2WC& M<05[!2A)V9E4UH,I69,KECHI74@NE$&6W&*NK*<0,/^QF"#R= WWJ30%FH]-
M6P@0?I6<$_KUTZOCH*AMS0_F(9^^'S15%7^[:=IWLK===V75V@EQRN17+9;_M0 QM8O,'M;59LU18HF&S1MRQ<.4R17%<3VL)V7+I4ZE=UO"@:0PW7V_*+IYP
M]E$'B:,7(9UCZ>V;PP>7G_+J(H68EK5D@8X^@L700X0:>M3V4"3T<:,BO-RH^ZO MV^1V7@!K@T A9LZ*$\,3S@Q3PZISSUFW=$-XN17:;LCSW,6=&@!F19:]MIB8 MVD%^[+
<)\##8G7H*93?X%E/V.-UGT)[X_;T1WO35O#+'T=&'A\)CWF0X.5D5_.8D#L-!O5I4AYS:NS8<9EU<\2U91T:E MD8Q(B]%FHZ<7T(RXI*LBL,,,PZ"M5(50H$]&Y0Y$-/"KG2,G/'P.#_,
M]I=M#86YTM205QT2+A#4"W%&P&(Q1OT#-8QX,TIE=0T#.[D7%@E0#BFI),# M.:HJ&T"W 5'U*-'FGG8O^+D#X]Q(&-@T%>^79'XDA625D@:M":XZ1<0>HM0[M1.
>:;HP^I*7OFU]N:!X*VT7=7%_ 4=R+UN;&H@<;8M5A5T/$=>-,B1:.ZF(M)%\(PYAERO'S;JHLMG(SY\LQZ.->LW<\K8YC3Z(H%@CH>/HCIMG:MZ:8!
M/>3+,# -9((LX5R&,&]PF0#136@79V":E,@4(KIUX?)T'K,7"1N5%*2%GFC; M59?OK7VR$2TN'?0?47/)8=K!G-$+Z]*:?]4=:1R_@LF_ M1<$6)Z,AU6QNB=3?5D¥\):59$"^ B$+R7-
J|:Q2--WF]>3L1>U?Q'I,0R23/ MAUZRMH2Z"'V?E0Z%)>CHF%%P7H .05(?6-M!D_*%%?=QCA;4FD8.QN)"S!99 MTI%R;$RI^$)PF&;?.$.*\[QH(3L[+ AMY>>5IVJZPP4*?FT'#^OY3LS4C
.[$[MRU-D(92"8.GXI<3]H+P B])<_%SR.=YL[,Y%]D@4Z&D'ZKET],GGBU\NQ"SY M%,P\W E[F#'#|^)YEV@?O"]XM[Q_&"-X&KD+-)+7O6M|,. ^2X;RUU<+/;]6I
MWGF(BEWGG=>_6M[Y#TZVL.:\(%"DV9E8(& MM=B5I[#DQ>N-6.VV^,269H46Z65LD^]M#V)#B]_5L&[K
MTE?/N%2NE."_U,A)/2.,'B1,XF[5FSWUV.6,DFUCQF(P268C[P%9J[7H7C07 MU#/YRZV@O!R.G<)*BSA4VU)C04;6+.+@!KV8/39<:*,;Y[]R3'1)YZ"8;_62 M)GXB?1064N,Y MVP&W
ER4^);SI@7SQ5]7C0R!?12#!%)/ZM!,74SW?X[>?]+&&78#= =5.]# MW#%,9%F(N>%ZN ?HO=9@!E_BOB?1.5 M=$=$VQKPRL^[LLR7 M6Y-T4HPK.30N
$Q20FDD,_X@"HX*-6[EP#N\/6P2D5=>VO,#&954V^2R.RU$'#K]24[WUW<&I M!=/!NYCZ8^A<*)\"FJ&)=T'C"0.C1KJXL7QG/D3[E.NDU.!G<_"\C)9$?G%)
MOL@LLBXL74S7Cj7=0>5T88>;V4 PI743Y$]*>Z1YP+R (A%=Y$-RW^GPH-&? MX(!J_E)WCP))BV!J0QZOZGB^5H[$+:>4RQ[GYQGM'+G<1&09!J]%6;A?*OJW M68?
V78OFX2=.29A?(!A5 ^^_3VK("RC7G+*@:1QSER{3) L)75EM|XL1'&L'-MWD]\-0.D=$*AM_D>0EBJ%8L+ _)XBW.]*@=Q2 \&R+3N:CR4@;)*Z'#2MU8=@:=$'21 MA@>K32?
9]7HCO3!U(9N)]!V*N-.6"B]EWB8/VSSA8BU^SG @M)NTC8IFN=2/*(#'X$GH_^',U\68@V5S\Y+6(>W!]6WXN28RV''E#9/[P!OPH M>A5<;#\%?-H^\LI\;# .*$/-K=-4/-
L45>_,.'G8(N"9X$1Q+59@<5KRYX\RV MV,W53]+2 HJ9"*>BMA#!Y\,V!O]- XGMWUWNQM89VX;S]+KT+LCESHY/5S&;.WS]A=IU/KT,I5Q@QG?8KJU#LCX[
M.'SVTP6ZT!9UE9]1U"R:GM&T-.F'M=']3$TIOY;/@\]A*/(9.,HE5>MSNT. MYAYT@8+56^O6UF8NU/Q;NZZL!XC;FI6??A$A>&]H<28.=&(R/KHI3KJFE81JH+WQ8T+*2#A(=&DXS
MC(9_1C&#FB)*$U)45P'_DEEG(/!.5)G#L_AQBP);)ADF##!0YHX-,O+*T$]VIZND^:,%7)"NN/[SFKPIQ0M$ MTB4QZ&(<9][7\[Z>]ZTY[IV/A%UV235:6P<: ;;N$1+5?>L MNF?
5W\BJ_6[,Y=QZCA-;U#CK5Z-;AAPV+A=+7I>O<$%P!NBS&3$1]"1S3HH M2%((|3_A^X^CUQ@]:G$VG[_7_"[+RP^NCX!CA^2@.CM-H*M,WTB5[!]M$$8<' MVOG(W1'1FRT2-
VX]U&E'C^2"ER$GP>MYQ-082%OU@&^.X0U^8#+4&E23 M>9$G#F(P%*&GOM?"C!$ORXNYE/]>1*D#VCS2=*0RQRYO6=5#[C&DH(JCZ(3X M+B!F[X4\ZOEHST&T@?XG6!-
,"'Z9@P@UGXC4J:+GH_T M?*3G(VO-1_Y0<(>6?_OI QH,$YO;?Q^4I9WEA=P25WZ0+_65909I/N_0H4Q MJ4 F^^1%G45@$L%8MY#)HDXY!-X&0%52/C?KZ),5U-
IF79,='@O4N,,^=^HY3L]QUIGCT044'GF KD&#;SRRJ<>S\\MSE MY^4;^W$&U]&5M3C!^%3(,,.IZ4W#GJ_T?&5-^_H")SCC6,-U+,T*IP)QAYY9
MT0C0&]QB03N)8M>T4%IW21]V#C0V76D]+8HEZNS&5DA8]Q_V5O&O7P-)#(]\ M_&51CX.CX93&6FHUMY&RF(X0.CO-0+M-TW!5<%>G9W$X-_M;M*!M0]#;Z'1@TAKAJ7FN$E-
ML4:86>UQDK.V=;0^W*(GEOVW"*MN>7:..+N M!ZOH>XEUP@T&P>Z!?6W?2ZSO}7;?>XG=>9XKDC'>6+<>N*FTD3HS@_56EZW7
MF7]=Z,'J3'\P6OI"W;GOYN\]/,!E@):4IPW4;PLJ");#$XO9PXRX$B{36;.MUK);_WXH3CV_Z/G%(^87PAZ,0[=#KXA-4^)4).6$45UCN+X!4>0W"\\1RVIQ M!KAPD#!E*\"S6#])NW/
'}DO2FE)$4G_3-+\]H[?A(U]9^_;\5'#D4I=(6 M@^+]32H6)XZ-D1[E=]$(9;@X :%K&C^8?+L'+(IA[3XM?R(U-4U$L*/7,Y M?U&FK3[Q<323>LQD,5\ME"0V68.RGG"SY"-
MT3R()GD#V#?,0,DN&)ZP*5 M,Q;RN>5USOE0UYGV4>&$5,YA<-D!XE=*9LX?U3B?+/-)VL5#"C;7!7%?]5) MV;"-^A-#IY-HD#A$>C*S*2 M)G<4L5BIW#Q$QT*#4'2#
&*BA*3;B448S]BC- &.]C$FDOI&@*,%V%M':_ M[\V>VS.CGAFM,3-2/9>=A\C22"U_O>WAHFWM@&X?:M/BT]3^AY0L\3UIPG1.5<<=Y]&;6?)V6*;$F_"0'M
M8Y/LD**>29R!OYCFF9ES&=&0784A3&,XP-2(@W-,/6%^5Z"]B(;&>S[QEZK2 ML+ ,UEA*D,-HVR;ZQ?Q5,VP[IW&X'B)75SQNRN"Y:XMP13C78]8?E%F'P?%\ M@-
X9W(5+N/K+](KH@N0DBN>]O=BSXYX=WRX[+I ,RXV%!7-73;>\LIUM&O>= M=EQ;R)WUK^U6T9AF2]L821+\ W2Z5MCZJPMFBTC,?
@.68\N]KM4G&*4#YF"^Q<,+8".R[M7&%XT*'[SN;2.#U;V1W(=2&F;@-`MVGM2E0KQ%Z7(T?,V+]J:&G94, L?=IU!})::.L5#7?;K¥\,SG;M^;9"\NW!]Q.6Y_IV- MJOC%H*^-
OECKS_(@JK@5C!,UIB7,#3^#]^2Z]8MES MH9X+73\7.LXWCR=10B\A#G-*FANG"',,72O/_-"<=;@)3O)M8/\]:3$:3OP MI90X19TD7I-#5\GC+
{YC%"$ME:,%\XQ2V/OF@"1OVX6D1PXV3B(9W]A-M<[?>R({1 M6=@%6XI2Y+\B?>=Q7)/^)W_$4:WIT,BOL+I*:DXD$9IC;A+U2K;35WY
MA3"2IA;"3_;U^@WR2_&,29X_^XAKSQ]Z_K ^_,%P[^]G%$(A9$ 6I&#SYFW3 M,J09#8B8@I?U>!QEXE="SV6RI,C*$YAO9111OO^-XW1+#L"9]@*?DU@,Dj?
MIU!!D2(>"G&D>FK@0WL7EE/6DB:GUY+K=6U6S$]WM$]O*-# ^]H> M[ZC',fH^O*-%BKO ^?46T]+/LX[TI7G\-W!U]SOL'JYF]#\GS]!('@I#F2\Y MY^"%RU/VZDO;J:$9%X8W
$'EK>],+]YJXO]"1+J,CX)7TY62H_C@>)H.K-^59 MJ-L=FC(ND@&$@8X6]*,3;LQ>/\FAA(FB4(0$4\50 +]F"\)1GQ0[SHJB).D MVC/KHT'N]6+C0H>70%,B<=) [-F >);
!0N8*$>;0>X=K61-VXZ2'-N$&+0DK MJ6L+>YJT". ^9"1\88O7I6M4>&[\ M"X;&3/$[*>{)M)ES6N:LS]MO4H=#>&V3?Y,Y\%2)]) FM,R9>F4Q<4//S*=) M')CL)"GRC(OV,"KS-;
(1#Z1I^8HEO%#V@"0V84]K&!7)>>A>-W-:.W2P.^,< MRVRBY?3ES%C}JW_AB*%F/;:4<2QI0AQ!]_#9.YB8=W_-W]H21')A44DDPL3&PKSDL%LZ M5K']K06]]5&6.,D,>-
>XS>%9,^N/2+)S36;Y M2(P!*;89%P#P&!F&NT_/8_LFI:A7B32&DQ$8F!.#Z8K+6P)/HC#VRL)L)/" MX5@"^?:\4@P$0IM*&BMH/%KXDV$1W8M5R1(4+4UDP
!D6+|_^4E_H9QO>0,?_3_;PV!QP_CRB>==@_6$_"WB"\HKZ.B.BGRJ MO1K$2@>]>36WU1"6W:>Y=OP9R&CT)VAU)DWY@X=79TU%&)K1S ZS@>@+P$ODDC:$5&NTT]@U
M6UQ("\!'HYHDA9HV+NTM].1GROA_B"9P=QUGK27&APVUZ MF,,,,L8/\7]G0* WT:7GA"K.#"+KMWBI9(Y;Z-J2NY=.;,,NQ%-_YF$7=,SC MB5CV?;NI>%TFD2&]:U=6/!\4C=/D]9-)D.-
:A#BR2W/4;Y:QXI_F^U#4 M'#S^S?6O:>)TCOBW 3U!@692.1#1;H/)8C_FSMY-TA=QA6,,T^0;6?^\$\5N M.@ZWE=')4!SJTZ^48-
.V$I=2'&$./7^@"=4F/B3]KP_TM>AS5B'LA\N.#W1 M5M]F4X-ZL!A=6K'F'+@]6H&9\+J(IY#BQ/!G08&5A +P-F2+FAF9%9_6$U% MY"\S'6)6UQ/I*)&ADG_K\9.HB0S;(HYS4*#-8
M!)AG-8?347V/T&S JQ@Z*2DZ7N^9F4J$ND*T:&3A.(123M%,"XJ,Z]RZ)..B M!TXT*HD5O# (ZME@L/F_K_I0^.0K7R'7?(.=J.A."_HT_65(J;0@C7WB61 M:,,;!KX
9P%DH;@N6369DD$_X-+.7$N* M5=/E=29XN;2JXGUVC7B)=27Z(7O/.%?O3OHO*M08-VI3]/E-1 M6N+(#YFO/-_/$A2ZN9B=,Q_F30*$<]4K:2,*,8*3KB.*AQP1X\WJE?AX34B:
MS1+@"8MC.E;Z*/ZPNNW;>_+;/*$CC*4*YMEW)X]HHA!\|%!]0T MC5T#'X"^!3;+K82^Z3+|SXKQ]/T*:KHS \2&#^MWA{(?S!%C8==\));..B6LI M&^B@G?_B3FI)-
O,=_C9N;]VH]G+.\,R8@QPZK]?25BP @*#A,9[WC34%T\O0 M%*[*.S+^\93A<"U&_#DU=,3IL/_SFCRE+IA1X^<5"P/[9:VGN4@LI,+6KO@[N:H/\5M:8I4/A,# MU<3)K$,A6"[_UO-
HGAP'_A$?T/88O.U=I-VFE[SMRD/N`$WTV/AAA4JBYBE*.MW8%G?.(JANX>?VXV?3CMF<,C#8.'PSAF?Z<_IY5AP;?;1>Y-:=A[=FZ]P#>R M >345WG7=N)ID5V E$.#V,YM^!CM8J7):
;KKU?!%&:;O0^^D2O>9^4FI-5NK,Q[1>QOS/P-1^_&?D.+/B,HVDA6)G^]\#>]'T M] F C,XJ'HC3;2^SQ@=KGCN="0U.MYR<#YU39I2,;3+19T\:@^I$?%
MFS:!!F]GLG::?XN9.WG#_3=6>7SC(Q6+PTHY L'LPB#R9G-3QSU-MDKJE-=>2$K3O+.'PV(ZV&<2L^9BVA MXN7WX(1'5[5=%!:^>NJL11SK)ZBV2?DMI'N=4)F9]\>6;]Y?
K.^'N;3,:\/_,T^PU*;4 :^_2VM_DOZKXM%'1XR^US M97=@7Z#9U97*5N'/?ZZV6[K65V4_%*N_OJ5G:4(1VZ]3UL[RU++3PRU[;I]' MX?V!B]W6[9]EA3==.XO1DZ!&1D]2/_1R
B=\RPE2;B=/M7U]<[. H_,+[SZ M?[L+7I,5SLC "9]XO9:@7@T6ETHXG6621P4^L'1I +R)XM%4QLRB -%EV7]T(\P$VYGO<.M:9222QL%X,,:4A6<4\?32G@A,D#0QBDS[I\4@J8=:
<.HK2'^C#3ZLZ+25FH%4 MHG3,K!H84;;"T74ZAG07.TNRQWAC(8->]1*_Z5.V]KS/ZJIY&[;Y8U?U*/W! M9)V0"=93>WJ@Z3DM50*)C,[A -+AQD E@O#$"9PJL^=V%8[5 :'7M'9JG96-
A) M,6@=P#$&J'#;283;]C56=O.9!+-@K=FKQ9]Y^,\?!45!2X=8RS-9/EQ^4M=/-MO&=ZG$\\\0B@)G_@K;)1P#0^D\1.G),4YD]K[K'R1W%V\XB85N8S;E\?];[#
MR:[VRZ[@*B/UZF#)Y!A,AZ,2TFR03.%)(MFMP<#0?CI"%AP6 EU5UFS8ZTQH M=5B"RFX;"ZAZH+ UY:=$47V BY^EZ\R=&RL?Z=I>:*9FR5AHD:)6]HV5J_']/6H26 ^#IP227\X
1J^$R MGA.'I26RI6G[M!K< I/Q\=N_@!IE3,H/>_YMZNR<;[.!_ M#C+Y#;NPWL&359B* (5EW/>AW#(B@\QM5QURQ))M[?FENJWZ&$]'C,J M#5* M$ -_9H9N^<5)Y!%R;6*?<-
K"5;Q0T"" $&)QK*&,1-4ZL"55(ASHND.691N[M+ 1N5=,WY//2.)I9/MZ59U*G?\YX |<.JAE('C@Y6@2K*A.L!2^.S2)F X>(M9-\FJ(81UJR.11K\SH_DL'#6C;8^\!*[(,:-
E(E*7F(5FY^3'3M_6 ME8&O /B?F8FET__1G?Y_7+8K]ET[_1^_5'1D;_1\F[2]<4;#B $]*OT*8. M>F8^QNC_TGS>B!:OK\DSO1,JX9.C]>18<(R[
M>Y>|"W<;JW(Z'6U7,.K+._%NIMQ20SMPE_I9,P!W* Q#5R7F._AKE[OKY,JJ MPS'EF[^6,NF3>\U/1CGT]+Q)KVVI*GV7PNJT5/A+T@QSGY=/@]'6 ZK%6'J:
M_R\^^^(+QFW;G%,6MHY'U>0$?>Y56'B5M.=FP!H&GR1H;K88VJV]50\D";+O*I\>*WS3EGKM@PCT3C-O49$44CPZ;SH<'/\Y%5I9D
M@FV=,#FDI^]4{.]Q"*KS:9ES+^~_)B<2H^BVS[[*'SSFBWGH"EQRY/9*B6/4[C>NB+&F8738RKR MH#(U=\5>006>6>\612$M+],.AH6CUG:2A^3$;P+.V[-R5FKR].FR\L+'3M*"
M8U]BD>KLWX'63$I^V400;\\O*QZDUWU/@BOJX-S_;)'D7A,WW(S%D=-U$;$ M9C/73L'B.\.1(+VI\)-'3>K)NW$3J.8+Q"Z_),^^Z-LWISZ(1QTR="\:@+
M0.IF9<"_T!'S[#C6M,'>D$NFXC]_9<_CE_2/W3RKN%N(=(*R']EI.LYT['V>-MS*/E8IE%@PN/QK41N/>W"!ONCV)WE.)+00BU5L:5-$W,++&?JL76F<03>^1Y M&;$+"B3G!2C-
V6BX9WG-L'V?],7Z!""E+SY[_1?7;_A?GS__5-N#9"/8H%4] MMU(+=#YM ;N_]F7')-1#C]_,/N$-F(@]*>D-'X^:2#VWM2;2KCO\Z)R,9[_-
QF?:R7AJ,7W^[_Q(9^U_4X/\@5:64\+UZ/0X[\\&MO_U+WS-OWF^Y@M7],GZ MMW-9E$2]8>;A^<*ZONSB91=_!+LX(@NZ4!W6@,07O;VLK>O
M>6^G9@1F!!SDO%;J;)3Z,K2I9SC3FF0.WY%A7+;IMV7[7[%VIVNK(XDJB9* MHUN?SEAQF211P#.NXC^E+_.YY4HF_7C+^NDM$?VZ[T#)^T5O8?I0K-?EQ-%% M@L1WJ{XR-
>T:16&A"K)>G5)9+0 <8:]N?0(96.BX$;G40O$AD[GAD]]@= 2Y MA0.C?N]*S!-IF"]UE\7<++^,^(7-/*[>S[E186(*C2566W;S MLINO>3>G4&PCU'O8V@*E1E4FY52SH&W9U\N^7O;U-
>]KL,%A!|\-ISE1#E1> MZHK9=] H> 2?T&9?BFY,=ULVU3_*\(\T)/B-C3R]D-+]OOB !8#L!B J58 M$]*I3K;\2>BHN:>'=O>PE9=MO&SC;!|&43>)EDW=5D=EIV[|-QEYU[USI6>
MG..H*L&>6T@[-(3@# 'WLIN7W:SLYFO>S19/1[AAZL56A<:R[HV)D4DR*X5J:MR$0QN$>K:E19 26P[(@$-@$5]"B;\;_+6"(Q4XL=N++;[412048QG#=T7^[0
M95C6H1M^.KCA%ZUO+PQOEQC>_L-NNS"\+0QO"\/;NQDLIB?6'+]DU-Y$B[WXL!?:DB>9],\3MQCF?9:Y+^HK1 .+:./,RQV(@6>M0<,[.U8R(:]E4?+U9X MHC-5-NH='Y/HA{(23-
06=,*6N*<3L(P/=O8LF8KE0_@VD\,@'_:5)/!WK,_1 M,T,'O2RS+4CU#D*A3&@>;"\U-&%,MQ!^H%>&@LXBMI$KBN0\ ,!IXZ?6!,3 M_;
!LF.Y%*6'.&8(;'T2$(FK"\N]VHB6%RDN6B8M>*.'+N+IH)/H#X>0=G)@FV8]!=L&19N M#<83B0MM],O@>+15;F?SP-@[#08E[8S'SG+<_&P?X]M9 D7>XC6($)E$WN^_ M9
6P4,\US=Q5DC@8&_"PK93L;^I7G'\5;)HER^" #<>ON,7;>)KIQ\3_?:1] M&+I:N/+)*$#PY6>LAFJ8%82SJ7|HL9B&B=V'C0MNS)3VR9X[B]+'&'70'H8]:
M8>LPNS:=W*)V6C)&"X9PR5C^.&{}0>P.1L]*H4;I4Z'!+AB\4U2'HGT54 M+'\Q1J^JE8RV5*X7^[+#EX_$ MQC"68!,]$"SN\IKCIB:#4K)HI0EY$A
R_,#<<]QV+&T9!1#04.]3LFICE MF"BC+9M]V=S+YK[FS0WQW@Z6X(E$^K,8^,A!$4HA.1(4[E3 R4-0%]D=@EM*^Z[3/1=3V6ITA+G[CG M-
2&S[<;,7BH@[Y$%5^T,B\\LHL%6RS81V;!1)O ZY63WJ>,[Z2$?&A=X_ K ML;]5^42RM=HBM=F72+*DY >7Y40*P51NZ79DAG3?"'EZ5J1'^=L
M;=B>^2BYG\'V$N19K$/BWVX=QM0TVE_R[43GS01U:M"Q8%5&33!SQB$S^5>= M?(TQ8_NV%DVZKKICVJ;"Z#B=@^$%0NOROA\75NW%1"PFXLI-A&8NRPV++#K-Y
MZ%&K!M2I?6ZO .;]/BVVFM1]%P6ZT5?>-K'0V@_D M,6AF8%)]?0C(7D'T+>*.3F+.Z"3'];0I^PJ* :NB%&SD|. I* VF/$@(*NT^
M>AGHE"=O1F2$<65.DQY:S_28>1RN^F;U@BZC/Q4\ZV7, MSY^CL%DH&)?=F72-/*%389^;GUI MVU'=MVYQ\AR1%508*_?HP!Y-^W3,!+'5C/V#L7,.X6FV7G9]YV25T4K.J,2V MM-
2U53O^] MGFK2EZ0V^4(?$AU&ZWXHN9I>GVY6;QC-E_7*VB?E>]+1@)%_Q'ZC3WV'G MFLQS;. ^*#5M %X6M'_]0=MCGJ6?S5]N4[[?0%V(%/RF3Z7#$"G_X[+&M] NQ-MPD*LL!
KO$_3XV"'!|>G:]B^_!FGR '9P,'WO$Z9,4\>C|(=V)&^^?QT\G M<"OV$ZU!4<>%|PB$Q;. %G#T?X=IMP&%@ 8.>L0HKHO91#06!ST4_]-G:]B8 MG1+J'?&]H4EM632^
+O(/#;V6ET?0D(S3G ZA35@:+9\PYCB; M7(H#[?ETT MJ9EA\NQQX4U?W/^%_/TT C^M!G0^/_P.'5IMP&O*I@(J4/;(757@VCM RO M7L%A^K$\'&L:Z!?K=3L,]_\NZ4A$UP9?Z06-

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j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{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| M[/>K7=W>:|IH#8S<70ML0:VLADX[#],OP#']\6+N@"852B>Y"WHSQGW&+\AB[NA7](3D 0&5H]!TUN8^1#Y.,& 1 M82<;7HH!YA@)H@;VQOO3,$K,_(4!4> >N3!OP*[8Y64GP19K9HPJY2 M@6<[!-2;YM]= (ZCSH] 3WX!=#$A%H"06A)D0KOWV//W&5IT7]#OH+AU[R M6EB1NC@>ZXHS5,?]!;H+,[7Y;[MB?3-4OHO4Y+YAVQ>$-K,Q2'\C%7:<7UZD@[F9?O%,9Q#[_LOJ_E=VM8 MU$O(;FZP*Q=.O((C?5!X#=;M*$(PZC#" 7"YV5:*# ^=NYJ-0'"P&8C$0BX'X MD X*FCJ/ ^?FU]>+9D!! ,J#]/#W<|=BV?O+WE_V_L>S]^_*JM9';X%:X"94 M8 =)(@>%)N=8!:.$? W(IB"@ROE:00E3IUMRIKC1?N#!!KBI@O'_ADI". +J5A, MQ6(]/F0$@FLC.&]_FVV5C2Z4FGH5<)(G8"T!E5+@**6\5'M=V:.E!N:5/P48/OLY4D,PAWA(BAZZ,J4"9M03U M1]*;DGJ12FM1D'O@"E?5W)4]'WIX^PA1,EJ1'-";M8!WZ1.>IE/$#=?OT!''M-22WE5#(SHI"AO<#T)R52#MIIK9+6Y\C1)9$QU2G7.MVP&>M:$(:[IE7,*&O M:V64,J9,IUAC QEP02S=4_MBN'$1ST25RM38@S<%8T#L*:RB0KZ4%N5B_J MOBWP[.]WXA]FRPRJT.4A@2/4JLF%+,E=|!$O@T;E715''E'+X>GQ*VH M$V*,5Q6DGM(P"M W5Y6AR^E+=E(1!"Q[Q1VA0]NN>L:/;6>:/W-,M9-+EGOQ-MR-LN2D6B:1>4'^*4XK7$KJ#JXAC1[3].W%"1,N$+H+4___?G-(T!S 5SC;?O M=0F:W4%']@FWI6I]H:$C3G7";/A0=!)/RH9S\+;8:=N/<#D1I$99VPLC/-=$ MG(AZY@-D6;OTEB[8L^\461FR?/@EP+[73[S,:%"H\-B]2#//8<]5G+!]-F7P+X?^O[]]UN CK3 }ENE655(G'D3B\)=,DA{10MCO.9-61H7QX#WICSE3T:IMKZ3EA% M%-;MR&++X4I==*%R!B"\&3>PM.#[S%>AL3A(!YU\N,V^:V\1_+L9+8,:,8230N MVINPL8\BYW84X&E+]G749'*%\"P:1&%B,3<@4BH$:4WBEAEY #T>6@:GC(W2-MISGZ#$@@I37$(569S=BD28V3&Y1O^R,OWD%=FG8<>N/:Z#?MT1],@(:SUS54-MM\ )EXSOA5,M.$SX:|<\= >3;8*>5+IRL MNXF9Z6=/UNRF8]L@L^K]C@3OU,-FX:?XF/@IOECX*19^BH6?XL/Q4^1QA$#S M1$SDK G)CHODOSL|:S$+AR%3FVLG${QSV"X]'T\SC:|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|G.\V?14I.Y[8 ML&@XS-D9&-3I6\R<*>7)/4#;=-59,2\'7'D^OEQ_-P*.BF-HP0OY.8I#E/_M4K*PK=[%.DF.W&V^'7++,S'X+E1#F5UI L^ CU[.=#,_^151*BV8O5:M1*TLH*4Y.NXW10>FLH;&\]? P>F6WECHB?"CX)-QW5\RS3: M"L2^L)G5[,JEZ_O1HX(*;3AK;6V#2^*%J5VQG,ICEVEIWEJEDXY5/UH^5=? M;YN^C@42PB]O8<38.,[UDV%>$>^@B(A#7'\#%G 4_ZV422? X&C16@Q3A0<5. M 1H]-E*O_< %8_4/? "C[G,>(3ZA!WU]I^VL,?]H#&>,KAEP@65NOH^$[6B@-MBNT5X"=#>0^SA)9A9?26O+WC_3IGAF6O)M5OG7O MHU!5/=`946A1;)3FDW0358-4?2F,;!M&+R(S)T&IC\GFR3481(>U\HA'X)6D M[A=?W:?,UB?;'O$AID-1RD!%DA)-8>E&@*N/KY[$7[M\>K/6V&5=D"E[-. "EX1AOELHG,P#%S,E:,,3'$B,9GFCO\4=TSZG.2W^,:,E.S,9< MQ"RG/E_ZA1Q/+UDBOL!0]H\L!3SS*?NISB&,XI8;C=5!2K-3GQ6&K\H"6& MF[N^$_6C)O/Y(7+O6IH_SQ3[&:N1\CT%+9NT51@2F)2W@)/C0AQ>AV3[2+?BLD^@W2V|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`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|Q@Q(X"O4;7MR^/T+S>=]6 5/^6 M%HCT3R0>V$AH(O5II)IPEO7*BM^O(I4"!3\CTVIW8:>81UU]]1.8#Q/^ZH0\ M]AK&_^HMYXO,:9ELN:$=M/=)ZP6 58 49_O C%^U({5D% XU)??/;YOSH@ MYX96@*]2LT7H*]RF]XZ7A-L$!&C52=T'\6#9()_4BE?Z^_V>/ 6L/V>8-E6W M&0\]=4R5ZUQ$UA""WX$5)ZL+#T8XFV=8>]"A$$I:>7(V90)W>LSS7WCT/MY=H*_,BZ#D$U)N!')*- U(DQ&'N M2;<$XV~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{T=QE6YIICNAO M55V^76QXY"X_O=8"T7R;_1WGW0"253]A20&=#C<_3&K-\[A7#E0<'LRI2O M#6)-9";FF2>,2-M"^S[%;#C#D MN_GQ1%L6RRASK=&NC MLT,@N&LE39XP419^GT+/(#D)KW7S#D7X@L[P0EA'P3:-Y,&SR')'JN\K7K6 M^L#3TM G5'?/B-C]>__]GSU4F_PLJ1! MX#8H'K RZ;8'94@ETS/(@]]\##0R?2W$,=@-RMI@TX>%A:OSEYA6-9WL,M%6 MC<%,M07*B&X;1^%X&)AH:V.$;.YRAP)=P1@!,FQ=#LX?LZ595@O.7Q.4R-GMS@;[T&&UV592!|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|MOR[VR!Z//LW[*AB-* WDY/W0.6GY&\(YY%"=E%8#ZP MB#USC\CD4I"C-:S$BF;^+- __IX=#O_96O=I]^?C8G8F%]T/.W:@ ?OD$+=MG MR 6ECSCXOGQ$=D9*]]HI'OD'I^6)Y&HW[:@^+:_#_\[,. (<)/^: MN2P4*B1Y;94|557)6M6INHQ1M:1@9K!$/_,8)'$L48]R? #F.,/H4'TDL&>Y M;D2=/%4/C#&L_P+B^U:AE7"=;3?79>MZU8-M-^AYE13,3=\D>.?G7MMA#T]" MA\)1C:-$]. >$C>KUVZDN$RG@ZACX2-,1C3Q_F*<51]+2A&?5OMV(? 40W!:IK(J_MF2O/ZN)3Z1Y=#MN)GJ*MS*D=Y.LEI2NPEYJ@Q:;4S@J^U^>6 MZ&2X1\'LF$^G/8%\'0%7NIK"M1)_2WT2%&8[GUF2]{:1C[*$?D24IMU[)T(M?.@%A(@;FE UN0NL/)? =:CFFG^28SK+8A@>C4 ,:LAB_\W|_6]GO+51_*'&@-M\""OD)..A4T1AMQLV1%P|+@'<%M,H^&TH.PQ9A09V7W/|MQV"9_FH:_M&[^'X.S;>1R'D/AGP7LW39I'INGL9*2[*- I)5Z2&YM8#5EW2]EYG:[B\)7.G MY&_6!D]FLN/5P8DF27Z9^;I9_:?7$+<[)RN6G4+ZF7-7'$_4G7(;BR6>+YAKP M'**W.1=?/DQD|0C#\S.ZU1A4MVH'=[K8ISG*,*:$2EO:P9=LN MV_9*MBU%,]#]H>.]R!'+R%"*\'?SMKSE?XH<5PMYQ&5K+UMV=I7 MLK6/R-\8C^0L4F'9KLMV7;;KE6Q7[*MUV]7;$(ZTT)>MN6S-M96>R=;4V#:> MIG"5VI.;U'"WO(IZ_I,@;U0U/+(I+?0)RYY>]O05]6ENXDS^<3]V=Z&];IC(MONPJ?:#*Q+X-Y,"7O6WR/U7SM[&S'ERA=E>Y\K;K5&]7_G00D9"?;@.NL5#Q M,155_B0(4D& YD4'$;#A/W!;P9:,,*525S:[*]8^K?W.LGBDZ_&L?%*H: N^ MH=#LWB=!N]5A:L P+Y7CH!Y\'FT10G_]?c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{$:(:RM&E/H:^BC MR,B4L7=87H5&)WKDDQPF?/%&]=/0G,%04[54\/:MWG:%_24(OBQYU7%N5_M?O\R08GF1">)5W^S-G\H>VA &^,=8#1:.47C$#7(^[!K4ZI.6&=HQ\,%M\3 M*-)&S4O*\'!<*Z(5JRA\H0fY.V39:K2F0^G&^I#.5DH"[<&CA3R.0A6YF(*G M-@5F!OJ!=XE316%#ONI:._9"3\ZAELA06 MEL+"[f6P8$ZB-/U6PZDX/UYY.!4++A[$/,X;'LNH*IL.L48Y =*Y,+*KY+,P"6C72&(+_.M?IOZ9/I0_6.,/:N'9<RXR7!PZDJ44R3HYM)-UA=M>=Z"CB"N)T; M%"']?ARVJ&$FXAO@@99]O>SK95]?Q[F/+J1+""V#[UV2,_A+R*NWN6<=UQL MC4? Z%%K2"Q6%+-?IR6VX&+%F\^\4F+#;A6FP"LG ;KN3,V^:.&Y16A4=Z'<M(GD>SCFAEA*)6=6 VJO[!+@;*V-/]&6.=3F MEYN&OU=A%SJ'YC/5: ![E<=*63C@EIKHD!Z&JGZK'4]^%'FIDT59_TGZ,9TA]H%\E;79@Y7].F[=4^>_W]1<&E?)I-F4A&O_1#VRHM>>]OWtT=A_2Y\URCN4.\$ M.QS[_4#.|.%F]6KL\$=0VQ4.F<#Z3V!> WJ'11KZ__*=S7A8!]8\5,KY?K!& M":%OI:=9W>_;]' &H(30#K/&TQ"I'54N:-A#NPW4\ZPC% 03$1T!:.CYEL]6&C]+=(Z'XSS=4(4_&2&DO MQ\E0@&H0+D#Z5@V4+:Z- Y'+L,X&OOX]57PU9F=EA01)#MJ!$XOOLJR. 2+OR MK8WY$)D\K)7?IT(P(PI?6(BL.S(OI-IW@[^8-_/2 [A^D"(R'$NQ0^ H+`]<(.M;M;<.QY+9H-3?EW14NG5W>N"/1@%4NLV$6!]F;%,)$XF+]'Q+&+1 %J/@Y"1TN9-*8^+HR8%RCG9LL?)/Y"IM67/C9'BKOX_T M+?GQ@54PY4&]:TLD@*T"W^XY4\[;;>@. ?XNK>1)W)R72<,0)IQ1_0O@'*5 MUX^L:U2QNI&VQP//:Q*,%QI2*7*H$*)Z(Z[APSA7H?";?,J4|21LKF*T\WET$ MC-&2Q(?|[|2UUL'X|>6!W4CO$J/N%PF !+B3@Q55<,JI, M."CM9;U(%"-RQ>'>T& [*)&FP(CWC%74,Z!]V!Q=*8-7RBY.7[];99M2W%BSX-^A.HJ!X"O1*_2W0S1 ,YH08G4JD+?M(O^E!6_&:|:LG525^+NBI%K-B4$8^NR MB+M5Q2] ((9@HLV(;W>S>E'W;7&F\"G',\K|\"KB,Y4=ELQ(*,Y*C#.>842?V&@: M5&ZN?$FY[1*U%/0]X!%M'!<;FL!D$21#S$G(H"*^>E8 :5">RQ 430@]=-1 MR3:DY5]Q9]L8E$>YRO!PY79O 9U_9_K>T&Y:40^=V1!S=B9?8I%=/DB97,(_MCBU@L_JX4]80.]HKN$T081L3&9#5R8I&4QODCCK_83-7K(HZ,9>;R"*XYU:C M=2[?2RN_'MK;(*M7Z? WU7O.,4T"*_Y!K3]EEAR#X*9R[_XX49RG=T"OKM+*_M)X)<]PG)5(1ZZWY91)SY0XV6%TX_$Q_Z_6?:MY1$C]@D0:1V2Z;JZ+A#4+@)_9SW?:: RSCC\(>TG%/DL: MC=W*Z\,PB& (*1Z@^[-4S$/=3=7..X<&MDZK=A*MQ+$XOOLJR. 2+OR MK8WY$)D\K)7?IT(P(PI?6(BLSOH

*MQ3@/$/U74I(49QVQ]7A4/]T_0L,"SV?9K;F MRHE9]%T8CR&G8IDZ+O$.TFIF!D8 "3OF1#. ^#7*K-<%QU"5;23Q/%/1^>1: M>5N28SR >E'$?+=>!YOB@V#4(X#F\/*

P74F//F!D"T!]^&S?WA=6U<] +UIW M,HER34W+K42T&"1W8R,,"$F>O$A=4*6(&^IN]W7+B55 AJ@'_!4X:TW'>QL*

MNRC,N.B\^XP%4R(]"E7T5@,'= ;@@/M?"9K4DZ6JB@9"SN#3;N?.+VU39R3 M><>+R$ @T&-&.X>U*3*UOD_20CF4;[G*RH7G:D.6#Y5EJV:>^"4^%2,7645T M+*

*<2EH%4KKU3NWIY-0E[H"ZX8N22FS F[ET++B>B27Z MKTB73.D A_QZ>;\QHI}O1(YEW$#<7%IHL<.-II+@,9@$S:38GW8<6C18A*K*1*

M36=FYF8G+&K0!"N0M!RI2GG0I4MLO&:W@P-*)G&QJ5BQ\:@ M73%1-=VG22Y4-RROT0?41-.4FDRD38!&^P95"YQGB8A/40;G@A0$OB%?U2&*

*MOTU/"U98=W9/*FZ.>#E%)U':7"[&>T@L,-96Z!AP=[[?O#8PK]RS,NJO>V;_M1IP)+::F+]VSV#%3L: Q,6+N>VC^U)X<;",;(WU)M[,Z\R9<%N4]UK]*

MEXJ3F'+47\CRT,>4A\N[M!.7/++P@DVNJ'C$FF*F5/$Z(3_NM MP"TW8YHI&QNN"N:R7$]-MO4^44~>(VMMS%A=7@JI=SZTNV@\'>;.EPS9@4!'G=0O$_(?SN,

*M>]O'(K/Z8V(M;,V=/09_?+-O..!K.?#A6TZ(.7WI?F!B6_,TS 2T@K0-N# M2OTM\[KF5\(&CE<)"@IL3T+YQ'>F]S!$G'XPAZ*8+#VSQY(-.0ZI%.#P!++F*

*M]UUZ==Z\T6\5E&"97%UG)'5,D?7^D0(H(1'"()?^):+X\)Y5Y5A,PC@]\/OR M<,'9OEG]E=X>Q*N(_X$_-N.@Q@Q0X1RZ5?V#D0ZVR6W*DC'9<(6(^=7+&+)<*

M(G"M=H7OH=!6CU%\ HIU03??".3UXC]_AY+H[+&1B%-LWMS#1J =*(;:>^ M/51WF5V@$6P-R[[W@]6C!#Q49\Y;S AM0A"23>GXJ;48"^P&C6U%0QETV>*

MJQ6@PTD9A"9%FAQW+VLWT"D#;KKUL!D-ZY-88&AG-PLA,O?I;TE+T<5C[Y M1$:\,8RZ0WH+CE7/21$(\-G,>:]C36FLI*\$;3F:=8~>C8^3?>HO#6%YFLZVC);,-^>ERG7?=FN,*

*MLG#4EKK(@5&7(OZ9=_,+GY[_!9=7@]MO+Z7CS>AR^@M&OPFPH_0@DO&Y]!8< M&$F&S:4&& T!P!U<@I.GZ]9,D,<$L-L1 F(QU80B1?+*S:?%1C)+2-JINO! M;VAJSOH,-*

*>L;:>7\PI*S)K'4 MAA]+M'1HEK"N1\'HW849GMJ%U&(AM5A(+9Z8HVXVY.%&Y..9II$E7[7J-X,H M7W/SDGX<)F8#]DHQ;XYC?E(8FZ3*V6C%,*&.T M^3\XVQ;M!?*

()-44OC<#A)QTE4\E953B-:!YR;Q8[L-B!QOY;,%IBPV M9;$IS\)#3%M;ZJ%04S+0!]6/,#L5"0O3B%LNM-,Q7&1[Z88.Q1+|K?:G>6)<C.1)+K]C-*

-0]KZK90AO52/.MPBX1KRRU$QZZ2E@[>4Z>>W;)V#:2" MA8[UA\EG,U#L!&^C#[&8K,5D+2;K2DS66=F*87W:<7ZYN1]=[W<"2>3^_K$9 M.@Z,N-V93-FV92^)S8\6C@R)+?

#Y)C+1^!8S,/MTIX3NS0&\4VBA MU>T.Y=\R:),:UL5G6@S08H"NQ0!-(-.VP9V>;M9T[+,P.6,K(@;,;-G:R]9> MMO:5;&TAM[GGNHD%0 AUZ&(.97)E8>[!CSR_3YK$A MOH.M-^4B",]

MJB-H3>;_G%NL!>*8X6BI.%XN27IM:0_>_Y[.M1BJ^]0>Z79DE4H?)5RR.R-Q2K\M#"]6&T_,7+M>OB5^0W?(([L86<3ZJ$Z&"MSR 7:*;#P=RY]V=*E4@6X[*

*MB-C'1ME0CRV-%L^'-&/95,S?]L#.KGKNBF-*PJSC50H*K3KEL:=J:FB28?%# MT69F)>] NCPVA5,W 4. 9BWX;5C]9OYF/&+I;K&!@2YA/(%U7,HB,,67]&LM M?*

*HFWUGU%T<=M*4($[L6SO2-=O[,@MHR& 7-&!E=;N,Z?&D2]O;7>/;!PM(Z, M",RY^TQ8"U5LR6FWR+191@6.^+;20 ?SS-6=C&O>KG6NP$2/-7D,#\$YA!+|-MQ[NQGM)YUG,9]*

*[&/K7C):+A M>13XICU:4T]D#*7*0!]J09=4]ANXI\Q<I-]$3+8.OX/HE696.?R]"X3*2(TO5 ML%MP%TQ5YT?%QS& DRBOI:K-BG6M(U&;;]!%_J:QVO&%S1$$FUQ99*

M8J0;P)].QALV]W6?:W.::AGL\&;U9S)QZ#50^EL^*DTPFZ49M/4J1](,;;MJ MRHY"0=D^8L'R9SLC00#! +6+C$1MV M#\S: &:@Q7H^A??\858:[?

*&EZO4ZV>%9.Y+W;M.2;H%?.H!%4EF5W?P-NR" M2"W&E',SEP#6BE{JC,U-5A*0I2OLJ[61_ LW"[,3E _N:VO);(0B(-V-;@-5 MRO/:F=E!;J&.A-W2CBYL;NI&9=\ZET&*

(U3F^\7D=4!%#MI9_0@5?L;03U" M/SB=?,OYQWM)-II<4W;++T2\3F]0>Z79DE4H?)5RR.R-Q2K\M#"]6&T_ ,7+M>OB5^0W?(([L86<3ZJ$Z&"MSR 7:;#P=RY]V=*E4@6X[*

*<;,_/*I0WK%SA:0K8TYTP4^+2>6$S0KO8 MK^= A8NFB1"LY4E)(>TW -7'U'(#C;EV<$3T/)M.Q_YN,::U;\'.OFNPW-G M4#./,4N/4'!3GSH4C%E3D5A:*.1S((=1*H1D?H%(-)3)QIF3&*

*/HS=AURK,H@ZPTN3$#MCEG\Q\:,K7@EQO,KVP+KR2#AR*HY5KBDR1-[:%'_I9|!Q@U' M*,KU!VV1_?0YN&?4,Z8C2=A\GD-]>]I\>BIY>8(:03RV<\) 3UW&CST2U3H*

MGL,7[46;AE;_&"PYMJN&_KEC!9D;L\]7O>9KM\4-P4NP^@:DLBF& M$<6.NL)%"E"R4OS7\Z?DW,4>200QA5MDUAIAKR/TM1X(W84M15WE) \GQDA]

*M!R%NBFEL&SG+08*4YF;U9>B/E?+<5HB'\3R1K,?(2*4H-R\A=CL(91(9*E] MY3OFR8U7M&3\)3V3*/0F"1UDPP*:F8CHN)@*5ZHU4&\!1-W^/6L^$HY#/34 MA?*

*+\F9M#\[\,$?'"3*$%< PXX7^*4]/S1+]-##PA<*P@>3>,^B,#RP'VFAA U0MY=9-OHRQ7JZ(UZ77ZUO< M;5 A/TF]/A-O&?2UOWB&J2. C% 8329XXS@S;9=G@G-P,E9]"?T[U'A8V:;]*

M04/.O,^8GO9P&!M-D$B^A^>,9U"56-;Q=?P>VP#H05[&\G.\H*X@\LH,]U; M:CUGD\QRNW^BO,T+]VY8 &_>%KQ:6XG38_X9[:(ZU\F524Y_)/-$HG!9V8:

M'$\5Z^4PMWG7(OGX>1C%MG6]FHV2I5''+IFR=,]0H_7)6=GKW%7]5,_M=M;A:G&)?1%5,M=M;A-C&)?1%5#I+0,@%$>FT:]3'4QE&E85M_=I=%(HS3F?8$!,KU:KRWW3RX)EPI!UC+1E0F>B2)TKQR5*

M_5LLY4P\[&;U(K9.U)PPL&AE/^4-/#0KE'/5=T_+=:*362'(Q_@Q]QU.5U/-M[E=;R5T]R'6H@3"(3-5*46!QH13//8VA.'+I8#57B),'M@UD CE?0PN?W:0GQ>_B]F3-*

*V.RC(=YV\V;T_1IXXD);],G5E)E<%=GEC;WX/UQAG- MHVW;R'*M?A]%BE-$71.J).>)=X9G+G)JR*.+T31?+PNM78_E5,\Q!A90BCDS MG5)/4GK?K ,Q<&0AVB)R;NU:JCP#>*

*K541Z8PL(4 QDM1L>]SG#G2C%,\D0 ME\]%V 8]W>22MFI?\<#65"^0!441Y^@]+5!S@1_ 5H<9CC*XUW>=19]%"SS*

MP>D95'"(DQRN@SXS3A<:#YJE'2+,LV#>;O\$/"^[!@8MUCB#T;F+>'@3 K(-M)>B07.B\Q-+0SAAKW?.Q\/".#)]#YZ2LGY!889?3(-RBC-QPIMMGO35YM_K$ MM2P4DRQ?*

(4F[(F7LZ+0@TZ&KG.5449+]_:?%NPR_SPPZLQA![WE2[^QZ[.8A MK:./+;4R=[$1^N:.R2=>ER4=,\RC+X_&%0HCS)>=[D ?H0{XHA;Y[Q34<_ M2%\:N')*\7(RY-+NDF2,OG#?*

*EIDYO1^]LMJ8)8D&659BND!5T0E63;R&CTC M3*91&K74P41EI7V<3@:%%DX#\[\05)=_!GLM(1$5PP,NW0 MQ

MP&&W^G2>3_M_VO^W;_"/'MG#/G1"W.#8DM &UGGO $0W -4R59XDO)OLEPF-3'I#X.5-CC M-S+P/@&CWV";+QJ7+<^FY/RTB;=-?,5WV M:Y=6SWM/NRD6?:>A-^^8 T2C[0C7B;E_],(2#G[0$MS3/9WBTX:?-OP=V:?#, MD^3'=]H7>:,HB]S^_E"OMN?HN[C:@K:C;#W^QUFY;:>VN&FC3QOJ;F]T0!X!-M%LP0LTH;G-G,"ALXQ*)54&,+4]43-QM51;4,"-X^&Y3Y&Y=+-7OK&1@>P&> M%VY9-7=EC%;]W/9K_#'9!Y(;F-3&W5 ;@I4,\93C9C6JY.A>'(\3-X2=N[\--M-\1G^MB)&V+BAIBX(0Y#.G4<>.$$OPX%B2-MD"8,S\DYH=.,2>35^9 8PF\:-1M8IO2*C#KNUF332:VP!"&"/_1PV?LV&PR%@-MX"'\R.YRC(7L >&LU74*+]R -/=?CA!6&[?U327F>Z'0GC1C.T.SC&#'!Q$S(]E0 1">@+'6?HV_%)53),."X1NI(Q0ND ML*D?8K1\@!++;YVG8,N[4N9#>)N1G^,TW==;PCF!P69*P@+P^$&VO;!^],,L*.M".+_^[]?/GWRQ=>0@XW+&,=0A #$7DO%DC9Y48'&E/W]0O"GN[.&,*IU/S + MFU7,IEH(I$@ Q@QL7V,/07',EW')],B95E.)54NH;)C[2?5%T^(%3P.W;IUU-@KQD3.&ZN0:U9DS$X/S>1^0_ 93!@04D1E'$. MUGT+1.H1\L<)Q'3/^7M]'-L33E,VLTW?>*

(7:\LDC6V@L>PDU%M=\T!Q;Q=[# MJ#\GW-F#F$R,@UXW/.9A^GANI)>2<5]RU15S<&,L>](SQ*NB&.RV53.I&6$-M&\&8"Q.&

*(SX3HM*8*TK,$N=QQE6D51>0BI.K+Y$I.,B84B7&V+A'Y6[Q>L> MX8E]]ZY>0.G\]?#1[V9^>9H)7OLY^]:EDSLP%S9,YDN;*/))¥06VT9.5>]\!(*.M)8*H[XDU!@"\1B']+-$QM&*

*(;B1OL6]@4NHWU3JK[<2YU+E'\-M8CB'[H)DSI)$AG_3U?X'7(<80U&*2*.>,;HI;UST6R:QAJ>Z(6(:?(+F81X0-M9@GY4;DLO#[3LA.GEHPE'-WTNT#6L3V:?*

*2>DTM\UNGSAN(JGOST\H]VC0NR(MO!8+Y=\,8MKV625K:8@C+/O+C!APNG;RZ)D_AFEN%ELS' HI)[-> M]>L%OR6/<*X,':*;"B[Z%W4NS'6:,?**4AMP/GYE=]QE](RKX]U:]=T?*

+WHBT M.]HF[-OP 3TA7%"P1F4UB*B#VO9%&CT6VF;Q"'''!9: MIY#Q>0$EC<]P(?#<$_3WZ7]_.'Z@[%QE.@_3P&K>"(E'.[@D88-K]1_"UOL_://OG!(78RM_Q:1] S3U! M_#5_2W\!^?*

*KA?.S^$CT(%/K<^0(VE)R]T)-=$*G)L9#(0A41> M%/&%YH&C0:AV=ED*DG?TNV7YO@3SXRAIP0AA@5R('W=PEX]FK_L&0YBSL<$[*

M4=^<+%.F!%78;_KL8@L90DW]&:!OLOFQ>S.*)\/8J0URQH!SBE Q^$VB"U]' M"#TN-U2/-WTTN55MD8M/-'DZAU#H+ ^"I5GJ4XXB\$* 314GT2AJFD82IL./1ZP% JA6HR=RM_?K& *Z>AJK,0H]K319*3 M@I@4Q*0@#]X@LK6C\$@OJ8/%$>0K!U(Y(HCS&3A&HYM7+C8 O7T3NN.26M, M6F/2&H!ZZDGU3&6DEUW&G5*

MH9&-0:R.\HFD)Q@I":F[==$)WM(PTTZ!M_.ZZL/L^!=I&$KFR4B6G76+-_M5U(3A7_AT;;Z\9&L\YHX6;GA;OP"]O7]^R\!E3>%I&[=5'ME "TDNSQ7Y_U M3:=1>U/Y=H1\\,Q]R-

;;D@K"9M_7\XY2OD\?/WU"M/2N.LV RX.879$[H8Y' MI5GK]!Rf<1O0^U9IX1=.N)DDCB@IDJV'UW+%(XAZPBU;&]-C.%^*+;(LS@@Z

*M%74B^Y3<+!S%C\;UV^73;'P7V+*BDH*8;D235[P%>Q M4]Z6/DKXC?<_"4-OG)-6PXB5&(-V! MG-5U\,Y]TI"(5.)).K"<5V(K3FAM$%,68SE*;3VY((%2-.,?,PAA3N3#+-*

MH,LERQSDMf\DV^T(#J;OH2)>+'7+I-CT#^%,7R5>>GPTLIAP.1+::.3V^O*.M+[STH\$T8O[SOM%[HQB!)DIW/R:,(&Y@Z@&-"DXN-MHJ(F*#*ND9;K39YDUGEA0\U)I2OEMWKI-*

S5F?N3F<[^1B9&BF?G_]$H'1X1T M,%&]BA9>IB[B_V|\SK3<>M^>:.0F932P972*V.<>%$E68/0;?WY2MN= MI:O+WCM4;F8A@Y[%]H]VSVKZ?;K>L#Z'2+6N%)0EJ/Y:/$?*

YT1+#8C^3\G(4 M[]$-HIV.@L.^R8O66RP-QIH9HU{J.AHNA5)GI(V6W.M)5"44(@X7*#B!C867 M@*8(6*OC98Y.^ X3%]T!D:C'E_7*T(TI#'!O."<;&[2DV/_+==&O.9N!8[>^*

MJ4(-3+++I;ECDNEOX(?ZWL-(UY(O4G]RF'*$_J5]V\]FP ML8)>/5+]6&(\?U\81\3+<%"K60PT2 M:U)S1#]Y_A<\;G$6M;,II$<@58KW3 M^?IU% _^2CD0X1#9$--+8VN\MD-*

_.T[A%/LM!0!55DNJN& MB&1T>+F.SR$}(@0?E.K<0MV:JN=^'T')U_7-%SS$Y7XIB" V>2W,/2L^N(S-# M:<%Y/.B-9"5SYGZ3XK&9UHWJ_O;" (Ij_P]HT'U>%]5?47(-#6"@_KPRY0(*

MD.@#;3N@AE=,8E5}TP#Z8AQW/22#E:9FBHJN< #)"N=5(#%%2@QO:(!(D%X7Z)B55J5E1DC(L5!> MRMJ%C-/@T3<%%X787]>=NU;Q.. MSH2C, ^'H?.3<^(>C") ZS0F: MD.PN-*

;9&U&N'!0#2D_*Z+8_1 MH58.IA<52%+C]<,)@T:K*C(/¥\|_9315L,I)F2E+X%'E_"36VD3;PLM8A1(=VUM'UQM*UR2!F%S*

*MW"7RWE\W4MMIG6H"D.TOF%-2"^.H2\5E6)9]&QY/_(@>TCK MZ;>W..>Q25:,,B_*7SI%WH@$8).Z=\'9*B_H>+|[:7!HXMQ]MHBJS8HW?++1IF*

*MA5CYS9_WRR+S+YGWV/$7/%P:@6S]>6A_#L1=7M+*>NNTZ8#A .IF).+S8'G% M:/S&:04]('C*C$ D_?9^SS (_$Y"QV1'/$\NTHI2$5$]*U0R!%%= M*Y?3(BY1+&W!3!#^E[K,7-*

DF6UTK59(M3UM.,L,ET6Y\D(0&DA64&NA$1#N\5@%X1%)YDI<4ABQ:>AX"6*% M:BL+3M@4R,%L%155JAX-3/U2L9R9F2:R+9E\DFE+(EU$'9W.K0676EHAI'.6 M,00

>+'ZO2$9W#JYZ>UG4^V^S]!X%,ET0YP M:TVW+;9YW+K<9JR"$0A2AELSC;.>@'P-"^$U-I EJ=[_4Z.<3U.@$ M-3!IC?YJIX?Z7505ORO:]|/7&1T84SO'@3J)?C]ZJ=EO0! H#<*

ZG6Q)&\B MP 8&Z(+0#%)!CTMH^!'K#5M(MY,'7H'&9)W_9I)EB6;.%&<"1@&YW*%C.+ M++VPB4PP%$7ZS4B7P8I0WI$F?<'4],3*

*M@$O2L^UG'C@R"I=B6KX#&@C,;$#,=7%P/QK63 J"-#GNI)43*MSI M:E#N")=3[DB //Z9\25A5A==;^ ?_9HRF-@\,54)W:Z5V[L\,BB@5W_T?@1E M@'"*Q1B%+R(EJ+3[;*

*(#*PP_9F[$']'T?>8'59ZQT0%_LW59;]O"O=@T!$H#1!I^;P:=8T0;UZQ;#@!07S6V MT(7+"'"Z!00>HR8SWVGOD UWR5M1(AT!D[$CK5Z 4:1SWN+4]L,#(Y_-K@+"?*

*MXDF*WT0_V)HI4SPFXB8LO2ZLUQ)CI+Y #4MNLBU+H:)Z2-=WRPZV.'LH2S]M MN4,9(S[SFB8%(4I:(R,,K"52)-39 "5+7F:8%+CP*@Q^-@EFDI +!TKSLM/5 ML 8%I)#IG#P,]*

_8G3^ QY/(LA1RB;8 YMF%8U"(@)I/HBP% +9,&F.U'],? M=NW6;]CU3!FL&4?48+E$$3!853MHM7O(S1 M>46,F$YS=#/0H3F\KU>K&DOI[/%G^X&'=91M*

+X0I%G!PXC[R&,RW??BM5 M$CQC=+:;O)'&@C:,O-*M/<$79+S,1$:,BF*.9?>H%WQ;%^_UH#1V[=S!OJVEH<98H4 M]1f\<$%#)?1#/CA/0=>#)XL18G0ZZJR3X\2.,AZY!SC8;17*

*];P.#+)%40ZEB MT&'$,Q(TXUVXX2/%,C[NY#0F7*Z;3PO1!K1$R*A305L1YQ,;W6KY6#/G-$HC5IDX%<8U3889!>$S>===E>A-:4U/5F:,R_/VGZ;[?J/[LYH>]2@)3UKM2"_"@1:G:#&1S*

*M(17G9P7V*M/2A3CLG#N)_60SZ%V8_F2^_1T@L'6O2/ZKS*#P$5$$R)2H*T2T[K+=G@9*>86MC1;"A=9TU"=J\I M"&AS;W9\4 $\>'1H#OO=-1SO?*

()2O:S)6RV:GST0U^'U\9.864HH4W%>B+9) &3%?(7+G)B%5)/,\-UOHA M#.8;'_6W=OC^D5,6 7*=Z[V7PH!3E^>\XXU#01IAG<7,0SF2D^JG6J%##H:Z# M/PDG#SFV%-*

F(#'5VB9;!.IX\++L1=WS@>\W3UM06B80E0;,@74W#UCL(2[N M\HZ[LQ9P>9PS%)+7G5&6+OMIB=RZ$C%RJT&Z9-4"_-P], I8]"%))Y); =K@ M)H>T?*

Q%KSG&W2(,K#N2.+SIP@$.G17^!-%_C.RX.G]ZH7P&UUD67_%_YZ('U?H=DFH'I["V M%(?^%[_6@N-O.T9BMZ\&8K :V)9Y=D:-M'2U2S&;&1]T^7GML6-./Q?

*%$JQ!O3TWRP^(TE0_?0OEP*CK_R+87U*-[&&D@J;.P?V7L-2%GBB5N*0XNXZ0WE3QXJ)RUZ6M;6:!E'X$;C.MG*2<>JSGI(6&= MHN8P)I?*

_0LH\VT&N>X_6&2B:O82)H:S3+!0.05B>EU14[M_IO[Z?IHKZX+;, M>YZU8>^J9KKD(;^NL^ZS+_Z.I7/2-C>3-KKQ59MZZ6[82_?:9&>&DGS39\"Y MRV9%_N^?]%7,;'\R(U-

\^*$LI[_*Sl.,SJTCK]>_Sl.C&?Z>^7_^9"Z;G60E M'Z>O^9K,I.A3W!BETWL_<X/U&:;_AS%[77AJUBG;5Z.!$,M5NG9]F!VCM.M;WXFR9 92@_\I"

(N#:B2V;/\|G3QT[_$ZV(/M%12#6S"S9KLS(]^+[M^LK8]'T3%!2 !RGA/RX7D<^"B'R'VO&3;(5@V/_')__|ZM&S MQY\0RLR_?^^6^5^_ZYKR1W23O5W!V.3'3?.CO_@;&!^?

*T*HNGW!Q_/D73Y]^ M,G/M,MO -&IZIP;D+2U*%"KR&(I[50?),I[<+EY_ M, Y647%&ZUU?7C[_3S|/>'8O^PW!XL'JH2DH>:4ECL?+[|%'"}>+Y-4<66,2SN!TU,%^,VF?4;!SPL?*

*"_-&QYN]T!9*T4 M5,/ X*IE61V>3.C@RP;TV>,O^27]JK\+Y6&SDT?_>32RT7^30,ZGR>EYG>/V MELTH]^&L6!1=&PZ\^,'EY]WGP9QZ)5?\#O83MZ=SP"8 _5X#^/<&<\EA$XJ: MV%*

*7X; FD2[Z9 ^*PB>*P_ZT:+NNGKM!6OS 6B.13YK3AC;$ M_>7?F_C07_9CV1Y 2F1M+13PMT7S*2VXEUY_-H3EW@-8.XI8+,_^^I>K4'\/ M,SU?2*

*GG8Z3"L9[&^V;LI3=@FV*C[!IT1W'$\VSUBR MJR]=M ,ZSKL@4AKB=|_^Q_L@GSUY?G36K3]b[Z NF3+([^B)H7O.FD!2"%6*

*MN)4_Y=VRI[Z]MX)Y.M*1Q'/TI/'32]J2_#=/'S]^>@0M?)_DY^G1DW_[LPO0 MY[]*@ C.9ER(>$[V2M)7CS^_6I)F#YY\23W +X[2JY\|>_[XX7V3LR>/GQR] M^?[D#DK:Q[[9&TK-*

S/([FW??SMY47(_^>RE]>_=LA4Y>_,,.KM!MZ@$]>C]F M'QB&[\?PO*G7^V1YYM;9?5W.%)??3LMIE_-%5B[5OT3VE5I=[NGBOGSU>EI< MN[@O$74H_A!K^-^WQ-]/:VK7]-*

ENX\MXOZP_O7DW+:I?U!]O7=;]7]L_V1\7%2O.M;[A MYB6JOTW"\(KI'I.(Z "D#H.81K0?)8G$D_#%'ZG>Z@:%&S^8X"WW\E'_D@!>_MK/8?3Y\I^ 0J0@&W.#M#P4*/-*

A!T3^5\]"AT&!V;"NQ5$8B\T+L)E &=A@I1 MB3[$'B:/]MOSH=,_M/;W>K6XW9_S#3]^>O$]!;YY\,,DQ9M7W[IX=3)/OGCS_8NCC\DC/Q^=DIO<

*MN6M,^KK(\])=;IZO>8>/O<&S+SI*D]N-21KDV7F2;DFDO.?G%";95>G%6G7 M%YGA:&]QL-]L_WK9R Y3UL "<4MO\&G[Z:^_Z9OWCO^YX'I\V]R[Z9T.V&4 M6Q/(CU2/-*

Y"'C[D!KPK4W?AD0D@WGJA;/("\<4G(S:1&H$QZOW]+.^YTC8<8M M_/;XY,=`T>G=&P6X<][]5S?TY_P_O638AU3D&"0 ,C8 T (.! &5X7S%0 #0 M@ $Q"0 97A?-S(R-#$V+FAT;5!+

*0(4 Q0 (,,. 7EE1]!N\ZQ$.#< M 1 " = . !P;'-E+3(P,C0P.3,P+GAS9%!+ 0(4 Q0 M (,,. 7EF2$.&SA0H *>0 5 " >H@ !P;'-E+3(P M,C0P.3,P7V-A;"YX;6Q02P$"% ,4 " #C@%Y9(YZZ*49$*

*#4(08 %0 M @ &B*P <&QS92TR,#(T,#D5,%]D9668N>&UL4$L! A0#% M @ XX!>6500IZUE6 D>0$!4 (!&W -'L XML 69 plse20240930c_10g_htm.xml IDEA: XBRL DOCUMENT*

0001625101 2024-01-012024-09-30 0001625101 2024-10-25 0001625101 2024-09-30 0001625101 2021-12-31 0001625101 2024-07-012024-09-30 0001625101 2023-07-012023-09-30 0001625101 2023-01-012023-09-30 0001625101 2023-12-31 0001625101 2022-12-31 0001625101 2023-09-30 0001625101 us-gaap:CommonStockMember

2024-06-30 0001625101 us-gaap:AdditionalPaidInCapitalMember 2024-06-30 0001625101 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-06-30 0001625101 us-gaap:RetainedEarningsMember 2024-06-30 0001625101 2024-06-30 0001625101 plse:RightsOfferingMember 2024-07-012024-09-30 0001625101 us-gaap:CommonStockMemberplse:RightsOfferingMember 2024-07-012024-09-30 0001625101 us-gaap:AdditionalPaidInCapitalMemberplse:RightsOfferingMember 2024-07-012024-09-30 0001625101 us-gaap:AccumulatedOtherComprehensiveIncomeMemberplse:RightsOfferingMember 2024-07-012024-09-30 0001625101 us-gaap:RetainedEarningsMemberplse:RightsOfferingMember 2024-07-012024-09-30 0001625101 us-gaap:CommonStockMember 2024-07-012024-09-30 0001625101 us-gaap:AdditionalPaidInCapitalMember 2024-07-012024-09-30 0001625101 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-07-012024-09-30 0001625101 us-gaap:RetainedEarningsMember 2024-07-012024-09-30 0001625101 plse:AtmOfferingMember 2024-07-012024-09-30 0001625101 us-gaap:CommonStockMemberplse:AtmOfferingMember 2024-07-012024-09-30 0001625101 us-gaap:AdditionalPaidInCapitalMemberplse:AtmOfferingMember 2024-07-012024-09-30 0001625101 us-gaap:AccumulatedOtherComprehensiveIncomeMemberplse:AtmOfferingMember 2024-07-012024-09-30 0001625101 us-gaap:RetainedEarningsMemberplse:AtmOfferingMember 2024-07-012024-09-30 0001625101 us-gaap:CommonStockMember 2024-09-30 0001625101 us-gaap:AdditionalPaidInCapitalMember 2024-09-30 0001625101 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-09-30 0001625101 us-gaap:RetainedEarningsMember 2024-09-30 0001625101 us-gaap:CommonStockMember 2023-12-31 0001625101 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001625101 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0001625101 us-gaap:RetainedEarningsMember 2023-12-31 0001625101 plse:RightsOfferingMember 2024-01-012024-09-30 0001625101 us-gaap:CommonStockMemberplse:RightsOfferingMember 2024-01-012024-09-30 0001625101 us-gaap:AdditionalPaidInCapitalMemberplse:RightsOfferingMember 2024-01-012024-09-30 0001625101 us-gaap:AccumulatedOtherComprehensiveIncomeMemberplse:RightsOfferingMember 2024-01-012024-09-30 0001625101 us-gaap:RetainedEarningsMemberplse:RightsOfferingMember 2024-01-012024-09-30 0001625101 us-gaap:CommonStockMember 2024-01-012024-09-30 0001625101 us-gaap:AdditionalPaidInCapitalMember 2024-01-012024-09-30 0001625101 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-01-012024-09-30 0001625101 us-gaap:RetainedEarningsMember 2024-01-012024-09-30 0001625101 plse:AtmOfferingMember 2024-01-012024-09-30 0001625101 us-gaap:CommonStockMemberplse:AtmOfferingMember 2024-01-012024-09-30 0001625101 us-gaap:AdditionalPaidInCapitalMemberplse:AtmOfferingMember 2024-01-012024-09-30 0001625101 us-gaap:AccumulatedOtherComprehensiveIncomeMemberplse:AtmOfferingMember 2024-01-012024-09-30 0001625101 us-gaap:RetainedEarningsMemberplse:AtmOfferingMember 2024-01-012024-09-30 0001625101 us-gaap:CommonStockMember 2023-06-30 0001625101 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0001625101 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-06-30 0001625101 us-gaap:RetainedEarningsMember 2023-06-30 0001625101 2023-06-30 0001625101 us-gaap:CommonStockMember 2023-07-012023-09-30 0001625101 us-gaap:AdditionalPaidInCapitalMember 2023-07-012023-09-30 0001625101 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-07-012023-09-30 0001625101 us-gaap:RetainedEarningsMember 2023-07-012023-09-30 0001625101 us-gaap:CommonStockMember 2023-09-30 0001625101 us-gaap:AdditionalPaidInCapitalMember 2023-09-30 0001625101 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-09-30 0001625101 us-gaap:RetainedEarningsMember 2023-09-30 0001625101 us-gaap:CommonStockMember 2022-12-31 0001625101 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001625101 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0001625101 us-gaap:RetainedEarningsMember 2022-12-31 0001625101 us-gaap:PrivatePlacementMember 2023-01-012023-09-30 0001625101 us-gaap:CommonStockMemberus-gaap:PrivatePlacementMember 2023-01-012023-09-30 0001625101 us-gaap:AdditionalPaidInCapitalMemberus-gaap:PrivatePlacementMember 2023-01-012023-09-30 0001625101 us-gaap:AccumulatedOtherComprehensiveIncomeMemberus-gaap:PrivatePlacementMember 2023-01-012023-09-30 0001625101 us-gaap:RetainedEarningsMemberus-gaap:PrivatePlacementMember 2023-01-012023-09-30 0001625101 us-gaap:CommonStockMember 2023-01-012023-09-30 0001625101 us-gaap:AdditionalPaidInCapitalMember 2023-01-012023-09-30 0001625101 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-012023-09-30 0001625101 us-gaap:RetainedEarningsMember 2023-01-012023-09-30 0001625101 us-gaap:WarrantMember 2024-01-012024-09-30 0001625101 us-gaap:WarrantMember 2023-01-012023-09-30 0001625101 us-gaap:EmployeeStockOptionMember 2024-01-012024-09-30 0001625101 us-gaap:EmployeeStockOptionMember 2023-01-012023-09-30 0001625101 us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Member 2024-09-30 0001625101 us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel2Member 2024-09-30 0001625101 us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel3Member 2024-09-30 0001625101 us-gaap:MoneyMarketFundsMember 2024-09-30 0001625101 us-gaap:FairValueInputsLevel1Member 2024-09-30 0001625101 us-gaap:FairValueInputsLevel2Member 2024-09-30 0001625101 us-gaap:FairValueInputsLevel3Member 2024-09-30 0001625101 us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Member 2023-12-31 0001625101 us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel2Member 2023-12-31 0001625101 us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel3Member 2023-12-31 0001625101 us-

gaap:MoneyMarketFundsMember 2023-12-31 0001625101 us-gaap:FairValueInputsLevel1Member 2023-12-31 0001625101 us-gaap:FairValueInputsLevel2Member 2023-12-31 0001625101 us-gaap:FairValueInputsLevel3Member 2023-12-31 0001625101 2023-01-012023-12-31 0001625101 us-gaap:LeaseholdImprovementsMember 2024-09-30 0001625101 us-gaap:LeaseholdImprovementsMember 2023-12-31 0001625101 plse:LaboratoryEquipmentMember 2024-09-30 0001625101 plse:LaboratoryEquipmentMember 2023-12-31 0001625101 us-gaap:FurnitureAndFixturesMember 2024-09-30 0001625101 us-gaap:FurnitureAndFixturesMember 2023-12-31 0001625101 us-gaap:SoftwareAndSoftwareDevelopmentCostsMember 2024-09-30 0001625101 us-gaap:SoftwareAndSoftwareDevelopmentCostsMember 2023-12-31 0001625101 us-gaap:ConstructionInProgressMember 2024-09-30 0001625101 us-gaap:ConstructionInProgressMember 2023-12-31 0001625101 plse:AcquiredPatentsAndLicensesMember 2024-09-30 0001625101 plse:AcquiredPatentsAndLicensesMember 2023-12-31 0001625101 us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember 2014-01-012014-12-31 0001625101 us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember 2014-12-31 0001625101 plse:The2024RightOfferingMember 2024-03-28 0001625101 plse:WarrantsIssuedIn2024RightsOfferingMember 2024-03-28 0001625101 plse:The2024RightOfferingMember 2024-03-282024-03-28 0001625101 plse:RightsOfferingMember 2024-07-03 0001625101 plse:RightsOfferingMember 2024-07-032024-07-03 0001625101 plse:RightsOfferingWarrantsMember 2024-07-03 0001625101 plse:RobertWDugganMemberplse:RightsOfferingMember 2024-07-032024-07-03 0001625101 plse:RobertWDugganMemberus-gaap:PrivatePlacementMember 2023-04-302023-04-30 0001625101 plse:RobertWDugganMemberus-gaap:PrivatePlacementMember 2023-04-30 0001625101 plse:LoanAgreementMember 2023-04-302023-04-30 0001625101 plse:RightsOfferingMember 2022-06-092022-06-09 0001625101 plse:RightsOfferingMember 2022-06-09 0001625101 plse:RightsOfferingWarrantsMember 2022-06-09 0001625101 srt:BoardOfDirectorsChairmanMemberplse:RightsOfferingMember 2022-06-09 0001625101 plse:RightsOfferingWarrantsMemberplse:VestingOfFirstHalfMember 2024-07-03 0001625101 plse:RightsOfferingWarrantsMemberplse:VestingOfSecondHalfMember 2024-07-03 0001625101 plse:RightsOfferingWarrantsMember 2024-09-30 0001625101 plse:RightsOfferingWarrantsMember 2023-12-31 0001625101 plse:RightsOfferingWarrantsMember 2023-01-012023-12-31 0001625101 plse:RightsOfferingWarrantsMember 2023-01-012023-06-15 0001625101 plse:RightsOfferingWarrantsMember 2023-09-30 0001625101 plse:The2017PlanMember 2017-01-012017-12-31 0001625101 plse:The2017PlanMember 2017-12-31 0001625101 plse:The2017PlanMember 2023-01-012023-01-01 0001625101 plse:The2017PlanMember 2023-12-012023-12-31 0001625101 plse:The2017PlanMember 2024-09-30 0001625101 plse:The2017InducementEquityIncentivePlanMember 2017-11-30 0001625101 plse:The2017InducementEquityIncentivePlanMember 2017-11-012017-11-30 0001625101 srt:MaximumMemberus-gaap:EmployeeStockOptionMemberplse:The2017InducementEquityIncentivePlanMember 2017-11-012017-11-30 0001625101 plse:The2017InducementEquityIncentivePlanMemberus-gaap:ShareBasedCompensationAwardTrancheOneMember 2017-11-012017-11-30 0001625101 plse:The2017InducementEquityIncentivePlanMember 2021-05-012021-05-31 0001625101 plse:The2017InducementEquityIncentivePlanMember 2024-03-012024-03-31 0001625101 plse:The2017InducementEquityIncentivePlanMember 2024-09-30 0001625101 plse:The2015Plan2017PlanAndInducementPlanMember 2023-12-31 0001625101 plse:The2015Plan2017PlanAndInducementPlanMember 2023-01-012023-09-30 0001625101 plse:The2015Plan2017PlanAndInducementPlanMember 2024-01-012024-09-30 0001625101 plse:The2015Plan2017PlanAndInducementPlanMember 2024-09-30 0001625101 plse:TimebasedOptionsMemberus-gaap:ShareBasedCompensationAwardTrancheOneMember 2024-01-012024-09-30 0001625101 plse:TimebasedOptionsMember 2023-12-31 0001625101 plse:TimebasedOptionsMember 2023-01-012023-12-31 0001625101 plse:TimebasedOptionsMember 2024-01-012024-09-30 0001625101 plse:TimebasedOptionsMember 2024-09-30 0001625101 plse:PerformanceOptionsMember 2023-12-31 0001625101 plse:PerformanceOptionsMember 2023-01-012023-12-31 0001625101 plse:PerformanceOptionsMember 2024-01-012024-09-30 0001625101 plse:PerformanceOptionsMember 2024-09-30 0001625101 plse:PerformancebasedOptionsMember 2024-01-012024-09-30 0001625101 plse:MarketbasedOptionsMember 2023-12-31 0001625101 plse:MarketbasedOptionsMember 2023-01-012023-12-31 0001625101 plse:MarketbasedOptionsMember 2024-01-012024-09-30 0001625101 plse:MarketbasedOptionsMember 2024-09-30 0001625101 srt:MinimumMemberplse:TimebasedAndPerformanceOptionsMember 2024-07-012024-09-30 0001625101 srt:MaximumMemberplse:TimebasedAndPerformanceOptionsMember 2024-07-012024-09-30 0001625101 plse:TimebasedAndPerformanceOptionsMember 2023-07-012023-09-30 0001625101 srt:MinimumMemberplse:TimebasedAndPerformanceOptionsMember 2024-01-012024-09-30 0001625101 srt:MaximumMemberplse:TimebasedAndPerformanceOptionsMember 2024-01-012024-09-30 0001625101 srt:MinimumMemberplse:TimebasedAndPerformanceOptionsMember 2023-01-012023-09-30 0001625101 srt:MaximumMemberplse:TimebasedAndPerformanceOptionsMember 2023-01-012023-09-30 0001625101 plse:TimebasedAndPerformanceOptionsMember 2024-07-012024-09-30 0001625101 plse:TimebasedAndPerformanceOptionsMember 2024-01-012024-09-30 0001625101 plse:TimebasedAndPerformanceOptionsMember 2023-01-012023-09-30 0001625101 srt:MinimumMemberplse:MarketbasedOptionsMember 2024-07-012024-09-30 0001625101 srt:MaximumMemberplse:MarketbasedOptionsMember 2024-07-012024-09-30 0001625101 srt:MinimumMemberplse:MarketbasedOptionsMember 2023-07-012023-09-30 0001625101 srt:MaximumMemberplse:MarketbasedOptionsMember 2023-07-012023-09-30 0001625101 srt:MinimumMemberplse:MarketbasedOptionsMember 2024-01-012024-09-30 0001625101 srt:MaximumMemberplse:MarketbasedOptionsMember 2024-01-012024-09-30 0001625101 srt:MinimumMemberplse:MarketbasedOptionsMember 2023-01-012023-09-30 0001625101 srt:MaximumMemberplse:MarketbasedOptionsMember 2023-01-012023-09-30 0001625101 plse:MarketbasedOptionsMember 2024-07-012024-09-30 0001625101 plse:MarketbasedOptionsMember 2024-09-30 0001625101 plse:MarketbasedOptionsMember 2023-07-012023-09-30 0001625101 plse:MarketbasedOptionsMember 2023-01-012023-09-30 0001625101 plse:The2017EmployeeStockPurchasePlanMember 2017-12-31 0001625101 plse:The2017EmployeeStockPurchasePlanMember 2024-09-30 0001625101 plse:The2017EmployeeStockPurchasePlanMember 2024-01-012024-09-30 0001625101 srt:MinimumMemberplse:The2017EmployeeStockPurchasePlanMember 2024-07-012024-09-30 0001625101 srt:MaximumMemberplse:The2017EmployeeStockPurchasePlanMember 2024-07-012024-09-30 0001625101 srt:MinimumMemberplse:The2017EmployeeStockPurchasePlanMember 2023-07-012023-09-30 0001625101 srt:MaximumMemberplse:The2017EmployeeStockPurchasePlanMember 2023-07-012023-09-30 0001625101 srt:MinimumMemberplse:The2017EmployeeStockPurchasePlanMember 2024-01-012024-09-30 0001625101 srt:MaximumMemberplse:The2017EmployeeStockPurchasePlanMember 2024-01-012024-09-30 0001625101 srt:MinimumMemberplse:The2017EmployeeStockPurchasePlanMember 2023-01-012023-09-30 0001625101 srt:MaximumMemberplse:The2017EmployeeStockPurchasePlanMember 2023-01-012023-09-30 0001625101 plse:The2017EmployeeStockPurchasePlanMember 2024-07-012024-09-30 0001625101 plse:The2017EmployeeStockPurchasePlanMember 2023-07-012023-09-30 0001625101 plse:The2017EmployeeStockPurchasePlanMember 2023-01-012023-09-30 0001625101 us-gaap:ResearchAndDevelopmentExpenseMember 2024-07-012024-09-30 0001625101 us-gaap:ResearchAndDevelopmentExpenseMember 2023-07-012023-09-30 0001625101 us-gaap:ResearchAndDevelopmentExpenseMember 2024-01-012024-09-30 0001625101 us-gaap:ResearchAndDevelopmentExpenseMember 2023-01-012023-09-30 0001625101 us-gaap:GeneralAndAdministrativeExpenseMember 2024-07-012024-09-30 0001625101 us-gaap:GeneralAndAdministrativeExpenseMember 2023-07-012023-09-30 0001625101 us-gaap:GeneralAndAdministrativeExpenseMember 2024-01-012024-09-30 0001625101 us-gaap:GeneralAndAdministrativeExpenseMember 2023-01-012023-09-30 0001625101 plse:TimebasedOptionsMember 2024-07-012024-09-30 0001625101 plse:TimebasedOptionsMember 2023-07-012023-09-30 0001625101 plse:TimebasedOptionsMember 2023-01-012023-09-30 0001625101 plse:PerformancebasedOptionsMember 2024-07-012024-09-30 0001625101 plse:PerformancebasedOptionsMember 2023-07-012023-09-30 0001625101 plse:PerformancebasedOptionsMember 2023-01-012023-09-30 0001625101 plse:EmployeeStokPurchasePlanMember 2024-07-012024-09-30 0001625101 plse:EmployeeStokPurchasePlanMember 2023-07-012023-09-30 0001625101 plse:EmployeeStokPurchasePlanMember 2024-01-012024-09-30 0001625101 plse:EmployeeStokPurchasePlanMember 2023-01-012023-09-30 0001625101 plse:TwoThousandTwentyTowLoanAgreementMemberplse:RobertWDugganMember 2022-09-20 0001625101 plse:TwoThousandTwentyTowLoanAgreementMemberplse:RobertWDugganMember 2023-01-012023-12-31 0001625101 plse:LoanAgreementMember 2023-04-30 0001625101 plse:CorporateHeadquartersInHaywardCaliforniaMember 2017-07-31 0001625101 plse:ExpansionPremises1Memberplse:CorporateHeadquartersInHaywardCaliforniaMember 2019-05-31 0001625101 plse:ExpansionPremises2Memberplse:CorporateHeadquartersInHaywardCaliforniaMember 2019-05-31 0001625101 plse:LetterAgreementMemberplse:RobertWDugganMember 2022-05-312022-05-31 0001625101 plse:LetterAgreementMemberplse:RobertWDugganMember 2023-05-312023-05-31 0001625101 plse:LetterAgreementMemberplse:RobertWDugganMember 2024-09-30 0001625101 plse:LetterAgreementMemberplse:RobertWDugganMember 2022-09-202022-09-20 0001625101 us-gaap:EmployeeSeveranceMember 2023-02-012023-02-28 0001625101 2023-02-012023-02-28 0001625101 plse:NextOneToFourYearsMemberus-gaap:SubsequentEventMember 2024-10-012024-10-31 0001625101 us-gaap:EmployeeStockOptionMember 2024-01-012024-09-30 shares thunderdome:item iso4217:USD iso4217:USD shares utr:Y pure utr:D utr:sqft0001625101Pulse Biosciences, Inc.false--12-31Q32024 0.0010.0015000000050000000000000.0010.0015000000005000000006151600061516000551440005514400036400024000364000240006000900000100000400000060000001200 gaap/2024#CostsAndExpensesfalsefalsefalsefalse10-Qtrue2024-09-30false001-34899DE46-5696597601 Brickell Key DriveMiamiFL33131510906-4600Common Stock, par value $0.001 per sharePLSENASDAQYesYesNon-accelerated Filertruefalsefalse6151667779033000443650001381000963000804140004532800012210001528000138600018860002791000279100065880007256000646000365000930460063711150003369150007913100044360000930460005915400000000000770300047200021674000199800059520003780000143220001104300013655000112520003599600031041000013655000-11252000-35996000-3104100097500068600017960007640009750006860001796000764000-12680000-10566000-34200000-30277000-0-0-0-0-12680000-10566000-34200000-30277000-12680000-10566000-34200000-30277000-0.21-0.19-0.6-0.64610660000568660005716900047288000-34200000-30277000391000404000500000499000679300038370003940003430007000-114000-668000-596000-194000-1740007000409000-777000-6560000-668000-27199000-26259000720078000-72000-78000478000395000596490000153600014828000498000367000-06000222000-06193900015584000034668000-10753000443650006113900079033000503860001300013000477000000065249000300000720000552280005500038534900003584350002696900060000006000596300000059636000142000100015650000015660001050000476000004760004000001820000018200010000000002982000002982000000012680000-12680000615160006200045018400003711150007913100055144000550003812200000336915000443600006000000600059630000005963600014200010001565000001566000111000049800000498000011800004780000047800010000000004770000000477000000477000000-0-0477000000679300000679300000-34200000-34200000061516000620004501840000-37111500079131000547710005500037486100003144160006050000013500003090000030900085000010300000103000010000010000179800000179800000-10566000-10566000549910005500037707200000-32498200052145000372350003700029242000000-294705000-22480001002300010000652330000065243000723800070001482100000148280003470001000394000003950001480000367000003670000383700000383700000-30277000-30277000549910005500037707200000-32498200052145000 1. Description of the Business   Pulse Biosciences, Inc. is a novel bioelectric medicine company committed to health innovation using its patented Nano-pulse Stimulation ("NPS") technology, a revolutionary energy modality that delivers nanosecond-duration pulses of electrical energy, each less than a millionth of a second long, to nonthermally clear targeted cells while sparing adjacent noncellular materials. NPS technology, also referred to as Nanosecond Pulsed-Field Ablation ("nsPFA" or "nano-PFA") technology when used to ablate cellular tissue, can be used to treat a variety of medical conditions for which an optimal solution remains unfulfilled. The Company developed its proprietary CellFX System, a novel nano-PFA delivery platform, and commercialized the initial application of its nano-PFA technology to treat benign lesions of the skin. In parallel, the Company has designed a variety of applicators, or disposables, to explore the potential use of the CellFX platform to treat disorders in other medical specialties, such as cardiology, gastroenterology, gynecology, and ear, nose and throat. These applicators include devices for open surgical procedures, endoscopic or minimally invasive procedures, and endoluminal catheters, and each has been used in preclinical studies. Based on our preclinical experience and the potential to significantly improve outcomes for patients in a large and growing market, the Company decided in 2022 to focus its primary efforts on the use of nsPFA energy and the CellFX platform in the treatment of atrial fibrillation ("AF") and in a select few other markets where it could have a profound positive impact on healthcare for both patients and providers, such as soft tissue ablation.   The Company was incorporated in Nevada on May 19, 2014. On June 18, 2018, the Company reincorporated from the State of Nevada to the State of Delaware. The Company is located in Miami, Florida, and continues to maintain its offices in Hayward, California. The Company maintains a website at www.pulsebiosciences.com where general information about the Company is available.   The Company's activities are subject to significant risks and uncertainties, including the need for additional capital. The Company does not currently have any material cash flows from operations. It currently generates no revenue and will need to raise additional capital to finance its operations. However, there can be no assurances that the Company will be able to obtain additional financing on acceptable terms and in the amounts necessary

to fully fund its operating requirements. 2. Summary of Significant Accounting Policies   Basis of Presentation   The accompanying unaudited condensed consolidated financial statements have been prepared on a basis consistent with the Company's December 31, 2023 audited Consolidated Financial Statements and include all adjustments, consisting of only normal recurring adjustments, necessary to fairly state the information set forth herein. The condensed consolidated financial statements have been prepared in accordance with the applicable rules and regulations of the Securities and Exchange Commission (the "SEC") and, as permitted by such rules and regulations, omit certain information and footnote disclosures necessary to present the financial statements in accordance with accounting principles generally accepted in the United States ("U.S. GAAP"). The condensed consolidated balance sheet as of December 31, 2023 was derived from the audited consolidated financial statements as of that date but does not include all of the information and footnotes required by U.S. GAAP for complete financial statements. These condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company's Annual Report on Form 10-K for the year ended December 31, 2023. The results of operations for the three-month and nine-month periods ended September 30, 2024, are not necessarily indicative of the results to be expected for the entire year or any future periods.   Principles of Consolidation   The accompanying condensed consolidated financial statements include the financial statements of Pulse Biosciences, Inc. and its wholly-owned subsidiaries. Intercompany balances and transactions, if any, have been eliminated in consolidation.   Use of Estimates   The preparation of financial statements in conformity with U.S. GAAP requires the Company to make estimates that affect the amounts reported in the financial statements and accompanying notes to the financial statements. Estimates include, but are not limited to, the valuation and recognition of stock-based compensation, the valuation of equity-classified subscription rights, inventory valuation, warranty obligations, income taxes, and the useful lives assigned to long-lived assets. The Company evaluates its estimates and assumptions based on historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances dictate. Actual results could differ materially from these estimates.   Significant Accounting Policies   The Company's significant accounting policies are described in the Company's Annual Report on Form 10-K for the year ended December 31, 2023. The Company continually evaluates the accounting policies and estimates used in preparing the consolidated financial statements. During both the year ended December 31, 2023, and the nine-month period ended September 30, 2024, the Company issued stock options to certain employees which contain market conditions related to overall market capitalization. Additionally, the Company has issued stock options to certain employees which contain performance conditions related to certain financial measures and achievements of strategic and operational milestones.   Stock-Based Compensation   The Company's stock-based compensation programs include stock options and an employee stock purchase program.   The Company periodically issues stock options to officers, directors, employees, and consultants for services rendered. Such issuances vest and expire according to terms established at the issuance date. Stock-based payments to officers, directors and employees, including grants of employee stock options, are recognized in the financial statements based on their grant date fair values, which are estimated using the Black-Scholes option-pricing model. Stock-based compensation expense is charged to operations on a straight-line basis over the vesting period. The Company has granted stock options with both time-based as well as performance-based vesting conditions. For stock awards with performance-based vesting conditions, the Company does not recognize compensation expense until it is probable that the performance-based vesting condition will be achieved. The analysis to determine such probability involves estimates and judgements from management and the estimate of expense may be revised periodically.   The Company has also issued certain stock options with market-based vesting conditions. These vesting conditions relate to the achievement of certain market capitalization targets of the Company. The grant date fair value for these stock options was determined using a Monte Carlo simulation. The expense is recognized over the requisite service period for each tranche of the awards. The requisite service period is the service period derived from the Monte Carlo simulation model. If the market capitalization targets are met sooner than the derived service period, the Company will accelerate the recognition of stock-based compensation expense to reflect the cumulative expense associated with the vested shares. The Monte Carlo simulation requires the Company to make assumptions and judgements about the variables used in the calculation including the expected term, volatility of the Company's common stock, an assumed risk-free interest rate, and cost of equity. The assumptions used in the option-pricing model represent management's best estimates. If factors change and different assumptions are used, the Company's stock-based compensation expense could be materially different in the future.   See Note 6 for a detailed discussion of the Company's stock plans and stock-based compensation expense.   Product Warranty   The Company provides a standard warranty on eligible products which provides the customer assurances that the products comply with the agreed-upon specifications. The standard warranty does not provide any services in addition to those assurances. The Company accrued a warranty reserve for products sold based upon the best estimate of the nature, frequency, and costs of future claims. These estimates are inherently uncertain given the short history of sales, and changes to the historical or projected warranty experience may cause material changes to the warranty reserve in the future. In June 2023, the Company reduced the accrued warranty liability to zero. Based upon the Company's shift in focus, there are a limited number of consoles currently covered under the standard warranty. All inventory has been fully written off, therefore the only incremental costs to fulfill a warranty claim in 2024 would be shipping costs or the costs to replace the CellFX nsPFA electrode, which would be immaterial in nature.   Warranty accrual activity consisted of the following for the three-month and nine-month periods ended September 30, 2024 and 2023 (in thousands):   <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> Three Months Ended September 30, </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> Nine Months Ended September 30, </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2024 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2023 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2024 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2023 </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 52%;"> Beginning balance </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family:

"Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">50</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Add: Accruals for warranties issued during the period</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Less: Adjustment for inventory at cost and excessive and obsolete inventory</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(50</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Ending balance</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family: "Times New Roman", font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i></i></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Net Loss per Share</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt; text-align: justify;">The Company calculates basic net loss per share by dividing net loss by the weighted-average number of shares of common stock outstanding during the period. Diluted net loss per share is computed by giving effect to all potential dilutive common stock equivalents outstanding during the period. For purposes of this calculation, options to purchase common stock and common stock warrants are considered common stock equivalents. Potential common shares that have an anti-dilutive effect (i.e., those that increase income per share or decrease loss per share) are excluded from the calculation of diluted net loss per share.</p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt;"> </p> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: left; text-indent: 27pt;">Based on the Accounting Standards Codification ("ASC") <em style="font: inherit;">260-<em style="font: inherit;">10-<em style="font: inherit;">55, <i>Earnings Per Share - Implementation Guidance and Illustrations</i>, the Company determined that the <em style="font: inherit;">2024 Rights Offering (Note <em style="font: inherit;">6), contained a bonus element. A rights offering is deemed to have a bonus element when the exercise price at issuance is less than fair value of the Company's stock. The Company has retroactively adjusted earnings per share and weighted average number of shares outstanding for the bonus element for prior periods presented.</p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt; text-align: justify;">Basic and diluted net loss per common share is the same for all periods presented because all warrants, stock options and restricted stock units outstanding are anti-dilutive.</p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt; text-align: justify;">The following outstanding stock options, and warrants were excluded from the computation of diluted net loss per share for the periods presented because including them would have had an anti-dilutive effect:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;"><em style="font: inherit;">Nine Months Ended September 30,</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">2024</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">2023</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> <p style="margin: 0pt; font-size: 10pt; font-family: "Times New Roman";">Common stock warrants</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">5,857,680</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">—</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"> <p style="margin: 0pt; font-size: 10pt; font-family: "Times New Roman";">Common stock options</p> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">12,327,332</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">7,902,948</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Total</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">18,185,012</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">7,902,948</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i></i></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Recent Accounting Pronouncements <em style="font: inherit;">Not Yet Adopted</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: left; text-indent: 27pt;">In <em style="font: inherit;"> March 2024, the FASB issued ASU <em style="font: inherit;">No. <em style="font: inherit;">2024-<em style="font: inherit;">02, <i>Codification Improvements - Amendments to Remove References to the Concepts Statements</i>, an amendment of the FASB Accounting Standards Codification. The amendments in this ASU are related to the removal of various references to FASB Concept Statements from the codification to make clear distinctions between authoritative and non-authoritative literature in the codification. This ASU is effective for fiscal years beginning after <em style="font: inherit;"> December 15, 2024, with early adoption permitted. The Company does <em style="font: inherit;">not believe this standard will have an impact on its consolidated financial statements and related disclosures.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt;">As of <em style="font: inherit;"> September 30, 2024, there were <em style="font: inherit;">no additional

material changes to the information provided regarding recent accounting pronouncements in Note 2, “Summary of Significant Accounting Policies” in the Company’s Form 10-K for the fiscal year ended December 31, 2023. Basis of Presentation   The accompanying unaudited condensed consolidated financial statements have been prepared on a basis consistent with the Company’s December 31, 2023 audited Consolidated Financial Statements and include all adjustments, consisting of only normal recurring adjustments, necessary to fairly state the information set forth herein. The condensed consolidated financial statements have been prepared in accordance with the applicable rules and regulations of the Securities and Exchange Commission (the “SEC”) and, as permitted by such rules and regulations, omit certain information and footnote disclosures necessary to present the financial statements in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”). The condensed consolidated balance sheet as of December 31, 2023 was derived from the audited consolidated financial statements as of that date but does not include all of the information and footnotes required by U.S. GAAP for complete financial statements. These condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023. The results of operations for the three-month and nine-month periods ended September 30, 2024, are not necessarily indicative of the results to be expected for the entire year or any future periods.   Principles of Consolidation   The accompanying condensed consolidated financial statements include the financial statements of Pulse Biosciences, Inc. and its wholly-owned subsidiaries. Intercompany balances and transactions, if any, have been eliminated in consolidation.   Use of Estimates   The preparation of financial statements in conformity with U.S. GAAP requires the Company to make estimates that affect the amounts reported in the financial statements and accompanying notes to the financial statements. Estimates include, but are not limited to, the valuation and recognition of stock-based compensation, the valuation of equity-classified subscription rights, inventory valuation, warranty obligations, income taxes, and the useful lives assigned to long-lived assets. The Company evaluates its estimates and assumptions based on historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances dictate. Actual results could differ materially from these estimates.   Stock-Based Compensation   The Company’s stock-based compensation programs include stock options and an employee stock purchase program.   The Company periodically issues stock options to officers, directors, employees, and consultants for services rendered. Such issuances vest and expire according to terms established at the issuance date. Stock-based payments to officers, directors and employees, including grants of employee stock options, are recognized in the financial statements based on their grant date fair values, which are estimated using the Black-Scholes option-pricing model. Stock-based compensation expense is charged to operations on a straight-line basis over the vesting period. The Company has granted stock options with both time-based as well as performance-based vesting conditions. For stock awards with performance-based vesting conditions, the Company does not recognize compensation expense until it is probable that the performance-based vesting condition will be achieved. The analysis to determine such probability involves estimates and judgements from management and the estimate of expense may be revised periodically.   The Company has also issued certain stock options with market-based vesting conditions. These vesting conditions relate to the achievement of certain market capitalization targets of the Company. The grant date fair value for these stock options was determined using a Monte Carlo simulation. The expense is recognized over the requisite service period for each tranche of the awards. The requisite service period is the service period derived from the Monte Carlo simulation model. If the market capitalization targets are met sooner than the derived service period, the Company will accelerate the recognition of stock-based compensation expense to reflect the cumulative expense associated with the vested shares. The Monte Carlo simulation requires the Company to make assumptions and judgements about the variables used in the calculation including the expected term, volatility of the Company’s common stock, an assumed risk-free interest rate, and cost of equity. The assumptions used in the option-pricing model represent management’s best estimates. If factors change and different assumptions are used, the Company’s stock-based compensation expense could be materially different in the future.   See Note 6 for a detailed discussion of the Company’s stock plans and stock-based compensation expense.   Product Warranty   The Company provides a standard warranty on eligible products which provides the customer assurances that the products comply with the agreed-upon specifications. The standard warranty does not provide any services in addition to those assurances. The Company accrued a warranty reserve for products sold based upon the best estimate of the nature, frequency, and costs of future claims. These estimates are inherently uncertain given the short history of sales, and changes to the historical or projected warranty experience may cause material changes to the warranty reserve in the future. In June 2023, the Company reduced the accrued warranty liability to zero. Based upon the Company’s shift in focus, there are a limited number of consoles currently covered under the standard warranty. All inventory has been fully written off, therefore the only incremental costs to fulfill a warranty claim in 2024 would be shipping costs or the costs to replace the CellFX nsPFA electrode, which would be immaterial in nature.   Warranty accrual activity consisted of the following for the three-month and nine-month periods ended September 30, 2024 and 2023 (in thousands):   <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> Three Months Ended September 30, </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> Nine Months Ended September 30, </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2024 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2023 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 52%;"> Beginning balance </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">50</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Add: Accruals for warranties issued during the period </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td><td style="width: 1%; font-family: "Times New

Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr><tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Less: Adjustment for inventory at cost and excessive and obsolete inventory </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(50</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Ending balance </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr></tbody></table>   <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> Three Months Ended September 30, </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> Nine Months Ended September 30, </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td></tr><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2024 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2023 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2024 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2023 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 52%;"> Beginning balance </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Add: Accruals for warranties issued during the period</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Less: Adjustment for inventory at cost and excessive and obsolete inventory</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(50</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Ending balance</p> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr></tbody></table>

</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> 000500000000000-500000000 Net Loss per Share   The Company calculates basic net loss per share by dividing net loss by the weighted-average number of shares of common stock outstanding during the period. Diluted net loss per share is computed by giving effect to all potential dilutive common stock equivalents outstanding during the period. For purposes of this calculation, options to purchase common stock and common stock warrants are considered common stock equivalents. Potential common shares that have an anti-dilutive effect (i.e., those that increase income per share or decrease loss per share) are excluded from the calculation of diluted net loss per share.   Based on the Accounting Standards Codification ("ASC") 260-10-55, Earnings Per Share - Implementation Guidance and Illustrations, the Company determined that the 2024 Rights Offering (Note 6), contained a bonus element. A rights offering is deemed to have a bonus element when the exercise price at issuance is less than fair value of the Company's stock. The Company has retroactively adjusted earnings per share and weighted average number of shares outstanding for the bonus element for prior periods presented.   Basic and diluted net loss per common share is the same for all periods presented because all warrants, stock options and restricted stock units outstanding are anti-dilutive.   The following outstanding stock options, and warrants were excluded from the computation of diluted net loss per share for the periods presented because including them would have had an anti-dilutive effect: <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Nine Months Ended September 30, </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2024 </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2023 </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> Common stock warrants </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">5,857,680</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">—</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"> Common stock options </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">12,327,332</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">7,902,948</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> Total </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">18,185,012</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">7,902,948</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table>   <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Nine Months Ended September 30, </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2024 </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2023 </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> Common stock warrants </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">5,857,680</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">—</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"> Common stock options </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">12,327,332</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">7,902,948</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding: 0px 0px 1px; margin: 0px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> Total </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">18,185,012</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">7,902,948</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> 585768001232733279029481818501279029482 Recent Accounting Pronouncements Not Yet Adopted   In March 2024, the FASB issued ASU No. 2024-02, Codification Improvements - Amendments to Remove References to the Concepts Statements, an amendment of the FASB Accounting Standards Codification. The amendments in this ASU are related to the removal of various references to FASB Concept Statements from the codification to make clear distinctions between authoritative and non-authoritative literature in the codification. This ASU is effective for fiscal years beginning after December 15, 2024, with early adoption permitted. The Company does not believe this standard will have an impact on its consolidated financial statements and related disclosures.   As of September 30, 2024, there were no additional material changes to the information provided regarding recent accounting pronouncements in Note 2, "Summary of Significant Accounting Policies" in the Company's Form 10-K for the fiscal year ended December 31, 2023. 3. Fair Value of Financial Instruments   The authoritative guidance with respect to fair value established a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three levels, and requires that assets and liabilities carried at fair value be classified and disclosed in one of three categories, as presented below.   Level 1 - Observable inputs such as quoted prices in active markets for an identical asset or liability that the Company

has the ability to access as of the measurement date. Financial assets and liabilities utilizing Level 1 inputs include money market funds.   Level 2 - Inputs, other than quoted prices included within Level 1, which are directly observable for the asset or liability or indirectly observable through corroboration with observable market data. The Company did not classify any of its investments within Level 2 of the fair value hierarchy.   Level 3 - Unobservable inputs for which there is little or no market data for the asset or liability which requires the reporting entity to develop its own assumptions. The Company did not classify any of its investments within Level 3 of the fair value hierarchy.   The following table sets forth the fair value of the Company's financial instruments measured on a recurring basis as of September 30, 2024 and December 31, 2023, respectively (in thousands):   <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman"; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td colspan="14" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> September 30, 2024 </td><td style="font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt; width: 29.5%;"> Assets </td><td style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; width: 22.5%;"> Classification </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Level 1 </td><td style="font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Level 2 </td><td style="font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Level 3 </td><td style="font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Total </td><td style="font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt;"> Money market funds </td><td style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> Cash and cash equivalents </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">76,386</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">—</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">—</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">76,386</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td colspan="2" style="font-family: "Times New Roman"; font-size: 10pt;"> Total assets measured at fair value </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">76,386</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">—</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td><td style="width: 9%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">—</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td><td style="width: 9%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">—</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td><td style="width: 9%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">76,386</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="margin: 0pt; font-family: "Times New Roman"; font-size: 10pt;"> </p> <p style="margin: 0pt; font-family: "Times New Roman"; font-size: 10pt;"> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman"; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"><em style="font: inherit;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td colspan="14" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;">December 31, 2023</p> </td><td style="font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt; width: 29.6%;"> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt;">Assets</p> </td><td style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; width: 22.4%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Classification</p> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Level 1</p> </td><td style="font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Level 2</p> </td><td style="font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Level 3</p> </td><td style="font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Total</p> </td><td style="font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt;"> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt;">Money market funds</p> </td><td style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Cash and cash equivalents</p> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">41,184</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">—</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">—</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">41,184</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td colspan="2" style="font-family: "Times New Roman"; font-size: 10pt;"> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;"><em style="font: inherit;">Total assets measured at fair value</p> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">41,184</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">—</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 3px; margin-

left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">—</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">41,184</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table>   The Company did not have any financial liabilities measured on a recurring basis as of September 30, 2024 or December 31, 2023. <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman"; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td colspan="14" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> September 30, 2024 </td><td style="font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt; width: 29.5%;"> Assets </td><td style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; width: 22.5%;"> Classification </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Level 1 </td><td style="font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Level 2 </td><td style="font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Level 3 </td><td style="font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Total </td><td style="font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt;"> Money market funds </td><td style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> Cash and cash equivalents </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">76,386</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">—</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">—</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">76,386</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td colspan="2" style="font-family: "Times New Roman"; font-size: 10pt;"> Total assets measured at fair value </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">76,386</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">—</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">76,386</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman"; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"><em style="font: inherit;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td colspan="14" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;">December 31, 2023</p> </td><td style="font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt; width: 29.6%;"> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt;">Assets</p> </td><td style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; width: 22.4%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Classification</p> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Level 1</p> </td><td style="font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Level 2</p> </td><td style="font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Level 3</p> </td><td style="font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Total</p> </td><td style="font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt;"> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt;">Money market funds</p> </td><td style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Cash and cash equivalents</p> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">41,184</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">—</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">—</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">41,184</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td colspan="2" style="font-family: "Times New Roman"; font-size: 10pt;"> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;"><em style="font: inherit;">Total assets measured at fair value</p> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">41,184</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">—</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">—</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-

family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">41,184</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table>
7638600000763860007638600000763860004118400004118400004118400004118400000 4. Balance Sheet Components   Property and Equipment, Net   Property and equipment, net consisted of the following (in thousands):   <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> September 30, </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> December 31, </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2024 </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> Leasehold improvements </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2,519</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2,519</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> Laboratory equipment </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,318</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,247</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> Furniture, fixtures and equipment </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">966</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">966</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> Software </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">272</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">272</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> Construction in progress </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">14</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">—</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> Total property and equipment </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">5,089</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">5,004</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> Less: Accumulated depreciation and amortization </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(3,868</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(3,476</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt; width: 70%; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"> Total property and equipment, net </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);">1,221</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);">1,528</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;"> </td></tr> </tbody></table>   Depreciation expense was $0.1 million for each of the three-month periods ended September 30, 2024 and 2023, and $0.4 million for each of the <em style="font: inherit;">nine-month periods ended <em style="font: inherit;"> September 30, 2024 and <em style="font: inherit;">2023, respectively.</p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt;">Intangible Assets, Net</p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 27pt;">Intangible assets primarily consist of acquired licenses to utilize certain patents, know-how and technology relating to the Company's NPS technology for biomedical applications acquired from Old Dominion University Research Foundation ("ODURF"), Eastern Virginia Medical School, and the University of Southern California. In addition, the Company entered into a Sponsored Research Agreement with Old Dominion University's Frank Reidy Research Center for Bioelectrics, which includes certain intellectual property rights arising from the research. The Company is amortizing the intangible assets over an estimated useful life of 12 years.</p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt; text-align: justify;">Intangible assets, net consisted of the following (in thousands):</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">September 30,</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">December 31,</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">2024</p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">2023</p> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Acquired patents and licenses</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">7,985</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">7,985</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> Less: Accumulated amortization </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(6,599</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td

style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(6,099</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt; width: 70%; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"> Total intangible assets, net </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);">1,386</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);">1,886</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;"> </td></tr> </tbody></table>   A schedule of the amortization of intangible assets for the remainder of 2024 and the succeeding two fiscal years is as follows (in thousands):   <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 85%;"> Years ending December 31: </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> 2024 (remaining 3 months) </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">165</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">2025</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">665</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">2026</p> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">556</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"> <p style="margin: 0pt; font-size: 10pt; font-family: "Times New Roman"; text-indent: 9pt;">Total</p> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);">1,386</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;"> </td></tr> </tbody></table>   Accrued Expenses   Accrued expenses consisted of the following (in thousands):   <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> September 30, </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> December 31, </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> 2024 </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> 2023 </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> Compensation expense </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3,111</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3,199</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> Clinical trial fees and costs </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">80</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">84</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> Professional fees </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">424</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">343</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> Other </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">206</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">188</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt; width: 70%; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"> Total accrued expenses </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);">3,821</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);">3,814</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;"> </td></tr> </tbody></table> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> September 30, </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> December 31, </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2024 </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2023 </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> Leasehold improvements </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2,519</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2,519</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> Laboratory equipment </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,318</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td

style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,247</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> Furniture, fixtures and equipment </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">966</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">966</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> Software </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">272</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">272</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> Construction in progress </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">14</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">—</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> Total property and equipment </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">5,089</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">5,004</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> Less: Accumulated depreciation and amortization </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(3,868</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(3,476</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt; width: 70%; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"> Total property and equipment, net </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);">1,221</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);">1,528</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;"> </td></tr> </tbody></table>

25190002519000131800012470009660009660009660002720002720001400005089000500400038680003476000122100015280001000004000001P12Y <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> September 30, </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> December 31, </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2024 </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2023 </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> Acquired patents and licenses </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">7,985</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">7,985</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> Less: Accumulated amortization </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(6,599</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(6,099</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt; width: 70%; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"> Total intangible assets, net </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);">1,386</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);">1,886</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;"> </td></tr> </tbody></table> 79850007985000659900060990001386000188600 0 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 85%;"> Years ending December 31: </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> 2024 (remaining 3 months) </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">165</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">2025</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">665</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">2026</p> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">556</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"> <p style="margin: 0pt; font-size: 10pt; font-family: "Times New Roman"; text-indent: 9pt;">Total</p> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);">1,386</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;"> </td></tr> </tbody></table> 16500066500055600001386000 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> September 30, </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> December 31, </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New

Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2024 </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2023 </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> Compensation expense </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3,111</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3,199</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> Clinical trial fees and costs </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">80</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">84</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> Professional fees </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">424</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">343</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> Other </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">206</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">188</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt; width: 70%; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px;"> Total accrued expenses </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);">3,821</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; padding-top: 0px; padding-right: 0px; padding-left: 0px; margin: 0px; border-bottom: 3px double rgb(0, 0, 0);">3,814</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding: 0px 0px 3px; margin: 0px;"> </td></tr> </tbody></table> 31110003199000800008400042400034300020600018800038210003814000 5. Goodwill   In 2014, the Company acquired three companies (the "Acquisitions") for aggregate consideration of $5.5 million. In accordance with ASC Topic 805, Business Combinations, the Company recorded goodwill of $2.8 million in connection with the Acquisitions as the consideration paid exceeded the fair value of the net tangible assets and the intangible assets acquired.   In accordance with ASC Topic 350, Intangibles-Goodwill and Other (as amended by Accounting Standards Update 2017-04), the Company reviews goodwill for impairment at least annually or whenever any events or circumstances indicate that it is more likely than not that the fair value of a reporting unit is less than its carrying amount. As of September 30, 2024, there were no indicators of impairment and it was determined that no impairment of goodwill existed.   355000002800000 6. Stockholders' Equity and Stock-Based Compensation   2024 Rights Offering and Subscription Rights   On March 28, 2024, the Company announced that its Board of Directors ("Board") unanimously approved plans to initiate a rights offering, whereby the Company would distribute non-transferable subscription rights at no charge to all holders of the Company's common stock, par value $0.001 per share (the "Common Stock"), as of the close of business on a record date to be determined. On May 20, 2024, the Company announced that the Board had set May 31, 2024 as the record date (the "Record Date"). All holders of Common Stock as of the Record Date received non-transferable subscription rights to purchase up to an aggregate of six million units (the "2024 Units") with an aggregate offering value of up to $60 million (the "2024 Rights Offering") at a price per 2024 Unit equal to the lesser of: (i) $10 (the "Initial Price") and (ii) the volume weighted average price of the Common Stock for the ten trading day period through and including the expiration date, June 26, 2024 (the "Expiration Date"), of the Rights Offering (the "Alternate Price"). Each subscription right entitled the holder to purchase 0.10864186 2024 Units for each share of Common Stock owned as of the Record Date. Each 2024 Unit consisted of one share of Common Stock and two warrants, each being a warrant to purchase one-half of one share of Common Stock. The subscription rights were to expire and have no value if they were not exercised prior to the Expiration Date. The Company determined that the equity-classified subscription rights represent a pro-rata distribution issued to existing stockholders as of the Record Date, which is based on a purchase price of $10 per 2024 Unit as compared to (1) the price of $11.55 per one share of Common Stock on the Record Date, plus (2) the value of the warrants on the Record Date. The Company determined the fair value of the equity-classified subscription rights as of the Record Date, which involved the use of a Monte Carlo simulation to value the underlying warrants. The Monte Carlo simulation was based on certain significant unobservable inputs, such as a risk-free interest rate, stock price volatility, dividend yield, and expected term of the rights offering. The fair value of the equity-classified subscription rights was $47.7 million and was recorded in equity on the balance sheet as part of additional paid-in capital. The deemed pro-rata distribution to shareholders of $47.7 million was reflected as an offsetting reduction in additional paid-in capital. The Company is in an accumulated deficit position and has elected a policy of recognizing the deemed pro-rata distribution to shareholders as a reduction to additional paid-in capital rather than a further increase to its accumulated deficit.   On July 3, 2024, the Company announced the closing of its 2024 Rights Offering. The 2024 Rights Offering resulted in the sale of six million 2024 Units, at a price of $10.00 per 2024 Unit. Each 2024 Unit consisted of one share of the Company's common stock, par value $0.001 per share, and two warrants, each being a warrant to purchase one-half of one share of common stock. The common stock and warrants comprising the 2024 Units separated upon the closing of the 2024 Rights Offering and were issued individually. A total of 5,999,998 shares of common stock and warrants to acquire up to approximately an additional six million shares of common stock were issued in the offering. The Company received aggregate gross proceeds from the 2024 Rights Offering of $60 million. If exercised, additional gross proceeds of up to $66 million may be received through the exercise of warrants issued in the 2024 Rights Offering. See 2024 Rights Offering Warrants below for additional details of the warrants. Robert W. Duggan, the Company's majority stockholder and Co-Chairman, purchased approximately 88% of the units offered through the 2024 Rights Offering.   Private Placement Securities Purchase Agreement   On April 30, 2023, the Company entered into a Securities Purchase Agreement with Robert W. Duggan, the Company's majority stockholder and Co-Chairman, pursuant to which the Company agreed to issue and sell to Mr. Duggan 10,022,937 shares of the Company's common stock, par value $0.001 per share, in a Private Placement, at a price per share of $6.51. The parties completed the Private Placement on May 9, 2023, after satisfying all pre-closing conditions, and the Company issued the full number of shares to Mr. Duggan. The shares were paid for through the cancellation of the principal sum of $65.0 million borrowed by the Company pursuant to the 2022 Loan Agreement (See Note 7), together with all accrued and unpaid interest outstanding owed at the time of closing.   2022 Rights Offering   On June 9, 2022, the Company completed a rights offering (the "2022 Rights Offering") resulting in the sale of 7,317,072 units (the "2022 Units"), at a price of $2.05 per 2022 Unit, with each 2022 Unit consisting of one share of the Company's common stock, par value $0.001 per share, and one warrant (the "2022 Rights Offering Warrants") to purchase one share of common stock at a price of $2.05 per share. The common stock and warrants comprising the 2022 Units separated upon the closing of the 2022 Rights Offering and were issued individually. 7,317,072 shares of common stock and warrants to acquire up to an additional 7,317,072 shares of common stock were issued in the 2022 Rights Offering. The Company received aggregate gross proceeds from the 2022 Rights Offering of $15 million. In May 2023, the Company delivered an irrevocable notice of redemption to warrant holders and, on June 16, 2023, it redeemed the last of the outstanding 2022 Rights Offering Warrants at a price of $0.01 per warrant share. See the Common Stock Warrants section below for further details. Robert W. Duggan, the Company's majority stockholder and Co-Chairman, purchased approximately 56% of the shares offered through the <em style="font:

inherit;">2022 Rights Offering.   Common Stock Warrants   2024 Rights Offering Warrants   In connection with the 2024 Rights Offering, the Company issued 2024 Rights Offering Warrants to purchase a total of 5,999,999 shares of its common stock at an exercise price of $11.00 per whole share, which equals 110% of the subscription price for the Units. The aggregate number of shares of our common stock issuable upon the exercise of each set of warrants included in a given subscription for Units was rounded up to the nearest whole share. Warrants are exercisable immediately and will expire on the fifth anniversary of the closing of the 2024 Rights Offering. Half of the warrants issued in the rights offering are redeemable for $0.01 per underlying share of common stock, on not less than thirty days' written notice, if the volume weighted average price of the Company's common stock equals or exceeds 150% of the exercise price for the warrants, or $16.50, for twenty consecutive trading days. The other half of the warrants issued in the rights offering are redeemable for $0.01 per underlying share of common stock, on not less than thirty days' written notice, if the volume weighted average price of the Company's common stock equals or exceeds 200% of the exercise price for the warrants, or $22.00, for twenty consecutive trading days. In both cases the Company can not redeem the warrants prior to the date that is three months after the issuance date. As of September 30, 2024, there were 2024 Rights Offering Warrants to purchase up to 5,857,680 shares of common stock, in aggregate, outstanding.   2022 Rights Offering Warrants   In connection with the 2022 Rights Offering, the Company issued 2022 Rights Offering Warrants to purchase a total of 7,317,072 shares of its common stock at an exercise price of $2.05. The 2022 Rights Offering Warrants were subject to redemption by the Company for $0.01 per underlying share of common stock, on not less than 30 days written notice, if the volume weighted average price of the Company's common stock equaled or exceeded 200% of the exercise price for the warrants, subject to adjustment, per share, for 20 consecutive trading days, provided that the Company could not redeem the warrants prior to the date that was three months after the issuance date. On May 10, 2023, the Company issued a press release announcing that on May 9, 2023 the terms for warrant redemption had been met. Pursuant to the redemption, the Company redeemed 66,175 warrants on the redemption date, June 16, 2023. Prior to the redemption date, warrants to purchase 7,250,897 shares were exercised, generating approximately $14.9 million of total gross proceeds to the Company. As of <em style="font: inherit;"> September 30, 2024, there were no <em style="font: inherit;">2022 Rights Offering Warrants outstanding.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Equity Plans</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:27pt;"><i><em style="font: inherit;">2017 Equity Incentive Plan and <em style="font: inherit;">2017 Inducement Equity Incentive Plan</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: "Times New Roman", font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt; text-align: justify;">The Board previously adopted, and the Company's stockholders approved, the Company's <em style="font: inherit;">2017 Equity Incentive Plan (the <em style="font: inherit;">"2017 Plan"). </p> <p style="font-family: "Times New Roman", font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"> </p> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt; text-align: justify;">The <em style="font: inherit;">2017 Plan has a 10-year term and provides for the grant of stock options, stock appreciation rights, restricted stock, RSUs, performance units, and performance shares to employees, directors and consultants of the Company and any parent or subsidiary of the Company, as the Compensation Committee of the Board <em style="font: inherit;"> may determine. Subject to an annual evergreen increase and adjustment in the case of certain capitalization events, the Company initially reserved 1,500,000 shares of the Company's common stock for issuance pursuant to awards under the <em style="font: inherit;">2017 Plan. In addition, shares remaining available under the Company's <em style="font: inherit;">2015 Equity Incentive Plan, as amended (the <em style="font: inherit;">"2015 Plan"), and shares reserved but <em style="font: inherit;">not issued pursuant to outstanding equity awards that expire or terminate without being exercised or that are forfeited or repurchased by the Company will be added to the shares of common stock available for issuance under the <em style="font: inherit;">2017 Plan. The <em style="font: inherit;">2017 Plan is administered by the Board's Compensation Committee. Effective at both <em style="font: inherit;"> January 1, 2024 and <em style="font: inherit;">2023, the number of shares of common stock available under the <em style="font: inherit;">2017 Plan increased by 1,200,000, respectively, pursuant to the evergreen provision of the <em style="font: inherit;">2017 Plan. Under the evergreen provision of the <em style="font: inherit;">2017 Plan, the share increase is determined based on the least of (i) 1,200,000 shares, (ii) 4% of the Company's common stock outstanding at <em style="font: inherit;"> December 31 of the immediately preceding year, or (iii) such number of shares as determined by the Board. Additionally, the number of shares of common stock available under the <em style="font: inherit;">2017 Plan increased by 1,375,000 shares as a result of a stockholder vote held at a special meeting of stockholders in <em style="font: inherit;"> December 2023. As of <em style="font: inherit;"> September 30, 2024, a total of 78,490 shares of common stock remained available for issuance under the <em style="font: inherit;">2017 Plan.</p> <p style="font-family: "Times New Roman", font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"> </p> <p style="font-family: "Times New Roman", font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt; text-align: justify;">During <em style="font: inherit;"> November 2017, the Board adopted the <em style="font: inherit;">2017 Inducement Equity Incentive Plan (the "Inducement Plan") and reserved 1,000,000 shares of the Company's common stock for issuance pursuant to equity awards granted under the Inducement Plan. The Inducement Plan was adopted without stockholder approval.</p> <p style="font-family: "Times New Roman", font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"> </p> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt; text-align: justify;">The Inducement Plan has a 10-year term and provides for the grant of equity-based awards, including non-statutory stock options, RSUs, restricted stock, stock appreciation rights, performance shares, and performance units, and its terms are substantially similar to the <em style="font: inherit;">2017 Plan, including with respect to treatment of equity awards in the event of a "merger" or "change in control" as defined under the Inducement Plan. Options issued under the Inducement Plan <em style="font: inherit;"> may have a term up to ten years and have variable vesting provisions. New hire grants to non-executive employees generally vest 25% per year starting upon the first anniversary of the grant. New hire grants to executive employees generally consist of both time-vesting and performance-vesting options. Equity-based awards issued under the Inducement Plan are only issuable to individuals <em style="font: inherit;">not previously engaged as employees or individuals returning to employment with the Company following a bona-fide period of non-employment. In <em style="font: inherit;"> May 2021, the Board approved an amendment to the Inducement Plan to reserve an additional 1,000,000 shares of the Company's common stock for issuance pursuant to the Inducement Plan. And, in <em style="font: inherit;"> March 2024, the Board approved a <em style="font: inherit;">second amendment to the Inducement Plan to reserve an additional 2,000,000 shares of the Company's common stock for issuance pursuant to the Inducement Plan. As of <em style="font: inherit;"> September 30, 2024, 1,642,626 shares of common stock remained available for issuance under the Inducement Plan.</p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 27pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:27pt;">A summary of stock option activity under the <em style="font: inherit;">2015 Plan, <em style="font: inherit;">2017 Plan, and Inducement Plan for the <em style="font: inherit;">nine-months ended <em style="font: inherit;"> September 30, 2024 is presented below:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman"; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td colspan="10" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;"><em style="font: inherit;">Stock Options Outstanding</p> </td><td style="font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Number of shares</p> </td><td style="font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Weighted average exercise price</p> </td><td style="font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Weighted average remaining life (in years)</p> </td><td style="font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt; width: 55%;"> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt;">Balances — December 31, 2023</p> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">9,466,036</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">9.01</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">7.78</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt;"> Options granted </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">3,017,643</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">10.38</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="text-align: right; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt;"> Options exercised </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 12%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; text-align: right;">(110,847</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 12%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; text-align: right;">4.49</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td

style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt;"> Options canceled </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">(9,542</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">15.19</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="text-align: right; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt;"> Options expired </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(35,958</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid black;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid black;">19.82</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid black;"> </td><td style="text-align: right; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid black;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt;"> Balances — September 30, 2024 </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">12,327,332</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">9.35</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 3px double black;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">7.67</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt;"> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt;">Exercisable — September 30, 2024</p> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">4,178,088</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">13.32</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 3px double black;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">5.06</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td></tr> </tbody></table>   Time-based Options   The Company awards time-based options which vest and become exercisable, subject to the individual's continued employment or service through the applicable vesting date. Time-based options can have various vesting schedules, most commonly new hire grants which generally vest 25% per year starting upon the first anniversary of the grant.   A summary of the time-based stock option activity under the 2015 Plan, 2017 Plan and Inducement Plan for the nine-months ended September 30, 2024 is presented below: <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman"; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td colspan="10" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Stock Options Outstanding </td><td style="font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Number of shares </td><td style="font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Weighted average exercise price </td><td style="font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Weighted average remaining life (in years) </td><td style="font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt; width: 55%;"> Balances — December 31, 2023 </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">6,141,906</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">10.48</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">7.07</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt;"> Options granted </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">2,123,643</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">11.3</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="text-align: right; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt;"> Options exercised </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 12%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; text-align: right;">(100,897</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 12%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; text-align: right;">4.65</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt;"> Options canceled </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">(6,542</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">20.82</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="text-align: right; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt;"> Options expired </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(34,958</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid black;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid black;">20.3</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid black;"> </td><td style="text-align:

right; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid black;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt;"> Balances — September 30, 2024 </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">8,123,152</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">10.71</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 3px double black;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">7.18</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt;"> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt;">Exercisable — September 30, 2024</p> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">3,745,410</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">13.97</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 3px double black;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">4.84</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td></tr> </tbody></table>   The fair value of the time-based options granted during the nine-month period ended September 30, 2024 was $18.7 million.</p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 27pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 27pt;"><i>Performance-based Options</i></p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 27pt;">Certain stock options awarded by the Company contain performance conditions related to certain financial measures and achievements of strategic and operational milestones. Once a specific performance condition is fulfilled, the associated options will fully vest and become exercisable.</p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 27pt;">A summary of the performance-based option activity under the <em style="font: inherit;">2017 Plan and Inducement Plan for the <em style="font: inherit;">nine-months ended <em style="font: inherit;"> September 30, 2024 is presented below:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman"; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td colspan="10" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;"><em style="font: inherit;">Stock Options Outstanding</p> </td></tr><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Number of shares</p> </td><td style="font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Weighted average exercise price</p> </td><td style="font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Weighted average remaining life (in years)</p> </td><td style="font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt; width: 55%;"> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt;">Balances — December 31, 2023</p> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">1,224,130</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">5.51</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">8.53</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt;"> Options granted </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">39,000</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">8.44</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="text-align: right; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt;"> Options exercised </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 12%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; text-align: right;">(9,950</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 12%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; text-align: right;">2.92</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt;"> Options canceled </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">(3,000</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">2.92</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="text-align: right; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt;"> Options expired </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(1,000</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid black;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid black;">2.92</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid black;"> </td><td style="text-align: right; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid black;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt;"> Balances — September 30, 2024 </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,249,180</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">5.63</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 3px double black;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">7.84</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt;"> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt;">Exercisable — September 30, 2024</p> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">432,678</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">$</td><td

style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">7.69</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 3px double black;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">6.98</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td></tr> </tbody></table>   The fair value of the performance-based options granted during the nine-month period ended September 30, 2024 was $0.3 million.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt;"><i>Market-based Options</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt; text-align: justify;">Certain stock options awarded by the Company contain market conditions related to achievement of certain market capitalization targets. The options will vest and become exercisable once the specific market capitalization targets are fulfilled. </p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt;"> </p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt; text-align: justify;">A summary of the market-based option activity under the <em style="font: inherit;">2017 Plan for the <em style="font: inherit;">nine-months ended <em style="font: inherit;"> September 30, 2024 is presented below:</p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman"; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td colspan="10" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;">Stock Options Outstanding</p> </td><td style="font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Number of shares</p> </td><td style="font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Weighted average exercise price</p> </td><td style="font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Weighted average remaining life (in years)</p> </td><td style="font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt; width: 55%;"> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt;">Balances — December 31, 2023</p> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 12%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; text-align: right;">2,100,000</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">6.78</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 12%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; text-align: right;">9.44</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt;"> Options granted </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">855,000</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">8.16</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="text-align: right; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt;"> Options exercised </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 12%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 12%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt;"> Options canceled </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 12%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 12%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt;"> Balances — September 30, 2024 </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2,955,000</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">7.18</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 3px double black;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">8.95</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt;"> Exercisable — September 30, 2024 </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 12%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);">—</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 3px double black;"> </td><td style="width: 12%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double black;">—</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 3px double black;"> </td><td style="width: 12%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double black;">—</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td></tr> </tbody></table>   The fair value of the market-based options granted during the nine-month period ended September 30, 2024 was $5.3 million.   The Company estimates the fair value of time-based and performance-based stock options on the grant date using the Black-Scholes option pricing model. The estimated fair value of these employee stock options is amortized on a straight-line basis over the requisite service period of the awards. The Company reviews, and when deemed appropriate, updates the assumptions used on a periodic basis. The fair value of time-based and performance-based stock options was estimated using the following weighted-average assumptions: <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Three Months Ended September 30, </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td

style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Nine Months Ended September 30, </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2024 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2023 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2022 </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 52%;"> Expected term in years </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">5.0 - 6.3</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">5.0</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">5.0 - 6.3</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">5.0 - 6.3</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Expected volatility </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">93% - 97%</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">93%</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">91% - 97%</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">89% - 94%</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Risk-free interest rate </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"> 4.5% </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"> 3.7% </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">4.0% - 4.5%</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"> 3.7% - 3.8% </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Dividend yield </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> </tbody></table>   The Company estimates the fair value of market-based stock options on the grant date using a Monte Carlo simulation model. The estimated fair value of these employee stock options is amortized over the requisite service period for each tranche of the awards. The requisite service period is the service period derived from the Monte Carlo simulation model. If the market capitalization targets are met sooner than the derived service period, the Company will accelerate the recognition of stock-based compensation expense to reflect the cumulative expense associated with the vested shares. The fair value of market-based stock options was estimated using the following weighted-average assumptions: <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Three Months Ended September 30, </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Nine Months Ended September 30, </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2024 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2023 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2022 </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 52%;"> Expected term in years </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">2.2 - 4.2</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">4.0 - 6.3</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size:

10pt; margin-left: 0pt; text-align: center;">2.2 - 5.8</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">4.0 - 6.3</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Expected volatility </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"> 90% </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"> 90% </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr><tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Risk-free interest rate </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"> 3.9% </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"> 3.7 - 3.8% </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"> 3.9% - 4.4% </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"> 3.4 - 3.8% </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Dividend yield </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> </tbody></table>   2017 Employee Stock Purchase Plan   The Board previously adopted, and the Company's stockholders approved, the Company's 2017 Employee Stock Purchase Plan (the "2017 ESPP").   The 2017 ESPP is a broad-based plan that provides employees of the Company and its designated affiliates with the opportunity to become stockholders through periodic payroll deductions that are applied towards the purchase of Company common shares at a discount from the then-current market price. Subject to adjustment in the case of certain capitalization events, a total of 250,000 common shares of the Company were available for purchase at adoption of the 2017 ESPP. Pursuant to the 2017 ESPP, the annual share increase pursuant to the evergreen provision is determined based on the least of (i) 450,000 shares, (ii) 1.5% of the Company's common stock outstanding at December 31 of the immediately preceding year, or (iii) such number of shares as determined by the Board. In 2024, the Company reserved an additional 450,000 shares under the 2017 ESPP pursuant to the evergreen provision. In 2023, the Board waived the evergreen provision and no additional shares were reserved under the 2017 ESPP. During the nine months ended September 30, 2024, the Company issued 117,539 shares of common stock under the 2017 ESPP. As of September 30, 2024, 445,779 shares of common stock remained available for issuance under the 2017 ESPP.   The Company estimates the fair value of ESPP grants on their grant date using the Black-Scholes option pricing model. The estimated fair value of ESPP grants is amortized on a straight-line basis over the requisite service period of the grants. The Company reviews, and when deemed appropriate, updates the assumptions used on a periodic basis. The Company utilizes its estimated volatility in the Black-Scholes option pricing model to determine the fair value of ESPP grants. The fair value of ESPP grants was estimated using the following weighted-average assumptions: <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Three Months Ended September 30, </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Nine Months Ended September 30, </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2024 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2023 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2024 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2023 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 52%;"> Expected term in years </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">0.5 - 1.0</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">0.5 - 1.0</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">0.5 - 1.0</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">0.5 - 1.0</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Expected volatility </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"> 98% </td>

<td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"> 83% </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"> 98% </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"> 83% </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Risk-free interest rate </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">4.4% - 5.3%</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">5.4% - 5.5%</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">4.9% - 5.3%</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">5.1% - 5.5%</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Dividend yield </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> </tbody></table>   Stock-based Compensation   Total stock-based compensation expense consisted of the following (in thousands):   <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Three Months Ended September 30, </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Nine Months Ended September 30, </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2024 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2023 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2024 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2023 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Research and development </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">1,108</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">982</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">3,058</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">1,758</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> General and administrative </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,874</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">816</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">3,735</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,079</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Total stock-based compensation expense </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2,982</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,798</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">6,793</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">3,837</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table>   As of <em style="font:

inherit;"> September 30, 2024, not all of the performance conditions of the performance options are probable to be achieved. Compensation expense has only been recognized for those conditions that are assumed to be probable.   Total stock-based compensation expense by award type was as follows (in thousands):   <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Three Months Ended September 30, </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Nine Months Ended September 30, </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2024 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2023 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 52%;"> Time-based options </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">2,131</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">1,200</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">4,609</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">2,754</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Performance-based options </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">5</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">87</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">27</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">292</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> Market-based options </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">788</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">464</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">1,978</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">622</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> ESPP </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">58</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">47</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">179</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">169</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Total stock-based compensation expense </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2,982</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,798</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">6,793</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">3,837</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table>
0.0016000000010101 1.554770000047700000101 0.0012599999860000000660000000.88100229370.0016.516500000073170722.050.0012.057317072731707215000000.010.5 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman"; text-indent: 0px;"> <tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td colspan="10" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Stock Options Outstanding </td><td style="font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Number of shares </td><td style="font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td

colspan="2" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Weighted average exercise price </td><td style="font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Weighted average remaining life (in years) </td><td style="font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt; width: 55%;"> Balances — December 31, 2023 </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">9,466,036</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">9.01</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">7.78</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt;"> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Options granted</p> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">3,017,643</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">10.38</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="text-align: right; font-family: "Times New Roman"; font-size: 10pt;"><em style="font: inherit;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt;"> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Options exercised</p> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 12%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; text-align: right;">(110,847</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 12%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; text-align: right;">4.49</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"><em style="font: inherit;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt;"> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Options canceled</p> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">(9,542</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">15.19</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="text-align: right; font-family: "Times New Roman"; font-size: 10pt;"><em style="font: inherit;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt;"> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Options expired</p> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(35,958</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid black;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid black;">19.82</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid black;"> </td><td style="text-align: right; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid black;"><em style="font: inherit;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt;"> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt;">Balances — September 30, 2024</p> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">12,327,332</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">9.35</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 3px double black;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">7.67</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt;"> Exercisable — September 30, 2024 </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">4,178,088</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">13.32</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 3px double black;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">5.06</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td></tr> </tbody></table> 94660369.01P7Y9M10D301764310.381108474.499954215.193595819.82123273329.35P7Y8M1D417808813.32P5Y21D0.25 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman"; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td colspan="10" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;">Stock Options Outstanding</p> </td><td style="font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Number of shares</p> </td><td style="font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Weighted average exercise price</p> </td><td style="font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Weighted average remaining life (in years)</p> </td><td style="font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt; width: 55%;"> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt;">Balances — December 31, 2023</p> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">6,141,906</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">10.48</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">7.07</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt;"> Options granted </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">2,123,643</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">11.3</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="text-align: right; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt;"> Options exercised </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 12%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; text-align: right;">(100,897</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: "Times New Roman"; font-size:

10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 12%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; text-align: right;">4.65</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt;"> Options canceled </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">(6,542</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">20.82</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="text-align: right; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt;"> Options expired </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(34,958</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid black;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid black;">20.3</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid black;"> </td><td style="text-align: right; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid black;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt;"> Balances — September 30, 2024 </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">8,123,152</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">10.71</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 3px double black;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">7.18</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt;"> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt;">Exercisable — September 30, 2024</p> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">3,745,410</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">13.97</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 3px double black;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">4.84</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td></tr> </tbody></table> 614190610.48P7Y25D212364311.31008974.65654220.823495820.3812315210.71P7Y2M4D374541013.97P4Y10M2D18700000 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman"; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td colspan="10" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Stock Options Outstanding </td><td style="font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Number of shares </td><td style="font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Weighted average exercise price </td><td style="font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Weighted average remaining life (in years) </td><td style="font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt; width: 55%;"> Balances — December 31, 2023 </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">1,224,130</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">5.51</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">8.53</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt;"> Options granted </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">39,000</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">8.44</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="text-align: right; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt;"> Options exercised </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 12%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; text-align: right;">(9,950</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 12%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; text-align: right;">2.92</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt;"> Options canceled </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">(3,000</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">2.92</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="text-align: right; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt;"> Options expired </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(1,000</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid black;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid black;">2.92</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid black;"> </td><td style="text-align: right; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid black;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt;"> Balances — September 30, 2024 </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,249,180</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width:

1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">5.63</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 3px double black;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">7.84</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt;"> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt;">Exercisable — September 30, 2024</p> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">432,678</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">7.69</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 3px double black;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">6.98</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td></tr></tbody></table> 12241305.51P8Y6M10D390008.4499502.9230002.9210002.9212491805.63P7Y10M2D4326787.69P6Y11M23D <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman"; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td colspan="10" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Stock Options Outstanding </td><td style="font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Number of shares </td><td style="font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Weighted average exercise price </td><td style="font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Weighted average remaining life (in years) </td><td style="font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt; width: 55%;"> Balances — December 31, 2023 </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 12%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; text-align: right;">2,100,000</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">6.78</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 12%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; text-align: right;">9.44</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt;"> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Options granted</p> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">855,000</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">8.16</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="text-align: right; font-family: "Times New Roman"; font-size: 10pt;"><em style="font: inherit;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt;"> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Options exercised</p> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 12%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 12%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"><em style="font: inherit;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt;"> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Options canceled</p> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 12%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 12%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"><em style="font: inherit;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt;"> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt;">Options expired</p> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">—</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid black;"> </td><td style="width: 12%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid black;">—</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid black;"><em style="font: inherit;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt;"> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt;">Balances — September 30, 2024</p> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2,955,000</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">7.18</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 3px double black;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">8.95</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt;"> Exercisable — September 30, 2024 </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 12%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);">—</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 3px double black;"> </td><td style="width: 12%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double black;">—</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt; border-bottom: 3px double black;">—</td><td style="font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td></tr> </tbody></table> 21000006.78P9Y5M8D8550008.16-00-00-0029550007.18P8Y11M12D005300000 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Three Months Ended September 30, </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Nine Months Ended September 30, </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align:

center; margin: 0pt;">2024 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2023 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2024 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2023 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 52%;"> Expected term in years </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">5.0 - 6.3</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">5.0</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">5.0 - 6.3</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">5.0 – 6.3</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Expected volatility </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">93% - 97%</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">93%</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">91% - 97%</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">89% – 94%</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Risk-free interest rate </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"> 4.5% </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"> 3.7% </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">4.0% - 4.5%</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"> 3.7% - 3.8% </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Dividend yield </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> </tbody></table> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Three Months Ended September 30, </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Nine Months Ended September 30, </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2024 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2023 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 52%;"> Expected term in years </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">2.2 - 4.2</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">4.0 - 6.3</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">2.2 - 5.8</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">4.0 - 6.3</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Expected volatility </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"> 90% </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"> 90% </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td>

<td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"> 90% </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"> 90% </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Risk-free interest rate </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"> 3.9% </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"> 3.7 - 3.8% </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"> 3.9% - 4.4% </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"> 3.4 - 3.8% </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Dividend yield </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> </tbody></table>
P5YP6Y3M18DP5YP5YP6Y3M18DP5YP6Y3M18D0.930.970.930.910.970.890.940.0450.0370.040.0450.0370.038P2Y2M12DP4Y2M12DP4YP6Y3M18DP2Y2M12DP5Y9M18DP4YP6
<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Three Months Ended September 30, </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Nine Months Ended September 30, </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2024 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2023 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2024 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2023 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 52%;"> Expected term in years </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">0.5 - 1.0</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">0.5 - 1.0</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">0.5 - 1.0</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Expected volatility </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"> 98% </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"> 83% </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"> 98% </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"> 83% </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Risk-free interest rate </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">4.4% - 5.3%</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">5.4% - 5.5%</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">4.9% - 5.3%</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">5.1% - 5.5%</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Dividend yield </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left:

0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr></tbody></table> P0Y6MP1YP0Y6MP1YP0Y6MP1YP0.980.830.980.830.0440.0530.0540.0550.0490.0530.0510.055 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Three Months Ended September 30, </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Nine Months Ended September 30, </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2024 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2023 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2024 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2023 </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 52%;"> Research and development </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">1,108</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">982</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">3,058</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">1,758</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">General and administrative </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,874</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">816</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">3,735</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,079</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Total stock-based compensation expense </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2,982</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,798</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">6,793</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">3,837</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> 110800098200030580001758000187400081600037350002079000298200017980006793000383700 0 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"><tbody><tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Three Months Ended September 30, </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Nine Months Ended September 30, </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2024 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2023 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2024 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2023 </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 52%;"> Time-based options </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">2,131</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">1,200</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">4,609</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">2,754</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Performance-based options </td><td style="width: 1%; font-family: "Times New

Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">5</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">87</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">27</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">292</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr><tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> Market-based options </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">788</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">464</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">1,978</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0">622</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td></tr><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> ESPP </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">58</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">47</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">179</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">169</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Total stock-based compensation expense </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2,982</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,798</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">6,793</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">3,837</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table>

2131000120000046090002754000500008700027000292000788000464000197800062200058000470001790001690002982000179800067930003837000 7. Commitments and Contingencies   2022 Loan Agreement   On September 20, 2022, the Company and Robert W. Duggan, the Company's majority stockholder and Co-Chairman, entered into a Loan Agreement ("2022 Loan Agreement") in connection with Mr. Duggan lending the principal sum of $65.0 million to the Company. The 2022 Loan Agreement bore interest at a rate per annum equal to 5.0%, payable quarterly commencing on January 1, 2023, with the principal sum payable on March 20, 2024. On March 17, 2023, the Company and Mr. Duggan amended certain terms of the 2022 Loan Agreement. There were no changes to the interest rate, but the principal sum repayment date was changed to September 30, 2024. During the year ended December 31, 2023, the Company made cash payments of $1.7 million for accrued interest on the loan, and recorded an additional $1.1 million of interest expense in relation to the 2022 Loan Agreement. On April 30, 2023, the Company entered into a Securities Purchase Agreement with Mr. Duggan, pursuant to which the Company agreed to issue and sell to Mr. Duggan 10,022,937 shares of the Company's common stock, par value $0.001 per share, in a Private Placement, at a price per share of $6.51. These shares were paid for through the cancellation of the amounts then owed by the Company under the 2022 Loan Agreement, the principal sum of $65.0 million and all accrued and unpaid interest outstanding, which totaled approximately $0.2 million as of April 30, 2023. The parties completed the Private Placement on May 9, 2023 and, upon closing and satisfaction of the outstanding debt, the 2022 Loan Agreement terminated, without early termination fees or penalties being owed by the Company. No additional amounts are owed to Mr. Duggan under the 2022 Loan Agreement.   Operating Leases   In January 2017, the Company entered into a five-year lease (the "Existing Lease") for approximately 15,700 square feet for its corporate headquarters located in Hayward, California. The lease commenced in July 2017.   In May 2019, the Company entered into Lease Amendment 1 (the "Lease Amendment") in relation to the Existing Lease and added the lease of new premises of approximately 13,300 square feet and 21,300 square feet, ("Expansion Premises 1" and "Expansion Premises 2", respectively). Additionally, the term of the Existing Lease was extended to October 2029 to be coterminous with Expansion Premises 1 and Expansion Premises 2.   The Company evaluated the lease amendment under the provisions of ASC 842. It concluded that the Lease Amendment would be accounted for as a single contract with the Existing Lease because the additional lease payments due to the Lease Amendment was not commensurate with the right-of-use asset granted to the Company. Though the Lease Amendment was accounted for as a single contract, the Existing Premises, Expansion Premises 1 (occupied in November 2019) and Expansion Premises 2 (occupied in May 2020) are accounted for as separate lease components. Accordingly, the Company measured and allocated consideration to each lease component as of the modification date.   Supplemental balance sheet information related to leases (in thousands):   <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman"; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> September 30, </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> December 31, </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt; width: 70%;"> Assets: </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2024 </td><td style="font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2023 </td><td style="font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt;"> <p style="font-family: "Times New

Roman"; font-size: 10pt; font-variant: normal; margin: 0pt;">Right-of-use assets </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">6,588</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">7,256</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td></tr> </tbody></table>   <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman"; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> September 30, </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt;"> December 31, </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt; width: 70%;"> Liabilities: </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2024 </td><td style="font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2023 </td><td style="font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt;"> Current operating lease liabilities </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">1,193</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">1,058</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt;"> Non-current operating lease liabilities </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">7,174</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">8,086</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt;"> Total lease liabilities </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">8,367</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">9,144</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table>   Total cash paid for operating lease liabilities (in thousands):   <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman"; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Nine Months Ended September 30, </td><td style="font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2024 </td><td style="font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2023 </td><td style="font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt; width: 70%;"> Cash paid for operating lease liabilities </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">1,425</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">1,376</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td></tr> </tbody></table>   Maturities of operating lease liabilities were as follows (in thousands):   <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 85%;"> Year ending December 31: </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> 2024 (remaining 3 months) </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">485</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">2025</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,977</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">2026</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2,046</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">2027</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2,117</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Thereafter</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">4,074</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;">Total lease payments</p> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">10,699</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Less imputed interest</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(2,332</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;">Total lease liabilities</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">8,367</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table>   Weighted-average remaining lease term and discount rate, as of September 30, 2024, were as follows: <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman"; text-indent: 0px;"><tbody><tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt; width: 85%;"> Weighted-average remaining lease term </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">5.08</td><td style="width: 1%; font-

family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt;"> Weighted-average discount rate </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">10</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">%</td></tr> </tbody></table>   Rent expense, including common area maintenance charges, was approximately $0.6 million for each of the three-month periods ended September 30, 2024 and 2023, respectively, and was approximately $1.8 million and $1.7 million for the <em style="font: inherit;">nine-month periods ended <em style="font: inherit;"> September 30, 2024 and <em style="font: inherit;">2023, respectively.</p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt; text-align: justify;"> </p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt; text-align: justify;"><i>Legal Proceedings</i></p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt; text-align: justify;"> </p> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt -1pt; text-indent: 27pt; text-align: justify;">From time to time, we <em style="font: inherit;"> may be involved in a variety of claims, lawsuits, investigations, and proceedings relating to securities laws, product liability, patent infringement, contract disputes, and other matters relating to various claims that arise in the normal course of our business, including the matter described below. The outcome of any legal proceedings is unpredictable but, regardless of outcome, they can have an adverse impact on us because of defense and settlement costs, diversion of management resources, negative publicity, reputational harm, and other factors. We maintain insurance that <em style="font: inherit;"> may provide coverage for such matters, including customary employment practices liability insurance.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;"> </p> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 27pt;">In <em style="font: inherit;"> November 2022, the employment of our former Chief Financial Officer, Sandra Gardiner, terminated. Ms. Gardiner's departure was <em style="font: inherit;">not the result of any disagreement with the Company on any matter relating to its operations, accounting policies or practices, although the Company determined that she was <em style="font: inherit;">not eligible to receive any severance benefits under the terms and conditions of her then existing employment agreement. In <em style="font: inherit;"> March 2023, Ms. Gardiner filed an arbitration demand with JAMS seeking severance benefits and other remedies, alleging breach of contract and unlawful termination in violation of public policy, among other things. We believe that Ms. Gardiner's claims are without merit and we intend to vigorously defend ourselves against them. Because of the difficulty in predicting the outcome of any legal proceeding, the Company is <em style="font: inherit;">not able to conclude that a liability is probable and cannot predict what the final outcome of Ms. Gardiner's arbitration proceeding will likely be or provide a reasonable estimate for the range of ultimate possible loss, if any. However, at this time, we believe that the final resolution of this matter will <em style="font: inherit;">not adversely affect our consolidated position, results of operations, or cash flows.</p> <p style="text-align: justify; font-size: 10pt; font-family: "Times New Roman"; margin: 0pt;"> </p> 650000000517000001100000100229370.0016.516500000020000015700133002130 0 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman"; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">September 30,</p> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">December 31,</p> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt; width: 70%;"> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt;">Assets:</p> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">2024</p> </td><td style="font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">2023</p> </td><td style="font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt;"> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt;">Right-of-use assets</p> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">6,588</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">7,256</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td></tr> </tbody></table> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman"; text-indent: 0px;"> <tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">December 31,</p> </td><td style="font-family: "Times New Roman"; font-size: 10pt; width: 70%;"> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt;">Liabilities:</p> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">2024</p> </td><td style="font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">2023</p> </td><td style="font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt;"> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt;">Current operating lease liabilities</p> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">1,193</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">1,058</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt;"> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt;">Non-current operating lease liabilities</p> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">7,174</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">8,086</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt;"> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;">Total lease liabilities</p> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">8,367</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">9,144</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman"; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;"><em style="font: inherit;">Nine Months Ended September 30,</p> </td><td style="font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">2024</p> </td><td style="font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman"; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">2023</p> </td><td style="font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt; width: 70%;"> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt;">Cash paid for operating lease liabilities</p> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">1,425</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">1,376</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td></tr> </tbody></table> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 85%;"> Year ending December 31: </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal;

margin: 0pt;">2024 (remaining 3 months) </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">485</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">2025</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,977</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">2026</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2,046</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">2027</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2,117</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Thereafter</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">4,074</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;">Total lease payments</p> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">10,699</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Less imputed interest</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(2,332</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt;">Total lease liabilities</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">8,367</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman"; text-indent: 0px;"><tbody><tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt; width: 85%;"> Weighted-average remaining lease term </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">5.08</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman"; font-size: 10pt;"> Weighted-average discount rate </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">10</td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">%</td></tr> </tbody></table>
6588000725600011930001058000717400080860008367000914400014250001376000485000197700020460002117000407400010699000233200083670000P5Y29D0.106000001
8. Segment Reporting   The Company operates and manages the business as one reportable and operating segment. The Company's Chief Executive Officer acts as the chief operating decision maker ("CODM") of the Company. The CODM reviews the results of the Company on a consolidated basis. All of the Company's long-lived assets are based in the United States. 9.   Related Party Transactions   In May 2022, the Company determined not to renew its annual director and officer liability insurance policy due to disproportionately high premiums quoted by insurance companies. Instead, on May 31, 2022, the Company and Robert W. Duggan, majority stockholder and Co-Chairman, entered into a letter agreement (the "Letter Agreement") pursuant to which Mr. Duggan agreed with the Company to personally provide indemnity coverage for a one-year period, and he agreed to deposit cash and/or marketable securities into a third-party escrow, as security for these obligations, if requested by the Company. On May 31, 2023, the last day of the one-year period, the Company paid Mr. Duggan a fee of $1.0 million in consideration of the obligations set forth in the Letter Agreement. As of September 30, 2024, there were no additional amounts owed to Mr. Duggan under the Letter Agreement.   On September 20, 2022, the Company and Robert W. Duggan, the Company's majority stockholder and Co-Chairman, entered into the 2022 Loan Agreement in connection with Mr. Duggan lending the principal sum of $65.0 million to the Company. On April 30, 2023, the Company entered into a Securities Purchase Agreement with Mr. Duggan, pursuant to which the Company agreed to issue and sell to Mr. Duggan 10,022,937 shares of the Company's common stock, par value $0.001 per share, in a Private Placement, at a price per share of $6.51. These shares were paid for through the cancellation of the amounts then owed by the Company under the 2022 Loan Agreement, the principal sum of $65.0 million and all accrued and unpaid interest outstanding, which totaled approximately $0.2 million as of April 30, 2023. Upon closing of the Private Placement and satisfaction of the outstanding debt, the 2022 Loan Agreement terminated, without early termination fees or penalties being owed by the Company. No additional amounts are owed to Mr. Duggan under the 2022 Loan Agreement. See Note 7 for further details.
10000000650000001002293700.0016.5165000000200000 10.   Restructuring Charges   In February 2023, the Company eliminated seven positions and incurred a discrete restructuring related charge of $0.1 million which was fully recorded in February 2023 and the related expenses are included within total cost and expenses on the condensed consolidated statement of operations for the nine months ended September 30, 2023. This charge represents the total amount incurred in connection with the activity. 100000 11.   Subsequent Events   In October 2024, the Board approved changes to the performance-based vesting conditions of certain unvested outstanding common stock option awards that were improbable of vesting. Specifically, certain performance-based stock option awards were changed to time-based vesting criteria and certain performance-based stock option awards were changed to market-based vesting criteria. Based on our preliminary analysis, the Company estimates it will recognize approximately $12 million of stock-based compensation expense over the next 1 to 4 years from these modified stock option awards.   12000000 Item 5. Other Information   Trading Arrangements   During the three-month period ended September 30, 2024, none of our directors or officers (as defined in Rule 16a-1(f) under the Exchange Act) adopted or terminated a "Rule 10b5-1 trading arrangement" or a "non-Rule 10b5-1 trading arrangement" as such terms are defined under Item 408 of Regulation S-K. '

"